
<html lang="en"     class="pb-page"  data-request-id="4deece62-a414-47f9-ad31-a2230c85d84f"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.0c00182;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-11"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase" /></meta><meta name="dc.Creator" content="Justin T.  Ernst" /></meta><meta name="dc.Creator" content="Peggy A.  Thompson" /></meta><meta name="dc.Creator" content="Christian  Nilewski" /></meta><meta name="dc.Creator" content="Paul A.  Sprengeler" /></meta><meta name="dc.Creator" content="Samuel  Sperry" /></meta><meta name="dc.Creator" content="Garrick  Packard" /></meta><meta name="dc.Creator" content="Theodore  Michels" /></meta><meta name="dc.Creator" content="Alan  Xiang" /></meta><meta name="dc.Creator" content="Chinh  Tran" /></meta><meta name="dc.Creator" content="Christopher J.  Wegerski" /></meta><meta name="dc.Creator" content="Boreth  Eam" /></meta><meta name="dc.Creator" content="Nathan P.  Young" /></meta><meta name="dc.Creator" content="Sarah  Fish" /></meta><meta name="dc.Creator" content="Joan  Chen" /></meta><meta name="dc.Creator" content="Haleigh  Howard" /></meta><meta name="dc.Creator" content="Jocelyn  Staunton" /></meta><meta name="dc.Creator" content="Jolene  Molter" /></meta><meta name="dc.Creator" content="Jeff  Clarine" /></meta><meta name="dc.Creator" content="Andres  Nevarez" /></meta><meta name="dc.Creator" content="Gary G.  Chiang" /></meta><meta name="dc.Creator" content="Jim R.  Appleman" /></meta><meta name="dc.Creator" content="Kevin R.  Webster" /></meta><meta name="dc.Creator" content="Siegfried H.  Reich" /></meta><meta name="dc.Description" content="Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component o..." /></meta><meta name="Description" content="Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component o..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="May 29, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00182" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00182" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00182" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00182" /></link>
        
    
    

<title>Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00182" /></meta><meta property="og:title" content="Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0046.jpeg" /></meta><meta property="og:description" content="Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation–incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00182"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00182">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00182&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00182&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00182&amp;href=/doi/10.1021/acs.jmedchem.0c00182" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 11</span><span class="cit-fg-pageRange">, 5879-5955</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/11" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00168" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.0c00230" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Justin T. Ernst</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Justin T. Ernst</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Inception Therapeutics, 6175 Nancy Ridge Drive, San Diego, California 92121, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#e08a85928e9394a0898e83859094898f8e9498ce838f8d"><span class="__cf_email__" data-cfemail="4f252a3d213c3b0f26212c2a3f3b2620213b37612c2022">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Justin+T.++Ernst">Justin T. Ernst</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9229-3925" title="Orcid link">http://orcid.org/0000-0002-9229-3925</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peggy A. Thompson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peggy A. Thompson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peggy+A.++Thompson">Peggy A. Thompson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christian Nilewski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christian Nilewski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christian++Nilewski">Christian Nilewski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Paul A. Sprengeler</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Paul A. Sprengeler</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Sprengeler">Paul A. Sprengeler</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Samuel Sperry</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Samuel Sperry</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Samuel++Sperry">Samuel Sperry</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Garrick Packard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Garrick Packard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Inception Therapeutics, 6175 Nancy Ridge Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Garrick++Packard">Garrick Packard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Theodore Michels</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Theodore Michels</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">GossamerBio., 3013 Science Park Road, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Theodore++Michels">Theodore Michels</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Alan Xiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Alan Xiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">WuXi AppTec, 6114 Nancy Ridge Drive, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Alan++Xiang">Alan Xiang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Chinh Tran</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chinh Tran</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chinh++Tran">Chinh Tran</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christopher J. Wegerski</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christopher J. Wegerski</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+J.++Wegerski">Christopher J. Wegerski</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Boreth Eam</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Boreth Eam</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Calporta Therapeutics, 11099 North Torrey Poines Rd., La Jolla, California 92037, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Boreth++Eam">Boreth Eam</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Nathan P. Young</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Nathan P. Young</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Casma Therapeutics, 400 Technology Square, Cambridge, California 02139, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Nathan+P.++Young">Nathan P. Young</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah Fish</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah Fish</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Plexium, Inc., 11585 Sorrento Valley Rd., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah++Fish">Sarah Fish</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joan Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joan Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joan++Chen">Joan Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Haleigh Howard</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Haleigh Howard</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Providence Portland Medical Center, 4805 NE Glisan Street, Portland, Oregon 97213, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Haleigh++Howard">Haleigh Howard</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jocelyn Staunton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jocelyn Staunton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jocelyn++Staunton">Jocelyn Staunton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jolene Molter</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jolene Molter</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jolene++Molter">Jolene Molter</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeff Clarine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeff Clarine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">GossamerBio., 3013 Science Park Road, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeff++Clarine">Jeff Clarine</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Andres Nevarez</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Andres Nevarez</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Escient Pharmaceuticals, 10578 Science Center Dr., San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Andres++Nevarez">Andres Nevarez</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Gary G. Chiang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Gary G. Chiang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Gary+G.++Chiang">Gary G. Chiang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3004-7400" title="Orcid link">http://orcid.org/0000-0003-3004-7400</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jim R. Appleman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jim R. Appleman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Primmune Therapeutics, 3210 Merryfield Row, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jim+R.++Appleman">Jim R. Appleman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin R. Webster</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin R. Webster</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Frontier Medicines Corp., 151 Oyster Point Blvd., South San Francisco, California 94080, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+R.++Webster">Kevin R. Webster</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Siegfried H. Reich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Siegfried H. Reich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">eFFECTOR Therapeutics, 11180 Roselle Street, San Diego, California 92121, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Siegfried+H.++Reich">Siegfried H. Reich</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6840-2618" title="Orcid link">http://orcid.org/0000-0002-6840-2618</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00182&amp;href=/doi/10.1021%2Facs.jmedchem.0c00182" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 11</span><span class="cit-pageRange">, 5879–5955</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">May 29, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>1 February 2020</li><li><span class="item_label"><b>Published</b> online</span>29 May 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 11 June 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00182" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00182</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D5879%26pageCount%3D77%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJustin%2BT.%2BErnst%252C%2BPeggy%2BA.%2BThompson%252C%2BChristian%2BNilewski%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D11%26contentID%3Dacs.jmedchem.0c00182%26title%3DDesign%2Bof%2BDevelopment%2BCandidate%2BeFT226%252C%2Ba%2BFirst%2Bin%2BClass%2BInhibitor%2Bof%2BEukaryotic%2BInitiation%2BFactor%2B4A%2BRNA%2BHelicase%26numPages%3D77%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D5955%26publicationDate%3DJune%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00182"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2528</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">22</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00182" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Justin&quot;,&quot;last_name&quot;:&quot;T. Ernst&quot;},{&quot;first_name&quot;:&quot;Peggy&quot;,&quot;last_name&quot;:&quot;A. Thompson&quot;},{&quot;first_name&quot;:&quot;Christian&quot;,&quot;last_name&quot;:&quot;Nilewski&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Sprengeler&quot;},{&quot;first_name&quot;:&quot;Samuel&quot;,&quot;last_name&quot;:&quot;Sperry&quot;},{&quot;first_name&quot;:&quot;Garrick&quot;,&quot;last_name&quot;:&quot;Packard&quot;},{&quot;first_name&quot;:&quot;Theodore&quot;,&quot;last_name&quot;:&quot;Michels&quot;},{&quot;first_name&quot;:&quot;Alan&quot;,&quot;last_name&quot;:&quot;Xiang&quot;},{&quot;first_name&quot;:&quot;Chinh&quot;,&quot;last_name&quot;:&quot;Tran&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;J. Wegerski&quot;},{&quot;first_name&quot;:&quot;Boreth&quot;,&quot;last_name&quot;:&quot;Eam&quot;},{&quot;first_name&quot;:&quot;Nathan&quot;,&quot;last_name&quot;:&quot;P. Young&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;Fish&quot;},{&quot;first_name&quot;:&quot;Joan&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Haleigh&quot;,&quot;last_name&quot;:&quot;Howard&quot;},{&quot;first_name&quot;:&quot;Jocelyn&quot;,&quot;last_name&quot;:&quot;Staunton&quot;},{&quot;first_name&quot;:&quot;Jolene&quot;,&quot;last_name&quot;:&quot;Molter&quot;},{&quot;first_name&quot;:&quot;Jeff&quot;,&quot;last_name&quot;:&quot;Clarine&quot;},{&quot;first_name&quot;:&quot;Andres&quot;,&quot;last_name&quot;:&quot;Nevarez&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;G. Chiang&quot;},{&quot;first_name&quot;:&quot;Jim&quot;,&quot;last_name&quot;:&quot;R. Appleman&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;R. Webster&quot;},{&quot;first_name&quot;:&quot;Siegfried&quot;,&quot;last_name&quot;:&quot;H. Reich&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;05&quot;,&quot;day&quot;:&quot;29&quot;,&quot;issue&quot;:&quot;11&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;5879-5955&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00182&quot;},&quot;abstract&quot;:&quot;Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (i.e., rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation–incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of eFT226 (Zotatifi&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00182&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00182" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00182&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00182" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00182&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00182" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00182&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00182&amp;href=/doi/10.1021/acs.jmedchem.0c00182" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00182" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00182" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (9 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00182%26sid%3Dliteratum%253Aachs%26pmid%3D32470302%26genre%3Darticle%26aulast%3DErnst%26date%3D2020%26atitle%3DDesign%2Bof%2BDevelopment%2BCandidate%2BeFT226%252C%2Ba%2BFirst%2Bin%2BClass%2BInhibitor%2Bof%2BEukaryotic%2BInitiation%2BFactor%2B4A%2BRNA%2BHelicase%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D11%26spage%3D5879%26epage%3D5955%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (10)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=290888" title="Liquid liquid equilibrium">Liquid liquid equilibrium</a>,</li><li><a href="/action/doSearch?ConceptID=291241" title="Phenyls">Phenyls</a>,</li><li><a href="/action/doSearch?ConceptID=291454" title="Solubility">Solubility</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/11" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/jmcmar.2020.63.issue-11/20200611/jmcmar.2020.63.issue-11.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0046.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dysregulation of protein translation is a key driver for the pathogenesis of many cancers. Eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase, is a critical component of the eIF4F complex, which regulates cap-dependent protein synthesis. The flavagline class of natural products (<i>i.e.</i>, rocaglamide A) has been shown to inhibit protein synthesis by stabilizing a translation–incompetent complex for select messenger RNAs (mRNAs) with eIF4A. Despite showing promising anticancer phenotypes, the development of flavagline derivatives as therapeutic agents has been hampered because of poor drug-like properties as well as synthetic complexity. A focused effort was undertaken utilizing a ligand-based design strategy to identify a chemotype with optimized physicochemical properties. Also, detailed mechanistic studies were undertaken to further elucidate mRNA sequence selectivity, key regulated target genes, and the associated antitumor phenotype. This work led to the design of <b>eFT226</b> (Zotatifin), a compound with excellent physicochemical properties and significant antitumor activity that supports clinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02485" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02485" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The dysregulation of messenger RNA (mRNA) translation is a common feature in malignancies, demonstrated by an upregulation of oncoproteins, growth factors, and signal transduction proteins associated with proliferation, survival, and metastasis.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4">(1−4)</a> The expression of oncogenic drivers is held under tight translational control and is regulated by the eukaryotic translation initiation factor 4F (eIF4F) complex.<a onclick="showRef(event, 'ref5 ref6'); return false;" href="javascript:void(0);" class="ref ref5 ref6">(5,6)</a> The eIF4F complex consists of the 5′-mRNA cap binding protein eIF4E, a large scaffolding protein eIF4G and the DEAD box RNA helicase eukaryotic initiation factor 4A (eIF4A). eIF4A functions in an ATP-dependent manner to unwind an mRNA secondary structure to enable ribosome scanning and translation initiation.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The eIF4F subunits are frequently overexpressed in various malignancies; therefore, targeting the components of the eIF4F complex to renormalize dysregulated translation is an emerging strategy in anticancer drug discovery.<a onclick="showRef(event, 'ref2 ref7 ref8 ref9 ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref2 ref7 ref8 ref9 ref10 ref11">(2,7−11)</a> Our efforts focused on the identification of inhibitors of eIF4A-mediated translation.</div><div class="NLM_p last">Activation of eIF4F has a direct role in tumorigenesis due to increased synthesis of oncogenes with highly structured 5′-UTRs that are dependent on enhanced eIF4A RNA helicase activity for translation.<a onclick="showRef(event, 'ref1 ref2 ref3 ref4 ref5 ref6 ref12'); return false;" href="javascript:void(0);" class="ref ref1 ref2 ref3 ref4 ref5 ref6 ref12">(1−6,12)</a> Several natural product classes have been reported to inhibit eIF4A-mediated translation and exhibit antiproliferative and antitumor phenotypes both <i>in vitro</i> and <i>in vivo</i>.<a onclick="showRef(event, 'ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15 ref16 ref17 ref18 ref19 ref20">(13−20)</a> The flavaglines, exemplified by silvestrol (<b>1</b>) and rocaglamide A (<b>2</b>), have been shown to bind and stabilize a translation incompetent RNA/eIF4A complex. Recent studies demonstrate that the formation of a ternary complex between eIF4A, mRNA, and rocaglamide A is specific for polypurine motifs in the 5′-UTR of select mRNAs resulting in a small molecule sequence-selective translational repressor.<a onclick="showRef(event, 'ref21 ref22'); return false;" href="javascript:void(0);" class="ref ref21 ref22">(21,22)</a> Hippuristanol (<b>3</b>), an oxygenated steroid, has been shown to bind an allosteric site in the C-terminal domain of eIF4A and stabilizes a conformation that is incompatible with RNA binding.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Pateamine A (<b>4</b>) has been reported to irreversibly bind eIF4A, resulting in the stabilization of an RNA/eIF4A complex discordant with translation.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Numerous drug discovery efforts have been invested in the flavaglines, however, to date, none of these programs have led to the advancement of a development candidate into human clinical studies. Major challenges include overcoming poor drug-like properties such as metabolic instability and poor solubility, as well as developing a robust synthetic methodology to produce the drug substance on a scale necessary to support clinical development. Thus, one of our main tactics in exploiting the flavagline class of molecules was to focus on improving physicochemical properties. The optimization of properties such as log <i>P</i> and aqueous solubility were important to support controlled intravenous delivery of an optimal therapeutic dose. Herein we report on our design efforts that led to the identification of <b>eFT226</b>, the first eIF4A inhibitor to enter human clinical studies.<img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0047.gif" alt="" id="dgr1" /></img></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Optimization of the Flavagline-Based Natural Products to Yield <b>EFT226</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28565" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28565" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">From the known flavagline-based derivatives, we focused our initial attention on rocaglamide A (<b>2</b>) which has published literature supporting its mechanism for inhibiting eIF4A-mediated translation.<a onclick="showRef(event, 'ref13 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref13 ref25 ref26">(13,25,26)</a> During the design and development of <b>eFT226</b>, an X-ray crystal structure of a rocaglamide derivative/mRNA/eIF4A1 complex had not been published. Utilizing reported eIF4A1 mutational data (mutations conferring resistance to flavagline derivatives),<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> a small molecule crystal structure of a flavagline from the Cambridge Structural Database (CSD), and an X-ray structure of related isoform eIF4A3 bound to polyuracil RNA (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a>),<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> a molecular model was devised to analyze the potential binding complex formed between RNA, rocaglamide A, and eIF4A1 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>). In this model, the phenyl A and D rings of rocaglamide A are positioned to promote pi-stacking with the RNA bases at the RNA/eIF4A1 interface (see <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> for compound ring assignment). The phenyl D and E rings are proposed to bind into two adjacent hydrophobic pockets on eIF4A1 which contain amino acid residues that have been shown through mutational studies to be critical for small molecule binding. A predicted hydrogen bond between an N–H side chain of Gln 195 and rocaglamide A’s carbonyl oxygen of the dimethyl amide group provides additional protein ligand stabilization. This model allowed us to make key inferences to aid in design, namely: (1) a key contributor to the binding interaction could be pi-stacking between the mRNA bases, the benzofuran and one of the phenyl rings of the natural product; (2) the phenyl ring distal to the mRNA binds in a pocket of quite limited size and thus might accommodate limited substitution; (3) the potential importance of the hydrogen bond between Gln 195 and the small molecule; and (4) that silvestrol’s dioxane ring likely binds in an open site on the opposite side of the RNA from the rocaglamide core and thus may not be an efficient binding element. Although this model was useful, it was considered low resolution, prompting the development of additional computational methodologies for assessing compound designs.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Modeled binding mode of rocaglamide A (pink) to a complex formed by poly-U RNA (light blue) and eIF4A3 (dark blue). Residues of eIF4A shown to confer resistance to rocaglamide analogues are highlighted in (yellow), PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We were intrigued at the outset of the program by the unique three-dimensional structure of the flavagline core, a result of five contiguous stereocenters in the molecule on a five-membered-ring. Unlike six-membered-rings, the conformations of five-membered rings are much less predictable because they undergo pseudorotation. Understanding the preferred conformation of this system and how this is related to the observed phenotypes and potency SAR for this class of molecules was deemed critical for the optimization process that could offer a ligand-based modeling methodology for evaluating potential compounds. <i>Ab initio</i>, density functional theory (DFT) calculations performed on rocaglamide A predicted the low energy conformation to have an intramolecular hydrogen bond between the secondary hydroxyl and the methoxy group at the 8-position. Importantly, the preferred low energy torsional angle between the phenyl D and E rings was found to be approximately 40° (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). We hypothesized that this preferred torsion might be a prerequisite for potent binding to the protein–RNA complex and might be utilized to prioritize potential targets. DFT calculations that drove the aryl–aryl torsional angle between ±60° at 5° increments of a flavagline molecule produced an energy profile, an example of which is shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a> for rocaglamide A. It was discovered that cores that embodied a 40-degree aryl–aryl torsion as a preferred low-energy conformation tended to display highest potency while cores without a low energy 40° torsion generally did not produce potent molecules. This model was used prospectively to filter out molecular designs lacking the desired energy profile.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0008.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Conformational analysis of rocaglamide A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, an X-ray crystal structure (2 Å resolution) of the ternary complex formed between eIF4A1, rocaglamide A, and a polypurine RNA sequence was disclosed (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Interestingly, the binding mode of rocaglamide A in the crystal structure is quite analogous to our proposed model and confirms the 40° aryl–aryl torsion hypothesis. The X-ray structure discloses an additional hydrogen bonding interaction between the rocaglamide tertiary hydroxyl and N7 of an adjacent RNA guanine base. This interaction is hypothesized to impart sequence selectivity for the stabilization of purine sequences to eIF4A1.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0009.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of a ternary complex formed between rocaglamide A, eIF4A1, and a polypurine RNA sequence showing the hydrogen bond from the tertiary hydroxyl group to the purine N7, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9">5ZC9</a>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Initial efforts focused on optimization of the phenyl A ring of rocaglamide A to promote pi-stacking with the RNA base and impart sequence selectivity. We reasoned that the pi-stacking interaction with RNA could potentially accommodate a heterocycle in place of the phenyl A ring, a strategy that would lower the lipophilicity of the core. Replacement of the phenyl A ring in the rocaglamide system with a heterocycle is unprecedented in the literature. We focused on utilizing pyridine as a replacement as this would be a minimal structural change and one that could greatly reduce the log <i>P</i>(−0.67) of the scaffold. Incorporation of the pyridine nitrogen at the 8-position of the core was explored first because the nitrogen at this position could potentially mimic the methoxy group’s hydrogen bond acceptor properties and eliminating one of the methoxy groups would further reduce the lipophilicity of the system. As stated earlier, conformational analysis of rocaglamide A indicated that the methoxy oxygen at the 8-position forms a 7-membered intramolecular hydrogen bond with the secondary hydroxyl at the 1-position, reinforcing the bioactive conformation of the natural product core. Replacement with a pyridine would enable a six-membered intramolecular hydrogen bonding arrangement. Pyridine <b>5</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) was synthesized and was found to be 25-fold less potent than rocaglamide A in the MDA-MB-231 breast cancer cell proliferation assay. It should also be noted that for racemates, the potencies are assumed to be 50% as potent as the active enantiomer (the opposite enantiomers are completely inactive; data not shown). To fully evaluate this structural change, the des-8-methoxy derivative of rocaglamide A was also prepared (<b>6</b>) and was found to be 5-fold more potent than <b>5</b>. Interestingly, lipophilic ligand efficiency (LLE) analysis showed that the loss in potency for the pyridine system is entirely driven by a reduction in clog <i>P</i> (<b>5</b> and <b>6</b> are iso-LLE). To further reduce the lipophilicity and potentially improve potency [as well as ligand efficiency (LE) and LLE], the 4′-methoxy group was replaced with a nitrile, a modification previously reported in the literature to improve the potency of the rocaglamide system.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Nitrile analogue <b>7</b> was found to have threefold improved potency versus <b>5</b>, an increase similar to that reported for this modification in related chemotypes. Modeling of compound <b>7</b> in the binding pocket suggested that the nitrile group fits into a narrow groove formed by the RNA and eIF4A and is positioned to potentially interact with the side chain of Asn 167 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). We were encouraged at this point because compound <b>7</b> has similar LE and LLE values as rocaglamide A, however with a significant overall reduction in clog <i>P</i> (−1.2 logs). A review of the literature suggested that replacement of the 6-position methoxy of the rocaglamide core with either a chloro or nitrile group could also improve potency.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Chloro analogue <b>8</b> showed slightly improved potency versus <b>7</b> while maintaining LLE, whereas the nitrile analogue <b>9</b> exhibited modestly reduced potency, however, with an improved LLE. An X-ray structure was obtained for compound <b>8</b> and confirmed the intramolecular hydrogen bond between the secondary hydroxyl and the pyridine nitrogen (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>).<named-content content-type="anchor" rid="fig6" type="simple"></named-content> The structure also showed a torsional angle of 40° between the D and E phenyl rings, consistent with earlier conformational analyses conducted with rocaglamide A.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0010.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modeling of compound <b>7</b> in the binding pocket formed from eIF4A in complex with poly-U RNA, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0011.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray structure for compound <b>8</b> highlighting the intramolecular hydrogen bond between the secondary hydroxyl and the pyridine nitrogen and the 40° Ar–Ar torsion.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR Data for Flavagline Derivatives <b>2–23</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0040.gif" alt="" id="GRAPHIC-d7e851-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">R<sub>8</sub></th><th class="colsep0 rowsep0" align="center">R<sub>6</sub></th><th class="colsep0 rowsep0" align="center">R<sub>4′</sub></th><th class="colsep0 rowsep0" align="center">cell IC<sub>50</sub> nM</th><th class="colsep0 rowsep0" align="center" char=".">clog <i>P</i></th><th class="colsep0 rowsep0" align="center" char=".">LE</th><th class="colsep0 rowsep0" align="center" char=".">LLE</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b> (-)</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">20 ± 9</td><td class="colsep0 rowsep0" align="char" char=".">3.72</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">990</td><td class="colsep0 rowsep0" align="char" char=".">3.05</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">198 ± 51</td><td class="colsep0 rowsep0" align="char" char=".">3.73</td><td class="colsep0 rowsep0" align="char" char=".">0.28</td><td class="colsep0 rowsep0" align="char" char=".">3.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">159 ± 84</td><td class="colsep0 rowsep0" align="char" char=".">2.56</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">87 ± 26</td><td class="colsep0 rowsep0" align="char" char=".">2.92</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">385 ± 147</td><td class="colsep0 rowsep0" align="char" char=".">1.73</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">4.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">52 ± 15</td><td class="colsep0 rowsep0" align="char" char=".">4.49</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">19 ± 3</td><td class="colsep0 rowsep0" align="char" char=".">4.01</td><td class="colsep0 rowsep0" align="char" char=".">0.33</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">68 ± 18</td><td class="colsep0 rowsep0" align="char" char=".">3.24</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">4.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">38 ± 1</td><td class="colsep0 rowsep0" align="char" char=".">3.40</td><td class="colsep0 rowsep0" align="char" char=".">0.30</td><td class="colsep0 rowsep0" align="char" char=".">4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">26 ± 2</td><td class="colsep0 rowsep0" align="char" char=".">2.91</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td><td class="colsep0 rowsep0" align="char" char=".">5.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">283 ± 142</td><td class="colsep0 rowsep0" align="char" char=".">3.40</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="char" char=".">3.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">601 ± 266</td><td class="colsep0 rowsep0" align="char" char=".">2.22</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">143 ± 24</td><td class="colsep0 rowsep0" align="char" char=".">3.98</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">160 ± 46</td><td class="colsep0 rowsep0" align="char" char=".">4.19</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">2.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">3.62</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CF<sub>2</sub>H</td><td class="colsep0 rowsep0" align="left">241 ± 58</td><td class="colsep0 rowsep0" align="char" char=".">3.67</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">320 ± 68</td><td class="colsep0 rowsep0" align="char" char=".">4.36</td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">603 ± 167</td><td class="colsep0 rowsep0" align="char" char=".">4.51</td><td class="colsep0 rowsep0" align="char" char=".">0.23</td><td class="colsep0 rowsep0" align="char" char=".">1.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b> (-)</td><td class="colsep0 rowsep0" align="left">N</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">1.84</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p">The decreased potency with nitrile <b>9</b> was the first indication of divergence of potency SAR between the pyridine and phenyl A-ring systems. Comparison of phenyl analogues <b>6</b>, <b>10–14</b> with an LLE analysis (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) indicated that the increase in potency with 6-chloro substitution is driven by a lipophilicity increase, whereas both 4′-nitrile and 6-nitrile substitutions lead to potency increases <i>via</i> enthalpic contributions. Interestingly, the analogous plot with pyridines <b>5</b>, <b>7–9</b>, and <b>15–16</b> (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) indicated that the potency increase with 4′-nitrile substitution is enthalpically driven, but both the increase in potency with 6-chloro substitution and the decrease in potency with 6-nitrile substitution follow iso-LLE shifts, indicative of lipophilic-driven potency changes. It should be noted that the permeability properties of the 6-nitrile analogues were similar to the 6-methoxy analogues; thus, variations in cell permeability were ruled out as possible explanations for the observed potency SAR (data not shown). One explanation for the SAR differences between the pyridine and phenyl systems could be subtle differential effects of ring substitution on the pi stacking interactions with RNA in the ternary complex.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0012.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. LLE plot for ring A phenyl series. Iso-LLE changes between compounds are shown with yellow arrows while changes resulting in LLE improvement are shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0013.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. LLE plot for ring A pyridine series. Iso-LLE changes between compounds are shown with yellow arrows while changes resulting in LLE improvement are shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Utilizing chloro analogue <b>8</b> the 4′-position was further interrogated (analogues <b>17–23</b> in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), focusing on functional groups previously unexplored in the literature at this position of the molecule. Ultimately, all changes at this position resulted in a loss of potency versus the nitrile substituent.</div><div class="NLM_p">Modifications to the dimethyl amide functionality at the 2-position of compound <b>8</b> were also explored (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Complete removal of the amide side chain (<b>24</b>) resulted in a significant reduction in potency. Interestingly, the secondary (<b>25</b>) and primary amide (<b>26</b>) derivatives had slightly improved or equal potency, respectively. However, in both cases the permeability was reduced (CACO AB = 0.5 × 10<sup>–6</sup> cm/s) versus tertiary amide <b>8</b> (CACO AB = 1.8 × 10<sup>–6</sup> cm/s). Several amide isosteres were also tested (<b>27–30</b>), as well as the amino and alcohol analogues <b>31</b> and <b>32</b>, respectively, and all were found to be less potent than the parent system.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Modifications to the 2-Position of the Flavagline Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0041.gif" alt="" id="GRAPHIC-d7e1641-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char="±">cell IC<sub>50</sub> nM</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">670 ± 12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b> (-)</td><td class="colsep0 rowsep0" align="left">CONHMe</td><td class="colsep0 rowsep0" align="char" char="±">32 ± 4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b> (-)</td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">90 ± 24</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">2-oxazole</td><td class="colsep0 rowsep0" align="char" char="±">236 ± 63</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub>N(Me)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">304 ± 73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub>NHMe</td><td class="colsep0 rowsep0" align="char" char="±">2037 ± 978</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b> (-)</td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub>Me</td><td class="colsep0 rowsep0" align="char" char="±">3018 ± 110</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b> (-)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>N(Me)<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">239 ± 123</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub>OH</td><td class="colsep0 rowsep0" align="char" char="±">1465 ± 1657</td></tr></tbody></table></div></div><div class="NLM_p">At this point, further exploration of the pyridine A ring was conducted to improve potency while continuing to optimize the physicochemical properties of the scaffold. Analogues <b>33–36</b> were synthesized to probe the optimal pyridine regioisomers of this system (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). The 7-position pyridyl isomers, having either cyano substitution at the 6-position (<b>33</b>) or methoxy substitution at the 8-position (<b>34</b>), demonstrated modest potency. Interestingly, the 6-position pyridyl isomer (<b>35</b>), utilizing the methoxy substitution at the 8-position, was found to be 2–3-fold more potent than <b>8</b> (equal LE and improved LLE <i>vs</i><b>8</b>) and within 2-fold of the potency of rocaglamide A. This was a striking result given previous reports of the importance of 6-position substitution (phenyl A ring chemotype) for potency.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> Also intriguing, the 5-pyridyl isomer (<b>36</b>) is inactive, further demonstrating that subtle electronic differences in the A-ring can have a dramatic impact on potency. Modeling of <b>36</b> in the RNA/eIF4A binding site indicated that the lone pair of electrons of the 5-pyridine would be in close proximity to the polar RNA backbone, a situation that would be highly disfavored for binding (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0014.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Binding model for compound <b>36</b>. The 3.9 Å contact between the pyridine nitrogen of <b>36</b> and one of the phosphate ether oxygens of the RNA backbone is shown, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Profiles of Pyridine Analogues <b>33–36</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0042.gif" alt="" id="GRAPHIC-d7e1883-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">cell IC<sub>50</sub> nM</th><th class="colsep0 rowsep0" align="center" char=".">clog <i>P</i></th><th class="colsep0 rowsep0" align="center" char=".">LE</th><th class="colsep0 rowsep0" align="center" char=".">LLE</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b> (-)</td><td class="colsep0 rowsep0" align="left">308 ± 84</td><td class="colsep0 rowsep0" align="char" char=".">1.93</td><td class="colsep0 rowsep0" align="char" char=".">0.26</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">314 ± 19</td><td class="colsep0 rowsep0" align="char" char=".">2.96</td><td class="colsep0 rowsep0" align="char" char=".">0.27</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b> (-)</td><td class="colsep0 rowsep0" align="left">33 ± 9</td><td class="colsep0 rowsep0" align="char" char=".">2.56</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b> (<i>rac</i>)</td><td class="colsep0 rowsep0" align="left">>1000</td><td class="colsep0 rowsep0" align="char" char=".">2.96</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td></tr></tbody></table></div></div><div class="NLM_p">Based on the improved potency and LLE relative to <b>8</b>, compound <b>35</b> was selected for further optimization. Analysis of the DMPK properties of <b>35</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) revealed poor CACO permeability and aqueous solubility; however, a good rat PK profile was observed following intravenous dosing. The poor aqueous solubility was a concern as this could potentially create formulation challenges for clinical studies utilizing IV infusions. Therefore, a strategy was sought that could greatly improve the aqueous solubility of the scaffold as well as improve permeability properties. Replacement of the dimethyl amide group at the 2-position with a solubilizing basic amine side chain was revisited in the context of analogue <b>35</b>. Previously, replacement with the dimethylamino-methylene side chain in the 8-pyridyl series resulted in a 2–3-fold loss of potency (<b>31</b><i>vs</i><b>8</b>). The analogous analogue was prepared in the 6-pyridyl series (<b>37</b>) and was found to be within 2-fold of the potency of dimethyl amide <b>35</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The basic amine side chain greatly improved the aqueous solubility of the scaffold (>20 mg/mL for <b>37</b><i>vs</i> 0.22 mg/mL for <b>35</b>) while maintaining the overall LE. The LLE of <b>37</b>, however, was slightly reduced versus <b>35</b>. Compound <b>37</b> showed no inhibition in a hERG functional patch-clamp assay, a liability often associated with basic molecules. However, incorporation of the basic amine did further increase Pgp-mediated efflux and resulted in higher rat IV clearance (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Given the solubility advantages of the amine side chain, an extensive effort was conducted to optimize this group to maintain the attractive solubility, potency, and hERG off-target profiles and mitigate issues with efflux and IV clearance. A focused library (compounds <b>38–52</b>) was generated in which the sterics, lipophilicity, and p<i>K</i><sub>a</sub> properties of the amine side chain of <b>37</b> were modulated (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). Analogues with similar basicity as <b>37</b> (<i>i.e.</i>, <b>40</b>, <b>41</b>, <b>49</b>, <b>50</b>, <b>52</b>), regardless of sterics and lipophilicity of the amine, were found to have poor permeability properties. Reducing the p<i>K</i><sub>a</sub> of the amine (<i>i.e.</i>, analogues <b>42–46</b>, <b>51</b>) in general reduced efflux, but also reduced antiproliferative potency. Analysis of hERG SAR indicated a strong correlation to lipophilicity (preferred range clog <i>P</i> < 2.5) but not to p<i>K</i><sub>a</sub> (comparing analogues <b>41</b> and <b>42</b>). Ultimately, the library was unsuccessful in identifying amine-containing candidates in the 6-pyridyl series with the desired potency, hERG, and permeability properties.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Potency, Solubility, CACO Permeability and <i>in Vivo</i> Rat PK (1 mg/kg) Properties for <b>35</b>, <b>37</b>, <b>53</b>, and <b>eFT226</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0043.gif" alt="" id="GRAPHIC-d7e2145-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char="±">cell IC<sub>50</sub> nM</th><th class="colsep0 rowsep0" align="center" char=".">LE</th><th class="colsep0 rowsep0" align="center" char=".">LLE</th><th class="colsep0 rowsep0" align="center">solubility mg/mL</th><th class="colsep0 rowsep0" align="center" char=".">CACO AB 1 × 10<sup>–6</sup> cm/s</th><th class="colsep0 rowsep0" align="center" char=".">CACO ER</th><th class="colsep0 rowsep0" align="center">hERG IC<sub>50</sub> μM</th><th class="colsep0 rowsep0" align="center" char=".">Cl mL/min/kg</th><th class="colsep0 rowsep0" align="center" char=".">Vdss L/kg</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub> h</th><th class="colsep0 rowsep0" align="center" char=".">AUC h μg/mL</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b> (-)</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 9</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">4.9</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="char" char=".">0.65</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="char" char=".">18</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td><td class="colsep0 rowsep0" align="char" char=".">2.0</td><td class="colsep0 rowsep0" align="char" char=".">0.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b> (-)</td><td class="colsep0 rowsep0" align="char" char="±">54 ± 4</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">4.6</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="char" char=".">0.21</td><td class="colsep0 rowsep0" align="char" char=".">22</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">39</td><td class="colsep0 rowsep0" align="char" char=".">5.2</td><td class="colsep0 rowsep0" align="char" char=".">2.9</td><td class="colsep0 rowsep0" align="char" char=".">0.44</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b> (-)</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 3</td><td class="colsep0 rowsep0" align="char" char=".">0.29</td><td class="colsep0 rowsep0" align="char" char=".">5.3</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="char" char=".">1.0</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">10.3</td><td class="colsep0 rowsep0" align="char" char=".">11.0</td><td class="colsep0 rowsep0" align="char" char=".">0.73</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>eFT226</b> (-)</td><td class="colsep0 rowsep0" align="char" char="±">10.6 ± 0.9</td><td class="colsep0 rowsep0" align="char" char=".">0.31</td><td class="colsep0 rowsep0" align="char" char=".">6.5</td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="char" char=".">2.5</td><td class="colsep0 rowsep0" align="char" char=".">4</td><td class="colsep0 rowsep0" align="left">>10</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">13.0</td><td class="colsep0 rowsep0" align="char" char=".">4.4</td><td class="colsep0 rowsep0" align="char" char=".">0.39</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR Studies for 2-Position Amine Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0044.gif" alt="" id="GRAPHIC-d7e2399-autogenerated" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0045.gif" alt="" id="gr40" /></img><div></div></div><div class="NLM_p last">At this stage it was decided to analyze the 2-position amino side chain in the context of the 7-pyridyl system (represented by analogues <b>33</b> and <b>34</b>), with the expectation that this system might have improved permeability due to increased shielding of the pyridine nitrogen. It was also reasoned that a potency increase was possible by combining substitutions at the 8 and 6-positions of the A-ring (mimicking the original substitution pattern of rocaglamide A). Thus, compound <b>53</b> was prepared and found to be 3–4 fold more potent versus <b>37</b> (equal LE and improved LLE; <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) and maintained excellent aqueous solubility. Compound <b>53</b> also showed an improved CACO profile, however, the efflux ratio was still deemed to be too high (efflux was viewed as a risk for potential MDR-based resistance mechanisms). Analogue <b>53</b> was evaluated in rat IV PK and found to have reduced clearance versus <b>37</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). To mitigate the efflux liability of this system, the PSA was reduced by replacing the 6-position nitrile with a methoxy group. This modification ultimately led to the discovery of <b>eFT226</b>, an analogue with similar potency as compound <b>53</b>, however with improved LE, LLE, CACO permeability, and reduced efflux (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). It is interesting to note that despite significant optimization efforts at the 8 and 6-positions, ultimately <b>eFT226</b> retained the A-ring bis-methoxy substitution pattern found in rocaglamide A. As stated previously, two prioritized goals for the program were to identify a development candidate with reduced lipophilicity and increased aqueous solubility versus the rocaglamide natural products. The experimentally measured log <i>P</i> and log <i>D</i> 7.4 values for <b>eFT226</b> are 2.6 and 1.5, respectively, thus demonstrating a high level of lipophilic optimization (<b>eFT226</b> LLE = 6.5). The thermodynamic aqueous solubility of <b>eFT226</b>, driven in large part by the basic dimethylamino side chain (p<i>K</i><sub>a</sub> = 8.6), is > 20 mg/mL (as HCl salt), representing a significant improvement versus rocaglamide A. Both of these properties greatly enhance the drug-ability of <b>eFT226</b> facilitating intravenous delivery.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Characterization of Clinical Candidate <b>eFT226</b></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Sequence recognition motifs within the 5′-UTR of select target genes have been shown to drive sensitivity to rocaglate inhibition of eIF4A1.<a onclick="showRef(event, 'ref21 ref22 ref28'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref28">(21,22,28)</a> The sequence specificity of <b>eFT226</b> for polypurine (AGAGAG), G-quadruplex like (GGCGGC), or control 5′-UTR recognition motifs was tested using surface plasmon resonance. Direct binding studies showed that eIF4A1 alone bound weakly (3–8 μM) to RNA and only in the presence of ATP. Addition of <b>eFT226</b> induced the formation of an RNA sequence-dependent ternary complex between eIF4A1 and polypurine (AGAGAG) RNA motifs in a nucleotide (ATP, ADP) independent manner. <b>eFT226</b> increased the binding affinity (<i>K</i><sub>D</sub>) of eIF4A1 to an AGAGAG polypurine RNA oligonucleotide by >100-fold in the presence of ATP (<i>K</i><sub>D</sub> 21–69 nM) due to a change in binding kinetic rates resulting in a slow off rate and prolonged residence time for eIF4A1 bound to the polypurine RNA motif (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>),<named-content content-type="anchor" rid="fig10" type="simple"></named-content> a mechanism of inhibition similar to that reported for Rocaglamide A (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>).<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a><b>eFT226</b> did not induce a stable ternary complex with RNA oligonucleotides containing GGCGGC, CCGCCG, or CAACAA sequence motifs (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>), nor was binding observed for eIF4A1 to DNA oligo sequences (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_001.pdf" class="ext-link">Supporting Information</a>), demonstrating the selectivity of the <b>eFT226</b> induced ternary complex.</div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0015.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <b>eFT226</b> enhances formation of eIF4A1/RNA complex. Sensograms of eIF4A1 binding to rAGA surface in the presence (solid) or absence (dashed) of <b>eFT226</b>. The sensograms were fitted using a global fitting function to determine the equilibrium dissociation constant and binding kinetics. Running buffer contained 14.4 mM Hepes pH 7.4, 108 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.36 mM TCEP, 1 mM ATP, and 1% dimethyl sulfoxide (DMSO). Data were collected at 25 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Binding Characteristics of <b>eFT226</b>-Induced Ternary Complex Formation with Different RNA Sequences</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">RNA sequence</th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub> (μM) with <b>eFT226</b></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub> (μM) without <b>eFT226</b></th><th class="colsep0 rowsep0" align="center"><i>K</i><sub>D</sub> (μM) with Roc A</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AGAGAG + ATP</td><td class="colsep0 rowsep0" align="left">0.021 (±0.001)</td><td class="colsep0 rowsep0" align="left">8.0 (±0.9)</td><td class="colsep0 rowsep0" align="left">0.156 (±0.007)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GGCGGC + ATP</td><td class="colsep0 rowsep0" align="left">3.19 (±0.03)</td><td class="colsep0 rowsep0" align="left">8.0 (±0.3)</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCGCCG + ATP</td><td class="colsep0 rowsep0" align="left">9.6 (±0.4)</td><td class="colsep0 rowsep0" align="left">3.27 (±0.06)</td><td class="colsep0 rowsep0" align="left">NA</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAACAA + ATP</td><td class="colsep0 rowsep0" align="left">2.43 (±0.01)</td><td class="colsep0 rowsep0" align="left">3.78 (±0.05)</td><td class="colsep0 rowsep0" align="left">NA</td></tr></tbody></table><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">RNA sequence</th><th class="colsep0 rowsep0" align="center" char=".">half-life <i>t</i><sub>1/2</sub>, s</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AGAGAG + ATP + <b>eFT226</b></td><td class="colsep0 rowsep0" align="char" char=".">79</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AGAGAG + AMP-PNP + <b>eFT226</b></td><td class="colsep0 rowsep0" align="char" char=".">2311</td></tr></tbody></table></div></div><div class="NLM_p">The binding kinetics for the formation of the ternary complex with eIF4A1–<b>eFT226</b>–AGAGAG RNA was evaluated when ATP was replaced with AMP-PNP, a nonhydrolysable analogue of ATP. After formation of the ternary complex, the SPR surfaces were washed with buffer containing only ATP or AMP-PNP to evaluate the ternary complex dissociation. The dissociation rate of eIF4A1 from the polypurine RNA was ∼30-fold slower when using the nonhydrolysable ATP analogue, suggesting that ATP hydrolysis results in a conformational change that destabilizes the eIF4A1–<b>eFT226</b>–polypurine RNA complex (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Collectively, these results demonstrate that <b>eFT226</b> is a potent and reversible inhibitor of eIF4A through the formation of a stable ternary complex with select polypurine RNA motifs.</div><div class="NLM_p">To determine whether the sequences that facilitate the formation of the ternary complex enable selective inhibition of protein synthesis with <b>eFT226</b> treatment, MDA-MB-231 cells were transiently transfected with a luciferase reporter system containing specific tandem sequence motif repeats in the 5′-UTR (see <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Treatment with <b>eFT226</b> inhibited translation of each reporter construct in a dose-dependent manner (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). However, <b>eFT226</b> was 16-145-fold more effective at inhibiting luciferase reporter gene expression for the GGCGGC and AGAGAG constructs, respectively, versus a CAACAA sequence element (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). These data are consistent with the order of binding affinity observed <i>in vitro</i> and the antiproliferative potency of <b>eFT226</b> in the MDA-MB-231 tumor cell line. In addition, eFT226 was not effective at inhibiting translation for the reporter construct containing a complementary CCGCCG motif.</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <b>eFT226</b> inhibition of reporter gene expression is dependent upon the 5′ UTR sequence. Relative luciferase expressed by luciferase reporter mRNAs containing 5′-UTRs encoding unique 6-mer sequence motifs. The luciferase reporter gene constructs were transiently transfected into the MDA-MB-231 cell line and treated with increasing concentrations of <b>eFT226</b> for 4 h in triplicate. Data were fitted to a four-parameter dose response curve. AGAGAG (green); GGCGGC (blue); CCGCCG (red) and CAACAA (black).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Sequence Specificity of <b>eFT226</b> Translational Regulation in a Cell-Based Assay</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" char="." /></col><col align="char" char="." /></col><col align="char" char="±" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">5′-UTR sequence motif</th><th class="colsep0 rowsep0" align="center" char="±"><b>eFT226</b> IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">Roc A IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">hippuristanol IC<sub>50</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char="±">CHX IC<sub>50</sub> (nM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AGAGAG</td><td class="colsep0 rowsep0" align="char" char="±">1.5 ± 0.4</td><td class="colsep0 rowsep0" align="left" char=".">4.7</td><td class="colsep0 rowsep0" align="char" char=".">426</td><td class="colsep0 rowsep0" align="char" char="±">226 ± 55</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GGCGGC</td><td class="colsep0 rowsep0" align="char" char="±">13.8 ± 2.0</td><td class="colsep0 rowsep0" align="left" char=".">47</td><td class="colsep0 rowsep0" align="char" char=".">369</td><td class="colsep0 rowsep0" align="char" char="±">101 ± 10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCGCCG</td><td class="colsep0 rowsep0" align="char" char="±">92 ± 18</td><td class="colsep0 rowsep0" align="left" char=".">135</td><td class="colsep0 rowsep0" align="char" char=".">210</td><td class="colsep0 rowsep0" align="char" char="±">87 ± 6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAACAA</td><td class="colsep0 rowsep0" align="char" char="±">218 ± 55</td><td class="colsep0 rowsep0" align="left" char=".">231</td><td class="colsep0 rowsep0" align="char" char=".">204</td><td class="colsep0 rowsep0" align="char" char="±">142 ± 12</td></tr></tbody></table></div></div><div class="NLM_p">Additional translational inhibitors were evaluated in the luciferase reporter assay (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Rocaglamide A demonstrated 5′-UTR sequence dependent inhibition of luciferase reporter gene expression similar to <b>eFT226</b>, consistant with interacting at the same binding site. Hippuristanol, an initiation inhibitor which binds at the C-terminus of eIF4A and blocks RNA binding, inhibited luciferase reporter gene expression with an IC<sub>50</sub> of 200–400 nM; however, inhibition was independent of the sequence motif in the 5′-UTR (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>). Inhibition by cycloheximide (CHX), an elongation inhibitor, also showed no dependence on 5′-UTR sequence. These findings are consistent with <b>eFT226</b> inhibition converting eIF4A into a sequence-selective translational repressor.</div><div class="NLM_p">The selectivity of <b>eFT226</b> for eIF4A was shown by introducing a mutation into the putative drug binding site of the eIF4A1 gene in the <b>eFT226</b> sensitive HAP1 cell line. Based on literature and molecular modeling of the putative drug binding site, a mutation was introduced in eIF4A1 converting phenylalanine 163 to leucine (F163L).<a onclick="showRef(event, 'ref25 ref29'); return false;" href="javascript:void(0);" class="ref ref25 ref29">(25,29)</a> Treatment of tumor cell lines with <b>eFT226</b> (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>) downregulates the expression of several key oncogenic proteins, including c-MYC, MCL-1, and Cyclin D1. To examine if this effect of <b>eFT226</b> is altered in eIF4A1 F163L cells, HAP1 wt and eIF4A1 F163L cells were treated for 24 h with either DMSO or increasing concentrations of <b>eFT226</b> followed by Western blot analysis. A dose-dependent decrease in the protein levels of <b>eFT226</b> target genes such as c-MYC, MCL-1, and Cyclin D1 was observed in the parental HAP1 cells; however, the protein levels remained unchanged in the <b>eFT226</b> treated HAP1 eIF4A1 F163L mutant clone (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>). These results indicate that mutation of eIF4A1 suppresses the ability of <b>eFT226</b> to diminish steady-state protein levels, supporting that eIF4A is the cellular target of this compound.</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Downregulation of eIF4A target genes by <b>eFT226</b> is rescued with eIF4A1 F163L knock-in mutation. Protein levels of eIF4A sensitive genes after treatment with <b>eFT226</b> for 24 h in HAP1 wt or eIF4A1 F163L mutant cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To investigate if <b>eFT226</b>-dependent growth inhibition is affected by the F163L eIF4A1 mutation, proliferation assays were conducted with parental HAP1 and eIF4A1 F163L mutant HAP1 cells. 72 h treatment with <b>eFT226</b> yielded striking differences in proliferation between the parental and eIF4A1 F163L HAP1 cells, as shown in a representative experiment in <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>. The eIF4A1 F163L clone was ∼60-fold less sensitive to the antiproliferative effects of <b>eFT226</b> (average IC<sub>50</sub> = 371 <i>vs</i> 6.3 nM in parental HAP1 cells). Importantly, treating with hippuristanol, a structurally distinct eIF4A inhibitor, led to equivalent growth arrest in parental and eIF4A1 F163L HAP1 cells, consistent with unique binding sites for these different class of compounds targeting eIF4A1. These data indicate that <b>eFT226</b> mediates growth repression through eIF4A1. Although both eIF4A1 and eIF4A2 have been reported to cycle through the eIF4F complex <i>in vitro</i>, the ability of an eIF4A1 selective mutation to rescue <b>eFT226</b>’s cellular phenotype supports eIF4A1 as the anticancer target. The mutational studies reported here also suggest that eIF4A1 is the target of <b>eFT226</b>; however, because eIF4A2 is expressed at a much lower level than eIF4A1 in this cell line, we cannot rule out the role of eIF4A2.</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. eIF4A1 mutation (F163L) rescues <b>eFT226</b> activity linking antitumor phenotype to eIF4A1 inhibition. (A) Potent inhibition of cell growth was observed with 72 h <b>eFT226</b> treatment of HAP1 wild-type cells. The HAP1 eIF4A1 F163L mutant cells were resistant to <b>eFT226</b> treatment. (B) eIF4A1 F163L mutation demonstrated resistance only to <b>eFT226</b>. Mutation at this binding site did not rescue the antiproliferative effect of hippuristanol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>eFT226</b> was also evaluated in a CEREP panel of 114 <i>in vitro</i> radioligand binding and enzyme assays covering a diverse range of off-target enzymes, receptors, ion channels, and transporters at a concentration of 10 μM. Significant activity, defined as exceeding 50% binding or inhibition, was detected for only one target (54% inhibition of Ca<sup>2+</sup> channel; L, diltiazem site), indicating that <b>eFT226</b> is a very selective ligand for eIF4A.</div><div class="NLM_p">The antiproliferative activity and mechanism of action were further evaluated in the MDA-MB-231 breast cancer cell line. The concentration for 50% inhibition of MDA-MB-231 cell proliferation (IC<sub>50</sub>) with <b>eFT226</b> treatment was determined to be 10.6 ± 0.9 nM (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Cell cycle analysis showed a dose-dependent increase in the G2/M population, indicating cell cycle arrest in response to <b>eFT226</b> treatment (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>A). A dose-dependent increase in the percentage of apoptotic and dead cells measured by annexin V and PI (propidium iodide) staining was also seen with <b>eFT226</b> treatment (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>B).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. <b>eFT226</b> modulates key drivers of tumorigenesis in a dose-dependent manner. (A) Cell cycle progression was assessed by DNA staining using DRAQ5 and monitoring fluorescence by flow cytometry. Tumor cells treated with increasing concentrations of <b>eFT226</b> for 24 h resulted in G2 arrest. (B) Incubation of MDA-MB-231 tumor cells with increasing concentrations of <b>eFT226</b> for 24 h were analyzed by annexin (V+) and PI flow cytometry. A dose-dependent increase in cells undergoing apoptosis and cell death (V+ PI+) was observed with <b>eFT226</b> treatment. (C) Treatment of MDA-MB-231 cancer cells with <b>eFT226</b> downregulates the protein levels of <b>eFT226</b>-sensitive target genes (Cyclin D1 and BCL2) as analyzed by Western blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Exposure of MDA-MB-231 cells to <b>eFT226</b> for 24 h confirmed that eIF4A-dependent oncoproteins were rapidly downregulated at the protein level relative to control. Potent downregulation of Cyclin D1 and BCL2 was observed whereas the protein level of housekeeping genes (<i>i.e.</i>, GAPDH) were unchanged (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>C). Modulation of these target genes is consistent with the observed block in cell cycle progression and induction of apoptosis.</div><div class="NLM_p">The antitumor efficacy of <b>eFT226</b> was assessed in the MDA-MB-231 orthotopic xenograft model treated once weekly for 2 weeks with drug or vehicle control administered IV. Treatment with 1 mg/kg of <b>eFT226</b> Q1W led to 122% tumor growth inhibition or regression throughout the duration of the study (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>A). <b>eFT226</b> was well tolerated as seen by a lack of body weight loss (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>B). <b>eFT226</b> demonstrated good cross-species IV PK and low plasma protein binding (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). The aqueous solubility of <b>eFT226</b> is excellent (>20 mg/mL), allowing for simple formulations to be utilized for intravenous delivery.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0006.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. <b>eFT226</b> efficacy in orthotopic MDA-MB-231 TNBC model. (A) Athymic nude mice (10 mice/group) implanted in the mammary fat pad with MDA-MB-231 cells were treated once weekly (Q1W) with either vehicle or <b>eFT226</b> by IV for 14 days to assess effect on tumor growth. Treatment with <b>eFT226</b> results in tumor regression during the treatment duration. (B) Effect of vehicle or drug treatment on body weight change over the course of treatment in tumor bearing mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Nonclinical <b>eFT226</b> Plasma Protein Binding and Pharmacokinetic Parameters after a Single Intravenous Bolus Dose</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="colsep0 rowsep0" align="center"><i>T</i><sub>1/2</sub></th><th class="colsep0 rowsep0" align="center">CL</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>ss</sub></th><th class="colsep0 rowsep0" align="center" char=".">plasma protein binding</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">(h)</th><th class="colsep0 rowsep0" align="center">(mL/min/kg)</th><th class="colsep0 rowsep0" align="center">(L/kg)</th><th class="colsep0 rowsep0" align="left" char=".">% bound</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mouse</td><td class="colsep0 rowsep0" align="left">10.9</td><td class="colsep0 rowsep0" align="left">15.8</td><td class="colsep0 rowsep0" align="left">12.1</td><td class="colsep0 rowsep0" align="char" char=".">74.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="left">4.39</td><td class="colsep0 rowsep0" align="left">48.3</td><td class="colsep0 rowsep0" align="left">13</td><td class="colsep0 rowsep0" align="char" char=".">73.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="left">NR<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left"><12.4<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">17.8<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="char" char=".">81.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monkey</td><td class="colsep0 rowsep0" align="left">14.9</td><td class="colsep0 rowsep0" align="left">11.7</td><td class="colsep0 rowsep0" align="left">12.2</td><td class="colsep0 rowsep0" align="char" char=".">63.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="left">NA</td><td class="colsep0 rowsep0" align="char" char=".">66.8</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last"><i>T</i><sub>1/2</sub> not reported (NR) due to insufficient terminal phase characterization. In lieu of <i>V</i><sub>ss</sub> estimate, <i>V</i><sub>d</sub> (dose/<i>C</i><sub>0</sub>) was calculated and reported in this table. CL estimated from AUC<sub>0–<i>t</i></sub>.</p></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i13">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01024" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01024" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Targeting dysregulated translation is a growing strategy in oncology-based drug discovery. The expression of many key oncoproteins is translationally controlled by eIF4A and the eIF4F complex. The flavagline natural product class, represented by rocaglamide A, is known to inhibit translation through the stabilization of a ternary complex between the natural product, eIF4A, and select mRNA sequences. Herein we describe the optimization of rocaglamide A, focusing on improving the drug-like properties of this system, to yield the development candidate <b>eFT226</b> (Zotatifin). <b>eFT226</b> is a potent, highly selective inhibitor of eIF4A-mediated translation with excellent physicochemical properties. Similar to rocaglamide A, specificity for polypurine RNA sequences was demonstrated. <b>eFT226</b> revealed good cross-species IV PK and was shown to be highly efficacious and well tolerated in a triple negative breast cancer orthotopic xenograft model with once weekly dosing, supportive of its advancement into human clinical studies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Synthetic Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75610" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75610" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Several synthetic approaches toward flavagline natural products, such as silvestrol (<b>1</b>), and rocaglamide A (<b>2</b>), as well as analogues thereof, have been published in recent years.<a onclick="showRef(event, 'ref14 ref15 ref16 ref17 ref18 ref19 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref14 ref15 ref16 ref17 ref18 ref19 ref30 ref31">(14−19,30,31)</a> Out of these, the [3 + 2]-photocycloaddition approach disclosed by Porco and co-workers is arguably the most efficient one, as it provides rapid access to the flavaglines’ sterically congested cyclopenta[<i>b</i>]benzofuran core.<a onclick="showRef(event, 'ref19 ref32 ref33 ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref19 ref32 ref33 ref34 ref35 ref36">(19,32−36)</a> Three steps consisting of a [3 + 2]-photocycloaddition of substituted flavonoles with methyl cinnamates, followed by base-induced ketol rearrangement and directed reduction, constitute the key sequence of this biomimetic strategy (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0016.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Key Steps in Porco’s Synthetic Approach toward Silvestrol (<b>1</b>) and Rocaglamide a (<b>2</b>) Using a Biomimetic Photocycloaddition Strategy</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The conciseness and efficiency of Porco’s approach prompted us to investigate its utility in the synthesis of the novel rocaglamide-inspired eIF4A inhibitors discussed in this paper (<a class="ref internalNav" href="#sch2" aria-label="Schemes 2">Schemes 2</a>–<named-content content-type="anchor" rid="sch3" type="simple"></named-content><named-content content-type="anchor" rid="sch4" type="simple"></named-content><named-content content-type="anchor" rid="sch5" type="simple"></named-content><named-content content-type="anchor" rid="sch6" type="simple"></named-content><named-content content-type="anchor" rid="sch7" type="simple"></named-content><named-content content-type="anchor" rid="sch8" type="simple"></named-content><named-content content-type="anchor" rid="sch9" type="simple"></named-content><named-content content-type="anchor" rid="sch10" type="simple"></named-content><named-content content-type="anchor" rid="sch11" type="simple"></named-content><named-content content-type="anchor" rid="sch12" type="simple"></named-content><named-content content-type="anchor" rid="sch13" type="simple"></named-content><named-content content-type="anchor" rid="sch14" type="simple"></named-content><named-content content-type="anchor" rid="sch15" type="simple"></named-content><named-content content-type="anchor" rid="sch16" type="simple"></named-content><named-content content-type="anchor" rid="sch17" type="simple"></named-content><named-content content-type="anchor" rid="sch18" type="simple"></named-content><named-content content-type="anchor" rid="sch19" type="simple"></named-content><named-content content-type="anchor" rid="sch20" type="simple"></named-content><named-content content-type="anchor" rid="sch21" type="simple"></named-content><named-content content-type="anchor" rid="sch22" type="simple"></named-content><named-content content-type="anchor" rid="sch23" type="simple"></named-content><a class="ref internalNav" href="#sch24" aria-label="24">24</a>).<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> A salient feature of the work described herein is the successful application of this strategy to the synthesis of analogues featuring heterocyclic A-rings (<i>cf.</i><b>5</b>, <b>7–9</b>, <b>15–53</b>, <b>eFT226</b>; see <b>1</b> and <b>2</b> in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> for labeling of the rings and numbering).</div><figure id="sch2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0027.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Route toward Carbocyclic A-Ring Analogues <b>6</b> and <b>10–14</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0033.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. (A) Synthesis of <i>rac</i>-<b>6</b>; (a) MeI, Acetone, rt (92%); (b) <i>p</i>-MeO-benzaldehyde, NaOH, MeOH, 90%; (c) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, 20%; (d) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (e) NaOMe, MeOH, 100 °C; (f) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 36% over Three Steps; (g) LiOH, MeOH, Water, 84%; (h) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 33%; (B) Synthesis of <i>rac</i>-<b>10</b>. (a) <i>p</i>-MeO-benzaldehyde, NaOH, MeOH, 89%; (b) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, Water, 63%; (c) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (d) NaOMe, MeOH, 80 °C; (e) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 52% over Three Steps; (f) LiOH, MeOH, Water, 86%; (g) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 90%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0034.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. (A) Synthesis of <i>rac</i>-<b>11</b>; (a) <i>p</i>-Br-benzaldehyde, NaOH, MeOH, 90 °C, Quant.; (b) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, 47%; (c) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (d) NaOMe, MeOH, 90 °C; (e) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 31% over Three Steps; (f) LiOH, MeOH, Water, 93%; (g) HNMe<sub>2</sub>–HCl, EDC-HCl, HOBt, DIPEA, DCM, 85%; (h) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 120 °C, 14%; (B) Synthesis of <i>rac</i>-<b>12</b> and <i>rac</i>-<b>13</b>; (a) <i>p</i>-MeO-benzaldehyde, NaOH, MeOH, Reflux, 40%; (b) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, 46%; (c) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (d) NaOMe, MeOH, 90 °C; (e) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 29% over Three Steps; (f) LiOH, THF, Water, 71%; (g) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 69%; (h) Pd(OH)<sub>2</sub>, Ethyl Acetate, rt; (i) MeI, K<sub>2</sub>CO<sub>3</sub>, Acetone, rt, 77% over Two Steps; (j) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 120 °C, 45%; (k) <i>p</i>-MeO-benzaldehyde, NaOH, MeOH, Reflux, 81%; (l) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, 58%; (m) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (n) NaOMe, MeOH, 80 °C; (o) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 63% over Three Steps; (p) LiOH, MeOH, Water; (q) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 95% over Two Steps; (r) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc; (s) Tf<sub>2</sub>O, DCM, 56%; (t) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 110 °C, 25%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0035.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <i>rac</i>-<b>14</b>; (a) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 100 °C, 81%; (b) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, 81%; (c) Tf<sub>2</sub>O, DIPEA, DCM, THF, 51%; (d) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 120 °C, 86%; (e) LiOH, MeOH, Water, 69%; (f) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 41%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch6" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0036.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Envisioned Synthetic Route toward 8-Aza Analogues <i>rac</i>-<b>5</b> and Enantiopure <b>7–9</b> and <b>15–23</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch7" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0037.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. (A) Synthesis of Key Intermediate <b>90</b>; (a) NaOMe, MeOH, Reflux (85%); (b) MeMgCl, THF, −20 °C to rt, 65%; (c) HBr, AcOH, 150 °C, 35%; (d) MeI, K<sub>2</sub>CO<sub>3</sub>, Acetone 0 °C to rt; (B) Synthesis of analogues <i>rac</i>-<b>5</b> and (−)-<b>7</b>; (a) <i>para</i>-Methoxybenzaldehyde, NaOH, MeOH, Reflux; (b) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, 0 °C to rt, 23% over Two Steps; (c) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (d) NaOMe, MeOH, 80 °C; (e) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 24% over Three Steps; (f) LiOH, MeOH, H<sub>2</sub>O, rt, 77%; (g) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, 8%; (h) 4-Bromobenzaldehyde, NaOH, MeOH, Reflux; (i) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, 0 °C to rt; (j) Methyl Cinnamate, MeCN, MeOH, DCM, rt, <i>h</i>ν; (k) NaOMe, MeOH, 80 °C; (l) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 7% over Five Steps; (m) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C; (n) LiOH, MeOH, H<sub>2</sub>O, rt; (o) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, 15% over Three Steps; (p) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch8" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0038.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. (A) Synthesis of Key Intermediate <b>98</b>; (a) BnOH, NaH, THF, rt, 84%; (b) MeMgBr, THF, −30 °C to rt, 64%; (c) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, 65%; (B) Synthesis of Analogues <b>15</b> and <b>17–23</b>. (a) NaOH, 4-Substituted Benzaldehyde <b>61</b>, MeOH, Δ; (b) H<sub>2</sub>O<sub>2</sub>, NaOH, EtOH/DCM, rt; (c) Methyl Cinnamate, MeCN, MeOH, DCM, <i>h</i>ν; (d) NaOMe, MeOH, Δ; (e) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt; (f) LiOH, THF/Water, rt; (g) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM; (h) Chiral HPLC Separation; (C) Synthesis of analogue <b>8</b>. (a) <i>para</i>-Bromobenzaldehyde, NaOH, MeOH, Reflux, 61%; (b) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, DCM, rt, 31%; (c) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (d) NaOMe, MeOH, 70 °C; (e) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 55% over Three Steps; (f) LiOH, MeOH, H<sub>2</sub>O, rt, Quant.; (h) EDC, HOBt, DIPEA, DCM, 0 °C, Then Me<sub>2</sub>NH–HCl, rt, 86%; (i) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 83%; (j) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch9" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0039.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. (A) Synthesis of Key Intermediate <b>109</b>; (a) BnOH, NaH, THF, 0 °C to rt; (b) MeMgBr, THF, −30 °C to rt; (c) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, rt, 89%; (d) K<sub>2</sub>CO<sub>3</sub>, BnBr, Acetone, 94%; (B) Synthesis of Analogues (−)-<b>9</b> and (−)-<b>16</b>; (a) 4-Bromobenzaldehyde, NaOH, MeOH, 85 °C, 59%; (b) H<sub>2</sub>O<sub>2</sub>, NaOH, EtOH/DCM, rt, 53%; (c) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (d) NaOMe, MeOH, 70 °C; (e) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 38% over Three Steps; (f) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 125 °C (97%); (g) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, rt, 97%; (h) Tf<sub>2</sub>O, DIPEA, DCM, −78 °C to 0 °C, 77%; (i) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 125 °C; (j) LiOH, THF/Water, 37% over Two Steps; (k) TEA, Me<sub>2</sub>NH–HCl, T3P, DCM/EtOAc, rt, 31%; (l) Chiral HPLC Separation; (m) NaOH, 4-Methoxybenzaldehyde, MeOH, Reflux; (n) H<sub>2</sub>O<sub>2</sub>, NaOH, EtOH/DCM, rt; (o) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, <i>h</i>ν; (p) NaOMe, MeOH, 70 °C; (q) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt; (r) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, 7% over Six Steps; (s) Tf<sub>2</sub>O, DIPEA, DCM, −78 °C to rt; (t) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 85 °C; (u) LiOH, THF/Water, rt; (v) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, 19% over Four Steps; (w) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch10" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0017.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of <i>rac</i>-<b>24</b>; (a) <b>114</b>, DCC, DCM, rt; (b) AIBN, Bu<sub>3</sub>SnH, C<sub>6</sub>H<sub>6</sub>, 80 °C, 10% over Two Steps; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 16%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch11" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0018.jpeg" id="gr26" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of <i>rac</i>-<b>27</b>, (−)-<b>31</b>, and <i>rac</i>-<b>32</b>; (a) NHMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 0 °C to rt, 76%; (b) BH<sub>3</sub>-DMS, THF, 0 °C to rt, Then MeOH, 0 °C to Reflux, 61%; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 130 °C, 46%; (d) Chiral HPLC Separation; (e) EDC, HOBt, DIPEA, 0 °C, Then <b>118</b>, 0 °C to 35 °C, 64%; (f) HCl(aq), THF, rt; (g) PPh<sub>3</sub>, I<sub>2</sub>, TEA, DCM, rt, 21% over Two Steps; (h) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 150 °C, 23%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch12" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0019.jpeg" id="gr27" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of <i>rac</i>-<b>32</b>, (−)-<b>25</b>, and (−)-<b>26</b>; (a) LAH, THF, 0 °C to rt, 49%; (b) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, Water, MW, 100 °C, 71%; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 125 °C, 78%; (d) LiOH, MeOH, Water, rt, 78%; (e) EDC, HOBt, DIPEA, DCM, 0 °C, Then NH<sub>4</sub>Cl, rt, 78%; (f) Chiral HPLC Separation; (g) EDC, HOBt, DIPEA, DCM, 0 °C, Then MeNH<sub>2</sub>–HCl, rt, 90%; (h) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch13" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0020.jpeg" id="gr28" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of <i>rac</i>-<b>28</b> and <i>rac</i>-<b>29</b>. (a) <b>121</b>, DCM, MeOH, MeCN, rt, <i>h</i>ν; (b) NaOMe, MeOH, 80 °C; (c) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 2% over Three Steps; (d) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 7%; (e) <b>123</b>, DCM, MeOH, MeCN, rt, <i>h</i>ν; (f) NaOMe, MeOH, 80 °C; (g) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 9% over Three Steps; (h) TFA, Triflic acid, DCM, 92%; (i) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 125 °C, 8%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch14" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0021.jpeg" id="gr29" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of (−)-<b>30</b>; (a) LiCl, DMSO, 150 °C, 33%; (b) Sodium Methanesulfinate, CuBr<sub>2</sub>, DBU, DMSO, rt; (c) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 4% over Two Steps; (d) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMSO, 150 °C, 72%; (e) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch15" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0022.jpeg" id="gr30" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Synthesis of (−)-<b>33</b>; (a) EDC, HOBt, DIPEA, <b>129</b>-HCl, DCM, 0 °C to rt, 63%; (b) MeMgBr, THF, 0 °C to rt, 88%; (c) AcOH, HCl (aq), 100 °C, 68%; (d) 4-Bromobenzaldehyde, NaOH, MeOH, DCM, 90 °C, 97%; (e) H<sub>2</sub>O<sub>2</sub>, aq NaOH, MeOH, rt, 30%; (f) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (g) NaOMe, MeOH, 90 °C; (h) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 28% over Three Steps; (i) LiOH, THF, H<sub>2</sub>O, rt, 91%; (j) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 to 40 °C, 71%; (k) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 150 °C, 36%; (l) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch16" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0023.jpeg" id="gr31" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of <i>rac</i>-<b>34</b>; (a) NBS, DCM, 0 °C, 92%; (b) <b>137</b>, cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Toluene, 100 °C, Then HCl (aq) 49%; (c) NaNO<sub>2</sub>, H<sub>2</sub>SO<sub>4</sub>, Dioxane, Water, 0 to 50 °C, 37%; (d) 4-Bromobenzaldehyde, NaOH, MeOH, Reflux, 68%; (e) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, 0 °C to rt, 32%; (f) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (g) NaOMe, MeOH, 80 °C; (h) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 1% over Three Steps; (i) LiOH, THF, H<sub>2</sub>O, rt, 67%; (j) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, Quant.; (k) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 19%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch17" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0024.jpeg" id="gr32" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of (−)-<b>35</b>; (a) PMBOH, NaH, THF, 0 °C to rt, 76%; (b) NaOMe, MeOH, 80 °C, 46%; (c) MeMgBr, THF, 0 °C to rt; Then HCl(aq), rt, 52%; (d) <i>para</i>-bromobenzaldehyde, NaOH, MeOH, Reflux, 80%; (e) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, DCM, 0 °C to rt, 29%; (f) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, hn; (g) NaOMe, MeOH, 80 °C; (h) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 35% over Three Steps; (i) LiOH, MeOH, H<sub>2</sub>O, rt, 79%: (j) NHMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 0 °C to rt, 65%; (k) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C; 50%; (l) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch18" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0025.jpeg" id="gr33" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of <i>rac</i>-<b>36</b>. (a) <i>t</i>-BuOK, MeOH, 80 °C; (b) EDC, HOBt, DIPEA, <b>129</b>-HCl, DCM, 0 °C to rt, 75% over Two Steps; (c) MeMgBr, Et<sub>2</sub>O, THF, 0 °C to rt; (d) PMB-OH, NaH, THF, 0 °C to rt, 47% over Two Steps; (e) TFA, DCM, 0 °C to rt; (f) 4-Bromobenzaldehyde, NaOH, MeOH, 80 °C; (g) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, DCM, rt, 40% over Three Steps; (h) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (i) NaOMe, MeOH, 80 °C; (j) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 3% over Three Steps; (k) LiOH, MeOH, H<sub>2</sub>O, rt, 93%; (l) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, 38%; (m) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 22%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch19" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0026.jpeg" id="gr34" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. General Synthesis of 6-Aza-2-amine analogues Enantiopure <b>37</b>, <b>40–44</b>, <b>46–48</b>, <b>50</b>, <b>51</b>, and Racemic <b>38</b>, <b>39</b>; (a) R<sub>2</sub>NH, EDC, HOBT, DCM, or R<sub>2</sub>NH, HATU, DIPEA, DMF; (b) BH<sub>3</sub>-DMS, THF, Δ, Then MeOH, Δ; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, Δ; (d) Chiral HPLC Separation (for <b>37</b>, <b>40–44</b>, <b>46–48</b>, <b>50</b>, and <b>51</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch20" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0028.jpeg" id="gr35" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of (+)-<b>45</b>. (a) TFAA, TEA, DCM, 0 °C to rt; (b) BH<sub>3</sub>-DMS, THF, 60 °C, Then MeOH, Δ; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, MW, 140 °C, 24% over Three Steps; (d) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch21" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0029.jpeg" id="gr36" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of (−)-<b>49</b>. (a) TBSOTf, 2,6-Lutidine, DCM, 0<sup>o</sup>C-rt; Then (H<sub>2</sub>CO)<sub>n</sub>, NaOAc, NaBH(OAc)<sub>3</sub>, rt, 55%; (b) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch22" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0030.jpeg" id="gr37" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of <i>rac</i>-<b>52</b>; (a) BH<sub>3</sub>-DMS, THF, 0 °C to rt, Then MeOH, 70 °C, 93%; (b) MsCl, Pyridine, 0 °C to rt, 80%; (c) KCN, DMSO, 80 °C, 58%; (d) 10% NaOH (aq), THF, 125 °C, 94%; (e) Me<sub>2</sub>NH–HCl, EDC-HCl, HOBT, DIPEA, DCM, 0 °C to rt, 92%; (f) Me<sub>2</sub>NH, THF, T3P, EtOAc, 80 °C, 47%; (g) BH<sub>3</sub>-DMS, THF, 0 °C to rt, Then MeOH, 0 °C to 70 °C, 71%; (h) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 19%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch23" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0031.jpeg" id="gr38" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Azaflavonols <b>174</b> and <b>175</b>; (a) BnOH, NaH, DMF, 0 °C, 72%; (b) NaOMe, MeOH, Toluene, 70 °C, 56%; (c) <i>n</i>-BuLi, THF, −75 °C, Then Acetaldehyde, 65%; (d) DMP, DCM, 75%; (e) H<sub>2</sub>, Cat. Pd/C, EtOAc, 88%; (f) <i>para</i>-Bromobenzaldehyde, NaOMe, MeOH, DMF, Quant.; (g) NaOH (aq), H<sub>2</sub>O<sub>2</sub> (aq), EtOH, DCM, Water, 19%; (h) NaOMe, MeOH, DMF, 80 °C, 98%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch24" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0032.jpeg" id="gr39" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Completion of the Synthesis of (−)-<b>53</b> and (−)-<b>eFT226</b>; (a) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM (R = Cl) or Methyl Cinnamate (<b>55</b>), CHCl<sub>3</sub>, TFE (R = OMe), 0 °C, <i>h</i>ν; (b) NaOMe, MeOH, 60 °C; (c) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 27% (R = Cl), 40% (R = OMe) (Yield over Three Steps); (d) LiOH, MeOH, Water, 50 °C (R = Cl), 90%, or LiOH(aq), MeOH, THF, rt (R = OMe), 93%; (e) HATU, DIPEA, Me<sub>2</sub>NH, THF, DMF, rt, 95% (R = Cl), 92% (R = OMe); (f) BH<sub>3</sub>-DMS, THF, 40 °C, Then MeOH, 65–70 °C, 88% (R = Cl), 89% (R = OMe); (g) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, Water, MW, 120 °C, 63% (R = Cl), 73% (R = OMe); (h) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Analogues Containing Carbocyclic A-Rings</h3><div class="NLM_p">The general synthesis of 8-unsubstituted, A-carbocyclic rocaglamide analogues <b>6</b> and <b>10–14</b>, featuring electron withdrawing as well as electron donating substituents in the 6- and 4′-positions of the rocaglamide scaffold, is shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>.</div><div class="NLM_p">While the overall synthetic strategy shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a> was applied to the synthesis of all A-ring carbocyclic targets, it is noteworthy that the exact timing of the incorporation of the desired 6- and 4′-substituents depended on the target and was largely dictated by synthetic feasibility as well as availability of the required starting materials. More specifically, and as shown in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a> and <a class="ref internalNav" href="#sch4" aria-label="4">4</a>, the synthesis of compounds <i>rac</i>-<b>6</b> and <i>rac</i>-<b>10</b> relied on an early installation of the desired 6- and 4′-substituents. Thus, the synthesis of <i>rac</i>-<b>6</b> commenced with the regioselective O-methylation of resacetophenone (92% yield), followed by aldol condensation (90% yield) (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>a). The so-obtained chalcone was then treated with hydrogen peroxide under basic conditions, which induced an oxidative Algar–Flynn–Oyamada (AFO) cyclization<a onclick="showRef(event, 'ref38 ref39 ref40'); return false;" href="javascript:void(0);" class="ref ref38 ref39 ref40">(38−40)</a> to give <b>69</b> in a modest but sufficient yield of 20%.</div><div class="NLM_p">At this point, flavonol <b>69</b> was subjected to a [3 + 2]-cycloaddition with methyl cinnamate (<b>55</b>) under photochemical conditions. In general, it proved favorable to simply remove the excess methyl cinnamate chromatographically upon completion of the reaction and move the otherwise unpurified crude product through the sequence of base induced ketol-rearrangement and directed ketone reduction to ultimately give compound <b>70</b>, which was obtained in 36% yield over three steps. Saponification of the ester in <b>70</b> (84% yield) followed by amide coupling (33% yield) completed the synthesis of <i>rac</i>-<b>6</b>. The synthesis of <i>rac</i>-<b>10</b> followed a closely related synthetic strategy as detailed in <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>b, starting from appropriately substituted acetophenone <b>71</b> with the 6-Cl substituent in place. It is noteworthy that in this case, the yields of both the AFO cyclization to give <b>72</b> (63%) and the key photocycloaddition/ketol-rearrangement/directed reduction sequence (<b>72</b> → <b>73</b>, 52% over three steps) were significantly improved compared to the sequence leading to <i>rac</i>-<b>6</b>, an observation that might point at the impact of the electronic nature of the chalcone and the flavonol system on the efficiency of the AFO reaction and photocycloaddition, respectively.</div><div class="NLM_p">The synthesis of analogues <i>rac</i>-<b>11</b>–<i>rac</i>-<b>13</b> relied on a late stage introduction of substituents at the 4′- and 6-positions but otherwise followed the same strategy as discussed for compounds <i>rac</i>-<b>6</b> and <i>rac</i>-<b>10</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>). Compound <i>rac</i>-<b>11</b> was obtained in an eight-step sequence, starting with the aldol condensation of methyl ketone <b>71</b> and <i>para</i>-bromobenzaldehyde (quantitative), followed by AFO cyclization (47% yield) (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>a). The subsequent conversion of flavonol <b>74</b> to intermediate <b>75</b> was achieved <i>via</i> the previously established photocycloaddition/ketol-rearrangement/directed reduction sequence, which proceeded in an overall yield of 31%. Ester hydrolysis (93%), EDC/HOBt-mediated amide coupling (85%), and palladium-catalyzed 4′-cyanation (14%) afforded analogue <i>rac</i>-<b>11</b>.</div><div class="NLM_p">Analogues <i>rac</i>-<b>12</b> and <i>rac</i>-<b>13</b> were successfully synthesized starting from monobenzylated resacetophenone <b>76</b> (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>b). In the case of <i>rac</i>-<b>12</b>, compound <b>76</b> was successfully transformed into flavonol <b>77</b> (18% overall), which was converted into <b>78</b> in three steps utilizing the established phtotochemical protocol (29% overall). As detailed in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>b, compound <b>78</b> was then subjected to straightforward ester hydrolysis, amide coupling, hydrogenolytic debenzylation, O-methylation to install the 6-methoxy group, and finally palladium-catalyzed cyanation to install the 4′-CN moiety and provide <i>rac</i>-<b>12</b>. Compound <i>rac</i>-<b>13</b> was synthesized in analogous 10 steps, starting from <b>76</b>, as described in detail in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>b. In this case, aldol condensation with <i>para</i>-methoxybenzaldehyde followed by AFO reaction gave <b>79</b> (47% overall), photocycloaddition/ketol-rearrangement/directed reduction gave <b>80</b> (63% overall), and ester hydrolysis, amide coupling, debenzylation, triflation, and palladium-catalyzed cyanation afforded compound <i>rac</i>-<b>13</b>.</div><div class="NLM_p last">Finally, analogue <i>rac</i>-<b>14</b> could be synthesized starting from a key intermediate in the synthesis of <i>rac</i>-<b>12</b>, that is, <b>78</b> (<a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>). Thus, the 4′-CN group could be successfully introduced <i>via</i> Pd-catalyzed cyanation of <b>78</b> (81%). In a three-step sequence involving hydrogenolytic debenzylation, triflation, and Pd-catalyzed cyanation, the 6-benzyloxy group was then replaced with the 6-CN group in 36% overall yield. Ester saponification (69%) followed by amide coupling (41%) completed the synthesis of <i>rac</i>-<b>14</b>.</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Synthesis of 8-Aza Analogues Featuring Different Substituents in the 6- and 4′-Positions</h3><div class="NLM_p">Focusing on the expansion of the photochemical synthetic strategy to include systems featuring heterocyclic A-rings, we envisioned the general strategy outlined in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a> for the synthesis of 8-aza analogues.</div><div class="NLM_p">As evident from this general approach, the initial development of a concise synthetic route toward functionalized 2-acetyl-3-hydroxypyridine analogues (<i>cf.</i><b>83</b>, <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>) was essential. In this context, the synthesis of analogues <i>rac</i>-<b>5</b> and (−)-<b>7</b> required 2-acetyl-3-hydroxy-5-methoxypyridine (<b>90</b>), which could be obtained in four straightforward steps starting from commercially available 2-cyano-3,5-difluoropyridine (<b>86</b>), as detailed in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>a. This intermediate was successfully utilized in the synthesis of analogues <i>rac</i>-<b>5</b> and (−)-<b>7</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>b). Thus, aldol condensation of <b>90</b> with <i>para</i>-methoxybenzaldehyde followed by AFO cyclization gave <b>91</b> in 23% yield over two steps. The crucial photocycloaddition/ketol rearrangement/directed reduction sequence then diastereoselectively transformed <b>91</b> into ester <b>92</b> (24% yield over three steps), which in turn was then converted into final target <i>rac</i>-<b>5</b><i>via</i> ester saponification and amide coupling. Importantly, the successful synthesis of <i>rac</i>-<b>5</b> using the photochemical strategy validated this approach for the synthesis of flavaglines featuring heterocyclic A-rings.</div><div class="NLM_p">Compound (−)-<b>7</b> was obtained in a similar fashion, which suggested that differently substituted azaflavonols could be successfully used as photocycloaddition partners. Thus, the synthesis of (−)-<b>7</b> commenced with the aldol condensation of <b>90</b> with <i>para</i>-bromobenzaldehyde. AFO reaction then afforded azaflavonol <b>93</b> and was followed by photochemical, stepwise conversion of the latter intermediate into <b>94</b>. Although this sequence proceeded in only low yields (7% over five steps), it enabled the preparation of enough material for the completion of this target, which was accomplished in a three-step sequence followed by chiral HPLC separation as outlined in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>b.</div><div class="NLM_p">The synthesis of 8-aza 6-Cl analogues <b>8</b>, <b>15</b>, and <b>17–23</b> featuring electron-donating as well as electron-withdrawing substituents in the 4′-position started from 2-acetyl-3-hydroxy-5-chloropyridine (<b>98</b>), which could be readily prepared in three steps from 2-cyano-3-nitro-5-chloro pyridine (<b>95</b>) (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>a).</div><div class="NLM_p">With key pyridine <b>98</b> in hand, the previously established strategy featuring a photocycloaddition-ketol rearrangement sequence was envisioned for the construction of the sterically congested cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine cores of 8-aza 6-Cl analogues <b>8</b>, <b>15</b>, and <b>17–23</b> (<a class="ref internalNav" href="#sch8" aria-label="Schemes 8">Schemes 8</a>b,c).</div><div class="NLM_p">With respect to compounds <b>15</b> and <b>17–23</b>, an early-stage introduction of the desired 4′-substituent <i>via</i> aldol condensation of <b>98</b> with an appropriately substituted benzaldehyde <b>61</b> proved synthetically most favorable (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>b). All but one required benzaldehyde (<i>cf.</i><b>61</b>) were commercially available, the exception being the somewhat unstable <i>para</i>-difluoromethyl benzaldehyde, which was freshly prepared from 1-bromo-4-(difluoromethyl)benzene <i>via</i> bromo-lithium exchange followed by quenching with DMF (see the <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a> for details).</div><div class="NLM_p">While all of these analogues (<b>15</b> and <b>17–23</b>) were successfully obtained using the strategy outlined in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>, it is noteworthy that the exact yields for each of the following steps (in particular the AFO reaction: 14–78%, and the photocycloaddition/ketol rearrangement/directed reduction sequence: 7–26%) appeared to depend on the nature of the 4′ substituents, although no clear trend with respect to the effect of electron-donating or electron-withdrawing character of those substituents on the yields became evident (see <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a> for details). The two final steps (ester saponification, amide coupling; see steps f-g, <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>b) generally proceeded in a rather uneventful fashion and afforded the desired targets as a racemic mixture of both enantiomers, which could easily be separated by chiral HPLC (step h, <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>b).</div><div class="NLM_p">Compound (−)-<b>8</b> was synthesized in a similar fashion, but in this case the synthesis relied on a late stage introduction of the 4'-cyano substituent (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>c). Initially, aldol condensation of <b>98</b> with <i>para</i>-bromobenzaldehyde followed by oxidative AFO cyclization led to azaflavonol <b>102</b> in 19% overall yield. Photocycloaddtion, ketol rearrangement, and diastereoselective ketone reduction led to key intermediate <b>103</b> in good yields (55%). Ester hydrolysis to give acid <b>104</b> and subsequent amide coupling (86% overall) was then followed by high-yielding Pd-catalyzed 4′-cyanation (83%) to provide access to analogue <b>8</b> in racemic form. The racemate was then resolved using chiral HPLC to give enantiopure analogue (−)-<b>8</b>.</div><div class="NLM_p">Compounds (−)-<b>9</b> and (−)-<b>16</b> were synthesized as detailed in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. Key pyridine <b>109</b> was synthesized in four steps from commercially available 2-cyano-3,5-dichloropyridine (<b>105</b>) (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>a) <i>via</i> S<sub>N</sub>Ar replacement of both chlorides with benzylalcohol (step a), followed by Grignard-addition to the nitrile to install the methyl ketone moiety (step b), hydrogenolytic removal of both benzyl groups (step c, 89%), and regioselective monobenzylation of the 5-OH group over the 3-OH group, taking advantage of the fact that the latter is engaged in a hydrogen bond with the methyl ketone in the 2-position (step d, 94%).</div><div class="NLM_p last">At this point, enantiopure (−)-<b>9</b> and (−)-<b>16</b> could be obtained utilizing the same strategy that had successfully been applied to other 8-aza analogues (<a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>b), beginning with aldol condensation of <b>109</b> with a suitable benzaldehyde and subsequent AFO reaction. Thus, <b>110</b> was prepared from <b>109</b> in two steps (steps a,b; 28% overall) and further transformed into <b>111</b> (steps c–e, 38% overall). A series of functional group manipulations as well as chiral HPLC separation then completed the synthesis of (−)-<b>9</b>. Analogously, azaflavonol <b>112</b> was could be prepared from <b>109</b> (steps m,n) and subsequently converted into <b>113</b> in three steps (steps o–q). Again, the functional group manipulations including debenzylation (step r; 7% over six steps), triflation of the resulting C6 phenol, and subsequent cyanation followed by stepwise conversion of the C2 ester to the corresponding dimethyl amide (steps s–v; 19% over four steps) afforded <i>rac</i>-<b>16</b>, which was subjected to chiral HPLC separation to provide enantiopure (−)-<b>16</b>.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Modification of the 2-Position in 8-Aza Analogues</h3><div class="NLM_p">Acid <b>104</b>, which had been previously prepared in the context of the synthesis of analogue (−)-<b>8</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>c, step f), proved to be a valuable intermediate in the synthesis of 2-unsubstituted and various 2-substituted 8-aza analogues. Thus, 2-unsubstituted analogue <i>rac</i>-<b>24</b> was synthesized from <b>104</b><i>via</i> Barton-decarboxylation (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>, steps a,b), followed by Pd-catalyzed cyanation (step c).</div><div class="NLM_p">2-(dimethylamino)methyl-substituted analogue (−)-<b>31</b> could be conveniently prepared from acid <b>104</b><i>via</i> EDC-mediated amide coupling (76% yield) and amide reduction with borane–DMS complex (61% yield) to give amine <b>117</b>, followed by Pd-catalyzed cyanation (46%) and chiral HPLC separation (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>). 2-Oxazole-substituted analogue <i>rac</i>-<b>27</b> was prepared from acid <b>104</b> in four steps, starting with the coupling of <b>104</b> with amine primary <b>118</b> to give amide <b>119</b> in 64% yield (step e, <a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>). Hydrolysis of the acetal with aqueous hydrochloric acid (step f) followed by cyclodehydration (step g; 21%, two steps) and Pd-catalyzed cyanation (step h; 23%) gave <i>rac</i>-<b>27</b>.</div><div class="NLM_p">The synthesis of <i>rac</i>-<b>32</b>, (−)-<b>25</b>, and (−)-<b>26</b> is shown in <a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>. Reduction of ester <b>103</b> with LAH, followed by cyanation gave access to triol <i>rac</i>-<b>32</b> (<a class="ref internalNav" href="#sch12" aria-label="Scheme 12">Scheme 12</a>). Introduction of the 4′-cyano group (step c; 78%) followed by ester saponification (step d; 78%) led to acid <b>120</b>. High-yielding EDC/HOBt-mediated amide coupling using the HCl salts of ammonia and methylamine, followed by chiral HPLC separation, provided (−)-<b>26</b> and (−)-<b>25</b>, respectively.</div><div class="NLM_p">It was discovered that α,β-unsaturated β-aryl sulfonamides were suitable alkene components for the photocycloaddition with azaflavonols, as detailed in <a class="ref internalNav" href="#sch13" aria-label="Scheme 13">Scheme 13</a>. Thus, photocycloaddition of previously synthesized azaflavonol <b>102</b> with α,β-unsaturated sulfonamides <b>121</b> and <b>123</b>, followed by base-induced ketol rearrangement and directed reduction, gave <b>122</b> in 2% overall yield and <b>124</b> in 9% overall yield, respectively. Although the observed yields for this sequence are substantially lower than the yield observed for the analogous sequence of <b>102</b> with methyl cinnamate (<b>55</b>) (<i>cf.</i><a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>c, steps c–e, 56% overall yield), the approach still allowed for the preparation of enough material of <b>122</b> and <b>124</b> to complete the synthesis of <i>rac</i>-<b>28</b> and <i>rac</i>-<b>29</b>, respectively. Thus, <b>122</b> was successfully transformed into <i>rac</i>-<b>28</b><i>via</i> Pd-catalyzed 4′-cyanation in low yields (7%). <b>124</b> was subjected to high yielding acidic N-debenzylation (92%, followed by Pd-catalyzed cyanation, which again—as in the case of <i>rac</i>-<b>28</b>—proceeded in rather low yields of 8% to give <i>rac</i>-<b>29</b>.</div><div class="NLM_p last">In the case of analogue (−)-<b>30</b>, a different approach for the installation of the methyl sulfone moiety was identified (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>). Krapcho-decarboxylation with the 1-ketone in place gave <b>126</b> (<a class="ref internalNav" href="#sch14" aria-label="Scheme 14">Scheme 14</a>) in 33% yield. Copper(II)bromide-mediated sulfonylation with sodium methanesulfinate<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> followed by directed reduction with sodium triacetoxyborohydride provided methyl sulfone <b>127</b> in 4% overall yield. 4′-Cyanation (72%) followed by chiral separation completed the synthesis of (−)-<b>30</b>.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> Synthesis 5-, 6-, and 7-Aza analogues</h3><div class="NLM_p">The synthesis of other 5-, 6-, and 7-aza analogues was achieved utilizing the same photochemical strategy that had successfully been used for the synthesis of 8-aza analogues discussed above (<a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>), highlighting the generality of this approach in the synthesis of rocaglamide analogues featuring A-ring pyridines. The synthesis of <i>rac</i>-<b>35</b> is shown in <a class="ref internalNav" href="#sch15" aria-label="Scheme 15">Scheme 15</a>. The required acetyl pyridine <b>131</b> was synthesized in three steps from commercially available acid <b>128</b><i>via</i> Weinreb amide formation, Grignard addition to obtain the methyl ketone, and <i>O</i>-demethylation (steps a–c). Aldol condensation and AFO reaction then led to azaflavonol <b>132</b>. Using the established photochemistry/ketol rearrangement/directed reduction protocol, <b>132</b> was transformed into <b>133</b> in three steps (steps f–h, 28% overall). Ester hydrolysis followed by amide coupling proceeded as expected to give <b>134</b>. The subsequent 4′,6-dicyanation (step k) occurred in 36% yield using conditions closely related to those utilized in the synthesis of (−)-<b>8</b> and was followed by chiral HPLC separation to provide (−)-<b>33</b>.</div><div class="NLM_p">7-aza analogue <i>rac</i>-<b>34</b> was synthesized as detailed in <a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a>. In this case, the required pyridine <b>139</b> was obtained in three steps from 2-methoxy-4-aminopyridine <b>135</b><i>via</i> electrophilic bromination (step a, 92%), Pd-catalyzed coupling with enol ether stannane <b>137</b>, which was followed by acidic hydrolysis of the resulting enolether to the desired methyl ketone (step b, 49%) and conversion of the amino group into a hydroxy group <i>via</i> the transient diazonium salt (step c, 37%). From this point on, a familiar sequence (steps d–k) was pursued to complete the synthesis of <i>rac</i>-<b>34</b> (see <a class="ref internalNav" href="#sch16" aria-label="Scheme 16">Scheme 16</a> for details). It is noteworthy that the three-step conversion of <b>140</b> to <b>141</b> proceeded in unusually low yields (<i>ca.</i> 1% overall). While suboptimal electronic match between azaflavonol <b>140</b> and methyl cinnamate (<b>55</b>) in the photocycloaddition step might contribute to this outcome, this observation is difficult to rationalize at this point, given the moderate to good yields for this sequence observed in other cases described herein. The remaining three steps proceeded as expected to give <i>rac</i>-<b>34</b>.</div><div class="NLM_p">The synthesis of 6-aza analogue (−)-<b>35</b> is shown in <a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>. 3,5-Dichloro-4-cyanopyridine was subjected to a selective S<sub>N</sub>Ar reaction with sodium <i>para</i>-methoxybenzylate at 0 °C, leading to intermediate <b>143</b> (76%). Displacement of the second chloride under S<sub>N</sub>Ar with sodium methoxide occurred under more forcing conditions (80 °C) to give <b>144</b>, which was then reacted with methylmagnesium bromide to afford, upon treatement with aqueous HCl, key pyridine <b>145</b>. The established two step procedure (aldol condensation, AFO reaction) transformed <b>145</b> into azaflavonol <b>146</b>. The latter was successfully transformed into aza-rocaglate intermediate <b>147</b> using the well-established three step procedure featuring the photocycloaddition with methyl cinnamate (<b>55</b>) as a key step, which proceeded with an acceptable overall yield of 35% over three steps. Functional group modifications followed by chiral separation ultimately afforded analogue (−)-<b>35</b>.</div><div class="NLM_p last">The synthesis of analogue <i>rac</i>-<b>36</b> required the preparation of key pyridone <b>153</b> (<a class="ref internalNav" href="#sch18" aria-label="Scheme 18">Scheme 18</a>). This was achieved in a five-step sequence starting from 2,6-dichloronicotinic acid (<b>150</b>), involving regioselective S<sub>N</sub>Ar reaction with methanol in the presence of potassium <i>t</i>-butoxide (step a), followed by Weinreb amide formation (step b) and Grignard addition (step c) to provide methyl ketone <b>152</b>, S<sub>N</sub>Ar with deprotonated PMB-alcohol (step d), and acidic PMB deprotection (step e). Transformation of <b>153</b> into <b>154</b><i>via</i> aldol condensation and AFO reaction proceeded as expected; however, the three-step conversion of <b>154</b> to <b>155</b> was associated with very low yields of only 3%, again suggesting an inefficient photocycloaddition, potentially as a result of suboptimal electronic match of both cycloaddition partners. The remaining steps (k–m) proceeded as expected to provide 5-aza analogue <i>rac</i>-<b>36</b>.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> Synthesis of 6-Aza Analogues Featuring Basic Amines in the 2-Position</h3><div class="NLM_p">The majority of analogues featuring basic amine substituents in the 2-position, that is, enantiopure <b>37</b>, <b>40–44</b>, <b>46–48</b>, <b>50,</b> and <b>51</b>, as well as racemic <b>38</b> and <b>39</b>, could be prepared in a straightforward way starting from key carboxylic acid <b>148</b> (<a class="ref internalNav" href="#sch19" aria-label="Scheme 19">Scheme 19</a>), which had been prepared in the context of the synthesis of (−)-<b>35</b> (<a class="ref internalNav" href="#sch17" aria-label="Scheme 17">Scheme 17</a>). Thus, in each of these cases, amide coupling of <b>148</b> with an appropriate amine gave access to amide <b>157</b>. Borane reduction then transformed the amide into the corresponding amine <b>158</b>, which was subjected to 4′-cyanation and, for <b>37</b>, <b>40–44</b>, <b>46–48</b>, <b>50</b>, and <b>51</b>, chiral separation to provide the desired final compound (for details, see the <a class="ref internalNav" href="#sec6" aria-label="Experimental Section">Experimental Section</a>).</div><div class="NLM_p">The remaining 6-aza analogues of the focused amine library, that is, (+)-<b>45</b>, (−)-<b>49</b>, and <i>rac</i>-<b>52</b>, were synthesized as shown in <a class="ref internalNav" href="#sch20" aria-label="Schemes 20">Schemes 20</a>–<a class="ref internalNav" href="#sch22" aria-label="22">22</a>. The synthesis of (+)-<b>45</b> utilized <b>158b</b>, an intermediate in the synthesis of <i>rac</i>-<b>38</b> (<a class="ref internalNav" href="#sch20" aria-label="Scheme 20">Scheme 20</a>). This compound was first trifluoroacetylated. Subsequent amide reduction then gave <b>160</b>, which was subjected to Pd-catalyzed cyanation (24% yield over three steps) to give <i>rac</i>-<b>45</b>. Chiral separation then provided analogue (+)-<b>45</b>.</div><div class="NLM_p">Amine analogue (−)-<b>49</b> was prepared from <i>rac</i>-<b>48</b> (<a class="ref internalNav" href="#sch21" aria-label="Scheme 21">Scheme 21</a>). <i>In situ</i> TBS protection of the secondary alcohol followed by reductive amination with concomitant desilylation (step a, 55%) was followed by chiral HPLC separation to obtain enantiopure (−)-<b>49</b>. It is noteworthy that the initial TBS protection was crucial for the success of the sequence, as in the absence of a protective group the secondary alcohol at C1 reacts with the iminium generated <i>in situ</i> in the reductive amination step to form a cyclic aminal.</div><div class="NLM_p last">The final route toward analogue <i>rac</i>-<b>52</b> is shown in <a class="ref internalNav" href="#sch22" aria-label="Scheme 22">Scheme 22</a>. Homologation of acid <b>148</b> was achieved in a four-step sequence, involving borane reduction (step a), mesylation of the resulting primary alcohol (step b), displacement of the mesylate with cyanide (step c), and basic nitrile hydrolysis (step d) to give <b>163</b> in 41% overall yield. Initial attempts to achieve an amide coupling with <b>163</b> only led to formation of lactone <b>164</b> (92%), which could then be transformed into amide <b>165</b> in a separate step in 47% yield. Amide reduction to give <b>166</b> (71%) and subsequent Pd-catalyzed cyanation (19%) completed the synthesis of <i>rac</i>-<b>52</b>.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> Synthesis of (−)-<b>53</b> and <b>eFT226</b></h3><div class="NLM_p">6,8-disubstituted 7-aza analogues (−)-<b>53</b> and <b>eFT226</b> were synthesized using closely related routes (<a class="ref internalNav" href="#sch23" aria-label="Schemes 23">Schemes 23</a> and <a class="ref internalNav" href="#sch24" aria-label="24">24</a>). The synthesis of the key azaflavonol intermediates <b>174</b> and <b>175</b> is shown in <a class="ref internalNav" href="#sch23" aria-label="Scheme 23">Scheme 23</a> and commenced with the regioselective transformation of 2,4,6-trichloropyridine (<b>167</b>) into <b>168</b><i>via</i> S<sub>N</sub>Ar with sodium benzylate at 0 °C (72% yield). A second S<sub>N</sub>Ar reaction at elevated temperatures was used to install the methoxy group and afforded <b>169</b> in 56% yield. Regioselective, directed lithiation followed by quenching with acetaldehyde led to secondary alcohol <b>170</b> (65%), which was oxidized to ketone (<b>171</b>, 75%). Hydrogenolytic debenzylation was carried out in ethyl acetate to avoid reductive dechlorination and provided hydroxypyridine <b>172</b> in 88% yield. Aldol condensation with <i>para</i>-bromobenzaldehyde followed by AFO cyclization gave <b>174</b>, a critical intermediate in the synthesis of (−)-<b>53</b> (see below), in 19% overall yield. It was found that modification of the 6-position and installation of the methoxy group that is present in <b>eFT226</b> was synthetically most feasible at this stage of the synthesis, while its installation later on proved challenging. Thus, treatment of <b>174</b> with sodium methoxide in MeOH/DMF at 80 °C yielded azaflavonol <b>175</b>, a key intermediate in the synthesis of <b>eFT226</b>.</div><div class="NLM_p">Both key azaflavonols <b>174</b> and <b>175</b> were utilized in the synthesis of (−)-<b>53</b> and (−)-<b>eFT226</b>, respectively, as outlined in <a class="ref internalNav" href="#sch24" aria-label="Scheme 24">Scheme 24</a>. Thus, the established three step sequence of photocycloaddition/ketol rearrangement/directed reduction transformed <b>174</b> into <b>176</b> in 27% yield. Ester hydrolysis, amide coupling and amide reduction (75% overall) gave <b>177</b>. Pd-catalyzed 4′,6-dicyanation (63%) and chiral HPLC separation completed the synthesis of (−)-<b>53</b>. <b>eFT226</b> was synthesized using the same strategy. In the three-step sequence converting <b>175</b> to <b>178</b> best results were obtained when chloroform/2,2,2-trifluoroethanol (TFE) was used as the solvent system in the photocycloaddition step,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> in which case the overall yield over three steps was 40%. Installation of the dimethylaminomethyl sidechain <i>via</i> ester hydrolysis/amide coupling/amide reduction (<b>178</b> → <b>179</b>) was achieved in 76% yield over three steps. Pd-catalyzed 4′-cyanation led to racemic <b>eFT226</b> in 73% yield, which was then subjected to chiral HPLC separation to afford enantiopure (−)-<b>eFT226</b>. A crystal structure analysis of (−)-<b>eFT226</b> single crystals was successfully obtained and confirmed the structural assignment (<a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig15" id="" class=" internalNav">15</a></a>).</div><figure id="fig15" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0007.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. X-ray structure of (−)-<b>eFT226</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i45">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74407" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74407" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec6_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> Reagents</h3><div class="NLM_p last">Hippuristanol and Rocaglamide A were synthesized and QCed at Julilant Life Sciences (Uttar Pradesh, India). Cycloheximide was purchased from Sigma-Aldrich (St. Louis, MO).</div></div><div id="sec6_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> Liver Microsome Stability</h3><div class="NLM_p">Incubations were conducted at 1 μM test article (TA), 0.5 mg/mL liver microsomal protein in 100 mM phosphate buffer (PB; pH 7.4), 2 mM NADPH at 37 °C with a final organic concentration of 0.1% DMSO, and 0.9% acetonitrile (MeCN). Liver microsomes used in these experiments were obtained from BioIVT (Hicksville, NY).</div><div class="NLM_p last">Each TA stock solution (10 mM DMSO) was diluted to 1 mM with DMSO and then diluted an additional 10-fold with MeCN to 100 μM. Stock microsomes (20 mg/mL) are thawed and diluted into PB to 0.633 mg/mL. A solution of NADPH was made in PB at 8.33 mg/mL. The diluted microsomes were added to a 96-well plate (98.75 μL) designated as master plate. The 100 μM TA (1.25 μL) was spiked into the master plate and, following a 10 min preincubation period, reactions were initiated by transferring equal aliquots from the master plate (40 μL) to two clean plates. To one of these plates (T0 control plate), 100 μL of MeCN containing an internal standard (IS) was added. To the other plate (T30 reaction plate), NADPH solution (10 μL) was added to initiate the reaction. To the T0 control plate, NADPH solution was added (10 μL) and the plate was vortexed at 1000 rpm for 5 min to precipitate protein. After the 30 min incubation period, the T30 plate was taken from the incubator, and 100 μL MeCN with IS was added. Subseqeuntly the plate was vortexed at 1000 rpm for 5 min to quench reactions. Precipitated proteins were removed by centrifugation, and supernatants were transferred to new 96-well polypropylene plates. Plates were capped with pierceable septa and subjected to bioanalysis by LC/MS/MS. The MS model used was an AB SCIEX TripleTOF 5600+ operated in electrospray ionization TOF MS (+) mode. All experiments were run in duplicate, and the mean percent remaining at 30 min was determined as follows.<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_m001.gif" alt="" id="_i48" /></img></span></div></div><div id="sec6_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> Caco-2 Permeability and Efflux Studies</h3><div class="NLM_p">CACOReady 96-well kits were purchased from ADMECell (Alameda, CA). Two weeks after seeding, ADMECell ships the kits in a proprietary semi-solid medium. The media was changed after arrival, and all assays were performed on day 21 post-seeding. A 10 mM stock solution of each TA was prepared and stored at −20 °C until needed for experimentation. A working buffer was prepared in Hanks’ balanced salt solution (HBSS) with 10 mM HEPES and 15 mM glucose at pH 7.4. An acceptor buffer was prepared from the working buffer with an addition of 1% bovine serum albumin. The dosing buffer was prepared from the working buffer with the addition of TA resulting in a final concentration of 5 μM TA and 1% DMSO. Prior to the start of the assay cell junction, integrity was assessed by transepithelial electrical resistance (TEER). For use in the assay, wells required a TEER measurement of at least 500 Ω·cm<sup>2</sup>. Apical and basolateral sides of the cell monolayers were washed once with HBSS. Apical-to-basolateral (A-to-B) experiments were dosed with 65 μL of dosing buffer (75 μL final volume) on the apical side of the cell monolayer and 250 μL of acceptor buffer on the basolateral side of the cell monolayer. Basolateral-to-apical (B-to-A) experiments were dosed with 250 μL of dosing buffer on the basolateral side of the cell monolayer and 65 μL of acceptor buffer (75 μL final volume) on the apical side of the cell monolayer. Cell monolayers were incubated at 37 °C with 5% CO<sub>2</sub> in a humidified incubator for 2 h. After the assay, cell junction integrity was again tested for damage with a Lucifer yellow permeability assay. In order for cells to be of considered viable, Lucifer yellow paracellular flux needed to be less than 0.3%. Post assay, concentrations of TA from acceptor and donor compartments were determined by LC/MS/MS using standard calibrators ranging in concentration from 0.001 to 5 μM. The MS model used was a Sciex API 4000 operated in electrospray ionization MRM-(+) mode. Calculations of <i>P</i><sub>app</sub> and efflux were performed according to the following formulas<span class="NLM_disp-formula" id="ueq2"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_m002.gif" alt="" id="_i50" /></img></span>where dQ/d<i>t</i>: the amount of TA in the acceptor (nmol) over the duration of the assay (seconds). A: area of transwell (cm<sup>2</sup>). <i>C</i><sub>0</sub>: concentration of TA in the donor well at the start of the assay (μM). <i>P</i><sub>app,BA</sub>: apparent permeability of TA in the B-to-A direction. <i>P</i><sub>app,AB</sub>: apparent permeability of the TA in the A-to-B direction.</div><div class="NLM_p last">Assignment of specific P-gp efflux was accomplished for some compounds (<i>e.g.</i>, <b>eFT226</b>) by conducting additional bi-direction permeability assays which included a P-gp inhibitor (valspodar, 5 μM) in the dosing buffer. These experiments consistently attenuated efflux.</div></div><div id="sec6_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>In Vivo</i> Pharmacokinetics</h3><div class="NLM_p last">Jugular vein-catheterized Spague dawley rats of both genders were administered a single IV bolus dose of each TA <i>via</i> the saphenous vein, at a nominal level of 1 mg/kg (free base) in a suitable formulation. Following dosing, blood was collected from all animals <i>via</i> jugular vein into microtubes containing K<sub>2</sub>EDTA at 0.083, 0.25, 0.50, 1, 2, 4, 8, and 24 h post-dose. Blood samples were initially stored on ice and subsequently centrifuged to separate plasma. Plasma samples were kept on ice prior to storage in a −80 °C freezer until time of processing for bioanalysis. Plasma bioanalysis was performed on all time points using bioanalytical methods that included using protein precipitation followed by liquid chromatography–mass spectrometry (LC/MS) analysis. The MS model used was an AB SCIEX TripleTOF 5600+ operated in electrospray ionization TOF MS (+) mode. The analyte quantified was the respective free base form of each TA. Bioanalytical time versus concentration data were imported into Phoenix 64 WinNonlin software and PK parameters calculated using noncompartemental analysis.</div></div><div id="sec6_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Thermodynamic Solubility</h3><div class="NLM_p last">Dry powders of each TA were weighed into 1 dram vials. Deionized water was added to each vial to reach the desired nominal free base concentration of 20 mg/mL. Compounds isolated as the HCl salt (<i>i.e.</i>, <b>37</b>, <b>53</b>, <b>eFT226</b>) incorporated a salt correction factor of ∼1.08 mg TA per mg of free base during the weighing process. Teflon-coated StirStix were added to each dram vial and then capped. Samples were placed on a plate heater (Watlow, St. Louis, MO) with the temperature set to 37C and covered with a Styrofoam cover. Samples were heated and stirred on a magnetized paddles stirrer (V&P Scientific, San Diego, CA) for 18 h. Post incubation, samples were filtered in an AcroPrep Advance 1 mL 0.2 μm Supor filter plate (Pall Corporations, Ann Arbor, MI). The filtrate (60 μL) was added to 20 μL of DMSO and analyzed by HPLC-UV (Agilent 1100 series, Santa Clara, CA) with appropriate standard(s) to determine soluble concentration in each experiment. TAs solutions determined to be above the standard(s) concentration were further diluted using a 3:1 deionized water/DMSO solution to below the highest standard concentration.</div></div><div id="sec6_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> p<i>K</i><sub>a</sub>/log <i>P</i></h3><div class="NLM_p last">Ionization constants (p<i>K</i><sub>a</sub>’s) and octanol water partition coefficients (log <i>P</i>, log <i>D</i> 7.4) were determined at Pion, Inc (Billerica, MA). A PULSE instrument (Pion Inc.) was used to measure pH of the solutions. The instrument was equipped with three precision dispensers (capable of adding a minimum volume of 0.042 μL and a high-impedance (1015 Ω) pH circuit. The double junction combination pH electrode was standardized using the Avdeef–Bucher four–parameter equation. The standard aqueous method based on potentiometric titration routinely determines p<i>K</i><sub>a</sub> values from 3 to 11. The cosolvent method is narrower by about 1 pH unit, specifically due to electrode calibration in the presence of organic solvents. Furthermore, if precipitation of the compound occurred during pH-metric titrations, that may affect the results increasing the error limits on the p<i>K</i><sub>a</sub> determination. In these cases, the p<i>K</i><sub>a</sub> value cannot be reliably determined. The aqueous p<i>K</i><sub>a</sub> values were extrapolated from the p<i>K</i><sub>a</sub> values in cosolvents as a reciprocal function of the dielectric constant (ε) of each of the co-solvent mixture using Yasuda–Shedlovsky extrapolation procedure. The extrapolation plots are used to calculate the aqueous p<i>K</i><sub>a</sub> from the p<i>K</i><sub>a</sub> (p<sub>s</sub>K<sub>a</sub>) measured in cosolvent. However, if p<sub>s</sub><i>K</i><sub>a</sub> values are outside of the pH region specified for the method, the aqueous p<i>K</i><sub>a</sub> cannot be determined. log <i>P</i>/log <i>D</i> values are calculated based on the difference between accurately determined aqueous p<i>K</i><sub>a</sub> values and pKa determined in the presence of 1-octanol (p<sub>o</sub><i>K</i><sub>a</sub>). In cases when the p<sub>o</sub><i>K</i><sub>a</sub> or/and p<i>K</i><sub>a</sub> values cannot be reliably determined, the log <i>P</i>/log <i>D</i> results are reported as “Not Available” (N/A). The p<i>K</i><sub>a</sub> experiments for the compound have been performed using the potentiometric and the UV-metric methods. The log <i>P</i>/log <i>D</i> experiments were performed using the potentiometric method.</div></div><div id="sec6_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Biacore Binding Studies</h3><div class="NLM_p">RNA 18-mer oligonucleotides were custom synthesized from GE Healthcare Dharmacon Inc (Chicago, IL) and biotinylated on the 3′ end and contained the following repeat sequences:</div><div class="NLM_p">(AGAGAG): 5′-A.G.A.G.A.G.A.G.A.G.A.G.A.G.A.G.A.G-Bi-3′;</div><div class="NLM_p">(GGCGGC): 5′G.G.C.G.G.C.G.G.C.G.G.C.G.G.C.G.G.C–Bi-3′;</div><div class="NLM_p">(CCGCCG): 5′C.C.G.C.C.G.C.C.G.C.C.G.C.C.G.C.C.G-Bi-3′; and</div><div class="NLM_p">(CAACAA): 5′-C.A.A.C.A.A.C.A.A.C.C.A.C.C.A.C.C.A-Bi-3′</div><div class="NLM_p last">Full length recombinant eIF4A1 protein was prepared at Beryllium Discovery (Bainbridge Island, WA) and was kept at −80 °C until use in the following storage buffer: 20 mM Tris pH 7.5, 200 mM NaCl, 1% glycerol, and 1 mM TCEP. Biacore studies were conducted at Biosensor Tools (Salt Lake City, UT) on a ProteOn XPR36 protein interaction array system BioRad (Hercules, CA) using NLC sensor chips functionalized with streptavidin for capturing biotinylated biomolecules. Running buffer contained 14.4 mM Hepes pH 7.4, 108 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.36 mM TCEP, 1 mM ATP, and 1% DMSO. Data were collected at 25 °C. The formation of the ternary complex was tested with eIF4A1 and <b>eFT226</b> in the presence or absence of nucleotides (ATP and AMP-PNP). Once the complex was formed on the RNA surface, dissociation of eIF4A1 was determined by washing the surface for 110 s in the presence of compound and ATP, followed by a wash without compound (ATP only). Response data for the full concentration series were fit globally to a 1:1 interaction model using the data processing and analysis software Scrubber, BioLogic Software (Canberra, Australia).</div></div><div id="sec6_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Cell-Based Reporter Assay</h3><div class="NLM_p">Seven tandem repeats of various sequence motifs (see <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>) were cloned into the 5′-UTR of the luciferase reporter vector pGL3 (Promega Corp., Madison, WI) at Genewiz (San Diego). DNA templates were PCR amplified using Phusion High-fidelity PCR Master Mix (New England Biolabs, Ipswich, MA) from the reporter vector using the forward and reverse primers described in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a> that incorporates the T7 promoter sequence for subsequent RNA transcription. Reactions were purified using the Qiagen PCR clean up kit and eluted in 50 μL water. RNA was transcribed from the DNA templates using the mMESSAGE mMACHINE T7 Ultra kit (Ambion ThermoFisher, Waltham, MA). RNA was purified with the RNA Mega Clear Kit and eluted with 30 μL elution buffer (Ambion ThermoFisher, Waltham, MA). Using the manufacturer’s instructions, RNA was transiently transfected in bulk into exponentially growing MDA-MB-231 cancer cells using the TransIT mRNA transfection kit (Mirus Bio, Madison, WI), and the transfected cells were then seeded into 96-well plates. The transfected cells were treated with various concentrations of translation inhibitors (<b>eFT226</b>, RocA, hippuristanol, and cycloheximide) or control (DMSO) for 4 h at 37 °C. Cells were rinsed with 100 μL of PBS and lysed using 50 μL of 1x passive lysis buffer (Promega Corp., Madison, WI). After shaking for 20 min at room temperature, 100 μL of luciferase assay reagent (Promega Corp., Madison, WI) was added, and luminescence was quantitated using a Victor (PerkinElmer) plate reader. The data were fitted using GraphPad Prism (GraphPad Software, La Jolla, CA) and a four-parameter dose response equation.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. 5′-UTR Sequence Motifs</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CAACAA</td><td class="colsep0 rowsep0" align="left">5′-AAGCTTGAA(CAACAA)<sub>13</sub>CACCCCATGG-3′</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AGAGAG</td><td class="colsep0 rowsep0" align="left">5′-AAGCTTGAA(<b>AGAGAG</b>CAACAA)<sub>6</sub><b>AGAGAG</b>CACCCCATGG-3′</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CCGCCG</td><td class="colsep0 rowsep0" align="left">5′-AAGCTTGAA(<b>CCGCCG</b>CAACAA)<sub>6</sub><b>CCGCCG</b>CACCCCATGG-3’</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GGCGGC</td><td class="colsep0 rowsep0" align="left">5′-AAGCTTGAA(<b>GGCGGC</b>CAACAA)<sub>6</sub><b>GGCGGC</b>CACCCCATGG-3′</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Reporter Construct Forward and Reverse qPCR Primers.</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">forward (CAACAA)</td><td class="colsep0 rowsep0" align="left">5′-GGGCACTAATACGACTCACTATAGGAAGCTTGAA(CAA)<sub>26</sub>CACC-3′</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">forward (AGAGAG)</td><td class="colsep0 rowsep0" align="left">5′-GGGCACTAATACGACTCACTATAGGAAGCTTGAA(<b>AGAGAG</b>CAACAA)<sub>6</sub><b>AGAGAG</b>CACC-3′</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">forward (CCGCCG)</td><td class="colsep0 rowsep0" align="left">5′-GGGCACTAATACGACTCACTATAGGAAGCTTGAA(<b>CCGCCG</b>CAACAA)<sub>6</sub><b>CCGCCG</b>CACC-3′</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">forward (GGCGGC)</td><td class="colsep0 rowsep0" align="left">5′-GGGCACTAATACGACTCACTATAGGAAGCTTGAA(<b>GGCGGC</b>CAACAA)<sub>6</sub><b>GGCGGC</b>CACC-3′</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">reverse (Firefly)</td><td class="colsep0 rowsep0" align="left">5′-TTACACGGCGATCTTTCCGCCCTT-3′</td></tr></tbody></table></div></div></div><div id="sec6_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> Generation of HAP1 eIF4A1 F163L Cell Line</h3><div class="NLM_p last">The pSpCas9 BB-2A-Puro (PX459) v2.0 vector containing the Cas9 nuclease and a sgRNA targeting the sequence surrounding F163 in human eIF4A1 (5′-CATATCAAACACACG GCCAG-3′) was purchased from Genescript (Piscataway, NJ). The ssODN donor template (5′GCCTGTATCGGGGGCACCAACGTGCGTGCTGAGGTGCAGAAACTGCAGAT GGAAGCTCCCCACATCATCGTGGGTACACCTGGCCGTGTGCTCGATATGCTTAACCGGAGATACCTGTGTGAGTAATTCGGTTCTCCAATCCCCTGGGTCACTTTGCTCTTGTGCACG-3′; PAM mutation is italicized, F163L mutation underlined and novel TaqαI restriction site is in bold) was purchased from Integrated DNA Technologies (Coralville, IA). The vector and ssODN were cotransfected into exponentially-growing HAP1 cells (Horizon Discovery, Cambridge, UK) using X-tremeGENE 9 (Roche; Basel, Switzerland), and 2 days later, a single cell suspension was transferred into 96-well plates at approximately 1 cell/well. After 2 weeks, following gDNA extraction each clone was assayed for the presence of the TaqαI restriction site by PCR amplification and subsequent restriction enzyme digest of the region of interest in human eIF4A1 (Herculase DNA polymerase from Agilent Technologies; Santa Clara, CA and TaqαI from New England Biolabs; Ipswich, MA). The undigested PCR product from potential positive clones was ligated into the TOPO-Blunt vector (ThermoFisher, Waltham, MA) and subjected to Sanger sequencing to verify correct nucleotide changes.</div></div><div id="sec6_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Cell Culture, Antibodies, and Immunoblotting</h3><div class="NLM_p">MDA-MB-231 (ATCC, Manassas, VA) and HAP1 cells were maintained in DMEM supplemented with 10% FBS and 1× penicillin/streptomycin. The GAPDH antibody was purchased from Santa Cruz Biotechnology (Dallas, TX). The c-MYC antibody was purchased from Abcam (Cambridge, UK). The Cyclin D1 antibody was purchased from Cell Marque (Rocklin, CA). Antibodies against MCL-1, BCL2, and eIF4A1 were purchased from Cell Signaling Technology (Danvers, MA). Secondary antibodies (Goat anti-rabbit IRDye-680, Goat anti-mouse IRDye-800, Donkey anti-rabbit IRDye-800CW, and Donkey anti-mouse IRDye-680RD) for Odyssey infrared imaging were purchased from LI-COR (Lincoln, NE).</div><div class="NLM_p last">For immunoblotting, exponentially growing cells were seeded into 6-well plates at 0.5 million cells/mL and cultured overnight followed by treatment with the indicated concentrations of <b>eFT226</b> or DMSO for 24 h. Cells were pelleted by centrifugation, washed once with ice-cold PBS and lysed in 1× cell lysis buffer from Cell Signaling Technology (Danvers, MA) supplemented with a final concentration of 1 mM PMSF. Protein concentrations in cell lysates were quantitated by BCA protein assay from Thermofisher Scientific (Waltham, MA) and equal amounts of total protein were resolved by SDS-PAGE, immunoblotted with the indicated antibodies and visualized by LI-COR Odyssey imager.</div></div><div id="sec6_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> Cell Proliferation Assay</h3><div class="NLM_p last">Exponentially growing cells were seeded at 2000–5000 cells per well in 96-well flat bottom white polystyrene plates (Thermo Fisher) and cultured overnight. The following day, compound was added in a 3-fold dilution series along with a DMSO control. The final DMSO concentration was 0.1%. Cells were incubated for 72 h at 37 °C in a CO<sub>2</sub> incubator. Baseline viability of untreated cells was measured on the day of treatment and proliferation was measured after 72 h of treatment using CellTiter-Glo reagent from Promega (Madison, WI) according to manufactures instructions. Dose–response curves were plotted using Prism 6 software, and IC<sub>50</sub> values were calculated using a 4 parameter, variable slope nonlinear regression model. Calculation of % inhibition: % inhibition = 1 – (((cells + inhibitor) – baseline)/((cells + DMSO) – baseline))) × 100.</div></div><div id="sec6_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> Analysis of Cell Cycle</h3><div class="NLM_p last">Exponentially growing cells were seeded in 96-well plates and cultured overnight. Cells were then treated with <b>eFT226</b> or DMSO for 24 h. Cells were washed once with PBS, dissociated from plates by adding Trypsin–EDTA (0.25%) from Thermofisher Scientific (Waltham, MA), and incubated at 37 °C for 3 min. Trypsin is neutralized with culture medium containing 20% FBS, and the cell suspension is transferred to a round bottom 96-well plate. Cells are left to rest at room temperature for 15 min before washing with PBS. Cells are stained with LIVE/DEAD Fixable Dead Cell Stain kit from Thermo Fisher Scientific (Waltham, MA) and formalin fixed. Cell cycle was assessed by DNA staining using DRAQ5 from Thermo Fisher Scientific (Waltham, MA). Fluoresence of the cells was analyzed by flow cytometry using Attune NxT flow cytometer from Thermofisher Scientific (Waltham, MA).</div></div><div id="sec6_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> Analysis of Apoptosis and Cell Death</h3><div class="NLM_p last">For analysis of apoptosis by Annexin V staining, exponentially growing cells were seeded at 10,000 cells per well in a 96-well tissue culture treated plates and cultured overnight. Cells were then treated with <b>eFT226</b> or DMSO for 24 h. Apoptosis and cell death are measured using BD Annexin V FITC Apoptosis Detection Kit from BD Biosciences (San Jose, CA) according to the manufacturer’s instructions. Briefly, cells were washed once with PBS, dissociated from plates by adding Trypsin–EDTA (0.25%) from Thermofisher Scientific (Waltham, MA), and incubated at 37 °C for 3 min. Trypsin is neutralized with culture medium containing 20% FBS, and the cell suspension is transferred to a round bottom 96-well plate. Cells are left to rest at room temperature for 15 min before washing once with PBS and resuspended in 1× annexin V binding buffer containing annexin V and PI. Cells were incubated at room temperature for 15 min followed by dilution in 1× annexin V binding buffer. Fluorescence of the cells was analyzed by flow cytometry using Attune NxT flow cytometer Thermo Fisher Scientific (Waltham, MA).</div></div><div id="sec6_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> <i>In Vivo</i> Efficacy Studies</h3><div class="NLM_p last">All animal studies were carried out in accordance with the guidelines established by the Institutional Animal Care and Use Committee at Explora BioLabs (San Diego, CA). For MDA-MB-231 xenografts, athymic nude ((NCr) nu/nu fisol, Simonsen) were implanted orthotopically in the mammary fat pad with 5 × 10<sup>6</sup> cells in 0.1 mL of unsupplemented DMEM and an equal volume (1:1) ratio of Matrigel (BD Biosciences) for tumor development. When the mean tumor sizes reached approximately 170 mm<sup>3</sup> (MDA-MB-231), the mice were randomized and size-matched into vehicle and treatment groups. The tumor size was measured in length and width with a caliper twice a week. The tumor volume was calculated by the formula <i>L</i> × <i>W</i> × <i>W</i>/2 according to NCI standards. Body weights were collected prior to study start, and twice a week during the study. <b>eFT226</b> was formulated in 5% dextrose in water (D5W), heated and/or vortexed to make a clear solution.</div></div><div id="sec6_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Computation</h3><div id="sec6_15_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> Rocaglamide A binding model</h4><div class="NLM_p last">The protein employed for the model was the PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a> structure of eIF4E3 from the pdb database because this was the only eIF4A structure at the time that had an RNA strand bound.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> The initial conformation of rocaglamide A was obtained using a rocaglamide analogue structure from the Cambridge Structural Database (CSD), FROJM03. The structure of rocaglamide A was constructed in 3D from this starting model using the editing tools available in Benchware 3D and minimized in the gas phase using the MMFF. The resulting 3D model was placed by hand into the <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a> protein structure with a Connelly surface representation displayed to reveal potential binding pockets of the protein in the region supported by the mutational data.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Only one pose was deemed reasonable for further study, and it was minimized in the presence of the protein using the MMFF and Benchware. Subsequent models of compounds 7 and 36 were generated from the rocaglamide A model by editing the structure with the 3D tools of Benchware and minimizing in the gas phase using the MMFF; no re-optimization to the protein was performed.</div></div><div id="sec6_15_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> Torsional modeling</h4><div class="NLM_p last">All torsional studies were performed using Spartan ’14 version 1.1.8 from Wavefunction, Inc. For each derivative of interest, the structure was constructed in 3D using the editing tools in Spartan and the equilibrium geometry calculated using DFT and either EDF2 or B3LYP at the 6-31G* level of theory. The torsional energy surface was then generated by driving the C1′–C3a–C3–C1″ from 60° to −30 or −60 in 5° increments using the energy profile function. Plots were generated with the torsional angle value on the <i>x</i>-axis and the relative energy on the <i>y</i>-axis using the smooth function to draw a line.</div></div></div><div id="sec6_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> Chemistry</h3><div class="NLM_p">All reagents and solvents were used as purchased from commercial sources unless otherwise noted. Microwave reactions were performed with a Biotage Initiator focused beam microwave reactor. Reactions were monitored, and analytical purities were assessed on the following instruments: Waters Acquity UPLC with SQD mass equipped with Acquity UPLC BEH C-18 (2.1 × 100 mm, 1.7 μm) and Acquity UPLC HSS T3 (2.1 × 100 mm, 1.8 μm) columns (LCMS); Shimadzu LC-10AD liquid chromatograph system equipped with a Shimadzu SCL-10A System controller and SPD-10A UV/Vis detector, a PerkinElmer Series 200 Autosampler and a Phenomenex Gemini NX-C18 column (3 μm, 30 × 4.6 mm) (LCMS). Analytical chiral separations and determinations of enantiomeric excesses were performed using a Waters Alliance 2695 Separations Module with Waters 2998 Photo Diode Array Detector (HPLC) or a Waters Acquity UPCC with a Waters Photo Diode Array detector (UPCC/analytical SFC) equipped with Diacel Chiralpak IA (4.6 × 250 mm, 5 μm), Diacel Chiralpak IC (4.6 × 250 mm, 5 μm), or Diacel Chiralpak IG (4.6 × 250 mm, 5 μm) columns. Final compounds for biological evaluation were obtained in ≥95% purity as determined by LCMS.</div><div class="NLM_p">Flash column chromatography was performed with a Teledyne ISCO CombiFlash Rf200+ system or a Yamazen Smart Flash EPLC W-Prep 2XY system using normal-phase silica columns (230–400 mesh). HPLC purification was performed using a Waters automated purification system with Waters 2767 sample controller, 2545 binary gradient pump, and 2998 Photo Diode Array Detector/2489 UV Detector; or a Gilson automated purification system equipped with a Gilson 215 liquid handler and 333 and 334 pumps using Phenomenex Gemini NX-C18 columns (10 μm, 250 × 30 mm or 10 μm, 250 × 50 mm). SFC purification was performed on a Waters SFC 200q system with waters 2489 UV/vis detector. Chiral SFC separations were performed using Diacel Chiralpak IA (21 × 250 mm, 5 μm), Diacel Chiralpak IC (30 × 250 mm, 5 μm), and Diacel Chiralpak IG (21 × 250 mm, 5 μm) columns.</div><div class="NLM_p"><sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker 400 MHz Avance III HD Nanobay with a BBFO probe, Bruker 400 MHz Avance II with a Dual 13C probe, Agilent MR400 spectrometer, Bruker DRX 500, and Bruker AV-500 spectrometer. Coupling constants (<i>J</i>) are reported in hertz (Hz). Chemical shifts (δ) of NMR spectra are reported in parts per million (ppm) and are calibrated using residual undeuterated solvent for <sup>1</sup>H NMR [<sup>1</sup>H = 7.26 (CHCl<sub>3</sub>), 2.50 (D<sub>5</sub>H-DMSO) ppm] and <sup>13</sup>C deuterated solvent for <sup>13</sup>C NMR [39.52 (DMSO-<i>d</i><sub>6</sub>) ppm] as an internal reference at 298 K.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> The following abbreviations were used to designate the multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, b = broad.</div><div class="NLM_p">High-resolution mass spectrometry (HRMS) was performed using a Triple TOF 5600+ mass spectrometer (hybrid quadrupole time-of-flight platform; AB Sciex) connected to a 1290 UHPLC system (Agilent). The mass spectrometer was operated in electrospray positive ionization mode (ESI+). Acquisition was a full scan from <i>m</i>/<i>z</i> 100 to 1000 with a pulser frequency of 18.092 kHz and accumulation time of 250 ms.</div><div class="NLM_p">Optical rotations were measured using an Optical activity ltd polarimeter (model: polAAr 3002).</div><div class="NLM_p">Single-crystal X-ray diffraction studies were carried out on a Bruker D8 Platinum<sup>135</sup> CCD diffractometer equipped with Cu Kα radiation (λ = 1.5478).</div><div class="NLM_p">Photocycloadditions were carried out using the following equipment: Medium Pressure Mercury Vapor Lamp (Vendor: SAIC, INDIA; model: MVL4; Power Supply model: MVL41, wattage: 400 W, diameter: 22 mm); Amit Scientific UV reactor (250 mL/500 mL/1000 mL/5 L/10 L).</div><div id="sec6_16_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> Synthesis of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-Dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>6</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0058.gif" alt="" id="dgr2" /></img><div id="sec6_16_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 1-(2-Hydroxy-4-methoxyphenyl)ethan-1-one (<b>S1</b>)</h5><div class="NLM_p last">To a solution of 1-(2,4-dihydroxyphenyl)ethan-1-one (<b>68</b>) (50.0 g, 329 mmol) in acetone (500 mL), potassium carbonate (136.0 g, 984.0 mmol) was added at room temperature. The reaction mixture was stirred for 15 min at room temperature, and then methyl iodide (20 mL, 46 g 0.32 mol) was added. The reaction mixture was stirred at room temperature for 16 h, after which acetone was removed under reduced pressure, and the solid obtained was washed with ice cold water 3 times and dried under high vacuum, affording 1-(2-hydroxy-4-methoxyphenyl)ethan-1-one (<b>68</b>) as a white solid. Yield: 50.0 g (0.301 mol, 92%). MS (ESI) <i>m</i>/<i>z</i>: 165.07 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.80 (d, <i>J</i> = 8.8 Hz, 1H), 6.49–6.44 (m, 2H), 3.79 (s, 3H), 2.55 (s, 3H).</div></div><div id="sec6_16_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (<i>E</i>)-1-(2-Hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S2</b>)</h5><div class="NLM_p last">To a solution of 1-(2-hydroxy-4-methoxyphenyl)ethan-1-one (<b>S1</b>) (50.0 g, 301 mmol) in methanol (250 mL), sodium hydroxide (36.0 g, 900 mmol) was added followed by 4-methoxybenzaldehyde (55.0 g, 404 mmol). The reaction was then heated to reflux for 1 h. Afterward, the reaction mix was cooled and the solid was obtained by filtration, washed with water, and dried under high vacuum to afford (<i>E</i>)-1-(2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S2</b>) as a yellow solid. Yield: 77.0 g (271 mmol, 90%). MS (ESI) <i>m</i>/<i>z</i>: 285.2 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.22 (d, <i>J</i> = 8.5 Hz, 1H), 7.91–7.76 (m, 4H), 7.01 (d, <i>J</i> = 7.9 Hz, 2H), 6.52–6.47 (m, 2H), 3.82 (s, 6H).</div></div><div id="sec6_16_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 3-Hydroxy-7-methoxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-One (<b>69</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(2-hydroxy-4-methoxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S2</b>) (77.0 g, 271 mmol) in ethanol (500 mL) at room temperature, sodium hydroxide (32.0 g, 800 mmol, 10% aq solution) was added, followed by hydrogen peroxide (19 mL, 810 mmol). The reaction mixture was stirred for 2 h at room temperature (reaction is exothermic), after which the reaction mixture was cooled and neutralized to pH ≈ 7 by the addition of 5 N hydrochloric acid. The precipitate was collected by filtration and dried under vacuum to afford 3-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-one (<b>69</b>) as a pale yellow solid. Yield: 16.0 g (53.6 mmol, 20%). MS (ESI) <i>m</i>/<i>z</i>: 299.10 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.31 (br s, 1H), 8.18 (d, <i>J</i> = 7.9 Hz, 2H), 7.97 (d, <i>J</i> = 8.5, 1H), 7.25 (s, 1H), 7.10 (d, <i>J</i> = 8.1, 2H), 7.02 (d, <i>J</i> = 8.1, 1H), 3.90 (s, 3H), 3.84 (s, 3H).</div></div><div id="sec6_16_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> <i>rac</i>-Methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-5-Hydroxy-8-methoxy-2-(4-methoxyphenyl)-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S3</b>)</h5><div class="NLM_p last">A solution of 3-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-one (16.0 g, 53.6 mmol) and methyl cinnamate (86.9 g, 536 mmol) in dichloromethane (200 mL), acetonitrile (100 mL) and methanol (100 mL) was placed in a UV reactor flask. The reaction mixture was irradiated under 400 watts UV light for 15 h. After completion, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel by eluting the compound with 5% methanol in dichloromethane. The desired fractions were concentrated under reduced pressure to afford methyl <i>rac</i>-(3<i>S</i>,4<i>S</i>,5<i>R</i>)-5-hydroxy-8-methoxy-2-(4-methoxyphenyl)-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S3</b>) as a brown solid. Yield: 18.0 g, crude.</div></div><div id="sec6_16_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> <i>rac</i>-Methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-8b-Hydroxy-6-methoxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S4</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl 8a-hydroxy-5-methoxy-2a-(4-methoxyphenyl)-8-oxo-2-phenyl-2,2a,8,8a-tetrahydro-1<i>H</i>-cyclobuta[<i>b</i>]chromene-1-carboxylate (<b>S3</b>) (18.0 g) was suspended in methanol (250 mL), treated with 25% sodium methoxide in methanol (90 mL. 85 g solution; 21 g, 0.39 mol NaOMe), and heated to 100 °C for 2 h. The solvent was then removed under reduced pressure. The crude product was then diluted with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulphate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-8b-hydroxy-6-methoxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S4</b>) as a brown solid. Yield: 18.0 g, crude.</div></div><div id="sec6_16_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-Dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>70</b>)</h5><div class="NLM_p last">A solution of crude <i>rac</i>-methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-8b-hydroxy-6-methoxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (18.0 g) in acetonitrile (360 mL) was cooled to 0 °C, and acetic acid (22.35 mL, 390.8 mmol) and sodium triacetoxyborohydride (49.77 g, 234.8 mmol) were added at 0 °C. The mixture was stirred for 12 h at room temperature. Afterward, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated and dried over sodium sulphate, filtered, and concentrated to give the crude product. The crude product was then purified by silica gel column chromatography eluting with 2–3% in methanol in dichloromethane. The desired fractions were concentrated to afford <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>70</b>) as a white solid. Yield: 8.0 g (19 mmol, 36% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 461.01 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.30 (d, <i>J</i> = 8.4 Hz, 2H), 7.16 (d, <i>J</i> = 9.4 Hz, 1H), 7.05–7.00 (m, 5H), 6.82 (d, <i>J</i> = 7.0 Hz, 2H), 6.64–6.62 (m, 3H), 6.52–6.47 (m, 1H), 5.73 (t, <i>J</i> = 8.4 Hz, 1H), 5.28 (s, 1H), 4.75 (t, <i>J</i> = 12.5 Hz, 1H), 4.05–4.00 (m, 1H), 3.89–3.83 (m, 1H), 3.77 (s, 3H), 3.74 (s, 1H), 3.67 (s, 3H), 3.46 (s, 3H).</div></div><div id="sec6_16_1_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic Acid (<b>S5</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>70</b>) (8.0 g, 19 mmol) in methanol/water (3:1, 200 mL), lithium hydroxide (9.97 g, 416 mmol) was added. The reaction was stirred for 16 h at room temperature. The reaction mixture was then cooled to 0 °C and acidified to pH ≈ 3 with 1 N hydrochloric acid. The precipitate was collected by filtration and dried under high vacuum to afford (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S5</b>) as an off-white solid. Yield: 7.0 g (16 mmol, 84%). MS (ESI) <i>m</i>/<i>z</i>: 449.02 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.05 (br s, 1H), 7.29 (d, <i>J</i> = 8.36 Hz, 1H), 7.06–7.00 (m, 5H), 6.88 (d, <i>J</i> = 7.3 Hz, 2H), 6.63–6.55 (m, 3H), 6.51–6.44 (m, 1H), 5.64–5.58 (m, 1H), 5.28–5.20 (m, 1H), 4.73 (d, <i>J</i> = 7.1 Hz, 1H), 4.01 (d, <i>J</i> = 7.1 Hz, 1H), 3.77–3.73 (m, 4H), 3.62 (s, 3H).</div></div><div id="sec6_16_1_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-Dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>6</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S5</b>) (7.0 g, 14 mmol) in dichloromethane (140 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (8.9 g, 47 mmol), hydroxybenzotriazole (6.3 g, 47 mmol), and Hünig’s base (16.8 mL, 12.5 g, 96.4 mmol) were added at 0 °C. The reaction mixture was stirred for 5 min. Dimethylamine·HCl (6.34 g, 77.8 mmol) was then added at the same temperature and the reaction was stirred for 16 h at room temperature. After completion, the reaction mass was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to give the crude product which was purified by silica gel column chromatography eluting with 70–90% EtOAc in hexanes to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,8b-dihydroxy-6-methoxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>6</b>) as an off-white solid. Yield: 2.2 g (4.6 mmol, 33%). MS (ESI) <i>m</i>/<i>z</i>: 476.01 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 476.2068 [M + H]<sup>+</sup>; found, 476.2069; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.38 (d, <i>J</i> = 8.3 Hz, 1H), 7.09 (d, <i>J</i> = 2.0 Hz, 2H), 7.03–6.95 (m, 3H), 6.78 (d, <i>J</i> = 6.7 Hz, 2H), 6.67–6.64 (m, 3H), 6.51–6.48 (m, 1H), 5.44 (d, <i>J</i> = 4 Hz, 1H), 5.12 (s, 1H), 4.88 (t, <i>J</i> = 8.3 Hz, 1H), 4.12 (d, <i>J</i> = 13.2 Hz, 1H), 3.94 (dd, <i>J</i> = 8.6, 13.1 Hz, 1H), 3.78 (s, 3H), 3.64 (s, 3 H), 3.17 (s, 3H), 2.71 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.61, 161.18, 159.02, 157.55, 139.04, 129.04, 128.73, 128.18, 127.70, 127.24, 125.69, 122.69, 112.14, 106.90, 100.71, 95.96, 90.94, 77.52, 55.34, 54.80, 54.34, 46.92, 36.38, 35.07.</div></div></div><div id="sec6_16_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i77" class="anchor-spacer"></div><h4 class="article-section__title" id="_i77"> Synthesis of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>10</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0069.gif" alt="" id="dgr3" /></img><div id="sec6_16_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> (<i>E</i>)-1-(4-Chloro-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S6</b>)</h5><div class="NLM_p last">To a solution of 1-(4-chloro-2-hydroxyphenyl)ethan-1-one (<b>71</b>) (10.0 g, 58.6 mmol) in methanol (60 mL), sodium hydroxide (7.0 g, 180 mmol) and 4-methoxybenzaldehyde (7.9 g, 58 mmol) were successively added. The reaction mixture was heated to reflux for 30 min, then cooled. The resulting solid was collected by filtration, washed with water, and dried under high vacuum to afford (<i>E</i>)-1-(4-chloro-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S6</b>) as a yellow solid. Yield: 15.0 g (52.1 mmol, 89%). MS (ESI) <i>m</i>/<i>z</i>: 287.06 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.10–7.93 (m, 2H), 7.81 (d, <i>J</i> = 8.2 Hz, 2H), 7.76–7.68 (m, 1H), 7.02 (d, <i>J</i> = 8.4 Hz, 2H), 6.87 (br s, 2H), 3.82 (s, 3H).</div></div><div id="sec6_16_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> 7-Chloro-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-One (<b>72</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(4-chloro-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S6</b>) (15.0 g, 52.1 mmol) in ethanol (100 mL) and water (60 mL) at room temperature, sodium hydroxide (8.3 g, 0.21 mol, 10% aq solution) was added, followed by hydrogen peroxide (14.6 g, 129 mmol, 30% aq solution) at room temperature. The reaction mixture was stirred for 1 h at room temperature (exothermic) and then cooled and neutralized to pH ≈ 7 by addition of 6 N hydrochloric acid. The resulting precipitate was collected by filtration and dried under vacuum to afford 7-chloro-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-one (<b>72</b>) as a pale yellow solid. Yield: 10.0 g (33.0 mmol, 63%). MS (ESI) <i>m</i>/<i>z</i>: 302.42 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.61 (s, 1H), 8.21 (d, <i>J</i> = 8.7 Hz, 2H), 8.09 (d, <i>J</i> = 8.5 Hz, 1H), 7.98 (s, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 1H), 7.13 (d, <i>J</i> = 8.7 Hz, 2H), 3.85 (s, 3H).</div></div><div id="sec6_16_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> <i>rac</i>-methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-8-Chloro-5-hydroxy-2-(4-methoxyphenyl)-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S7</b>)</h5><div class="NLM_p last">A solution of 7-chloro-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-one (<b>72</b>) (10.0 g, 33.0 mmol) and methyl cinnamate (53.6 g, 330 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated under 400 W UV light for 24 h in a UV reactor flask. The solvent was then removed under reduced pressure, and the residue was purified by eluting through a plug of silica gel with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl 5-chloro-8a-hydroxy-2a-(4-methoxyphenyl)-8-oxo-2-phenyl-2,2a,8,8a-tetrahydro-1<i>H</i>-cyclobuta[<i>b</i>]chromene-1-carboxylate (<b>S7</b>) as a brown solid. Yield: 15.0 g, crude.</div></div><div id="sec6_16_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> <i>rac</i>-Methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-Chloro-8b-hydroxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S8</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-8-chloro-5-hydroxy-2-(4-methoxyphenyl)-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S7</b>) (15.0 g) was suspended in methanol (150 mL), treated with 25% sodium methoxide in methanol (50 mL solution; 12 g NaOMe, 0.22 mol), and then heated at 70 °C for 2 h. Afterward, the solvent was removed under reduced pressure and the remaining crude product was treated with saturated aqueous ammonium chloride solution and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-chloro-8b-hydroxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S8</b>) as a brown solid. Yield: 14.0 g, crude.</div></div><div id="sec6_16_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>73</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-chloro-8b-hydroxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S8</b>) (14.0 g) was added to a solution of sodium triacetoxyborohydride (38.0 g, 179 mmol) in acetonitrile (300 mL) and acetic acid (18.0 mL). This mixture was stirred for 4 h at room temperature. After completion, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel (100–200 mesh) column chromatography eluting with 50% ethyl acetate in hexanes. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>73</b>) as a white solid. Yield: 8.0 g (17.1 mmol, 52% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 465.31 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.38 (d, <i>J</i> = 8.0 Hz, 1H), 7.14 (s, 1H), 7.05–6.98 (m, 6H), 6.84 (d, <i>J</i> = 7.16 Hz, 2H), 6.63 (d, <i>J</i> = 8.4 Hz, 2H), 5.85 (d, <i>J</i> = 5.6 Hz, 1H), 5.57 (s, 1H), 4.74 (t, <i>J</i> = 6.3 Hz, 1H), 4.07 (d, <i>J</i> = 13.9 Hz, 1H), 3.90 (dd, <i>J</i> = 13.7 Hz, 7.0 Hz, 1H), 3.62 (s, 3H), 3.52 (s, 3H).</div></div><div id="sec6_16_2_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic Acid (<b>S9</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S8</b>) (3.0 g, 6.4 mmol) in methanol/water (3:1, 120 mL), lithium hydroxide (3.70 g, 154 mmol) was added. The reaction mixture was stirred for 4 h at room temperature and then cooled to 0 °C and acidified with 5 N hydrochloric acid to pH ≈ 3. The resulting precipitate was collected by filtration and dried under high vacuum to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S9</b>) as an off-white solid. Yield: 2.5 g (5.5 mmol, 86%). MS (ESI) <i>m</i>/<i>z</i>: 450.99 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.28 (d, <i>J</i> = 7.9 Hz, 1H), 7.11 (d, <i>J</i> = 7.2 Hz, 2H), 7.05 (s, 1H), 7.0 (t, <i>J</i> = 7.3 Hz, 2H), 6.96–6.90 (m, 4H), 6.57 (d, <i>J</i> = 8.7 Hz, 2H), 5.29 (s, 1H), 4.36 (d, <i>J</i> = 5.4 Hz, 1H), 4.10 (d, <i>J</i> = 13.5 Hz, 1H), 3.59 (s, 3H).</div></div><div id="sec6_16_2_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>10</b>)</h5><div class="NLM_p last">To a solution of (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S9</b>) (2.5 g, 5.5 mmol) in dichloromethane (55 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (3.1 g, 16 mmol), hydroxybenzotriazole (2.2 g, 16 mmol), and Hünig’s base (5.6 mL, 32 mmol) were added. The mixture was stirred for 5 min at 0 °C, after which dimethylamine hydrochloride (2.25 g, 27.6 mmol) was added at same temperature. Then, the reaction mixture was stirred for 8 h at room temperature, after which it was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography eluting with 70–90% ethyl acetate in hexanes to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-chloro-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>10</b>) as a white solid. Yield: 2.4 g (5.0 mmol, 90%). MS (ESI) <i>m</i>/<i>z</i>: 480.10 [M + 1]<sup>+</sup>; UPLC: 98.93%; HRMS (ESI): calcd, 480.1572 [M + H]<sup>+</sup>; found, 480.1590; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.46 (d, <i>J</i> = 8.0 Hz, 1H), 7.22 (d, <i>J</i> = 10.0 Hz, 1H), 7.16 (d, 1.4, 2H), 7.08–6.97 (m, 4H), 6.79 (d, <i>J</i> = 7.0 Hz, 2H), 6.67 (d, <i>J</i> = 8.7 Hz, 2H), 5.60 (d, <i>J</i> = 6.1 Hz, 1H), 5.42 (s, 1H), 4.89 (t, <i>J</i> = 6.5 Hz, 1H), 4.14 (d, <i>J</i> = 13.2 Hz, 1H), 3.98 (dd, <i>J</i> = 8.2 Hz, 13.1 Hz, 1H), 3.64 (s, 3H), 3.18 (s, 3H), 2.71 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.40, 158.68, 157.67, 138.71, 133.67, 129.85, 129.79, 128.69, 127.73, 127.65, 127.30, 125.79, 120.30, 112.20, 110.67, 101.05, 90.83, 77.42, 54.81, 54.49, 46.95, 36.40, 35.09.</div></div></div><div id="sec6_16_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i85" class="anchor-spacer"></div><h4 class="article-section__title" id="_i85"> Synthesis of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Chloro-3a-(4-cyanophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>11</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0080.gif" alt="" id="dgr4" /></img><div id="sec6_16_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> (<i>E</i>)-3-(4-Bromophenyl)-1-(4-chloro-2-hydroxyphenyl)prop-2-en-1-one (<b>S10</b>)</h5><div class="NLM_p last">To a solution of 1-(4-chloro-2-hydroxyphenyl)ethan-1-one (<b>71</b>) (5.0 g, 29 mmol) in methanol (10 mL), sodium hydroxide (3.5 g, 88 mmol) was added, followed by 4-bromobenzaldehyde (5.4 g, 30 mmol). The reaction mixture was heated to reflux at 90 °C for 2 h. Then, the mixture was cooled and the solid was collected by filtration, washed with water, and dried under high vacuum to afford (<i>E</i>)-3-(4-bromophenyl)-1-(4-chloro-2-hydroxyphenyl)prop-2-en-1-one (<b>S10</b>) as a yellow solid. Yield: 10.0 g (29.6 mmol, quant.). MS (ESI) <i>m</i>/<i>z</i>: 337.12 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.56 (d, <i>J</i> = 16.1 Hz, 1H), 7.66–7.47 (m, 5H), 7.17 (d, <i>J</i> = 9.9 Hz, 1H), 6.22 (d, <i>J</i> = 12.7 Hz, 1H), 5.91 (d, <i>J</i> = 7.4 Hz, 1H).</div></div><div id="sec6_16_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> 2-(4-Bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-chromen-4-one (<b>74</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-3-(4-bromophenyl)-1-(4-chloro-2-hydroxyphenyl)prop-2-en-1-one (<b>S10</b>) (10.0 g, 29.6 mmol) in ethanol (10 mL) at room-temperature, sodium hydroxide (3.5 g, 88 mmol, 10% aq solution) and subsequently hydrogen peroxide (30% aq solution, 2.0 mL, 2.22 g, 0.66 g H<sub>2</sub>O<sub>2</sub>, 19.6 mmol) were added. The reaction mixture was stirred for 2 h at room temperature (reaction is exothermic). Then, it was cooled and neutralized to pH ≈ 7 by addition of 6 N hydrochloric acid. The resulting precipitate was collected by filtration and dried under vacuum to afford 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-chromen-4-one (<b>74</b>) as a pale yellow solid. Yield: 5.0 g (14 mmol, 47%). MS (ESI) <i>m</i>/<i>z</i>: 351.09 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 8.6 Hz, 2H), 8.10 (d, <i>J</i> = 8.6 Hz, 1H), 7.99 (s, 1H), 7.78 (d, <i>J</i> = 8.6 Hz, 2H), 7.51 (d, <i>J</i> = 8.5 Hz, 1H).</div></div><div id="sec6_16_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> <i>rac</i>-Methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-Bromophenyl)-8-Chloro-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S11</b>)</h5><div class="NLM_p last">A solution of 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-chromen-4-one (<b>74</b>) (5.0 g, 14 mmol) and methyl cinnamate (<b>55</b>) (23.0 g, 142 mmol) in dichloromethane (100 mL), acetonitrile (60 mL), and methanol (60 mL) was irradiated under 400 W UV light for 48 h in a UV reactor flask. Then, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with 5% methanol in dichloromethane. The desired fractions were concentrated under reduced pressure to afford methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-bromophenyl)-8-chloro-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S11</b>) as a brown solid. Yield: 3.5 g, crude.</div></div><div id="sec6_16_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> <i>rac</i>-Methyl (3<i>S</i>, 3a<i>R</i>, 8b<i>R</i>)-3a-(4-Bromophenyl)-6-Chloro-8b-hydroxy-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S12</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-bromophenyl)-8-chloro-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S11</b>) (3.5 g) was suspended in methanol (20 mL), treated with 25% sodium methoxide in methanol (8.0 mL, 7.6 g solution; 1.9 g NaOMe, 35 mmol), and heated at 90 °C for 3 h. Then, the solvent was removed under reduced pressure. The crude product was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-3a-(4-bromophenyl)-6-chloro-8b-hydroxy-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S11</b>) as a brown solid. Yield: 3.0 g, crude.</div></div><div id="sec6_16_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Bromophenyl)-6-Chloro-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>75</b>)</h5><div class="NLM_p last">A solution of crude <i>rac</i>-methyl (3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-3a-(4-bromophenyl)-6-chloro-8b-hydroxy-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S12</b>) (3.0 g) in acetonitrile (50 mL) was cooled to 0 °C, and acetic acid (3.3 mL, 3.5 g, 58 mmol) and sodium triacetoxyborohydride (7.4 g, 35 mmol) were added. The resulting mixture was stirred for 6 h at room temperature. Then, the mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated and dried over sodium sulfate, filtered, and concentrated to give the crude product which was purified by silica gel column chromatography eluting with 2–3% in methanol in dichloromethane. The desired fractions were concentrated to afford <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-6-chloro-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>75</b>) as a yellow solid. Yield: 2.2 g (4.3 mmol, 31% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 517.12 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.35 (d, <i>J</i> = 8.0 Hz, 1H), 7.25 (d, <i>J</i> = 8.4 Hz, 2H), 7.16 (s, 1H), 7.07–7.00 (m, 6H), 6.90 (d, <i>J</i> = 7.2 Hz, 2H), 5.93 (d, <i>J</i> = 5.6 Hz, 1H), 5.84 (d, <i>J</i> = 5.8 Hz, 1H), 4.72 (t, <i>J</i> = 6.1 Hz, 1H), 4.19 (d, <i>J</i> = 13.0, 1H), 4.09–4.00 (m, 2H), 3.54 (s, 3H).</div></div><div id="sec6_16_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Bromophenyl)-6-Chloro-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic Acid (<b>S13</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-6-chloro-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>75</b>) (2.2 g, 4.3 mmol) in methanol/water (3:1, 10.3 mL), lithium hydroxide (2.04 g, 85.4 mmol) was added. The reaction mixture was stirred for 16 h at room temperature, then cooled to 0 °C and acidified with 1 N hydrochloric acid to pH ≈ 3. The resulting precipitate was collected by filtration and dried under high vacuum to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-6-chloro-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S13</b>) as an off-white solid. Yield: 2.0 g (4.0 mmol, 93%). MS (ESI) <i>m</i>/<i>z</i>: 503.02 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.18 (s, 1H), 7.34 (d, <i>J</i> = 8.0 Hz, 1H), 7.26 (d, <i>J</i> = 10.2 Hz, 2H), 7.23 (s, 1H), 7.15–6.99 (m, 6H), 6.91 (d, <i>J</i> = 7.2 Hz, 2H), 5.76 (t, <i>J</i> = 5.8 Hz, 1H), 5.68 (d, <i>J</i> = 11.6 Hz, 1H), 4.68 (t, <i>J</i> = 5.9 Hz, 1H), 4.18–4.02 (m, 1H), 3.93–3.79 (m, 1H).</div></div><div id="sec6_16_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Bromophenyl)-6-chloro-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S14</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-6-chloro-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S13</b>) (2.0 g, 4.0 mmol) in dichloromethane (50 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.15 g, 6.00 mmol), hydroxybenzotriazole (0.9 g, 7 mmol) and Hünig’s base (1.5 g, 12 mmol) were added at 0 °C. The reaction mixture was stirred for 5 min at this temperature. Dimethylamine hydrochloride (3.25 g, 39.9 mmol) was then added at same temperature. The mixture was stirred for 16 h at room temperature. It was next diluted with dichloromethane and washed with cold water. The organic layer was separated and dried over sodium sulfate, filtered and concentrated to give the crude product, which was purified by silica gel column chromatography eluting with 70–90% ethyl acetate in hexane to afford (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-6-chloro-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S14</b>) as yellow solid. Yield: 1.8 g (3.4 mmol, 85%). MS (ESI) <i>m</i>/<i>z</i>: 528.15 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.44 (d, <i>J</i> = 8.0 Hz, 1H), 7.28 (d, <i>J</i> = 8.6 Hz, 2H), 7.18 (d, <i>J</i> = 1.6 Hz, 1H), 7.12 (d, <i>J</i> = 8.6 Hz, 2H), 7.05–6.99 (m, 4H), 6.84 (d, <i>J</i> = 7.1 Hz, 2H), 5.61 (d, <i>J</i> = 6.0 Hz, 1H), 5.57 (s, 1H), 4.87 (t, <i>J</i> = 7.3 Hz, 1H), 4.23 (d, <i>J</i> = 13.1 Hz, 1H), 4.08–4.02 (m, 1H), 3.20 (s, 3H), 2.71 (s, 3H).</div></div><div id="sec6_16_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Chloro-3a-(4-cyanophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>11</b>)</h5><div class="NLM_p last">To a solution of (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-6-chloro-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S14</b>) (1.0 g, 1.9 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10 mL), zinc cyanide (0.33 g, 2.8 mmol) was added. The mixture was purged with argon for 5 min, after which tetrakis(triphenylphosphine)palladium(0) (0.43 g, 0.37 mmol) was added. The mixture was purged with argon for an additional 5 min and then stirred for 2 h at 120 °C. Afterward, the reaction mixture was cooled to room temperature and filtered through Celite. The filtrate was washed with water and the organic layer was concentrated under reduced pressure. The crude product was purified by preparative HPLC to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-chloro-3a-(4-cyanophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl 2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>11</b>) as an off-white solid. Yield: 0.13 g (0.27 mmol, 14%). MS (ESI) <i>m</i>/<i>z</i>: 475.17 [M + 1]<sup>+</sup>; UPLC 97.95%; HRMS (ESI): calcd, 475.1419 [M + H]<sup>+</sup>; found, 475.1431; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.56 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 8.0 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.20 (d, <i>J</i> = 1.6 Hz, 1H), 7.07–6.96 (m, 4H), 6.84 (d, <i>J</i> = 7.2 Hz, 2H), 5.68 (s, 1H), 5.63 (d, <i>J</i> = 6.0 Hz, 1H), 4.88 (t, <i>J</i> = 6.8 Hz, 1H), 4.30 (d, <i>J</i> = 13.2 Hz, 1H), 4.14 (dd, <i>J</i> = 13.1, 7.8 Hz, 1H), 3.22 (s, 3H), 2.73 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.16, 158.48, 141.84, 138.10, 134.20, 133.88, 130.58, 129.33, 129.10, 128.56, 127.56, 127.52, 126.06, 120.74, 110.72, 109.17, 101.10, 91.67, 77.54, 55.09, 47.19, 36.46, 35.15.</div></div></div><div id="sec6_16_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i94" class="anchor-spacer"></div><h4 class="article-section__title" id="_i94"> Synthesis of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Cyanophenyl)-1,8b-dihydroxy-6-methoxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>12</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0091.gif" alt="" id="dgr5" /></img><div id="sec6_16_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> (<i>E</i>)-1-(4-(Benzyloxy)-2-hydroxyphenyl)-3-(4-bromophenyl)prop-2-en-1-one (<b>S15</b>)</h5><div class="NLM_p last">To a solution of 1-(4-(benzyloxy)-2-hydroxyphenyl)ethan-1-one (<b>76</b>) (50.0 g, 206 mmol) in methanol (300 mL), sodium hydroxide (24.79 g, 619.8 mmol) was added followed by 4-bromobenzaldehyde (38.29 g, 207.0 mmol). The reaction mixture was refluxed for 1 h. Then, it was cooled, and the solid was obtained by filtration, washed with water, and dried under high vacuum to afford (<i>E</i>)-1-(4-(benzyloxy)-2-hydroxyphenyl)-3-(4-bromophenyl)prop-2-en-1-one (<b>S15</b>) as a yellow solid. Yield: 34.0 g (83.1 mmol, 40%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.22 (d, <i>J</i> = 15.3 Hz, 1H), 8.10 (d, <i>J</i> = 9.4 Hz, 1H), 7.79 (d, <i>J</i> = 8.2 Hz, 2H), 7.64 (d, <i>J</i> = 8.2 Hz, 3H), 7.45–7.34 (m, 6H), 6.42 (s, 2H), 5.15 (s, 2H).</div></div><div id="sec6_16_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> 7-(Benzyloxy)-2-(4-bromophenyl)-3-hydroxy-4<i>H</i>-chromen-4-one (<b>77</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(4-(benzyloxy)-2-hydroxyphenyl)-3-(4-bromophenyl)prop-2-en-1-one (<b>S15</b>) (34.00 g, 83.07 mmol) in ethanol (500 mL), sodium hydroxide (11.32 g, 283.0 mmol, 10% aq solution) and hydrogen peroxide (6.6 mL, 0.28 mol) were subsequently added at room temperature. The reaction mixture was stirred for 2 h at room temperature (reaction is exothermic!). Afterward, the reaction mixture was cooled and neutralized to pH ≈ 7 by addition of 5 N hydrochloric acid. The solid precipitate was collected by filtration and dried under vacuum to afford 7-(benzyloxy)-2-(4-bromophenyl)-3-hydroxy-4<i>H</i>-chromen-4-one (<b>77</b>) as a pale yellow solid. Yield: 16.0 g (37.8 mmol, 46%). MS (ESI) <i>m</i>/<i>z</i>: 422 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.75 (s, 1H), 8.16 (d, <i>J</i> = 8.2 Hz, 2H), 8.01 (d, <i>J</i> = 8.7 Hz, 1H), 7.77 (d, <i>J</i> = 8.2 Hz, 2H), 7.51–7.36 (m, 6H), 7.11 (d, <i>J</i> = 8.3 Hz, 1H), 5.27 (s, 2H).</div></div><div id="sec6_16_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> <i>rac</i>-(3<i>R</i>,4<i>S</i>,5<i>S</i>)-8-(Benzyloxy)-2-(4-bromophenyl)-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepin-4-yl Acetate (<b>S16</b>)</h5><div class="NLM_p last">A solution of 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>77</b>) (7.00 g, 16.5 mmol) and methyl cinnamate (<b>55</b>) (26.8 g, 165 mmol) in dichloromethane (100 mL), acetonitrile (50 mL), and methanol (50 mL) was irradiated in a UV reactor flask for 24 h under 400 W UV light. The solvent was then removed under reduced pressure and the remaining solid was purified over a plug of silica gel by eluting the compound with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(3<i>R</i>,4<i>S</i>,5<i>S</i>)-8-(benzyloxy)-2-(4-bromophenyl)-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepin-4-yl acetate (<b>S16</b>). Yield: 8.8 g, crude.</div></div><div id="sec6_16_4_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> <i>rac</i>-Methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-8b-hydroxy-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S17</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-(3<i>R</i>,4<i>S</i>,5<i>S</i>)-8-(benzyloxy)-2-(4-bromophenyl)-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepin-4-yl acetate (<b>S16</b>) (8.8 g) was suspended in methanol (50 mL), treated with sodium methoxide (25% in methanol, 8.8 mL, 8.3 g solution; 2.1 g, 38 mmol, NaOMe), and heated to 90 °C for 3 h. Next, the solvent was removed under reduced pressure. The crude product was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over anhydrous sodium sulphate, and concentrated under reduced pressure to give <i>rac</i>-methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-8b-hydroxy-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S17</b>) as brown oil. Yield: 8.9 g, crude.</div></div><div id="sec6_16_4_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>78</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (18.41 g, 86.86 mmol) and crude <i>rac</i>-methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-8b-hydroxy-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S17</b>) (8.30 g) in acetonitrile (100 mL) at 0 °C, acetic acid (8.64 mL, 9.06 g, 150 mmol) was added. The resulting mixture was stirred for 4 h at room temperature and then partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product which was purified by silica gel column chromatography by eluting with 30% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>78</b>) as an off-white solid. Yield: 2.6 g (4.4 mmol, 29% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 585 [M – 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.47 (d, <i>J</i> = 7.3 Hz, 2H), 7.41 (t, <i>J</i> = 7.2 Hz, 2H), 7.35–7.23 (m, 4H), 7.07–6.99 (m, 5H), 6.88 (d, <i>J</i> = 7.2 Hz, 2H), 6.73 (s, 1H), 6.61 (d, <i>J</i> = 2.0 Hz, 1H), 5.75 (t, <i>J</i> = 3.7 Hz, 1H), 5.46 (s, 1H), 5.21 (s, 2H), 4.71 (t, <i>J</i> = 6.4 Hz, 1H), 4.14 (d, <i>J</i> = 13.9 Hz, 1H), 4.05–3.96 (m, 1H), 3.52 (s, 3H).</div></div><div id="sec6_16_4_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(Benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic Acid (<b>S18</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>78</b>) (2.6 g, 4.4 mmol) in tetrahydrofuran and water (3:1, 80 mL), lithium hydroxide (2.5 g, 104 mmol) was added. The reaction mixture was stirred for 16 h at room temperature, then cooled to 0 °C and acidified with 1 M hydrochloric acid to pH ≈ 3. The precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S18</b>) as an off-white solid. Yield: 1.79 g (3.12 mmol, 71%); MS (ESI) <i>m</i>/<i>z</i>: 571.27 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_4_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(Benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S19</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S18</b>) (1.79 g, 3.12 mmol) in dichloromethane (25 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.797 g, 9.374 mmol), 1-hydroxybenzotriazole (1.29 g, 9.55 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (3.19 mL, 18.3 mmol) were added at 0 °C. The mixture was stirred for 5 min. Dimethylamine hydrochloride (1.29 g, 15.8 mmol) was then added at the same temperature, and the reaction was stirred for 16 h at room temperature. Then, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated and dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was recrystallized from ethanol to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>11</b>) as a white solid. Yield: 1.29 g (2.14 mmol, 69%.) MS (ESI) <i>m</i>/<i>z</i>: 600.02 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.47 (d, <i>J</i> = 7.2 Hz, 2H), 7.42 (t, <i>J</i> = 7.1 Hz, 2H), 7.36–7.26 (m, 4H), 7.13 (d, <i>J</i> = 8.5 Hz, 2H), 7.03–6.96 (m, 3H), 6.82 (d, <i>J</i> = 7.2 Hz, 2H), 6.75 (d, <i>J</i> = 2.0 Hz, 1H), 6.59 (dd, <i>J</i> = 2.0 Hz, 8.3 Hz, 1H), 5.47 (d, <i>J</i> = 5.9 Hz, 1H), 5.29 (s, 1H), 5.14 (s, 2H), 4.87 (t, <i>J</i> = 7.16 Hz, 1H). 4.21 (d, <i>J</i> = 13.1 Hz, 1H), 4.05–3.99 (m, 1H), 3.20 (s, 3H), 2.67 (s, 3H).</div></div><div id="sec6_16_4_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Bromophenyl)-1,6,8b-trihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S20</b>)</h5><div class="NLM_p last">A flask containing ethyl acetate (40 mL) was charged with <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S19</b>) (1.08 g, 1.80 mmol). Palladium hydroxide (0.246 g, 1.75 mmol, 50% wet) was added at room temperature under nitrogen. The reaction was flushed with hydrogen gas twice and stirred at room temperature for 6 h under hydrogen pressure. The reaction mixture was then passed through Celite, and the filtrate was concentrated under reduced pressure to afford (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-1,6,8b-trihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>12</b>) as a brown oil. Yield: 1.0 g (crude), MS (ESI) <i>m</i>/<i>z</i>: 509.98 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_4_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Bromophenyl)-1,6,8b-trihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S21</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-1,6,8b-trihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S20</b>) (0.8 g, 2 mmol) in acetone (30 mL), methyl iodide (0.300 g, 2.11 mmol), and potassium carbonate (0.552 g, 3.99 mmol) were added. The mixture was stirred for 16 h at room temperature, then diluted with dichloromethane, and washed with cold water. The organic layer was separated and dried over anhydrous sodium sulphate, filtered, and concentrated to give crude <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-1,6,8b-trihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S21</b>) as an off-white solid. Yield: 0.800 g (1.53 mmol, 77%); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.35 (d, <i>J</i> = 8.3 Hz, 1H), 7.28 (d, <i>J</i> = 8.4 Hz, 2H), 7.12 (d, <i>J</i> = 8.4, 2H), 7.05–6.96 (m, 3H), 6.83 (d, <i>J</i> = 7.1 Hz, 2H), 6.67 (d, <i>J</i> = 1.8 Hz, 1H), 6.53–6.50 (dd, <i>J</i> = 2.1 Hz, 8.3 Hz, 1H), 5.47 (d, <i>J</i> = 6.0 Hz, 1H), 5.29 (s, 1H), 4.86 (t, <i>J</i> = 6.9 Hz, 1H), 4.20 (d, <i>J</i> = 13.3, 1H), 4.04–3.83 (m, 1H), 3.78 (s, 3H), 3.24 (s, 3H), 2.72 (s, 3H).</div></div><div id="sec6_16_4_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Cyanophenyl)-1,8b-dihydroxy-6-methoxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>12</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-bromophenyl)-1,8b-dihydroxy-6-methoxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S21</b>) (0.20 g, 0.38 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (2 mL), zinc cyanide (0.134 g, 1.14 mmol) was added. The mixture was degassed with argon for 5 min. Tetrakis(triphenylphosphine)palladium(0) (0.044 g, 0.038 mmol) was added to the reaction mixture which was then degassed for another 5 min and then heated at 120 °C for 1 h. Afterward, the reaction was cooled to room temperature and filtered through Celite. The filtrate was concentrated and treated with ice-cold water. The resulting crude precipitate was collected by filtration and purified by column chromatography in 100–200 silica mesh by eluting with 20–70% ethyl acetate in hexanes. Then, the desired fractions were concentrated under vacuum to afford (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-cyanophenyl)-1,8b-dihydroxy-6-methoxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>12</b>) as an off-white solid. Yield: 0.08 g (0.17 mmol, 45%). HRMS (ESI): calcd, 471.1914 [M + H]<sup>+</sup>; found, 471.1929; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.55 (d, <i>J</i> = 8.3 Hz, 2H), 7.36 (dd, <i>J</i> = 8.3 Hz, 14.7 Hz, 3H), 7.04–6.95 (m, 3H), 6.83 (d, <i>J</i> = 7.2 Hz, 2H), 6.69 (d, <i>J</i> = 2 Hz, 1H), 6.52 (dd, <i>J</i> = 2.2 Hz, 8.4 Hz,1H), 5.49 (d, <i>J</i> = 5.9 Hz, 1H), 5.39 (s, 1H), 4.88 (t, <i>J</i> = 6.4 Hz, 1H), 4.27 (d, <i>J</i> = 13.2 Hz, 1H), 4.08 (dd, <i>J</i> = 8.0, 13.2 Hz, 1H), 3.78 (s, 3H), 3.21 (s, 3H), 2.72 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.37, 161.33, 158.84, 142.40, 138.41, 130.53, 128.64, 128.62, 127.52, 127.47, 125.97, 121.89, 118.91, 108.98, 107.31, 100.80, 95.98, 91.75, 77.62, 55.39, 54.93, 47.10, 36.44, 35.13.</div></div></div><div id="sec6_16_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i105" class="anchor-spacer"></div><h4 class="article-section__title" id="_i105"> Synthesis of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Cyano-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>13</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0094.gif" alt="" id="dgr6" /></img><div id="sec6_16_5_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> (<i>E</i>)-1-(4-(Benzyloxy)-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S22</b>)</h5><div class="NLM_p last">To a solution of 1-(4-(benzyloxy)-2-hydroxyphenyl)ethan-1-one (<b>76</b>) (25.0 g, 103 mmol) in methanol (117 mL), sodium hydroxide (12.4 g, 310 mmol) and <i>p</i>-methoxybenzaldehyde (14.0 g, 103 mmol) were added successively. The reaction mixture was refluxed for 30 min and then cooled. The precipitated solid was collected by filtration, washed with water, and dried under high vacuum to afford (<i>E</i>)-1-(4-(benzyloxy)-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S22</b>) as a yellow solid. Yield: 30.0 g (83.2 mmol, 81%). MS (ESI) <i>m</i>/<i>z</i>: 361 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.1 (br s, 1H), 7.97 (d, <i>J</i> = 14.4 Hz, 1H), 7.85 (d, <i>J</i> = 7.0 Hz, 2H), 7.75 (d, <i>J</i> = 15.1 Hz, 1H), 7.47–7.34 (m, 6H), 7.02 (d, <i>J</i> = 7.5 Hz, 2H), 6.50 (s, 2H), 5.18 (s, 2H), 3.82 (s, 3H).</div></div><div id="sec6_16_5_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> 7-(Benzyloxy)-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-one (<b>79</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(4-(benzyloxy)-2-hydroxyphenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S22</b>) (30.0 g, 83.2 mmol) in ethyl acetate (100 mL) at room temperature, sodium hydroxide (6.6 g, 170 mmol, 10% aq solution) and hydrogen peroxide (14 g, 0.41 mol, 30% aq solution) were added. The reaction mixture was stirred for 2 h at room temperature (reaction is exothermic). The reaction mixture was then cooled and neutralized to pH ≈ 7 by addition of 6 N hydrochloric acid. The resulting precipitate was collected by filtration and dried under vacuum to afford 7-(benzyloxy)-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-one (<b>79</b>) as a pale yellow solid. Yield: 18.0 g (48.1 mmol, 58%); MS (ESI) <i>m</i>/<i>z</i>: 375.27 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 7.8 Hz, 2H), 8.00 (d, <i>J</i> = 5.9 Hz, 1H), 7.51–7.49 (m, 1H), 7.42–3.88 (m, 6H), 7.17–7.12 (m, 2H), 5.27 (s, 2H), 3.85 (s, 3H).</div></div><div id="sec6_16_5_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> <i>rac</i>-Methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-8-(Benzyloxy)-5-hydroxy-2-(4-methoxyphenyl)-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S23</b>)</h5><div class="NLM_p last">A solution of 7-(benzyloxy)-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-chromen-4-one (<b>79</b>) (9.0 g, 24 mmol) and methyl cinnamate (<b>55</b>) (39.0 g, 240 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated with 400 W UV light in a UV reactor flask for 15 h. Then, the solvent was removed under reduced pressure, and the residue was purified by eluting through a plug of silica gel with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-8-(benzyloxy)-5-hydroxy-2-(4-methoxyphenyl)-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S23</b>). Yield: 15.0 g, crude.</div></div><div id="sec6_16_5_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> <i>rac</i>-Methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-(Benzyloxy)-8b-hydroxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S24</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-8-(benzyloxy)-5-hydroxy-2-(4-methoxyphenyl)-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanobenzo[<i>b</i>]oxepine-4-carboxylate (<b>S23</b>) (12.8 g) was suspended in methanol (100 mL), treated with 25% sodium methoxide in methanol (20 mL solution, 4.7 g NaOMe, 87 mmol), and heated at 70 °C for 1 h. The solvent was then removed under reduced pressure, and the crude product was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-(benzyloxy)-8b-hydroxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S24</b>). Yield: 10.0 g, crude.</div></div><div id="sec6_16_5_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(Benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>80</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>R</i>)-6-(benzyloxy)-8b-hydroxy-3a-(4-methoxyphenyl)-1-oxo-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S24</b>) (10.0 g) was added to a solution of sodium triacetoxyborohydride (23.6 g, 111 mmol) in acetonitrile (200 mL) and acetic acid (11 mL, 190 mmol). The resulting mixture was stirred for 4 h at room temperature. Then, it was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product which was purified by silica gel column chromatography eluting with 60% ethyl acetate in hexanes. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>80</b>) as a pale yellow solid. Yield: 7.0 g (13.0 mmol, 63% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 539.33 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.47 (d, <i>J</i> = 7.0 Hz, 2H), 7.41 (t, <i>J</i> = 7.5 Hz, 2H), 7.35 (d, <i>J</i> = 7.0 Hz, 1H), 7.30 (d, <i>J</i> = 8.3 Hz, 1H), 7.05–7.01 (m, 4H), 6.82 (d, <i>J</i> = 7.2 Hz, 2H), 6.72 (s, 1H), 6.63 (d, <i>J</i> = 8.6 Hz, 2H), 6.58 (d, <i>J</i> = 8.2 Hz, 1H), 5.73 (d, <i>J</i> = 5.8, 1H), 5.29 (s, 1H), 5.13 (s, 2H), 4.75 (t, <i>J</i> = 6.6 Hz, 1H), 4.02 (s, 1H), 3.86 (dd, <i>J</i> = 7.2 Hz, 13.9 Hz, 1H), 3.62 (s, 3H), 3.51 (s, 3H).</div></div><div id="sec6_16_5_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(Benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic Acid (<b>S25</b>)</h5><div class="NLM_p last">To a solution of methyl <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>80</b>) (4.0 g, 7.4 mmol) in methanol/water (3:1, 120 mL), lithium hydroxide (4.2 g, 180 mmol) was added. The reaction mixture was stirred for 3 h at room temperature, then cooled to 0 °C and acidified with 5 N hydrochloric acid to pH ≈ 3. The resulting precipitate was collected by filtration and dried under high vacuum to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S25</b>) as an off-white solid. Yield: 6.0 g (crude). MS (ESI) <i>m</i>/<i>z</i>: 523.1 [M – 1]<sup>−</sup>;<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.47 (d, <i>J</i> = 7.5 Hz, 2H), 7.41 (t, <i>J</i> = 7.7 Hz, 2H), 7.34 (d, <i>J</i> = 7.2 Hz, 1H), 7.21 (d, <i>J</i> = 8.2 Hz, 1H), 7.06–6.96 (m, 7H), 6.65 (s, 1H), 6.58 (d, <i>J</i> = 8.8 Hz 2H), 6.53 (d, <i>J</i> = 9.5 Hz, 1H), 5.11 (s, 2H), 5.03 (s, 1H), 4.45 (d, <i>J</i> = 4.92 Hz, 1H), 4.02 (d, <i>J</i> = 13.2 Hz, 1H), 3.60 (s, 3H), 3.51–3.42 (m, 1H).</div></div><div id="sec6_16_5_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(Benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S26</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (4.0 g, 7.6 mmol) in dichloromethane (40 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (4.38 g, 22.8 mmol), hydroxybenzotriazole (3.09 g, 20.2 mmol), and DIPEA (8.0 mL, 45.9 mmol) were added at 0 °C. This mixture was stirred for 5 min at 0 °C. Then, dimethylamine hydrochloride (3.09 g, 38.16 mmol) was added, and the mixture was stirred for 8 h at room temperature. Afterward, the mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated and dried over sodium sulfate, filtered, and concentrated to give the crude product which was purified by silica gel column chromatography eluting with 70–90% ethyl acetate in hexane to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S26</b>) as a white solid. Yield: 4 g (7.2 mmol, 95% over two steps). MS (ESI) <i>m</i>/<i>z</i>: 552.25 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.48 (d, <i>J</i> = 7.3 Hz, 2H), 7.43–7.29 (m, 4H), 7.07 (d, <i>J</i> = 8.4 Hz, 2H), 7.03–6.97 (m, 3H), 6.78 (d, <i>J</i> = 6.9 Hz, 2H), 6.73 (s, 1H), 6.66 (d, <i>J</i> = 8.3 Hz, 2H), 6.57 (d, <i>J</i> = 8.0 Hz, 1H), 5.45 (d, <i>J</i> = 5.9 Hz, 1H), 5.13 (s, 3H), 4.89 (t, <i>J</i> = 6.4 Hz, 1H), 4.13 (d, <i>J</i> = 13 Hz, 1H), 3.94 (dd, <i>J</i> = 3.9 Hz, 12.3 Hz, 1H), 3.64 (s, 3H), 3.17 (s, 3H), 2.71 (s, 3H).</div></div><div id="sec6_16_5_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,6,8b-trihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S27</b>)</h5><div class="NLM_p last">To a solution of (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S26</b>) (2.0 g, 3.6 mmol) in ethyl acetate (100 mL), palladium hydroxide (0.66 g, 4.7 mmol) was added. The reaction mixture was stirred under a hydrogen atmosphere for 2 h at room temperature and then filtered through Celite and concentrated under vacuum to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,6,8b-trihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S27</b>) as an off-white solid. Yield: 1.5 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 460.4 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_5_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-2-(dimethylcarbamoyl)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-6-yl Trifluoromethanesulfonate (<b>S28</b>)</h5><div class="NLM_p last">To a solution of crude <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-1,6,8b-trihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<b>S27</b>) (1.4 g) in dichloromethane (100 mL) at 0 °C, DIPEA (1.28 mL, 7.35 mmol) was added. Triflic anhydride (3.34 mmol) diluted in dichloromethane (10 mL) was added dropwise to the reaction mixture while it was stirred at −40 °C for 1 h. Then, the reaction mixture was neutralized with saturated sodium bicarbonate solution and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to afford (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-2-(dimethylcarbamoyl)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-6-yl trifluoromethanesulfonate (<b>S28</b>) as an off-white solid. Yield: 1.0 g (1.7 mmol, 56% over two steps). MS (ESI) <i>m</i>/<i>z</i>: 592.0 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_5_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Cyano-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>13</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-2-(dimethylcarbamoyl)-1,8b-dihydroxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-6-yl trifluoromethanesulfonate (<b>S28</b>) (0.50 g, 0.84 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (20 mL), zinc cyanide (0.3 g, 3 mmol) was added. The reaction mixture was degassed with argon for 15 min. Tetrakis(triphenylphosphine)palladium(0) (0.09 g, 0.084 mmol) was added to the reaction mixture. The mixture was degassed for an additional 5 min and then heated at 110 °C for 1 h. Next, the reaction mixture was cooled to room temperature and filtered through Celite. The filtrate was concentrated and treated with ice-cold water, and the resulting precipitate was collected by filtration. The crude product was purified by silica gel column chromatography eluting with 90% ethyl acetate in hexanes to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-cyano-1,8b-dihydroxy-3a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>13</b>) as an off-white solid. Yield: 0.10 g (0.21 mmol, 25%), MS (ESI) <i>m</i>/<i>z</i>: 471.17 [M + 1]<sup>+</sup>; UPLC: 96.39%; HRMS (ESI): calcd, 471.1914 [M + H]<sup>+</sup>; found, 471.1927; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.63 (d, <i>J</i> = 7.7 Hz, 1H), 7.56 (s, 1H), 7.41 (d, <i>J</i> = 7.3 Hz, 1H), 7.08 (d, <i>J</i> = 8.6 Hz, 2H), 7.04–6.98 (m, 3H), 6.80 (d, <i>J</i> = 7.1 Hz, 2H), 6.67 (d, <i>J</i> = 8.8 Hz, 2H), 5.70 (d, <i>J</i> = 6.0 Hz, 1H), 5.66 (s, 1H), 4.91 (t, <i>J</i> = 7.0 Hz, 1H), 4.15 (d, <i>J</i> = 13.1 Hz, 1H), 4.0 (dd, <i>J</i> = 7.88 Hz, 13.1 Hz, 1H), 3.64 (s, 3H), 3.19 (s, 3H), 2.71 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.24, 157.79, 157.75, 138.51, 136.50, 129.71, 128.69, 127.74, 127.34, 127.31, 125.86, 124.67, 119.01, 113.79, 112.24, 111.75, 100.95, 91.06, 77.52, 54.82, 54.70, 47.05, 36.41, 35.10.</div></div></div><div id="sec6_16_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Synthesis of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>14</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0095.gif" alt="" id="dgr7" /></img><div id="sec6_16_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(Benzyloxy)-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>81</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-bromophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>78</b>) (1.50 g, 2.55 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5.0 mL), zinc cyanide (0.899 g, 7.65 mmol) was added. The reaction mixture was degassed with argon for 5 min. Then, tetrakis(triphenylphosphine)palladium (0.442 g, 0.382 mmol) was added. The mixture was degassed for an additional 5 min and then incubated at 100 °C for 1 h in a microwave reactor. The mixture was then filtered through Celite and washed with ethyl acetate. The filtrate was concentrated, ice water was added, and the resulting precipitate was collected by filtration and washed with ethanol and pentane to afford methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>81</b>) as a white solid. Yield: 1.1 g (2.1 mmol, 81%). MS (ESI) <i>m</i>/<i>z</i>: 332.3 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.47 (d, <i>J</i> = 7.2 Hz, 2H), 7.41 (t, <i>J</i> = 7.1 Hz, 2H), 7.36–7.30 (m, 3H), 7.25 (d, <i>J</i> = 8.4 Hz, 1H), 7.07–6.98 (m, 3H), 6.89 (d, <i>J</i> = 7.1 Hz, 2H), 6.76 (d, <i>J</i> = 1.9 Hz, 1H), 6.61 (d, <i>J</i> = 8.3 Hz, 1H), 5.73 (s, 1H), 5.57 (s, 1H), 5.13 (s, 2H). 4.71 (t, <i>J</i> = 6.5 Hz, 1H), 3.54 (s, 3H).</div></div><div id="sec6_16_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Cyanophenyl)-1,6,8b-trihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S29</b>)</h5><div class="NLM_p last">A flask containing ethyl acetate (10 mL) was charged with <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-(benzyloxy)-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>81</b>) (1.1 g, 2.1 mmol), and palladium hydroxide (50% wet, 0.579 g, 4.12 mmol) was added at room temperature. The reaction mixture was purged with hydrogen twice and stirred under hydrogen pressure for 16 h. Then, the reaction mixture was filtered through Celite. The filtrate was concentrated under reduced pressure to afford <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-cyanophenyl)-1,6,8b-trihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S29</b>) as a white solid. Yield: 0.76 g (1.7 mmol, 81%). MS (ESI) <i>m</i>/<i>z</i>: 442.00 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.52 (s, 1H), 7.49 (d, <i>J</i> = 8.1 Hz, 2H), 7.25 (d, <i>J</i> = 8.3 Hz, 2H), 7.13 (d, <i>J</i> = 8.1 Hz, 1H), 7.06–6.99 (m, 3H), 6.87 (d, <i>J</i> = 7.2 Hz, 2H), 6.42 (d, <i>J</i> = 1.7 Hz, 1H), 6.37 (d, <i>J</i> = 8.32 Hz, 1H), 5.66 (d, <i>J</i> = 5.8 Hz, 1H), 5.46 (s, 1H), 4.68 (t, <i>J</i> = 6.4 Hz, 1H), 4.20 (d, <i>J</i> = 13.4 Hz, 1H), 4.01 (dd, <i>J</i> = 6.3 Hz, 13.2 Hz, 1H), 3.58 (s, 3H).</div></div><div id="sec6_16_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-Cyanophenyl)-1,8b-dihydroxy-3-phenyl-6-(((trifluoro-methyl)sulfonyl)oxy)-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S30</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-cyanophenyl)-1,6,8b-trihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S19</b>) (0.76 g, 1.7 mmol) in dichloromethane and tetrahydrofuran (1:1, 10.0 mL) at −78 °C, DIPEA (0.350 mL, 2.00 mmol) and triflic anhydride (0.307 mL, 1.82 mmol) were added successively. The reaction mixture was stirred for 3 h at −78 °C. Then, the reaction was quenched with sodium bicarbonate solution (5.0 mL) and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-6-(((trifluoromethyl)-sulfonyl)oxy)-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S30</b>) as a brown solid. Yield: 0.50 g (0.87 mmol, 51%). MS (ESI) <i>m</i>/<i>z</i>: 574.36 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.54–7.48 (m, 3H), 7.33–7.30 (m, 3H), 7.09–6.99 (m, 4H), 6.92 (d, <i>J</i> = 7.4 Hz, 1H), 5.98–5.96 (m, 2H), 5.75 (s, 1H), 4.74 (t, <i>J</i> = 6.0 Hz, 1H), 4.28 (d, <i>J</i> = 13.8 Hz, 1H), 4.13 (dd, <i>J</i> = 6.1, 13.7 Hz, 1H), 3.55 (s, 3H).</div></div><div id="sec6_16_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> <i>rac</i>-Methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>82</b>)</h5><div class="NLM_p last">To a solution of methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-6-(((trifluoromethyl)-sulfonyl)oxy)-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>S30</b>) (0.50 g, 0.87 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5.0 mL), zinc cyanide (0.305 g, 2.60 mmol) was added. The reaction mixture was degassed with argon for 5 min. Tetrakis(triphenylphosphine)palladium (0.442 g, 0.382 mmol) was added and degassing was continued for an additional 5 min. Then, the mixture was irradiated at 120 °C for 1 h in a microwave reactor. The mixture was filtered through Celite, washed with ethyl acetate, and concentrated to give the crude product which was purified by silica gel column chromatography eluting with 30% ethyl acetate in hexanes. The desired fractions were concentrated under reduced pressure to afford methyl (1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>82</b>) as a white solid. Yield: 0.34 g (0.75 mmol, 86%), MS (ESI) <i>m</i>/<i>z</i>: 451.03 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic Acid (<b>S31</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylate (<b>82</b>) (0.34 g, 0.75 mmol) in tetrahydrofuran and water (3:1, 10 mL), lithium hydroxide (0.40 g, 17 mmol) was added. The reaction mixture was stirred for 16 h at room temperature, then cooled to 0 °C, and acidified with citric acid solution to pH ≈ 2–3. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S31</b>) as a white solid. Yield: 0.23 g (0.52 mmol, 69%). MS (ESI) <i>m</i>/<i>z</i>: 437.40 [M – 1]<sup>−</sup>. 1H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.11 (s, 1H), 7.58 (s, 1H), 7.52–7.48 (s, 3H), 7.44 (d, <i>J</i> = 7.4 Hz, 1H), 7.29 (d, <i>J</i> = 8.3 Hz, 2H), 7.08–7.04 (m, 2H), 7.00 (d, <i>J</i> = 6.9 Hz, 2H), 6.95 (d, <i>J</i> = 7.2 Hz, 2H), 4.70 (d, <i>J</i> = 5.7 Hz, 1H), 4.28 (d, <i>J</i> = 13.6 Hz, 1H), 4.05–3.98 (m, 2H).</div></div><div id="sec6_16_6_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-Cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>14</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxylic acid (<b>S31</b>) (0.23 g, 0.52 mmol) in dichloromethane (10 mL), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.105 g, 0.786 mmol), hydroxybenzotriazole (0.106 g, 0.786 mmol), and DIPEA (0.20 g, 1.5 mmol) were added at room temperature. The mixture was stirred for 5 min. Dimethylamine hydrochloride (0.042 g, 0.515 mmol) was then added, and stirring was continued for 16 h at room temperature. Then, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product which was purified by silica gel column chromatography eluting with 60–70% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-(1<i>R</i>,2<i>R</i>,3<i>S</i>,3a<i>R</i>,8b<i>S</i>)-6-cyano-3a-(4-cyanophenyl)-1,8b-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-3-phenyl-2,3,3a,8b-tetrahydro-1<i>H</i>-cyclopenta[<i>b</i>]benzofuran-2-carboxamide (<i>rac</i>-<b>14</b>) as a white solid. Yield: 0.10 g (0.21 mmol, 41%). MS (ESI) <i>m</i>/<i>z</i>: 466.16 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 466.1761 [M + H]<sup>+</sup>; found, 466.1784; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.61–7.57 (m, 3H), 7.55 (s, 1H), 7.44 (d, <i>J</i> = 7.7 Hz, 1H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.05–6.97 (m, 3H), 6.85 (d, <i>J</i> = 7.2 Hz, 2H),5.91 (s, 1H), 5.73 (d, <i>J</i> = 6.0 Hz, 1H), 4.90 (t, <i>J</i> = 6.9 Hz, 1H), 4.33 (d, <i>J</i> = 13.1 Hz, 1H), 4.18 (dd, <i>J</i> = 7.4 Hz, 13.2 Hz, 1H), 3.23 (s, 3H), 2.73 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.00, 157.61, 141.50, 137.92, 135.75, 130.61, 129.22, 128.54, 127.58, 127.54, 126.11, 125.10, 118.89, 118.79, 113.84, 111.97, 109.28, 100.98, 91.91, 77.66, 55.30, 47.32, 36.48, 35.17.</div></div></div><div id="sec6_16_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-Dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>5</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0096.gif" alt="" id="dgr8" /></img><div id="sec6_16_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> 3,5-Dimethoxypicolinonitrile (<b>87</b>)</h5><div class="NLM_p last">To a solution of 3,5-difluoropicolinonitrile (<b>86</b>) (50 g, 360 mmol) in methanol (80 mL), sodium methoxide (25% in methanol, 50 mL, 12 g NaOMe, 0.22 mol) was added. The reaction mixture was refluxed at 100 °C for 12 h. After completion, the solvent was removed under reduced pressure and the crude product was treated with saturated ammonium chloride solution (50 mL). The precipitated solid was collected by filtration, washed with water, and dried under vacuum to afford 3,5-dimethoxypicolinonitrile (<b>87</b>) as a white solid. Yield: 42.0 g (256 mmol, 85%). MS (ESI) <i>m</i>/<i>z</i>: 165.23 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.37 (d, <i>J</i> = 2.0 Hz, 1H), 8.02 (d, <i>J</i> = 1.9 Hz, 1H), 3.97 (s, 3H), 3.95 (s, 3H).</div></div><div id="sec6_16_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> 1-(3,5-Dimethoxypyridin-2-yl)ethan-1-one (<b>88</b>)</h5><div class="NLM_p last">To a solution of 3,5-dimethoxypicolinonitrile (<b>87</b>) (42.0 g, 256 mmol) in dry tetrahydrofuran (100 mL) at −20 °C, methyl magnesium chloride (255.8 mL, 767.4 mmol) was added dropwise over a period of 30 min. The reaction mixture was slowly brought to room temperature and stirred for additional 12 h. After completion, the reaction was quenched with 6 M hydrochloric acid, acidified to pH ≈ 3, and extracted with ethyl acetate. The organic layer was washed with 1 M sodium hydroxide solution and water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 1-(3,5-dimethoxypyridin-2-yl)ethan-1-one (<b>88</b>) as a yellow oil. Yield: 30.0 g (166 mmol, 65%). MS (ESI) <i>m</i>/<i>z</i>: 181.61 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.97 (d, <i>J</i> = 1.6 Hz, 1H), 6.81 (d, <i>J</i> = 1.7 Hz, 1H), 3.92 (s, 3H), 3.89 (s, 3H), 2.61 (s, 3H).</div></div><div id="sec6_16_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> 1-(3,5-Dihydroxypyridin-2-yl)ethan-1-one (<b>89</b>)</h5><div class="NLM_p last">A sealed tube was charged with 1-(3,5-dimethoxypyridin-2-yl)ethan-1-one (<b>88</b>) (30.0 g, 166 mmol). Hydrobromic acid (33% in acetic acid, 300 mL) was added, and the reaction mixture was heated at 150 °C for 16 h. Volatiles were then removed under reduced pressure and the crude product was basified to pH ≈ 8 using 10% sodium hydroxide. Ethyl acetate (300 mL) was added. The solution was passed through a Celite bed which was then washed with ethyl acetate (100 mL). The organic layer was separated from the combined filtrate and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 1-(3,5-dihydroxypyridin-2-yl)ethan-1-one (<b>89</b>) as a brown oil. Yield: 9.0 g (59 mmol, 35%); MS (ESI) <i>m</i>/<i>z</i>: 152.0 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.06 (s, 1H), 11.51 (br s, 1H), 7.85 (d, <i>J</i> = 1.96 Hz, 1H), 6.66 (d, <i>J</i> = 1.96 Hz, 1H), 2.59 (s, 3H).</div></div><div id="sec6_16_7_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> 1-(3-Hydroxy-5-methoxypyridin-2-yl)ethan-1-one (<b>90</b>)</h5><div class="NLM_p last">To a solution of 1-(3,5-dihydroxypyridin-2-yl)ethan-1-one (<b>89</b>) (9.0 g, 59 mmol) in acetone (100 mL) at 0 °C, potassium carbonate (24.3 g, 176 mmol) was added followed by methyl iodide (8.3 g, 58 mmol). The reaction mixture was then stirred at room temperature for 6 h, after which the solvent was distilled off and water (20 mL) was added. The aq phase was extracted with 5% methanol in dichloromethane (100 mL). The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 1-(3-hydroxy-5-methoxypyridin-2-yl)ethan-1-one (<b>90</b>) as an off-white solid. Yield: 8.5 g, crude. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.15 (s, 1H), 7.97 (d, <i>J</i> = 2.2 Hz, 1H), 7.00 (d, <i>J</i> = 2.2 Hz, 1H), 3.89 (s, 3H), 2.62 (s, 3H).</div></div><div id="sec6_16_7_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> (<i>E</i>)-1-(3-Hydroxy-5-methoxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S32</b>)</h5><div class="NLM_p last">To a solution of 1-(3-hydroxy-5-methoxypyridin-2-yl)ethan-1-one (<b>90</b>) (8.5 g, 50 mmol) in methanol (50 mL), sodium hydroxide (6.1 g, 150 mmol) was added followed by 4-methoxybenzaldehyde (6.9 g, 50 mmol). The reaction mixture was heated refluxed for 4 h, after which it cooled to room temperature. The solid obtained was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-1-(3-hydroxy-5-methoxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S32</b>) as a yellow solid. Yield: 9.0 g, crude; MS (ESI) <i>m</i>/<i>z</i>: 286.23 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_7_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> 3-Hydroxy-7-methoxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>91</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(3-hydroxy-5-methoxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>90</b>) (9.0 g, 32 mmol) in methanol (50 mL) at 0 °C, sodium hydroxide (3.78 g, 93.8 mmol) was added followed by hydrogen peroxide (10.7 mL, 94.7 mmol). The reaction mixture was stirred for 6 h at room temperature (reaction is exothermic!). It was then cooled and neutralized to pH ≈ 7 by the addition of 6 M hydrogen chloride. The precipitated solid was filtered and dried under vacuum to afford 3-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>91</b>) as a yellow solid. Yield: 3.5 g (12 mmol, 23%). MS (ESI) <i>m</i>/<i>z</i>: 300.08 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.42–8.36 (m, 3H), 7.73 (s, 1H), 7.07 (d, J = 7.56 Hz, 2H), 3.97 (s, 3H), 3.83 (s, 3H), 3.65 (br s, 1H).</div></div><div id="sec6_16_7_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> <i>rac</i>-Methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-9-hydroxy-3-methoxy-6-(4-methoxyphenyl)-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S33</b>)</h5><div class="NLM_p last">A solution of 3-hydroxy-7-methoxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>91</b>) (3.5 g, 11 mmol) and methyl cinnamate (<b>55</b>) (19 g, 120 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was placed in a UV reactor flask. The reaction mixture was irradiated for 15 h under 400 W UV light. Afterward, the solvent was removed under reduced pressure and the residual solid was purified over a plug of silica gel by eluting the compound with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-9-hydroxy-3-methoxy-6-(4-methoxyphenyl)-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S33</b>) as a light yellow solid. Yield: 3.0 g, crude.</div></div><div id="sec6_16_7_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-8a-hydroxy-3-methoxy-5a-(4-methoxyphenyl)-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S34</b>)</h5><div class="NLM_p last">The crude compound <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-9-hydroxy-3-methoxy-6-(4-methoxyphenyl)-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S33</b>) was suspended in methanol (30 mL) and treated with 25% sodium methoxide in methanol (30 mL, 28 g, 7.1 g NaOMe, 0.13 mol). The reaction mixture was heated at 80 °C for 2 h, after which the solvent was removed under reduced pressure. The crude product was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-8a-hydroxy-3-methoxy-5a-(4-methoxyphenyl)-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]-furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S34</b>).</div></div><div id="sec6_16_7_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>92</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (8.27 g, 39.0 mmol) and <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-8a-hydroxy-3-methoxy-5a-(4-methoxyphenyl)-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S34</b>) (3.0 g, 6.5 mmol) in acetonitrile (50 mL), acetic acid (3.9 g, 65 mmol) was added. The resulting mixture was stirred for 4 h at room temperature after which it was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product which was then purified by silica gel column chromatography eluting with 50% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>92</b>) as an off-white solid. Yield: 1.2 g (2.6 mmol, 24% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 464.29 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.87 (d, <i>J</i> = 2.2 Hz, 1H), 7.15 (d, <i>J</i> = 2.2 Hz, 1H), 7.07–6.99 (m, 5H), 6.92 (d, <i>J</i> = 7.3 Hz, 2H), 6.58 (d, <i>J</i> = 8.8 Hz, 2H), 5.47 (d, <i>J</i> = 5.3 Hz, 1H), 4.66 (t, <i>J</i> = 5.24 Hz, 1H), 4.31 (d, <i>J</i> = 13.8 Hz, 1H), 4.03–3.97 (m, 2H), 3.85 (s, 3H), 3.59 (s, 3H), 3.54 (s, 3H).</div></div><div id="sec6_16_7_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-Dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S35</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S35</b>) (1.2 g, 2.6 mmol) in methanol and water (3:1, 20 mL), lithium hydroxide (1.49 g, 62.2 mmol) was added, and the reaction was stirred for 16 h at room temperature. The reaction mixture was then cooled to 0 °C and acidified with 1 M hydrochloric acid to pH ≈ 2–3. The precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S35</b>) as an off-white solid. Yield: 0.9 g (2.0 mmol, 77%); MS (ESI) <i>m</i>/<i>z</i>: 450.28 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_7_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-Dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>5</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S35</b>) (0.9 g, 2.0 mmol) in dichloromethane (30 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (1.15 g, 7.41 mmol), hydroxybenzotriazole (0.8 g, 5.2 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (1.55 g, 12.0 mmol) were added. The mixture was stirred for 5 min. Dimethylamine hydrochloride (0.814 g, 10.0 mmol) was then added at the same temperature, and the mixture was stirred for 12 h at room temperature, after which it was diluted with dichloromethane and washed with cold water. The organic layer was separated and dried over sodium sulphate, filtered, and concentrated to give the crude product which was purified by silica gel column chromatography eluting with 70–90% ethyl acetate in hexanes to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-dihydroxy-3-methoxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>5</b>) as an off-white solid. Yield: 0.077 g (0.16 mmol, 8%). MS (ESI) <i>m</i>/<i>z</i>: 477.22 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 477.2020 [M + H]<sup>+</sup>; found, 477.2021; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.89 (d, <i>J</i> = 2.4 Hz, 1H), 7.20 (d, <i>J</i> = 2.4 Hz, 1H), 7.09–7.00 (m, 4H), 6.94–6.98 (m, 1H), 6.86 (d, <i>J</i> = 7.2 Hz, 2H), 6.64 (d, <i>J</i> = 9.2 Hz, 2H), 5.61 (s, 1H), 5.05 (d, <i>J</i> = 5.2 Hz, 1H), 4.84 (t, <i>J</i> = 6.0 Hz, 1H), 4.31 (d, <i>J</i> = 13.2 Hz, 1H), 4.09 (dd, <i>J</i> = 13.2 Hz, 6.4 Hz, 1H), 3.86 (s, 3H), 3.61 (s, 3H), 3.22 (s, 3H), 2.74 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO): δ/ppm 168.46, 157.59, 157.04, 153.51, 142.99, 138.77, 130.27, 128.56, 127.96, 127.79, 127.30, 125.68, 112.04, 103.12, 101.80, 89.03, 78.12, 55.93, 55.40, 54.77, 47.87, 36.45, 35.14.</div></div></div><div id="sec6_16_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i135" class="anchor-spacer"></div><h4 class="article-section__title" id="_i135"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Cyanophenyl)-8,8a-dihydroxy-3-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>7</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0097.gif" alt="" id="dgr9" /></img><div id="sec6_16_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> (<i>E</i>)-3-(4-Bromophenyl)-1-(3-hydroxy-5-methoxypyridin-2-yl)prop-2-en-1-one (<b>S36</b>)</h5><div class="NLM_p last">To a solution of 1-(3-hydroxy-5-methoxypyridin-2-yl)ethan-1-one (<b>90</b>) (8.0 g, 49 mmol) in methanol (120 mL), sodium hydroxide (5.74 g, 144 mmol) was added followed by 4-bromobenzaldehyde (8.85 g, 47.8 mmol). The mixture was heated to reflux for 2 h. Then, the reaction mixture was cooled and the resulting solid was collected by filtration, washed with water, and dried under vacuum to afford crude (<i>E</i>)-3-(4-bromophenyl)-1-(3-hydroxy-5-methoxypyridin-2-yl)prop-2-en-1-one as a yellow solid. Yield: 14.0 g. UPLC: 89.75%; MS (ESI) <i>m</i>/<i>z</i>: 334.01 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.44 (d, <i>J</i> = 16.0 Hz, 1H), 7.60–7.58 (m, 4H), 7.40 (d, <i>J</i> = 2 Hz, 1H), 7.22 (d, <i>J</i> = 2.0 Hz, 1H), 6.20 (s, 1H), 3.69 (s, 3H).</div></div><div id="sec6_16_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> 2-(4-Bromophenyl)-3-hydroxy-7-methoxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>93</b>)</h5><div class="NLM_p last">To a solution of crude (<i>E</i>)-3-(4-bromophenyl)-1-(3-hydroxy-5-methoxypyridin-2-yl)prop-2-en-1-one (14.0 g) in ethanol (200 mL) at room temperature, sodium hydroxide (11.73 g, 293.3 mmol) was added followed by hydrogen peroxide (30% aq, 23.25 mL, 7.742 g H<sub>2</sub>O<sub>2</sub>, 227.6 mmol). This reaction mixture was stirred for 1 h (reaction is exothermic). Then, the mixture was cooled and neutralized to pH ≈ 7 by addition of 6 N hydrochloric acid. The resulting precipitate was collected by filtration and dried under vacuum to afford crude 2-(4-bromophenyl)-3-hydroxy-7-methoxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one as a pale yellow solid. Yield: 12.0 g. UPLC: 72.42%; MS (ESI) <i>m</i>/<i>z</i>: 348.05 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.98 (br s, 1H), 8.48 (s, 1H), 8.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.82–77 (m, 3H), 3.98 (s, 3H).</div></div><div id="sec6_16_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>94</b>)</h5><div class="NLM_p last">A solution of crude 2-(4-bromophenyl)-3-hydroxy-7-methoxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (6.0 g) and methyl cinnamate (27.9 g, 172 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated under 400 W UV light for 15 h in a UV reactor flask. After this time, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford crude methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-6-(4-bromophenyl)-9-hydroxy-3-methoxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S37</b>) (3.5 g, crude). This crude compound (<b>S37</b>) was suspended in methanol (20 mL) and treated with 25% sodium methoxide in methanol (20 mL, 19 g solution; 4.8 g, 89 mmol NaOMe). This mixture was heated at 70 °C for 1 h. Then, the solvent was removed under reduced pressure, and the crude product was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to give crude methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-8a-hydroxy-3-methoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S38</b>). The crude material (<b>S38</b>) (3.5 g) was added to a solution of sodium triacetoxyborohydride (9.72 g, 4.58 mmol) in acetonitrile (30 mL) and acetic acid (4.57 mL, 4.79 g, 79.8 mmol), and the resulting mixture was stirred for 4 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography eluting with 50% ethyl acetate in hexanes. The desired fractions were concentrated to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>94</b>) as a pale yellow solid. Yield: 0.80 g (<i>ca.</i> 1.6 mmol, 7% over five steps). UPLC: 90.64%; MS (ESI) <i>m</i>/<i>z</i>: 510.03 [M + 1]<sup>−</sup>.</div></div><div id="sec6_16_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Cyanophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S39</b>)</h5><div class="NLM_p last">To a mixture of methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>94</b>) (0.80 g, <i>ca.</i> 1.6 mmol) in dimethylformamide at room temperature, zinc cyanide (1.123 g, 9.562 mmol) and zinc dust (0.022 g, 0.336 mmol) were added. The mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino) ferrocene (0.041 g, 0.0740 mmol) and tris(dibenzylideneacetone)dipalladium (0.078 g, 0.0852 mmol) were added to the reaction mixture which was then degassed with argon for an additional 5 min and then heated at 140 °C for 2 h. After completion, the reaction was cooled to room temperature and filtered with Celite. The filtrate was concentrated and treated with ice-cold water, the solid precipitate was collected by filtration, and the crude product was triturated with <i>n</i>-pentane. The so-obtained solid was collected by filtration and dried under vacuum to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S39</b>) as a brown solid. Yield: 0.75 g (crude). UPLC: 61.54%; MS (ESI) <i>m</i>/<i>z</i>: 459.35 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.89 (d, <i>J</i> = 2.2 Hz, 1H), 7.47 (d, <i>J</i> = 8.3 Hz, 2H), 7.29 (d, <i>J</i> = 8.4 Hz, 2H), 7.22–6.53 (m, 6H), 5.99 (s, 1H), 5.60 (d, <i>J</i> = 5.36 Hz 1H), 4.63 (t, <i>J</i> = 5.28 Hz, 1H), 4.49 (d, <i>J</i> = 13.76 Hz, 1H), 4.18 (dd, <i>J</i> = 4.6 Hz, 13.9 Hz, 1H), 3.85 (s, 3H), 3.66 (s, 3H).</div></div><div id="sec6_16_8_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Cyanophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S40</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S39</b>) (0.75 g, crude) in methanol/water (3:1, 12 mL), lithium hydroxide (monohydrate, 0.411 g, 9.80 mmol) was added. The reaction mixture was stirred for 6 h at room temperature. After this time, the reaction mixture was cooled to 0 °C and acidified with 1 M citric acid to pH ≈ 5. The resulting precipitate was collected by filtration and dried under vacuum to afford (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S40</b>) as an off-white solid. Yield: 0.6 g (crude). UPLC: 61.54%; MS (ESI) <i>m</i>/<i>z</i>: 445.35 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.87 (d, <i>J</i> = 2.2 Hz, 1H), 7.47 (d, <i>J</i> = 7.5 Hz, 2H), 7.25 (d, <i>J</i> = 8.4 Hz, 2H), 7.06–6.87 (m, 6H), 5.87 (s, 1H), 4.54 (s 1H), 4.48 (d, <i>J</i> = 4.46 Hz,1H), 3.91 (br s, 1H), 3.85 (s, 3H).</div></div><div id="sec6_16_8_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> (−)-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>7</b>)</h5><div class="NLM_p last">To a solution of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-3-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S40</b>) (0.6 g, crude) in methylene chloride (30 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.77 g, 4.0 mmol), hydroxybenzotriazole (0.54 g, 4.0 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.04 g, 8.05 mmol) were added. This mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.55 g, 6.8 mmol) was added, and the mixture was stirred for 12 h at room temperature. After this time, the mixture was diluted with methylene chloride and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by reverse-phase prep-HPLC to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-3-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>7</b>) as a white solid. The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Yield: 110 mg (0.233 mmol, 15% over 3 steps). Peak 1 (54 mg, (−)-<b>7</b>), [α]<sub>D</sub> −106° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 6.86, ee >99%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.9 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (d, <i>J</i> = 8.5 Hz, 2H), 7.34 (d, <i>J</i> = 8.5 Hz, 2H), 7.21 (d, <i>J</i> = 2.4 Hz, 1H), 7.05 (s, 1H), 7.02 (d, <i>J</i> = 7.5 Hz, 1H), 6.96 (d, <i>J</i> = 7.2 Hz, 1H), 6.90 (d, <i>J</i> = 7.4 Hz, 2H), 5.88 (s, 1H), 5.16 (br s, 1H), 4.77 (br s, 1H), 4.54 (d, <i>J</i> = 13.2 Hz, 1H), 4.25 (dd, <i>J</i> = 13.2, 5.8 Hz, 1H), 3.86 (s, 3H), 3.26 (s, 3H), 2.77 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.22, 157.04, 142.39, 142.03, 138.29, 130.67, 130.31, 128.50, 127.68, 127.49, 125.87, 118.85, 109.59, 109.00, 102.87, 101.62, 90.56, 78.01, 56.06, 55.95, 48.42, 36.54, 35.22; MS (ESI) <i>m</i>/<i>z</i>: 472.37 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 472.1867 [M + H]<sup>+</sup>; found, 472.1866; UPLC: 96.33%. Peak 2 (45 mg, (+)-<b>7</b>), [α]<sub>D</sub> +147.1° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 12.85, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.9 (d, <i>J</i> = 2.4 Hz, 1H), 7.52 (d, <i>J</i> = 8.6 Hz, 2H), 7.35 (d, <i>J</i> = 8.4 Hz, 2H), 7.22 (d, <i>J</i> = 2.2 Hz, 1H), 7.05 (s, 1H), 7.03 (d, <i>J</i> = 7.6 Hz, 1H), 6.97 (d, <i>J</i> = 7.2 Hz, 1H), 6.91 (d, <i>J</i> = 7.4 Hz, 2H), 5.88 (s, 1H), 5.17 (br s, 1H), 4.78 (d, <i>J</i> = 5.6 Hz, 1H), 4.55 (d, <i>J</i> = 13.2 Hz, 1H), 4.27 (dd, <i>J</i> = 13.2, 5.6 Hz 1H), 3.86 (s, 3H), 3.26 (s, 3H), 2.77 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 472.37 [M + 1]<sup>+</sup>; UPLC: 99.95%.</div></div></div><div id="sec6_16_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i142" class="anchor-spacer"></div><h4 class="article-section__title" id="_i142"> Synthesis of (−)-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>15</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0048.gif" alt="" id="dgr10" /></img><div id="sec6_16_9_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i143" class="anchor-spacer"></div><h5 class="article-section__title" id="_i143"> 3-(Benzyloxy)-5-chloropicolinonitrile (<b>96</b>)</h5><div class="NLM_p last">A flask containing tetrahydrofuran (250 mL) under nitrogen at room temperature was charged with 5-chloro-3-nitropicolinonitrile (<b>95</b>) (25.0 g, 136 mmol), and sodium hydride (11.0 g, 458 mmol) was added. The suspension was stirred for 30 min, after which benzyl alcohol (29.5 mL, 30.68 g, 284 mmol) was added, and stirring was continued for another 3 h. Then, the reaction was cooled to 0 °C and quenched with saturated NH<sub>4</sub>Cl solution. The mixture was diluted with ethyl acetate (200 mL). The organic layer was separated, washed with water (2 × 50 mL) and brine (50 mL), dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. The crude product was treated with pentane (100 mL) to obtain a solid which was collected by filtration and dried under vacuum to afford 3-(benzyloxy)-5-chloropicolinonitrile (<b>96</b>) as a brownish solid. Yield: 28.0 g (114 mmol, 84%). MS (ESI) <i>m</i>/<i>z</i>: 245.09 [M – 1]<sup>+</sup>; LCMS: 97.31%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.40 (s, 1H), 8.18 (s, 1H), 7.49–7.37 (m, 5H), 5.37 (s, 2H).</div></div><div id="sec6_16_9_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> 1-(3-(Benzyloxy)-5-chloropyridin-2-yl)ethan-1-one (<b>97</b>)</h5><div class="NLM_p last">To a solution of 3-(benzyloxy)-5-chloropicolinonitrile (<b>96</b>) (28.0 g, 114 mmol) in dry tetrahydrofuran (250 mL) at −30 °C, methyl magnesium chloride (3 M, 114.0 mL, 342.0 mmol) was added dropwise over a period of 30 min. The reaction mixture was slowly brought to room temperature and stirred for 2 h. The reaction was then quenched with 6 N HCl (pH ≈ 3) and stirred for another 2 h. The mixture was extracted with ethyl acetate (200 mL) and the organic layer was separated, washed with 1 N NaOH solution (50 mL) and then water (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford 1-(3-(benzyloxy)-5-chloropyridin-2-yl)ethan-1-one (<b>97</b>) as a yellow oil. Yield: 19.0 g, crude. LCMS: 79.76%; MS (ESI) <i>m</i>/<i>z</i>: 262.10 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.29 (d, <i>J</i> = 1.1 Hz, 1H), 7.95 (d, <i>J</i> = 1.1 Hz, 1H), 7.49–7.30 (m, 5H), 5.28 (s, 2H), 2.53 (s, 3H).</div></div><div id="sec6_16_9_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> 1-(5-Chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>)</h5><div class="NLM_p">A flask containing ethyl acetate (300 mL) was charged with crude 1-(3-(benzyloxy)-5-chloropyridin-2-yl)ethan-1-one (<b>97</b>) (19.0 g) and palladium(II) hydroxide (50% wet) (10.0 g, 35.6 mmol) at room temperature. The reaction mixture was purged with hydrogen twice and stirred under hydrogen pressure for 16 h. Next, the reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure to afford 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) as a brown oil.</div><div class="NLM_p last">Yield: 8.0 g, crude. UPLC: 83.70%; MS (ESI) <i>m</i>/<i>z</i>: 170.03 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 11.70 (br s, 1H), 8.35 (s, 1H), 7.71 (d, <i>J</i> = 1.1 Hz, 1H), 2.59 (s, 3H).</div></div><div id="sec6_16_9_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i146" class="anchor-spacer"></div><h5 class="article-section__title" id="_i146"> (<i>E</i>)-1-(5-Chloro-3-hydroxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>99a</b>)</h5><div class="NLM_p last">To a solution of crude 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) (8.0 g) in methanol (50 mL), sodium hydroxide (5.6 g, 140 mmol) was added followed by 4-methoxybenzaldehyde (<b>61a</b>) (6.9 mL, 7.7 g, 57 mmol). The mixture was heated to reflux for 30 min. After this time, the reaction mixture was cooled, and the solid was collected by filtration, washed with water, and then dried under high vacuum to afford (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>99a</b>) as a yellow solid. Yield: 10.5 g, crude. UPLC: 84.19%; MS (ESI) <i>m</i>/<i>z</i>: 290.02 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.14 (d, <i>J</i> = 16.0 Hz, 1H), 7.58 (d, <i>J</i> = 8.6 Hz, 2H), 7.41 (d, <i>J</i> = 16.1 Hz, 1H), 7.31 (s, 1H), 6.98 (d, <i>J</i> = 8.6 Hz, 2H), 6.66 (s, 1H), 3.79 (s, 3H).</div></div><div id="sec6_16_9_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147"> 7-Chloro-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100a</b>)</h5><div class="NLM_p last">To a solution of crude (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>99a</b>) (10.5 g) in ethanol (100 mL) at room temperature, sodium hydroxide (10.0 g, 250 mmol) was added followed by hydrogen peroxide (10.73 mL 30% aq solution, 3.57 g H<sub>2</sub>O<sub>2</sub>, 105 mmol). The reaction mixture was stirred for 1 h at room temperature (reaction is exothermic!). Then, the mixture was cooled to room temperature and neutralized to pH ≈ 7 by addition of 6 N HCl. The resulting precipitate was collected by filtration and dried under vacuum to afford 7-chloro-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one as a brick-red solid. Yield: 6.5 g, crude. UPLC: 71.3%; MS (ESI) <i>m</i>/<i>z</i>: 304.17 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.46 (s, 1H), 7.13 (d, <i>J</i> = 7.3 Hz, 2H), 6.88 (d, <i>J</i> = 7.3 Hz, 2H), 5.94 (s, 1H), 3.74 (s, 3H).</div></div><div id="sec6_16_9_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101a</b>)</h5><div class="NLM_p last">A solution of 7-chloro-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100a</b>) (6.5 g, crude) and methyl cinnamate (34.7 g, 214 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated under 400 W UV light for 15 h in a UV reactor flask. Then, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford intermediate <b>S41a</b> (4.0 g, crude). The crude compound (<b>S41a</b>) was suspended in methanol (30 mL) and treated with 25% sodium methoxide in methanol (30 mL, 28 g solution; 7.0 g, 0.13 mol NaOMe). The mixture was heated at 70 °C for 1 h. Then, the solvent was removed under reduced pressure, and the crude product was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-5a-(4-methoxyphenyl)-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42a</b>) (2.8 g, crude). Crude compound (<b>S42a</b>) (2.8 g) was added to a solution of sodium triacetoxyborohydride (8.9 g, 42 mmol) in acetonitrile (30 mL) and acetic acid (3.6 mL, 60.2 mmol). The resulting mixture was stirred for 4 h at room temperature. Then, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution (50 mL) and ethyl acetate (100 mL). The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel column chromatography eluting with 50% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101a</b>) as a yellow solid. Yield: 0.70 g. UPLC: 70.6%; MS (ESI) <i>m</i>/<i>z</i>: 464.29 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 1.9 Hz, 1H), 7.67 (s, 1H), 7.41–7.27 (m, 2H), 7.10–6.91 (m, 6H), 6.57 (d, <i>J</i> = 8.8 Hz, 1H), 5.98 (s, 1H), 5.69–5.67 (m, 1H), 4.65–4.63 (m, 1H), 4.43–4.36 (m, 1H), 4.09–4.01 (m, 1H), 3.58 (s, 3H), 3.56 (s, 3H).</div></div><div id="sec6_16_9_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i149" class="anchor-spacer"></div><h5 class="article-section__title" id="_i149"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S43a</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101a</b>) (0.70 g, from previous step; used without further purification) in methanol/water (3:1, 12 mL), lithium hydroxide (0.539 g, 22.5 mmol) was added. The reaction mixture was stirred for 6 h at room temperature, then cooled to 0 °C, and acidified with 1 N HCl to pH ≈ 3. The resulting precipitate was collected by filtration and dried under vacuum to afford (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43a</b>) as an off-white solid. Yield: 0.40 g. UPLC: 85.43%; MS (ESI) <i>m</i>/<i>z</i>: 452.11 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.15 (d, <i>J</i> = 1.7 Hz, 1H), 7.63 (d, <i>J</i> = 1.4 Hz, 1H), 7.11–6.87 (m, 7H), 6.56 (d, <i>J</i> = 8.9 Hz, 2H), 5.87 (s, 1H), 4.57 (br s, 1H), 4.39 (d, <i>J</i> = 13.8 Hz, 1H), 3.87–3.83 (m, 1H), 3.51 (s, 3H).</div></div><div id="sec6_16_9_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> (−)-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>15</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43a</b>) (0.4 g, from previous step; used without further purification) in methylene chloride (30 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.508 g, 3.27 mmol), hydroxybenzotriazole (0.35 g, 2.3 mmol), and DIPEA (0.9 mL, 0.7 g, 5.17 mmol) were added. The mixture was stirred for 5 min. Dimethylamine hydrochloride (0.357 g, 4.37 mmol) was added to the mixture which was then stirred for 12 h at room temperature. After this time, the mixture was diluted with methylene chloride (25 mL) and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography eluting with 70–90% ethyl acetate in hexanes to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>15</b>) as a white solid. Yield: 100 mg (0.208 mmol, <i>ca.</i> 2% over nine steps). The enantiomers were separated using a Chiralpak IB (4.6 × 250) mm column. Peak 1 (30 mg,(−)-<b>15</b>), [α]<sub>D</sub> −179.0° (<i>c</i> 0.1, CHCl<sub>3</sub>), ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 2.0 Hz, 1H), 7.68 (d, <i>J</i> = 2.0 Hz, 1H), 7.04–7.02 (m, 4H), 6.95 (t, <i>J</i> = 7.6 Hz, 1H), 6.89 (d, <i>J</i> = 7.6 Hz, 2H), 6.61 (d, <i>J</i> = 8.8 Hz, 2H), 5.22 (d, <i>J</i> = 5.6 Hz, 1H), 4.75 (t, <i>J</i> = 5.6 Hz, 1H), 4.48 (d, <i>J</i> = 13.2 Hz, 1H), 4.19 (dd, <i>J</i> = 6.0 Hz, 13.2 Hz 1H), 3.60 (s, 3H), 3.25 (s, 3H), 2.76 (s, 3H); 13C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.28, 157.61, 153.37, 150.07, 140.27, 138.66, 130.90, 128.53, 127.87, 127.82, 127.33, 125.65, 117.16, 111.96, 102.20, 90.13, 77.95, 55.93, 54.76, 48.30, 36.54, 35.20; MS (ESI) <i>m</i>/<i>z</i>: 481.33 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 481.1525 [M + H]<sup>+</sup>; found, 481.1522; UPLC: 99.92%. Peak-2 (50 mg, (+)-<b>15</b>), [α]<sub>D</sub> +180.0° (<i>c</i> 0.1, CHCl<sub>3</sub>), ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 2.0 Hz, 1H), 7.68 (d, <i>J</i> = 2.0 Hz, 1H), 7.04–7.02 (m, 4H), 6.95 (t, <i>J</i> = 7.4 Hz, 1H), 6.89 (d, <i>J</i> = 7.6 Hz, 2H), 6.61 (d, <i>J</i> = 8.8 Hz, 2H), 5.22 (d, <i>J</i> = 5.5 Hz, 1H), 4.75 (t, <i>J</i> = 5.6 Hz, 1H), 4.48 (d, <i>J</i> = 13.6 Hz, 1H), 4.18 (dd, <i>J</i> = 5.6 Hz, 13.6 Hz, 1H), 3.60 (s, 3H), 3.25 (s, 3H), 2.76 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 481.33 [M + 1]<sup>+</sup>; UPLC: 99.26%.</div></div></div><div id="sec6_16_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i151" class="anchor-spacer"></div><h4 class="article-section__title" id="_i151"> (−)-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>17</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0049.gif" alt="" id="dgr11" /></img><div id="sec6_16_10_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i152" class="anchor-spacer"></div><h5 class="article-section__title" id="_i152"> (<i>E</i>)-1-(5-Chloro-3-hydroxypyridin-2-yl)-3-(<i>p</i>-tolyl)prop-2-en-1-one (<b>99b</b>)</h5><div class="NLM_p last">To a solution of 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) (6.0 g, 35 mmol) in methanol (30 mL), sodium hydroxide (4.19 g, 105 mmol), and 4-methylbenzaldehyde (<b>61b</b>) (4.19 g, 34.9 mmol) were added. The reaction mixture was heated at 85 °C for 2 h. Then, the reaction mixture was cooled, and the resulting precipitate was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(<i>p</i>-tolyl)prop-2-en-1-one (<b>99b</b>) as a yellow solid. Yield: 5.0 g (18 mmol, 52%). MS (ESI) <i>m</i>/<i>z</i>: 274.13 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.24 (d, <i>J</i> = 15.9 Hz, 1H), 7.80 (d, <i>J</i> = 7.9 Hz, 1H), 7.54 (d, <i>J</i> = 7.6 Hz, 2H), 7.44–7.35 (m, 2H), 7.22 (d, <i>J</i> = 7.2 Hz, 2H), 6.71 (br s, 1H), 2.32 (s, 3H).</div></div><div id="sec6_16_10_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153"> 7-Chloro-3-hydroxy-2-(<i>p</i>-tolyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100b</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(<i>p</i>-tolyl)prop-2-en-1-one (<b>99b</b>) (5.0 g, 18 mmol) in ethanol/dichloromethane (1:1, 20 mL) at room temperature, sodium hydroxide (6.45 g, 161 mmol) was added followed by 30% hydrogen peroxide (4.8 mL, 1.6 g H<sub>2</sub>O<sub>2</sub>, 47 mmol). The reaction mixture was stirred for 1 h (reaction is exothermic!). Then, the mixture was cooled and neutralized with 6 M hydrochloric acid. The resulting precipitate was collected by filtration and dried under vacuum to afford 7-chloro-3-hydroxy-2-(<i>p</i>-tolyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100b</b>) as a brown solid. Yield: 1.66 g (5.77 mmol, 32%). MS (ESI) <i>m</i>/<i>z</i>: 288.14 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.78 (s, 1H), 8.66 (s, 1H), 8.18 (d, <i>J</i> = 7.9 Hz, 2H), 7.47 (d, <i>J</i> = 7.9 Hz, 2H), 2.39 (s, 3H).</div></div><div id="sec6_16_10_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> <i>rac</i>-Methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-Chloro-9-hydroxy-10-oxo-7-phenyl-6-(<i>p</i>-tolyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41b</b>)</h5><div class="NLM_p last">A solution of 7-chloro-3-hydroxy-2-(<i>p</i>-tolyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100b</b>) (1.3 g, 4.5 mmol) and methyl cinnamate (<b>55</b>) (6.99 g, 43.1 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated for 15 h under 400 W UV light in a UV reactor flask. After this time, the solvent was removed under reduced pressure, and the residue was purified by Combi-flash (12 g, RediSep column) using ethyl acetate as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6-(<i>p</i>-tolyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41b</b>). Yield: 1.1 g, crude.</div></div><div id="sec6_16_10_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i155" class="anchor-spacer"></div><h5 class="article-section__title" id="_i155"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-Chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42b</b>)</h5><div class="NLM_p last">The crude methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6-(<i>p</i>-tolyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41b</b>) (1.1 g) was suspended in methanol (10 mL), and sodium methoxide (25% in methanol, 10 mL, 9.5 g solution, 2.4 g NaOMe, 44 mmol NaOMe) was added to this suspension. The reaction mixture was heated at 90 °C for 1 h. Then, the solvent was removed under reduced pressure, the reaction was quenched with ammonium chloride solution, and the mixture was extracted with ethyl acetate. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42b</b>). Yield: 0.9 g; crude.</div></div><div id="sec6_16_10_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101b</b>)</h5><div class="NLM_p last">To a solution of crude methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42b</b>) (0.9 g) in acetonitrile (10 mL), sodium triacetoxyborohydride (2.54 g, 11.9 mmol) and acetic acid (1.1 mL, 1.2 g, 19 mmol) were added. The resulting mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by Combi-flash (4 g, RediSep column) using 70% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101b</b>) as a light yellow solid. Yield: 0.25 g (0.56 mmol, 12% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 452.33 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.17 (d, <i>J</i> = 9.6 Hz, 1H), 7.67 (s, 1H), 7.38 (d, <i>J</i> = 6.0 Hz, 2H), 7.28–6.95 (m, 5H), 6.82 (d, <i>J</i> = 8.0 Hz, 2H), 5.98 (s, 1H), 5.68 (s, 1H), 4.64 (s, 1H), 4.43 (d, <i>J</i> = 14.4 Hz, 1H), 4.10–4.05 (m, 1H), 3.56 (s, 3H), 2.09 (s, 3H).</div></div><div id="sec6_16_10_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S43b</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101b</b>) (0.25 g, 0.56 mmol) in tetrahydrofuran and water (3:1, 4.0 mL), lithium hydroxide (0.26 g, 9.6 mmol) was added. The reaction mixture was stirred for 6 h at room temperature. After this time, the reaction mixture was cooled to 0 °C and acidified with 1 M hydrogen chloride to pH ≈ 3. The resulting precipitate was collected by filtration, washed with water, and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43b</b>) as a yellow solid. Yield: 0.13 g (0.29 mmol, 51%). MS (ESI) <i>m</i>/<i>z</i>: 438.32 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.16 (s, 1H), 8.17 (s, 1H), 7.66 (s, 1H), 7.06–7.03 (m, 2H), 6.98–6.92 (m, 4H), 6.82 (d, <i>J</i> = 8.1 Hz, 2H), 5.93 (s, 1H), 4.64 (d, <i>J</i> = 4.5 Hz, 1H), 4.41 (d, <i>J</i> = 13.7 Hz, 1H), 4.03–3.94 (m, 1H), 2.08 (s, 3H).</div></div><div id="sec6_16_10_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> (−)-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>17</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43b</b>) (0.13 g, 0.30 mmol) in dichloromethane (5.0 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.046 g, 0.240 mmol), 1-hydroxybenzotriazole (anhydrous, 0.067 g, 0.496 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.15 mL, 0.11 g, 0.86 mmol) were added. The reaction mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.032 g, 0.392 mmol) was added at 0 °C, and the mixture was stirred at room temperature for 16 h. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by Combi-flash (4 g, RediSep column) using 70% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford racemic (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(<i>p</i>-tolyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>17</b>) as a white solid. Yield: 0.07 g (0.15 mmol, 50%). MS (ESI) <i>m</i>/<i>z</i>: 465.32 [M + 1]<sup>+</sup>. The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (13 mg, (+)-<b>17</b>); [α]<sub>D</sub> +212.0° (<i>c</i> 0.1, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 10.18 min, ee >95%; MS (ESI) <i>m</i>/<i>z</i>: 465.32 [M + 1]<sup>+</sup>; UPLC 97.1%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 2.0 Hz, 1H), 7.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.11–6.94 (m, 5H), 6.90 (d, <i>J</i> = 8.2 Hz, 2H), 6.86 (d, <i>J</i> = 8.2 Hz, 2H), 5.88 (s, 1H), 5.23 (t, <i>J</i> = 5.5, 1H), 4.77 (t, <i>J</i> = 5.6 Hz, 1H), 4.51 (d, <i>J</i> = 13.2 Hz, 1H), 4.23–4.18 (dd, <i>J</i> = 13.2, 5.6 Hz, 1H), 3.25 (s, 3H), 2.76 (s, 3H), 2.11 (s, 3H). Peak-2 (9 mg, (−)-<b>17</b>); [α]<sub>D</sub> −191.1° (<i>c</i> 0.1, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 22.4 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 465.32 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 465.1576 [M + H]<sup>+</sup>; found, 465.1571; UPLC 99.8%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 2.0 Hz, 1H), 7.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.03–6.94 (m, 5H), 6.90 (d, <i>J</i> = 8.2 Hz, 2H), 6.86 (d, <i>J</i> = 8.2 Hz, 2H), 5.88 (s, 1H), 5.23 (d, <i>J</i> = 5.6, 1H), 4.77 (t, <i>J</i> = 5.6 Hz, 1H), 4.50 (d, <i>J</i> = 13.2 Hz, 1H), 4.23–4.18 (dd, <i>J</i> = 13.2, 5.6 Hz, 1H), 3.25 (s, 3H), 2.76 (s, 3H), 2.11 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.29, 153.40, 150.04, 140.28, 138.64, 135.22, 132.88, 130.91, 127.87, 127.33, 127.27, 127.18, 125.65, 117.15, 102.34, 90.26, 77.97, 55.93, 48.37, 36.57, 35.22, 20.54.</div></div></div><div id="sec6_16_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i159" class="anchor-spacer"></div><h4 class="article-section__title" id="_i159"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>18</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0050.gif" alt="" id="dgr12" /></img><div id="sec6_16_11_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i160" class="anchor-spacer"></div><h5 class="article-section__title" id="_i160"> (<i>E</i>)-1-(5-Chloro-3-hydroxypyridin-2-yl)-3-(4-chlorophenyl)prop-2-en-1-one (<b>99c</b>)</h5><div class="NLM_p last">To a solution of 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) (4.0 g, 23 mmol) in methanol (20 mL), sodium hydroxide (2.8 g, 70 mmol) was added followed by 4-chlorobenzaldehyde (<b>61c</b>) (3.3 g, 23 mmol). The reaction mixture was heated to reflux for 10 min. Then, the reaction mixture was cooled to room temperature and diluted with water (20 mL). The precipitated solid was collected by filtration, washed with water and <i>n</i>-pentane, and dried under vacuum to afford (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-chlorophenyl)prop-2-en-1-one (<b>99c</b>) as a yellow solid. Yield: 6.1 g (21 mmol, 90%). MS (ESI) <i>m</i>/<i>z</i>: 292.15 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.30 (d, <i>J</i> = 16.0 Hz, 1H), 7.68 (d, <i>J</i> = 8.4 Hz, 2H), 7.47 (d, <i>J</i> = 8.4 Hz, 2H), 7.43 (d, <i>J</i> = 16.0 Hz, 1H), 7.31 (d, <i>J</i> = 2.0 Hz, 1H), 6.66 (d, <i>J</i> = 2.0 Hz, 1H).</div></div><div id="sec6_16_11_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i161" class="anchor-spacer"></div><h5 class="article-section__title" id="_i161"> 7-Chloro-2-(4-chlorophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100c</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-chlorophenyl)prop-2-en-1-one (<b>99c</b>) (7.0 g, 24 mmol) in ethanol (400 mL) and dichloromethane (66 mL) at 0 °C, 10% aq sodium hydroxide (31 mL, 67 g solution, 6.7 g NaOH, 170 mmol) was added followed by 30% aq hydrogen peroxide (37.5 mL, 41.6 g solution, 12.5 g H<sub>2</sub>O<sub>2</sub>, 367 mmol). The reaction mixture was stirred for 30 min at room temperature (reaction is exothermic!). Then, the mixture was cooled and neutralized to pH ≈ 7 with 6 M hydrochloric acid. The mixture was extracted with ethyl acetate (100 mL). The organic layer was separated, washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The so-obtained solid was triturated with ethanol, filtered, and dried under vacuum to afford 7-chloro-2-(4-chlorophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100c</b>) as a light yellow solid. Yield: 2.81 g (9.12 mmol, 43%). MS (ESI) <i>m</i>/<i>z</i>: 308.04 [M + 1] <sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 10.20 (br s, 1H), 8.80 (br s, 1H), 8.62 (br s, 1H), 8.27 (d, <i>J</i> = 7.6 Hz, 2H), 7.68–7.62 (m, 2H).</div></div><div id="sec6_16_11_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i162" class="anchor-spacer"></div><h5 class="article-section__title" id="_i162"> <i>rac</i>-Methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-Chloro-6-(4-chlorophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41c</b>)</h5><div class="NLM_p last">A solution of 7-chloro-2-(4-chlorophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100c</b>) (2.8 g, 9.1 mmol) and methyl cinnamate (<b>5</b>, 14.7 g, 90.3 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated for 8 h under 400 W UV light in a UV reactor flask. After this time, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-6-(4-chlorophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41c</b>) as a brown solid. Yield: 3.1 g, crude.</div></div><div id="sec6_16_11_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i163" class="anchor-spacer"></div><h5 class="article-section__title" id="_i163"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-Chloro-5a-(4-chlorophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42c</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-6-(4-chlorophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41c</b>) (3.1 g) was suspended in methanol (30 mL) and treated with 25% sodium methoxide in methanol (20 mL, 19 g solution, 4.7 g NaOMe, 87 mmol). The reaction mixture was heated at 80 °C for 2 h. After this time, the solvent was removed under reduced pressure. The crude product was treated with aqueous ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-5a-(4-chlorophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42c</b>). Yield: 2.35 g, crude.</div></div><div id="sec6_16_11_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i164" class="anchor-spacer"></div><h5 class="article-section__title" id="_i164"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101c</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (6.23 g, 29.4 mmol) and <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-5a-(4-chlorophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42c</b>) (2.3 g) in acetonitrile (60 mL), acetic acid (2.9 mL, 3.0 g, 50 mmol) was added. The resulting mixture was stirred for 18 h at room temperature. Then, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography using 60% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101c</b>) as a white solid. Yield: 1.1 g (2.3 mmol, 26% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 472.15 [M + 1] <sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (s, 1H), 7.69 (s, 1H), 7.36–7.05 (m, 6H), 6.99–6.97 (m, 3H), 6.15 (s, 1H), 5.76 (d, <i>J</i> = 5.2 Hz, 1H), 4.63 (t, 5.2 Hz, 1H), 4.52 (d, <i>J</i> = 14.0 Hz, 1H), 4.14 (dd, <i>J</i> = 5.2 Hz, 13.2 Hz, 1H), 3.57 (s, 3H).</div></div><div id="sec6_16_11_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i165" class="anchor-spacer"></div><h5 class="article-section__title" id="_i165"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S43c</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101c</b>) (1.0 g, 2.1 mmol) in methanol, tetrahydrofuran, and water (3:2:1, 18 mL), lithium hydroxide (0.89 g, 37 mmol) was added. The reaction mixture was stirred for 3 h at room temperature. After this time, the reaction mixture was cooled to 0 °C and acidified with 1 M hydrochloric acid to pH ≈ 2–3. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43c</b>) as a white solid. Yield: 0.55 g (1.2 mmol, 57%). MS (ESI) <i>m</i>/<i>z</i>: 458.14 [M + 1] <sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.2 (br s, 1H), 8.19 (s, 1H), 7.68 (s, 1H), 7.06–7.00 (m, 9H), 6.08 (s, 1H), 4.60 (s, 1H), 4.48 (d, <i>J</i> = 14.0 Hz, 1H), 4.00 (d, <i>J</i> = 13.6 Hz, 1H).</div></div><div id="sec6_16_11_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i166" class="anchor-spacer"></div><h5 class="article-section__title" id="_i166"> (−)-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>18</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43c</b>) (0.3 g, 0.7 mmol) in dichloromethane (8 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.30 g, 1.9 mmol), 1-hydroxybenzotriazole (0.29 g, 2.1 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.69 mL, 0.51 g, 3.9 mmol) were added. The mixture was stirred for 5 min. Dimethylamine hydrochloride (0.27 g, 3.3 mmol) was then added at the same temperature, and the reaction was stirred for 48 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to give the crude product which was purified by silica gel column chromatography using 2–3% dichloromethane in methanol as the eluent. The desired fractions were concentrated under reduced pressure to afford racemic (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-chlorophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>18</b>) as a white solid. The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (64 mg, (+)-<b>18</b>), [α]<sub>D</sub> +212.3° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 9.727 min, ee >99%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.70 (d, <i>J</i> = 2.0 Hz, 1H), 7.14 (d, <i>J</i> = 8.8 Hz, 2H), 7.05 (m, 4H), 6.95 (d, <i>J</i> = 7.2 Hz, 1H), 6.91 (d, <i>J</i> = 7.4 Hz, 2H), 6.04 (s, 1H), 5.28 (d, <i>J</i> = 5.7 Hz, 1H), 4.7 (t, <i>J</i> = 5.4 Hz, 1H), 4.57 (d, <i>J</i> = 13.2 Hz, 1H), 4.25 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.26 (s, 3H), 2.77 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.13, 153.30, 149.66, 140.54, 138.41, 135.17, 131.13, 130.96, 129.29, 127.83, 127.47, 126.43, 125.81, 117.18, 101.94, 90.70, 77.90, 56.15, 48.58, 36.59, 35.25; UPLC: 99.92%. Peak-2 (68 mg, (−)-<b>18</b>), [α]<sub>D</sub> −209.6° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 23.133 min, ee >99%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.70 (d, <i>J</i> = 2.0 Hz, 1H), 7.13 (d, <i>J</i> = 8.8 Hz, 2H), 7.03 (m, 4H), 6.95 (d, <i>J</i> = 7.4 Hz, 1H), 6.91 (d, <i>J</i> = 7.4 Hz, 2H), 6.04 (s, 1H), 5.29 (d, <i>J</i> = 5.6 Hz, 1H), 4.73 (t, <i>J</i> = 5.4 Hz, 1H), 4.57 (d, <i>J</i> = 13.2 Hz, 1H), 4.25 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.26 (s, 3H), 2.77 (s, 3H); HRMS (ESI): calcd, 485.1029 [M + H]<sup>+</sup>; found, 485.1035; UPLC: 99.83%.</div></div></div><div id="sec6_16_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-fluorophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>19</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0051.gif" alt="" id="dgr13" /></img><div id="sec6_16_12_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i168" class="anchor-spacer"></div><h5 class="article-section__title" id="_i168"> (<i>E</i>)-1-(5-Chloro-3-hydroxypyridin-2-yl)-3-(4-fluorophenyl)prop-2-en-1-one (<b>99d</b>)</h5><div class="NLM_p last">To a solution of 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) (5.0 g, 29 mmol) in methanol (25 mL), sodium hydroxide (3.5 g, 88 mmol) was added followed by 4-fluorobenzaldehyde (<b>61d</b>) (4.35 g, 35.0 mmol). The reaction mixture was heated at 80 °C for 1 h. Then, the reaction mixture was cooled and the precipitated solid was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-fluorophenyl)prop-2-en-1-one (<b>99d</b>) as a pale yellow solid. Yield: 4.2 g (15 mmol, 52%). MS (ESI) <i>m</i>/<i>z</i>: 276.16 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.23 (d, <i>J</i> = 16.0 Hz, 1H), 7.72–7.68 (dd, <i>J</i> = 13.6, 5.9 Hz, 2H), 7.43 (d, <i>J</i> = 15.8 Hz, 1H), 7.33 (s, 1H), 7.26–7.21 (dd, <i>J</i> = 17.6, 8.9 Hz, 2H), 6.69 (s, 1H).</div></div><div id="sec6_16_12_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i169" class="anchor-spacer"></div><h5 class="article-section__title" id="_i169"> 7-Chloro-2-(4-fluorophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100d</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-fluorophenyl)prop-2-en-1-one (<b>99d</b>) (3.0 g, 11 mmol) in ethanol and dichloromethane (1:1, 100 mL), sodium hydroxide solution (10% aq, 30.0 mL, 33.3 g solution, 3.33 g NaOH, 83.3 mmol) was added followed by hydrogen peroxide (30% aq, 6.7 mL, 7.4 g solution, 2.2 g H<sub>2</sub>O<sub>2</sub>, 66 mmol) at room temperature. The reaction mixture was stirred for 1 h (reaction is exothermic). Then, the reaction mixture was poured into ice-cold water, neutralized with 6 M hydrochloric acid, and extracted with dichloromethane (100 mL). The organic layer was separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was triturated with diethyl ether and <i>n</i>-pentane to afford 7-(chloro)-2-(4-fluoroophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100d</b>) as a yellow solid. Yield: 2.5 g (8.6 mmol, 78%). MS (ESI) <i>m</i>/<i>z</i>: 290.07 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_12_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i170" class="anchor-spacer"></div><h5 class="article-section__title" id="_i170"> <i>rac</i>-Methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-Chloro-6-(4-fluorophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41d</b>)</h5><div class="NLM_p last">A solution of 7-(chloro)-2-(4-fluoroophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100d</b>) (2.5 g, 8.6 mmol) and methyl cinnamate (<b>55</b>) (13.9 g, 85.7 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated under 400 W UV light for 16 h in a UV reactor flask. After this time, the solvent was removed under reduced pressure, and the residue was purified by Combi-flash (24 g, RediSep column) using ethyl acetate as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-6-(4-fluorophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41d</b>). Yield: 2.5 g, crude.</div></div><div id="sec6_16_12_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i171" class="anchor-spacer"></div><h5 class="article-section__title" id="_i171"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-Chloro-5a-(4-fluorophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42d</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-6-(4-fluorophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41d</b>) (1.3 g) was suspended in methanol (15 mL), treated with sodium methoxide (25% in methanol, 15 mL, 14 g solution, 3.5 g NaOMe, 66 mmol), and heated at 80 °C for 1 h. Then, the solvent was removed under reduced pressure, and the reaction mixture was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-5a-(4-fluorophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42d</b>). Yield: 1.4 g, crude.</div></div><div id="sec6_16_12_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i172" class="anchor-spacer"></div><h5 class="article-section__title" id="_i172"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-fluorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101d</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (1.8 g, 8.5 mmol) and crude <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-(chloro)-5a-(4-fluorophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42d</b>) (1.3 g) in acetonitrile (50 mL), acetic acid (1.7 mL, 1.8 g, 30 mmol) was added. The resulting mixture was stirred for 4 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by Combi-flash (4 g, RediSep column) using 50% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-fluorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101d</b>) as a light yellow solid. Yield: 0.32 g (0.71 mmol, 17% over 3 steps). MS (ESI) <i>m</i>/<i>z</i>: 456.17 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.19 (s, 1H), 7.68 (s, 1H), 7.12–7.04 (m, 4H), 7.00–6.95 (m, 3H), 6.84–6.80 (m, 2H), 6.12 (s, 1H), 5.73 (d, <i>J</i> = 5.9 Hz, 1H), 4.63 (d, <i>J</i> = 5.4 Hz, 1H), 4.47 (d, <i>J</i> = 13.3 Hz, 1H), 4.15–4.10 (dd, <i>J</i> = 13.2, 4.4 Hz, 1H), 3.56 (s, 3H).</div></div><div id="sec6_16_12_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i173" class="anchor-spacer"></div><h5 class="article-section__title" id="_i173"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-fluorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S43d</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-fluoroophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101</b>) (0.30 g, 0.66 mmol) in methanol and water (3:1, 12 mL), lithium hydroxide (0.158 g, 6.60 mmol) was added. The reaction mixture was stirred for 6 h at room temperature. After this time, the reaction mixture was cooled to 0 °C and acidified with 6 M hydrochloric acid to pH ≈ 3. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-fluorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43</b>) as a yellow solid. Yield: 0.25 g (0.57 mmol, 86%). MS (ESI) <i>m</i>/<i>z</i>: 442.20 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.11 (br s, 1H), 8.19 (s, 1H), 7.67 (s, 1H), 7.10–7.06 (m, 4H), 7.04–6.98 (m, 3H), 6.84–6.80 (dd, <i>J</i> = 17.2, 8.64 Hz, 2H), 6.06 (s, 1H), 5.69 (br s, 1H), 4.63 (d, <i>J</i> = 4.5 Hz, 1H), 4.43 (d, <i>J</i> = 13.9 Hz, 1H), 4.01–3.96 (dd, <i>J</i> = 12.8, 3.5 Hz, 1H).</div></div><div id="sec6_16_12_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i174" class="anchor-spacer"></div><h5 class="article-section__title" id="_i174"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-fluorophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>19</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-fluorophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43d</b>) (0.25 g, 0.57 mmol) in dichloromethane (10 mL), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.32 g, 1.7 mmol), 1-hydroxybenzotriazole (0.23 g, 1.7 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.6 mL, 0.4 g, 3 mmol) were added at 0 °C. The reaction mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.23 g, 2.8 mmol) was added at the same temperature, and the mixture was stirred for 16 h at 40 °C. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to provide the crude product, which was purified by Combi-flash (12 g, RediSep column) using 5% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-fluorophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>19</b>). Yield: 100 mg (0214 mmol, 37%). The enantiomers were separated by chiral preparative HPLC [Chiralpak ID (4.6 × 250) mm]; peak 1 (26 mg, (+)-<b>19</b>); [α]<sub>D</sub> +182.2° (<i>c</i> 0.3, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 5.88 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 469.34 [M + 1]<sup>+</sup>; UPLC: 99.07%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 1.9 Hz, 1H), 7.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.16–7.13 (m, 2H), 7.02 (t, <i>J</i> = 7.2 Hz, 2H), 6.97–6.93 (m, 1H), 6.90–6.87 (m, 4H), 6.01 (s, 1H), 5.28 (d, <i>J</i> = 5.6 Hz, 1H), 4.75 (t, <i>J</i> = 5.5 Hz, 1H), 4.53 (d, <i>J</i> = 13.3 Hz, 1H), 4.22 (dd, <i>J</i> = 13.2, 5.4 Hz, 1H), 3.26 (s, 3H), 2.77 (s, 3H). Peak-2 (34 mg, (−)-<b>19</b>); [α]<sub>D</sub> −201.4° (<i>c</i> 0.29, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 10.86 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 469.34 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 469.1325 [M + H]<sup>+</sup>; found, 469.1326; UPLC: 99.78%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 1.9 Hz, 1H), 7.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.16–7.13 (m, 2H), 7.03 (t, <i>J</i> = 7.2 Hz, 2H), 6.97–6.82 (m, 4H), 6.01 (s, 1H), 5.28 (d, <i>J</i> = 5.6 Hz, 1H), 4.75 (t, <i>J</i> = 5.5 Hz, 1H), 4.53 (d, <i>J</i> = 13.2 Hz, 1H), 4.22 (dd, <i>J</i> = 13.3, 5.4 Hz, 1H), 3.26 (s, 3H), 2.77 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.17, 160.78 (d, <i>J</i> = 242 Hz), 153.29, 149.79, 140.48, 138.49, 132.19 (d, <i>J</i> = 3.0 Hz), 130.94, 129.41 (d, <i>J</i> = 7.7 Hz), 127.83, 127.40, 125.75, 117.19, 113.23 (d, <i>J</i> = 21.1 Hz), 101.98, 90.48, 77.92, 56.17, 48.47, 36.57, 35.23.</div></div></div><div id="sec6_16_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i175" class="anchor-spacer"></div><h4 class="article-section__title" id="_i175"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>20</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0052.gif" alt="" id="dgr14" /></img><div id="sec6_16_13_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i176" class="anchor-spacer"></div><h5 class="article-section__title" id="_i176"> 4-(Difluoromethyl)benzaldehyde (<b>61e</b>)</h5><div class="NLM_p last">To a solution of 1-bromo-4-(difluoromethyl)benzene (<b>S44</b>) (20.0 g, 96.6 mmol) in dry tetrahydrofuran (200 mL), <i>n</i>-butyllithium in hexanes (2.5 M, 38.6 mL, 96.5 mmol) was added dropwise over a period of 30 min at −78 °C. The reaction mixture was stirred for 1 h at −78 °C. Then, <i>N</i>,<i>N</i>-dimethylformamide (35.3 mL, 33.3 g, 456 mmol) was added at same temperature and the mixture was stirred for 1 h. The reaction mixture was then brought to 0 °C, treated with saturated ammonium chloride solution, and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by Combi-flash (12 g, RediSep column) using 2% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated below 30 °C under reduced pressure to afford unstable 4-(difluoromethyl)benzaldehyde (<b>61e</b>) as a light yellow liquid, which was immediately used in the next step. Yield: 9.0 g (58 mmol, 60%). MS (ESI) <i>m</i>/<i>z</i>: poor ionization; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 10.29 (s, 1H), 7.98 (d, <i>J</i> = 8.0 Hz, 2H), 7.69 (d, <i>J</i> = 7.9 Hz, 2H), 6.85–6.57 (m, 1H).</div></div><div id="sec6_16_13_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i177" class="anchor-spacer"></div><h5 class="article-section__title" id="_i177"> (<i>E</i>)-1-(5-Chloro-3-hydroxypyridin-2-yl)-3-(4-(difluoromethyl)phenyl)prop-2-en-1-one (<b>99e</b>)</h5><div class="NLM_p last">To a solution of 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) (10.4 g, 60.6 mmol) in methanol (50 mL), sodium hydroxide (7.3 g, 180 mmol) and 4-(difluoromethyl)benzaldehyde (<b>61e</b>) (9.5 g, 61 mmol) were added. The reaction mixture was heated at 90 °C for 1 h. Then, it was cooled, and the resulting solid was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-(difluoromethyl)phenyl)prop-2-en-1-one (<b>99e</b>) as a yellow solid. Yield: 20.0 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 308.3 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.38 (d, <i>J</i> = 16.0 Hz, 1H), 7.79 (d, <i>J</i> = 7.5 Hz, 2H), 7.60 (d, <i>J</i> = 7.6 Hz, 2H), 7.49 (d, <i>J</i> = 16.0 Hz, 1H), 7.38 (s, 1H), 7.28–6.91 (m, 1H), 6.77 (s, 1H).</div></div><div id="sec6_16_13_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i178" class="anchor-spacer"></div><h5 class="article-section__title" id="_i178"> 7-Chloro-2-(4-(difluoromethyl)phenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100e</b>)</h5><div class="NLM_p last">To a solution of crude (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-(difluoromethyl)phenyl)prop-2-en-1-one (<b>99e</b>) (20.0 g) in ethanol/dichloromethane (150 mL), 10% aq sodium hydroxide (129 mL, 143 g solution, 14.3 g NaOH, 358 mmol) was added followed by 30% aq hydrogen peroxide (26.5 mL, 29.4 g solution, 8.82 g H<sub>2</sub>O<sub>2</sub>, 259 mmol) at room temperature. The reaction mixture was stirred for 1 h (reaction is exothermic). Then, the reaction mixture was cooled and neutralized with 6 M hydrochloric acid to pH ≈ 7. The mixture was concentrated in vacuo, and the precipitated solid was filtered and dried under vacuum to afford 7-chloro-2-(4-(difluoromethyl)phenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100e</b>) as a yellow solid. Yield: 3.0 g (9.3 mmol, 15% over two steps). MS (ESI) <i>m</i>/<i>z</i>: 322.17 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 10.26 (br s, 1H), 8.81 (s, 1H), 8.64 (s, 1H), 8.36 (d, <i>J</i> = 8.0 Hz, 2H), 7.98 (d, <i>J</i> = 8.2 Hz, 2H), 7.27–6.84 (m, 1H).</div></div><div id="sec6_16_13_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i179" class="anchor-spacer"></div><h5 class="article-section__title" id="_i179"> <i>rac</i>-Methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-Chloro-6-(4-(difluoromethyl)phenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41e</b>)</h5><div class="NLM_p last">A solution of 7-chloro-2-(4-(difluoromethyl)phenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100e</b>) (3.0 g, 9.3 mmol) and methyl cinnamate (<b>55</b>) (13.82 g, 85.21 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated for 16 h under 400 W UV light in a UV reactor flask. After this time, the solvent was removed under reduced pressure, and the crude product was purified by Combi-flash (12 g, RediSep column) using ethyl acetate as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-6-(4-(difluoromethyl)phenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41e</b>) as a brown solid. Yield: 3.0 g, crude.</div></div><div id="sec6_16_13_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i180" class="anchor-spacer"></div><h5 class="article-section__title" id="_i180"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-Chloro-5a-(4-(difluoromethyl)phenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42e</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-6-(4-(difluoromethyl)phenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41e</b>) (3.0 g) was suspended in methanol (30 mL), treated with sodium methoxide (25% in methanol, 25 mL, 24 g solution, 5.9 g NaOMe, 110 mmol NaOMe), and heated at 90 °C for 3 h. After this time, the solvent was removed under reduced pressure. The mixture was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-5a-(4-(difluoromethyl)phenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42e</b>) as a brown solid. Yield: 2.5 g, crude, MS (ESI) <i>m</i>/<i>z</i>: 486.19 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_13_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i181" class="anchor-spacer"></div><h5 class="article-section__title" id="_i181"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101e</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (5.2 g, 25 mmol) and <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-5a-(4-(difluoromethyl)phenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42e</b>) (2.5 g, crude) in acetonitrile (50 mL), acetic acid (2.4 mL, 2.52 g, 42.0 mmol) was added. The resulting mixture was stirred at room temperature for 4 h. Then, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by Combi-flash (12 g, RediSep) using 30% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101e</b>) as an off-white solid. Yield: 1.0 g (2.0 mmol, 22% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 486.29 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 1.8 Hz, 1H), 7.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.26–7.22 (m, 4H), 7.06–6.96 (m, 6H), 6.17 (s, 1H), 5.75 (d, <i>J</i> = 5.6 Hz, 1H), 4.65 (t, <i>J</i> = 5.2 Hz, 1H), 4.52 (d, <i>J</i> = 13.8 Hz, 1H), 4.22–4.17 (dd, <i>J</i> = 13.6, 4.2 Hz, 1H), 3.54 (s, 3H).</div></div><div id="sec6_16_13_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i182" class="anchor-spacer"></div><h5 class="article-section__title" id="_i182"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S43e</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101e</b>) (1.2 g, 2.5 mmol) in methanol and water (3:1, 16 mL), lithium hydroxide (0.55 g, 23.0 mmol) was added. The reaction mixture was stirred at room temperature for 16 h. After this time, the reaction mixture was cooled to 0 °C and acidified with 1 M hydrochloric acid to pH ≈ 3. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43e</b>) as a yellow solid. Yield: 1.05 g (2.2 mmol, 88%). MS (ESI) <i>m</i>/<i>z</i>: 472.2 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.14 (s, 1H), 7.64 (s, 1H), 7.20–7.15 (m, 7H), 7.04–7.00 (dd, <i>J</i> = 14.7, 7.5 Hz, 2H), 6.94–6.91 (dd, <i>J</i> = 14.0, 6.7 Hz, 1H), 6.91–6.67 (m, 1H), 5.94 (s, 1H), 4.50 (d, <i>J</i> = 13.9 Hz, 1H), 4.41 (br s, 1H), 3.69 (d, <i>J</i> = 14.7 Hz, 1H).</div></div><div id="sec6_16_13_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i183" class="anchor-spacer"></div><h5 class="article-section__title" id="_i183"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>20</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43e</b>) (0.6 g, 1.3 mmol) in dichloromethane (50 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.72 g, 3.8 mmol), 1-hydroxybenzotriazole (0.513 g, 3.80 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.34 mL, 0.994 g, 7.69 mmol) were added. The reaction mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.514 g, 6.30 mmol) was added at same temperature and the mixture was stirred for 16 h at 40 °C. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to provide the crude product, which was purified by Combi-flash (4 g, RediSep) using 70% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford racemic (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-(difluoromethyl)phenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>20</b>) as a white solid. Yield: 400 mg (0.799 mmol, 61%). The enantiomers were separated by chiral preparative HPLC [Chiralpak ID (4.6 × 250) mm]. Peak 1 (116 mg, (+)-<b>20</b>), [α]<sub>D</sub> +218.2° (<i>c</i> 0.25, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 8.37 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 501.40 [M + 1]<sup>+</sup>; UPLC: 99.38%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.72 (d, <i>J</i> = 2.0 Hz, 1H), 7.28–7.22 (m, 4H), 7.03–6.91 (m, 5H), 6.85 (t, <i>J</i> = 56.0 Hz, 1H), 6.06 (s, 1H), 5.30 (d, <i>J</i> = 5.6 Hz, 1H), 4.76 (t, <i>J</i> = 5.6 Hz, 1H), 4.60 (d, <i>J</i> = 13.2 Hz, 1H), 4.30 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.28 (s, 3H), 2.78 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.15, 153.30, 149.69, 140.55, 139.05 (t, <i>J</i> = 2.1 Hz), 138.35, 131.94 (t, <i>J</i> = 21.9 Hz), 130.97, 127.82, 127.43, 125.78, 123.82 (t, <i>J</i> = 6.1 Hz), 117.23, 114.87 (t, <i>J</i> = 235 Hz), 102.11, 90.76, 77.95, 56.21, 48.58, 36.60, 35.25. Peak-2 (129 mg, (−)-<b>20</b>), [α]<sub>D</sub> −190° (<i>c</i> 0.28, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 18.28 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 501.40 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 501.1387 [M + H]<sup>+</sup>; found, 501.1397; UPLC: 99.29%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.72 (d, <i>J</i> = 2.0 Hz, 1H), 7.28 (dd, <i>J</i> = 16.8 Hz, 8.4 Hz, 4H), 7.03–6.91 (m, 5H), 6.85 (t, <i>J</i> = 56.0 Hz, 1H), 6.06 (s, 1H), 5.30 (d, <i>J</i> = 5.6 Hz, 1H), 4.76 (t, <i>J</i> = 5.6 Hz, 1H), 4.60 (d, <i>J</i> = 13.2 Hz, 1H), 4.30 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.28 (s, 3H), 2.79 (s, 3H).</div></div></div><div id="sec6_16_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i184" class="anchor-spacer"></div><h4 class="article-section__title" id="_i184"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>21</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0053.gif" alt="" id="dgr15" /></img><div id="sec6_16_14_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i185" class="anchor-spacer"></div><h5 class="article-section__title" id="_i185"> (<i>E</i>)-1-(5-Chloro-3-hydroxypyridin-2-yl)-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one (<b>99e</b>)</h5><div class="NLM_p last">To a solution of 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) (6.0 g, 35 mmol) in methanol (20 mL), sodium hydroxide (4.2 g, 0.11 mol) and 4-(trifluoromethyl)benzaldehyde (<b>61e</b>) (6.1 g, 35 mmol) were added. The reaction mixture was heated at 90 °C for 1 h. After this time, the reaction mixture was cooled, and the resulting precipitate was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one (<b>99e</b>) as a yellow solid. Yield: 6.0 g (18 mmol, 51%). MS (ESI) <i>m</i>/<i>z</i>: 328.26 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.41 (d, <i>J</i> = 16.0 Hz, 1H), 7.86 (d, <i>J</i> = 7.6 Hz, 2H), 7.75 (d, <i>J</i> = 7.9 Hz, 2H), 7.49 (d, <i>J</i> = 16.1 Hz, 1H), 7.36 (s, 1H), 6.73 (s, 1H).</div></div><div id="sec6_16_14_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i186" class="anchor-spacer"></div><h5 class="article-section__title" id="_i186"> 7-Chloro-3-hydroxy-2-(4-(trifluoromethyl)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100f</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-(trifluoromethyl)phenyl)prop-2-en-1-one (<b>99f</b>) (6.0 g, 18 mmol) in ethanol and dichloromethane (1:1, 200 mL) at room temperature, 10% aq sodium hydroxide (50.1 mL sln, 5.56 g NaOH, 139 mmol) was added followed by 30% aq hydrogen peroxide (12.5 mL sln, 4.16 g H<sub>2</sub>O<sub>2</sub>, 122 mmol). The reaction mixture was stirred for 30 min (reaction is exothermic!). After this time, the reaction mixture was cooled and neutralized with 6 M hydrogen chloride to pH ≈ 7. Then, the dichloromethane was removed by distillation, and the precipitated solid was collected by filtration and washed with ethanol and <i>n</i>-pentane. The so-obtained material was dried under vacuum to afford 7-chloro-3-hydroxy-2-(4-(trifluoromethyl)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100f</b>) as a light orange solid. Yield: 3.5 g (10 mmol, 56%). MS (ESI) <i>m</i>/<i>z</i>: 342.06 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.74 (s, 1H), 8.60 (s, 1H), 8.57 (d, <i>J</i> = 7.0 Hz, 2H), 7.85 (d, <i>J</i> = 8.2 Hz, 2H).</div></div><div id="sec6_16_14_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i187" class="anchor-spacer"></div><h5 class="article-section__title" id="_i187"> <i>rac</i>-Methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-Chloro-9-hydroxy-10-oxo-7-phenyl-6-(4-(trifluoromethyl)-phenyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41f</b>)</h5><div class="NLM_p last">A solution of 7-chloro-3-hydroxy-2-(4-(trifluoromethyl)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100f</b>) (3.0 g, 8.8 mmol) and methyl cinnamate (<b>55</b>) (14.2 g, 87.6 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated for 24 h under 400 W UV light in a UV reactor flask. After this time, the solvent was removed under reduced pressure, and the residue was purified by Combi-flash (24 g RediSep column) using ethyl acetate as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6-(4-(trifluoromethyl)-phenyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41f</b>) as a sticky brown solid. Yield: 3.0 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 504.39 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_14_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i188" class="anchor-spacer"></div><h5 class="article-section__title" id="_i188"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-Chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(4-(trifluoromethyl)-phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42f</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6-(4-(trifluoromethyl)-phenyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41f</b>) (3.0 g) was suspended in methanol (30 mL) and treated with 25% sodium methoxide in methanol (30 mL, 28 g solution, 7.1 g NaOMe, 13 mmol). This mixture was heated at 90 °C for 3 h. After this time, the solvent was removed under reduced pressure. The crude product was treated with aqueous ammonium chloride and extracted with ethyl acetate. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42f</b>) as a sticky brown solid. Yield: 2.5 g, crude; MS (ESI) <i>m</i>/<i>z</i>: 504.10 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_14_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i189" class="anchor-spacer"></div><h5 class="article-section__title" id="_i189"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethyl)-phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101f</b>)</h5><div class="NLM_p last">To a solution of crude <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42f</b>) (2.5 g) in acetonitrile (250 mL) at 0 °C, sodium triacetoxyborohydride (6.0 g, 28 mmol) and acetic acid (3.0 mL, 3.2 g, 52 mmol) were added. The resulting mixture was stirred for 10 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by Combi-flash (12 g RediSep column) using 70% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101f</b>) as an off-white solid. Yield: 1.1 g (2.1 mmol, 25% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 506.8 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 1.8 Hz, 1H), 7.72 (d, <i>J</i> = 1.8 Hz, 1H), 7.37–7.30 (m, 4H), 7.07–6.97 (m, 5H), 6.23 (s, 1H), 5.80–5.74 (dd, <i>J</i> = 16.3, 4.0 Hz, 1H), 4.65 (t, <i>J</i> = 5.0 Hz, 1H), 4.55 (d, <i>J</i> = 13.7 Hz, 1H), 4.24–4.19 (dd, <i>J</i> = 13.8, 4.7 Hz, 1H), 3.58 (s, 3H).</div></div><div id="sec6_16_14_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i190" class="anchor-spacer"></div><h5 class="article-section__title" id="_i190"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S43f</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101f</b>) (1.1 g, 2.1 mmol) in methanol and water (3:1, 13 mL), lithium hydroxide monohydrate (2.19 g, 52.2 mmol) was added. The reaction mixture was stirred for 3 h at room temperature. After this time, the reaction mixture was cooled to 0 °C and acidified with 6 M hydrogen chloride to pH ≈ 6. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43f</b>) as an off-white solid. Yield: 900 mg (1.83 mmol, 87%). MS (ESI) <i>m</i>/<i>z</i>: 492.5 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.15 (d, <i>J</i> = 1.6 Hz, 1H), 7.65 (d, <i>J</i> = 1.6 Hz, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 2H), 7.24 (d, <i>J</i> = 8.0 Hz, 2H), 7.17 (d, <i>J</i> = 6.8 Hz, 2H), 7.05–7.01 (dd, <i>J</i> = 15.2, 7.6 Hz, 2H), 6.94 (d, <i>J</i> = 6.8 Hz, 1H), 5.97 (s, 1H), 4.52 (d, <i>J</i> = 13.6 Hz, 1H), 4.41 (s, 1H), 3.66 (br s, 1H).</div></div><div id="sec6_16_14_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i191" class="anchor-spacer"></div><h5 class="article-section__title" id="_i191"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>21</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43f</b>) (0.90 g, 1.8 mmol) in dichloromethane (50 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.0 g, 5.2 mmol), 1-hydroxybenzotriazole (0.74 g, 4.8 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (1.9 mL, 1.4 g, 11 mmol) were added. This reaction mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.74 g, 9.1 mmol) was added at same temperature, and the mixture was stirred for 20 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product which was purified by Combi-flash (4 g RediSep column) using 5% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(4-(trifluoromethyl)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>21</b>) as an off-white solid. Yield: 0.5 g (0.96 mmol, 54%). The enantiomers were separated by chiral preparative HPLC [Chiralpak ID (4.6 × 250) mm]. Peak 1 (50 mg, (+)-<b>21</b>); [α]<sub>D</sub> +212.0° (<i>c</i> 0.1, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 6.26 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 519.30 [M + 1]<sup>+</sup>; UPLC 97%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.74 (d, <i>J</i> = 2.0 Hz, 1H), 7.35 (dd, <i>J</i> = 13.6 Hz, 8.9 Hz, 4H), 7.04–7.00 (m, 2H), 6.96–6.91 (m, 3H), 6.13 (s, 1H), 5.34 (d, <i>J</i> = 5.6 Hz, 1H), 4.77 (t, <i>J</i> = 5.4 Hz, 1H), 4.64 (d, <i>J</i> = 13.2 Hz, 1H), 4.34 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.28 (s, 3H), 2.78 (s, 3H). Peak-2 (50 mg, (−)-<b>21</b>); [α]<sub>D</sub> −194.5° (<i>c</i> 0.1, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 12.49 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 519.31 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 519.1292 [M + H]<sup>+</sup>; found, 519.1293; UPLC 99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.74 (d, <i>J</i> = 2.0 Hz, 1H), 7.35 (dd, <i>J</i> = 13.6 Hz, 8.9 Hz, 4H), 7.04–7.00 (m, 2H), 6.96–6.91 (m, 3H), 6.13 (s, 1H), 5.34 (d, <i>J</i> = 5.6 Hz, 1H), 4.77 (t, <i>J</i> = 5.4 Hz, 1H), 4.64 (d, <i>J</i> = 13.2 Hz, 1H), 4.34 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.28 (s, 3H), 2.78 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.05, 153.25, 149.51, 140.93, 140.67, 138.20, 131.00, 128.24, 127.78, 127.47, 126.91 (q, <i>J</i> = 31.4 Hz), 125.84, 124.23 (q, <i>J</i> = 272 Hz), 123.20 (q, <i>J</i> = 3.8 Hz), 117.26, 101.94, 90.96, 77.92, 56.31, 48.68, 36.60, 35.26.</div></div></div><div id="sec6_16_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i192" class="anchor-spacer"></div><h4 class="article-section__title" id="_i192"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>22</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0054.gif" alt="" id="dgr16" /></img><div id="sec6_16_15_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i193" class="anchor-spacer"></div><h5 class="article-section__title" id="_i193"> (<i>E</i>)-1-(5-Chloro-3-hydroxypyridin-2-yl)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-one (<b>99g</b>)</h5><div class="NLM_p last">To a solution of 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) (7.0 g, 41 mmol) and 4-(trifluoromethoxy)benzaldehyde (<b>61g</b>) (7.75 g, 40.8 mmol) in methanol (35 mL), sodium hydroxide (4.89 g, 122 mmol) was added. This reaction mixture was heated to reflux for 30 min. Then, the reaction mixture was cooled to room temperature and diluted with water (50 mL). The resulting precipitate was collected by filtration, washed with water and then <i>n</i>-pentane, and dried under vacuum to afford (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-(trifluoromethoxy)-phenyl)prop-2-en-1-one (<b>99g</b>) as a yellow solid. Yield: 7.1 g (21 mmol, 50%); MS (ESI) <i>m</i>/<i>z</i>: 342.18 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.22 (d, <i>J</i> = 16.08 Hz, 1H), 7.92 (d, <i>J</i> = 4.92 Hz, 2H), 7.89 (s, 1H), 7.73 (d, <i>J</i> = 16.24 Hz, 1H), 7.43 (d, <i>J</i> = 7.24 Hz, 2H), 7.31 (s, 1H).</div></div><div id="sec6_16_15_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i194" class="anchor-spacer"></div><h5 class="article-section__title" id="_i194"> 7-Chloro-3-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100g</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-(trifluoromethoxy)phenyl)prop-2-en-1-one (<b>99g</b>) (5.0 g, 15 mmol) in ethanol (50 mL) at 0 °C, 10% aq sodium hydroxide (36.1 mL, 40.1 g solution, 4.01 g, 100 mmol) was added followed by 30% aq hydrogen peroxide (11.15 mL, 12.38 g solution, 3.713 g H<sub>2</sub>O<sub>2</sub>, 101.5 mmol). The reaction mixture was stirred for 30 min at room temperature (reaction is exothermic). Then, the mixture was cooled and neutralized by the addition of 6 M hydrochloric acid to pH ≈ 7. The resulting precipitate was collected by filtration, washed with ethanol and then pentane, and dried under vacuum to afford 7-chloro-3-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100g</b>) as a white solid. Yield: 2.8 g (7.8 mmol, 52%). MS (ESI) <i>m</i>/<i>z</i>: 356.14 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 10.22 (br s, 1H), 8.81 (s, 1H), 8.62 (s, 1H), 8.34 (d, <i>J</i> = 7.4 Hz, 2H), 7.60 (d, <i>J</i> = 6.7 Hz, 2H).</div></div><div id="sec6_16_15_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i195" class="anchor-spacer"></div><h5 class="article-section__title" id="_i195"> <i>rac</i>-Methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-Chloro-9-hydroxy-10-oxo-7-phenyl-6-(4-(trifluoromethoxy)-phenyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (S41g)</h5><div class="NLM_p last">A solution of 7-chloro-3-hydroxy-2-(4-(trifluoromethoxy)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100g</b>) (2.8 g, 7.8 mmol) and methyl cinnamate (<b>55</b>) (12.69 g, 78.24 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated under 400 W UV light in a UV reactor flask for 24 h. After this time, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting the compound with 5% methanol in dichloromethane. The desired fractions were concentrated under reduced pressure to afford methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6-(4-(trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41g</b>) as a brown solid. Yield: 3.0 g, crude.</div></div><div id="sec6_16_15_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i196" class="anchor-spacer"></div><h5 class="article-section__title" id="_i196"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-Chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42g</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6-(4-(trifluoromethoxy)phenyl)-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41g</b>) (3.0 g) was suspended in methanol (60 mL) and treated with 25% sodium methoxide in methanol (12.4 mL, 11.7 g solution, 2.93 g NaOMe, 54.2 mmol). The reaction was heated at 80 °C for 4 h. After this time, the solvent was removed under reduced pressure. The crude product was diluted with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42g</b>) as a brown solid. Yield: 3.0 g, crude.</div></div><div id="sec6_16_15_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i197" class="anchor-spacer"></div><h5 class="article-section__title" id="_i197"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101g</b>)</h5><div class="NLM_p last">A solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42g</b>) (3.0 g) in acetonitrile (60 mL) was cooled to 0 °C. To this solution acetic acid (3.46 g, 57.6 mmol) and sodium triacetoxyborohydride (7.3 g, 34 mmol) were added. The resulting mixture was stirred for 12 h at room temperature. After completion, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography using 2–3% in methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101g</b>) as a white solid. Yield: 0.6 g (1.2 mmol, 15% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 522.2 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 1.8 Hz, 1H), 7.70 (s, 1H), 7.20 (d, <i>J</i> = 8.7 Hz, 2H), 7.06–6.95 (m, 7H), 6.21 (s, 1H), 5.76 (d, <i>J</i> = 5.7 Hz, 1H), 4.66 (t, <i>J</i> = 5.1 Hz, 1H), 4.49 (d, <i>J</i> = 13.8 Hz, 1H), 4.17–4.13 (dd, <i>J</i> = 13.8, 4.7 Hz, 1H), 3.57 (s, 3H).</div></div><div id="sec6_16_15_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i198" class="anchor-spacer"></div><h5 class="article-section__title" id="_i198"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethoxy)-phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S43g</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101g</b>) (0.6 g, 1.2 mmol) in a mixture of methanol, tetrahydrofuran. and water (2:1:1, 12 mL) was added lithium hydroxide (anhydrous, 0.27 g, 11 mmol). The reaction mixture was stirred for 6 h at room temperature. Then, it was concentrated, cooled to 0 °C, and acidified with 1 M hydrochloric acid to pH ≈ 2–3. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43g</b>) as an off-white solid. Yield: 0.45 g (0.89 mmol, 74%). MS (ESI) <i>m</i>/<i>z</i>: 506.19 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.17 (s, 1H), 7.66 (s, 1H), 7.16 (d, <i>J</i> = 8.6 Hz, 2H), 7.04–6.96 (m, 7H), 6.07 (s, 1H), 4.53 (br s, 1H), 4.46 (d, <i>J</i> = 13.8 Hz, 1H), 3.84–3.81 (m, 1H).</div></div><div id="sec6_16_15_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i199" class="anchor-spacer"></div><h5 class="article-section__title" id="_i199"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>22</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43g</b>) (0.3 g, 0.6 mmol) in dichloromethane (10 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.275 g, 1.77 mmol), hydroxybenzotriazole (0.271 g, 2.00 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.58 mL, 0.43 g, 3.32 mmol) were added. This reaction mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.241 g, 2.96 mmol) was added at the same temperature, and the mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography using 2–3% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford racemic (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a-(4-(trifluoromethoxy)phenyl)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>22</b>) as an off-white solid. Yield: 0.146 g (0.273 mmol, 45%). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (79 mg, (+) -<b>22</b>), [α]<sub>D</sub> +211° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 5.982 min, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.71 (d, <i>J</i> = 2.0 Hz, 1H), 7.24 (d, <i>J</i> = 8.8 Hz, 2H), 7.04–6.98 (m, 4H), 6.94 (t, <i>J</i> = 7.2 Hz, 1H), 6.89 (d, <i>J</i> = 7.6 Hz, 2H), 6.10 (s, 1H), 5.31 (d, <i>J</i> = 5.6 Hz, 1H), 4.76 (t, <i>J</i> = 5.4 Hz, 1H), 4.55 (d, <i>J</i> = 13.6 Hz, 1H), 4.25 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.26 (s, 3H), 2.77 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 535.36 [M + 1]<sup>+</sup>; UPLC: 98.9%. Peak-2 (67 mg, (−)-<b>22</b>), [α]<sub>D</sub> −217.4° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 12.093 min, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.71 (d, <i>J</i> = 2.0 Hz, 1H), 7.24 (d, <i>J</i> = 8.8 Hz, 2H), 7.04–6.98 (m, 4H), 6.95 (t, <i>J</i> = 6.8 Hz, 1H), 6.89 (d, <i>J</i> = 7.6 Hz, 2H), 6.10 (s, 1H), 5.31 (d, <i>J</i> = 5.6 Hz, 1H), 4.76 (t, <i>J</i> = 5.4 Hz, 1H), 4.55 (d, <i>J</i> = 13.2 Hz, 1H), 4.25 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.26 (s, 3H), 2.77 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.09, 153.22, 149.66, 146.84, 140.59, 138.32, 135.51, 130.97, 129.33, 127.79, 127.39, 125.76, 118.91, 117.25, 101.85, 90.63, 77.94, 56.31, 48.53, 36.57, 35.24. MS (ESI) <i>m</i>/<i>z</i>: 535.39 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 535.1242 [M + H]<sup>+</sup>; found, 535.1254; UPLC: 99.57%.</div></div></div><div id="sec6_16_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i200" class="anchor-spacer"></div><h4 class="article-section__title" id="_i200"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-5a-(4-(methylsulfonyl)phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>23</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0055.gif" alt="" id="dgr17" /></img><div id="sec6_16_16_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i201" class="anchor-spacer"></div><h5 class="article-section__title" id="_i201"> (<i>E</i>)-1-(5-Chloro-3-hydroxypyridin-2-yl)-3-(4-(methylsulfonyl)phenyl)prop-2-en-1-one (<b>99h</b>)</h5><div class="NLM_p last">To a solution of 1-(5-chloro-3-hydroxypyridin-2-yl)ethan-1-one (<b>98</b>) (4.0 g, 23 mmol) in methanol (20 mL), sodium hydroxide (2.8 g, 70 mmol) was added followed by 4-(methylsulfonyl)benzaldehyde (<b>61h</b>) (4.3 g, 23 mmol). The reaction mixture was heated to reflux for 30 min. Then, the mixture was cooled to room temperature and diluted with water (20 mL). The resulting precipitate was collected by filtration, washed with water and then <i>n</i>-pentane, and dried under vacuum to afford (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-(methylsulfonyl)phenyl)prop-2-en-1-one (<b>99h</b>) as a yellow solid. Yield: 5.3 g (16 mmol, 70%). MS (ESI) <i>m</i>/<i>z</i>: 338.15 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.36 (d, <i>J</i> = 14.4 Hz, 1H), 7.97 (s, 4H), 7.76–7.65 (m, 2H), 7.11 (br s, 1H), 3.24 (s, 3H).</div></div><div id="sec6_16_16_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i202" class="anchor-spacer"></div><h5 class="article-section__title" id="_i202"> 7-Chloro-3-hydroxy-2-(4-(methylsulfonyl)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100h</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(5-chloro-3-hydroxypyridin-2-yl)-3-(4-(methylsulfonyl)-phenyl)prop-2-en-1-one (<b>99h</b>) (5.3 g, 16 mmol) in ethanol (30 mL) and dichloromethane (6 mL) at 0 °C, 10% aq sodium hydroxide (40 mL, 44 g solution, 4.4 g NaOH, 110 mmol) was added followed by 30% hydrogen peroxide in water (11.3 mL, 12.5 g solution, 3.76 g H<sub>2</sub>O<sub>2,</sub> 111 mmol). The reaction mixture was stirred for 30 min at room temperature (reaction is exothermic). Then, the reaction mixture was cooled and neutralized to pH ≈ 7 by the addition of 6 M hydrochloric acid. The mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with water and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The solid obtained was triturated with <i>n</i>-pentane and ethanol, filtered, and dried under vacuum to afford 7-chloro-3-hydroxy-2-(4-(methylsulfonyl)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100h</b>) as a light brown solid. Yield: 0.80 g (2.3 mmol, 14%). MS (ESI) <i>m</i>/<i>z</i>: 352.13 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 10.50 (br s, 1H), 8.82 (s, 1H), 8.66 (s, 1H), 8.45 (d, <i>J</i> = 6.2 Hz, 2H), 8.12 (d, <i>J</i> = 6.7 Hz, 2H).</div></div><div id="sec6_16_16_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i203" class="anchor-spacer"></div><h5 class="article-section__title" id="_i203"> <i>rac</i>-Methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-Chloro-9-hydroxy-6-(4-(methylsulfonyl)phenyl)-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41h</b>)</h5><div class="NLM_p last">A solution of 7-chloro-3-hydroxy-2-(4-(methylsulfonyl)phenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>100h</b>) (1.9 g, 5.4 mmol) and methyl cinnamate (<b>55</b>) (8.8 g, 54 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated under 400 W UV light in a UV reactor flask for 8 h. After this time, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting the compound with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-9-hydroxy-6-(4-(methylsulfonyl)phenyl)-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41h</b>) as a brown solid. Yield: 2.5 g, crude.</div></div><div id="sec6_16_16_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i204" class="anchor-spacer"></div><h5 class="article-section__title" id="_i204"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-Chloro-8a-hydroxy-5a-(4-(methylsulfonyl)phenyl)-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42h</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-chloro-9-hydroxy-6-(4-(methylsulfonyl)phenyl)-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S41h</b>) (2.5 g) was suspended in methanol (30 mL), treated with 25% sodium methoxide in methanol (15 mL, 14 g solution, 3.5 g NaOMe, 66 mmol), and heated at 80 °C for 2 h. Then, the solvent was removed under reduced pressure. The crude product was diluted with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-5a-(4-(methylsulfonyl)phenyl)-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42h</b>). Yield: 1.6 g, crude.</div></div><div id="sec6_16_16_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i205" class="anchor-spacer"></div><h5 class="article-section__title" id="_i205"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-5a-(4-(methylsulfonyl)phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101h</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (3.96 g, 18.8 mmol), a solution of the crude methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-chloro-8a-hydroxy-5a-(4-(methylsulfonyl)phenyl)-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S42h</b>) (1.6 g) in acetonitrile (30 mL) and acetic acid (1.78 mL, 1.87 g, 31.1 mmol) was added. The resulting mixture was stirred for 12 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography using 2–3% dichloromethane in methanol as the eluent. The desired fractions were concentrated to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-(methylsulfonyl)phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101h</b>) as a brown solid. Yield: 0.6 g (1.2 mmol, 22% over three steps); MS (ESI) <i>m</i>/<i>z</i>: 516.1 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (s, 1H), 7.73 (s, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 2H), 7.36 (d, <i>J</i> = 8.3 Hz, 2H), 7.07–6.96 (m, 5H), 6.28 (s, 1H), 5.79 (d, <i>J</i> = 5.5 Hz, 1H), 4.66 (t, <i>J</i> = 5.1 Hz, 1H), 4.56 (d, <i>J</i> = 13.8 Hz, 1H), 4.26–4.22 (dd, <i>J</i> = 13.8, 4.4 Hz, 1H), 3.58 (s, 3H), 3.02 (s, 3H).</div></div><div id="sec6_16_16_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i206" class="anchor-spacer"></div><h5 class="article-section__title" id="_i206"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-5a-(4-(methylsulfonyl)phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S43h</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-(methylsulfonyl)-phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>101h</b>) (0.6 g, 1.2 mmol) in a mixture of methanol, tetrahydrofuran, and water (2:1:1, 12 mL), lithium hydroxide (anhydrous, 0.27 g, 11 mmol) was added. The reaction mixture was stirred for 2 h at room temperature. After completion, the reaction mixture was cooled to 0 °C and acidified with 1 M hydrochloric acid to pH ≈ 2–3. The precipitate was filtered and dried under vacuum to afford (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-(methylsulfonyl)phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43h</b>) as an off-white solid. Yield: 0.45 g (0.90 mmol, 75%); MS (ESI) <i>m</i>/<i>z</i>: 502.04 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.30 (br s,1H), 8.21 (s, 1H), 7.73 (s, 1H), 7.55 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (d, <i>J</i> = 8.6 Hz, 2H), 7.06–6.96 (m, 5H), 6.23 (s, 1H), 5.75 (br s, 1H), 4.65 (br s, 1H), 4.52 (d, <i>J</i> = 13.6 Hz, 1H), 4.11 (m, 1H), 3.01 (s, 3H).</div></div><div id="sec6_16_16_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i207" class="anchor-spacer"></div><h5 class="article-section__title" id="_i207"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-5a-(4-(methylsulfonyl)phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>23</b>)</h5><div class="NLM_p last">To a solution of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-5a-(4-(methylsulfonyl)-phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S43h</b>) (0.3 g, 0.6 mmol) in dichloromethane (8 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.28 g, 1.8 mmol), hydroxybenzotriazole (0.27 g, 2.0 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.46 g, 3.6 mmol) were added. The mixture was stirred for 10 min. Then, dimethylamine hydrochloride (0.24 g, 2.9 mmol) was then added at the same temperature, and the reaction mixture was stirred for 32 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product. This was purified by silica gel column chromatography using 2–3% dichloromethane in methanol as the eluent. The desired fractions were concentrated under reduced pressure to afford racemic (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-5a-(4-(methylsulfonyl)phenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>23</b>) as an off-white solid. Yield: 0.159 g (0.30 mmol, 50%). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (47 mg, (+)-<b>23</b>), [α]<sub>D</sub> +196.1° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 8.089 min, ee >99%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.74 (d, <i>J</i> = 2.0 Hz, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.04 (t, <i>J</i> = 7.2 Hz, 2H), 6.96 (t, <i>J</i> = 9.6 Hz, 3H), 6.16 (br s, 1H), 5.38 (br s, 1H), 4.77 (d, <i>J</i> = 5.2 Hz, 1H), 4.64 (d, <i>J</i> = 13.6 Hz, 1H), 4.35 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.28 (s, 3H), 3.03 (s, 3H), 2.78 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 529.35 [M + 1]<sup>+</sup>; UPLC: 99.92%. Peak-2 (44 mg, (−)-<b>23</b>), [α]<sub>D</sub> −173.2° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 16.147 min, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.74 (d, <i>J</i> = 2.0 Hz, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.41 (d, <i>J</i> = 8.4 Hz, 2H), 7.04 (t, <i>J</i> = 7.2 Hz, 2H), 6.96 (t, <i>J</i> = 9.6 Hz, 3H), 6.18 (br s, 1H), 5.36 (br s, 1H), 4.77 (d, <i>J</i> = 5.2 Hz, 1H), 4.64 (d, <i>J</i> = 13.2 Hz, 1H), 4.35 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.28 (s, 3H), 3.03 (s, 3H), 2.98 (s, 3H); 13C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.03, 153.18, 149.49, 142.12, 140.71, 138.68, 138.08, 131.00, 128.40, 127.79, 127.51, 125.90, 124.99, 117.31, 101.98, 91.00, 77.91, 56.37, 48.68, 43.53, 36.61, 35.25. MS (ESI) <i>m</i>/<i>z</i>: 529.34 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 529.1195 [M + H]<sup>+</sup>; found, 529.1201; UPLC: 99.83%.</div></div></div><div id="sec6_16_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i208" class="anchor-spacer"></div><h4 class="article-section__title" id="_i208"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>8</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0056.gif" alt="" id="dgr18" /></img><div id="sec6_16_17_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i209" class="anchor-spacer"></div><h5 class="article-section__title" id="_i209"> (<i>E</i>)-3-(4-Bromophenyl)-1-(5-chloro-3-hydroxypyridin-2-yl)prop-2-en-1-one (<b>S44</b>)</h5><div class="NLM_p last">To a solution of l-(5-chloro-3-hydroxypyridin-2-yl)ethan-<span class="smallcaps smallerCapital">l</span>-one (<b>98</b>) (10.0 g, 58.3 mmol) and sodium hydroxide (7.0 g, 0.18 mol) in methanol (100 mL), 4-bromobenzaldehyde (10.75 g, 58.10 mmol) was added, and the reaction mixture was heated to reflux for 30 min. After completion, the reaction mixture was cooled and the precipitated solid was collected by filtration, washed with water, and dried under high vacuum to afford (<i>E</i>)-3-(4-bromophenyl)-1 -(5-chloro-3-hydroxypyridin-2-yl)prop-2-en-1-one (<b>S44</b>) as a yellow solid. Yield: 12.0 g (35.4 mmol, 61%); MS (ESI) <i>m</i>/<i>z</i>: 338.95 [M + 1]<sup>+</sup>. The so-obtained material was directly used in the next step without further purification.</div></div><div id="sec6_16_17_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i210" class="anchor-spacer"></div><h5 class="article-section__title" id="_i210"> 2-(4-Bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>102</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-3-(4-bromophenyl)-l-(5-chloro-3-hydroxypyridin-2-yl)prop-2-en-<span class="smallcaps smallerCapital">l</span>-one (<b>S44</b>) (12.0 g, 35.4 mmol) and sodium hydroxide (10.0 g, 250 mmol) in ethanol (120 mL) and dichloromethane (40 mL), hydrogen peroxide (<i>ca.</i> 30% in water, 8.97 mL, 9.96 g solution; 2.99 g, 87.9 mmol) was added at room temperature. The reaction mass was stirred for 1 h at room temperature (reaction is exothermic). Then, the reaction mixture was cooled and neutralized to pH ≈ 7 by addition of 6 M hydrochloric acid. The precipitated solid was collected by filtration and dried under vacuum to afford 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>102</b>) as a pale yellow solid. Yield: 4.0 g (11 mmol, 31%). MS (ESI) <i>m</i>/<i>z</i>: 352.2 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub><a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a>): δ/ppm 10.23 (s, 1H), 8.80 (d, <i>J</i> = 2.0 Hz, 1H), 8.61 (d, <i>J</i> = 2.0 Hz, 1H), 8.17 (d, <i>J</i> = 8.8 Hz, 2H), 7.79 (d, <i>J</i> = 8.8 Hz, 2H).</div></div><div id="sec6_16_17_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i211" class="anchor-spacer"></div><h5 class="article-section__title" id="_i211"> <i>rac</i>-Methyl (7<i>S</i>,8<i>S</i>,9<i>R</i>)-6-(4-Bromophenyl)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S45</b>)</h5><div class="NLM_p last">A solution of 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>102</b>) (25.0 g, 70.9 mmol) and methyl cinnamate (<b>55</b>) (171.2 g, 1.056 mol) in dichloromethane (800 mL), acetonitrile (400 mL), and methanol (400 mL) was irradiated under 400 W UV light for 16 h in a UV reactor flask. Then, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting the compound with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford crude (7<i>S</i>,8<i>S</i>,9<i>R</i>)-6-(4-bromophenyl)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>7</b>) as a yellow-brown solid. Yield: 30.0 g, crude; MS (ESI) <i>m</i>/<i>z</i>: 514.12 [M + 1]<sup>+</sup>. Used without further purification.</div></div><div id="sec6_16_17_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i212" class="anchor-spacer"></div><h5 class="article-section__title" id="_i212"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-Bromophenyl)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>125</b>)</h5><div class="NLM_p last">Crude <i>rac</i>-(7<i>S</i>,8<i>S</i>,9<i>R</i>)-6-(4-bromophenyl)-3-chloro-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S45</b>) (9.0 g) was suspended in methanol (100 mL) and treated with 25% sodium methoxide in methanol (20.0 mL, 18.9 g solution; 4.73 g, 87.6 mmol NaOMe). The reaction mixture was heated at 80 °C for 3 h. After this time, the solvent was removed under reduced pressure. The crude product was diluted with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>125</b>). Yield: 9.0 g, crude. Used without further purification.</div></div><div id="sec6_16_17_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i213" class="anchor-spacer"></div><h5 class="article-section__title" id="_i213"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>103</b>)</h5><div class="NLM_p last">Acetic acid (9.9 mL, 10 g, 0.17 mol) was added to a solution of sodium triacetoxyborohydride (22.23 g, 104.9 mmol) and crude methyl <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>125</b>) (9.0 g) in acetonitrile (90 mL) at 0 °C. The resulting mixture was stirred for 4 h at room temperature. Then, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to get the crude product, which was purified by silica gel column chromatography eluting with 1–5% methanol in dichloromethane. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>103</b>) as an off-white solid. Yield: 6.0 g (11.6 mmol, 55%). MS (ESI) <i>m</i>/<i>z</i>: 516.13 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub><a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.69 (d, <i>J</i> = 2.0 Hz, 1H), 7.22–7.18 (m, 2H), 7.10–6.97 (m, 7H), 6.15 (s, 1H), 5.75 (d, <i>J</i> = 5.8 Hz, 1H), 4.63 (dd, <i>J</i> = 5.8, 4.8 Hz, 1H), 4.51 (d, <i>J</i> = 13.9 Hz, 1H), 4.15 (dd, <i>J</i> = 13.9, 4.8 Hz, 1H), 3.57 (s, 3H).</div></div><div id="sec6_16_17_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i214" class="anchor-spacer"></div><h5 class="article-section__title" id="_i214"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>104</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>103</b>) (3.3 g, 6.4 mmol) in methanol/water (3:1, 11 mL) was added lithium hydroxide (3.68 g, 154 mmol). The reaction mixture was stirred for 3 h at room temperature. Then, it was cooled to 0 °C and acidified with 5 M hydrogen chloride to pH ≈ 3. The resulting precipitate was collected by filtration and dried under high vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>104</b>) as an off-white solid that was used without further purification. Yield: 3.2 g (6.4 mmol, quantitative). MS (ESI) <i>m</i>/<i>z</i>: 502.02 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.13 (s, 1H), 7.61 (d, 1H), 7.21–7.16 (m, 4H), 7.04 (t, <i>J</i> = 7.4 Hz, 2H), 6.95 (d, <i>J</i> = 8.3 Hz, 3H), 5.8 (s, 1H), 4.47 (d, <i>J</i> = 14.0 Hz, 1H), 4.35 (s, 1H), 3.57 (d, <i>J</i> = 13.2 Hz, 1H), 3.40–3.33 (m, 1H).</div></div><div id="sec6_16_17_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i215" class="anchor-spacer"></div><h5 class="article-section__title" id="_i215"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S46</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>104</b>) (3.2 g, 6.4 mmol) in dichloromethane (30 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (3.6 g, 19 mmol), hydroxybenzotriazole (2.8 g, 21 mmol), and DIPEA (7.3 mL, 5.4 g, 42 mmol) were added. This mixture was stirred for 5 min at this temperature, then dimethylamine hydrochloride (2.8 g, 34 mmol) was added and the mixture was stirred for 12 h at room temperature. The reaction mixture was then diluted with dichloromethane and washed with cold water. The organic layer was separated and dried over sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography eluting with 70–90% ethyl acetate in hexanes to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S46</b>) as a white solid. Yield: 2.9 g (5.5 mmol, 86%). MS (ESI) <i>m</i>/<i>z</i>: 529.05 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.19 (s, 1H), 7.69 (s, 1H), 7.21 (d, <i>J</i> = 8.4 Hz, 2H), 7.06–7.01 (m, 4H), 6.97 (d, <i>J</i> = 6.6 Hz 1H), 6.92 (d, <i>J</i> = 7.1 Hz, 2H), 6.04 (s, 1H), 5.75 (s, 1H), 5.29 (d, <i>J</i> = 5.6 Hz, 1H), 4.72 (d, <i>J</i> = 4.8 Hz, 1H), 4.57 (d, <i>J</i> = 13.3 Hz, 1H), 4.25 (dd, <i>J</i> = 5.2 Hz, 12.9 Hz, 1H), 3.26 (s, 3H), 2.77 (s, 3H).</div></div><div id="sec6_16_17_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i216" class="anchor-spacer"></div><h5 class="article-section__title" id="_i216"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>8</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S46</b>) (1.5 g, 2.8 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (25 mL), zinc cyanide (6.0 g, 51 mmol) and zinc (0.022 g, 0.034 mmol) were added. The mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.041 g, 0.074 mmol) and tris(dibenzylideneacetone)-dipalladium (0.078 g, 0.085 mmol) were added. The mixture was degassed for another 5 min and then heated at 140 °C for 1 h. The mixture was then cooled to room temperature and passed through Celite. The filtrate was concentrated and treated with ice-cold water. The precipitated crude product was purified by reverse-phase prep HPLC. The desired fractions were concentrated under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>8</b>) as an off-white solid. Yield: 1.1 g (2.3 mmol, 83%). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (40 mg, (−)-<b>8</b>), [α]<sub>D</sub> −180.5° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 7.95 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 476.35 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 476.1372 [M + H]<sup>+</sup>; found, 476.1365; UPLC: 98.31%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.73 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (d, <i>J</i> = 8.6 Hz, 2H), 7.03 (t, <i>J</i> = 7.2 Hz, 2H), 6.97–6.91 (m, 3H), 6.15 (s, 1H), 5.34 (d, <i>J</i> = 5.6 Hz, 1H), 4.73 (t, <i>J</i> = 5.2 Hz, 1H), 4.66 (d, <i>J</i> = 13.2 Hz, 1H), 4.34 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.28 (s, 3H), 2.78 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.00, 153.22, 149.39, 142.06, 140.72, 138.12, 131.00, 130.27, 128.48, 127.76, 127.52, 125.89, 118.80, 117.25, 109.10, 101.94, 91.20, 77.88, 56.39, 48.78, 36.60, 35.26. Peak 2 (41 mg, (+)-<b>8</b>), [α]<sub>D</sub> +180° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 15.19 min, ee >98.5%; MS (ESI) <i>m</i>/<i>z</i>: 476.35 [M + 1]<sup>+</sup>; UPLC: 98.76%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.73 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.33 (d, <i>J</i> = 8.6 Hz, 2H), 7.03 (t, <i>J</i> = 7.2 Hz, 2H), 6.97–6.91 (m, 3H), 6.15 (s, 1H), 5.34 (d, <i>J</i> = 5.8 Hz, 1H), 4.73 (t, <i>J</i> = 5.4 Hz, 1H), 4.66 (d, <i>J</i> = 13.2 Hz, 1H), 4.34 (dd, <i>J</i> = 13.2, 5.4 Hz, 1H), 3.28 (s, 3H), 2.78 (s, 3H).</div></div></div><div id="sec6_16_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i217" class="anchor-spacer"></div><h4 class="article-section__title" id="_i217"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>9</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0057.gif" alt="" id="dgr19" /></img><div id="sec6_16_18_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i218" class="anchor-spacer"></div><h5 class="article-section__title" id="_i218"> 3,5-Bis (benzyloxy)picolinonitrile (<b>106</b>)</h5><div class="NLM_p last">A flask containing THF (500 mL) was charged with 3, 5-dichloropicolinonitrile (<b>105</b>) (65.0 g, 377.2 mmol) under nitrogen, and sodium hydride (27.2 g, 1.13 mol) was added at 0 °C. The suspension was stirred at room temperature for 30 min, benzyl alcohol (81.37 mL, 84.62 g, 782.5 mmol) was added, and stirring was continued for another 3 h. Then, the reaction was quenched with saturated ammonium chloride solution at 0 °C. The mixture was extracted with ethyl acetate (1000 mL). The organic layer was separated, washed with water (2 × 200 mL) and brine (100 mL), dried over sodium sulfate, concentrated, and triturated with pentane. The precipitate was collected by filtration and dried under vacuum to afford 3,5-bis(benzyloxy)picolinonitrile (<b>106</b>) as an off-white solid. Yield: 130.0 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 317.21 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.12 (s, 1H), 7.55 (s, 1H), 7.48–7.30 (m, 10H), 5.35 (s, 2H), 5.30 (s, 2H).</div></div><div id="sec6_16_18_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i219" class="anchor-spacer"></div><h5 class="article-section__title" id="_i219"> 1-(3,5-Bis(benzyloxy)pyridin-2-yl)ethan-1-one (<b>107</b>)</h5><div class="NLM_p last">To a solution of 3,5-bis(benzyloxy)-picolinonitrile (<b>106</b>) (70.0 g, crude) in dry tetrahydrofuran (700 mL) at −30 °C, methyl magnesium bromide (78.37 mL, 664.5 mmol) was added dropwise over a period of 30 min. The reaction mixture was slowly brought to room temperature and stirred for 2 h. After completion, the reaction was quenched with 6 N hydrochloric acid and stirred for 2 h. The mixture was extracted with ethyl acetate. The organic layer was washed with 1 N sodium hydroxide solution and water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 1-(3,5-bis(benzyloxy)pyridin-2-yl)ethan-1-one (<b>107</b>) as a yellow oil. Yield: 82.0 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 334.16 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_18_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i220" class="anchor-spacer"></div><h5 class="article-section__title" id="_i220"> 1-(3,5-Dihydroxypyridin-2-yl)ethan-1-one (<b>108</b>)</h5><div class="NLM_p last">A flask containing ethyl acetate (500 mL) was charged with 1-(3,5-bis(benzyloxy)pyridin-2-yl)ethan-1-one (<b>107</b>) (82.0 g, crude) and palladium hydroxide (34.47 g, 50% wet). The reaction was flushed with hydrogen gas twice and stirred at room temperature for 16 h under hydrogen pressure. After completion, the reaction mixture was filtered through Celite and concentrated under reduced pressure to afford 1-(3,5-dihydroxypyridin-2-yl)ethan-1-one (<b>108</b>) as a brown oil. Yield: 40.0 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 153.04 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.06 (s, 1H), 11.25–11.18 (br s, 1H), 7.93 (s, 1H), 6.66 (s, 1H), 2.59 (s, 3H).</div></div><div id="sec6_16_18_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i221" class="anchor-spacer"></div><h5 class="article-section__title" id="_i221"> 1-(5-(Benzyloxy)-3-hydroxypyridin-2-yl)ethan-1-one (<b>109</b>)</h5><div class="NLM_p last">A flask containing acetone (250 mL) was charged with 1-(3,5-dihydroxypyridin-2-yl)ethan-1-one (<b>108</b>) (40.0 g, crude) and potassium carbonate (72.15 g, 522.1 mmol) under nitrogen. Benzyl bromide (<b>S47</b>) (21.7 mL, 31.2 g, 182 mmol) was added, and the mixture was stirred for another 3 h. Then, volatiles were removed under reduced pressure, and the crude residue was suspended in ethyl acetate (200 mL) and washed with water (2 × 150 mL) and brine (150 mL). The organic layer was separated, dried over sodium sulfate, concentrated, and triturated with pentane. The solid was isolated by filtration and dried under vacuum to afford 1-(5-(benzyloxy)-3-hydroxypyridin-2-yl)ethan-1-one (<b>109</b>) as a brown solid. Yield: 50.0 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 244.04 [M – 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ/ppm 12.26 (s, 1H), 7.99 (s, 1H), 7.46–7.32 (m, 5H), 6.90 (s, 1H), 5.12 (s, 2H), 2.69 (s, 3H).</div></div><div id="sec6_16_18_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i222" class="anchor-spacer"></div><h5 class="article-section__title" id="_i222"> (<i>E</i>)-1-(5-(Benzyloxy)-3-hydroxypyridin-2-yl)-3-(4-bromophenyl)prop-2-en-1-one (<b>S48</b>)</h5><div class="NLM_p last">To a solution of 1-(5-(benzyloxy)-3-hydroxypyridin-2-yl)ethan-1-one (<b>109</b>) (50.0 g, 206 mmol) in methanol (100 mL), sodium hydroxide (24.69 g, 617.3 mmol) was added followed by 4-bromobenzaldehyde (38.06 g, 205.7 mmol). The reaction mixture was heated at 85 °C for 2 h and then cooled to room temperature. The resulting solid was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-1-(5-(benzyloxy)-3-hydroxypyridin-2-yl)-3-(4-bromophenyl)prop-2-en-1-one (<b>S48</b>) as a yellow solid. Yield: 50.2 g (122 mmol, 59%). MS (ESI) <i>m</i>/<i>z</i>: 410.05 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.46 (d, <i>J</i> = 16 Hz, 1H), 7.43–7.18 (m, 11H), 6.24 (s, 1H), 5.00 (s, 2H).</div></div><div id="sec6_16_18_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i223" class="anchor-spacer"></div><h5 class="article-section__title" id="_i223"> 7-(Benzyloxy)-2-(4-bromophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>110</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(5-(benzyloxy)-3-hydroxypyridin-2-yl)-3-(4-bromophenyl)prop-2-en-1-one (<b>S48</b>) (20.0 g, 48.7 mmol) in ethanol/dichloromethane (1:1, 100 mL) at room temperature, sodium hydroxide (13.7 g, 343 mmol) was added followed by hydrogen peroxide (15.11 mL 30% aq sln, 5.03 g H<sub>2</sub>O<sub>2</sub>, 148 mmol). The reaction mixture was stirred for 1 h (reaction is exothermic). Then, the mixture was cooled and neutralized by addition of 6 N hydrochloric acid. The precipitate was collected by filtration and dried under vacuum to afford 7-(benzyloxy)-2-(4-bromophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>110</b>) as a yellow solid. Yield: 11.0 g (25.9 mmol, 53%). MS (ESI) <i>m</i>/<i>z</i>: 426.03 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.96 (s, 1H), 8.55 (s, 1H), 8.16 (d, <i>J</i> = 8.6 Hz, 2H), 7.92 (s, 1H), 7.89 (d, <i>J</i> = 8.6 Hz, 2H), 7.53 (d, <i>J</i> = 7.5 Hz, 2H), 7.46–7.42 (m, 3H), 5.33 (s, 2H).</div></div><div id="sec6_16_18_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i224" class="anchor-spacer"></div><h5 class="article-section__title" id="_i224"> <i>rac</i>-Methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-(Benzyloxy)-6-(4-bromophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S49</b>)</h5><div class="NLM_p last">A solution of 7-(benzyloxy)-2-(4-bromophenyl)-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>110</b>) (11.0 g, 25.9 mmol) and methyl cinnamate (<b>55</b>) (42.28 g, 260.7 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated under 400 W UV light for 15 h in a UV reactor flask. Then, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-(benzyloxy)-6-(4-bromophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S49</b>) as a brown solid Yield: 11.2 g, crude.</div></div><div id="sec6_16_18_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i225" class="anchor-spacer"></div><h5 class="article-section__title" id="_i225"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-(Benzyloxy)-5a-(4-bromophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S50</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-3-(benzyloxy)-6-(4-bromophenyl)-9-hydroxy-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-carboxylate (<b>S49</b>) (11.0 g) was suspended in methanol (100 mL), treated with 25% sodium methoxide in methanol (110 mL, 104 g solution, 26.0 g NaOMe, 481 mmol NaOMe), and heated at 80 °C for 1 h. Then, the solvent was removed under reduced pressure. The crude product was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-(benzyloxy)-5a-(4-bromophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S50</b>) as a brown solid. Yield: 11.0 g, crude.</div></div><div id="sec6_16_18_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i226" class="anchor-spacer"></div><h5 class="article-section__title" id="_i226"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(Benzyloxy)-5a-(4-bromophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>111</b>)</h5><div class="NLM_p last">The crude methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-(benzyloxy)-5a-(4-bromophenyl)-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S50</b>) (11.0 g) was added to a solution of sodium triacetoxyborohydride (23.4 g, 110 mmol) in acetonitrile (100 mL) and acetic acid (11.3 mL, 188 mmol), and the resulting mixture was stirred for 4 h at room temperature. It was then partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure obtain the crude product, which was purified by silica gel column chromatography eluting with 50% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(benzyloxy)-5a-(4-bromophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>111</b>) as a light yellow solid. Yield: 5.7 g (9.7 mmol, 38% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 588.38 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.95 (d, <i>J</i> = 2.0 Hz, 1H), 7.56–7.48 (m, 2H), 7.44–7.40 (m, 2H), 7.37–7.36 (m, 1H), 7.28–7.18 (m, 3H), 7.09–6.95 (m, 7H), 5.88 (s, 1H), 5.57–5.56 (br s, 1H), 5.20 (s, 2H), 4.63 (s, 1H), 4.43–4.40 (m, 1H), 4.11–4.10 (m, 1H), 3.55 (s, 3H).</div></div><div id="sec6_16_18_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i227" class="anchor-spacer"></div><h5 class="article-section__title" id="_i227"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(Benzyloxy)-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S51</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(benzyloxy)-5a-(4-bromophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>111</b>) (5.0 g, 8.5 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (50.0 mL) at room temperature, zinc cyanide (6.12 g, 52.1 mmol) and zinc dust (0.055 g, 0.841 mmol) were added. The mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino) ferrocene (0.124 g, 0.224 mmol) and tris(dibenzylideneacetone)dipalladium (0.233 g, 0.254 mmol) were added, degassing was continued for 5 min, and the mixture was heated to 120 °C for 2 h. After completion, the reaction mixture was cooled to room temperature, filtered through Celite, concentrated, and treated with ice-cold water. The precipitate was collected by filtration and dried under vacuum to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(benzyloxy)-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S51</b>) as a brown solid. Yield: 4.4 g (8.2 mmol, 97%). MS (ESI) <i>m</i>/<i>z</i>: 534.18 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.97 (s, 1H), 7.58–7.48 (m, 3H), 7.46–7.40 (m, 2H), 7.37–7.34 (m, 1H), 7.29–7.27 (m, 2H), 7.16–6.93 (m, 7H), 5.99 (s, 1H), 5.63 (s, 1H), 5.20 (s, 2H), 4.64–4.62 (m, 1H), 4.51–4.47 (m, 1H), 4.20–4.16 (m, 1H), 3.57 (s, 3H).</div></div><div id="sec6_16_18_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i228" class="anchor-spacer"></div><h5 class="article-section__title" id="_i228"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Cyanophenyl)-3,8,8a-trihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S52</b>)</h5><div class="NLM_p last">A flask containing ethyl acetate (50 mL) was charged with <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(benzyloxy)-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S51</b>) (2.5 g, 4.68 mmol) and palladium hydroxide (1.66 g, 11.8 mmol, 50% wet) at room temperature. The reaction mixture was flushed with hydrogen gas twice and stirred at room temperature for 16 h under hydrogen pressure. The mixture was filtered through Celite bed, and the filtrate was concentrated under reduced pressure to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-3,8,8a-trihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S52</b>) as a brown oil. Yield: 2.01 g (4.52 mmol, 97%), MS (ESI) <i>m</i>/<i>z</i>: 443.15 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_18_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i229" class="anchor-spacer"></div><h5 class="article-section__title" id="_i229"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Cyanophenyl)-8,8a-dihydroxy-6-phenyl-3-((trifluoro-methyl)sulfonyl)oxy)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S53</b>)</h5><div class="NLM_p last">A flask containing dichloromethane (200 mL) was charged with <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-3,8,8a-trihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S52</b>) (2.01 g, 4.52 mmol) under nitrogen, and <i>N</i>, <i>N</i>-diisopropylethylamine (0.57 g, 4.4 mmol) was added at −78 °C, followed by triflic anhydride (1.06 mL, 1.78 g, 6.31 mmol). The reaction mixture was stirred at −78 °C for 45 min. Then, the reaction mixture was quenched with saturated NaHCO<sub>3</sub> solution at 0 °C and extracted with dichloromethane (100 mL). The organic layer was separated, washed with water (2 × 50 mL), and washed with brine (50 mL) and then dried over sodium sulfate, concentrated, and triturated with pentane. The precipitate was collected by filtration and dried under vacuum to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-3-((trifluoromethyl)-sulfonyl)oxy)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S53</b>) as a yellow solid. Yield: 2.01 g (3.49 mmol, 77%). MS (ESI) <i>m</i>/<i>z</i>: 577.1 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_18_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i230" class="anchor-spacer"></div><h5 class="article-section__title" id="_i230"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S54</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-3-(((trifluoromethyl)sulfonyl)oxy)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S53</b>) (2.0 g, 3.47 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (20.0 mL) at room temperature, zinc cyanide (2.4 g, 20.43 mmol) and zinc (0.027 g, 0.413 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (51.0 mg, 0.092 mmol) and tris(dibenzylideneacetone) dipalladium (95 mg, 0.10 mmol) were added, degassing was continued for 5 min, and the mixture was heated at 100 °C for 3 h. The reaction was cooled to room temperature and filtered through Celite. The filtrate was concentrated and treated with ice-cold water. The precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S54</b>) as a yellow solid. Yield: 1.9 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 454.38 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.64 (s, 1H), 8.05 (s, 1H), 7.98 (s, 1H), 7.47 (d, <i>J</i> = 8.1 Hz, 2H), 7.28 (d, <i>J</i> = 8.1 Hz, 2H), 7.06–6.92 (m, 4H), 6.47 (s, 1H), 5.91–5.86 (m, 1H), 4.60–4.57 (m, 1H), 4.51–4.95 (m, 1H), 4.29–4.21 (m, 1H), 3.58 (s, 3H).</div></div><div id="sec6_16_18_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i231" class="anchor-spacer"></div><h5 class="article-section__title" id="_i231"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S55</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (1.9 g, crude) in methanol/water (3:1, 12 mL), lithium hydroxide (0.237 g, 9.90 mmol) was added. The reaction mixture was stirred for 6 h at room temperature and then cooled to 0 °C and acidified with 1 N hydrochloric acid to pH ≈ 3. The precipitate was collected by filtration and dried under vacuum to afford (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S55</b>) as a yellow solid. Yield: 0.55 g (1.3 mmol, 37% over two steps). MS (ESI) <i>m</i>/<i>z</i>: 438.32 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.0–13.0 (br s, 1H), 8.63 (s, 1H), 8.13 (s, 1H), 7.47 (d, <i>J</i> = 8.2 Hz, 2H), 7.26 (d, <i>J</i> = 8.1 Hz, 2H), 7.06–6.98 (m, 5H), 6.40 (s, 1H), 4.66–4.65 (m, 1H), 4.57–4.54 (m, 1H), 4.11–4.07 (m, 1H).</div></div><div id="sec6_16_18_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i232" class="anchor-spacer"></div><h5 class="article-section__title" id="_i232"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>9</b>)</h5><div class="NLM_p last">A flask containing dichloromethane (10 mL) was charged with (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (0.5 g, 1.1 mmol). Triethylamine (0.46 mL, 3.3 mmol) and dimethylamine hydrochloride (0.139 g, 1.70 mmol) were added at 0 °C. The mixture was stirred for 5 min, treated with propylphosphonic anhydride (50% in ethyl acetate; 0.139 mL, 0.149 g solution, 74.2 mg PPA, 0.234 mmol) at the same temperature, and then stirred for 4 h at room temperature. The reaction mixture was then diluted with dichloromethane and washed with cold water. The organic layer was separated and dried over sodium sulfate, filtered, and concentrated to give a crude product, which was purified by silica gel column chromatography eluting with 70–90% ethyl acetate in hexanes to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>9</b>) as a white solid. Yield: 160 mg (0.342 mmol, 31%). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (35 mg, (−)-<b>9</b>), [α]<sub>D</sub> −202.0° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 5.99 min, ee >99%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.63 (d, <i>J</i> = 1.6 Hz, 1H), 8.05 (d, <i>J</i> = 1.6 Hz, 1H), 7.5 (d, <i>J</i> = 8.4 Hz, 2H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.03 (t, <i>J</i> = 7.2 Hz, 2H), 6.95 (t, <i>J</i> = 8.8 Hz, 3H), 6.37 (s, 1H), 5.45 (d, <i>J</i> = 5.6 Hz, 1H), 4.76 (t, <i>J</i> = 5.2 Hz, 1H), 4.70 (d, <i>J</i> = 13.2 Hz, 1H), 4.36 (dd, <i>J</i> = 13.6, 4.8 Hz, 1H), 3.28 (s, 3H), 2.79 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 167.82, 155.54, 152.10, 145.69, 141.76, 137.97, 130.28, 128.45, 127.80, 127.54, 125.92, 119.66, 118.75, 117.08, 109.20, 108.70, 101.63, 91.67, 77.99, 56.58, 48.95, 36.62, 35.28. MS (ESI) <i>m</i>/<i>z</i>: 467.37 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 467.1714 [M + H]<sup>+</sup>; found, 467.1709; UPLC: 98.66%. Peak-2 (26 mg, (+)-<b>9</b>), [α]<sub>D</sub> +242° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 8.46 min, ee >95%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.63 (d, <i>J</i> = 1.6 Hz, 1H), 8.05 (d, <i>J</i> = 1.6 Hz, 1H), 7.5 (d, <i>J</i> = 8.4 Hz, 2H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.03 (t, <i>J</i> = 7.2 Hz, 2H), 6.95 (t, <i>J</i> = 9.2 Hz, 3H), 6.37 (s, 1H), 5.46 (d, <i>J</i> = 6 Hz, 1H), 4.76 (t, <i>J</i> = 5.2 Hz, 1H), 4.70 (d, <i>J</i> = 13.2 Hz, 1H), 4.37 (dd, <i>J</i> = 13.2 Hz, 4.4 Hz, 1H), 3.28 (s, 3H), 2.78 (s, 3H), MS (ESI) <i>m</i>/<i>z</i>: 467.37 [M + 1]<sup>+</sup>, UPLC: 99.95%.</div></div></div><div id="sec6_16_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i233" class="anchor-spacer"></div><h4 class="article-section__title" id="_i233"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>16</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0059.gif" alt="" id="dgr20" /></img><div id="sec6_16_19_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i234" class="anchor-spacer"></div><h5 class="article-section__title" id="_i234"> (<i>E</i>)-1-(5-(Benzyloxy)-3-hydroxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S56</b>)</h5><div class="NLM_p last">To a solution of 1-(5-(benzyloxy)-3-hydroxypyridin-2-yl)ethan-1-one (<b>109</b>) (42.0 g, 173 mmol) in MeOH (200 mL), sodium hydroxide (20.97 g, 524.3 mmol) was added followed by 4-methoxybenzaldehyde (<b>61a</b>) (31.97 g, 234.8 mmol). The reaction mixture was heated to reflux for 30 min AND then cooled. The resulting solid was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-1-(5-(benzyloxy)-3-hydroxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S56</b>) as a yellow solid. Yield: 62.3 g (crude). MS (ESI) <i>m</i>/<i>z</i>: 362.32 [M + 1]<sup>+</sup>, UPLC: 50%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.88 (d, <i>J</i> = 8.4 Hz, 1H), 7.67 (d, <i>J</i> = 8.4 Hz, 2H), 7.51–7.31 (m, 6H), 7.14 (d, <i>J</i> = 8.4 Hz, 1H), 6.97 (d, <i>J</i> = 8.0 Hz, 2H), 6.25 (s, 1H), 5.08 (s, 2H), 3.78 (s, 3H).</div></div><div id="sec6_16_19_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i235" class="anchor-spacer"></div><h5 class="article-section__title" id="_i235"> 7-(Benzyloxy)-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>112</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-1-(5-(benzyloxy)-3-hydroxypyridin-2-yl)-3-(4-methoxyphenyl)prop-2-en-1-one (<b>S56</b>) (54.0 g, crude) in ethanol (300 mL) at room temperature, sodium hydroxide (47.8 g, 1.19 mol) was added followed by hydrogen peroxide (30% aq sln, 27.6 mL, 9.19 g H<sub>2</sub>O<sub>2</sub>, 270 mmol). The reaction mixture was stirred for 1 h (reaction is exothermic!). After completion, reaction mass was cooled and neutralized to pH ≈ 7 with 6 N HCl at 0 °C. The solid precipitate was collected by filtration and dried under vacuum to afford 7-(benzyloxy)-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one as a pale yellow solid. Yield: 20.5 g (crude). UPLC: 59.5%, MS (ESI) <i>m</i>/<i>z</i>: 376.11 [M + 1] <sup>+</sup>, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.52 (s, 1H), 7.54 (d, <i>J</i> = 7.2 Hz, 2H), 7.49–7.33 (m, 5H), 7.13 (d, <i>J</i> = 8.4 Hz, 2H), 6.67 (s, 1H), 5.33 (s, 2H), 3.84 (s, 3H).</div></div><div id="sec6_16_19_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i236" class="anchor-spacer"></div><h5 class="article-section__title" id="_i236"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(Benzyloxy)-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>113</b>)</h5><div class="NLM_p last">A solution of 7-(benzyloxy)-3-hydroxy-2-(4-methoxyphenyl)-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>112</b>) (18.0 g, crude) and methyl cinnamate (<b>55</b>) (77.8 g, 480 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated with 400 W UV light for 15 h in a UV reactor flask. Then, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford product <b>S57</b> (15.0 g, crude). The crude compound (<b>S57</b>) was suspended in methanol (30 mL), treated with 25% sodium methoxide in methanol (30 mL, 28 g solution; 7.0 g, 0.13 mol NaOMe), and the mixture was heated at 70 °C for 1 h. Then, the solvent was removed under reduced pressure. The crude product was treated with ammonium chloride solution and extracted with EtOAc. The organic phase was dried over sodium sulfate and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-3-(benzyloxy)-8a-hydroxy-5a-(4-methoxyphenyl)-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo-[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S58</b>) (12.5 g, crude). The crude product (<b>S58</b>) was added to a solution of sodium triacetoxyborohydride (14.8 g, 69.8 mmol) in acetonitrile (130 mL) and acetic acid (13.93 mL, 23.27 mmol). The resulting mixture was stirred for 6 h at room temperature, then partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford the crude product, which was purified by silica gel column chromatography eluting with 50–70% ethyl acetate in hexanes. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(benzyloxy)-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo-[3,2-<i>b</i>]pyridine-7-carboxylate (<b>113</b>) as a pale brown solid. Yield: 4.5 g. UPLC: 70.6%; MS (ESI) <i>m</i>/<i>z</i>: 540.25 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.94 (d, <i>J</i> = 2.4 Hz, 1H), 7.68–7.34 (m, 5H), 7.22 (d, <i>J</i> = 2.4 Hz, 1H), 7.09–6.92 (m, 5H), 6.79 (d, <i>J</i> = 8.4 Hz, 2H), 6.59 (d, <i>J</i> = 8.8 Hz, 2H), 5.72 (s, 1H), 5.50 (d, <i>J</i> = 5.2 Hz, 1H), 4.96 (s, 2H), 4.67 (t, <i>J</i> = 5.6 Hz, 1H), 4.34 (d, <i>J</i> = 14.0 Hz, 1H), 4.03 (dd, <i>J</i> = 5.6 Hz, 14.0 Hz, 1H), 3.36 (s, 3H), 3.32 (s, 3H).</div></div><div id="sec6_16_19_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i237" class="anchor-spacer"></div><h5 class="article-section__title" id="_i237"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3,8,8a-Trihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S59</b>)</h5><div class="NLM_p last">A flask was charged with <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-(benzyloxy)-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>113</b>) (3.0 g, from previous step; used without further purification) in ethyl acetate (300 mL) at room temperature, and palladium(II) hydroxide (50% wet) (0.195 g) was added. The reaction mixture was flushed with hydrogen twice and stirred under hydrogen pressure at room temperature for 16 h. Then, the reaction mixture was filtered through Celite and the filtrate was concentrated under reduced pressure to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3,8,8a-trihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S59</b>) as a brown solid. Yield: 2.8 g (6.2 mmol, 7% over steps). UPLC: 99.0%; MS (ESI) <i>m</i>/<i>z</i>: 450.17 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.95 (s, 1H), 7.77 (s, 1H), 7.06–6.97 (m, 5H), 6.91 (d, <i>J</i> = 7.6 Hz, 2H), 6.08 (s, 1H), 6.58 (d, <i>J</i> = 8.8 Hz, 2H), 5.61 (s, 1H), 5.41 (d, <i>J</i> = 5.2 Hz, 1H), 4.66 (t, <i>J</i> = 5.6 Hz, 1H), 4.30 (d, <i>J</i> = 14.0 Hz, 1H), 4.04 (dd, <i>J</i> = 5.2 Hz, 13.6 Hz, 1H), 3.58 (s, 3H), 3.54 (s, 3H).</div></div><div id="sec6_16_19_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i238" class="anchor-spacer"></div><h5 class="article-section__title" id="_i238"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-Dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-3-((trifluoromethyl)sulfonyl)oxy)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S60</b>)</h5><div class="NLM_p last">A flask containing methylene chloride (300 mL) was charged with methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3,8,8a-trihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S59</b>) (2.2 g, 5.0 mmol), and DIPEA (0.94 g, 7.3 mmol) was added under nitrogen. The mixture was cooled to −78 °C, and triflic anhydride (1.79 g, 6.34 mmol) was added slowly. The reaction mixture was stirred for 30 min at −78 °C, brought to room temperature, and then stirred for 1 h. Then, the reaction was quenched with saturated NaHCO<sub>3</sub> solution at 0 °C. Methylene chloride (300 mL) was added. The organic layer was separated and washed first with water (2 × 50 mL) and then with brine (50 mL). The organic layer was separated again, dried over sodium sulfate, and concentrated. The solid was triturated with pentane, filtered, and dried under vacuum to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-3-((trifluoromethyl)sulfonyl)oxy)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S60</b>) as a brown solid. Yield: 2.5 g, crude. LCMS: 72.6%; MS (ESI) <i>m</i>/<i>z</i>: 582.05 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_19_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i239" class="anchor-spacer"></div><h5 class="article-section__title" id="_i239"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S61</b>)</h5><div class="NLM_p last">To a solution of crude methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-3-((trifluoromethyl)sulfonyl)oxy)-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S60</b>) (0.5 g) in dimethylformamide at room temperature, zinc cyanide (0.6 g, 5.1 mmol) and zinc (0.067 g, 0.102 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.023 g, 0.041 mmol) and tris(dibenzylideneacetone)dipalladium (0.025 g, 0.027 mmol) were added. Degassing was continued for 5 min, after which the mixture was heated at 140 °C for 1 h. After this time, the reaction was cooled to room temperature and filtered through Celite. The filtrate was concentrated and treated with ice-cold water. The resulting precipitate was collected by filtration and purified by reverse-phase prep HPLC. The desired fractions were concentrated under vacuum to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate as a yellow solid. Yield: 150 mg. UPLC: 82.1%; MS (ESI) <i>m</i>/<i>z</i>: 459.19 [M + 1] <sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.59 (s, 1H), 7.96 (s, 1H), 7.06–7.02 (m, 2H), 6.96–6.89 (m, 5H), 6.56 (d, <i>J</i> = 9.2 Hz, 2H), 6.19 (s, 1H), 5.78 (d, <i>J</i> = 5.2 Hz, 1H), 4.66 (d, <i>J</i> = 4.4 Hz, 1H), 4.46 (d, <i>J</i> = 13.6 Hz, 1H), 4.11 (t, <i>J</i> = 4.8 Hz, 1H), 3.56 (s, 6H).</div></div><div id="sec6_16_19_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i240" class="anchor-spacer"></div><h5 class="article-section__title" id="_i240"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>S62</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S61</b>) (0.42 g, from previous step; used without further purification) in tetrahydrofuran and water (3:1, 12 mL), lithium hydroxide (0.066 g, 2.76 mmol) was added. The reaction mixture was stirred for 6 h at room temperature, then cooled to 0 °C, and acidified with 1 N citric acid to pH ≈ 5. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid as an off-white solid. Yield: 0.3 g (crude). UPLC: 49%; MS (ESI) <i>m</i>/<i>z</i>: 443.19 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.1 (br s, 1H), 8.60 (s, 1H), 8.11 (s, 1H), 7.41–6.79 (m, 7H), 6.57 (d, <i>J</i> = 8.8 Hz, 2H), 6.16 (s, 1H), 5.75 (br s, 1H), 4.66 (s, 1H), 4.44 (d, <i>J</i> = 14.0 Hz, 1H), 4.04 (dd, <i>J</i> = 4.8 Hz, 13.6 Hz, 1H), 3.59 (s, 3H).</div></div><div id="sec6_16_19_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i241" class="anchor-spacer"></div><h5 class="article-section__title" id="_i241"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>16</b>)</h5><div class="NLM_p last">To a solution of crude <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>S62</b>) (0.3 g) in methylene chloride (30 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (0.388 g, 2.50 mmol), hydroxybenzotriazole (0.27 g, 2.0 mmol) and DIPEA (0.52 mg, 4.02 mmol) were added. The mixture was stirred for 5 min. Dimethylamine hydrochloride (0.274 g, 3.36 mmol) was then added at same temperature and the mixture was stirred for 12 h at room temperature. Then, the reaction mass was diluted with methylene chloride and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography eluting with 70–90% ethyl acetate in hexanes to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-8,8a-dihydroxy-5a-(4-methoxyphenyl)-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>16</b>) as a white solid. Yield: 250 mg (0.530 mmol, 19% over 4 steps). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (35 mg, (−)-<b>16</b>), [α]<sub>D</sub> −172.0° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 6.54, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.60 (s, 1H), 8.00 (s, 1H), 7.07–7.00 (m, 4H), 6.97 (d, <i>J</i> = 7.0 Hz, 1H), 6.91 (d, <i>J</i> = 7.2 Hz, 2H), 6.09 (s, 1H), 5.34 (d, <i>J</i> = 5.4 Hz, 1H), 4.76 (s, 1H), 4.54 (d, <i>J</i> = 12.8 Hz, 1H), 4.25 (dd, <i>J</i> = 13.5, 5.2 Hz, 1H), 3.59 (s, 3H), 3.26 (s, 3H), 2.77 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.12, 157.65, 156.18, 152.31, 145.25, 138.57, 128.52, 127.91, 127.62, 127.37, 125.68, 119.41, 117.21, 111.96, 108.53, 101.95, 90.83, 78.05, 56.19, 54.77, 48.55, 36.58, 35.24; MS (ESI) <i>m</i>/<i>z</i>: 472.33 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 472.1867 [M + H]<sup>+</sup>; found, 472.1863; UPLC: 98.98%. Peak-2 (35 mg, (+)-<b>16</b>), [α]<sub>D</sub> +152.0° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 10.65, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.60 (d, <i>J</i> = 1.4 Hz, 1H), 8.00 (d, <i>J</i> = 1.4 Hz, 1H), 7.05–7.01 (m, 4H), 6.97 (d, <i>J</i> = 7.2 Hz, 1H), 6.91 (d, <i>J</i> = 7.4 Hz, 2H), 6.61 (d, <i>J</i> = 8.8 Hz, 2H), 6.09 (s, 1H), 5.34 (d, <i>J</i> = 5.6 Hz, 1H), 4.76 (t, <i>J</i> = 5.2 Hz, 1H), 4.54 (d, <i>J</i> = 13.2 Hz, 1H), 4.25 (dd, <i>J</i> = 13.2, 5.2 Hz, 1H), 3.59 (s, 3H), 3.26 (s, 3H), 2.77 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 472.34 [M + 1]<sup>+</sup>; UPLC: 99.58%.</div></div></div><div id="sec6_16_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i242" class="anchor-spacer"></div><h4 class="article-section__title" id="_i242"> Synthesis of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<i>rac</i>-<b>24</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0060.gif" alt="" id="dgr21" /></img><div id="sec6_16_20_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i243" class="anchor-spacer"></div><h5 class="article-section__title" id="_i243"> <i>rac</i>-2-Thioxopyridin-1(2<i>H</i>)-yl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>115</b>)</h5><div class="NLM_p last">To a mixture of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>104</b>) (350 mg, 0.70 mmol) and 1-hydroxypyridine-2(1<i>H</i>)-thione (<b>114</b>) (443 mg, 3.48 mmol) in DCM (10 mL) was added <i>N</i>,<i>N′</i>-Dicyclohexylcarbodiimide (0.16 mL, 1.04 mmol), and the mixture was stirred vigorously for 4 h. LCMS analysis showed complete consumption of the acid starting material and desired product was observed. The reaction mixture was filtered to remove the urea and concentrated to provide the crude desired product, <i>rac</i>-2-thioxopyridin-1(2<i>H</i>)-yl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>115</b>). MS (ESI) <i>m</i>/<i>z</i>: 611.2 [M + 1]<sup>+</sup>. The crude product was used directly in the following step.</div></div><div id="sec6_16_20_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i244" class="anchor-spacer"></div><h5 class="article-section__title" id="_i244"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>116</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-2-thioxopyridin-1(2<i>H</i>)-yl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (115) in benzene (50 mL) was treated with tributylstannane (0.55 mL, 2.03 mmol) and azobisisobutyronitrile (22 mg, 0.14 mmol). The mixture was heated at 80 °C and stirred vigorously in the absence of light for 3 h. After this time, the reaction mixture was concentrated <i>in vacuo</i>, redissolved in <i>N</i>,<i>N</i>-dimethylformamide, and filtered through a 5-μm membrane. The crude material was purified by reverse-phase HPLC to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (116) as a white solid. Yield: 0.031 g (0.068 mmol, 10%). MS (ESI) <i>m</i>/<i>z</i>: 460.1 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ/ppm 8.23 (s, 1H), 7.69 (s, 1H), 7.30–7.26 (m, 2H), 7.21–7.13 (m, 3H), 7.05–7.01 (m, 4H), 5.01 (dd, <i>J</i> = 5.7, 3.4 Hz, 1H), 4.20 (dd, <i>J</i> = 11.6, 6.7 Hz, 1H), 2.89–2.78 (m, 1H).</div></div><div id="sec6_16_20_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i245" class="anchor-spacer"></div><h5 class="article-section__title" id="_i245"> <i>rac</i>-4-((5a<i>R</i>,6<i>S</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>24</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>116</b>) (10.9 mg, 0.0238 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (3 mL), zinc cyanide (17 mg, 0.14 mmol) and zinc (1 mg, 0.015 mmol) were added and the mixture was degassed with nitrogen for 15 min. 1,1′-Bis(diphenylphosphino)ferrocene (1 mg, 0.0015 mmol) and tris(dibenzylideneacetone)dipalladium (1 mg, 0.0011 mmol) were added to the above reaction, and degassing was continued for another 5 min followed by heating at 140 °C for 1 h. After completion, the reaction mixture was cooled to room temperature and filtered. The filtrate was purified by reverse-phase prep HPLC to provide the desired product then purified by preparatory thin-layer chromatography (DCM/MeOH) and prep HPLC to afford <i>rac</i>-4-((5a<i>R</i>,6<i>S</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>24</b>) as a white powder. Yield: 0.0015 g (0.0037 mmol, 16%). MS (ESI) <i>m</i>/<i>z</i>: 405.1 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>): δ/ppm 8.21 (s, 1H), 7.62 (s, 1H), 7.47–7.38 (m, 2H), 7.36–7.26 (m, 2H), 7.17–7.12 (m, 3H), 7.01–6.97 (m, 2H), 5.00 (dd, <i>J</i> = 5.7, 2.7 Hz, 1H), 4.23 (dd, <i>J</i> = 12.4, 6.7 Hz, 1H), 2.87 (td, <i>J</i> = 13.2, 5.6 Hz, 1H), 2.38–2.30 (m, 1H).</div></div></div><div id="sec6_16_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i246" class="anchor-spacer"></div><h4 class="article-section__title" id="_i246"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>31</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0061.gif" alt="" id="dgr22" /></img><div id="sec6_16_21_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i247" class="anchor-spacer"></div><h5 class="article-section__title" id="_i247"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S63</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>104</b>) (5.0 g, 10.0 mmol) in dichloromethane (100 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (5.73 g, 36.9 mmol), hydroxybenzotriazole (4.58 g, 29.9 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (12.16 mL, 9.023 g, 69.80 mmol) were added. The mixture was stirred for 5 min. Dimethylamine hydrochloride (4.06 g, 49.8 mmol) was then added at the same temperature, and the reaction was stirred for 16 h at room temperature. The reaction mass was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography eluting with 1–5% methanol in dichloromethane. The desired fractions were concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S63</b>) as a white solid. Yield: 4.0 g (7.6 mmol, 76%). MS (ESI) <i>m</i>/<i>z</i>: 529.16 [M + 1]<sup>+</sup>. 1H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.19 (s, 1H), 7.69 (s, 1H), 7.21 (d, <i>J</i> = 8.2 Hz, 2H), 7.09–7.02 (m, 4H), 6.97 (d, <i>J</i> = 6.9 Hz, 1H), 6.92 (d, <i>J</i> = 6.9 Hz, 1H), 6.04 (s, 1H), 5.75 (s, 1H), 5.28 (d, <i>J</i> = 5.6 Hz, 1H), 4.72 (d, <i>J</i> = 5.2 Hz, 1H), 4.57 (d, <i>J</i> = 13.0 Hz, 1H), 4.25 (dd, <i>J</i> = 14.1 Hz, 5.3 Hz, 1H), 3.26 (s, 3H), 2.77 (s, 3H).</div></div><div id="sec6_16_21_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i248" class="anchor-spacer"></div><h5 class="article-section__title" id="_i248"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-7-((dimethylamino)methyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>117</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S63</b>) (2.0 g, 3.8 mmol) in dry tetrahydrofuran (30 mL) at 0 °C, borane dimethyl sulfide complex (3.59 mL, 3.16 g, 41.6 mmol) was added dropwise over a period of 5 min. The reaction mixture was slowly brought to room temperature and stirred for additional 16 h. After this time, the reaction mixture was quenched with methanol at 0 °C and heated to reflux for 5 h. Then, solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with 1–5% methanol in dichloromethane. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-((dimethylamino)methyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>117</b>) as a white solid. Yield: 1.2 g (2.3 mmol, 61%). MS (ESI) <i>m</i>/<i>z</i>: 515.32 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.16 (s, 1H), 7.92 (s, 1H), 7.21 (d, <i>J</i> = 7.9 Hz, 2H), 7.12-7.08-7.02 (m, 7H), 6.01 (s, 1H), 4.45 (s, 1H), 3.87 (d, <i>J</i> = 14.1 Hz, 1H), 3.31–3.19 (m, 1H), 2.73–2.66 (m, 1H), 2.25 (s, 6H), 2.02–1.92 (m, 1H)</div></div><div id="sec6_16_21_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i249" class="anchor-spacer"></div><h5 class="article-section__title" id="_i249"> 4-((5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-7-((dimethylamino)methyl)-8,8a-dihydroxy-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile ((−)-<b>31</b>)</h5><div class="NLM_p">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-((dimethylamino)methyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>117</b>) (1.2 g, 2.3 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (48 mL) at room temperature, zinc cyanide (0.273 g, 2.32 mmol) and zinc dust (0.304 g, 4.65 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.025 g, 0.046 mmol) and tris(dibenzylideneacetone)dipalladium (0.064 g, 0.069 mmol) were added to the reaction. Degassing was continued for an additional 5 min, and the mixture was heated at 130 °C for 4 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to give the crude product which was purified by silica gel column chromatography eluting with 2–3% methanol in dichloromethane. The desired fractions were concentrated to afford <i>4</i>-((5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-7-((dimethylamino)methyl)-8,8a-dihydroxy-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>31</b>) as a white solid. Yield: 0.49 g (1.1 mmol, 46%). MS (ESI) <i>m</i>/<i>z</i>: 462.23 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 2.0 Hz, 1H), 7.63 (d, <i>J</i> = 2.0 Hz, 1H), 7.49 (d, <i>J</i> = 8.8 Hz, 2H), 7.36 (d, <i>J</i> = 8.8 Hz, 2H), 7.12–6.95 (m, 5H), 6.13 (s, 1H), 5.34 (br s, 1H), 4.44 (br s, 1H), 3.94 (d, <i>J</i> = 13.2 Hz, 1H), 3.28–3.17 (m, 1H), 2.61 (dd, <i>J</i> = 12.3, 10.0 Hz, 1H), 2.21 (s, 6H), 1.97 (dd, <i>J</i> = 12.3, 3.0, 1H);</div><div class="NLM_p last"><sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 153.09, 150.08, 142.20, 140.44, 136.87, 130.61, 130.17, 128.76, 128.39, 127.75, 126.35, 118.84, 116.68, 109.02, 102.85, 91.17, 78.26, 57.75, 56.27, 45.93, 43.92. The enantiomers were separated by chiral HPLC [Chiralpak IA (4.6 × 250) mm, 5μ], <i>n</i>-hexane/EtOH 20/80 V/V. Peak-1 (137 mg, (−)-<b>31</b>), [α]<sub>D</sub> −110.4° (<i>c</i> 0.26, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 4.580 min, ee: 98.5% MS (ESI) <i>m</i>/<i>z</i>: 462.23 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 462.1579 [M + H]<sup>+</sup>; found, 462.1581; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 1.6 Hz, 1H), 7.63 (d, <i>J</i> = 1.7 Hz, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.15–6.98 (m, 5H), 6.12 (s, 1H), 5.41 (br s, 1H), 4.45 (s, 1H), 3.93 (d, <i>J</i> = 13.9 Hz, 1H), 3.24 (br s, 1H), 2.66 (s, 1H), 2.59 (s, 1H), 2.25 (s, 6H). Peak-2 (133 mg, (+)-<b>31</b>), [α]<sub>D</sub> +105.4° (<i>c</i> 0.25, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 12.693 min, ee: 99.9%, MS (ESI) <i>m</i>/<i>z</i>: 462.23 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.18 (d, <i>J</i> = 1.6 Hz, 1H), 7.63 (d, <i>J</i> = 1.7 Hz, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.15–6.98 (m, 5H), 6.12 (s, 1H), 5.41 (br s, 1H), 4.45 (s, 1H), 3.93 (d, <i>J</i> = 13.9 Hz, 1H), 3.24 (br s, 1H), 2.66 (s, 1H), 2.59 (s, 1H), 2.25 (s, 6H).</div></div></div><div id="sec6_16_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i250" class="anchor-spacer"></div><h4 class="article-section__title" id="_i250"> Synthesis of 4-((5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-7-(oxazol-2-yl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>27</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0062.gif" alt="" id="dgr23" /></img><div id="sec6_16_22_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i251" class="anchor-spacer"></div><h5 class="article-section__title" id="_i251"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-<i>N</i>-(2,2-diethoxyethyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>119</b>)</h5><div class="NLM_p last">To a solution of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>104</b>) (1.4 g, 2.8 mmol) in dichloromethane (20 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (1.6 g, 8.3 mmol), 1-hydroxybenzotriazole (1.13 g, 8.36 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (2.88 mL, 2.14 g, 16.5 mmol) were added. The reaction mixture was stirred for 5 min. Then, 2,2-diethoxyethan-1-amine (<b>118</b>) (2.35 g, 17.6 mmol) was added at same temperature and the reaction mixture was stirred at 35 °C for 16 h. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by Combiflash (12 g, RediSep column) using 2% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-<i>N</i>-(2,2-diethoxyethyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>119</b>) as a light brown oil. Yield: 1.1 g (1.8 mmol, 64%). MS (ESI) <i>m</i>/<i>z</i>: 617.12 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.35 (t, <i>J</i> = 5.6 Hz, 1H), 8.19 (d, <i>J</i> = 1.8 Hz, 1H), 7.68 (d, <i>J</i> = 1.9 Hz, 1H), 7.23 (d, <i>J</i> = 8.6 Hz, 2H), 7.07–6.98 (m, 7H), 6.07 (s, 1H), 5.09 (d, <i>J</i> = 4.2 Hz, 1H), 4.54–4.51 (m, 2H), 4.36 (t, <i>J</i> = 5.3 Hz, 1H), 4.3 (dd, <i>J</i> = 14.0, 4.0 Hz, 1H), 3.55–3.49 (m, 2H), 3.42–3.35 (m, 2H), 3.17–3.07 (m, 2H), 1.12–1.05 (m, 6H).</div></div><div id="sec6_16_22_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i252" class="anchor-spacer"></div><h5 class="article-section__title" id="_i252"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>-(2-oxoethyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S65</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-<i>N</i>-(2,2-diethoxyethyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>119</b>) (1.0 g, 1.6 mmol) in tetrahydrofuran (5.0 mL), 2 N hydrochloric acid (5.0 mL) was added. The reaction mixture was stirred for 4 h at room temperature. After this time, the reaction mass diluted with ethyl acetate and the organic layer was separated and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>-(2-oxoethyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S65</b>) as a white solid. Yield: 0.91 g, crude, MS (ESI) <i>m</i>/<i>z</i>: 543.23 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.32 (s, 1H), 8.68 (t, <i>J</i> = 5.3 Hz, 1H), 8.2 (d, <i>J</i> = 1.9 Hz, 1H), 7.69 (d, <i>J</i> = 1.9 Hz, 1H), 7.23 (d, <i>J</i> = 8.6 Hz, 2H), 7.08–6.95 (m, 7H), 6.09 (br s, 1H), 4.6–4.53 (m, 2H), 4.1–4.03 (m, 1H), 3.84–3.81 (m, 2H).</div></div><div id="sec6_16_22_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i253" class="anchor-spacer"></div><h5 class="article-section__title" id="_i253"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-7-(oxazol-2-yl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>S66</b>)</h5><div class="NLM_p last">To a solution of crude <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>-(2-oxoethyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<b>S65</b>) (0.9 g) in dichloromethane (20.0 mL), triphenylphosphine (0.87 g, 3.3 mmol), iodine (0.83 g, 3.3 mmol) and triethylamine (0.86 mL, 0.62 g, 6.2 mmol) were added. The reaction mixture was stirred at room temperature for 16 h. After this time, the reaction mixture was diluted with dichloromethane and the organic layer was washed with water (2 × 20 mL) and brine (20 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated to dryness. The crude product was purified by Combiflash (4 g, RediSep column) using 2% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-(oxazol-2-yl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>S66</b>) as an off-white solid. Yield: 0.18 g (0.34 mmol, 21% over two steps). MS (ESI) <i>m</i>/<i>z</i>: 525.15 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.19 (s, 1H), 7.92 (s, 1H), 7.71 (s, 1H), 7.21 (d, <i>J</i> = 8.4 Hz, 2H), 7.1 (d, <i>J</i> = 8.4 Hz, 2H), 7.04–7.0 (m, 3H), 6.96 (d, <i>J</i> = 6.4 Hz, 3H), 6.24 (s, 1H), 5.52 (d, <i>J</i> = 5.0 Hz, 1H), 4.79 (d, <i>J</i> = 14.4 Hz, 1H), 4.61–4.58 (m, 1H), 3.10 (br s, 1H).</div></div><div id="sec6_16_22_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i254" class="anchor-spacer"></div><h5 class="article-section__title" id="_i254"> <i>rac</i>-4-((5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-7-(oxazol-2-yl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>27</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-(oxazol-2-yl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>S65</b>) (0.06 g, 0.11 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (1.0 mL) at room temperature, zinc cyanide (0.012 g, 0.10 mmol) and zinc (0.014 g, 0.21 mmol) were added. The mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.0013 g, 0.024 mmol) and tris(dibenzylideneacetone)-dipalladium (0.0026 g, 0.0028 mmol) were added to the reaction mixture, and degassing was continued for another 5 min. The reaction mixture was heated at 150 °C for 2 h. After this time, the reaction was cooled to room temperature and filtered with Celite. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by Combiflash (4 g, RediSep column) using 2% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure. The compound thus obtained was further purified by reverse-phase HPLC. The desired fractions were collected and lyophilized to afford <i>rac</i>-4-((5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-7-(oxazol-2-yl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>27</b>) as a white solid. Yield: 0.012 g (0.025 mmol, 23%). MS (ESI) <i>m</i>/<i>z</i>: 472.40 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 472.1059 [M + H]<sup>+</sup>; found, 472.1064; UPLC: 99.63%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 7.94 (s, 1H), 7.74 (d, <i>J</i> = 2.0 Hz, 1H), 7.49 (d, <i>J</i> = 8.5 Hz, 2H), 7.35 (d, <i>J</i> = 8.5 Hz, 2H), 7.04–6.94 (m, 6H), 6.36 (br s, 1H), 5.60 (br s, 1H), 4.85 (d, <i>J</i> = 14.0 Hz, 1H), 4.68 (dd,, <i>J</i> = 14.0, 4.2 Hz, 1H), 4.60 (d, <i>J</i> = 4.1 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 161.42, 153.44, 149.12, 141.78, 140.83, 139.60, 136.85, 131.01, 130.30, 128.39, 128.01, 127.69, 126.85, 126.28, 118.74, 117.11, 109.24, 102.04, 91.32, 79.66, 56.26, 46.05.</div></div></div><div id="sec6_16_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i255" class="anchor-spacer"></div><h4 class="article-section__title" id="_i255"> Synthesis of <i>rac</i>-((5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-7-(hydroxymethyl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>32</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0063.gif" alt="" id="dgr24" /></img><div id="sec6_16_23_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i256" class="anchor-spacer"></div><h5 class="article-section__title" id="_i256"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-7-(hydroxymethyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>S64</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>103</b>) (320 mg, 0.619 mmol) in tetrahydrofuran (4 mL) at 0 °C was added lithium aluminum hydride (LAH) (27 mg, 0.71 mmol) and the mixture was stirred at 0 °C for 30 min and then warmed up to rt. After another 1.5 h, another 13 mg (0.34 mmol) of LAH was added and stirring at room temperature was continued. After another 30 min, another 13 mg (0.34 mmol) of LAH was added. After 3 h (total reaction time), water and brine were carefully added, and the mixture was diluted with ethyl acetate. The phases were separated and the aq phase was extracted with ethyl acetate thrice. The combined organic phases were washed with brine, then dried (sodium sulfate), filtered, and concentrated. The crude product was purified by column chromatography (silica, methanol/dichloromethane, product eluted at 5% methanol). Yield: 165 mg, <i>ca.</i> 90% pure, <i>ca.</i> 49% yield; <i>ca.</i> 25 mg of this material were repurified by HPLC (C18, acetonitrile/water +0.1% trifluoroacetic acid) to give <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-(hydroxymethyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>S64</b>) as a fluffy white solid. MS (ESI) <i>m</i>/<i>z</i>: 487.9 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.17 (d, <i>J</i> = 2.1 Hz, 1H), 7.61 (d, <i>J</i> = 2.1 Hz, 1H), 7.21 (d, <i>J</i> = 8.7 Hz, 2H), 7.14–6.97 (m, 7H), 4.50 (d, <i>J</i> = 3.8 Hz, 1H), 3.88 (d, <i>J</i> = 14.2 Hz, 1H), 3.55 (dd, <i>J</i> = 10.6, 9.1 Hz, 1H), 3.43 (dd, <i>J</i> = 10.6, 3.1 Hz, 1H), 3.21–3.09 (m, 1H).</div></div><div id="sec6_16_23_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i257" class="anchor-spacer"></div><h5 class="article-section__title" id="_i257"> <i>rac</i>-4-((5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-7-(hydroxymethyl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>32</b>)</h5><div class="NLM_p last">In a 0.5–2 mL microwave vial, <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-(hydroxymethyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>S64</b>) (24.7 mg, 0.0505 mmol) was dissolved in <i>N</i>,<i>N</i>-dimethylformamide (0.50 mL) and water (0.05 mL). Zinc cyanide (19 mg, 0.16 mmol) and zinc (1.8 mg, 0.028 mmol) were added, and the mixture was degassed by bubbling argon through it for 5 min. 1,1′-Bis(diphenylphosphino)ferrocene (2.7 mg, 0.0049 mmol) and tris(dibenzylideneacetone)dipalladium(0) (2.8 mg, 0.0030 mmol) were added, and the mixture was incubated at 100 °C for 30 min. Then, the mixture was diluted with ethyl acetate and washed with water. The organic phase was dried (sodium sulfate), filtered, and concentrated. Purification by column chromatography (silica, methanol/dichloromethane, product eluted at 5% methanol) and subsequently by HPLC (C18, acetonitrile/water +0.1% trifluoroacetic acid) gave <i>rac</i>-4-((5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-7-(hydroxymethyl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>32</b>). Yield: 15.5 mg (0.0356 mmol, 71%); MS (ESI) <i>m</i>/<i>z</i>: 435.3 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 435.1106 [M + H]<sup>+</sup>; found, 435.1112; <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.19 (d, <i>J</i> = 2.0 Hz, 1H), 7.64 (d, <i>J</i> = 2.0 Hz, 1H), 7.49 (d, <i>J</i> = 8.6 Hz, 2H), 7.32 (d, <i>J</i> = 8.6 Hz, 2H), 7.14–6.96 (m, 5H), 4.52 (d, <i>J</i> = 3.9 Hz, 1H), 3.94 (d, <i>J</i> = 14.1 Hz, 1H), 3.57 (dd, <i>J</i> = 10.7, 9.6 Hz, 1H), 3.45 (dd, <i>J</i> = 10.7, 2.9 Hz, 1H), 3.26–3.14 (m, 1H).</div></div></div><div id="sec6_16_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i258" class="anchor-spacer"></div><h4 class="article-section__title" id="_i258"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>26</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0064.gif" alt="" id="dgr25" /></img><div id="sec6_16_24_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i259" class="anchor-spacer"></div><h5 class="article-section__title" id="_i259"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S67</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>103</b>) (0.45 g, 0.87 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5 mL) at room temperature, zinc cyanide (0.113 g, 0.962 mmol) and zinc (0.28 g, 4.2 mmol) were added. The mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.012 g, 0.022 mmol) and tris(dibenzylideneacetone)dipalladium (0.023 g, 0.025 mmol) were added to the reaction mixture, and degassing was continued for 5 min. The reaction mixture was heated at 125 °C for 3 h. After this time, the reaction mixture was cooled to room temperature and filtered through Celite. The filtrate was concentrated to obtain the crude product. This was purified by Combiflash (12 g, RediSep column) using 70% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S67</b>) as a white solid. Yield: 0.31 g (0.67 mmol, 77%). MS (ESI) <i>m</i>/<i>z</i>: 463.15 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (s, 1H), 7.72 (s, 1H), 7.47 (d, <i>J</i> = 8.2 Hz, 2H), 7.28 (d, <i>J</i> = 8.3 Hz, 2H), 7.08–6.87 (m, 5H), 6.26 (s, 1H), 5.80 (d, <i>J</i> = 5.7 Hz, 1H), 4.65–4.63 (m, 1H), 4.58–4.54 (m, 1H), 4.26–4.21 (m, 1H), 3.58 (s, 3H).</div></div><div id="sec6_16_24_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i260" class="anchor-spacer"></div><h5 class="article-section__title" id="_i260"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic Acid (<b>120</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (<b>S67</b>) (0.3 g, 0.6 mmol) in methanol and water (3:1, 10 mL), lithium hydroxide (0.077 g, 3.2 mmol) was added. This reaction mixture was stirred for 6 h at room temperature. After completion, the reaction mixture was cooled to 0 °C and acidified with 5% citric acid to pH ≈ 6. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>120</b>) as a white solid. Yield: 0.21 g (0.47 mmol, 78%). MS (ESI) <i>m</i>/<i>z</i>: 449.0 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (s, 1H), 7.71 (s, 1H), 7.47 (d, <i>J</i> = 8.2 Hz, 2H), 7.26 (d, <i>J</i> = 8.2 Hz, 2H), 7.08–6.97 (m, 5H), 6.19 (s, 1H), 4.62 (d, <i>J</i> = 4 Hz, 1H), 4.53 (d, <i>J</i> = 13.8 Hz, 1H), 4.06 (d, <i>J</i> = 12.6 Hz, 1H), 3.60 (br s, 1H)</div></div><div id="sec6_16_24_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i261" class="anchor-spacer"></div><h5 class="article-section__title" id="_i261"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>26</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>120</b>) (0.18 g, 0.40 mmol) in dichloromethane (5 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.16 g, 0.83 mmol), 1-hydroxybenzotriazole (0.108 g, 0.799 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.2 mL, 0.1 g, 1 mmol) were added. The reaction mixture was stirred for 5 min. Then, ammonium chloride (0.21 g, 3.9 mmol) was then added at same temperature and the mixture was stirred at room temperature for 16 h. After completion, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by Combiflash (4 g, RediSep column) using 70% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford racemic (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>26</b>) as an off-white solid. Yield: 0.14 g (0.31 mmol, 78%). MS (ESI) <i>m</i>/<i>z</i>: 448.12 [M + 1]<sup>+</sup>. The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak-1 (5 mg, (−)-<b>26</b>); [α]<sub>D</sub> −184.2° (<i>c</i> 0.27, DMSO); <i>R</i><sub><i>t</i></sub> 6.41 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 448.38 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 448.1059 [M + H]<sup>+</sup>; found, 448.1078; UPLC 97.6%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 1.8 Hz, 1H), 7.70 (d, <i>J</i> = 1.8 Hz, 1H), 7.51 (d, <i>J</i> = 8.4 Hz, 2H), 7.25 (d, <i>J</i> = 8.4 Hz, 2H), 7.10–6.96 (m, 5H), 6.16 (s, 1H), 5.31 (d, <i>J</i> = 4.5 Hz, 1H), 4.58–4.55 (m, 1H), 3.97 (dd, <i>J</i> = 14.0, 4.1 Hz, 1H). Peak-2 (7 mg, (+)-<b>26</b>); [α]<sub>D</sub> +128.8° (<i>c</i> 0.26, DMSO); <i>R</i><sub><i>t</i></sub> 11.06 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 448.37 [M + 1]<sup>+</sup>; UPLC 99.2%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.20 (d, <i>J</i> = 1.9 Hz, 1H), 7.70 (d, <i>J</i> = 1.9 Hz, 1H), 7.51 (d, <i>J</i> = 8.5 Hz, 2H), 7.25 (d, <i>J</i> = 8.5 Hz, 2H), 7.09–6.96 (m, 5H), 6.16 (s, 1H), 5.31 (d, <i>J</i> = 4.5 Hz, 1H), 4.57 (m, <i>J</i> = 7.8 Hz, 2H), 3.97 (dd, <i>J</i> = 13.8, 4.2 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 171.45, 153.44, 149.22, 142.05, 140.64, 137.45, 130.93, 130.27, 128.16, 127.93, 127.60, 126.16, 118.73, 117.04, 109.16, 102.16, 91.48, 79.47, 56.08, 50.96.</div></div></div><div id="sec6_16_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i262" class="anchor-spacer"></div><h4 class="article-section__title" id="_i262"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>25</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0065.gif" alt="" id="dgr26" /></img><div id="sec6_16_25_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i263" class="anchor-spacer"></div><h5 class="article-section__title" id="_i263"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide ((−)-<b>25</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylic acid (<b>120</b>) (0.13 g, 0.29 mmol) in dichloromethane (10 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.13 g, 0.67 mmol), 1-hydroxybenzotriazole (0.12 g, 0.89 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.5 mL, 0.4 g, 3 mmol) were added. The reaction mixture was stirred for 5 min. Then, methylamine hydrochloride (0.097 g, 1.4 mmol) was added at same temperature and the mixture was stirred for 16 h at 40 °C. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure to afford racemic (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxamide (<i>rac</i>-<b>25</b>) as a brown solid. Yield: 120 mg (0.260 mol, 90%). The enantiomers were separated by chiral preparative HPLC [Chiralpak IC (4.6 × 250) mm]. Peak 1 (22 mg, (+)-<b>25</b>); [α]<sub>D</sub> +51.4° (<i>c</i> 0.14, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 5.66 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 462.41 [M + 1]<sup>+</sup>; UPLC: 99.09%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 8.17 (q, <i>J</i> = 4.3 Hz, 1H), 7.71 (d, <i>J</i> = 2.0 Hz, 1H), 7.51 (d, <i>J</i> = 8.5 Hz, 2H), 7.25 (d, <i>J</i> = 8.5 Hz, 2H), 7.08–6.96 (m, 5H), 6.19 (s, 1H), 5.29 (d, <i>J</i> = 4.5 Hz, 1H), 4.61 (d, <i>J</i> = 14.0 Hz, 1H), 4.52 (t, <i>J</i> = 4.4 Hz, 1H), 3.95 (dd, <i>J</i> = 14.0, 4.4 Hz, 1H), 2.55 (d, <i>J</i> = 4.5 Hz, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 169.78, 153.41, 149.21, 141.98, 140.66, 137.32, 130.94, 130.27, 128.17, 127.88, 127.65, 126.21, 118.72, 117.05, 109.18, 102.10, 91.31, 79.51, 55.96, 51.24, 25.72. Peak-2 (18 mg, (−)-<b>25</b>); [α]<sub>D</sub> −178° (<i>c</i> 0.13, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 7.24 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 462.42 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 462.1215 [M + H]<sup>+</sup>; found, 462.1223; UPLC: 99.61%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 2.0 Hz, 1H), 8.17 (q, <i>J</i> = 4.3 Hz, 1H), 7.71 (d, <i>J</i> = 1.9 Hz, 1H), 7.51 (d, <i>J</i> = 8.5 Hz, 2H), 7.25 (d, <i>J</i> = 8.5 Hz, 2H), 7.08–6.96 (m, 5H), 6.19 (s, 1H), 5.29 (d, <i>J</i> = 4.5 Hz, 1H), 4.61 (d, <i>J</i> = 14.0 Hz, 1H), 4.52 (t, <i>J</i> = 4.4 Hz, 1H), 3.96 (dd, <i>J</i> = 14.0, 4.4 Hz, 1H), 2.56 (d, <i>J</i> = 4.6 Hz, 3H).</div></div></div><div id="sec6_16_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i264" class="anchor-spacer"></div><h4 class="article-section__title" id="_i264"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<i>rac</i>-<b>28</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0066.gif" alt="" id="dgr27" /></img><div id="sec6_16_26_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i265" class="anchor-spacer"></div><h5 class="article-section__title" id="_i265"> (6<i>S</i>,7<i>S</i>,8<i>S</i>,9<i>R</i>)-6-(4-Bromophenyl)-3-chloro-9-hydroxy-<i>N</i>,<i>N</i>-dimethyl-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-sulfonamide (<b>S68</b>)</h5><div class="NLM_p last">A solution of 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>102</b>) (1.5 g, 4.3 mmol) and (<i>E</i>)-<i>N</i>,<i>N</i>-dimethyl-2-phenylethene-1-sulfonamide (<b>121</b>) (4.50 g, 21.3 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated for 72 h under 400 W UV light in a UV reactor flask. After this time, the solvent was removed under reduced pressure. The crude product was purified by Combi-flash (4 g, RediSep column) using ethyl acetate as the eluent. The desired fractions were concentrated under reduced pressure to afford 5a-(4-bromophenyl)-3-chloro-7a-hydroxy-<i>N</i>,<i>N</i>-dimethyl-8-oxo-6-phenyl-5a,6,7a,8-tetrahydro-7<i>H</i>-cyclobuta[5,6]pyrano[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S68</b>) as a brown solid. Yield: 0.7 g, crude.</div></div><div id="sec6_16_26_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i266" class="anchor-spacer"></div><h5 class="article-section__title" id="_i266"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-Bromophenyl)-3-chloro-8a-hydroxy-<i>N</i>,<i>N</i>-dimethyl-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S69</b>)</h5><div class="NLM_p last">The crude 5a-(4-bromophenyl)-3-chloro-7a-hydroxy-<i>N</i>,<i>N</i>-dimethyl-8-oxo-6-phenyl-5a,6,7a,8-tetrahydro-7<i>H</i>-cyclobuta[5,6]pyrano[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S68</b>) (0.7 g) was suspended in methanol (20 mL) and treated with 25% sodium methoxide (25% in methanol, 10 mL, 9.5 g solution, 2.4 g NaOMe, 44 mmol). The reaction mixture was heated at 80 °C for 2 h. Then, the solvent was removed under reduced pressure, and the reaction mixture was treated with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-<i>N</i>,<i>N</i>-dimethyl-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>4</b>) as a brown solid. Yield: 0.35 g, crude.</div></div><div id="sec6_16_26_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i267" class="anchor-spacer"></div><h5 class="article-section__title" id="_i267"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>122</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (1.27 g, 3.73 mmol) and crude (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-<i>N</i>,<i>N</i>-dimethyl-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S69</b>) (0.35 g) in acetonitrile (20 mL), acetic acid (4.0 mL, 4.2 g, 70 mmol) was added. The resulting mixture was stirred for 15 h at room temperature. After this time, reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by Combi-flash (4 g, RediSep column) using 50% ethyl acetate in hexanes as the eluent. The compound was further purified by reverse-phase HPLC. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>122</b>) as a light yellow solid. Yield: 0.04 g (0.07 mmol, 2% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 565.06 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.19 (s, 1H), 7.65 (s, 1H), 7.21 (s, 5H), 7.14–7.02 (m, 4H), 6.35 (br s, 1H), 5.91 (br s, 1H), 4.85 (dd, <i>J</i> = 13.4, 3.1 Hz, 1H), 4.64 (br s, 1H), 4.52 (d, <i>J</i> = 13.6, Hz, 1H), 2.44 (s, 6H).</div></div><div id="sec6_16_26_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i268" class="anchor-spacer"></div><h5 class="article-section__title" id="_i268"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<i>rac</i>-<b>28</b>)</h5><div class="NLM_p last">To a solution of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>122</b>) (0.03 g, 0.053 mmol) in <i>N</i>,<i>N</i>-dimethylformamide at room temperature, zinc cyanide (0.005 g, 0.043 mmol) and zinc (0.001 g, 0.015 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.001 g, 0.001 mmol) and tris(dibenzylideneacetone)dipalladium (0.002 g, 0.002 mmol) were added to the reaction mixture, and degassing was continued for 5 min. The reaction mixture was heated at 140 °C for 1 h. After this time, the reaction mixture was cooled to room temperature and filtered with Celite. The filtrate was purified by Combi-flash (4 g, RediSep column) using 10% methanol in dichloromethane as the eluent. Finally, the compound was purified by reverse-phase HPLC. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<i>rac</i>-<b>28</b>) as an off-white solid. Yield: 0.002 g (0.004 mmol, 7%). MS (ESI) <i>m</i>/<i>z</i>: 512.45 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 512.1041 [M + H]<sup>+</sup>; found, 512.1039; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.20 (d, <i>J</i> = 1.9 Hz, 1H), 7.69 (d, <i>J</i> = 1.9 Hz, 1H), 7.49 (dd, <i>J</i> = 14.6 Hz, 8.9 Hz, 4H), 7.14 (d, <i>J</i> = 7.2 Hz, 2H), 7.08–6.99 (m, 3H), 6.44 (s, 1H), 5.97 (d, <i>J</i> = 6.2 Hz, 1H), 4.95 (dd, <i>J</i> = 13.8, 4.0 Hz, 1H), 4.65 (t, <i>J</i> = 6.0 Hz, 1H), 4.58 (d, <i>J</i> = 13.6, Hz, 1H), 2.46 (s, 6H).</div></div></div><div id="sec6_16_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i269" class="anchor-spacer"></div><h4 class="article-section__title" id="_i269"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-Chloro-5<i>a</i>-(4-cyanophenyl)-8,8<i>a</i>-dihydroxy-<i>N</i>-methyl-6-phenyl-5<i>a</i>,7,8,8<i>a</i>-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<i>rac</i>-<b>29</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0067.gif" alt="" id="dgr28" /></img><div id="sec6_16_27_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i270" class="anchor-spacer"></div><h5 class="article-section__title" id="_i270"> (<i>E</i>)-<i>N</i>-Benzyl-<i>N</i>-methyl-2-phenylethene-1-sulfonamide (<b>123</b>)</h5><div class="NLM_p last">(1) To a solution of styrene (<b>1</b>, 55.00 g, 528.1 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (50 mL) at 0 °C, sulfuryl chloride (142.0 g, 1052 mmol) was added. This reaction mixture was stirred at room temperature for 2 h. After this time, the mixture was quenched with ice-cold water (500 mL) and extracted with ethyl acetate (1000 mL). The organic layer was washed with water and brine, separated, and dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford (<i>E</i>)-2-phenylethene-1-sulfonyl chloride (<b>S71</b>) as a white solid. Yield: 90.0 g, crude. (2) To a solution of crude (<i>E</i>)-2-phenylethene-1-sulfonyl chloride (<b>S71</b>) (35.00 g) in dichloromethane (100 mL), triethylamine (25.0 mL, 18.1 g, 179 mmol) and <i>N</i>-methyl-1-phenylmethanamine (<b>S72</b>) (20 mL, 19 g, 160 mmol) were added. The reaction mixture was stirred at room temperature for 16 h. After this time, the solvent was removed under reduced pressure. The mixture was quenched with ice-cold aqueous sodium bicarbonate solution (300 mL) and extracted with ethyl acetate (1000 mL). The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product. This was purified by silica gel (100–200 mesh) column chromatography using 50% ethyl acetate in hexanes as eluents. The desired fractions were concentrated under reduced pressure to afford (<i>E</i>)-<i>N</i>-benzyl-<i>N</i>-methyl-2-phenylethene-1-sulfonamide (<b>123</b>) as a white solid. Yield: 9.0 g (31 mmol, 18%); MS (ESI) <i>m</i>/<i>z</i>: 288.23 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_27_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i271" class="anchor-spacer"></div><h5 class="article-section__title" id="_i271"> <i>rac</i>-(7<i>S</i>,8<i>S</i>,9<i>R</i>)-<i>N</i>-benzyl-6-(4-Bromophenyl)-3-chloro-9-hydroxy-<i>N</i>-methyl-10-oxo-7-phenyl-6,7,8,9-tetrahydro-6,9-methanooxepino[3,2-<i>b</i>]pyridine-8-sulfonamide (<b>S73</b>)</h5><div class="NLM_p last">A solution of 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>b</i>]pyridin-4-one (<b>102</b>) (3.0 g, 8.5 mmol) and (<i>E</i>)-<i>N</i>-benzyl-<i>N</i>-methyl-2-phenylethene-1-sulfonamide (<b>123</b>) (7.0 g, 24 mmol) in dichloromethane (100 mL), acetonitrile (50 mL), and methanol (50 mL) was irradiated under 400 W UV light for 96 h in a UV reactor flask. After this time, the solvent was removed under reduced pressure and the crude product was purified over a plug of silica gel (100–200 mesh) eluting with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford compound <b>S73</b> as a sticky brown solid. Yield: 1.3 g, crude.</div></div><div id="sec6_16_27_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i272" class="anchor-spacer"></div><h5 class="article-section__title" id="_i272"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-<i>N</i>-Benzyl-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-<i>N</i>-methyl-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S74</b>)</h5><div class="NLM_p last">The crude product from the previous step (<b>S73</b>) (1.30 g) was suspended in methanol (15 mL) and treated with 25% sodium methoxide in methanol (15 mL, 14 g solution, 3.5 g NaOMe, 66 mmol). The reaction was heated at 90 °C for 3 h. After this time, the solvent was removed under reduced pressure. The crude product was diluted with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-<i>N</i>-benzyl-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-<i>N</i>-methyl-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S74</b>) as a sticky brown solid. Yield: 1.3 g, crude.</div></div><div id="sec6_16_27_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i273" class="anchor-spacer"></div><h5 class="article-section__title" id="_i273"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-<i>N</i>-Benzyl-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>124</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (1.20 g, 5.66 mmol) and crude (5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-<i>N</i>-benzyl-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-<i>N</i>-methyl-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S74</b>) (0.6 g) in acetonitrile (10 mL), acetic acid (0.56 g, 9.3 mmol) was added. The resulting mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by Combi-flash (12 g RediSep column) using 50% ethyl acetate in hexanes as eluents. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-<i>N</i>-benzyl-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>124</b>) as a brown solid. Yield: 0.23 g (0.36 mmol, 9% over three steps); MS (ESI) <i>m</i>/<i>z</i>: 641.12 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_27_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i274" class="anchor-spacer"></div><h5 class="article-section__title" id="_i274"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S75</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-<i>N</i>-benzyl-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>124</b>) (0.190 g, 0.296 mmol) in dichloromethane (2 mL), trifluoroacetic acid (2.0 mL, 3.0 g, 26 mmol) and triflic acid (2.0 mL, 3.4 g, 23 mmol) were added. This reaction mixture was stirred for 3 h at room temperature. Then, the reaction was diluted with dichloromethane and washed with cold sodium bicarbonate aqueous solution. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>9</b>) as a brown solid. Yield: 0.18, crude. MS (ESI) <i>m</i>/<i>z</i>: 551.36 [M + 1]<sup>+</sup>,<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.19 (s, 1H), 7.77 (s, 1H), 7.44–7.42 (m, 2H), 7.22 (d, <i>J</i> = 8.1 Hz, 2H), 7.14 (d, <i>J</i> = 7.5 Hz, 2H), 7.00–6.84 (m, 3H), 6.28 (m, 1H), 5.84 (d, <i>J</i> = 5.3 Hz, 1H), 4.90 (m, 1H), 4.63 (m, 1H), 4.57 (d, <i>J</i> = 13.1 Hz, 1H), 2.81 (s, 3H).</div></div><div id="sec6_16_27_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i275" class="anchor-spacer"></div><h5 class="article-section__title" id="_i275"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-Chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<i>rac</i>-<b>29</b>)</h5><div class="NLM_p last">To a solution of crude <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<b>S75</b>) (0.065 g) in <i>N</i>,<i>N</i>-dimethylformamide (3.0 mL) at room temperature, zinc cyanide (0.028 g, 0.24 mmol) and zinc dust (0.031 g, 0.47 mmol) were added. This reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (1 mg, 0.002 mmol) and tris(dibenzylideneacetone)dipalladium (2 mg, 0.002 mmol) were added to the reaction mixture which was then degassed for an additional 5 min and heated at 125 °C for 6 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by Combi-flash (12 g RediSep column) using 3% methanol in dichloromethane as the eluent. The product was further purified by reverse preparative HPLC. The desired fractions were lyophilized to afford racemic (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-chloro-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>-methyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-sulfonamide (<i>rac</i>-<b>29</b>) as an off-white solid. Yield: 4 mg (0.008 mol, 8% over two steps). MS (ESI) <i>m</i>/<i>z</i>: 498.17 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 498.0885 [M + H]<sup>+</sup>; found, 498.0892; UPLC 98.3%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (s, 1H), 7.70 (s, 1H), 7.49 (d, <i>J</i> = 8.2 Hz, 2H), 7.40 (d, <i>J</i> = 8.2 Hz, 2H), 7.16 (d, <i>J</i> = 7.4 Hz, 2H), 7.01 (t, <i>J</i> = 7.2 Hz, 3H), 6.41 (s, 1H), 6.30 (d, <i>J</i> = 4.3 Hz, 1H), 5.90 (d, <i>J</i> = 5.9 Hz, 1H), 4.90 (dd, <i>J</i> = 4.0 Hz, 13.4 Hz, 1H), 4.69 (m, 1H), 4.60 (d, <i>J</i> = 13.8, 1H), 2.50 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ 153.18, 148.97, 141.07, 140.89, 134.94, 131.05, 130.19, 129.41, 127.16, 126.72, 118.74, 117.20, 115.84, 109.38, 102.38, 89.38, 78.67, 65.42, 56.58, 28.79.</div></div></div><div id="sec6_16_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i276" class="anchor-spacer"></div><h4 class="article-section__title" id="_i276"> Synthesis of 4-((5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-7-(methylsulfonyl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile ((−)-<b>30</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0068.gif" alt="" id="dgr29" /></img><div id="sec6_16_28_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i277" class="anchor-spacer"></div><h5 class="article-section__title" id="_i277"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-5a-(4-Bromophenyl)-3-chloro-8a-hydroxy-6-phenyl-5a,6,7,8a-tetrahydro-8<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-8-one (126)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-7-carboxylate (125) (3.0 g, 5.8 mmol) in dimethylsulfoxide (60 mL), lithium chloride (27.2 g, 0.642 mol) was added, and the mixture was stirred at 150 °C for 24 h. After this time, ice-cold water was added and the precipitate was isolated by filtration. The solid was dissolved in dichloromethane (100 mL) and washed with water (2 × 30 mL) and brine (20 mL). The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated. The so-obtained crude product was purified by Combi-flash (12 g, RediSep column) using 20% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-6-phenyl-5a,6,7,8a-tetrahydro-8<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-8-one (126) as an off-white solid. Yield: 0.85 g (1.9 mmol, 33%). MS (ESI) <i>m</i>/<i>z</i>: 455.92 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_28_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i278" class="anchor-spacer"></div><h5 class="article-section__title" id="_i278"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-5a-(4-Bromophenyl)-3-chloro-8a-hydroxy-7-(methylsulfonyl)-6-phenyl-5a,6,7,8a-tetrahydro-8<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-8-one (<b>S77</b>)</h5><div class="NLM_p last">To a solution of 1,8-diazabicyclo[5.4.0]undec-7-ene (3.0 mL, 20 mmol) in DMSO (10 mL) at room temperature, copper(II) bromide (51 mg, 0.23 mmol) was added under air. Then, (5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-6-phenyl-5a,6,7,8a-tetrahydro-8<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-8-one (<b>126</b>) (1.5 g, 3.3 mmol) and sodium methanesulfinate (<b>S76</b>) (3.36 g, 32.9 mmol) in DMSO (10.0 mL) at room temperature were added dropwise to the reaction mixture in under air. The reaction mixture was stirred at room temperature for 1 h. After completion (as determined by mass spectrometry), the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford (5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-7-(methylsulfonyl)-6-phenyl-5a,6,7,8a-tetrahydro-8<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-8-one (<b>S77</b>) as a brown semisolid. Yield: 0.5 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 532 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_28_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i279" class="anchor-spacer"></div><h5 class="article-section__title" id="_i279"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-7-(methylsulfonyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>127</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (1.19 g, 5.61 mmol) and crude <i>rac</i>-(5a<i>R</i>,6<i>S</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-7-(methylsulfonyl)-6-phenyl-5a,6,7,8a-tetrahydro-8<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-8-one (<b>S77</b>) (0.5 g) in acetonitrile (25 mL), acetic acid (0.56 mL, 0.59 g, 9.8 mmol) was added. The resulting mixture was stirred for 6 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by Combiflash (12 g, RediSep column) using 60% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-(methylsulfonyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>127</b>) as a white solid. Yield: 70 mg (0.13 mmol, 4% over two steps). MS (ESI) <i>m</i>/<i>z</i>: 536.08 [M + 1]<sup>+</sup>; UPLC 99.8%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 7.67 (d, <i>J</i> = 2.0 Hz, 1H), 7.24 (d, <i>J</i> = 8.7 Hz, 2H), 7.19–7.16 (m, 4H) 7.08–7.01 (m, 3H), 6.33 (br s, 1H), 6.20 (br s, 1H), 4.83 (dd, <i>J</i> = 4.0, 13.5 Hz, 1H), 4.77 (d, <i>J</i> = 4.4 Hz, 1H), 4.56 (d, <i>J</i> = 13.6 Hz, 1H), 2.84 (s, 3H).</div></div><div id="sec6_16_28_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i280" class="anchor-spacer"></div><h5 class="article-section__title" id="_i280"> 4-((5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-Chloro-8,8a-dihydroxy-7-(methylsulfonyl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile ((−)-30) and <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-7-(methylsulfonyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-3-carbonitrile (<i>rac</i>-<b>S78</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-(methylsulfonyl)-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-8,8a-diol (<b>127</b>) (0.13 g, 0.24 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5.0 mL) at room temperature, zinc cyanide (0.033 g, 0.28 mmol) and zinc (0.0016 g, 0.024 mmol) were added. The mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.013 g, 0.023 mmol) and tris(dibenzylideneacetone)-dipalladium (0.006 g, 0.007 mmol) were added to the reaction mixture, and degassing was continued for another 5 min. The reaction mixture was heated at 150 °C for 2 h. After this time, the reaction mixture was cooled to room temperature and filtered through Celite. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by reverse-phase prep-HPLC to afford <i>rac</i>-4-((5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-3-chloro-8,8a-dihydroxy-7-(methylsulfonyl)-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>30</b>) as an off-white solid (84 mg, 0.17 mmol, 72%) and <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>S</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-7-(methylsulfonyl)-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>b</i>]pyridine-3-carbonitrile (<i>rac</i>-<b>S78</b>) as an off-white solid (15 mg, 0.032 mmol, 13%). The enantiomers of <i>rac</i>-<b>30</b> were separated by chiral preparative HPLC [Chiralpak ID (4.6 × 250) mm] using 0.1% DEA in <i>n</i>-hexane/EtOH = 70/30(v/v) mobile phase. Peak 1 (30 mg, (+)-<b>30</b>); [α]<sub>D</sub> +48.5° (<i>c</i> 0.25, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 11.3 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 483.08 [M + 1]<sup>+</sup>; UPLC: 99.70%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.22 (d, <i>J</i> = 1.92 Hz, 1H), 7.71 (d, <i>J</i> = 1.8 Hz, 1H), 7.52 (d, <i>J</i> = 8.5 Hz, 2H), 7.44 (d, <i>J</i> = 8.5 Hz, 2H), 7.18 (d, <i>J</i> = 6.5 Hz, 2H), 7.07–7.00 (m, 3H), 6.45 (s, 1H), 6.26 (d, <i>J</i> = 6.2 Hz, 1H), 4.94 (dd, <i>J</i> = 4.0, 13.8 Hz, 1H), 4.78 (t, <i>J</i> = 6.2 Hz, 1H), 4.61 (d, <i>J</i> = 13.7 Hz, 1H), 2.86 (s, 3H). Peak-2 (33.0 mg, (−)-<b>30</b>); [α]<sub>D</sub> −46.6° (<i>c</i> 0.30, CHCl<sub>3</sub>); <i>R</i><sub><i>t</i></sub> 17.2 min, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 483.08 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 483.0776 [M + H]<sup>+</sup>; found, 483.0771; UPLC: 99.35%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.22 (d, <i>J</i> = 1.8 Hz, 1H), 7.71 (d, <i>J</i> = 1.8 Hz, 1H), 7.52 (d, <i>J</i> = 8.4 Hz, 2H), 7.44 (d, <i>J</i> = 8.5 Hz, 2H), 7.18 (d, <i>J</i> = 6.6 Hz 2H), 7.07–7.00 (m, 3H), 6.45 (s, 1H), 6.26 (d, <i>J</i> = 6.3 Hz, 1H), 4.94 (dd, <i>J</i> = 4.0 Hz, 13.6 Hz, 1H), 4.78 (t, <i>J</i> = 4.52 Hz, 1H), 4.62 (d, <i>J</i> = 13.8 Hz, 1H), 2.86 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 153.08, 148.72, 140.97, 140.86, 134.31, 131.12, 130.25, 129.67, 128.70, 127.21, 127.04, 118.70, 117.29, 109.55, 102.05, 89.69, 78.13, 66.91, 56.34, 41.96. <i>rac</i>-<b>S78</b>: MS (ESI) <i>m</i>/<i>z</i>: 474.11 [M + 1]<sup>+</sup>; UPLC 99.1%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.66 (d, <i>J</i> = 1.4 Hz, 1H), 8.04 (d, <i>J</i> = 1.4 Hz, 1H), 7.52 (d, <i>J</i> = 8.6 Hz, 2H), 7.45 (d, <i>J</i> = 8.4 Hz, 2H), 7.20 (d, <i>J</i> = 6.6 Hz, 2H), 7.07–7.02 (m, 3H), 6.66 (s, 1H), 6.38 (d, <i>J</i> = 6.3 Hz, 1H), 4.99 (dd, <i>J</i> = 3.7 Hz, 13.8 Hz, 1H), 4.83–4.80 (m, 1H), 4.65 (d, <i>J</i> = 13.7 Hz, 1H), 2.85 (s, 3H).</div></div></div><div id="sec6_16_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i281" class="anchor-spacer"></div><h4 class="article-section__title" id="_i281"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide ((−)-<b>33</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0070.gif" alt="" id="dgr30" /></img><div id="sec6_16_29_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i282" class="anchor-spacer"></div><h5 class="article-section__title" id="_i282"> 6-Chloro-<i>N</i>,4-dimethoxy-<i>N</i>-methylnicotinamide (<b>S79</b>)</h5><div class="NLM_p last">To a solution of 6-chloro-4-methoxynicotinic acid (<b>128</b>) (25.0 g, 133 mmol) in dichloromethane (300 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (38.44 g, 200.5 mmol), 1-hydroxybenzotriazole (30.40 g, 199.0 mmol), and DIPEA (69.8 mL, 51.8 g, 401 mmol) were added. The mixture was stirred for 5 min. Then, <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (<b>129</b>) (19.56 g, 200.5 mmol) was added at same temperature and the mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated and dried over sodium sulfate, filtered, and concentrated to give the crude product, which was recrystallized from ethanol to afford 6-chloro-<i>N</i>,4-dimethoxy-<i>N</i>-methylnicotinamide (<b>S79</b>) as a white solid. Yield: 19.3 g (83.7 mmol, 63%). MS (ESI) <i>m</i>/<i>z</i>: 231.17 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ/ppm 8.19 (s, 1H), 6.88 (s, 1H), 3.91 (s, 3H), 3.51 (s, 3H), 3.33 (s, 3H).</div></div><div id="sec6_16_29_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i283" class="anchor-spacer"></div><h5 class="article-section__title" id="_i283"> 1-(6-Chloro-4-methoxypyridin-3-yl)ethan-1-one (<b>130</b>)</h5><div class="NLM_p last">To a solution of 6-chloro-<i>N</i>,4-dimethoxy-<i>N</i>-methylnicotinamide (<b>S79</b>) (17.0 g, 73.7 mmol) in dry tetrahydrofuran (200 mL) at 0 °C, methyl magnesium bromide (26.43 mL, 221.7 mmol) was added dropwise over a period of 30 min. The reaction mixture was slowly brought to room temperature and stirred for 2 h. Then, the reaction mixture was treated with saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 1-(6-chloro-4-methoxypyridin-3-yl)ethan-1-one (<b>4</b>) as a yellow solid. Yield: 12.0 g (64.7 mmol, 88%). MS (ESI) <i>m</i>/<i>z</i>: 186.17 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.43 (s, 1H), 7.37 (s, 1H), 3.99 (s, 3H), 2.52 (s, 3H).</div></div><div id="sec6_16_29_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i284" class="anchor-spacer"></div><h5 class="article-section__title" id="_i284"> 1-(6-Chloro-4-hydroxypyridin-3-yl)ethan-1-one (<b>131</b>)</h5><div class="NLM_p last">To a solution of 1-(6-chloro-4-methoxypyridin-3-yl)ethan-1-one (<b>130</b>) (10.0 g, 53.9 mmol) in acetic acid (30.0 mL), 6 M aq hydrochloric acid (60.0 mL, 360 mmol) was added. The reaction mixture was refluxed at 100 °C for 16 h. Then, it was concentrated under reduced pressure, diluted with water, cooled to 0 °C, basified with 10% NaOH solution to pH ≈ 9–10, and extracted with ethyl acetate. The organic layer was concentrated to recover starting material. The aqueous layer was cooled to 0 °C and acidified with 6 M aq hydrochloric acid. The precipitated solid was collected by filtration and dried to afford 1-(6-chloro-4-hydroxypyridin-3-yl)ethan-1-one (<b>131</b>) as a brown solid. Yield: 6.3 g (37 mmol, 68%). MS (ESI) <i>m</i>/<i>z</i>: 170.08 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.43 (s, 1H), 8.65 (s, 1H), 7.06 (s, 1H), 2.49 (s, 3H).</div></div><div id="sec6_16_29_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i285" class="anchor-spacer"></div><h5 class="article-section__title" id="_i285"> (<i>E</i>)-3-(4-Bromophenyl)-1-(6-chloro-4-hydroxypyridin-3-yl)prop-2-en-1-one (<b>S80</b>)</h5><div class="NLM_p last">To a solution of 1-(6-chloro-4-hydroxypyridin-3-yl)ethan-1-one (<b>132</b>) (5.5 g, 32 mmol) in methanol (50 mL) and dichloromethane (20 mL), sodium hydroxide (3.84 g, 96.0 mmol) was added, followed by 4-bromobenzaldehyde (6.5 g, 35 mmol). The reaction mixture was heated at 90 °C for 1 h. Then, it was cooled to room temperature and the precipitated solid was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-3-(4-bromophenyl)-1-(6-chloro-4-hydroxypyridin-3-yl)prop-2-en-1-one (<b>S80</b>) as a yellow solid. Yield: 10.5 g (31.0 mmol, 97%). MS (ESI) <i>m</i>/<i>z</i>: 338.08 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.38 (d, <i>J</i> = 15.8 Hz, 1H), 8.13 (s, 1H), 7.62–7.55 (m, 4H), 7.42 (d, <i>J</i> = 15.8 Hz, 1H), 6.05 (s, 1H).</div></div><div id="sec6_16_29_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i286" class="anchor-spacer"></div><h5 class="article-section__title" id="_i286"> 2-(4-Bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>132</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-3-(4-bromophenyl)-1-(6-chloro-4-hydroxypyridin-3-yl)prop-2-en-1-one (<b>S80</b>) (10.0 g, 29.5 mmol) in methanol (150 mL) at room temperature, 10% sodium hydroxide (36 mL, 88.0 mmol) was added followed by hydrogen peroxide (30% aq sln, 6.57 mL, 2.19 g H<sub>2</sub>O<sub>2</sub>, 64.3 mmol). The reaction mixture was stirred for 1 h (reaction is exothermic!), then cooled, and neutralized with 6 M hydrogen chloride to pH ≈ 7. The precipitated solid was collected by filtration and dried under vacuum to afford 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>132</b>) as a yellow solid. Yield: 3.1 g (8.8 mmol, 30%). MS (ESI) <i>m</i>/<i>z</i>: 350.08 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.10 (s, 1H), 8.19 (d, <i>J</i> = 7.9 Hz, 2H), 8.04 (s, 1H), 7.78 (d, <i>J</i> = 8.3 Hz, 2H).</div></div><div id="sec6_16_29_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i287" class="anchor-spacer"></div><h5 class="article-section__title" id="_i287"> <i>rac</i>-Methyl (2<i>S</i>,3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-Bromophenyl)-8-chloro-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S81</b>)</h5><div class="NLM_p last">A solution of 2-(4-bromophenyl)-7-chloro-3-hydroxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>132</b>) (3.1 g, 8.8 mmol) and methyl cinnamate (<b>55</b>) (13.82 g, 85.21 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated for 24 h under 400 W UV light in a UV reactor flask. The solvent was then removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (2<i>S</i>,3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-bromophenyl)-8-chloro-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S81</b>). Yield: 3.1 g, crude.</div></div><div id="sec6_16_29_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i288" class="anchor-spacer"></div><h5 class="article-section__title" id="_i288"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-Bromophenyl)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S82</b>)</h5><div class="NLM_p last">The crude <i>rac</i>-methyl (2<i>S</i>,3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-bromophenyl)-8-chloro-5-hydroxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S81</b>) (3.1 g) was suspended in methanol (30 mL) and treated with sodium methoxide (25% in methanol, 20.0 mL, 18.9 g, 4.72 g NaOMe, 87.4 mmol NaOMe). The mixture was heated at 90 °C for 3 h. Then, the solvent was removed under reduced pressure. The mixture was diluted with ammonium chloride solution and extracted with ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S82</b>). Yield: 2.2 g, crude.</div></div><div id="sec6_16_29_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i289" class="anchor-spacer"></div><h5 class="article-section__title" id="_i289"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>133</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (5.2 g, 25 mmol) and crude <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S82</b>) (2.1 g) in acetonitrile (50 mL), acetic acid (2.4 mL, 2.5 g, 42 mmol) was added. The resulting mixture was stirred for 4 h at room temperature. Then, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography eluting with 30% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>133</b>) as an off-white solid. Yield: 1.21 g (2.34 mmol, 28% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 516.22 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.23 (s, 1H), 7.31 (s, 1H), 7.27 (d, <i>J</i> = 8.3 Hz, 2H), 7.09–7.02 (m, 5H), 6.90 (d, <i>J</i> = 7.0 Hz, 2H), 6.03 (s, 1H), 5.75 (s, 1H), 4.75 (t, <i>J</i> = 6.0 Hz, 1H), 4.17–4.09 (m, 2H), 3.54 (s, 3H).</div></div><div id="sec6_16_29_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i290" class="anchor-spacer"></div><h5 class="article-section__title" id="_i290"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic Acid (<b>S83</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>133</b>) (1.2 g, 2.3 mmol) in tetrahydrofuran and water (3:1, 15 mL), lithium hydroxide (0.55 g, 23 mmol) was added. The reaction mixture was stirred for 16 h at room temperature, then cooled to 0 °C and acidified with 1 M hydrogen chloride to pH ≈ 3. The precipitated solid was collected by filtration and dried under vacuum to afford (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic acid (<b>S83</b>) as an off-white solid. Yield: 1.05 g (2.09 mmol, 91%). MS (ESI) <i>m</i>/<i>z</i>: 502.06 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.22 (s, 1H), 7.30 (s, 1H), 7.27 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.01 (m, 5H), 6.92 (d, <i>J</i> = 7.3 Hz, 2H), 5.99 (s, 1H), 4.70 (d, <i>J</i> = 6.0 Hz 1H), 4.15–4.11 (m, 1H), 4.05–3.99 (m, 2H), 3.94–3.90 (dd, <i>J</i> = 5.7 Hz, 13.8 Hz, 1H).</div></div><div id="sec6_16_29_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i291" class="anchor-spacer"></div><h5 class="article-section__title" id="_i291"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>134</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic acid (<b>S83</b>) (0.7 g, 1.39 mmol) in dichloromethane (50 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.8 g, 4 mmol), 1-hydroxybenzotriazole (0.63 g, 4.7 mmol) and DIPEA (1.43 mL, 1.06 g, 8.20 mmol) were added. The mixture was stirred for 5 min. Dimethylamine hydrochloride (0.56 g, 6.9 mmol) was then added at same temperature, and the mixture was stirred for 16 h at 40 °C. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to give the crude product, which was purified by silica gel column chromatography eluting with 70% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>134</b>) as a white solid. Yield: 0.52 g (0.98 mmol, 71%). MS (ESI) <i>m</i>/<i>z</i>: 523.21 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.31 (s, 1H), 7.34–7.30 (m, 3H), 7.11 (d, <i>J</i> = 8.4 Hz, 2H), 7.06–7.00 (m, 3H), 6.83 (d, <i>J</i> = 7.2 Hz, 2H), 5.87 (s, 1H), 5.75 (s, 1H), 4.90 (t, <i>J</i> = 6.5 Hz, 1H), 4.20–4.16 (m, 2H), 4.12–4.01 (m, 1H), 3.20 (s, 3H), 2.72 (s, 3H).</div></div><div id="sec6_16_29_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i292" class="anchor-spacer"></div><h5 class="article-section__title" id="_i292"> (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-Cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide ((−)-<b>33</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>134</b>) (0.5 g, 0.9 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10.0 mL) at room temperature, zinc cyanide (0.66 g, 5.6 mmol) and zinc (0.007 g, 0.11 mmol) were added. The mixture was degassed with argon for 15 min. 1,1′-Bis(diphenylphosphino)ferrocene (0.013 g, 0.023 mmol) and tris(dibenzylideneacetone)dipalladium (0.026 g, 0.028 mmol) were added to the mixture and degassing was continued for another 5 min. The reaction mixture was heated at 150 °C for 2 h, then cooled to room temperature and filtered through Celite. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography eluting with 70% ethyl acetate in hexanes. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-3-cyano-5a-(4-cyanophenyl)-8,8a-dihydroxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<i>rac</i>-<b>33</b>) as a white solid. Yield: 150 mg (0.321 mmol, 36%). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (25 mg, (−)-<b>33</b>), [α]<sub>D</sub> −128.9° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 8.28 min, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.64 (s, 1H), 7.97 (s, 1H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.06–6.98 (m, 3H), 6.84 (d, <i>J</i> = 6.8 Hz, 2H), 6.14 (s, 1H), 5.98 (d, <i>J</i> = 6.4 Hz, 1H), 4.96 (t, <i>J</i> = 6.8 Hz, 1H), 4.27–4.16 (m, 2H), 3.23 (s, 3H), 2.73 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 167.68, 163.98, 150.72, 140.26, 137.36, 133.18, 130.81, 130.78, 128.44, 127.64, 127.58, 126.36, 118.69, 117.54, 112.97, 109.66, 102.88, 91.43, 77.23, 55.47, 47.28, 36.45, 35.19. MS (ESI) <i>m</i>/<i>z</i>: 467.43 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 467.1714 [M + H]<sup>+</sup>; found, 467.1729; UPLC: 99.09%. Peak-2 (9.0 mg, (+)-<b>33</b>), [α]<sub>D</sub> +126° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 10.67 min, ee >98%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.64 (s, 1H), 7.97 (s, 1H), 7.60 (d, <i>J</i> = 8.8 Hz, 2H), 7.38 (d, <i>J</i> = 8.4 Hz, 2H), 7.06–6.98 (m, 3H), 6.84 (d, <i>J</i> = 6.8 Hz, 2H), 6.14 (s, 1H), 5.98 (d, <i>J</i> = 6.4 Hz, 1H), 4.96 (t, <i>J</i> = 6.8 Hz, 1H), 4.27–4.16 (m, 2H), 3.23 (s, 3H), 2.73 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 467.47 [M + 1]<sup>+</sup>; UPLC: 99.17%.</div></div></div><div id="sec6_16_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i293" class="anchor-spacer"></div><h4 class="article-section__title" id="_i293"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-Dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<i>rac</i>-<b>34</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0071.gif" alt="" id="dgr31" /></img><div id="sec6_16_30_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i294" class="anchor-spacer"></div><h5 class="article-section__title" id="_i294"> 3-Bromo-2-methoxypyridin-4-amine (<b>136</b>)</h5><div class="NLM_p last">To a solution of 2-methoxypyridin-4-amine (<b>135</b>, 20.0 g, 161 mmol) in dichloromethane (200 mL) at 0 °C, <i>N</i>-bromosuccinimide (26.6 g, 149 mmol) was added. The reaction mixture was stirred at 0 °C for 30 min. Then, the mixture was quenched with ice-cold water (100 mL) and extracted with dichloromethane (300 mL). The organic layer was washed with water and brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was triturated with <i>n</i>-pentane and diethyl ether to afford 3-bromo-2-methoxypyridin-4-amine (<b>136</b>) as a yellow solid. Yield: 30.0 g (0.148 mol, 92%). MS (ESI) <i>m</i>/<i>z</i>: 203.09 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.59 (d, <i>J</i> = 5.6 Hz, 1H), 6.35 (d, <i>J</i> = 5.64 Hz, 1H), 6.20 (br s, 2H), 3.80 (s, 3H).</div></div><div id="sec6_16_30_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i295" class="anchor-spacer"></div><h5 class="article-section__title" id="_i295"> 1-(4-Amino-2-methoxypyridin-3-yl)ethan-1-one (<b>138</b>)</h5><div class="NLM_p last">To a solution of 3-bromo-2-methoxypyridin-4-amine (<b>136</b>) (25.0 g, 123 mmol) in toluene (250 mL) at room temperature, tributyl(1-ethoxyvinyl)stannane (<b>137</b>) (67.01 g, 185.5 mmol) was added. The reaction mixture was degassed with argon for 15 min. Then, bis(triphenylphosphine)palladium(II) chloride (8.6 g, 12 mmol) was added to the reaction mixture, degassing was continued for 5 min, and the reaction mixture was heated at 100 °C for 16 h. After this time, the reaction mixture was diluted with ethyl acetate (300 mL) and washed with water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product. This was treated with 1 N hydrochloric acid (100 mL), and the mixture was stirred at room temperature for 1 h. The mixture was then basified with NaHCO<sub>3</sub> solution up to pH ≈ 7, extracted with ethyl acetate (300 mL) and washed with water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography eluting with 10% ethyl acetate in hexane. The desired fractions were concentrated to afford 1-(4-amino-2-methoxypyridin-3-yl) ethan-1-one (<b>138</b>) as an off-white solid. Yield: 10.0 g (60.2 mmol, 49%); MS (ESI) <i>m</i>/<i>z</i>: 167.16 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_30_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i296" class="anchor-spacer"></div><h5 class="article-section__title" id="_i296"> 1-(4-Hydroxy-2-methoxypyridin-3-yl)ethan-1-one (<b>139</b>)</h5><div class="NLM_p last">To a solution of 1-(4-amino-2-methoxypyridin-3-yl)ethan-1-one (<b>137</b>) (10.0 g, 60.2 mmol) in 1,4-dioxane (250 mL) at 0 °C, 50% aq sulfuric acid solution (117.3 g, 1197 mmol) was added dropwise over a period of 30 min. A solution of sodium nitrite in water (16.5 g, 239 mmol) was added dropwise at 0 °C. The reaction mixture was heated at 50 °C for 1 h. After this time, the reaction mixture was quenched with 10% sodium hydroxide solution to pH ≈ 7 and extracted with ethyl acetate (200 mL). The organic layer was separated, washed water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by silica gel column chromatography eluting with 5% ethyl acetate in hexane. The desired fractions were concentrated to afford 1-(4-hydroxy-2-methoxypyridin-3-yl)ethan-1-one (<b>139</b>) as a yellow solid. Yield: 3.7 g (22 mmol, 37%). MS (ESI) <i>m</i>/<i>z</i>: no ionization; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.83 (s, 1H), 8.21 (d, <i>J</i> = 5.2 Hz, 1H), 6.60 (d, <i>J</i> = 6.0 Hz, 1H), 3.91 (s, 3H), 2.56 (s, 3H).</div></div><div id="sec6_16_30_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i297" class="anchor-spacer"></div><h5 class="article-section__title" id="_i297"> (<i>E</i>)-3-(4-Bromophenyl)-1-(4-hydroxy-2-methoxypyridin-3-yl)prop-2-en-1-one (<b>S84</b>)</h5><div class="NLM_p last">To a solution of 1-(4-hydroxy-2-methoxypyridin-3-yl)ethan-1-one (<b>139</b>) (3.7 g, 22 mmol) in methanol (40 mL), sodium hydroxide (2.6 g, 65 mmol) was added followed by 4-bromobenzaldehyde (4.0 g, 22 mmol). The reaction mixture was heated to reflux for 30 min. Then, the mixture was cooled to room temperature and diluted with water (20 mL). The resulting precipitate was collected by filtration, washed with water and <i>n</i>-pentane, and dried under vacuum to afford (<i>E</i>)-3-(4-bromophenyl)-1-(4-hydroxy-2-methoxypyridin-3-yl)prop-2-en-1-one (<b>S84</b>) as a yellow solid. Yield: 5.0 g (15 mmol, 68%). MS (ESI) <i>m</i>/<i>z</i>: 334.10 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.33–7.22 (m, 8H), 5.80 (br s, 1H), 3.65 (s, 3H)</div></div><div id="sec6_16_30_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i298" class="anchor-spacer"></div><h5 class="article-section__title" id="_i298"> 2-(4-Bromophenyl)-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>140</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-3-(4-bromophenyl)-1-(4-hydroxy-2-methoxypyridin-3-yl)prop-2-en-1-one (<b>S84</b>) (6.0 g, 18 mmol) in ethanol (60 mL) and dichloromethane (10 mL) at 0 °C, 10% aq sodium hydroxide (50 mL, 56 g solution, 5.6 g NaOH, 140 mmol) was added followed by 30% aq hydrogen peroxide (4.2 mL, 4.7 g solution, 1.4 g H<sub>2</sub>O<sub>2</sub>, 41 mmol). The reaction mixture was stirred for 30 min at room temperature (exothermic reaction). Then, the reaction mixture was cooled, neutralized to pH ≈ 7 by the addition of 6 M hydrochloric acid, and extracted with ethyl acetate (100 mL). The organic layer was washed with water and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The solid thus obtained was triturated with <i>n</i>-pentane and ethanol, filtered, and dried under vacuum to afford 2-(4-bromophenyl)-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>140</b>) as a yellow solid. Yield: 2.0 g (5.7 mmol, 32%). MS (ESI) <i>m</i>/<i>z</i>: 348.07 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.88 (br s, 1H), 8.30 (d, <i>J</i> = 6.0 Hz, 1H), 8.13 (d, <i>J</i> = 5.62 Hz, 2H), 7.78 (d, <i>J</i> = 5.64 Hz, 2H), 7.31 (d, <i>J</i> = 6.0 Hz, 1H), 4.07 (s, 3H).</div></div><div id="sec6_16_30_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i299" class="anchor-spacer"></div><h5 class="article-section__title" id="_i299"> <i>rac</i>-Methyl (2<i>S</i>,3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-Bromophenyl)-5-hydroxy-6-methoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S85</b>)</h5><div class="NLM_p last">A solution of 2-(4-bromophenyl)-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>140</b>) (2.0 g, 5.7 mmol) and methyl cinnamate (<b>55</b>) (9.34 g, 57.6 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated for 8 h under 400 W UV light in a UV reactor flask. After this time, the solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (2<i>S</i>,3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-bromophenyl)-5-hydroxy-6-methoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S85</b>) as a yellow sticky mass. Yield: 1.7 g, crude.</div></div><div id="sec6_16_30_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i300" class="anchor-spacer"></div><h5 class="article-section__title" id="_i300"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-Bromophenyl)-8a-hydroxy-1-methoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S86</b>)</h5><div class="NLM_p last">The crude compound <b>S85</b> (1.7 g) was suspended in methanol (20 mL) and treated with 25% sodium methoxide in methanol (15 mL 14 g solution, 3.5 g NaOMe, 66 mmol). The reaction mixture was heated at 80 °C for 2 h. Then, the solvent was removed under reduced pressure. The crude product was diluted with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-8a-hydroxy-1-methoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S86</b>). Yield: 1.6 g, crude.</div></div><div id="sec6_16_30_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i301" class="anchor-spacer"></div><h5 class="article-section__title" id="_i301"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>141</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (3.99 g, 18.8 mmol) and crude methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-8a-hydroxy-1-methoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S86</b>) (1.6 g) in acetonitrile (20 mL), acetic acid (1.77 g, 29.5 mmol) was added. The resulting mixture was stirred for 12 h at room temperature. After this time, the reaction mixture was partitioned between saturated aq sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by preparative HPLC and lyophilized to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>141</b>) as a yellowish solid. Yield: 0.03 g (0.06 mmol, 1% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 512.1 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.02 (d, <i>J</i> = 5.7 Hz, 1H), 7.20 (d, <i>J</i> = 8.8 Hz, 2H), 7.05–6.94 (m, 7H), 6.78 (<i>J</i> = 5.6 Hz, 1H), 5.56–5.53 (m, 2H), 4.65 (br s, 1H), 4.28–4.25 (m, 1H), 4.09–4.08 (m, 1H), 4.38 (s, 3H), 3.56 (s, 3H).</div></div><div id="sec6_16_30_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i302" class="anchor-spacer"></div><h5 class="article-section__title" id="_i302"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic Acid (<b>S87</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>141</b>) (0.03 g, 0.06 mmol) in tetrahydrofuran and water (3:1, 4 mL), lithium hydroxide (0.015 g, 0.63 mmol) was added, and the reaction mixture was stirred for 2 h at room temperature. Then, the reaction mixture was cooled to 0 °C and acidified with 1 M hydrochloric acid to pH ≈ 2–3. The precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic acid (<b>S87</b>) as a yellow solid. Yield: 0.02 g (0.04 mmol, 67%. MS (ESI) <i>m</i>/<i>z</i>: 498.24 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_30_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i303" class="anchor-spacer"></div><h5 class="article-section__title" id="_i303"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-8,8a-dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S88</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic acid (<b>S87</b>) (0.02 g, 0.04 mmol) in dichloromethane (2 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.019 g, 0.12 mmol), hydroxybenzotriazole (hydrate, 0.018 g, 0.12 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.04 g, 0.3 mmol) were added. This reaction mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.016 g, 0.20 mmol) was added at the same temperature, and the reaction was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography eluting with 2–3% dichloromethane in methanol. The desired fractions were concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S88</b>) as a yellow sticky mass. Yield: 0.02 g (0.04 mmol, quant.). MS (ESI) <i>m</i>/<i>z</i>: 525.15 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_30_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i304" class="anchor-spacer"></div><h5 class="article-section__title" id="_i304"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Cyanophenyl)-8,8a-dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<i>rac</i>-<b>34</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S88</b>) (0.02 g, 0.04 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (1.0 mL), zinc cyanide (0.026 g, 0.22 mmol) and zinc (0.001 g, 0.02 mmol) were added at room temperature. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.5 mg, 0.0009 mmol) and tris(dibenzylideneacetone) dipalladium (1.0 mg, 0.001 mmol) were added, degassing was continued for 5 min, and the reaction mixture was heated at 140 °C for 4 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by preparative HPLC and lyophilized to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-8,8a-dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<i>rac</i>-<b>34</b>) as a white solid. Yield: 3.5 mg (0.0074 mmol, 19%). MS (ESI) <i>m</i>/<i>z</i>: 472.44 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 472.1874 [M + H]<sup>+</sup>; found, 472.1867;<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (d, <i>J</i> = 5.6 Hz, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 2H), 7.33 (d, <i>J</i> = 8.4 Hz, 2H), 7.03 (t, <i>J</i> = 8.0 Hz, 2H), 6.96 (t, <i>J</i> = 7.2 Hz, 1H), 6.90 (d, <i>J</i> = 7.6 Hz, 2H), 6.83 (d, <i>J</i> = 5.6 Hz, 1H), 5.61 (s, 1H), 5.10 (br s, 1H), 4.75 (d, <i>J</i> = 5.2 Hz, 1H), 4.44 (d, <i>J</i> = 13.6 Hz, 1H), 4.26 (dd, <i>J</i> = 13.6, 5.2 Hz, 1H), 3.85 (s, 3H), 3.28 (s, 3H), 2.77 (s, 3H).</div></div></div><div id="sec6_16_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i305" class="anchor-spacer"></div><h4 class="article-section__title" id="_i305"> Synthesis of (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-cyanophenyl)-4b,5-Dihydroxy-4-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide ((−)-<b>35</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0072.gif" alt="" id="dgr32" /></img><div id="sec6_16_31_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i306" class="anchor-spacer"></div><h5 class="article-section__title" id="_i306"> 3-Chloro-5-((4-methoxybenzyl)oxy)isonicotinonitrile (<b>143</b>)</h5><div class="NLM_p last">To a solution of 3,5-dichloroisonicotinonitrile (<b>142</b>) (15.00 g, 86.71 mmol) in tetrahydrofuran (300 mL) at 0 °C, 60% sodium hydride (6.90 g, 174.40 mmol) was added followed by (4-methoxyphenyl)methanol (13.20 g, 95.53 mmol). The reaction mixture was stirred at room temperature for 2 h. After this time, the mixture was quenched with ice-cold water (100 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed with water and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 3-chloro-5-((4-methoxybenzyl)oxy)isonicotinonitrile (<b>143</b>) as a white solid. Yield: 18.0 g (65.5 mmol, 76%). Purity: 99.04%. MS (ESI) <i>m</i>/<i>z</i>: 275.16 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.78 (s, 1H), 8.54 (s, 1H), 7.44 (d, <i>J</i> = 7.0 Hz, 2H), 6.99 (d, <i>J</i> = 7.0 Hz, 2H), 5.38 (s, 2H), 3.76 (s, 3H).</div></div><div id="sec6_16_31_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i307" class="anchor-spacer"></div><h5 class="article-section__title" id="_i307"> 3-Methoxy-5-((4-methoxybenzyl)oxy)isonicotinonitrile (<b>144</b>)</h5><div class="NLM_p last">To a solution of 3-chloro-5-((4-methoxybenzyl)oxy)isonicotinonitrile (<b>143</b>) (14.00 g, 50.96 mmol) in methanol (160 mL), sodium methoxide (25% in methanol, 20 mL, 19 g solution, 4.7 g NaOMe, 87 mmol) was added. The reaction mixture was refluxed at 80 °C for 2 h. After this time, the solvent was removed under reduced pressure. The mixture was quenched with ice-cold water (100 mL) and extracted with ethyl acetate (100 mL). The organic layer was washed with water and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by silica gel column chromatography using 50% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated to afford 3-methoxy-5-((4-methoxybenzyl)oxy)isonicotinonitrile (<b>144</b>) as a white solid. Yield: 6.3 g (23.3 mmol, 46%). MS (ESI) <i>m</i>/<i>z</i>: 271.23 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_31_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i308" class="anchor-spacer"></div><h5 class="article-section__title" id="_i308"> 1-(3-Hydroxy-5-methoxypyridin-4-yl)ethan-1-one (<b>145</b>)</h5><div class="NLM_p last">To a solution of 3-methoxy-5-((4-methoxybenzyl)oxy)isonicotinonitrile (<b>144</b>) (6.30 g, 23.3 mmol) in dry tetrahydrofuran (250 mL) at 0 °C, methyl magnesium bromide solution (69.90 mL, 209.7 mmol) was added dropwise over a period of 30 min. The reaction mixture was slowly brought to room temperature and stirred for additional 12 h. After this time, the reaction mixture was quenched with 6 M hydrochloric acid to pH ≈ 3 and stirred for 3 h. The mixture was diluted with ethyl acetate (100 mL) and water (50 mL) and basified with sodium bicarbonate to pH ≈ 10. The organic layer was separated, washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude was purified by silica gel column chromatography using 60% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated to afford 1-(3-hydroxy-5-methoxypyridin-4-yl)ethan-1-one (<b>145</b>) as a light yellow solid. Yield: 2.0 g (12 mmol, 52%). MS (ESI) <i>m</i>/<i>z</i>: 168.17 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 10.52 (s, 1H), 7.96 (s, 1H), 7.93 (s, 1H), 3.85 (s, 3H), 2.41 (s, 3H).</div></div><div id="sec6_16_31_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i309" class="anchor-spacer"></div><h5 class="article-section__title" id="_i309"> (<i>E</i>)-3-(4-Bromophenyl)-1-(3-hydroxy-5-methoxypyridin-4-yl)prop-2-en-1-one (<b>S89</b>)</h5><div class="NLM_p last">To a solution of 1-(3-hydroxy-5-methoxypyridin-4-yl)ethan-1-one (<b>145</b>) (2.00 g, 12.0 mmol) in methanol (10 mL), sodium hydroxide (1.40 g, 35.0 mmol) was added followed by 4-bromobenzaldehyde (2.19 g, 11.8 mmol). The reaction was heated to reflux for 10 min. After this time, the reaction mixture was cooled to room temperature, diluted with water (20 mL), and extracted with 5% methanol in dichloromethane (100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated. The solid thus obtained was triturated with pentane, filtered, and dried under vacuum to afford (<i>E</i>)-3-(4-bromophenyl)-1-(3-hydroxy-5-methoxypyridin-4-yl)prop-2-en-1-one (<b>S89</b>) as a yellow solid. Yield: 3.2 g (9.6 mmol, 80%). MS (ESI) <i>m</i>/<i>z</i>: 334.14 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.75 (s, 1H), 7.68–7.58 (m, 5H), 7.25 (d, <i>J</i> = 16.6 Hz, 1H), 7.11 (d, <i>J</i> = 15.7 Hz, 1H), 3.74 (s, 3H).</div></div><div id="sec6_16_31_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i310" class="anchor-spacer"></div><h5 class="article-section__title" id="_i310"> (2-(4-Bromophenyl)-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[2,3-<i>c</i>]pyridin-4-one (<b>146</b>)</h5><div class="NLM_p last">To a solution of (<i>E</i>)-3-(4-bromophenyl)-1-(3-hydroxy-5-methoxypyridin-4-yl)prop-2-en-1-one (<b>S89</b>) (4.60 g, 13.8 mmol) in ethanol (70 mL) and dichloromethane (10 mL) at 0 °C, 10% aq sodium hydroxide solution (39 mL, 43 g solution, 4.3 g NaOH, 108 mmol) was added followed by 30% aq hydrogen peroxide (9.80 mL, 10.9 g solution, 1.09 g H<sub>2</sub>O<sub>2</sub>, 32.0 mmol). The reaction mixture was stirred for 30 min at room temperature (reaction is exothermic). Then, the reaction mixture was cooled and neutralized to pH ≈ 7 by the addition of 6 M hydrochloric acid. The mixture was extracted with ethyl acetate (100 mL). The organic layer was washed with water and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The solid thus obtained was triturated with ethanol, filtered, and dried under vacuum to afford (2-(4-bromophenyl)-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[2,3-<i>c</i>]pyridin-4-one (<b>146</b>) as a yellow solid. Yield: 1.4 g (4.0 mmol, 29%). MS (ESI) <i>m</i>/<i>z</i>: 348.07 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 9.90 (br s, 1H), 8.78 (s, 1H), 8.31 (s, 1H), 8.26–8.16 (m, 2H), 7.76–7.64 (m, 2H), 4.02 (s, 3H).</div></div><div id="sec6_16_31_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i311" class="anchor-spacer"></div><h5 class="article-section__title" id="_i311"> <i>rac</i>-Methyl (2<i>S</i>,3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-Bromophenyl)-5-hydroxy-6-methoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[2,3-<i>c</i>]pyridine-4-carboxylate (<b>S90</b>)</h5><div class="NLM_p last">A solution of (2-(4-bromophenyl)-3-hydroxy-5-methoxy-4<i>H</i>-pyrano [2,3-<i>c</i>]pyridin-4-one (<b>146</b>) (1.40 g, 4.02 mmol) and methyl cinnamate (55) (6.53 g, 40.3 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated under 400 W UV light in a UV reactor flask for 18 h. After this time, solvent was removed under reduced pressure, and the residue was purified over a plug of silica gel eluting the compound with ethyl acetate. The desired fractions were concentrated under reduced pressure to afford compound <b>S90</b> as a dark brown solid. Yield: 1.80 g, crude.</div></div><div id="sec6_16_31_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i312" class="anchor-spacer"></div><h5 class="article-section__title" id="_i312"> <i>rac</i>-Methyl (4b<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b-hydroxy-4-methoxy-5-oxo-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylate (<b>S91</b>)</h5><div class="NLM_p last">The crude compound <b>S90</b> (1.80 g) was suspended in methanol (25 mL) and treated with 25% sodium methoxide in methanol (15 mL, 14 g solution, 3.5 g NaOMe, 66 mmol). The reaction mixture was heated at 80 °C for 3 h. After this time, the solvent was removed under reduced pressure. The crude was diluted with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over sodium sulfate, and concentrated under reduced pressure to afford methyl (4b<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b-hydroxy-4-methoxy-5-oxo-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylate (<b>S91</b>) as a brown solid. Yield: 1.4 g, crude.</div></div><div id="sec6_16_31_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i313" class="anchor-spacer"></div><h5 class="article-section__title" id="_i313"> <i>rac</i>-Methyl (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylate (<b>147</b>)</h5><div class="NLM_p last">To a solution of sodium triacetoxyborohydride (3.40 g, 16.0 mmol) and crude methyl (4b<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b-hydroxy-4-methoxy-5-oxo-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylate (<b>S91</b>) (1.40 g) in acetonitrile (20 mL), acetic acid (1.65 g, 27.5 mmol) was added. The resulting mixture was stirred for 4 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography using 50% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford methyl (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylate (<b>147</b>) as a brown solid. Yield: 0.70 g (1.4 mmol, 35% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 512.2 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.09 (s, 1H) 7.98 (s, 1H), 7.19 (d, <i>J</i> = 8.2 Hz, 2H), 7.70–7.03 (m, 4H), 7.02–6.93 (m, 3H), 5.75 (s, 1H), 5.59 (d, <i>J</i> = 5.6 Hz, 1H), 4.68 (d, <i>J</i> = 4.8 Hz, 1H), 4.32 (d, <i>J</i> = 14.5 Hz, 1H), 4.10–4.01 (m, 1H), 3.87 (s, 3H), 3.56 (s, 3H).</div></div><div id="sec6_16_31_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i314" class="anchor-spacer"></div><h5 class="article-section__title" id="_i314"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic Acid (<b>148</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylate (<b>147</b>) (0.70 g, 1.4 mmol) in methanol and water (3:1, 20 mL), lithium hydroxide (0.32 g, 13 mmol) was added, and the reaction mixture was stirred for 2 h at room temperature. Then, the reaction mixture was cooled to 0 °C and acidified with 1 M hydrochloric acid to pH ≈ 2–3. The precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) as a white solid. Yield: 0.53 g (1.1 mmol, 79%). MS (ESI) <i>m</i>/<i>z</i>: 498.08 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.07 (s, 1H) 7.97 (s, 1H), 7.19 (d, <i>J</i> = 7.9 Hz, 2H), 7.07–7.95 (m, 7H), 4.63 (d, <i>J</i> = 4.0 Hz, 1H), 4.30 (d, <i>J</i> = 14.0 Hz, 1H), 3.93–3.82 (m, 4H).</div></div><div id="sec6_16_31_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i315" class="anchor-spacer"></div><h5 class="article-section__title" id="_i315"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>149</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (0.53 g, 1.1 mmol) in dichloromethane (25 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.49 g, 3.12 mmol), hydroxybenzotriazole (hydrate, 0.48 g, 3.1 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.82 g, 6.3 mmol) were added. The mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.43 g, 5.3 mmol) was added at the same temperature and the mixture was stirred for 28 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product. This was purified by silica gel column chromatography using 60–70% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>149</b>) as a white solid. Yield: 0.38 g (0.72 mmol, 65%). MS (ESI) <i>m</i>/<i>z</i>: 525.24 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.10 (s, 1H) 7.99 (s, 1H), 7.21 (d, <i>J</i> = 8.5 Hz, 2H), 7.10–7.01 (m, 4H), 6.97–6.94 (m, 1H), 6.90 (d, <i>J</i> = 7.4 Hz, 2H), 5.70 (s, 1H), 5.11 (d, <i>J</i> = 5.4 Hz, 1H), 4.75 (t, <i>J</i> = 5.0 Hz, 1H), 4.40 (d, <i>J</i> = 13.6 Hz, 1H), 4.18 (dd, <i>J</i> = 13.3, 5.1 Hz, 1H), 3.87 (s, 3H), 3.27 (s, 3H), 2.76 (s, 3H).</div></div><div id="sec6_16_31_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i316" class="anchor-spacer"></div><h5 class="article-section__title" id="_i316"> (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Cyanophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide ((−)-<b>35</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>149</b>) (0.38 g, 0.72 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5.0 mL) at room temperature, zinc cyanide (0.51 g, 4.3 mmol) and zinc dust (0.005 g, 0.076 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (8 mg, 0.01 mmol) and tris(dibenzylideneacetone)dipalladium (19 mg, 0.02 mmol) were added to the reaction mixture, which was then degassed for an additional 5 min and then heated at 140 °C for 16 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography using 2–3% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford racemic methyl (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-cyanophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<i>rac</i>-<b>35</b>) as a white solid. Yield: 0.169 g (0.358 mmol, 50%). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm]. Peak 1 (31 mg, (+)-<b>35</b>), [α]<sub>D</sub> +89.6° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 7.796 min, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.12 (s, 1H), 8.00 (s, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.32 (d, <i>J</i> = 8.5 Hz, 2H), 7.02 (t, <i>J</i> = 7.3 Hz, 2H), 6.94 (m, 3H), 5.80 (s, 1H), 5.17 (d, <i>J</i> = 5.4 Hz, 1H), 4.76 (t, <i>J</i> = 5.2 Hz, 1H), 4.49 (d, <i>J</i> = 13.4 Hz, 1H), 4.25 (dd, <i>J</i> = 13.4, 5.1 Hz, 1H), 3.87 (s, 3H), 3.29 (s, 3H), 2.77 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 472.43 [M + 1]<sup>+</sup>; purity: 99.32%. Peak-2 (26 mg, (−)-<b>35</b>), [α]<sub>D</sub> −89.5° (<i>c</i> 0.1, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 10.192 min, ee >99%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.12 (s, 1H), 8.00 (s, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.32 (d, <i>J</i> = 8.5 Hz, 2H), 7.02 (t, <i>J</i> = 7.3 Hz, 2H), 6.94 (m, 3H), 5.8 (s, 1H), 5.16 (d, <i>J</i> = 5.4 Hz, 1H), 4.76 (t, <i>J</i> = 5.2 Hz, 1H), 4.49 (d, <i>J</i> = 13.4 Hz, 1H), 4.25 (dd, <i>J</i> = 13.4, 5.1 Hz, 1H), 3.87 (s, 3H), 3.29 (s, 3H), 2.77 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 472.43 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 742.1867 [M + H]<sup>+</sup>; found, 472.1854; purity: 99.04%.</div></div></div><div id="sec6_16_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i317" class="anchor-spacer"></div><h4 class="article-section__title" id="_i317"> Synthesis of (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Cyanophenyl)-4b,5-dihydroxy-2-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxamide (<i>rac</i>-<b>36</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0073.gif" alt="" id="dgr33" /></img><div id="sec6_16_32_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i318" class="anchor-spacer"></div><h5 class="article-section__title" id="_i318"> 2-Chloro-6-methoxynicotinic Acid (<b>151</b>)</h5><div class="NLM_p last">To a suspension of 2,6-dichloronicotinic acid (<b>150</b>) (20.0 g, 104 mmol) in methanol (250 mL) under nitrogen, potassium <i>tert</i>-butoxide (35.0 g, 312 mmol) was added at room temperature. The reaction mixture was stirred at 80 °C for 24 h. After this time, the solvent was removed under reduced pressure and the crude product was treated with 6 M hydrochloric acid. The resulting precipitate was collected by filtration and dried under vacuum to afford 2-chloro-6-methoxynicotinic acid (<b>2</b>) as a white solid. Yield: 20.0 g, crude; MS (ESI) <i>m</i>/<i>z</i>: 188.06 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_32_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i319" class="anchor-spacer"></div><h5 class="article-section__title" id="_i319"> 2-Chloro-<i>N</i>,6-dimethoxy-<i>N</i>-methylnicotinamide (<b>S92</b>)</h5><div class="NLM_p last">To a solution of crude 2-chloro-6-methoxynicotinic acid (<b>151</b>) (20.0 g) in dichloromethane (400 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (30.6 g, 160 mmol), 1-hydroxybenzotriazole (21.6 g, 160 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (46.6 mL, 34.6 g, 268 mmol) were added. This mixture was stirred for 5 min. Then, <i>N</i>,<i>O</i>-dimethylhydroxylamine hydrochloride (<b>129</b>) (12.4 g, 127 mmol) was then added at same temperature and the reaction was stirred at room temperature for 4 h. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to afford 2-chloro-<i>N</i>,6-dimethoxy-<i>N</i>-methylnicotinamide (<b>S92</b>) as a yellow solid. Yield: 18.0 g (0.0781 mol, 75% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ/ppm 7.56 (d, <i>J</i> = 8.4 Hz, 1H), 6.70 (d, <i>J</i> = 8.4 Hz, 1H), 3.96 (s, 3H), 3.52 (s, 3H), 3.34 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 231.15 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_32_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i320" class="anchor-spacer"></div><h5 class="article-section__title" id="_i320"> 1-(2-Chloro-6-methoxypyridin-3-yl)ethan-1-one (<b>152</b>)</h5><div class="NLM_p last">To a solution of 2-chloro-<i>N</i>,6-dimethoxy-<i>N</i>-methylnicotinamide (<b>S92</b>) (18.0 g, 78.0 mmol) in dry tetrahydrofuran (200 mL), 3 M methyl magnesium bromide in diethyl ether (52.0 mL, 156 mmol) was added dropwise over a period of 30 min at 0 °C. The reaction mixture was slowly brought to room temperature and stirred for 2 h. Then, the reaction mixture was treated with saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 1-(2-chloro-6-methoxypyridin-3-yl)ethan-1-one (<b>152</b>) as a yellow solid. Yield: 14.0 g, crude; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ/ppm 7.97 (d, <i>J</i> = 8.4 Hz, 1H), 6.71 (d, <i>J</i> = 8.5 Hz, 1H), 3.99 (s, 3H), 3.68 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 186.14 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_32_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i321" class="anchor-spacer"></div><h5 class="article-section__title" id="_i321"> 1-(6-Methoxy-2-((4-methoxybenzyl)oxy)pyridin-3-yl)ethan-1-one (<b>S94</b>)</h5><div class="NLM_p last">To a solution of crude 1-(2-chloro-6-methoxypyridin-3-yl)ethan-1-one (<b>152</b>) (14.0 g) in tetrahydrofuran (100 mL) under nitrogen at 0 °C, sodium hydride (4.5 g, 190 mmol) was added. This mixture was stirred for 10 min. Then, 4-methoxybenzyl alcohol (<b>S93</b>) (11.0 mL, 12.2 g, 88.6 mmol) was added dropwise over a period of 30 min at 0 °C, and the mixture was stirred at room temperature for 2 h. Then, the reaction mixture was diluted with water (200 mL) and extracted with ethyl acetate (2 × 150 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel (100–200 mesh) column chromatography using 20% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford 1-(6-methoxy-2-((4-methoxybenzyl)oxy)pyridin-3-yl)ethan-1-one (<b>S94</b>) as a yellow solid. Yield: 10.5 g (0.0366 mmol, 47% over two steps). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ/ppm 8.15 (d, <i>J</i> = 8.4 Hz, 1H), 7.39 (d, <i>J</i> = 8.6 Hz, 2H), 6.91 (d, <i>J</i> = 8.7 Hz, 2H), 6.36 (d, <i>J</i> = 8.4 Hz, 1H), 5.44 (s, 2H), 3.98 (s, 3H), 3.82 (s, 3H), 2.59 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 288.23 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_32_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i322" class="anchor-spacer"></div><h5 class="article-section__title" id="_i322"> 3-Acetyl-6-methoxypyridin-2(1<i>H</i>)-one (<b>153</b>)</h5><div class="NLM_p last">To a solution of 1-(6-methoxy-2-((4-methoxybenzyl)oxy)pyridin-3-yl)ethan-1-one (<b>S94</b>) (10.5 g, 36.5 mmol) in dichloromethane (100 mL) at 0 °C, trifluoroacetic acid (2.0 mL, 3.0 g, 26 mmol) was added. This reaction mixture was stirred at room temperature for 2 h. Then, the mixture was treated with saturated aqueous sodium bicarbonate solution and extracted with dichloromethane. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford 3-acetyl-6-methoxypyridin-2(1<i>H</i>)-one (<b>153</b>) as a yellow solid. Yield: 5.0 g, crude; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 13.12 (br s, 1H), 8.20 (d, <i>J</i> = 8.5 Hz, 1H), 6.37 (d, <i>J</i> = 6.6 Hz, 1H), 3.89 (s, 3H), 2.55 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 168.17 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_32_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i323" class="anchor-spacer"></div><h5 class="article-section__title" id="_i323"> (<i>E</i>)-3-(3-(4-Bromophenyl)acryloyl)-6-methoxypyridin-2(1<i>H</i>)-one (<b>S95</b>)</h5><div class="NLM_p last">To a solution of 3-acetyl-6-methoxypyridin-2(1<i>H</i>)-one (<b>153</b>) (4.5 g, 27 mmol) in methanol (30.0 mL), sodium hydroxide (3.17 g, 79.3 mmol) and 4-bromobenzaldehyde (5.3 g, 28 mmol) were added. The reaction mixture was heated at 80 °C for 2 h. After this time, the reaction mixture was cooled, and the resulting solid was collected by filtration, washed with water, and dried under vacuum to afford (<i>E</i>)-3-(3-(4-bromophenyl)acryloyl)-6-methoxypyridin-2(1<i>H</i>)-one (<b>S95</b>) as a yellow solid. Yield: 8.5 g, crude; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.58 (d, <i>J</i> = 16.0 Hz, 1H), 7.82 (d, <i>J</i> = 8.3 Hz, 1H), 7.60 (d, <i>J</i> = 8.4 Hz, 2H), 7.53 (d, <i>J</i> = 8.4 Hz, 2H), 7.35 (d, <i>J</i> = 16.0 Hz, 1H), 5.51 (d, <i>J</i> = 8.4 Hz, 1H), 3.68 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 168.17 [M + 1]<sup>+</sup>; MS (ESI) <i>m</i>/<i>z</i>: 332.11 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_32_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i324" class="anchor-spacer"></div><h5 class="article-section__title" id="_i324"> 2-(4-Bromophenyl)-3-hydroxy-7-methoxy-4<i>H</i>-pyrano[2,3-<i>b</i>]pyridin-4-one (<b>154</b>)</h5><div class="NLM_p last">To a solution of crude (<i>E</i>)-3-(3-(4-bromophenyl)acryloyl)-6-methoxypyridin-2(1<i>H</i>)-one (<b>S95</b>) (6 g) in ethanol and dichloromethane (1:1, 200 mL) at room temperature, sodium hydroxide (10% aq, 50 mL, 56 g solution, 5.6 g NaOH, 140 mmol) was added followed by 30% hydrogen peroxide (14.1 mL, 15.7 g solution, 4.70 g H<sub>2</sub>O<sub>2</sub>, 138 mmol). The reaction mixture was stirred for 2 h (reaction is very exothermic!). After this time, the reaction mixture was cooled to 0 °C and brought to pH ≈ 8 using 6 M HCl. The solvent was removed under reduced pressure, and the resulting solid was collected by filtration. This solid was suspended in ethanol. This mixture was cooled to 0 °C and neutralized to pH ≈ 6 with 6 M hydrochloric acid. The resulting precipitate was again collected by filtration and dried under vacuum to afford 2-(4-bromophenyl)-3-hydroxy-7-methoxy-4<i>H</i>-pyrano[2,3-<i>b</i>]pyridin-4-one (<b>154</b>) as a yellow solid. Yield: 3.2 g (9.2 mmol, 40% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 348.16 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_32_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i325" class="anchor-spacer"></div><h5 class="article-section__title" id="_i325"> <i>rac</i>-Methyl (2<i>S</i>,4<i>R</i>,5<i>R</i>)-2-(4-Bromophenyl)-5-hydroxy-8-methoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[2,3-<i>b</i>]pyridine-4-carboxylate (<b>S96</b>)</h5><div class="NLM_p last">A solution of 2-(4-bromophenyl)-3-hydroxy-7-methoxy-4<i>H</i>-pyrano[2,3-<i>b</i>]pyridin-4-one (<b>11</b>, 3.0 g, 8.6 mmol) and methyl cinnamate (<b>55</b>) (1.4 g, 8.6 mmol) in dichloromethane (200 mL), acetonitrile (100 mL), and methanol (100 mL) was irradiated for 16 h under 400 W UV light in a UV reactor flask. After this time, the solvent was removed under reduced pressure, and the residue was purified by Combi-flash (12 g, RediSep) using ethyl acetate as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-methyl (2<i>S</i>,4<i>R</i>,5<i>R</i>)-2-(4-bromophenyl)-5-hydroxy-8-methoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[2,3-<i>b</i>]pyridine-4-carboxylate (<b>S96</b>) as a yellow solid. Yield: 1.3 g, crude. MS(ESI) <i>m</i>/<i>z</i>: 508.33 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_32_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i326" class="anchor-spacer"></div><h5 class="article-section__title" id="_i326"> <i>rac</i>-Methyl (4b<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b-hydroxy-2-methoxy-5-oxo-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylate (<b>S97</b>)</h5><div class="NLM_p last">The crude methyl (2<i>S</i>,4<i>R</i>,5<i>R</i>)-2-(4-bromophenyl)-5-hydroxy-8-methoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[2,3-<i>b</i>]pyridine-4-carboxylate (<b>S96</b>) (1.3 g) was suspended in methanol (13.0 mL), treated with sodium methoxide (25% in methanol, 13.0 mL, 12.3 g solution, 3.07 g NaOMe, 56.9 mmol), and heated at 80 °C for 2 h. After this time, the solvent was removed under reduced pressure and the reaction mixture was diluted with ammonium chloride solution and extracted with ethyl acetate. The organic phase was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford <i>rac</i>-methyl (4b<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b-hydroxy-2-methoxy-5-oxo-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylate (<b>S97</b>) as a brown solid. Yield: 1.1 g, crude; MS (ESI) <i>m</i>/<i>z</i>: 508.33 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_32_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i327" class="anchor-spacer"></div><h5 class="article-section__title" id="_i327"> <i>rac</i>-Methyl (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-2-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylate (<b>155</b>)</h5><div class="NLM_p last">To a solution of crude <i>rac</i>-methyl (4b<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b-hydroxy-2-methoxy-5-oxo-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylate (<b>S97</b>) (1.0 g) in acetonitrile (20.0 mL), sodium triacetoxyborohydride (2.7 g, 13 mmol) and acetic acid (1.23 mL, 1.29 g, 21.5 mmol) were added. The resulting mixture was stirred for 4 h at room temperature. After this time, the reaction mixture was partitioned between saturated aqueous sodium bicarbonate solution and ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to afford <i>rac</i>-methyl (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-2-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylate (<b>155</b>) as a white solid. Yield: 120 mg (0.234 mmol, 3% over three steps); MS (ESI) <i>m</i>/<i>z</i>: 512.32 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_32_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i328" class="anchor-spacer"></div><h5 class="article-section__title" id="_i328"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-2-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylic Acid (<b>S98</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-2-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylate (<b>16</b>, 110 mg, 0.215 mmol) in methanol and water (2:1, 6.0 mL), lithium hydroxide (20.0 mg, 0.835 mmol) was added and the reaction was stirred for 16 h at room temperature. After this time, the reaction mixture was cooled to 0 °C and acidified with 1 M hydrochloric acid to pH ≈ 3. The resulting precipitate was collected by filtration and dried under vacuum to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-2-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylic acid (<b>S98</b>) as a brown solid. Yield: 100 mg (0.201 mmol, 93%); MS (ESI) <i>m</i>/<i>z</i>: 496.16 [M – 1]<sup>−</sup>.</div></div><div id="sec6_16_32_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i329" class="anchor-spacer"></div><h5 class="article-section__title" id="_i329"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-2-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxamide (<b>156</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-2-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxylic acid (<b>S98</b>) (100 mg, 0.201 mmol) in dichloromethane (10.0 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (96.0 mg, 0.501 mmol), 1-hydroxybenzotriazole (76.0 mg, 0.562 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.213 mL, 158 mg, 1.22 mmol) were added. This mixture was stirred for 5 min. Dimethylamine hydrochloride (81.0 mg, 0.993 mmol) was then added at same temperature, and the mixture was stirred for 6 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by Combi-flash (4 g, RediSep) using 70% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-2-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxamide (<b>156</b>) as an off-white solid. Yield: 40.0 mg (0.076 mmol, 38%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.74 (d, <i>J</i> = 8.2 Hz, 1H), 7.30 (d, <i>J</i> = 8.5 Hz, 2H), 7.14 (d, <i>J</i> = 8.5 Hz, 2H), 7.06–6.99 (m, 3H), 6.84 (d, <i>J</i> = 7.0 Hz, 2H), 6.43 (d, <i>J</i> = 8.1 Hz, 1H), 5.64 (d, <i>J</i> = 6.2 Hz, 1H), 5.45 (s, 1H), 4.88–4.86 (m, 1H), 4.17 (d, <i>J</i> = 13.3 Hz, 1H), 4.05–4.00 (m, 1H), 3.88 (s, 3H), 3.20 (s, 3H), 2.72 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 525.28 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_32_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i330" class="anchor-spacer"></div><h5 class="article-section__title" id="_i330"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Cyanophenyl)-4b,5-dihydroxy-2-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxamide (<i>rac</i>-<b>36</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-2-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxamide (<b>156</b>) (40.0 mg, 0.076 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5.0 mL), zinc cyanide (18.0 mg, 0.153 mmol) and zinc (25.0 mg, 0.382 mmol) were added at room temperature. The mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (4.0 mg, 0.0072 mmol) and tris(dibenzylideneacetone) dipalladium (7.1 mg, 0.0078 mmol) were added to the reaction mixture and degassing was continued for another 5 min. The reaction mixture was then heated at 140 °C for 6 h. After this time, the mixture was cooled to room temperature and filtered through Celite. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by reverse-phase HPLC, and the desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-cyanophenyl)-4b,5-dihydroxy-2-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>b</i>]pyridine-6-carboxamide (<i>rac</i>-<b>36</b>) as an off-white solid. Yield: 8.0 mg (0.017 mmol, 22%). MS (ESI) <i>m</i>/<i>z</i>: 472.44 [M + 1]<sup>+</sup>; UPLC: 95.37%; HRMS (ESI): calcd, 472.1867 [M + H]<sup>+</sup>; found, 472.1871; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.75 (d, <i>J</i> = 8.0 Hz, 1H), 7.58 (d, <i>J</i> = 8.4 Hz, 2H), 7.40 (d, <i>J</i> = 8.1 Hz, 2H), 7.06–6.97 (m, 3H), 6.85 (d, <i>J</i> = 7.1 Hz, 2H), 6.46 (d, <i>J</i> = 8.0 Hz, 1H), 5.69 (d, <i>J</i> = 6.0 Hz, 1H), 5.57 (s, 1H), 4.92 (t, <i>J</i> = 7.7 Hz, 1H), 4.26 (d, <i>J</i> = 13.1 Hz, 1H), 4.12 (dd, <i>J</i> = 13.0, 8.0 Hz, 1H), 3.88 (s, 3H), 3.22 (s, 3H), 2.72 (s, 3H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 168.15, 164.72, 163.48, 141.57, 140.19, 137.99, 130.63, 128.58, 127.53, 127.49, 126.12, 118.82, 113.77, 109.20, 102.61, 99.30, 90.89, 77.42, 55.59, 53.59, 46.80, 36.43, 35.15.</div></div></div><div id="sec6_16_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i331" class="anchor-spacer"></div><h4 class="article-section__title" id="_i331"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((Dimethylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((+)-<b>37</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0074.gif" alt="" id="dgr34" /></img><div id="sec6_16_33_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i332" class="anchor-spacer"></div><h5 class="article-section__title" id="_i332"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-6-((dimethylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158a</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>,<i>N</i>-dimethyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>149</b>) (0.80 g, 1.52 mmol) in dry tetrahydrofuran (20 mL) at 0 °C, borane dimethylsulfide complex (1.30 mL, 1.04 g, 14.7 mmol) was added. The resulting mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was quenched with methanol at 0 °C and refluxed at 80 °C for 6 h. After this time, the reaction mixture was concentrated to give the crude product, which was purified by silica gel column chromatography using 0–5% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((dimethylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158a</b>) as a white solid. Yield: 0.41 g (0.80 mmol, 53%). MS (ESI) <i>m</i>/<i>z</i>: 511.17 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.02 (s, 1H), 7.95 (s, 1H), 7.21 (d, <i>J</i> = 8.5 Hz, 2H), 7.14–7.07 (m, 4H), 7.02–6.98 (m, 3H), 5.63 (s, 1H), 4.50 (s, 1H), 3.88 (s, 3H), 3.72 (d, <i>J</i> = 13.8 Hz, 1H), 3.16–3.06 (m, 1H), 2.35–2.12 (m, 8H), 2.06–1.90 (m, 1H).</div></div><div id="sec6_16_33_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i333" class="anchor-spacer"></div><h5 class="article-section__title" id="_i333"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((Dimethylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((+)-<b>37</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((dimethylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158a</b>) (0.4 g, 0.8 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10 mL) at room temperature, zinc cyanide (0.45 g, 3.83 mmol) and zinc dust (0.026 g, 0.39 mmol) were added, and the reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.021 g, 0.038 mmol) and tris(dibenzylideneacetone)dipalladium (0.035 g, 0.038 mmol) were added to the reaction mixture, which was then degassed for an additional 5 min and heated at 140 °C for 3 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography using 2–3% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford racemic 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((dimethylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>37</b>) as a white solid. Yield: 0.220 g (0.481 mmol, 60%). MS (ESI) <i>m</i>/<i>z</i>: 458.31 [M + 1]<sup>+</sup>. The enantiomers were separated by chiral preparative HPLC [Chiralpak ID (4.6 × 250) mm, 5μ]. Peak 1 (43 mg, (−)-<b>37</b>), <i>R</i><sub><i>t</i></sub> 10.667 min, ee = 99.24%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.96 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.05 (m, 2H), 7.01–6.97 (m, 3H), 5.73 (s, 1H), 4.48 (d, <i>J</i> = 3.8 Hz, 1H), 3.87 (s, 3H), 3.78 (d, <i>J</i> = 14.1 Hz, 1H), 3.19–3.12 (m, 1H), 2.20 (s, 6H), 1.97 (d, <i>J</i> = 12.8 Hz, 1H), 1.89 (s, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.78, 153.46, 142.61, 136.94, 130.13, 128.65, 128.54, 127.70, 127.06, 126.29, 125.45, 123.54, 118.91, 108.90, 101.87, 93.73, 77.44, 57.48, 56.33, 56.17, 45.82, 43.54. Peak-2 (38 mg, (+)-<b>37</b>), [α]<sub>D</sub> +25.0° (<i>c</i> 0.26, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 13.904 min, ee >97%; HRMS (ESI): calcd, 458.2074 [M + H]<sup>+</sup>; found, 458.2078; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.96 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.05 (m, 2H), 7.01–6.99 (m, 3H), 5.73 (s, 1H), 4.48 (d, <i>J</i> = 4.0 Hz, 1H), 3.87 (s, 3H), 3.78 (d, <i>J</i> = 14 Hz, 1H), 3.19–3.16 (m, 1H), 2.20 (s, 6H), 1.97 (d, <i>J</i> = 12.8 Hz, 1H), 1.88 (s, 2H).</div></div></div><div id="sec6_16_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i334" class="anchor-spacer"></div><h4 class="article-section__title" id="_i334"> Synthesis of <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-Dihydroxy-4-methoxy-6-((methylamino)-methyl)-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>38</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0075.gif" alt="" id="dgr35" /></img><div id="sec6_16_34_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i335" class="anchor-spacer"></div><h5 class="article-section__title" id="_i335"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>-methyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157b</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (2.00 g, 4.01 mmol) in dichloromethane (10 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrogen chloride (1.54 g, 8.03 mmol), 1-hydroxybenzotriazole (1.08 g, 8.03 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (2.07 g, 16.05 mmol, 2.8 mL) at 0 °C, and the mixture was stirred at 0 °C for 30 min. Then, methanamine (453.66 mg, 4.82 mmol, 33% in methanol) was added and the mixture was stirred at 25 °C for 12 h. LCMS showed that there was desired product detected. The reaction mixture was diluted with dichloromethane (20 mL) and washed with water (60 mL × 3). The organic phase was dried over anhydrous sodium sulfate and concentrated in vacuum. The crude product was purified by column chromatography (dichloromethane/methanol = 20/1) to afford the product <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>-methyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157b</b>) as a white solid. Yield: 1.86 g (3.64 mmol, 91%). MS (ESI) <i>m</i>/<i>z</i>: 511.0 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_34_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i336" class="anchor-spacer"></div><h5 class="article-section__title" id="_i336"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4-methoxy-6-((methylamino)methyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158b</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>-methyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157b</b>) (1.86 g, 3.64 mmol) in tetrahydrofuran (40 mL) was added borane dimethyl sulfide complex solution (10 M, 3.64 mL) at 0 °C, and the mixture was stirred at 25 °C for 30 min. Then, the mixture was refluxed at 60 °C for 2 h. TLC (dichloromethane/methanol = 10/1) showed that there was no starting material left. The reaction mixture was quenched with acetic acid (5 mL) at 0 °C, and the mixture was refluxed at 60 °C for 1 h. The reaction mixture was concentrated and washed with petroleum/ethyl acetate = 2: 1 (30 mL) and filtered. The filter-cake was diluted with water (30 mL) and extracted with ethyl acetate (10 mL × 2). The water phase was adjusted pH = 7–8 with saturated sodium bicarbonate and then extracted with ethyl acetate (20 mL × 3). The combined organic phase was dried over anhydrous sodium sulfate and concentrated in vacuum to afford the product <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-6-((methylamino)methyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158b</b>) as a white solid. Yield: 1.45 g (2.92 mmol, 80%). MS (ESI) <i>m</i>/<i>z</i>: 497.0 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.98 (s, 1H), 7.24 (d, <i>J</i> = 8.8 Hz, 2H), 7.13–7.08 (m, 4 H), 7.03–7.01 (m, 3 H), 5.68 (s, 1 H), 4.59 (d, <i>J</i> = 4.0 Hz, 1H), 3.89 (s, 3 H), 3.72 (d, <i>J</i> = 14.4 Hz, 1 H), 3.23–3.17 (m, 3 H), 2.81–2.78 (m, 1 H), 2.57–2.53 (m, 1 H), 2.37 (s, 3 H).</div></div><div id="sec6_16_34_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i337" class="anchor-spacer"></div><h5 class="article-section__title" id="_i337"> <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-Dihydroxy-4-methoxy-6-((methylamino)methyl)-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>38</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-6-((methylamino)methyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158b</b>) (300 mg, 0.60 mmol) in DMSO (3 mL) was added zinc cyanide (283 mg, 2.41 mmol) and zinc (79 mg, 1.21 mmol) at 25 °C, and the reaction mixture was degassed with nitrogen for 15 min. 1,1′-Bis(diphenylphosphino)ferrocene (67 mg, 0.12 mmol) and tris(dibenzylideneacetone)dipalladium (110 mg, 0.12 mmol) was added, and the mixture was stirred in microwave (100 w, 140 °C, 150 psi) for 2 h. LCMS showed the desired product. The reaction mixture was filtered, and the filtrate was concentrated in vacuum. The crude was purified by column chromatography (dichloromethane/methanol = 10/1) and monitored by LCMS. Then, the crude was purified by Prep-HPLC (Phenomenex Gemini C18 250 × 50 mm × 10 μm; mobile phase: [water (0.05% ammonia hydroxide v/v)–acetonitrile]; B %: 37%–62%, 30 min, 69% min) to afford the product <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-dihydroxy-4-methoxy-6-((methylamino)methyl)-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>38</b>) as a white solid. Yield: 99 mg (0.22 mmol, 37%). MS (ESI) <i>m</i>/<i>z</i>: 444.2 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 444.1918 [M + H]<sup>+</sup>; found, 444.1931; HPLC: 99.81%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.06 (s, 1H), 7.98 (s, 1H), 7.49 (d, <i>J</i> = 8.0 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.05 (m, 2H), 7.01–6.99 (m, 3H), 5.73 (s, 1H), 4.56 (d, <i>J</i> = 3.6 Hz, 1H), 3.89 (s, 3H), 3.82 (d, <i>J</i> = 14.0 Hz, 1H), 3.20–3.14 (m, 1H), 2.69–2.66 (m, 1H), 2.27 (s, 3H).</div></div></div><div id="sec6_16_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i338" class="anchor-spacer"></div><h4 class="article-section__title" id="_i338"> Synthesis of <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(Aminomethyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>39</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0076.gif" alt="" id="dgr36" /></img><div id="sec6_16_35_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i339" class="anchor-spacer"></div><h5 class="article-section__title" id="_i339"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157c</b>)</h5><div class="NLM_p last">To a suspension of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (2.50 g, 5.02 mmol) in dichloromethane (30 mL) was added 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (1.92 g, 10.03 mmol), 1-hydroxybenzotriazole (1.36 g, 10.03 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.95 g, 15.05 mmol). The mixture was stirred at 0 °C for 5 min, then ammonium chloride (322 mg, 6.02 mmol) was added, and the mixture was stirred at 20 °C for 12 h. The mixture was diluted with water (20 mL) and extracted with dichloromethane (60 mL × 2). The organic layer was dried and concentrated under reduced pressure to give a residue, which was purified by silica gel chromatography (dichloromethane: methanol = 20:1 to 10:1) to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157c</b>) as a light yellow solid. Yield: 2.00 g (4.02 mmol, 80%). MS (ESI) <i>m</i>/<i>z</i>: 497.0 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.07 (s, 1H), 7.97 (s, 1H), 7.71 (s, 1H), 7.22 (d, <i>J</i> = 8.4 Hz, 1H), 7.07–6.99 (m, 8H), 5.69 (s, 1H), 5.17 (d, <i>J</i> = 4.0 Hz, 1H), 4.60 (t, <i>J</i> = 4.4 Hz, 1H), 4.30 (d, <i>J</i> = 14.0 Hz, 1H), 3.91–3.90 (m, 1H), 3.87 (s, 3H).</div></div><div id="sec6_16_35_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i340" class="anchor-spacer"></div><h5 class="article-section__title" id="_i340"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(Aminomethyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158c</b>)</h5><div class="NLM_p last">To a suspension of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157c</b>) (2.00 g, 4.02 mmol) in tetrahydrofuran (40 mL) was added borane dimethyl sulfide complex (10 M, 4.02 mL) at 0 °C, and the mixture was heated to 60 °C for 0.5 h. The mixture was cooled to 0 °C, quenched with methanol (20 mL), and concentrated under reduced pressure to give a crude product, which was triturated in hexane/dichloromethane (10/1, 20 mL) and filtered off solid to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(aminomethyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158c</b>) as a white solid. Yield: 1.20 g (2.48 mmol, 62%). MS (ESI) <i>m</i>/<i>z</i>: 483.1 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_35_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i341" class="anchor-spacer"></div><h5 class="article-section__title" id="_i341"> <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(Aminomethyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>39</b>)</h5><div class="NLM_p last">A mixture of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(aminomethyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158b</b>) (500 mg, 1.03 mmol), zinc powder (67 mg, 1.03 mmol), zinc cyanide (1.21 g, 10.34 mmol), tris(dibenzylideneacetone)-dipalladium (95 mg, 103.4 μmol), and 1,1′-bis(diphenylphosphino)ferrocene (57 mg, 103.4 μmol) in DMSO (4 mL) was stirred at 130 °C under nitrogen and microwave irradiated (150 Psi, 40 W) for 1 h. The reaction mixture was purified by silica gel chromatography (dichloromethane/methanol = 20/1 to 10/1) to give the product, which was further purified by prep-HPLC (column: Phenomenex Gemini 150 × 25 mm × 10 μm; mobile phase: [water (0.05% ammonia hydroxide v/v)–acetonitrile]; B %: 40–70%, 10 min) to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(aminomethyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta-[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>39</b>) as a light yellow solid. Yield: 22 mg (0.051 mmol, 5%). MS (ESI) <i>m</i>/<i>z</i>: 430.1 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 430.1761 [M + H]<sup>+</sup>; found, 430.1776; HPLC: 99.89%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.06 (s, 1H), 7.98 (s, 1H), 7.50 (d, <i>J</i> = 8.8 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.08–7.04 (m, 2H), 7.01–6.99 (m, 3H), 5.68 (s, 1H), 4.59 (d, <i>J</i> = 4.4 Hz, 1H), 3.89 (s, 3H), 3.77 (d, <i>J</i> = 14.0 Hz, 1H), 3.06–2.90 (m, 1H), 2.67–2.60 (m, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.65, 153.54, 142.57, 136.99, 130.10, 128.67, 128.51, 127.62, 127.04, 126.26, 125.66, 123.73, 118.90, 108.91, 102.22, 93.67, 77.93, 56.71, 56.23, 47.63.</div></div></div><div id="sec6_16_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i342" class="anchor-spacer"></div><h4 class="article-section__title" id="_i342"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((Diethylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>40</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0077.gif" alt="" id="dgr37" /></img><div id="sec6_16_36_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i343" class="anchor-spacer"></div><h5 class="article-section__title" id="_i343"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-<i>N</i>,<i>N</i>-diethyl-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157d</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>1</b>, 1.50 g, 3.01 mmol) in dichloromethane (10 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbod-iimide hydrogen chloride (1.15 g, 6.02 mmol), 1-hydroxybenzotriazole (813 mg, 6.02 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (2.33 g, 18.06 mmol, 3.15 mL) at 0 °C, and the mixture was stirred at 0 °C for 30 min. Then, <i>N</i>-ethylethanamine (495 mg, 4.51 mmol, hydrochloride) was added and the mixture was stirred at 25 °C for 12 h. LCMS showed that there was desired product detected. The reaction mixture was washed with water (30 mL × 3). The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuum to give the crude. The crude was purified by column chromatography (dichloromethane/methanol = 20/1) to afford the product <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-<i>N</i>,<i>N</i>-diethyl-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>3</b>) as a yellow solid. Yield: 1.00 g, 55% yield; MS (ESI) <i>m</i>/<i>z</i>: 555.1 [M + 1] <sup>+</sup>.</div></div><div id="sec6_16_36_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i344" class="anchor-spacer"></div><h5 class="article-section__title" id="_i344"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-6-((diethylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158d</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-<i>N</i>,<i>N</i>-diethyl-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157d</b>) (1.00 g, 1.81 mmol) dissolved in tetrahydrofuran (10 mL) was added borane dimethyl sulfide complex solution (10 mol/L, 1.81 mL) at 0 °C, and the mixture was stirred at 25 °C for 30 min. Then, the mixture was refluxed at 60 °C for 2 h. LCMS showed that there was no starting material. The reaction mixture was quenched with acetic acid (3 mL) at 0 °C, and the mixture was refluxed at 60 °C for 1 h. LCMS showed that there was desired product detected. The reaction mixture was concentrated, and the residue was washed with petroleum/ethyl acetate = 2:1 (30 mL) and filtered. The filter cake was diluted with water (30 mL) and extracted with ethyl acetate (10 mL × 2). The aqueous layer was adjusted to pH = 7–8 with saturated sodium bicarbonate solution and then extracted with ethyl acetate (20 mL × 3). The combined organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated in vacuum to afford the product <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((diethylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158d</b>) as a white solid. Yield: 620 mg (1.12 mmol, 62%); MS (ESI) <i>m</i>/<i>z</i>: 539.1 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_36_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i345" class="anchor-spacer"></div><h5 class="article-section__title" id="_i345"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((Diethylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>40</b>)</h5><div class="NLM_p last">A mixture of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((diethylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158d</b>) (30 mg, 55.6 μmol), zinc powder (4 mg, 55.6 μmol), tris(dibenzylideneacetone)dipalladium(0) (5 mg, 5.56 μmol), bis(diphenylphosphino)ferrocene (3 mg, 5.56 μmol), and zinc cyanide (65 mg, 556 μmol) in DMSO (1 mL) was stirred at 130 °C under nitrogen in microwave (150 Psi, 40 W) for 1 h. The reaction mixture was directly purified by silica gel chromatography (dichloromethane/methanol = 20:1 to 10:1) to give the product. The enantiomers were separated by chiral Prep-HPLC (AD-3S_5_40_3.0 mL Column: Chiralpak AD-3 100 × 4.6 mm I.D, 3 μm mobile phase: 40% ethanol (0.05% DEA) in CO<sub>2</sub> flow rate: 3.0 mL/min AD-3S_4_5_40_3 mL; column: Chiralpak AD-3 100 × 4.6 mm I.D, 3 μm mobile phase: iso-propanol (0.05% DEA) in CO<sub>2</sub> from 5 to 40% flow rate: 3 mL/min wavelength: 220 nm) to afford two enantiomers. The two enantiomers were further purified by Prep-HPLC (column: Phenomenex Gemini C<sub>18</sub> 250 × 21.2 mm × 5 μm; mobile phase: [water (0.05% ammonia hydroxide v/v)–acetonitrile]; B %: 41–71%, 12 min) to give both enantiomeric products. Peak 1 ((−)-<b>40</b>, 1.1 mg), yield: 4%; [α]<sub>D</sub> −13.228° (<i>c</i> 0.08, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 0.562 min, ee = 100%; MS (ESI) <i>m</i>/<i>z</i>: 486.2 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 486.2387 [M + H]<sup>+</sup>; found, 486.2405; HPLC: 99.90%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.05 (m, 2H), 7.02–6.99 (m, 3H), 5.71 (s, 1H), 5.20 (s, 1H), 4.50 (d, <i>J</i> = 3.2 Hz, 1H), 3.88 (s, 3H), 3.84 (d, <i>J</i> = 14.4 Hz, 1H), 3.20–3.16 (m, 1H), 2.62–2.52 (m, 3H), 2.49–2.44 (m, 2H), 2.30–2.25 (m, 1H), 0.94 (t, <i>J</i> = 7.2 Hz, 6H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.86, 153.44, 142.66, 137.06, 130.12, 128.71, 128.53, 127.66, 127.01, 126.28, 125.41, 123.44, 118.91, 108.88, 101.92, 93.70, 77.96, 57.63, 56.14, 50.21, 46.57, 43.96, 11.52. Peak 2 ((+)-<b>40</b>, 2.2 mg), yield: 8%; [α]<sub>D</sub> +10.096° (<i>c</i> 0.08, CHCl<sub>3</sub>), +3.039° (<i>c</i> 0.08, methanol), <i>R</i><sub><i>t</i></sub> 1.317 min, ee = 99.72%; MS (ESI) <i>m</i>/<i>z</i>: 486.2 [M + 1]<sup>+</sup>; HPLC: 100%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 8.8 Hz, 2H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.05 (m, 2H), 7.02–6.99 (m, 3H), 5.73 (s, 1H), 5.22 (s, 1H), 4.50 (s, 1H), 3.88 (s, 3H), 3.84 (d, <i>J</i> = 14.0 Hz, 1H), 3.31–3.25 (m, 1H), 2.62–2.58 (m, 3H), 2.49–2.44 (m, 2H), 2.30–2.25 (m, 1H), 0.94 (t, <i>J</i> = 7.2 Hz, 6H).</div></div></div><div id="sec6_16_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i346" class="anchor-spacer"></div><h4 class="article-section__title" id="_i346"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-Dihydroxy-4-methoxy-7-phenyl-6-(piperidin-1-ylmethyl)-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>41</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0078.gif" alt="" id="dgr38" /></img><div id="sec6_16_37_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i347" class="anchor-spacer"></div><h5 class="article-section__title" id="_i347"> <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)(piperidin-1-yl)methanone (<b>157e</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (1.0 g, 2.0 mmol) in dichloromethane (25.0 mL), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (1.16 g, 6.05 mmol), hydroxybenzotriazole (0.82 g, 5.4 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (1.5 mL, 1.1 g, 8.6 mmol) were added at 0 °C. This reaction mixture was stirred for 5 min. Then, piperidine (<b>S99</b>) (0.297 g, 3.49 mmol) was then added at same temperature, and the reaction was stirred at room temperature for 5 h. After this time, the reaction mixture was diluted with dichloromethane (20 mL) and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by reverse-phase HPLC to afford <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (piperidin-1-yl)methanone (<b>157e</b>) as a white solid. Yield: 0.80 g (1.4 mmol, 71%). MS (ESI) <i>m</i>/<i>z</i>: 565.26 [M + 1]<sup>+</sup><sub>,</sub> UPLC: 99.79%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.09 (s, 1H), 7.98 (s, 1H), 7.20 (d, <i>J</i> = 8.0 Hz, 2H), 7.07–7.02 (m, 4H), 6.97–6.93 (m, 1H), 6.90 (d, <i>J</i> = 8.1 Hz, 2H), 5.71 (s, 1H), 5.11 (d, <i>J</i> = 5.4 Hz, 1H), 4.67 (t, <i>J</i> = 5.1 Hz, 1H), 4.47 (d, <i>J</i> = 13.3 Hz, 1H), 4.18 (dd, <i>J</i> = 4.9 Hz, 13.2 Hz, 1H), 3.87 (s, 3H), 3.73 (br s, 2H), 3.35 (m, 2H), 1.75–1.64 (m, 4H), 1.46–1.34 (m, 2H).</div></div><div id="sec6_16_37_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i348" class="anchor-spacer"></div><h5 class="article-section__title" id="_i348"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4-methoxy-7-phenyl-6-(piperidin-1-ylmethyl)-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158e</b>)</h5><div class="NLM_p last">To a solution of ((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (piperidin-1-yl)methanone (<b>157e</b>) (0.80 g, 1.4 mmol) in tetrahydrofuran at 0 °C, borane dimethylsulfide complex (1.2 mL, 0.96 g, 12.6 mmol) was added. The reaction mixture was stirred for 3 h at room temperature. After this time, the reaction mixture was quenched with methanol at 0 °C and then heated at 60 °C for 4 h. The solvents were concentrated to obtain the crude product which was purified by Combi-flash (4 g, RediSep column) using 7% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-6-(piperidin-1-ylmethyl)-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158e</b>) as a white solid. Yield: 0.4 g (0.7 mmol, 50%). MS (ESI) <i>m</i>/<i>z</i>: 551.1 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_37_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i349" class="anchor-spacer"></div><h5 class="article-section__title" id="_i349"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-Dihydroxy-4-methoxy-7-phenyl-6-(piperidin-1-ylmethyl)-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-c]pyridin-7a-yl)benzonitrile ((−)-<b>41</b>)</h5><div class="NLM_p last">To a mixture of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-6-(piperidin-1-ylmethyl)-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158e</b>) (0.4 g, 0.7 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (3.0 mL) at room temperature, zinc cyanide (0.508 g, 4.33 mmol) and zinc (0.047 g, 0.72 mmol) were added at room temperature, and the mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino) ferrocene (0.092 g, 0.166 mmol) and tris(dibenzylideneacetone)dipalladium (0.152 g, 0.166 mmol) were added to the reaction mixture and degassing was continued for another 5 min. The reaction mixture was heated at 140 °C for 2.5 h. After this time, the reaction mixture was cooled to room temperature and filtered with Celite. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product which was purified by Combi-flash (12 g, RediSep column) using 0–10% methanol in dichloromethane as the eluent. The product thus obtained was further purified by reverse-phase prep HPLC. The desired fractions were lyophilized to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-dihydroxy-4-methoxy-7-phenyl-6-(piperidin-1-ylmethyl)-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>41</b>) as a white solid. Yield: 0.350 g (0.7 mmol, quant.). The enantiomers were separated by chiral preparative HPLC [Chiralpak IA (4.6 × 250) mm] using 0.1% TEA in <i>n</i>-hexane/IPA(80/20) (v/v) mobile phase. Peak 1 (31 mg, (+)-<b>41</b>); [α]<sub>D</sub> +11.5° (<i>c</i> 0.34, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 14.5, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 498.32 [M + 1]<sup>+</sup>; UPLC: 97.70%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.96 (s, 1H), 7.51 (d, <i>J</i> = 8.2 Hz, 2H), 7.37 (d, <i>J</i> = 8.2 Hz, 2H), 7.12–7.07 (m, 2H), 7.05–6.99 (m, 3H), 5.72 (s, 1H), 4.50 (d, <i>J</i> = 3.6 Hz, 1H), 3.87 (s, 3H), 3.81 (d, <i>J</i> = 13.8 Hz, 1H), 2.32–2.27 (m, 3H), 2.09 (d, <i>J</i> = 11.6 Hz, 1H), 1.64 (s, 2H), 1.52–1.50 (m, 5H), 1.37 (s, 3H). Peak-2 (17 mg, (−)-<b>41</b>); [α]<sub>D</sub> −10.4° (<i>c</i> 0.23, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 22.8, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 497.91 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 498.2387 [M + H]<sup>+</sup>; found, 498.2382; UPLC: 99.60%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.96 (s, 1H), 7.48 (d, <i>J</i> = 8.2 Hz, 2H), 7.36 (d, <i>J</i> = 8.2 Hz, 2H), 7.08–7.05 (m, 2H), 7.01–6.96 (m, 3H), 5.72 (s, 1H), 5.38 (br s, 1H), 4.50 (d, <i>J</i> = 3.4 Hz, 1H), 3.87 (s, 3H), 3.80 (d, <i>J</i> = 14.0 Hz, 1H), 2.28–2.24 (m, 2H), 2.06 (d, <i>J</i> = 11.2 Hz, 1H), 1.88 (s, 4H), 1.59–1.51 (m, 4H), 1.40–1.37 (m, 2H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.82, 153.44, 142.64, 137.00, 130.11, 128.69, 128.54, 127.67, 126.97, 126.26, 125.43, 123.47, 118.91, 108.87, 101.94, 93.70, 77.62, 57.46, 56.13, 55.90, 54.73, 25.73, 24.06, 21.43.</div></div></div><div id="sec6_16_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i350" class="anchor-spacer"></div><h4 class="article-section__title" id="_i350"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((4,4-Difluoropiperidin-1-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>42</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0079.gif" alt="" id="dgr39" /></img><div id="sec6_16_38_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i351" class="anchor-spacer"></div><h5 class="article-section__title" id="_i351"> <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)(4,4-difluoropiperidin-1-yl)methanone (<b>157f</b>)</h5><div class="NLM_p last">To a solution of (4a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>S</i>)-4a-(4-bromophenyl)-7,7a-dihydroxy-2-(4-methoxybenzyl)-5-phenyl-2,4a,5,6,7,7a-hexahydrocyclopenta[4,5]furo[3,2-<i>c</i>]pyrazole-6-carboxylic acid (<b>148</b>) (0.9 g, 2 mmol) in dichloromethane (10 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.03 g, 5.37 mmol), 1-hydroxybenzotriazole (0.72 g, 5.41 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (1.65 mL, 1.22 g, 9.44 mmol) were added. This reaction mixture was stirred for 5 min. Then, 4,4-difluoropiperidine hydrochloride (<b>S100</b>) (1.4 g, 8.9 mmol) was added at the same temperature, and the mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography eluting with 0–4% methanol in dichloromethane. The desired fractions were concentrated to afford ((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (4,4-difluoropiperidin-1-yl)methanone (<b>157f</b>) as a white solid. Yield: 0.67 g (1.1 mmol, 55%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.10 (s, 1H), 8.00 (s, 1H), 7.20 (d, <i>J</i> = 8.36 Hz, 2H), 7.09 (d, <i>J</i> = 8.5 Hz, 2H), 7.02 (d, <i>J</i> = 7.1 Hz, 2H), 6.97–6.92 (m, 3H), 5.72 (s, 1H), 5.30 (d, <i>J</i> = 5.5 Hz, 1H), 4.73–4.70 (m, 1H), 4.44 (, <i>J</i> = 13.2 Hz, 1H), 4.29–4.24 (m, 1H), 4.03–3.98 (m, 1H), 3.88 (s, 3H), 3.78–3.70 (m, 2H), 3.34–3.30 (m, 1H), 2.32–2.20 (m, 2H), 2.03–1.88 (m, 2H); MS (ESI) <i>m</i>/<i>z</i>: 601.01 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_38_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i352" class="anchor-spacer"></div><h5 class="article-section__title" id="_i352"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-6-((4,4-difluoropiperidin-1-yl)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158f</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (4,4-difluoropiperidin-1-yl)methanone (<b>157f</b>) (0.6 g, 1 mmol) in dry tetrahydrofuran (25 mL) at 0 °C, borane dimethyl sulfide complex (1.0 mL, 0.80 g, 11 mmol) was added. The resulting mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was quenched with methanol at 0 °C and refluxed at 80 °C for 6 h. Then, the reaction mixture was concentrated to obtain the crude product which was purified by silica gel column chromatography using 1–5% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((4,4-difluoropiperidin-1-yl)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158f</b>) as a white solid. Yield: 0.560 g (0.953 mmol, 95%); <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.02 (s, 1H), 7.95 (s, 1H), 7.20 (d, <i>J</i> = 8.6 Hz, 2H), 7.15–7.12 (m, 2H), 7.10–7.06 (m, 2H), 7.00–6.98 (m, 3H), 5.62 (s, 1H), 5.00 (d, <i>J</i> = 5.2 Hz, 1H), 4.49 (s, 1H), 3.87 (s, 3H), 3.72 (d, <i>J</i> = 14.0 Hz, 1H), 3.20–3.17 (m, 1H), 2.67–2.60 (m, 4H), 2.14–2.08 (m, 1H), 2.03–1.87 (m, 4H); MS (ESI) <i>m</i>/<i>z</i>: 587.17 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_38_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i353" class="anchor-spacer"></div><h5 class="article-section__title" id="_i353"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((4,4-Difluoropiperidin-1-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>42</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((4,4-difluoropiperidin-1-yl)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158f</b>) (0.50 g, 0.85 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10 mL) at room temperature, zinc cyanide (0.59 g, 5.0 mmol) and zinc dust (0.006 g, 0.09 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.009 g, 0.02 mmol) and tris(dibenzylideneacetone)dipalladium (0.023 g, 0.025 mmol) were added to the reaction mixture which was degassed for an additional 5 min and then heated at 140 °C for 4 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography using 2–4% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((4,4-difluoropiperidin-1-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>42</b>) as a white solid. Yield: 0.325 g (0.609 mmol, 72%) (racemic mixture). The enantiomers were separated by chiral preparative HPLC [Chiralpak IC (4.6 × 250)mm, 5μ] in isocratic <i>n</i>-hexane/isopropanol 80/20 v/v. Peak-1 (79 mg, (+)-<b>42</b>), [α]<sub>D</sub> +10.0° (<i>c</i> 0.27, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 10.477 min, ee = 99.90%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.04 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 7.2 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–6.98 (m, 5H), 5.73 (s, 1H), 5.08 (d, <i>J</i> = 5.6 Hz, 1H), 4.51 (s, 1H), 3.88 (s, 3H), 3.80 (d, <i>J</i> = 14.0 Hz, 1H), 3.32 (s, 1H), 2.70–2.49 (m, 5H), 2.15 (d, <i>J</i> = 9.6 Hz, 1H), 1.97 (br s, 4H). Peak-2 (74 mg, (−)-<b>42</b>), [α]<sub>D</sub> −4.4° (<i>c</i> 0.27, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 13.904 min, ee = 99.42%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.04 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 7.2 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–6.98 (m, 5H), 5.73 (s, 1H), 5.08 (d, <i>J</i> = 5.6 Hz, 1H), 4.51 (s, 1H), 3.87 (s, 3H), 3.80 (d, <i>J</i> = 14.0 Hz, 1H), 3.32 (s, 1H), 2.70–2.49 (m, 5H), 2.15 (d, <i>J</i> = 9.6 Hz, 1H), 1.97 (br s, 4H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.79, 153.41, 142.57, 136.93, 130.09, 128.66, 128.57, 127.70, 126.95, 126.28, 125.47, 123.44, 122.89, 118.90, 108.90, 101.95, 93.78, 77.28, 57.37, 56.12, 54.10, 50.15 (t, <i>J</i> = 4.4 Hz), 43.44, 33.63 (t, <i>J</i> = 22 Hz); HRMS (ESI): calcd, 534.2199 [M + H]<sup>+</sup>; found, 534.2214.</div></div></div><div id="sec6_16_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i354" class="anchor-spacer"></div><h4 class="article-section__title" id="_i354"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4<i>b</i>,5-Dihydroxy-4-methoxy-6-(morpholinomethyl)-7-phenyl-4<i>b</i>,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7<i>a</i>-yl)benzonitrile ((−)-<b>43</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0081.gif" alt="" id="dgr40" /></img><div id="sec6_16_39_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i355" class="anchor-spacer"></div><h5 class="article-section__title" id="_i355"> <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)(morpholino)methanone (<b>157g</b>)</h5><div class="NLM_p last">To a solution of (4a<i>R</i>,5<i>S</i>,6<i>R</i>,7<i>R</i>,7a<i>S</i>)-4a-(4-bromophenyl)-7,7a-dihydroxy-2-(4-methoxybenzyl)-5-phenyl-2,4a,5,6,7,7a-hexahydrocyclopenta[4,5]furo[3,2-<i>c</i>]pyrazole-6-carboxylic acid (<b>148</b>) (1.2 g, 2.4 mmol) in dichloromethane (12 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.37 g, 7.15 mmol), 1-hydroxybenzotriazole (0.97 g, 7.2 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (2.21 mL, 1.64 g, 12.7 mmol) were added. This reaction mixture was stirred for 5 min. Morpholine (<b>S101</b>) (0.63 g, 7.2 mmol) was added at same temperature, and the mixture was stirred for 16 h at 40 °C. After completion, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography eluting with 0–4% methanol in dichloromethane. The desired fractions were concentrated to afford <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (morpholino)methanone (<b>157g</b>) as a white solid. Yield: 0.91 g (1.6 mmol, 67%). MS (ESI) <i>m</i>/<i>z</i>: 567 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.01 (s, 1H), 7.99 (s, 1H), 7.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.04 (m, 4H), 6.99–6.91 (m, 3H), 5.69 (s, 1H), 5.22 (d, <i>J</i> = 5.4 Hz, 1H), 4.68 (d, <i>J</i> = 5.0 Hz, 1H), 4.45 (d, <i>J</i> = 13.7 Hz, 1H), 4.23–4.19 (m, 1H), 3.88 (s, 4H), 3.78–3.45 (m, 7H).</div></div><div id="sec6_16_39_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i356" class="anchor-spacer"></div><h5 class="article-section__title" id="_i356"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4-methoxy-6-(morpholinomethyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158g</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (morpholino)methanone (<b>157g</b>) (0.8 g, 1.4 mmol) in dry tetrahydrofuran (20 mL) at 0 °C, borane dimethyl sulfide complex (1.1 mL, 0.88 g, 12 mmol) was added. The resulting mixture was stirred for 16 h at room temperature. After completion, the reaction mixture was quenched with methanol at 0 °C and refluxed at 80 °C for 6 h. Then, the reaction mixture was concentrated to obtain the crude product which was purified by silica gel column chromatography using 0–5% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-6-(morpholinomethyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158g</b>) as a white solid. Yield: 0.65 g (1.2 mmol, 86%). MS (ESI) <i>m</i>/<i>z</i>: 553.17 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.01 (s, 1H), 7.95 (s, 1H), 7.20 (d, <i>J</i> = 8.4 Hz, 2H), 7.13–7.06 (m, 4H), 7.04–6.82 (m, 3H), 5.61 (s, 1H), 5.02 (d, <i>J</i> = 5.0 Hz, 1H), 5.02–4.98 (m, 1H), 3.99 (s, 3H), 3.74 (d, <i>J</i> = 14.0 Hz, 1H), 3.66–3.53 (m, 4H), 3.23–3.12 (m, 1H), 2.60–2.49 (m, 4H), 2.36–2.26 (m, 1H), 2.05 (d, <i>J</i> = 12.6 Hz, 1H).</div></div><div id="sec6_16_39_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i357" class="anchor-spacer"></div><h5 class="article-section__title" id="_i357"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-Dihydroxy-4-methoxy-6-(morpholinomethyl)-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>43</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-6-(morpholinomethyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158g</b>) (0.6 g, 1.1 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10 mL) at room temperature, zinc cyanide (0.76 g, 6.5 mmol) and zinc dust (0.07 g, 1 mmol) were added. This reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.006 g, 0.01 mmol) and tris(dibenzylideneacetone)palladium (0.003 g, 0.003 mmol) were added to the reaction mixture which was then degassed for an additional 5 min and heated at 140 °C for 3 h. After completion, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel column chromatography using 3–4% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford racemic 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-dihydroxy-4-methoxy-6-(morpholinomethyl)-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>43</b>) as a white solid. Yield: 0.30 g (0.60 mmol, 55%) (racemic mixture). The enantiomers were separated by chiral preparative chiral HPLC [Chiralpak IA (4.6 × 250) mm, 5μ], <i>n</i>-hexane/EtOH = 30/70 v/v. Peak-1 (69 mg, (−)-<b>43</b>), [α]<sub>D</sub> −4.0° (<i>c</i> 0.45, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 5.548 min, ee >99.88%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.04 (s, 1H), 7.96 (s, 1H), 7.49 (d, <i>J</i> = 7.2 Hz, 2H), 7.38 (d, <i>J</i> = 8.0 Hz 2H), 7.09–7.00 (m, 5H), 5.70 (s, 1H), 5.10 (d, <i>J</i> = 4.4 Hz, 1H), 4.50 (s, 1H), 3.88 (s, 3H), 3.81 (d, <i>J</i> = 14.0 Hz, 1H), 3.61 (br s, 4H), 3.31(br s, 1H), 2.62–2.50 (m, 4H), 2.33 (br s, 1H), 2.09 (d, <i>J</i> = 12.0 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.81, 153.42, 142.60, 136.94, 130.10, 128.68, 128.56, 127.70, 126.95, 126.29, 125.45, 123.45, 118.91, 108.89, 101.94, 93.74, 77.26, 66.33, 57.31, 56.12, 55.54, 53.91, 42.76. HRMS (ESI): calcd, 500.2180 [M + H]<sup>+</sup>; found, 500.2185. Peak-2 (60 mg, (+)-<b>43</b>), [α]<sub>D</sub> +4.3° (<i>c</i> 0.28, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 8.285 min, ee >95.22%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.04 (s, 1H), 7.96 (s, 1H), 7.49 (d, <i>J</i> = 7.2 Hz, 2H), 7.38 (d, <i>J</i> = 8.0 Hz 2H), 7.09–7.00 (m, 5H), 5.70 (s, 1H), 5.10 (d, <i>J</i> = 4.4 Hz, 1H), 4.50 (s, 1H), 3.88 (s, 3H), 3.81 (d, <i>J</i> = 14.0 Hz, 1H), 3.61 (br s, 4H), 3.31(br s, 1H), 2.62–2.50 (m, 4H), 2.33 (br s, 1H), 2.09 (d, <i>J</i> = 12.0 Hz, 1H).</div></div></div><div id="sec6_16_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i358" class="anchor-spacer"></div><h4 class="article-section__title" id="_i358"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((2,2-Difluoroethyl)(methyl)amino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>44</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0082.gif" alt="" id="dgr41" /></img><div id="sec6_16_40_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i359" class="anchor-spacer"></div><h5 class="article-section__title" id="_i359"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-<i>N</i>-(2,2-difluoroethyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>-methyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157h</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (1.0 g, 2.0 mmol) in <i>N</i>,<i>N</i>- dimethylformamide (20 mL) at 0 °C, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (2.29 g, 6.02 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.8 mL, 1.3 g, 10 mmol) were added. The reaction mixture was stirred for 5 min. Then, 2,2-difluoroethan-1-amine hydrochloride (<b>S102</b>) (0.39 g, 4.1 mmol) was added and the reaction mixture was stirred for 4 h at room temperature. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by Combiflash (12 g, RediSep column) using 3% methanol in dichloromethane as the eluent. Further purification was done on reverse-phase preparative HPLC. The desired fractions were lyophilized to afford (4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-<i>N</i>-(2,2-difluoroethyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>-methyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157h</b>) as a brown solid. Yield: 0.6 g (1.0 mmol, 50%). UPLC: 99.64%; MS (ESI) <i>m</i>/<i>z</i>: 575.25 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.10 (s, 1H), 8.00 (s, 1H), 7.20 (d, <i>J</i> = 8.5 Hz, 2H), 7.09–7.01 (m, 4H), 6.97 (d, <i>J</i> = 7.0 Hz, 1H), 6.91 (d, <i>J</i> = 7.4 Hz, 2H), 6.56–6.29 (m, 1H), 5.74 (s, 1H), 5.22 (d, <i>J</i> = 5.5 Hz, 1H), 4.79 (t, <i>J</i> = 5.4 Hz, 1H), 4.45 (d, <i>J</i> = 10.0 Hz, 1H), 4.24 (dd, <i>J</i> = 5.0 Hz, 13.6 Hz, 1H), 3.80 (s, 3H), 3.68–3.56 (m, 2H), 3.38 (s, 3H).</div></div><div id="sec6_16_40_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i360" class="anchor-spacer"></div><h5 class="article-section__title" id="_i360"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-6-(((2,2-difluoroethyl)(methyl)amino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158h</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-<i>N</i>-(2,2-difluoroethyl)-4b,5-dihydroxy-4-methoxy-<i>N</i>-methyl-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157h</b>) (0.6 g, 1.0 mmol) in tetrahydrofuran at 0 °C, borane dimethylsulfide (1.0 mL, 0.80 g, 11 mmol) was added. The reaction mixture was heated at 60 °C for 5 h. After this time, the reaction mixture was quenched with methanol at 0 °C and then heated at 80 °C for 6 h. The solvents were concentrated, and the compound was dried to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-(((2,2-difluoroethyl) (methyl)amino)-methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158h</b>) as a brown solid. Yield: 0.55 g, crude. UPLC: 89.48%; MS (ESI) <i>m</i>/<i>z</i>: 559.57 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 8.09 (s, 1H), 8.02 (s, 1H), 7.22–7.03 (m, 9H), 5.96–5.36 (m, 1H), 4.65 (d, <i>J</i> = 4.0 Hz, 1H), 3.90 (s, 3H), 3.76–3.70 (m, 2H), 3.18–3.10 (m, 1H), 2.99–2.95 (m, 2 H), 2.74 (s, 3H), 2.38–2.27 (m, 2H).</div></div><div id="sec6_16_40_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i361" class="anchor-spacer"></div><h5 class="article-section__title" id="_i361"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((2,2-Difluoroethyl)(methyl)amino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>44</b>)</h5><div class="NLM_p last">To a mixture of crude <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-(((2,2-difluoroethyl) (methyl)amino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158h</b>) (0.55 g, from previous step; used without further purification) in <i>N</i>,<i>N</i>- dimethylformamide (5.0 mL) at room temperature, zinc cyanide (690 mg, 5.88 mmol) and zinc dust (13 mg, 0.20 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (16.0 mg, 0.029 mmol) and tris(dibenzylideneacetone)dipalladium (27.0 mg, 0.029 mmol) were added to the reaction mixture and degassing was continued for another 5 min. The reaction mixture was heated at 140 °C for 6 h. After this time, the reaction was cooled to room temperature and filtered with Celite. The filtrate was concentrated and treated with ice-cold water and the resulting precipitate was collected by filtration. The solid obtained was purified by Combiflash (12 g, RediSep column) using 30% ethyl acetate in hexanes as the eluent. The crude product was purified by reverse-phase preparative HPLC. The desired fractions were lyophilized to afford racemic 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((2,2-difluoroethyl) (methyl)amino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>44</b>) as a white solid. Yield: 0.12 g (0.24 mmol, 24% over two steps). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm] using 0.1% TEA in <i>n</i>-hexane/IPA = 80/20(v/v) mobile phase. Peak 1 (49 mg, (+)-<b>44</b>), [α]<sub>D</sub> +48.8° (<i>c</i> 0.24, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 9.414 min, ee >99%. MS (ESI) <i>m</i>/<i>z</i>: 508.29 [M + 1]<sup>+</sup>; UPLC: 99.36%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.08 (s, 1H), 7.95 (s, 1H), 7.47 (d, <i>J</i> = 8.6 Hz, 2H), 7.37 (d, <i>J</i> = 8.5 Hz, 2H), 7.09–6.98 (m, 5H), 6.33–6.06 (m, 1H), 4.56 (d, <i>J</i> = 3.5 Hz, 1H), 3.86 (s, 3H), 3.75 (d, <i>J</i> = 14.0 Hz, 1H), 3.31–2.87 (m, 2H), 2.66–2.60 (m, 3H), 2.53 (s, 3H). Peak 2 (49 mg, (−)-<b>44</b>), [α]<sub>D</sub> −10.8° (<i>c</i> 0.24, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 14.357 min, ee >99%. MS (ESI) <i>m</i>/<i>z</i>: 508.29 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 508.2042 [M + H]<sup>+</sup>; found, 508.2051; UPLC: 96.14%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.09 (s, 1H), 8.02 (s, 1H), 7.51 (d, <i>J</i> = 7.8 Hz, 2H), 7.40 (d, <i>J</i> = 7.1 Hz, 2H), 7.09–7.01 (m, 5H), 6.31–5.17 (m, 1H), 4.53 (d, <i>J</i> = 7.0 Hz,1H), 3.90 (s, 3H), 3.79 (d, <i>J</i> = 13.8, 1H), 3.15–2.95 (m, 2H), 2.53 (s, 3H), 2.40 (s, 3H); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.66, 153.50, 142.05, 136.15, 130.13, 128.59, 128.41, 127.79, 126.81, 126.54, 125.28, 123.67, 118.82, 109.09, 101.63, 93.79, 76.69, 57.36, 56.25, 54.92, 42.83, 41.31, 40.43.</div></div></div><div id="sec6_16_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i362" class="anchor-spacer"></div><h4 class="article-section__title" id="_i362"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((3,3-Difluoroazetidin-1-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((+)-<b>46</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0083.gif" alt="" id="dgr42" /></img><div id="sec6_16_41_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i363" class="anchor-spacer"></div><h5 class="article-section__title" id="_i363"> <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)(3,3-difluoroazetidin-1-yl)methanone (<b>157i</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (1.50 g, 3.01 mmol) in dichloromethane (20 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (1.72 g, 11.1 mmol), hydroxybenzotriazole (1.40 g, 9.14 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (3.20 g, 24.8 mmol) were added. The reaction mixture was stirred for 5 min. Then, 3,3-difluoroazetidine hydrochloride (1.16 g, 8.95 mmol) was added at the same temperature, and the mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product which was purified by silica gel column chromatography using 0–5% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (3,3-difluoroazetidin-1-yl)methanone (<b>157i</b>) as a white solid. Yield: 1.20 g (2.09 mmol, 69%). MS (ESI) <i>m</i>/<i>z</i>: 573.18 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.09 (s, 1H), 7.99 (s, 1H), 7.21 (d, <i>J</i> = 8.8 Hz, 2H), 7.08–7.03 (m, 4H), 6.99 (m, 3H), 5.67 (s, 1H), 5.34 (d, <i>J</i> = 5.2 Hz, 1H), 5.15 (d, <i>J</i> = 11.2 Hz, 1H), 4.75 (m, 2H), 4.36 (d, <i>J</i> = 13.6 Hz, 1H), 4.22 (br s, 3H), 4.02 (dd, <i>J</i> = 13.6, 5.2 Hz, 1H), 3.88 (s, 3H).</div></div><div id="sec6_16_41_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i364" class="anchor-spacer"></div><h5 class="article-section__title" id="_i364"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-6-((3,3-difluoroazetidin-1-yl)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158i</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (3,3-difluoroazetidin-1-yl)methanone (<b>157i</b>) (1.20 g, 2.09 mmol) in dry tetrahydrofuran (20 mL) at 0 °C, borane dimethyl sulfide complex (1.90 mL, 1.52 g, 20.0 mmol) was added at the same temperature, and the reaction mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with methanol at 0 °C and refluxed at 80 °C for 6 h. After this time, the reaction mixture was concentrated to obtain the crude product which was purified by silica gel column chromatography using 0–5% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((3,3-difluoroazetidin-1-yl)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158i</b>) as a white solid. Yield: 0.60 g (1.0 mmol, 51%). MS (ESI) <i>m</i>/<i>z</i>: 559.24 [M + 1] <sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.02 (s, 1H), 7.96 (s, 1H), 7.21 (d, <i>J</i> = 8.6 Hz, 2H), 7.13–7.08 (m, 4H), 7.02–6.99 (m, 3H), 5.65 (s, 1H), 5.17 (d, <i>J</i> = 5.2 Hz, 1H), 4.45 (t, <i>J</i> = 4.8 Hz, 1H), 3.87 (s, 3H), 3.69 (d, <i>J</i> = 16.0 Hz, 1H), 3.65–3.59 (m, 4H), 2.97 (t, <i>J</i> = 10.5 Hz, 1H), 2.76 (t, <i>J</i> = 11.4 Hz, 1H), 2.37 (d, <i>J</i> = 10.8 Hz, 1H).</div></div><div id="sec6_16_41_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i365" class="anchor-spacer"></div><h5 class="article-section__title" id="_i365"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((3,3-Difluoroazetidin-1-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((+)-<b>46</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((3,3-difluoroazetidin-1-yl)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158i</b>) (0.60 g, 1.1 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10 mL) at room temperature, zinc cyanide (0.60 g, 5.1 mmol) and zinc dust (0.0079 g, 0.12 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.012 g, 0.0208 mmol) and tris(dibenzylideneacetone)dipalladium (0.028 g, 0.0312 mmol) were added to the mixture which was degassed for additional 5 min and heated at 140 °C for 1 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product which was purified by silica gel column chromatography using 2–3% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((3,3-difluoroazetidin-1-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>46</b>) as a white solid. Yield: 0.330 g (0.653 mmol, 59%). MS (ESI) <i>m</i>/<i>z</i>: 506.27 [M + 1]<sup>+</sup>. The enantiomers were separated by chiral preparative HPLC [Chiralpak IC (4.6 × 250) mm, 5μ] in isocratic 0.1% triethylamine in hexane/isopropanol 80/20 v/v. Peak 1 (80 mg, (−)-<b>46</b>), [α]<sub>D</sub> −8.1° (<i>c</i> 0.43, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 10.350 min, ee = 99.54%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.37 (d, <i>J</i> = 8.4 Hz 2H), 7.10 (m, 2H), 7.02 (m, 3H), 5.74 (s, 1H), 5.23 (d, <i>J</i> = 5.2 Hz, 1H), 4.48 (t, <i>J</i> = 4.8 Hz, 1H), 3.88 (s, 1H), 3.81 (d, <i>J</i> = 14 Hz, 1H), 3.67 (m, 4H), 3.05 (m, 1H), 2.80 (m, 1H), 2.50 (br s, 1H); peak-2 (85 mg, (+)-<b>46</b>), [α]<sub>D</sub> +9.0° (<i>c</i> 0.43, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 14.833 min, ee = 99.18%, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.10 (m, 2H), 7.02 (m, 3H), 5.74 (s, 1H), 5.23 (d, <i>J</i> = 5.2 Hz, 1H), 4.48 (t, <i>J</i> = 4.8 Hz, 1H), 3.88 (s, 1H), 3.81 (d, <i>J</i> = 14 Hz, 1H), 3.67 (m, 4H), 3.05 (m, 1H), 2.80 (m, 1H), 2.50(br s, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.79, 153.40, 142.46, 136.66, 130.11, 128.72, 128.56, 127.78, 127.05, 126.37, 125.48, 123.41, 118.89, 117.39, 108.95, 101.80, 93.78, 76.96, 64.37 (t, <i>J</i> = 21.6 Hz), 56.99, 56.18, 55.42, 44.65; HRMS (ESI): calcd, 506.1886 [M + H]<sup>+</sup>; found, 506.1890.</div></div></div><div id="sec6_16_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i366" class="anchor-spacer"></div><h4 class="article-section__title" id="_i366"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((2-Oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>47</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0084.gif" alt="" id="dgr43" /></img><div id="sec6_16_42_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i367" class="anchor-spacer"></div><h5 class="article-section__title" id="_i367"> <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)(2-oxa-6-azaspiro[3.3]heptan-6-yl)methanone (<b>157j</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (1.0 g, 2.0 mmol) in <i>N</i>,<i>N</i>- dimethylformamide (20 mL) at 0 °C, HATU (2.29 g, 6.02 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (1.80 mL, 1.33 g, 10.3 mmol) were added. This reaction mixture was stirred for 5 min. Then, 2-oxa-6-azaspiro[3.3]heptane oxalate (<b>S104</b>) (1.44 g, 7.61 mmol) was added and the reaction mixture was stirred for 2 h at room temperature. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product which was purified by Combi-flash (12 g, RedisSep column) using 6% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)(2-oxa-6-azaspiro[3.3]heptan-6-yl)methanone (<b>157j</b>) as a white solid. Yield: 0.85 g (1.5 mmol, 73%). MS (ESI) <i>m</i>/<i>z</i>: 579.25 [M + 1]<sup>+</sup><sub>,</sub><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.08 (s, 1H), 7.98 (s, 1H), 7.20 (d, <i>J</i> = 8.6 Hz, 2H), 7.04–7.01 (m, 4H), 6.97–6.90 (m, 3H), 5.68 (s, 1H), 5.16 (d, <i>J</i> = 5.3 Hz, 1H), 4.77 (t, <i>J</i> = 6.8 Hz, 2H), 4.73–4.70 (m, 2H), 4.67 (d, <i>J</i> = 5.4 Hz, 2H), 4.49 (d, <i>J</i> = 8.9 Hz, 1H), 4.33 (d, <i>J</i> = 13.6 Hz, 1H), 3.97 (s, 2H), 3.87 (s, 3H), 3.83–3.79 (dd, <i>J</i> = 5.2, 13.9 Hz, 1H).</div></div><div id="sec6_16_42_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i368" class="anchor-spacer"></div><h5 class="article-section__title" id="_i368"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((2-Oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158j</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl) (2-oxa-6-azaspiro[3.3]heptan-6-yl)methanone (<b>157j</b>) (0.89 g, 1.5 mmol) in tetrahydrofuran (15 mL) at 0 °C, borane dimethylsulfide complex (0.23 mL, 0.18 g, 2.4 mmol) was added. The reaction mixture was stirred for 3 h at room temperature. After this time, the reaction mixture was quenched with methanol at 0 °C and then heated at 60 °C for 4 h. The solvents were concentrated to obtain the crude product which was purified by Combi-flash (4 g, RediSep column) using 7% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158j</b>) as a white solid. Yield: 0.55 g (0.97 mmol, 65%). MS (ESI) <i>m</i>/<i>z</i>: 565.72 [M + 1]<sup>+</sup><sub>.</sub><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.01 (s, 1H), 7.95 (s, 1H), 7.21 (d, <i>J</i> = 8.5 Hz, 2H), 7.11–7.07 (m, 4H), 7.02–6.93 (m, 3H), 5.61 (s, 1H), 5.32 (br s, 1H), 4.58 (s, 4H), 4.42 (s, 1H), 3.87 (s, 3H), 3.73–3.63 (m, 1H), 3.3 (s, 4H), 2.88 (br s, 1H), 2.58 (br s, 1H), 2.21 (br s, 1H).</div></div><div id="sec6_16_42_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i369" class="anchor-spacer"></div><h5 class="article-section__title" id="_i369"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((2-Oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>47</b>)</h5><div class="NLM_p last">To a mixture of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158j</b>) (0.55 g, 0.97 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10.0 mL) at room temperature, zinc cyanide (0.670 g, 5.71 mmol) and zinc dust (0.062 g, 0.95 mmol) were added. This reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino) ferrocene (0.139 g, 0.251 mmol) and tris(dibenzylideneacetone)dipalladium (0.266 g, 0.290 mmol) were added to the reaction mixture and degassing was continued for another 5 min. The reaction mixture was heated at 140 °C for 2.5 h. After this time, the reaction mixture was cooled to room temperature and filtered with Celite. This was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product which was purified by reverse-phase prep HPLC. The desired fractions were lyophilized to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((2-oxa-6-azaspiro[3.3]heptan-6-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>47</b>) as a white solid. Yield: 0.15 g (0.29 mmol, 30%). The enantiomers were separated by chiral preparative HPLC [Chiralpak IA (4.6 × 250) mm] using <i>n</i>-hexane/EtOH = 50/50 (v/v) mobile phase. Peak 1 (40 mg, (−)-<b>47</b>); [α]<sub>D</sub> −99.1° (<i>c</i> 0.29, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 5.661 min, ee 99.90%. MS (ESI) <i>m</i>/<i>z</i>: 512.28 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 512.2180 [M + H]<sup>+</sup>; found, 512.2180; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.03 (s, 1H), 7.96 (s, 1H), 7.48 (d, <i>J</i> = 8.2 Hz, 2H), 7.34 (d, <i>J</i> = 8.2 Hz, 2H), 7.09–7.06 (m, 2H), 7.01–6.97 (m, 3H), 5.72 (s, 1H), 5.40 (br s, 1H), 4.58 (d, <i>J</i> = 3.2 Hz, 4H), 4.44 (d, <i>J</i> = 2.5 Hz, 1H), 3.87 (s, 3H), 3.78 (d, <i>J</i> = 14.1 Hz, 1H), 3.29 (s, 4H), 2.94 (s, 1H), 2.69–2.49 (m, 1H), 2.25–2.17 (m, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.78, 153.43, 142.52, 136.68, 130.12, 128.68, 128.50, 127.74, 127.03, 126.35, 125.47, 123.44, 118.89, 108.93, 101.80, 93.69, 79.91, 77.64, 63.60, 56.85, 56.16, 55.60, 43.84, 38.59. Peak-2 (34 mg, (+)-<b>47</b>); [α]<sub>D</sub> +23.0° (<i>c</i> 0.259, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 22.48 min, ee 99.30%. MS (ESI) <i>m</i>/<i>z</i>: 512.24 [M + 1]<sup>+</sup>;<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.03 (s, 1H), 7.96 (s, 1H), 7.48 (d, <i>J</i> = 8.2 Hz, 2H), 7.34 (d, <i>J</i> = 8.2 Hz, 2H), 7.09–7.06 (m, 2H), 7.01–6.97 (m, 3H), 5.72 (s, 1H), 5.39 (br s, 1H), 4.60–4.56 (m, 4H), 4.44 (d, <i>J</i> = 2.5 Hz, 1H), 3.87 (s, 3H), 3.78 (d, <i>J</i> = 14.1 Hz, 1H), 3.29 (s, 4H), 2.94 (s, 1H), 2.69–2.50 (m, 1H), 2.25–2.17 (m, 1H).</div></div></div><div id="sec6_16_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i370" class="anchor-spacer"></div><h4 class="article-section__title" id="_i370"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((<i>tert</i>-Butylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((+)-<b>48</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0085.gif" alt="" id="dgr44" /></img><div id="sec6_16_43_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i371" class="anchor-spacer"></div><h5 class="article-section__title" id="_i371"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-<i>N</i>-(<i>tert</i>-butyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157k</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (5.0 g, 10.0 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (50 mL) at 0 °C were added 2-methylpropan-2-amine (6.0 g, 82 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (11.0 mL, 8.16 g, 63.2 mmol), <i>N</i>-(3-Dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide hydrochloride (5.70 g, 30.0 mmol) and 1-hydroxybenzotriazole (4.50 g, 33.3 mmol), and the reaction mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with ice cold water. The so-obtained precipitate was isolated by filtration and dissolved in 10% methanol in dichloromethane. The organic layer was dried over anhydrous sodium sulphate, filtered, and concentrated to give the crude product, which was purified by column chromatography using silica gel (100–200 mesh) and 0–4% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-<i>N</i>-(<i>tert</i>-butyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157k</b>) as a white solid. Yield: 1.80 g (3.25 mmol, 33%); MS (ESI) <i>m</i>/<i>z</i>: 553.41 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_43_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i372" class="anchor-spacer"></div><h5 class="article-section__title" id="_i372"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-6-((<i>tert</i>-butylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>157k</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-<i>N</i>-(<i>tert</i>-butyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxamide (<b>157k</b>) (1.8 g, 3.3 mmol) in dry tetrahydrofuran (20 mL) at 0 °C was dropwise added borane dimethyl sulfide complex (4.50 mL, 4.05 g, 53.3 mmol), and the reaction mixture was stirred at room temperature for 16 h. Then, the reaction was quenched with methanol at 0 °C and heated to reflux for 6 h. After this time, the solvent was removed under reduced pressure to give the crude product which was purified by column chromatography using silica gel (100–200 mesh) and 0–15% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((<i>tert</i>-butylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>157k</b>) as a white solid. Yield: 1.40 g (2.60 mmol, 79%). MS (ESI) <i>m</i>/<i>z</i>: 539.45 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_43_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i373" class="anchor-spacer"></div><h5 class="article-section__title" id="_i373"> (+)-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((<i>tert</i>-Butylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((+)-<b>48</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-((<i>tert</i>-butylamino)methyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158k</b>) (1.40 g, 2.59 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (20.0 mL) were added zinc cyanide (1.70 g, 14.5 mmol) and zinc dust (0.081 g, 1.24 mmol), and the reaction mixture was degassed with argon for 15 min. 1,1′-Bis(diphenylphosphino)ferrocene (0.114 g, 0.206 mmol) and tris(dibenzylideneacetone)dipalladium (0.14 g, 0.153 mmol) were then added to the mixture. Degassing was continued for additional 5 min, and the mixture was heated at 140 °C for 16 h. After this time, the reaction mixture was diluted with ice-cold water and extracted with ethyl acetate. The organic layer was washed with water, dried over anhydrous sodium sulfate, filtered, and concentrated to give a crude product which was purified by column chromatography using silica gel (100–200 mesh) and 0–15% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((<i>tert</i>-butylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>48</b>) as white solid. Yield: 0.820 g (1.69 mmol, 65%). MS (ESI) <i>m</i>/<i>z</i>: 486.49 [M + 1]<sup>+</sup>. The enantiomers were separated by chiral SFC [Chiralpak IG (4.6 × 150) mm, 5 μm], CO<sub>2</sub>/0.1% TEA in EtOH=(60/40) Peak 1 ((−)-<b>48</b>, 55 mg), [α]<sub>D</sub> −34.2° (<i>c</i> 0.25, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 1.73 min, ee: 99.9%; MS (ESI) <i>m</i>/<i>z</i>: 486.36 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.97 (s, 1H), 7.48 (d, <i>J</i> = 8.7 Hz, 2H), 7.35 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.05 (m, 2H), 7.00–6.98 (m, 3H), 5.76 (s, 1H), 5.65 (s, 1H), 4.54 (s, 1H), 3.88 (s, 3H), 3.85 (s, 1H), 3.05–3.01 (m, 1H), 2.62–2.57 (m, 2H), 1.57–1.52 (s, 1H), 0.98 (s, 9H). Peak-2 ((+)-<b>48</b>, 58 mg) [α]<sub>D</sub> +28.5° (<i>c</i> 0.27, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 2.42 min, ee: 99.88%; MS (ESI) <i>m</i>/<i>z</i>: 486.32 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 486.2387 [M + H]<sup>+</sup>; found, 486.2393; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.35 (d, <i>J</i> = 8.5 Hz, 2H), 7.09–7.05 (m, 2H), 7.00–6.98 (m, 3H), 5.77 (s, 1H), 5.66 (s, 1H), 4.54 (s, 1H), 3.88 (s, 3H), 3.85 (s, 1H), 3.15–3.10 (m, 1H), 2.62–2.56 (m, 2H), 1.64 (s, 1H), 0.94 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.69, 153.49, 142.61, 137.05, 130.09, 128.63, 128.52, 127.64, 126.96, 126.27, 125.60, 123.67, 118.90, 108.88, 102.12, 93.67, 78.49, 56.83, 56.18, 49.87, 45.46, 32.93, 28.54.</div></div></div><div id="sec6_16_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i374" class="anchor-spacer"></div><h4 class="article-section__title" id="_i374"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-8-Azabicyclo[3.2.1]octan-8-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>50</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0086.gif" alt="" id="dgr45" /></img><div id="sec6_16_44_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i375" class="anchor-spacer"></div><h5 class="article-section__title" id="_i375"> <i>rac</i>-((1<i>R</i>,5<i>S</i>)-8-Azabicyclo[3.2.1]octan-8-yl)((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methanone (<b>157l</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (0.05 g, 0.10 mmol) in dichloromethane (5.0 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (0.043 g, 0.28 mmol), hydroxybenzotriazole (0.04 g, 0.3 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.09 mL, 0.07 g, 0.5 mmol) were added. The reaction mixture was stirred for 5 min. Then, 8-azabicyclo[3.2.1]octane (<b>S106</b>) (0.016 g, 0.14 mmol) was added at the same temperature and the reaction mixture was stirred at room temperature for 5 h. After this time, the reaction mixture was diluted with dichloromethane (20 mL) and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by reverse-phase HPLC to afford <i>rac</i>-((1<i>R</i>,5<i>S</i>)-8-azabicyclo[3.2.1]octan-8-yl) ((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methanone (<b>157l</b>) as a white solid. Yield: 23.0 mg (0.039 mmol, 39%). MS (ESI) <i>m</i>/<i>z</i>: 591.18 [M + 1]<sup>+</sup>; UPLC 99.6%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>, at High temperature VT (373 K): δ/ppm 8.11 (s, 1H), 8.01 (s, 1H), 7.21 (d, <i>J</i> = 8.6 Hz, 2H), 7.11 (d, <i>J</i> = 8.1 Hz, 2H), 7.05–6.94 (m, 5H), 4.70 (d, <i>J</i> = 4.8 Hz, 1H), 4.52 (d, <i>J</i> = 13.2 Hz, 1H), 4.09–4.05 (m, 1H), 3.92 (s, 3H), 2.01–1.78 (m, 8H), 1.60–1.55 (m, 4H).</div></div><div id="sec6_16_44_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i376" class="anchor-spacer"></div><h5 class="article-section__title" id="_i376"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-8-Azabicyclo[3.2.1]octan-8-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158l</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-((1<i>R</i>,5<i>S</i>)-8-azabicyclo[3.2.1]octan-8-yl) ((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methanone (<b>157l</b>) (0.50 g, 0.85 mmol) in tetrahydrofuran (10 mL) at 0 °C, borane dimethyl sulfide (0.2 mL, 0.2 g, 2.1 mmol) was added. The reaction mixture was stirred for 3 h at room temperature. After this time, the reaction was quenched with methanol (5.0 mL) and again heated for 10 h at 60 °C. The mixture was concentrated to obtain the crude product, which was purified by Combiflash (12 g, RediSep column) using 5–20% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-8-azabicyclo[3.2.1]octan-8-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158l</b>) as an off-white solid. Yield: 0.45 g (crude). MS (ESI) <i>m</i>/<i>z</i>: 577.4 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_44_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i377" class="anchor-spacer"></div><h5 class="article-section__title" id="_i377"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-8-Azabicyclo[3.2.1]octan-8-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>50</b>)</h5><div class="NLM_p last">To a solution of crude <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-8-azabicyclo[3.2.1]octan-8-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (0.45 g) in <i>N</i>,<i>N</i>-dimethylformamide (5.0 mL) at room temperature, zinc cyanide (0.543 g, 4.62 mmol) and zinc (0.005 g, 0.08 mmol) were added. The mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.130 g, 0.234 mmol) and tris(dibenzylideneacetone)-dipalladium (0.214 g, 0.234 mmol) were added to the reaction and degassing was continued for another 5 min. The reaction mixture was heated at 140 °C for 3 h. After this time, the mixture was cooled to room temperature and filtered with Celite. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by Combiflash (4 g, RediSep column) using 0–15% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure. The so-obtained material was purified by reverse-phase preparative HPLC, and the desired fractions were lyophilized to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-8-azabicyclo[3.2.1]octan-8-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile as a white solid (<i>rac</i>-<b>50</b>). Yield: 140 mg (0.267 mmol, 31% over two steps). The enantiomers were separated by chiral preparative HPLC [Chiralpak IA (4.6 × 250) mm, 5μ]; 0.1% TEA in <i>n</i>-hexane/IPA = 60/40 (V/V); peak 1 (9 mg, (+)-<b>50</b>), [α]<sub>D</sub> +33.1° (<i>c</i> 0.27, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 9.36, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 523.93 [M + 1]<sup>+</sup>; UPLC: 98.8%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.06 (s, 1H), 7.97 (s, 1H), 7.47 (d, <i>J</i> = 8.4 Hz, 2H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–6.97 (m, 5H), 5.68 (s, 1H), 4.6 (d, <i>J</i> = 3.5 Hz, 1H), 3.95 (d, <i>J</i> = 13.9 Hz, 1H), 3.88 (s, 3H), 3.13–3.11 (m, 1H), 2.97 (br s, 1H), 1.90 (s, 2H), 1.76 (m, 1H), 1.74–1.31 (m, 10H); peak 2 (8 mg, (−)-<b>50</b>), [α]<sub>D</sub> −58.9° (<i>c</i> 0.25, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 14.22, ee >99%; MS (ESI) <i>m</i>/<i>z</i>: 524.31 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 524.2544 [M + H]<sup>+</sup>; found, 524.2547; UPLC: 97.3%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.06 (s, 1H), 7.97 (s, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.37 (d, <i>J</i> = 8.4 Hz, 2H), 7.07–6.98 (m, 5H), 6.05 (s, 1H), 5.69 (s, 1H), 4.6 (s, 1H), 3.95 (m, 1H), 3.88 (s, 3H), 3.12 (br s, 1H), 2.95 (br s, 1H), 2.60 (br s, 2H),1.76 (m, 1H), 1.59–1.14 (m, 10H); 13C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.87, 153.46, 142.58, 136.80, 130.07, 128.58, 128.47, 127.74, 127.04, 126.33, 125.46, 123.45, 118.85, 109.52, 108.88, 93.49, 78.92, 60.45, 57.02, 56.15, 50.14, 43.95, 30.69, 25.68, 15.92.</div></div></div><div id="sec6_16_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i378" class="anchor-spacer"></div><h4 class="article-section__title" id="_i378"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-3-Oxa-8-azabicyclo[3.2.1]octan-8-yl) methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7<i>aH</i>-cyclopenta [4,5]furo[2,3-<i>c</i>]pyridin-7<i>a</i>-yl)benzonitrile ((−)-<b>51</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0087.gif" alt="" id="dgr46" /></img><div id="sec6_16_45_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i379" class="anchor-spacer"></div><h5 class="article-section__title" id="_i379"> <i>rac</i>-((1<i>R</i>,5<i>S</i>)-3-Oxa-8-azabicyclo[3.2.1]octan-8-yl)((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5] furo[2,3-<i>c</i>]pyridin-6-yl)methanone (<b>157m</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (1.5 g, 3.0 mmol) in dichloromethane (20 mL) at 0 °C, 1-[bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium3-oxide hexafluorophosphate (1.71 g, 4.50 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (3.28 mL, 2.43 g, 18.8 mmol) were added. The reaction mixture was stirred for 5 min. Then, (1<i>R</i>,5<i>S</i>)-3-oxa-8-azabicyclo[3.2.1]octane hydrochloride (<b>S107</b>) (0.9 g, 8.0 mmol) was added at the same temperature and the reaction mixture was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. This was purified by silica gel (100–200 mesh size) column chromatography using 0–5% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-((1<i>R</i>,5<i>S</i>)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl) ((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methanone (<b>157m</b>) as a white solid. Yield: 1.70 g (2.86 mmol, 95%). MS (ESI) <i>m</i>/<i>z</i>: 593.21 [M + 1]<sup>+</sup>.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.10 (s, 1H), 7.99 (s, 1H), 7.19 (d, <i>J</i> = 8.0 Hz, 2H), 7.08–6.97 (m, 6H), 6.88 (d, <i>J</i> = 7.2 Hz, 1H), 5.73 (d, <i>J</i> = 6.8 Hz, 1H), 5.20 (m, 1H), 4.71–4.63 (m, 2H), 4.52–4.46 (m, 1H), 4.31 (br s, 1H), 4.10–4.05 (m, 1H),3.88 (s, 3H), 3.79–3.70 (m, 2H), 3.52 (br s, 2H), 2.08 (br s, 2H), 1.78–1.63 (m, 2H).</div></div><div id="sec6_16_45_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i380" class="anchor-spacer"></div><h5 class="article-section__title" id="_i380"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-3-Oxa-8-azabicyclo[3.2.1]octan-8-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>] Pyridine-4b,5-diol (<b>158m</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-((1<i>R</i>,5<i>S</i>)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl) ((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta [4,5] furo[2,3-<i>c</i>]pyridin-6-yl)methanone (<b>157m</b>) (1.20 g, 2.02 mmol) in dry tetrahydrofuran (20 mL) at 0 °C, borane dimethyl sulfide complex (1.90 mL, 1.52 g, 20.0 mmol) was added dropwise over a period of 5 min. The reaction mixture was slowly brought to room temperature and stirred for an additional 16 h. After this time, the reaction mixture was quenched with methanol at 0 °C and heated to reflux for 10 h. Then, the solvent was removed under reduced pressure, and the residue was purified by silica gel (100–200 mesh size) column chromatography using 0–5% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>] pyridine-4b,5-diol (<b>158m</b>) as a white solid. Yield: 1.0 g (crude). MS (ESI) 579.21 <i>m</i>/<i>z</i>: [M + 1] <sup>+</sup>.</div></div><div id="sec6_16_45_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i381" class="anchor-spacer"></div><h5 class="article-section__title" id="_i381"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-3-Oxa-8-azabicyclo[3.2.1]octan-8-yl) methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta [4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>51</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl)methyl)-7a-(4-bromophenyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158m</b>) (1.0 g, 1.7 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (10 mL) at room temperature, zinc cyanide (0.98 g, 8.3 mmol) and zinc dust (0.013 g, 0.20 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.019 g, 0.034 mmol) and tris(dibenzylideneacetone)-dipalladium (0.047 g, 0.051 mmol) were added to the reaction mixture which was degassed for an additional 5 min and heated at 130 °C for 2 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product. This was purified by silica gel (100–200 mesh size) column chromatography using 2–3% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-(((1<i>R</i>,5<i>S</i>)-3-oxa-8-azabicyclo[3.2.1]octan-8-yl)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>51</b>) as a white solid. Yield: 0.30 g (0.57 mmol, 28% over two steps). MS (ESI) <i>m</i>/<i>z</i>: 526.36 [M + 1]<sup>+</sup>. The enantiomers were separated by chiral SFC [CHIRALPAK IA (4.6 × 250) mm, 5μ] in CO<sub>2</sub>/0.1% TEA in MeOH (80/20). Peak 1 (72 mg, (−)-<b>51</b>), [α]<sub>D</sub> −26.5° (<i>c</i> 0.25, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 6.077 min, ee: 99.84%; MS (ESI) <i>m</i>/<i>z</i>: 526.26 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 536.2336 [M + H]<sup>+</sup>; found, 526.2350; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.97 (s, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–6.96 (m, 5H), 5.71 (s, 1H), 5.38 (s, 1H), 4.61 (s, 1H), 3.88 (s, 3H), 3.82 (d, <i>J</i> = 14.2 Hz, 1H), 3.56 (d, <i>J</i> = 7.6 Hz, 2H), 3.50 (t, <i>J</i> = 12.0 Hz, 1H), 3.38 (s, 1H), 3.15 (br s, 1H), 2.94 (s, 1H), 2.44–2.41 (m, 2H), 2.23 (d, <i>J</i> = 11.2 Hz, 1H), 1.69–1.62 (m, 4H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.87, 153.44, 142.63, 136.99, 130.08, 128.64, 128.55, 127.72, 126.97, 126.28, 125.45, 123.49, 118.91, 108.87, 102.04, 93.65, 77.82, 72.63, 72.44, 61.65, 60.02, 56.97, 56.14, 50.58, 44.69, 24.73, 24.49. Peak-2 (104 mg, (+)-<b>51</b>), [α]<sub>D</sub> +39.2° (<i>c</i> 0.258, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 7.813 min, ee: 99.68%; MS (ESI) <i>m</i>/<i>z</i>: 526.26 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.97 (s, 1H), 7.48 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.11–6.96 (m, 5H), 5.71 (s, 1H), 5.38 (br s, 1H), 4.61 (s, 1H), 3.88 (s, 3H), 3.84 (d, <i>J</i> = 13.6 Hz, 1H), 3.56 (d, <i>J</i> = 7.6 Hz, 2H), 3.50 (t, <i>J</i> = 12.0 Hz, 1H), 3.37 (s, 1H), 3.17 (br s, 1H),3.02 (s, 1H), 2.44–2.41 (m, 2H), 2.23 (d, <i>J</i> = 11.2 Hz, 1H), 1.69–1.62 (m, 4H).</div></div></div><div id="sec6_16_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i382" class="anchor-spacer"></div><h4 class="article-section__title" id="_i382"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-Dihydroxy-4-methoxy-6-((methyl(2,2,2-trifluoroethyl)amino)methyl)-7-phenyl-4b,5,6,7-tetrahydro-7<i>aH</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((+)-<b>45</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0088.gif" alt="" id="dgr47" /></img><div id="sec6_16_46_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i383" class="anchor-spacer"></div><h5 class="article-section__title" id="_i383"> <i>rac</i>-<i>N</i>-(((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methyl)-2,2,2-trifluoro-<i>N</i>-methylacetamide (<b>159</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-6-((methylamino)methyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>158b</b>) (0.8 g, 1.6 mmol) in dichloromethane (5.0 mL) at 0 °C, trifluoroacetic anhydride (0.4 g, 2 mmol) and triethylamine (0.7 mL, 0.5 g, 5 mmol) were added. The reaction mixture was stirred for 5 min at 0 °C, then warmed up to room temperature, and stirred for 30 min. After this time, the mixture was diluted with dichloromethane (20 mL) and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude product was purified by Combi-flash (12 g RediSep column) using 30% ethyl acetate in hexanes as the eluent. The desired fractions were concentrated to afford <i>N</i>-(((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methyl)-2,2,2-trifluoro-<i>N</i>-methylacetamide (<b>159</b>) as a yellow solid. Yield: 0.4 g. UPLC: 82.36%; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.99 (s, 1H), 7.27–7.21 (m, 2H), 7.12–7.02 (m, 7H), 5.52 (s, 1H), 5.36 (d, <i>J</i> = 5.8 Hz, 1H), 4.38 (br s,1H), 3.88 (s, 3H), 3.84 (d, <i>J</i> = 14.0 Hz, 1H), 3.63 (d, <i>J</i> = 13.3 Hz, 1H), 3.37–3.06 (m, 5H).</div></div><div id="sec6_16_46_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i384" class="anchor-spacer"></div><h5 class="article-section__title" id="_i384"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4-methoxy-6-((methyl(2,2,2-trifluoroethyl)amino)methyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>160</b>)</h5><div class="NLM_p last">To a solution of <i>N</i>-(((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methyl)-2,2,2-trifluoro-<i>N</i>-methylacetamide (<b>159</b>) (0.2 g, from previous step; used without further purification) in tetrahydrofuran (20 mL) at 0 °C, borane dimethylsulfide (0.3 mL, 0.2 g, 4 mmol) was added. The reaction mixture was heated at 60 °C for 6 h. After this time, the reaction was quenched with methanol at 0 °C and then heated at 90 °C for 16 h. The solvents were evaporated and the solid thus obtained was dried to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-6-((methyl(2,2,2-trifluoroethyl)-amino)methyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>160</b>) as a yellow solid. Yield: 0.15 g (crude). UPLC: 89.22%; MS (ESI) <i>m</i>/<i>z</i>: 579.2 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.02 (s, 1H), 7.96 (s, 1H), 7.21 (d, <i>J</i> = 8.6 Hz, 2H), 7.14 (d, <i>J</i> = 8.3 Hz, 2H), 7.07–7.00 (m, 5H), 5.62 (s, 1H), 5.04 (d, <i>J</i> = 5.5 Hz,1H), 4.48 (br s, 1H), 3.88 (s, 3H), 3.70 (d, <i>J</i> = 14.4, 1H), 3.37–3.17 (m, 4H), 2.49 (s, 3H), 2.37–2.32 (m, 1H).</div></div><div id="sec6_16_46_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i385" class="anchor-spacer"></div><h5 class="article-section__title" id="_i385"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-Dihydroxy-4-methoxy-6-((methyl(2,2,2-trifluoroethyl)amino)-methyl)-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((+)-<b>45</b>)</h5><div class="NLM_p last">To a mixture of crude <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4-methoxy-6-((methyl(2,2,2-trifluoroethyl)amino)methyl)-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>160</b>) (0.15 g) in <i>N</i>,<i>N</i>- dimethylformamide (10.0 mL) at room temperature, zinc cyanide (182 mg, 1.55 mmol) and zinc (3 mg, 0.05 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (4.0 mg, 0.007 mmol) and tris(dibenzylideneacetone)-dipalladium (7.0 mg, 0.008 mmol) were added to the reaction mixture and degassing was continued for another 5 min. The reaction mixture was heated at 140 °C for 16 h. After this time, the mixture was cooled to room temperature and filtered through Celite. The filtrate was concentrated, treated with ice-cold water, and the resulting precipitate was collected by filtration. The crude product was purified by Combi-flash (12 g RediSep column) using 30% ethyl acetate in hexanes as the eluent. Then, it further purified by reverse-phase preparative HPLC. The desired fractions were lyophilized to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-4b,5-dihydroxy-4-methoxy-6-((methyl(2,2,2-trifluoroethyl)amino)methyl)-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>45</b>) as a white solid. Yield: 0.10 g (0.19 mmol, 24% over three steps). The enantiomers were separated by chiral preparative HPLC [Chiralpak IB (4.6 × 250) mm] using <i>n</i>-hexane/EtOH(90/10) (v/v) mobile phase. Peak 1 (21 mg, (−)-<b>45</b>), [α]<sub>D</sub> −13.0° (<i>c</i> 0.2, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 12.65 min, ee >99%. MS (ESI) <i>m</i>/<i>z</i>: 526.45 [M + 1]<sup>+</sup>; UPLC: 99.29%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–6.97 (m, 5H), 5.72 (s, 1H), 5.11 (d, <i>J</i> = 5.7 Hz,1H), 4.59 (t, <i>J</i> = 5.0 Hz, 1H), 3.88 (s, 3H), 3.77 (d, <i>J</i> = 14.0 Hz, 1H), 3.42–2.75 (m, 4H), 2.46 (s, 3H), 2.39 (d, <i>J</i> = 11.0 Hz,1H). Peak-2 (22 mg, (+)-<b>45</b>),[α]<sub>D</sub> +14.5° (<i>c</i> 0.2, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 17.019 min, ee >99%. MS (ESI) <i>m</i>/<i>z</i>: 526.42 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 526.1948 [M + H]<sup>+</sup>; found, 526.1948; UPLC: 99.42%.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.97 (s, 1H), 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.39 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–6.97 (m, 5H), 5.71 (s, 1H), 5.11 (d, <i>J</i> = 5.4 Hz,1H), 4.50 (t, <i>J</i> = 5.0 Hz, 1H), 3.88 (s, 3H), 3.77 (d, <i>J</i> = 14.0, 1H), 3.42–2.73 (m, 4H), 2.46 (s, 3H), 2.39 (d, <i>J</i> = 11.5 Hz,1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.80, 153.39, 142.52, 136.83, 130.09, 128.68, 128.60, 127.70, 126.99, 126.44 (q, <i>J</i> = 282 Hz), 126.31, 125.44, 123.36, 118.91, 108.92, 101.85, 93.80, 76.97, 57.18, 56.66 (q, <i>J</i> = 29 Hz), 56.13, 54.51, 44.03, 43.35.</div></div></div><div id="sec6_16_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i386" class="anchor-spacer"></div><h4 class="article-section__title" id="_i386"> Synthesis of 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((<i>tert</i>-Butyl(methyl)amino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>49</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0089.gif" alt="" id="dgr48" /></img><div id="sec6_16_47_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i387" class="anchor-spacer"></div><h5 class="article-section__title" id="_i387"> 4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((<i>tert</i>-Butyl(methyl)amino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile ((−)-<b>49</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((<i>tert</i>-butylamino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>48</b>) (0.41 g, 0.84 mmol) in dichloromethane (10 mL) at 0 °C, 2,6-lutidine (0.24 mL, 0.22 g, 2.1 mmol) and <i>tert</i>-butyldimethylsilyltrifluoromethanesulfonate (0.30 mL, 0.35 g, 1.3 mmol) were added. This reaction mixture was stirred for 1 h at room temperature. The reaction was monitored by TLC. After completion of the reaction, the mixture was cooled to 0 °C. <i>p</i>-Formaldehyde (0.100 g, 3.33 mmol), sodium acetate (0.68 g, 0.83 mmol), and sodium triacetoxyborohydride (0.711 g, 3.35 mmol) were added. This reaction mixture was stirred at room temperature for 2 h. After this time, the reaction mixture was diluted with water, neutralized with sodium bicarbonate solution, and extracted with 10% methanol in dichloromethane. The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by column chromatography using silica gel (100–200 mesh) and 0–6% 7 M methanolic ammonia in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-6-((<i>tert</i>-butyl(methyl)amino)methyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>49</b>) as a white solid. Yield: 0.230 g (0.460 mmol, 55%). MS (ESI) <i>m</i>/<i>z</i>: 500.52 [M + 1]<sup>+</sup>. The enantiomers were separated by chiral HPLC [Chiralpak IC (4.6 × 250)mm, 5μ], 0.1% TEA in <i>n</i>-hexane/IPA = 70/30(v/v) peak 1 (50 mg, (+)-<b>49</b>), [α]<sub>D</sub> +33.2° (<i>c</i> 0.28, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 7.94 min, ee: 99.88%; MS (ESI) <i>m</i>/<i>z</i>: 500.37 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.96 (s, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.08–7.05 (m, 2H), 7.02–6.96 (m, 3H), 5.72 (s, 1H), 5.32 (br s, 1H), 4.50 (s, 1H), 3.93 (s, 1H), 3.87 (s, 3H), 3.13 (br s, 1H), 2.73 (br s, 1H), 2.25–2.19 (m, 3H), 1.25–1.22 (m, 1H), 0.94 (s, 9H). Peak-2 (52 mg, (−)-<b>49</b>) [α]<sub>D</sub> −35.2° (<i>c</i> 0.25, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 14.67 min, ee: 99.74%; MS (ESI) <i>m</i>/<i>z</i>: 500.40 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 500.2544 [M + H]<sup>+</sup>; found, 500.2558; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.04 (s, 1H), 7.96 (s, 1H), 7.48 (d, <i>J</i> = 8.5 Hz, 2H), 7.36 (d, <i>J</i> = 8.44 Hz, 2H), 7.08–7.05 (m, 2H), 7.02–6.98 (m, 3H), 5.72 (s, 1H), 5.32 (br s, 1H), 4.50 (s, 1H), 3.93 (s, 1H), 3.87 (s, 3H), 3.13 (br s, 1H), 2.73 (br s, 1H), 2.25–2.19 (m, 3H), 1.25–1.22 (m, 1H), 0.94 (s, 9H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.96, 153.41, 142.72, 137.06, 133.95, 130.09, 128.89, 128.54, 127.62, 127.05, 126.29, 125.35, 123.38, 118.93, 108.85, 101.92, 93.62, 77.85, 57.55, 56.16, 47.87, 44.66, 35.80, 25.76.</div></div></div><div id="sec6_16_48" class="NLM_sec NLM_sec_level_3"><div id="ac_i388" class="anchor-spacer"></div><h4 class="article-section__title" id="_i388"> Synthesis of <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-6-(2-(Dimethylamino)ethyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>52</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0090.gif" alt="" id="dgr49" /></img><div id="sec6_16_48_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i389" class="anchor-spacer"></div><h5 class="article-section__title" id="_i389"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-6-(hydroxymethyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>161</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-6-carboxylic acid (<b>148</b>) (5.0 g, 10 mol) in dry tetrahydrofuran (100 mL) at 0 °C, borane dimethyl sulfide complex (9.52 mL, 7.62 g, 100 mmol) was added dropwise over a period of 5 min. The reaction mixture was heated at 60 °C for 6 h. After completion, the reaction mixture was quenched with methanol at 0 °C and heated to reflux for 16 h. After this time, the solvent was removed under reduced pressure to obtain the crude product which was triturated with diethyl ether, filtered, and dried under vacuum to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-(hydroxymethyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>161</b>) as a white solid. Yield: 4.5 g (9.3 mmol, 93%). MS (ESI) <i>m</i>/<i>z</i>: 484.3 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.02 (br s, 1H), 7.96 (br s, 1H), 7.22 (d, <i>J</i> = 8.3 Hz, 2H), 7.12–7.06 (m, 4H), 7.01–6.98 (m, 3H), 5.61 (s, 1H), 5.04 (d, <i>J</i> = 5.0 Hz, 1H), 4.54 (s, 1H), 4.39–4.34 (m, 2H), 3.86 (s, 3H), 3.66 (d, <i>J</i> = 10.3 Hz, 1H), 3.53–3.51 (m, 2H).</div></div><div id="sec6_16_48_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i390" class="anchor-spacer"></div><h5 class="article-section__title" id="_i390"> <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methyl Methanesulfonate (<b>S109</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-(hydroxymethyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>161</b>) (4.5 g, 9.3 mmol) in pyridine (90 mL) at 0 °C, methane sulfonyl chloride (1.60 g, 14.0 mmol) was added. The resulting mixture was stirred at room temperature for 16 h. After this time, the solvent was removed under reduced pressure. The crude product was diluted with water and extracted with ethyl acetate. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel (100–200 mesh size) column chromatography using 5% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methyl methanesulfonate (<b>S109</b>) as a white solid. Yield: 4.20 g (7.47 mmol, 80%). MS (ESI) <i>m</i>/<i>z</i>: 562.3 [M + 1]<sup>+</sup>, <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.99 (s, 1H), 7.23 (d, <i>J</i> = 8.5 Hz, 2H), 7.20–7.09 (m, 4H), 7.04–7.02 (m, 3H), 5.51 (d, <i>J</i> = 5.4 Hz, 1H), 4.52 (s, 1H), 4.29–4.24 (m, 1H), 4.05 (d, <i>J</i> = 5.9 Hz, 1H), 3.89 (s, 3H), 3.77 (d, <i>J</i> = 14.9 Hz, 1H), 3.77 (d, <i>J</i> = 14.9 Hz, 1H), 3.56–3.49 (m, 1H), 3.08 (s, 3H).</div></div><div id="sec6_16_48_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i391" class="anchor-spacer"></div><h5 class="article-section__title" id="_i391"> <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)acetonitrile (<b>162</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-((4b<i>S</i>,5<i>R</i>,6<i>S</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)methyl methanesulfonate (<b>S109</b>) (4.20 g, 7.47 mmol) in dimethylsulfoxide (84 mL), potassium cyanide (4.86 g, 74.6 mmol) was added. The resulting mixture was heated at 80 °C for 16 h. After this time, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with ice-cold water and then brine. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product which was purified by silica gel (100–200 mesh size) column chromatography using 5% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)acetonitrile (<b>162</b>) as a yellow-brown solid. Yield: 2.1 g (4.3 mmol, 58%). MS (ESI) <i>m</i>/<i>z</i>: 493.33 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.07 (s, 1H), 7.99 (s, 1H), 7.22 (d, <i>J</i> = 8.6 Hz, 2H), 7.14–7.03 (m, 4H), 6.97–6.95 (m, 3H), 5.75 (s, 1H), 5.58 (d, <i>J</i> = 5.9 Hz, 1H), 4.50 (t, <i>J</i> = 5.4 Hz, 1H), 3.89 (s, 3H), 3.77 (d, <i>J</i> = 13.8 Hz, 1H), 3.50 (s, 1H), 3.39–3.31 (m, 1H), 1.98–1.97 (m, 1H).</div></div><div id="sec6_16_48_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i392" class="anchor-spacer"></div><h5 class="article-section__title" id="_i392"> <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)acetic acid (<b>163</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)acetonitrile (<b>162</b>) (0.8 g, 1.6 mmol) in tetrahydrofuran (4 mL) in a sealed tube, 10% aq sodium hydroxide solution (16 mL) was added. The reaction mixture was heated at 125 °C for 36 h. After this time, the reaction mixture was acidified using 1 N hydrochloric acid, and the resulting precipitate was collected by filtration. The crude product thus obtained was triturated with diethyl ether and dried under vacuum to afford <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)acetic acid (<b>163</b>) as a white solid. Yield: 0.75 g (1.5 mmol, 94%). MS (ESI) <i>m</i>/<i>z</i>: 512.3 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.08 (br s, 1H), 8.03 (s, 1H), 7.97 (s, 1H), 7.26–7.24 (m, 2H), 7.13–7.03 (m, 5H), 6.94–6.92 (m, 2H), 5.64 (s, 1H), 5.17 (s, 1H), 4.54 (s, 1H), 3.88 (s, 3H), 3.66 (d, <i>J</i> = 13.8 Hz, 1H), 2.07–2.03 (m, 2H).</div></div><div id="sec6_16_48_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i393" class="anchor-spacer"></div><h5 class="article-section__title" id="_i393"> <i>rac</i>-(3a<i>R</i>,4<i>S</i>,4a<i>R</i>,9b<i>S</i>,9cR)-4a-(4-Bromophenyl)-9b-hydroxy-9-methoxy-4-phenyl-3,3a,4,4a,9b,9c-hexahydro-2<i>H</i>-furo[3″,2″:4′,5′]cyclopenta[1′,2′:4,5]furo[2,3-<i>c</i>]pyridin-2-one (<b>164</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)acetic acid (<b>163</b>) (0.45 g, 0.88 mmol) in dichloromethane (9 mL) at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (0.50 g, 2.6 mmol), hydroxybenzotriazole (0.40 g, 2.6 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (1.09 mL, 0.807 g, 6.24 mmol) were added. The reaction mixture was stirred for 5 min. Then, dimethylamine hydrochloride (0.358 g, 4.19 mmol) was added at the same temperature, and the reaction was stirred for 16 h at room temperature. After this time, the reaction mixture was diluted with dichloromethane and washed with cold water. The organic layer was separated, dried over sodium sulfate, filtered, and concentrated to obtain the crude product which was purified by silica gel (100–200 mesh) column chromatography using 3% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-3a<i>R</i>,4<i>S</i>,4a<i>R</i>,9b<i>S</i>,9c<i>R</i>)-4a-(4-bromophenyl)-9b-hydroxy-9-methoxy-4-phenyl-3,3a,4,4a,9b,9c-hexahydro-2<i>H</i>-furo[3″,2″:4′,5′]cyclopenta[1′,2′:4,5]furo[2,3-<i>c</i>]pyridin-2-one (<b>164</b>) as an off-white solid. Yield: 0.40 g (0.81 mmol, 92%). MS (ESI) <i>m</i>/<i>z</i>: 494.31 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.17 (s, 1H), 8.12 (s, 1H), 7.35 (d, <i>J</i> = 8.4 Hz, 2H), 7.12–7.10 (m, 5H), 6.96 (d, <i>J</i> = 5.0, 2H), 6.01 (s, 1H), 5.36 (d, <i>J</i> = 6.5 Hz, 1H), 3.96 (s, 3H), 3.80–3.74 (m, 1H), 3.37 (s, 1H), 2.90 (dd, <i>J</i> = 7.9, 17.9 Hz, 1H), 1.99 (d, <i>J</i> = 17.8 Hz, 1H).</div></div><div id="sec6_16_48_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i394" class="anchor-spacer"></div><h5 class="article-section__title" id="_i394"> <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)-<i>N</i>,<i>N</i>-dimethylacetamide (<b>165</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(3a<i>R</i>,4<i>S</i>,4a<i>R</i>,9b<i>S</i>,9c<i>R</i>)-4a-(4-bromophenyl)-9b-hydroxy-9-methoxy-4-phenyl-3,3a,4,4a,9b,9c-hexahydro-2<i>H</i>-furo[3″,2″:4′,5′]cyclopenta[1′,2′:4,5]furo[2,3-<i>c</i>]pyridin-2-one (<b>164</b>) (0.25 g, 0.51 mmol) in a 2 M solution of dimethyl amine (20 mL) in tetrahydrofuran, <i>ca.</i> 50% propylphosphonic anhydride in ethyl acetate (3.2 mL, 3.4 g solution, 1.7 g propylphosphonic anhydride, 5.4 mmol) was added. The reaction mixture was heated at 80 °C for 16 h. After this time, the reaction mixture was diluted with water and extracted with ethyl acetate. The organic layer was washed with brine, separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product which was purified by silica gel (100–200 mesh size) column chromatography using 5% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)-<i>N</i>,<i>N</i>-dimethylacetamide (<b>165</b>) as a white solid. Yield: 0.13 g (0.24 mmol, 47%). MS (ESI) <i>m</i>/<i>z</i>: 539.43 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.03 (s, 1H), 7.96 (s, 1H), 7.25 (d, <i>J</i> = 8.3 Hz, 2H), 7.13–7.02 (m, 5H), 6.90 (d, <i>J</i> = 6.6 Hz, 2H), 5.59 (s, 1H), 5.06 (s, 1H), 4.49 (s, 1H), 3.87 (s, 3H), 3.67 (d, <i>J</i> = 14.6 Hz, 1H), 3.35 (br s, 1H), 2.80–2.79 (m, 6H), 2.79 (s, 3H), 2.00–1.96 (m, 1H), 1.33–1.29 (m, 1H).</div></div><div id="sec6_16_48_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i395" class="anchor-spacer"></div><h5 class="article-section__title" id="_i395"> <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-Bromophenyl)-6-(2-(dimethylamino)ethyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>166</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-2-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,6,7,7a-tetrahydro-5<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-6-yl)-<i>N</i>,<i>N</i>-dimethylacetamide (0.13 g, 0.24 mmol) in dry tetrahydrofuran (5.2 mL) at 0 °C, borane dimethyl sulfide complex (0.23 mL, 0.18 g, 2.4 mmol) was added dropwise over a period of 5 min. The reaction mixture was slowly brought to room temperature and stirred for additional 16 h. After this time, the reaction mixture was quenched with methanol (40 mL) at 0 °C and heated to reflux for 24 h. Then, the solvent was removed under reduced pressure and the crude product was purified by silica gel (100–200 mesh size) column chromatography using 10% methanol in dichloromethane as the eluent. The desired fractions were concentrated under reduced pressure to afford <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-(2-(dimethylamino)ethyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (<b>166</b>). Yield: 0.09 g (0.17 mmol, 71%); MS (ESI) <i>m</i>/<i>z</i>: 525.4 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.03 (s, 1H), 7.97 (s, 1H), 7.22 (d, <i>J</i> = 8.4 Hz, 2H), 7.13–7.01 (m, 5H), 6.96 (d, <i>J</i> = 7.3 Hz, 2H), 5.59 (s, 1H), 4.40 (d, <i>J</i> = 4.1 Hz, 1H), 3.89 (s, 3H), 3.39–3.31 (m, 1H), 3.16 (br s, 1H), 2.97–2.94 (m, 1H), 2.27 (br s, 6H), 1.43–1.33 (m, 2H), 1.29–1.10 (m, 2H).</div></div><div id="sec6_16_48_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i396" class="anchor-spacer"></div><h5 class="article-section__title" id="_i396"> <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-6-(2-(Dimethylamino)ethyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>52</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-7a-(4-bromophenyl)-6-(2-(dimethylamino)ethyl)-4-methoxy-7-phenyl-5,6,7,7a-tetrahydro-4b<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridine-4b,5-diol (0.09 g, 0.17 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (4 mL) at room temperature, zinc cyanide (0.12 g, 1.0 mmol) and zinc dust (0.00013 g, 0.0020 mmol) were added. This reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino)ferrocene (0.0018 g, 0.0032 mmol) and tetrakis(triphenylphosphine)palladium (0.0046 g, 0.0040 mmol) were added to the reaction mixture which was degassed for an additional 5 min and heated at 140 °C for 8 h. After this time, the reaction mixture was diluted with ethyl acetate and washed with cold water. The organic layer was separated, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by silica gel (100–200 mesh size) column chromatography using 6% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-4-((4b<i>S</i>,5<i>R</i>,6<i>R</i>,7<i>S</i>,7a<i>R</i>)-6-(2-(dimethylamino)ethyl)-4b,5-dihydroxy-4-methoxy-7-phenyl-4b,5,6,7-tetrahydro-7a<i>H</i>-cyclopenta[4,5]furo[2,3-<i>c</i>]pyridin-7a-yl)benzonitrile (<i>rac</i>-<b>52</b>) as a white solid. Yield: 0.015 g (0.032 mmol, 19%). MS (ESI) <i>m</i>/<i>z</i>: 472.28 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 472.2231 [M + H]<sup>+</sup>; found, 472.2251; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 8.05 (s, 1H), 7.97 (s, 1H), 7.50 (d, <i>J</i> = 8.4 Hz, 2H), 7.36 (d, <i>J</i> = 8.4 Hz, 2H), 7.09–7.05 (m, 2H), 7.01–6.96 (m, 3H), 5.68 (s, 1H), 4.42 (d, <i>J</i> = 4.0 Hz, 1H), 3.88 (s, 3H), 3.76 (d, <i>J</i> = 14.1 Hz, 1H), 3.03 (br s, 1H), 2.41–2.37 (m, 1H), 2.32–2.26 (m, 1H), 2.12 (s, 6H), 1.48 (br s, 1H), 1.41 (br s, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 155.64, 153.45, 142.63, 137.11, 130.12, 128.73, 128.52, 127.68, 126.99, 126.28, 125.60, 123.65, 118.91, 108.90, 101.78, 93.86, 77.45, 59.17, 56.98, 56.20, 45.24, 43.53, 24.19.</div></div></div><div id="sec6_16_49" class="NLM_sec NLM_sec_level_3"><div id="ac_i397" class="anchor-spacer"></div><h4 class="article-section__title" id="_i397"> Synthesis of (5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Cyanophenyl)-7-((dimethylamino)methyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-3-carbonitrile ((−)-<b>53</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0092.gif" alt="" id="dgr50" /></img><div id="sec6_16_49_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i398" class="anchor-spacer"></div><h5 class="article-section__title" id="_i398"> 4-(Benzyloxy)-2,6-dichloropyridine (<b>168</b>)</h5><div class="NLM_p last">To a solution of 2,4,6-trichloropyridine (<b>167</b>) (1.0 kg, 5.5 mol) in <i>N</i>,<i>N</i>-dimethylformamide (8.0 L) under nitrogen atmosphere at 0 °C, sodium hydride (55% dispersion in paraffin oil, 265.2 g, 6.078 mol) was added. This suspension was held at 0 °C for 15–20 min. Then, benzyl alcohol (596.6 mL, 620.5 g, 5.738 mol) was added, and the reaction mixture was stirred for another 1 h at the same temperature. After this time, the reaction mixture was poured into crushed ice and the resulting precipitate was collected by filtration and washed with water. The solid obtained was stirred in minimum hexane and collected again by filtration. The solid was dried under vacuum to afford 4-(benzyloxy)-2,6-dichloropyridine (<b>168</b>) as a white solid. Yield: 1.00 kg (3.94 mol, 72%). MS (ESI) <i>m</i>/<i>z</i>: 254.32 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.46–7.37 (m, 5H), 7.28 (s, 2H), 5.26 (s, 2H).</div></div><div id="sec6_16_49_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i399" class="anchor-spacer"></div><h5 class="article-section__title" id="_i399"> 4-(Benzyloxy)-2-chloro-6-methoxypyridine (<b>169</b>)</h5><div class="NLM_p last">To a solution of 4-(benzyloxy)-2,6-dichloropyridine (1.0 kg, 3.9 mol) in toluene (15.0 L) at room temperature, 25% sodium methoxide in methanol (1.70 L, 1.60 kg solution, 400 g NaOMe, 7.4 mol) was added. The reaction mixture was heated at 60 °C for 5 h. After this time, the reaction mixture was cooled to room temperature, poured into water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was recrystallized with chilled hexane to afford 4-(benzyloxy)-2-chloro-6-methoxypyridine (<b>169</b>) as a white solid. Yield: 541 g (2.17 mol, 56%). MS (ESI) <i>m</i>/<i>z</i>: 250.35 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.42–7.32 (m, 5H), 6.77 (d, <i>J</i> = 1.3 Hz, 1H), 6.43 (d, <i>J</i> = 1.2 Hz, 1H), 5.17 (s, 2H), 3.80 (s, 3H).</div></div><div id="sec6_16_49_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i400" class="anchor-spacer"></div><h5 class="article-section__title" id="_i400"> 1-(4-(Benzyloxy)-6-chloro-2-methoxypyridin-3-yl)ethan-1-ol (<b>170</b>)</h5><div class="NLM_p last">To a solution of 4-(benzyloxy)-2-chloro-6-methoxypyridine (<b>169</b>) (541 g, 2.17 mol) in tetrahydrofuran (550 mL) at −78 °C, 2.5 M <i>n</i>-buthyl lithium in hexane (1.043 L, 2.608 mol) was added. After this addition was completed, the reaction mixture was stirred at −78 °C for 30 min. Then, acetaldehyde (243.4 mL, 192.3 g, 4.370 mol) was added at the same temperature and the reaction mixture was maintained at that temperature for 2 h. After this time, the reaction mixture was quenched with saturated ammonium chloride solution and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel (100–200 mesh) column chromatography using 10–15% ethyl acetate in hexanes as the eluent to afford 1-(4-(benzyloxy)-6-chloro-2-methoxypyridin-3-yl)ethan-1-ol (<b>170</b>) as a white crystalline solid. Yield: 414 g (1.41 mol, 65%). MS (ESI) <i>m</i>/<i>z</i>: 294.41 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.46 (d, <i>J</i> = 7.1 Hz, 2H), 7.41 (t, <i>J</i> = 7.4 Hz, 2H), 7.35 (d, <i>J</i> = 7.0 Hz, 1H), 6.93 (s, 1H), 5.24 (s, 2H), 5.11 (m, 1H), 4.61 (d, <i>J</i> = 6.2 Hz, 1H), 3.83 (s, 3H), 1.38 (m, 3H).</div></div><div id="sec6_16_49_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i401" class="anchor-spacer"></div><h5 class="article-section__title" id="_i401"> 1-(4-(Benzyloxy)-6-chloro-2-methoxypyridin-3-yl)ethan-1-one (<b>171</b>)</h5><div class="NLM_p last">To a solution of 1-(4-(benzyloxy)-6-chloro-2-methoxypyridin-3-yl)ethan-1-ol (<b>170</b>) (414 g, 1.41 mol) in dichloromethane (8.300 L) at room temperature, water (10 mL) was added followed by the slow addition of Dess–Martin periodinane (719 g, 1.70 mol). The reaction mixture was stirred for 15 min. Then, the reaction mixture was filtered through Celite and washed with an excess of dichloromethane. The filtrate was washed with saturated sodium bicarbonate solution and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel (100–200 mesh) column chromatography using 0–10% ethyl acetate in hexanes as the eluent to afford 1-(4-(benzyloxy)-6-chloro-2-methoxypyridin-3-yl)ethan-1-one (<b>171</b>) as a white solid. Yield: 308.0 g (1.06 mol, 75%). MS (ESI) <i>m</i>/<i>z</i>: 292.12 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.4–7.35 (m, 5H), 7.11 (s, 1H), 5.27 (s, 2H), 3.84 (s, 3H), 2.38 (s, 3H).</div></div><div id="sec6_16_49_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i402" class="anchor-spacer"></div><h5 class="article-section__title" id="_i402"> 1-(6-Chloro-4-hydroxy-2-methoxypyridin-3-yl)ethan-1-one (<b>172</b>)</h5><div class="NLM_p last">1-(4-(benzyloxy)-6-chloro-2-methoxypyridin-3-yl)ethan-1-one (<b>171</b>) (23.35 g, 80.04 mmol) was dissolved in ethyl acetate (600 mL) under stirring in a 2 L round-bottom flask. A combination vacuum/nitrogen/hydrogen manifold was attached, and the atmosphere in the flask was removed and replaced with argon. Palladium (10%) on carbon (188 mg, 1.88 mmol) was added, and the atmosphere in the flask was removed and replaced with hydrogen. The resulting mixture was stirred vigorously at room temperature under hydrogen for 3 h. The reaction mixture was filtered through Celite, and the filter cake washed thoroughly with EtOAc. The filtrate was concentrated on a rotary evaporator and purified <i>via</i> silica gel chromatography (1% ethyl acetate in hexanes isocratic) to afford 1-(6-chloro-4-hydroxy-2-methoxypyridin-3-yl)ethan-1-one (<b>172</b>) as a white solid. Yield: 14.15 g (70.19 mmol, 88%). MS (ESI) <i>m</i>/<i>z</i>: 202.2 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 13.02 (s, 1H), 6.70 (s, 1H), 3.91 (s, 3H), 2.53 (s, 3H).</div></div><div id="sec6_16_49_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i403" class="anchor-spacer"></div><h5 class="article-section__title" id="_i403"> (<i>E</i>)-3-(4-Bromophenyl)-1-(6-chloro-4-hydroxy-2-methoxypyridin-3-yl)prop-2-en-1-one (<b>173</b>)</h5><div class="NLM_p last">To a 1 L round-bottom flask with a stir bar was added sequentially 1-(6-chloro-4-hydroxy-2-methoxypyridin-3-yl)ethan-1-one (<b>172</b>) (14.13 g, 70.09 mmol) 4-bromobenzaldehyde (13.34 g, 72.13 mmol), <i>N</i>,<i>N</i>-dimethylformamide (170 mL), and then sodium methoxide (25 wt % in methanol) (48.04 mL, 45.40 g solution; 11.35 g, 210.1 mmol NaOMe). The reaction mixture was stirred vigorously and heated at 50 °C under a reflux condenser for 20 min. The reaction mixture is initially clear and light yellow, but then a lot of solids precipitated. More <i>N</i>,<i>N</i>-dimethylformamide (50 mL) was added to keep the reaction stirring. The reaction mixture was poured onto a vigorously stirred mixture of 1 N HCl in water (210 mL, 210 mmol) and ice water (500 mL). The resulting light yellow mixture was stirred vigorously for 10 min and then solids were collected by vacuum filtration. The solids were washed with water and dried under high vacuum to afford (<i>E</i>)-3-(4-bromophenyl)-1-(6-chloro-4-hydroxy-2-methoxypyridin-3-yl)prop-2-en-1-one (<b>173</b>) as a yellow solid. Yield: 25.83 g (70.08 mmol, 100%). MS (ESI) <i>m</i>/<i>z</i>: 368.0, 369.9 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.72–7.67 (m, 2H), 7.65–7.59 (m, 2H), 7.40 (d, <i>J</i> = 16.2 Hz, 1H), 7.17 (d, <i>J</i> = 16.1 Hz, 1H), 6.60 (s, 1H), 3.81 (s, 3H).</div></div><div id="sec6_16_49_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i404" class="anchor-spacer"></div><h5 class="article-section__title" id="_i404"> 2-(4-Bromophenyl)-7-chloro-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>174</b>)</h5><div class="NLM_p last">10% aq sodium hydroxide (18.1 mL, 49.78 mmol) was added to a stirred mixture (not all dissolved) of (<i>E</i>)-3-(4-bromophenyl)-1-(6-chloro-4-hydroxy-2-methoxypyridin-3-yl)prop-2-en-1-one (<b>173</b>) (8.31 g, 22.54 mmol) in ethanol (160 mL) and DCM (40 mL) cooled with a room temperature water bath. After 1 min, 30% aq hydrogen peroxide (16.19 mL, 158.5 mmol) was added. The reaction mixture was stirred vigorously while being cooled with a room temperature water bath for 1 h. The reaction mixture was diluted with dichloromethane, poured onto saturated aqueous ammonium chloride (250 mL), and extracted three times with dichloromethane. The organics were concentrated on a rotary evaporator. The residual solids were shaken in a separatory funnel with DCM (1 L) and saturated aqueous ammonium chloride (250 mL). The layers were separated, and the water layer was extracted twice with DCM. The combined organics were dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated on a rotary evaporator. Ethyl acetate (10%) in hexanes (100 mL) was added to the residue, and the resulting mixture was heated to reflux with a heat gun. The mixture was capped and let stand 1 h at room temperature. Solids were collected by vacuum filtration, washed with 10% ethyl acetate in hexanes, and dried under high vacuum to afford 2-(4-bromophenyl)-7-chloro-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>174</b>) as an orange solid. Yield: 1.61 g (4.21 mmol, 19%). MS (ESI) <i>m</i>/<i>z</i>: 382.0, 384.0 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 10.01 (s, 1H), 8.15–8.09 (m, 2H), 7.80–7.75 (m, 2H), 7.55 (s, 1H), 4.02 (s, 3H).</div></div><div id="sec6_16_49_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i405" class="anchor-spacer"></div><h5 class="article-section__title" id="_i405"> <i>rac</i>-Methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-Bromophenyl)-8-chloro-5,10,10-trihydroxy-6-methoxy-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S110</b>)</h5><div class="NLM_p last">To a 500 mL round-bottom flask were added sequentially a stir bar, 2-(4-bromophenyl)-7-chloro-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>9</b>, 1.61 g, 4.21 mmol), methyl cinnamate (<b>10</b>, 6.83 g, 42.1 mmol), chloroform (80 mL), and TFE (80 mL). The reaction mixture was stirred vigorously and irradiated with 450 W UV light while being cooled with a 0 °C cold bath for 5 h. The reaction mixture was diluted with 3% triethylamine in ethyl acetate (15 mL), concentrated on a rotary evaporator with silica gel, and dried under high vacuum overnight. The residue was loaded into a loading column and purified <i>via</i> silica gel chromatography (0-5-100% EtOAc/hexanes) (column was pre-equilibrated with 10% EtOAc in hexanes with 3% triethylamine prior to equilibration with 0% hexanes) to afford 1.67 g of impure <i>rac</i>-methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-bromophenyl)-8-chloro-5,10,10-trihydroxy-6-methoxy-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S110</b>) an orange residue which was taken on to the next step without further purification. MS (ESI) <i>m</i>/<i>z</i>: 562.3, 564.2 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_49_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i406" class="anchor-spacer"></div><h5 class="article-section__title" id="_i406"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-Bromophenyl)-3-chloro-8a-hydroxy-1-methoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S111</b>)</h5><div class="NLM_p last">Sodium methoxide (25 wt % in methanol) (2.03 mL, 1.92 g sln; 0.480 g, 8.89 mmol NaOMe) was added to a stirred solution of impure <i>rac</i>-methyl (3<i>S</i>,4<i>S</i>,5<i>R</i>)-2-(4-bromophenyl)-8-chloro-5,10,10-trihydroxy-6-methoxy-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S110</b>) (1.67 g) in methanol (60 mL) at room temperature under argon. The clear yellow solution changed to dark orange colored. The reaction mixture was heated at 60 °C under a reflux condenser under argon for 40 min and then most of the solvent was removed on a rotary evaporator. The residue was partitioned between saturated aqueous ammonium chloride and ethyl acetate. The organics were washed with brine, dried over MgSO<sub>4</sub>, filtered, concentrated on a rotary evaporator, and dried under high vacuum to afford impure <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-1-methoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S111</b>) as an orange residue. Yield: 1.57 g (crude). MS (ESI) <i>m</i>/<i>z</i>: 544.0, 546.1 [M + 1]<sup>+</sup>. This material was carried on without further purification.</div></div><div id="sec6_16_49_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i407" class="anchor-spacer"></div><h5 class="article-section__title" id="_i407"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>176</b>)</h5><div class="NLM_p last">To a stirred solution of impure <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-3-chloro-8a-hydroxy-1-methoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S111</b>) (1.57 g) in MeCN (50 mL) at room temperature was added acetic acid (1.65 mL, 28.8 mmol) and then sodium triacetoxyborohydride (3.05 g, 14.4 mmol). The resulting reaction mixture was stirred vigorously at room temperature under argon for 40 min. Saturated aqueous ammonium chloride (20 mL) was added slowly dropwise, and the resulting mixture was partitioned between water and ethyl acetate. The organics were washed with saturated aqueous sodium bicarbonate and then brine, dried over MgSO<sub>4</sub>, filtered, concentrated on a rotary evaporator and purified <i>via</i> silica gel chromatography (12–22% EtOAc/hexanes) to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (Cpd. no. 136F) as a slightly yellow foam-solid. Yield: 631 mg (1.15 mmol, 27% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 546.1, 548.1 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.24–7.19 (m, 2H), 7.09–6.92 (m, 8H), 5.70–5.64 (m, 2H), 4.62 (t, <i>J</i> = 5.4 Hz, 1H), 4.31 (d, <i>J</i> = 13.9 Hz, 1H), 4.09 (dd, <i>J</i> = 14.0, 4.9 Hz, 1H), 3.83 (s, 3H), 3.57 (s, 3H).</div></div><div id="sec6_16_49_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i408" class="anchor-spacer"></div><h5 class="article-section__title" id="_i408"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic Acid (<b>S112</b>)</h5><div class="NLM_p last">To a stirred solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>1</b>, 1.09 g, 1.99 mmol) in methanol (40 mL) was added water (4 mL) and then lithium hydroxide (477 mg, 19.9 mmol). The resulting yellow reaction mixture was stirred vigorously and heated at 50 °C under a reflux condenser for 4.5 h. The reaction mixture was cooled with a 0 °C cold bath, and 1 N HCl in water (19.9 mL, 19.9 mmol) was added under vigorous stirring. A few more drops of 1 N HCl were added to make the mixture slightly acidic. Most of the methanol was removed on a rotary evaporator. The residue was extracted three times with dichloromethane. The combined organics were washed with brine, dried over MgSO<sub>4</sub>, filtered, concentrated on a rotary evaporator, and dried under high vacuum at 40 °C overnight to afford crude <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic acid (<b>S112</b>) as a white solid with yellow impurity. Yield: 961 mg (1.80 mmol, 90%). MS (ESI) <i>m</i>/<i>z</i>: 532.1, 534.0 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.23 (s, 1H), 7.24–7.18 (m, 2H), 7.06 (m, 2H), 7.03–6.94 (m, 5H), 6.93 (s, 1H), 5.62 (d, <i>J</i> = 8.3 Hz, 2H), 4.62 (t, <i>J</i> = 5.3 Hz, 1H), 4.29 (d, <i>J</i> = 13.9 Hz, 1H), 3.95 (dd, <i>J</i> = 14.0, 5.0 Hz, 1H), 3.84 (s, 3H).</div></div><div id="sec6_16_49_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i409" class="anchor-spacer"></div><h5 class="article-section__title" id="_i409"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S113</b>)</h5><div class="NLM_p last">HATU (686 mg, 1.80 mmol) was added to a stirred solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic acid (<b>S112</b>) (915 mg, 1.72 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (15 mL) at room temperature under argon. After 2 min, <i>N</i>,<i>N</i>-diisopropylethylamine (0.45 mL, 2.58 mmol) was added. The resulting reaction mixture was stirred at room temperature under argon for 20 min. Dimethylamine (2 M solution in THF) (2.58 mL, 5.15 mmol) was added, and the reaction mixture was stirred at room temperature under argon for 3 h. The reaction mixture was diluted with 90% ethyl acetate in hexanes, washed three times with water, once with brine, dried over MgSO<sub>4</sub>, filtered, concentrated on a rotary evaporator, and purified <i>via</i> silica gel chromatography (30–100% EtOAc/hexanes) to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S113</b>) as a white foam-solid. Yield: 917 mg (1.64 mmol, 95%). MS (ESI) <i>m</i>/<i>z</i>: 559.1, 561.1 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.25–7.20 (m, 2H), 7.07–7.00 (m, 4H), 6.99–6.93 (m, 2H), 6.89 (dt, <i>J</i> = 8.2, 1.2 Hz, 2H), 5.62 (s, 1H), 5.19 (d, <i>J</i> = 5.7 Hz, 1H), 4.69 (t, <i>J</i> = 5.5 Hz, 1H), 4.41 (d, <i>J</i> = 13.4 Hz, 1H), 4.18 (dd, <i>J</i> = 13.5, 5.2 Hz, 1H), 3.84 (s, 3H), 3.27 (s, 3H), 2.77 (s, 3H).</div></div><div id="sec6_16_49_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i410" class="anchor-spacer"></div><h5 class="article-section__title" id="_i410"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-7-((dimethylamino)methyl)-1-methoxy-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-8,8a-diol (<b>177</b>)</h5><div class="NLM_p last">Borane dimethyl sulfide complex (1.47 mL, 15.5 mmol) was added to a stirred solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-8,8a-dihydroxy-1-methoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S113</b>) (866 mg, 1.55 mmol) in THF (30 mL) at room temperature under a reflux condenser under argon. Some bubbling was observed. The reaction mixture was heated at 40 °C under a reflux condenser under argon for 3 h. After cooling to room temperature, wet methanol (20 mL) was added dropwise slowly. The resulting clear colorless reaction mixture was stirred vigorously and heated at 65 °C under a reflux condenser under argon for 36 h. The reaction mixture was loaded onto five 2 g Strata X-C ion exchange columns from Phenomenex. The columns were washed sequentially with acetonitrile, methanol, and then a mixture of 5% ammonium hydroxide in methanol/dichloromethane. Eluent containing the desired product was concentrated on a rotary evaporator and dried under high vacuum at 40 °C to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-3-chloro-7-((dimethylamino)methyl)-1-methoxy-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-8,8a-diol (<b>177</b>) as a white solid. Yield: 742 mg (1.36 mmol, 88%). MS (ESI) <i>m</i>/<i>z</i>: 545.2, 547.3; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.26–7.21 (m, 2H), 7.13–7.05 (m, 4H), 7.04–6.94 (m, 3H), 6.86 (s, 1H), 5.56 (s, 1H), 5.15 (s, 1H), 4.43 (s, 1H), 3.84 (s, 3H), 3.70 (d, <i>J</i> = 14.1 Hz, 1H), 3.08 (ddt, <i>J</i> = 14.0, 10.0, 3.6 Hz, 1H), 2.56 (m, 1H), 2.19 (s, 6H), 1.94 (d, <i>J</i> = 11.1 Hz, 1H).</div></div><div id="sec6_16_49_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i411" class="anchor-spacer"></div><h5 class="article-section__title" id="_i411"> (5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Cyanophenyl)-7-((dimethylamino)methyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-3-carbonitrile ((−)-<b>53</b>)</h5><div class="NLM_p last"><i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-3-chloro-7-((dimethyl-amino)methyl)-1-methoxy-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-8,8a-diol (<b>177</b>) (165 mg, 0.300 mmol), zinc cyanide (213 mg, 1.81 mmol), zinc powder (19.8 mg, 0.300 mmol), <i>N</i>,<i>N</i>-dimethylformamide (0.9 mL), and water (0.09 mL) were combined in a microwave vial with a stir bar. The resulting mixture was sparged with argon gas for 5 min. Pd<sub>2</sub>dba<sub>3</sub> (27.7 mg, 0.030 mmol) and dppf (33.5 mg, 0.060 mmol) were added, and the resulting mixture was sparged with argon gas for 5 min. The reaction mixture was sealed, stirred, and microwaved at 120 °C for 2 h. The reaction mixture was diluted with DMSO and methanol, filtered, and purified <i>via</i> preparatory HPLC (15–35% acetonitrile in water with 0.1% TFA). Fractions containing the desired product were loaded onto three 2 g Strata X-C ion exchange columns from Phenomenex. The columns were washed sequentially with water, acetonitrile, methanol, and then a mixture of 10% ammonium hydroxide, 20% dichloromethane, and 70% methanol. Fractions containing the desired product were combined, concentrated on a rotary evaporator, and dried under high vacuum at 40 °C to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-cyanophenyl)-7-((dimethylamino)methyl)-8,8a-dihydroxy-1-methoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-3-carbonitrile (<i>rac</i>-<b>53</b>) as a white solid. Yield: 91.6 mg (0.190 mmol, 63%). The enantiomers were separated by chiral preparative SFC [Chiralpak IG (4.6 × 250) mm, 5μ] using CO<sub>2</sub>:EtOH/TEA (60:40:0.1) mobile phase. Peak 1 ((−)-<b>53</b>), [α]<sub>D</sub> −36.4° (<i>c</i> 0.3, CHCl<sub>3</sub>), <i>R</i><sub><i>t</i></sub> 1.52 min, ee >99%. MS (ESI) <i>m</i>/<i>z</i>: 483.15 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 483.2027 [M + H]<sup>+</sup>; found, 483.2043; UPLC: 99.75; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.61–7.51 (m, 3H), 7.37 (d, <i>J</i> = 8.2 Hz, 2H), 7.10–7.06 (m, 2H), 7.02–6.98 (m, 3H), 5.86 (s, 1H), 5.35 (br s, 1H), 4.51 (s, 1H), 3.89 (s, 3H), 3.79 (d, <i>J</i> = 13.9 Hz, 1H), 3.17–3.16 (m, 1H), 2.62–2.60 (m, 1H), 2.23 (br s, 6H). 1.98 (br s, 1H). Peak 2 ((+)-<b>53</b>), SOR (not recorded, solubility issues) <i>R</i><sub><i>t</i></sub> 2.04 min, ee >99%. MS (ESI) <i>m</i>/<i>z</i>: 483.15 [M + 1]<sup>+</sup>; UPLC: 99.78%.<sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.54–7.50 (m, 3H), 7.35 (d, <i>J</i> = 8.2 Hz, 2H), 7.09–7.06 (m, 2H), 7.01–6.88 (m, 3H), 5.85 (s, 1H), 5.42 (br s, 1H), 4.59 (d, <i>J</i> = 3.0 Hz, 1H), 3.89 (s, 3H), 3.77 (d, <i>J</i> = 14.0 Hz, 1H), 3.18–3.16 (m, 1H), 2.58–2.50 (m, 1H), 2.21 (s, 6H), 1.96 (d, <i>J</i> = 10.3 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 165.96, 162.09, 141.54, 136.44, 130.27, 129.89, 128.63, 128.32, 127.74, 126.47, 118.77, 117.48, 114.85, 109.21, 108.53, 103.63, 92.62, 77.17, 57.40, 56.20, 53.88, 45.77, 43.40.</div></div></div><div id="sec6_16_50" class="NLM_sec NLM_sec_level_3"><div id="ac_i412" class="anchor-spacer"></div><h4 class="article-section__title" id="_i412"> Synthesis of 4-((5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridin-5a-yl)benzonitrile ((−)-<b>eFT226</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0093.gif" alt="" id="dgr51" /></img><div id="sec6_16_50_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i413" class="anchor-spacer"></div><h5 class="article-section__title" id="_i413"> 2-(4-Bromophenyl)-3-hydroxy-5,7-dimethoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>175</b>)</h5><div class="NLM_p last">To a stirred solution of 2-(4-bromophenyl)-7-chloro-3-hydroxy-5-methoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>174</b>) (32.0 g, 83.6 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (320 mL) at room temperature, 25% sodium methoxide in methanol (180.4 mL, 170.5 g solution, 42.62 g NaOMe, 789.0 mmol) was added under argon. The reaction mixture was heated at 80 °C for 1 h under an argon atmosphere. After this time, the reaction mixture was poured in ice-cold water and acidified up to pH ≈ 6 using 6 N hydrochloric acid. The resulting precipitate was collected by filtration, washed with water, and dried under vacuum. The solid thus obtained was stirred in diethyl ether, filtered, and dried under vacuum to afford 2-(4-bromophenyl)-3-hydroxy-5,7-dimethoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>175</b>) as a beige solid. Yield: 31.0 g (82.0 mmol, 98%); MS (ESI) <i>m</i>/<i>z</i>: 378.04 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 9.66 (br s, 1H), 8.10 (d, <i>J</i> = 8.00 Hz, 2H), 7.75 (d, <i>J</i> = 9.6 Hz, 2H), 6.61 (s, 1H), 4.02 (s, 3H), 3.95 (s, 3H).</div></div><div id="sec6_16_50_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i414" class="anchor-spacer"></div><h5 class="article-section__title" id="_i414"> <i>rac</i>-Methyl (2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-2-(4-Bromophenyl)-5-hydroxy-6,8-dimethoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S114</b>)</h5><div class="NLM_p last">A suspension of 2-(4-bromophenyl)-3-hydroxy-5,7-dimethoxy-4<i>H</i>-pyrano[3,2-<i>c</i>]pyridin-4-one (<b>175</b>) (31.0 g, 82.0 mmol) and methyl cinnamate (<b>55</b>) (132.95 g, 819.72 mmol) in chloroform (1000 mL) and TFE (1000 mL) was stirred vigorously in a UV reactor flask and irradiated with 400 W UV light for 48 h at 0–5 °C. After this time, the reaction mixture became a clear solution. The reaction mixture was diluted with 3% triethylamine in ethyl acetate (100 mL) and then concentrated under reduced pressure. The residue was purified by column chromatography eluting with 0–100% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-methyl (2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-2-(4-bromophenyl)-5-hydroxy-6,8-dimethoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S114</b>) as a sticky light brown solid. Yield: 39 g, crude MS (ESI) <i>m</i>/<i>z</i>: 540.12 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_50_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i415" class="anchor-spacer"></div><h5 class="article-section__title" id="_i415"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-Bromophenyl)-8a-hydroxy-1,3-dimethoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S115</b>)</h5><div class="NLM_p last">To a stirred solution of crude <i>rac</i>-methyl (2<i>R</i>,3<i>S</i>,4<i>R</i>,5<i>R</i>)-2-(4-bromophenyl)-5-hydroxy-6,8-dimethoxy-10-oxo-3-phenyl-2,3,4,5-tetrahydro-2,5-methanooxepino[3,2-<i>c</i>]pyridine-4-carboxylate (<b>S114</b>) (39 g) in methanol (390 mL) at room temperature, 25% sodium methoxide (46.8 mL, 44.2 g solution, 11.1 g NaOMe, 205 mmol) was added under argon. The reaction mixture was heated at 80 °C for 45 min under an argon atmosphere. After this time, the reaction mixture was concentrated to dryness under vacuum, and the residue was partitioned between saturated aqueous ammonium chloride and ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated on a rotary evaporator, and dried under high vacuum to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-8a-hydroxy-1,3-dimethoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S115</b>) as an orange foam. Yield: 38.0 g, crude. MS (ESI) <i>m</i>/<i>z</i>: 540.21 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_50_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i416" class="anchor-spacer"></div><h5 class="article-section__title" id="_i416"> <i>rac</i>-Methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>178</b>)</h5><div class="NLM_p last">To a stirred solution of crude <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8a<i>R</i>)-5a-(4-bromophenyl)-8a-hydroxy-1,3-dimethoxy-8-oxo-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>S116</b>) (38.0 g) in acetonitrile (1140 mL) at 0 °C, acetic acid (42.5 mL, 44.6 g, 743 mmol) and sodium triacetoxyborohydride (74.52 g, 351.6 mmol) were added under an argon atmosphere. The reaction mixture was stirred at room temperature for 1 h. After completion of the reaction, the reaction mixture was diluted with saturated aqueous sodium bicarbonate solution (1000 mL) and partitioned between water and ethyl acetate. The organic layer was separated, washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to obtain the crude product, which was purified by column chromatography by eluting with 10–50% ethyl acetate in hexanes. The desired fractions were concentrated to afford <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>178</b>) as a white solid. Yield: 18.0 g (33.2 mmol, 40% over three steps). MS (ESI) <i>m</i>/<i>z</i>: 542.52 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.20 (d, <i>J</i> = 8.4 Hz, 2H), 7.07–6.96 (m, 5H), 6.93 (d, <i>J</i> = 7.3 Hz, 2H), 6.09 (s, 1H), 5.44–5.41 (m, 2H), 4.60 (s, 1H), 4.27 (d, <i>J</i> = 13.9 Hz, 1H), 4.04 (dd, <i>J</i> = 14.0 Hz, 4.9 Hz, 1H), 3.84 (s, 6H), 3.56 (s, 3H); MS (ESI) <i>m</i>/<i>z</i>: 542.52 [M + 1]<sup>+</sup>.</div></div><div id="sec6_16_50_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i417" class="anchor-spacer"></div><h5 class="article-section__title" id="_i417"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic Acid (<b>S116</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-methyl (5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylate (<b>178</b>) (14.80 g, 27.29 mmol) in tetrahydrofuran/methanol/water (2:1:1, 300 mL) at room temperature, lithium hydroxide (6.53 g, 273 mmol) was added. The reaction mixture was stirred at room temperature for 1 h. After completion of reaction, the reaction mixture was concentrated under reduced pressure, and the crude product was diluted with ethyl acetate. The reaction mixture was cooled to 0 °C and acidified to pH ≈ 6 using 6 N hydrochloric acid. The compound was extracted with ethyl acetate, the organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic acid (<b>S116</b>) as a white solid. Yield: 13.50 g (25.5 mmol, 93%); MS (ESI) <i>m</i>/<i>z</i>: 526.21 [M – 1]<sup>−</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 12.22 (br s, 1H), 7.19 (d, <i>J</i> = 8.4 Hz, 2H), 7.04 (d, <i>J</i> = 7.4 Hz, 2H), 6.99 (d, <i>J</i> = 8.4 Hz, 3H), 6.94 (d, <i>J</i> = 7.4 Hz, 2H), 6.08 (s, 1H), 5.35 (s, 1H), 5.59 (s, 1H), 4.24 (d, <i>J</i> = 14.00 Hz, 1H), 3.91 (d, <i>J</i> = 4.8 Hz, 2H), 3.84 (s, 6H).</div></div><div id="sec6_16_50_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i418" class="anchor-spacer"></div><h5 class="article-section__title" id="_i418"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S117</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxylic acid (<b>S116</b>) (13.50 g, 25.55 mmol) in dichloromethane (270 mL) at 0 °C, HATU (14.53 g, 38.21 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (14.20 mL, 10.51 g, 81.30 mmol) were added. This reaction mixture was stirred for 5 min. Then, dimethylamine hydrochloride (10.34 g, 126.8 mmol) was added, and the reaction mixture was stirred for 2 h at room temperature. After this time, the reaction mixture was diluted with water. The organic layer was separated and the aqueous layer was extracted with dichloromethane. The combined organic layers were washed with water and then brine, dried over anhydrous sodium sulfate, filtered, and concentrated to obtain the crude product, which was purified by Combi-flash (80 g, RedisSep column) using 1–8% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S117</b>) as a white solid. Yield: 13.0 g (23.4 mmol, 92%); MS (ESI) <i>m</i>/<i>z</i>: 555.61 [M + 1]<sup>+</sup>; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.21 (d, <i>J</i> = 8.7 Hz, 2H), 7.05–7.00 (m, 4H), 6.96 (d, <i>J</i> = 6.9 Hz, 1H), 6.86 (d, <i>J</i> = 7.2 Hz, 2H), 6.10 (s, 1H), 5.36 (s, 1H), 4.93 (d, <i>J</i> = 5.1 Hz, 1H), 4.69 (t, <i>J</i> = 5.5 Hz, 1H), 4.35 (d, <i>J</i> = 13.2 Hz, 1H), 4.15–4.10 (m, 1H), 3.84 (s, 6H), 3.26 (s, 3H), 2.76 (s, 3H).</div></div><div id="sec6_16_50_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i419" class="anchor-spacer"></div><h5 class="article-section__title" id="_i419"> <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-Bromophenyl)-7-((dimethylamino)methyl)-1,3-dimethoxy-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-8,8a-diol (<b>179</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>R</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-8,8a-dihydroxy-1,3-dimethoxy-<i>N</i>,<i>N</i>-dimethyl-6-phenyl-5a,7,8,8a-tetrahydro-6<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-7-carboxamide (<b>S118</b>) (6.00 g, 10.8 mmol) in tetrahydrofuran (120 mL) at 0 °C, borane dimethyl sulfide complex (8.21 g, 108 mmol) was added. The reaction mixture was stirred overnight at room temperature. After this time, the reaction mixture was quenched with methanol at 0 °C and then heated at 60 °C for 16 h. The solvents were concentrated to obtain the crude product, which was purified by Combi-flash (40 g, RediSep column) using 2–10% methanol in dichloromethane as the eluent. The desired fractions were concentrated to afford <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-7-((dimethylamino)methyl)-1,3-dimethoxy-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-8,8a-diol (<b>179</b>) as a white solid. Yield: 5.20 g (9.60 mmol, 89%). MS (ESI) <i>m</i>/<i>z</i>: 541.32 [M + 1]<sup>+</sup><sub>;</sub><sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.22 (d, <i>J</i> = 8.2 Hz, 2H), 7.11–7.06 (m, 5H), 7.01 (d, <i>J</i> = 6.9 Hz, 1H), 6.95 (d, <i>J</i> = 7.4 Hz, 2H), 6.02 (s, 1H), 5.31 (s, 1H), 4.93 (br s, 1H), 4.41 (d, <i>J</i> = 3.5 Hz, 1H), 3.84 (s, 6H), 3.66 (d, <i>J</i> = 14.0 Hz, 1H), 3.08 (s, 1H), 2.58 (s, 1H), 2.23 (s, 6H).</div></div><div id="sec6_16_50_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i420" class="anchor-spacer"></div><h5 class="article-section__title" id="_i420"> 4-((5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-7-((Dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridin-5a-yl)benzonitrile ((−)-<b>eFT226</b>)</h5><div class="NLM_p last">To a solution of <i>rac</i>-(5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-5a-(4-bromophenyl)-7-((dimethylamino)methyl)-1,3-dimethoxy-6-phenyl-5a,6,7,8-tetrahydro-8a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridine-8,8a-diol (<b>179</b>) (8.50 g, 15.7 mmol) in <i>N</i>,<i>N</i>- dimethylformamide (85.0 mL) at room temperature, zinc cyanide (11.06 g, 94.18 mmol) and zinc (0.103 g, 1.58 mmol) were added. The reaction mixture was degassed with argon for 15 min. Then, 1,1′-bis(diphenylphosphino) ferrocene (1.740 g, 3.139 mmol) and tris(dibenzylideneacetone)dipalladium (1.437 g, 1.569 mmol) were added to the reaction mixture, and degassing was continued for another 5 min. The mixture was heated at 130 °C for 5 h. After this time, the reaction mixture was cooled to room temperature and filtered through Celite. The filtrate was diluted with ethyl acetate and washed with water. The organic layer was separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to obtain the crude product which was purified by flash column chromatography eluting with 0–10% methanol in dichloromethane. The desired fractions were concentrated to afford <i>rac</i>-4-((5a<i>R</i>,6<i>S</i>,7<i>S</i>,8<i>R</i>,8a<i>S</i>)-7-((dimethylamino)methyl)-8,8a-dihydroxy-1,3-dimethoxy-6-phenyl-6,7,8,8a-tetrahydro-5a<i>H</i>-cyclopenta[4,5]furo[3,2-<i>c</i>]pyridin-5a-yl)benzonitrile (<i>rac</i>-<b>eFT226</b>) as a white solid. Yield: 5.60 g (11.5 mmol, 73%). The enantiomers were separated by chiral SFC [CHIRALPAK IG (4.6 × 250)mm,5μ] in Carbon dioxide/Methanol:Triethylamine (60:40:0.2), peak 1 (1.56 g, (−)-<b>eFT226</b>), <i>R</i><sub><i>t</i></sub> 1.958 min, ee: 99.74%, [α]<sub>D</sub> −38.8° (<i>c</i> 0.25, CHCl<sub>3</sub>); MS (ESI) <i>m</i>/<i>z</i>: 488.20 [M + 1]<sup>+</sup>; HRMS (ESI): calcd, 488.2180 [M + H]<sup>+</sup>; found, 488.2182; <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 7.49 (d, <i>J</i> = 8.4 Hz, 2H), 7.34 (d, <i>J</i> = 8.4 Hz, 2H), 7.08–7.04 (m, 2H), 7.00–6.95 (m, 3H), 6.04 (s, 1H), 5.40 (s, 1H), 5.03 (br s, 1H), 4.42 (d, <i>J</i> = 3.8 Hz, 1H), 3.84 (s, 6H), 3.73 (d, <i>J</i> = 14.0 Hz, 1H), 3.14–3.08 (m, 1H), 2.58–2.56 (m, 1H), 2.20 (s, 6H), 1.96 (d, <i>J</i> = 10.7 Hz, 1H); <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>): δ/ppm 169.04, 164.05, 159.31, 142.64, 136.96, 130.12, 128.61, 128.47, 127.69, 126.28, 118.92, 108.87, 103.44, 102.85, 92.22, 83.77, 77.12, 57.21, 56.40, 53.50, 52.85, 45.79, 43.43. Peak-2 (1.55 g, (+)-<b>eFT226</b>), <i>R</i><sub><i>t</i></sub> 3.90 min, ee: 99.66%, [α]<sub>D</sub> +34.5° (<i>c</i> 0.20, CHCl<sub>3</sub>); MS (ESI) <i>m</i>/<i>z</i>: 488.20 [M + 1]<sup>+</sup>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>): δ 7.49 (d, <i>J</i> = 8.5 Hz, 2H), 7.34 (d, <i>J</i> = 8.5 Hz, 2H), 7.08–7.04 (m, 2H), 7.00–6.95 (m, 3H), 6.04 (s, 1H), 5.40 (s, 1H), 5.03 (br s, 1H), 4.42 (d, <i>J</i> = 4.1 Hz, 1H), 3.84 (s, 6H), 3.73 (d, <i>J</i> = 14.1 Hz, 1H), 3.14–3.08 (m, 1H), 2.58–2.56 (m, 1H), 2.20 (s, 6H), 1.97 (d, <i>J</i> = 9.7 Hz, 1H).</div></div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i421"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00182" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75358" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75358" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00182?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00182</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic schemes, analytical data, and molecular formula strings for all compounds and molecular model PDB files (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 9 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 10 (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_003.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 12A(<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_004.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 12B (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_005.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 13A (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_006.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 13B (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_007.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 14A (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_008.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 14B (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_009.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_010.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_001.pdf">jm0c00182_si_001.pdf (29.62 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_002.csv">jm0c00182_si_002.csv (29.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_003.csv">jm0c00182_si_003.csv (0.58 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_004.csv">jm0c00182_si_004.csv (0.43 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_005.csv">jm0c00182_si_005.csv (0.43 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_006.csv">jm0c00182_si_006.csv (0.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_007.csv">jm0c00182_si_007.csv (0.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_008.csv">jm0c00182_si_008.csv (0.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_009.csv">jm0c00182_si_009.csv (0.75 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_010.csv">jm0c00182_si_010.csv (5.54 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.0c00182" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75138" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75138" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Justin T. Ernst</span> - <span class="hlFld-Affiliation affiliation">Inception
Therapeutics, 6175 Nancy
Ridge Drive, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-9229-3925" title="Orcid link">http://orcid.org/0000-0002-9229-3925</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#ed87889f839e99ad84838e889d998482839995c38e8280"><span class="__cf_email__" data-cfemail="6e040b1c001d1a2e07000d0b1e1a0701001a16400d0103">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peggy A. Thompson</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christian Nilewski</span> - <span class="hlFld-Affiliation affiliation">Genentech,
Inc., 1 DNA Way, South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Sprengeler</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samuel Sperry</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Garrick Packard</span> - <span class="hlFld-Affiliation affiliation">Inception
Therapeutics, 6175 Nancy
Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Theodore Michels</span> - <span class="hlFld-Affiliation affiliation">GossamerBio., 3013 Science Park Road, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Alan Xiang</span> - <span class="hlFld-Affiliation affiliation">WuXi
AppTec, 6114 Nancy Ridge Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chinh Tran</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher J. Wegerski</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Boreth Eam</span> - <span class="hlFld-Affiliation affiliation">Calporta
Therapeutics, 11099 North
Torrey Poines Rd., La Jolla, California 92037, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nathan P. Young</span> - <span class="hlFld-Affiliation affiliation">Casma
Therapeutics, 400 Technology Square, Cambridge, California 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah Fish</span> - <span class="hlFld-Affiliation affiliation">Plexium,
Inc., 11585 Sorrento
Valley Rd., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joan Chen</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Haleigh Howard</span> - <span class="hlFld-Affiliation affiliation">Providence
Portland Medical Center, 4805 NE Glisan Street, Portland, Oregon 97213, United
States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jocelyn Staunton</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jolene Molter</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeff Clarine</span> - <span class="hlFld-Affiliation affiliation">GossamerBio., 3013 Science Park Road, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andres Nevarez</span> - <span class="hlFld-Affiliation affiliation">Escient Pharmaceuticals, 10578 Science Center Dr., San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary G. Chiang</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3004-7400" title="Orcid link">http://orcid.org/0000-0003-3004-7400</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jim R. Appleman</span> - <span class="hlFld-Affiliation affiliation">Primmune Therapeutics, 3210 Merryfield Row, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin R. Webster</span> - <span class="hlFld-Affiliation affiliation">Frontier Medicines Corp., 151 Oyster Point Blvd., South San Francisco, California 94080, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Siegfried H. Reich</span> - <span class="hlFld-Affiliation affiliation">eFFECTOR
Therapeutics, 11180 Roselle
Street, San Diego, California 92121, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6840-2618" title="Orcid link">http://orcid.org/0000-0002-6840-2618</a></span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Ac</td><td class="NLM_def"><p class="first last">acetyl</p></td></tr><tr><td class="NLM_term">Bn</td><td class="NLM_def"><p class="first last">benzyl</p></td></tr><tr><td class="NLM_term">Bu</td><td class="NLM_def"><p class="first last">butyl</p></td></tr><tr><td class="NLM_term">dba</td><td class="NLM_def"><p class="first last">dibenzylideneacetone</p></td></tr><tr><td class="NLM_term">DBU</td><td class="NLM_def"><p class="first last">1,8-diazabicyclo(5.4.0)undec-7-ene</p></td></tr><tr><td class="NLM_term">DCC</td><td class="NLM_def"><p class="first last">dicyclohexylcarbodiimide</p></td></tr><tr><td class="NLM_term">DCM</td><td class="NLM_def"><p class="first last">dichloromethane</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last">diisopropylethylamine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMS</td><td class="NLM_def"><p class="first last">dimethylsulfide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-ferrocenediyl-bis(diphenylphosphine)</p></td></tr><tr><td class="NLM_term">EDC</td><td class="NLM_def"><p class="first last"><i>N</i>-(3-dimethylaminopropyl)-<i>N</i>′-ethylcarbodiimide</p></td></tr><tr><td class="NLM_term">Et</td><td class="NLM_def"><p class="first last">ethyl</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">1-[(bis(dimethylamino)methylene]-1<i>H</i>-1,2,3-triazolo[4,5-<i>b</i>]pyridinium 3-oxid hexafluorophosphate</p></td></tr><tr><td class="NLM_term">HOBt</td><td class="NLM_def"><p class="first last">1-hydroxybenzotriazole</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">LAH</td><td class="NLM_def"><p class="first last">lithium aluminum hydride</p></td></tr><tr><td class="NLM_term">Me</td><td class="NLM_def"><p class="first last">methyl</p></td></tr><tr><td class="NLM_term">MW</td><td class="NLM_def"><p class="first last">microwave</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">Ph</td><td class="NLM_def"><p class="first last">phenyl</p></td></tr><tr><td class="NLM_term">PMB</td><td class="NLM_def"><p class="first last"><i>para</i>-methoxybenzyl</p></td></tr><tr><td class="NLM_term">T3P</td><td class="NLM_def"><p class="first last">propylphosphonic anhydride</p></td></tr><tr><td class="NLM_term">TBS</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl</p></td></tr><tr><td class="NLM_term">TEA</td><td class="NLM_def"><p class="first last">triethylamine</p></td></tr><tr><td class="NLM_term">TFAA</td><td class="NLM_def"><p class="first last">trifluoroacetic anhydride</p></td></tr><tr><td class="NLM_term">TFE</td><td class="NLM_def"><p class="first last">trifluoroethanol</p></td></tr><tr><td class="NLM_term">Tf<sub>2</sub>O</td><td class="NLM_def"><p class="first last">triflic anhydride</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">UV</td><td class="NLM_def"><p class="first last">ultraviolet</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i423">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28016" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28016" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 42 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sendoel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levorse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dill, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schramek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, E.</span></span> <span> </span><span class="NLM_article-title">Translation from unconventional 5’ start sites drives tumour initiation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>541</i></span>,  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1038/nature21036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnature21036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=28077873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1CltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=541&publication_year=2017&pages=494-499&author=A.+Sendoelauthor=J.+G.+Dunnauthor=E.+H.+Rodriguezauthor=S.+Naikauthor=N.+C.+Gomezauthor=B.+Hurwitzauthor=J.+Levorseauthor=B.+D.+Dillauthor=D.+Schramekauthor=H.+Molinaauthor=J.+S.+Weissmanauthor=E.+Fuchs&title=Translation+from+unconventional+5%E2%80%99+start+sites+drives+tumour+initiation&doi=10.1038%2Fnature21036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Translation from unconventional 5' start sites drives tumor initiation</span></div><div class="casAuthors">Sendoel, Ataman; Dunn, Joshua G.; Rodriguez, Edwin H.; Naik, Shruti; Gomez, Nicholas C.; Hurwitz, Brian; Levorse, John; Dill, Brian D.; Schramek, Daniel; Molina, Henrik; Weissman, Jonathan S.; Fuchs, Elaine</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">541</span>
        (<span class="NLM_cas:issue">7638</span>),
    <span class="NLM_cas:pages">494-499</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We are just beginning to understand how translational control affects tumor initiation and malignancy.  Here we use an epidermis-specific, in vivo ribosome profiling strategy to investigate the translational landscape during the transition from normal homeostasis to malignancy.  Using a mouse model of inducible SOX2, which is broadly expressed in oncogenic RAS-assocd. cancers, we show that despite widespread redns. in translation and protein synthesis, certain oncogenic mRNAs are spared.  During tumor initiation, the translational app. is redirected towards unconventional upstream initiation sites, enhancing the translational efficiency of oncogenic mRNAs.  An in vivo RNA interference screen of translational regulators revealed that depletion of conventional eIF2 complexes has adverse effects on normal but not oncogenic growth.  Conversely, the alternative initiation factor eIF2A is essential for cancer progression, during which it mediates initiation at these upstream sites, differentially skewing translation and protein expression.  Our findings unveil a role for the translation of 5' untranslated regions in cancer, and expose new targets for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9_HpXewJ0wLVg90H21EOLACvtfcHk0li2CaQDCPDzhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1CltA%253D%253D&md5=58b04f0f20c9c6b80893bef52758e8c6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature21036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21036%26sid%3Dliteratum%253Aachs%26aulast%3DSendoel%26aufirst%3DA.%26aulast%3DDunn%26aufirst%3DJ.%2BG.%26aulast%3DRodriguez%26aufirst%3DE.%2BH.%26aulast%3DNaik%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DN.%2BC.%26aulast%3DHurwitz%26aufirst%3DB.%26aulast%3DLevorse%26aufirst%3DJ.%26aulast%3DDill%26aufirst%3DB.%2BD.%26aulast%3DSchramek%26aufirst%3DD.%26aulast%3DMolina%26aufirst%3DH.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DFuchs%26aufirst%3DE.%26atitle%3DTranslation%2520from%2520unconventional%25205%25E2%2580%2599%2520start%2520sites%2520drives%2520tumour%2520initiation%26jtitle%3DNature%26date%3D2017%26volume%3D541%26spage%3D494%26epage%3D499%26doi%3D10.1038%2Fnature21036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulea, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span> <span> </span><span class="NLM_article-title">Targeting the translation machinery in cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1038/nrd4505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnrd4505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=25743081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFOgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=261-278&author=M.+Bhatauthor=N.+Robichaudauthor=L.+Huleaauthor=N.+Sonenbergauthor=J.+Pelletierauthor=I.+Topisirovic&title=Targeting+the+translation+machinery+in+cancer&doi=10.1038%2Fnrd4505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the translation machinery in cancer</span></div><div class="casAuthors">Bhat, Mamatha; Robichaud, Nathaniel; Hulea, Laura; Sonenberg, Nahum; Pelletier, Jerry; Topisirovic, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-278</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulation of mRNA translation is a frequent feature of neoplasia.  Many oncogenes and tumor suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumor cells, independent of the genetic make-up of the cancer.  Therefore, therapeutic agents that target components of the protein synthesis app. hold promise as novel anticancer drugs that can overcome intra-tumor heterogeneity.  In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7a57QrdxxsbVg90H21EOLACvtfcHk0li2CaQDCPDzhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFOgs70%253D&md5=51625a521b1d4f18887142383a8d28e8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd4505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4505%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DM.%26aulast%3DRobichaud%26aufirst%3DN.%26aulast%3DHulea%26aufirst%3DL.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DTopisirovic%26aufirst%3DI.%26atitle%3DTargeting%2520the%2520translation%2520machinery%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D261%26epage%3D278%26doi%3D10.1038%2Fnrd4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Truitt, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span> <span> </span><span class="NLM_article-title">New frontiers in translational control of the cancer genome</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnrc.2016.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=27112207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Omsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=288-304&author=M.+L.+Truittauthor=D.+Ruggero&title=New+frontiers+in+translational+control+of+the+cancer+genome&doi=10.1038%2Fnrc.2016.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New frontiers in translational control of the cancer genome</span></div><div class="casAuthors">Truitt, Morgan L.; Ruggero, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">288-304</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past several years have seen dramatic leaps in our understanding of how gene expression is rewired at the translation level during tumorigenesis to support the transformed phenotype.  This work has been driven by an explosion in technol. advances and is revealing previously unimagined regulatory mechanisms that dictate functional expression of the cancer genome.  In this Review we discuss emerging trends and exciting new discoveries that reveal how this translational circuitry contributes to specific aspects of tumorigenesis and cancer cell function, with a particular focus on recent insights into the role of translational control in the adaptive response to oncogenic stress conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWAtdm1QpVuLVg90H21EOLACvtfcHk0lj6murThMtZoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Omsr0%253D&md5=ed2f746a30588ab8c00022d696861ceb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.27%26sid%3Dliteratum%253Aachs%26aulast%3DTruitt%26aufirst%3DM.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26atitle%3DNew%2520frontiers%2520in%2520translational%2520control%2520of%2520the%2520cancer%2520genome%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D288%26epage%3D304%26doi%3D10.1038%2Fnrc.2016.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, A. E.</span></span> <span> </span><span class="NLM_article-title">The biological and therapeutic relevance of mRNA translation in cancer</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2011.16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnrclinonc.2011.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=21364523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltl2qsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=280-291&author=S.+P.+Blagdenauthor=A.+E.+Willis&title=The+biological+and+therapeutic+relevance+of+mRNA+translation+in+cancer&doi=10.1038%2Fnrclinonc.2011.16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The biological and therapeutic relevance of mRNA translation in cancer</span></div><div class="casAuthors">Blagden, Sarah P.; Willis, Anne E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">280-291</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The translation of mRNA is a tightly regulated process that is necessary for protein synthesis, and dysregulation of this process is assocd. with the development and progression of cancers.  This Review highlights the components of translation machinery and how alterations in these proteins and their principle upstream signaling pathways can impact on cancer.  Drugs that are currently being developed to target the translational machinery are also discussed.  Protein synthesis is a tightly regulated process that enables post-transcriptional control of gene expression.  Dysregulation of this process is assocd. with the development and progression of cancers because components of the translational machinery function at the point of convergence of aberrant cell signaling pathways.  Drugs designed to inhibit mRNA translation are currently in preclin. and early clin. development, and are likely to provide effective anticancer strategies in the future.  In this Review, we summarize the main components of translation and describe how alterations in these proteins and their principle upstream signaling pathways can impact on cancer.  The first inhibitors of translation, drugs designed to target eIF4E, have been trialed in hematol. malignancies, while antisense oligonucleotides against eIF4E are also due to enter clin. trials.  Here, we discuss the mode of action of drugs designed to inhibit mRNA translation and other promising therapies that are in preclin. development with the aim of becoming anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOj8bPdXMpxbVg90H21EOLACvtfcHk0lj6murThMtZoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltl2qsLc%253D&md5=c1768ad1220ec24f8ee3eee1fed27acb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.16%26sid%3Dliteratum%253Aachs%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26aulast%3DWillis%26aufirst%3DA.%2BE.%26atitle%3DThe%2520biological%2520and%2520therapeutic%2520relevance%2520of%2520mRNA%2520translation%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D280%26epage%3D291%26doi%3D10.1038%2Fnrclinonc.2011.16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">Targeting the eIF4F translation initiation complex: a critical nexus for cancer development</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-14-2789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1158%2F0008-5472.can-14-2789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=25593033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=250-263&author=J.+Pelletierauthor=J.+Graffauthor=D.+Ruggeroauthor=N.+Sonenberg&title=Targeting+the+eIF4F+translation+initiation+complex%3A+a+critical+nexus+for+cancer+development&doi=10.1158%2F0008-5472.can-14-2789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development</span></div><div class="casAuthors">Pelletier, Jerry; Graff, Jeremy; Ruggero, Davide; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-263</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Elevated protein synthesis is an important feature of many cancer cells and often arises as a consequence of increased signaling flux channeled to eukaryotic initiation factor 4F (eIF4F), the key regulator of the mRNA-ribosome recruitment phase of translation initiation.  In many cellular and preclin. models of cancer, eIF4F deregulation results in changes in translational efficiency of specific mRNA classes.  Importantly, many of these mRNAs code for proteins that potently regulate crit. cellular processes, such as cell growth and proliferation, enhanced cell survival and cell migration that ultimately impinge on several hallmarks of cancer, including increased angiogenesis, deregulated growth control, enhanced cellular survival, epithelial-to-mesenchymal transition, invasion, and metastasis.  By being positioned as the mol. nexus downstream of key oncogenic signaling pathways (e.g., Ras, PI3K/AKT/TOR, and MYC), eIF4F serves as a direct link between important steps in cancer development and translation initiation.  Identification of mRNAs particularly responsive to elevated eIF4F activity that typifies tumorigenesis underscores the crit. role of eIF4F in cancer and raises the exciting possibility of developing new-in-class small mols. targeting translation initiation as antineoplastic agents.  Cancer Res; 75(2); 250-63. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrANjeFfkVBWLVg90H21EOLACvtfcHk0lipPNemy3dMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWjsQ%253D%253D&md5=2b463beb4fa91704c0eb0ea32f9f2d8f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-14-2789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-14-2789%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DJ.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DTargeting%2520the%2520eIF4F%2520translation%2520initiation%2520complex%253A%2520a%2520critical%2520nexus%2520for%2520cancer%2520development%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D250%26epage%3D263%26doi%3D10.1158%2F0008-5472.can-14-2789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span> <span> </span><span class="NLM_article-title">eIF4F: A retrospective</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">24091</span>– <span class="NLM_lpage">24099</span>, <span class="refDoi"> DOI: 10.1074/jbc.r115.675280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1074%2Fjbc.r115.675280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=26324716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2kurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=24091-24099&author=W.+C.+Merrick&title=eIF4F%3A+A+retrospective&doi=10.1074%2Fjbc.r115.675280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">eIF4F: A Retrospective</span></div><div class="casAuthors">Merrick, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">24091-24099</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The original purifn. of the heterotrimeric eIF4F was published over 30 years ago (Grifo, J. A., Tahara, S. M., Morgan, M. A., Shatkin, A. J., and Merrick, W. C. (1983) J. Biol. Chem. 258, 5804-5810).  Since that time, numerous studies have been performed with the three proteins specifically required for the translation initiation of natural mRNAs, eIF4A, eIF4B, and eIF4F.  These have involved enzymic and structural studies of the proteins and a no. of site-directed mutagenesis studies.  The regulation of translation exhibited through the mammalian target of rapamycin (mTOR) pathway is predominately seen as the phosphorylation of 4E-BP, an inhibitor of protein synthesis that functions by binding to the cap binding subunit of eIF4F (eIF4E).  A hypothesis that requires the disassembly of eIF4F during translation initiation to yield free subunits (eIF4A, eIF4E, and eIF4G) is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQWuUV9H1Z7Vg90H21EOLACvtfcHk0lipPNemy3dMyA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2kurfP&md5=22603cc62fa11d6d64b3f8b024bdeea8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.r115.675280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.r115.675280%26sid%3Dliteratum%253Aachs%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26atitle%3DeIF4F%253A%2520A%2520retrospective%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D24091%26epage%3D24099%26doi%3D10.1074%2Fjbc.r115.675280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, E. Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, I. N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaghafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of pyridoneaminal eFT508 targeting dysregulated translation by selective mitogenactivated protein kinase interacting kinases 1 and 2 (MNK1/2) inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3516</span>– <span class="NLM_lpage">3540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3516-3540&author=S.+H.+Reichauthor=P.+A.+Sprengelerauthor=G.+G.+Chiangauthor=J.+R.+Applemanauthor=J.+Chenauthor=J.+Clarineauthor=B.+Eamauthor=J.+T.+Ernstauthor=Q.+Hanauthor=V.+K.+Goelauthor=E.+Z.+R.+Hanauthor=V.+Huangauthor=I.+N.+J.+Hungauthor=A.+Jemisonauthor=K.+A.+Jessenauthor=J.+Molterauthor=D.+Murphyauthor=M.+Nealauthor=G.+S.+Parkerauthor=M.+Shaghafiauthor=S.+Sperryauthor=J.+Stauntonauthor=C.+R.+Stumpfauthor=P.+A.+Thompsonauthor=C.+Tranauthor=S.+E.+Webberauthor=C.+J.+Wegerskiauthor=H.+Zhengauthor=K.+R.+Webster&title=Structure-based+design+of+pyridoneaminal+eFT508+targeting+dysregulated+translation+by+selective+mitogenactivated+protein+kinase+interacting+kinases+1+and+2+%28MNK1%2F2%29+inhibition&doi=10.1021%2Facs.jmedchem.7b01795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</span></div><div class="casAuthors">Reich, Siegfried H.; Sprengeler, Paul A.; Chiang, Gary G.; Appleman, James R.; Chen, Joan; Clarine, Jeff; Eam, Boreth; Ernst, Justin T.; Han, Qing; Goel, Vikas K.; Han, Edward Z. R.; Huang, Vera; Hung, Ivy N. J.; Jemison, Adrianna; Jessen, Katti A.; Molter, Jolene; Murphy, Douglas; Neal, Melissa; Parker, Gregory S.; Shaghafi, Michael; Sperry, Samuel; Staunton, Jocelyn; Stumpf, Craig R.; Thompson, Peggy A.; Tran, Chinh; Webber, Stephen E.; Wegerski, Christopher J.; Zheng, Hong; Webster, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3516-3540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulated translation of mRNA plays a major role in tumorigenesis.  Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphorylation of eIF4E and other mRNA binding proteins.  Modulation of these key effector proteins regulates mRNA, which controls tumor/stromal cell signaling.  Compd. 23 (eFT508, 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro-[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride), an exquisitely selective, potent dual MNK1/2 inhibitor, was designed to assess the potential for control of oncogene signaling at the level of mRNA translation.  The crystal structure-guided design leverages stereoelectronic interactions unique to MNK culminating in a novel pyridone-aminal structure described for the first time in the kinase literature.  Compd. 23 has potent in vivo antitumor activity in models of diffuse large cell B-cell lymphoma and solid tumors, suggesting that controlling dysregulated translation has real therapeutic potential.  Compd. 23 is currently being evaluated in Phase 2 clin. trials in solid tumors and lymphoma.  Compd. 23 is the first highly selective dual MNK inhibitor targeting dysregulated translation being assessed clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp-3GOuZu8bVg90H21EOLACvtfcHk0lh54J4OT2hwbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D&md5=1254b674aa7e6d2037a06bc10e64e4da</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01795%26sid%3Dliteratum%253Aachs%26aulast%3DReich%26aufirst%3DS.%2BH.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DEam%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DGoel%26aufirst%3DV.%2BK.%26aulast%3DHan%26aufirst%3DE.%2BZ.%2BR.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DHung%26aufirst%3DI.%2BN.%2BJ.%26aulast%3DJemison%26aufirst%3DA.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DNeal%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DG.%2BS.%26aulast%3DShaghafi%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DStumpf%26aufirst%3DC.%2BR.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DStructure-based%2520design%2520of%2520pyridoneaminal%2520eFT508%2520targeting%2520dysregulated%2520translation%2520by%2520selective%2520mitogenactivated%2520protein%2520kinase%2520interacting%2520kinases%25201%2520and%25202%2520%2528MNK1%252F2%2529%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3516%26epage%3D3540%26doi%3D10.1021%2Facs.jmedchem.7b01795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span> <span> </span><span class="NLM_article-title">eFT508, a potent and selective mitogen-activated protein kinase interacting kinase (MNK) 1 and 2 inhibitor, is efficacious in preclinical models of diffuse large B-cell lymphoma (DLBCL)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1554</span>, <span class="refDoi"> DOI: 10.1182/blood.v126.23.1554.1554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1182%2Fblood.V126.23.1554.1554" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=1554&author=K.+R.+Websterauthor=V.+K.+Goelauthor=I.+N.+Hungauthor=G.+S.+Parkerauthor=J.+Stauntonauthor=M.+Nealauthor=J.+Molterauthor=G.+G.+Chiangauthor=K.+A.+Jessenauthor=C.+J.+Wegerskiauthor=S.+Sperryauthor=V.+Huangauthor=J.+Chenauthor=P.+A.+Thompsonauthor=J.+R.+Applemanauthor=S.+E.+Webberauthor=P.+A.+Sprengelerauthor=S.+H.+Reich&title=eFT508%2C+a+potent+and+selective+mitogen-activated+protein+kinase+interacting+kinase+%28MNK%29+1+and+2+inhibitor%2C+is+efficacious+in+preclinical+models+of+diffuse+large+B-cell+lymphoma+%28DLBCL%29&doi=10.1182%2Fblood.v126.23.1554.1554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood.V126.23.1554.1554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V126.23.1554.1554%26sid%3Dliteratum%253Aachs%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DGoel%26aufirst%3DV.%2BK.%26aulast%3DHung%26aufirst%3DI.%2BN.%26aulast%3DParker%26aufirst%3DG.%2BS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DM.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DReich%26aufirst%3DS.%2BH.%26atitle%3DeFT508%252C%2520a%2520potent%2520and%2520selective%2520mitogen-activated%2520protein%2520kinase%2520interacting%2520kinase%2520%2528MNK%2529%25201%2520and%25202%2520inhibitor%252C%2520is%2520efficacious%2520in%2520preclinical%2520models%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%2520%2528DLBCL%2529%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D1554%26doi%3D10.1182%2Fblood.v126.23.1554.1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dreas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabritius, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzozka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzymski, T.</span></span> <span> </span><span class="NLM_article-title">Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: Recent progress in the development of MNK inhibitors</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170203123427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.2174%2F0929867324666170203123427" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1-28&author=A.+Dreasauthor=M.+Mikulskiauthor=M.+Milikauthor=C.-H.+Fabritiusauthor=K.+Brzozkaauthor=T.+Rzymski&title=Mitogen-activated+protein+kinase+%28MAPK%29+interacting+kinases+1+and+2+%28MNK1+and+MNK2%29+as+targets+for+cancer+therapy%3A+Recent+progress+in+the+development+of+MNK+inhibitors&doi=10.2174%2F0929867324666170203123427"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170203123427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170203123427%26sid%3Dliteratum%253Aachs%26aulast%3DDreas%26aufirst%3DA.%26aulast%3DMikulski%26aufirst%3DM.%26aulast%3DMilik%26aufirst%3DM.%26aulast%3DFabritius%26aufirst%3DC.-H.%26aulast%3DBrzozka%26aufirst%3DK.%26aulast%3DRzymski%26aufirst%3DT.%26atitle%3DMitogen-activated%2520protein%2520kinase%2520%2528MAPK%2529%2520interacting%2520kinases%25201%2520and%25202%2520%2528MNK1%2520and%2520MNK2%2529%2520as%2520targets%2520for%2520cancer%2520therapy%253A%2520Recent%2520progress%2520in%2520the%2520development%2520of%2520MNK%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D1%26epage%3D28%26doi%3D10.2174%2F0929867324666170203123427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polunovsky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Cap-dependent translation ignition factor eIF4E: An emerging anticancer drug target</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1002/med.21260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fmed.21260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=22495651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVegsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=786-814&author=Y.+Jiaauthor=V.+Polunovskyauthor=P.+B.+Bittermanauthor=C.+R.+Wagner&title=Cap-dependent+translation+ignition+factor+eIF4E%3A+An+emerging+anticancer+drug+target&doi=10.1002%2Fmed.21260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cap-Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target</span></div><div class="casAuthors">Jia, Yan; Polunovsky, Vitaly; Bitterman, Peter B.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">786-814</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cancer cells tend to be more highly dependent on cap-dependent translation than normal tissues.  Thus, proteins involved in the initiation of cap-dependent translation have emerged as potential anti-cancer drug targets.  Cap-dependent translation is initiated by the binding of the factor eIF4E to the cap domain of mRNA.  Detailed x-ray crystal and NMR structures are available for eIF4E in assocn. with cap-analogs, as well as domains of other initiation factors.  This review will summarize efforts to design potential antagonist of eIF4E that could be used as new pharmacol. tools and anti-cancer agents and.  Insights drawn from these studies should aid in the design of future inhibitors of eIF4E dependent translation initiation. © 2012 Wiley Periodicals, Inc.  Med Res Rev., 32, No. 4, 786-814, 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sMRELR1u_7Vg90H21EOLACvtfcHk0ljPhBAssSlD8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVegsrk%253D&md5=11e00c0ba286838a71b3ec3684e53e42</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fmed.21260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21260%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DPolunovsky%26aufirst%3DV.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DCap-dependent%2520translation%2520ignition%2520factor%2520eIF4E%253A%2520An%2520emerging%2520anticancer%2520drug%2520target%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2012%26volume%3D32%26spage%3D786%26epage%3D814%26doi%3D10.1002%2Fmed.21260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffries, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimaraes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design, synthesis, and evaluation of guanine derived inhibitors of the eIF4E mRNA-cap interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3837</span>– <span class="NLM_lpage">3851</span>, <span class="refDoi"> DOI: 10.1021/jm300037x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300037x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVWmurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3837-3851&author=X.+Chenauthor=D.+J.+Kopeckyauthor=J.+Mihalicauthor=S.+Jeffriesauthor=X.+Minauthor=J.+Heathauthor=J.+Deignanauthor=S.+Laiauthor=Z.+Fuauthor=C.+Guimaraesauthor=S.+Shenauthor=S.+Liauthor=S.+Johnstoneauthor=S.+Thibaultauthor=H.+Xuauthor=M.+Cardozoauthor=W.+Shenauthor=N.+Walkerauthor=F.+Kayserauthor=Z.+Wang&title=Structure-guided+design%2C+synthesis%2C+and+evaluation+of+guanine+derived+inhibitors+of+the+eIF4E+mRNA-cap+interaction&doi=10.1021%2Fjm300037x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA-Cap Interaction</span></div><div class="casAuthors">Chen, Xiaoqi; Kopecky, David J.; Mihalic, Jeff; Jeffries, Shawn; Min, Xiaoshan; Heath, Julie; Deignan, Jeff; Lai, SuJen; Fu, Zice; Guimaraes, Cristiano; Shen, Shanling; Li, Shyun; Johnstone, Sheree; Thibault, Stephen; Xu, Haoda; Cardozo, Mario; Shen, Wang; Walker, Nigel; Kayser, Frank; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3837-3851</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The eukaryotic initiation factor 4E (eIF4E) plays a central role in the initiation of gene translation and subsequent protein synthesis by binding the 5' terminal mRNA cap structure.  We designed and synthesized a series of novel compds. that display potent binding affinity against eIF4E despite their lack of a ribose moiety, phosphate, and pos. charge as present in m7-GMP.  The biochem. activity of compd. 33 (I) is 95 nM for eIF4E in an SPA binding assay.  More importantly, the compd. has an IC50 of 2.5 μM for inhibiting cap-dependent mRNA translation in a rabbit reticular cell ext. assay (RRL-IVT).  This series of potent, truncated analogs could serve as a promising new starting point toward the design of neutral eIF4E inhibitors with physicochem. properties suitable for cellular activity assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogPh6Sr7j9bVg90H21EOLACvtfcHk0lippkrjbMzbqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVWmurw%253D&md5=4e301c1c45a7770104553625e12e4a25</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm300037x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300037x%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKopecky%26aufirst%3DD.%2BJ.%26aulast%3DMihalic%26aufirst%3DJ.%26aulast%3DJeffries%26aufirst%3DS.%26aulast%3DMin%26aufirst%3DX.%26aulast%3DHeath%26aufirst%3DJ.%26aulast%3DDeignan%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DS.%26aulast%3DFu%26aufirst%3DZ.%26aulast%3DGuimaraes%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DKayser%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructure-guided%2520design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520guanine%2520derived%2520inhibitors%2520of%2520the%2520eIF4E%2520mRNA-cap%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3837%26epage%3D3851%26doi%3D10.1021%2Fjm300037x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parsyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svitkin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahbazian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gkogkas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">mRNA helicases: the tacticians of translational control</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1038/nrm3083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnrm3083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=21427765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Cqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=235-245&author=A.+Parsyanauthor=Y.+Svitkinauthor=D.+Shahbazianauthor=C.+Gkogkasauthor=P.+Laskoauthor=W.+C.+Merrickauthor=N.+Sonenberg&title=mRNA+helicases%3A+the+tacticians+of+translational+control&doi=10.1038%2Fnrm3083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">mRNA helicases: the tacticians of translational control</span></div><div class="casAuthors">Parsyan, Armen; Svitkin, Yuri; Shahbazian, David; Gkogkas, Christos; Lasko, Paul; Merrick, William C.; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-245</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The translation initiation step in eukaryotes is highly regulated and rate-limiting.  During this process, the 40S ribosomal subunit is usually recruited to the 5' terminus of the mRNA.  It then migrates towards the initiation codon, where it is joined by the 60S ribosomal subunit to form the 80S initiation complex.  Secondary structures in the 5' untranslated region (UTR) can impede binding and movement of the 40S ribosome.  The canonical eukaryotic translation initiation factor eIF4A (also known as DDX2), together with its accessory proteins eIF4B and eIF4H, is thought to act as a helicase that unwinds secondary structures in the mRNA 5' UTR.  Growing evidence suggests that other helicases are also important for translation initiation and may promote the scanning processivity of the 40S subunit, synergize with eIF4A to 'melt' secondary structures or facilitate translation of a subset of mRNAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5r1Ei2HDUf7Vg90H21EOLACvtfcHk0lippkrjbMzbqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Cqs7o%253D&md5=4f68eebff087ecff298216068c8824fa</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrm3083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3083%26sid%3Dliteratum%253Aachs%26aulast%3DParsyan%26aufirst%3DA.%26aulast%3DSvitkin%26aufirst%3DY.%26aulast%3DShahbazian%26aufirst%3DD.%26aulast%3DGkogkas%26aufirst%3DC.%26aulast%3DLasko%26aufirst%3DP.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DmRNA%2520helicases%253A%2520the%2520tacticians%2520of%2520translational%2520control%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D235%26epage%3D245%26doi%3D10.1038%2Fnrm3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of translation targeting eukaryotic translation initiation factor 4A</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>511</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/b978-0-12-396546-2.00020-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2FB978-0-12-396546-2.00020-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=22713332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2012&pages=437-461&author=R.+Cencicauthor=G.+Galicia-V%C3%A1zquezauthor=J.+Pelletier&title=Inhibitors+of+translation+targeting+eukaryotic+translation+initiation+factor+4A&doi=10.1016%2Fb978-0-12-396546-2.00020-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of translation targeting eukaryotic translation initiation factor 4A</span></div><div class="casAuthors">Cencic, Regina; Galicia-Vazquez, Gabriela; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">RNA Helicases</span>),
    <span class="NLM_cas:pages">437-461</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  DEAD-box RNA helicases eIF4AI and eIF4AII play key roles in recruiting ribosomes to mRNA templates during eukaryotic translation initiation.  Small-mol. inhibitors of eIF4AI and eIF4AII have been useful for chem. dissecting their role in translation in vitro and in vivo.  Here, the authors describe a screen performed on a small focused library of kinase inhibitors to identify a novel helicase inhibitor.  The authors describe assays that have been crit. for characterizing novel RNA helicase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3w-59Gyz4zbVg90H21EOLACvtfcHk0lippkrjbMzbqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChsbnI&md5=29a39b2b93cc52440f316cdd3e2c1e47</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396546-2.00020-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396546-2.00020-6%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DInhibitors%2520of%2520translation%2520targeting%2520eukaryotic%2520translation%2520initiation%2520factor%25204A%26jtitle%3DMethods%2520Enzymol.%26date%3D2012%26volume%3D511%26spage%3D437%26epage%3D461%26doi%3D10.1016%2Fb978-0-12-396546-2.00020-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescarbeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillotson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hearn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slocum, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helble, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahadoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wylie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. R.</span></span> <span> </span><span class="NLM_article-title">Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8859</span>– <span class="NLM_lpage">8878</span>, <span class="refDoi"> DOI: 10.1021/jm3011542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3011542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8859-8878&author=T.+Liuauthor=S.+J.+Nairauthor=A.+Lescarbeauauthor=J.+Belaniauthor=S.+Pelusoauthor=J.+Conleyauthor=B.+Tillotsonauthor=P.+O%E2%80%99Hearnauthor=S.+Smithauthor=K.+Slocumauthor=K.+Westauthor=J.+Helbleauthor=M.+Douglasauthor=A.+Bahadoorauthor=J.+Aliauthor=K.+McGovernauthor=C.+Fritzauthor=V.+J.+Palombellaauthor=A.+Wylieauthor=A.+C.+Castroauthor=M.+R.+Tremblay&title=Synthetic+silvestrol+analogues+as+potent+and+selective+protein+synthesis+inhibitors&doi=10.1021%2Fjm3011542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors</span></div><div class="casAuthors">Liu, Tao; Nair, Somarajan J.; Lescarbeau, Andre; Belani, Jitendra; Peluso, Stephane; Conley, James; Tillotson, Bonnie; O'Hearn, Patrick; Smith, Sherri; Slocum, Kelly; West, Kip; Helble, Joseph; Douglas, Mark; Bahadoor, Adilah; Ali, Janid; McGovern, Karen; Fritz, Christian; Palombella, Vito J.; Wylie, Andrew; Castro, Alfredo C.; Tremblay, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8859-8878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Misregulation of protein translation plays a crit. role in human cancer pathogenesis at many levels.  Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex.  Silvestrol has a complex chem. structure whose functional group requirements have not been systematically investigated.  Moreover, silvestrol has limited development potential due to poor drug-like properties.  Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position.  The ability of silvestrol and analogs to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5'-untranslated region UTR) relative to simple 5'UTR was detd. by a cellular reporter assay.  Simplified analogs of silvestrol such as compds. I and II were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonc7fkDD0PT7Vg90H21EOLACvtfcHk0lg1fWxWcJJYow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejsrjK&md5=158ef1ae2b7fb17aa9cf325e8e452f0f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm3011542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3011542%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DNair%26aufirst%3DS.%2BJ.%26aulast%3DLescarbeau%26aufirst%3DA.%26aulast%3DBelani%26aufirst%3DJ.%26aulast%3DPeluso%26aufirst%3DS.%26aulast%3DConley%26aufirst%3DJ.%26aulast%3DTillotson%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Hearn%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DSlocum%26aufirst%3DK.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DHelble%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DM.%26aulast%3DBahadoor%26aufirst%3DA.%26aulast%3DAli%26aufirst%3DJ.%26aulast%3DMcGovern%26aufirst%3DK.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DWylie%26aufirst%3DA.%26aulast%3DCastro%26aufirst%3DA.%2BC.%26aulast%3DTremblay%26aufirst%3DM.%2BR.%26atitle%3DSynthetic%2520silvestrol%2520analogues%2520as%2520potent%2520and%2520selective%2520protein%2520synthesis%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8859%26epage%3D8878%26doi%3D10.1021%2Fjm3011542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: Synthetic and biological studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1021/jm201263k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201263k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGmt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=558-562&author=C.+M.+Rodrigoauthor=R.+Cencicauthor=S.+P.+Rocheauthor=J.+Pelletierauthor=J.+A.+Porco&title=Synthesis+of+rocaglamide+hydroxamates+and+related+compounds+as+eukaryotic+translation+inhibitors%3A+Synthetic+and+biological+studies&doi=10.1021%2Fjm201263k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Rocaglamide Hydroxamates and Related Compounds as Eukaryotic Translation Inhibitors: Synthetic and Biological Studies</span></div><div class="casAuthors">Rodrigo, Christina M.; Cencic, Regina; Roche, Stephane P.; Pelletier, Jerry; Porco, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">558-562</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Racemic and nonracemic rocaglamide hydroxamates and racemic roglamate-derived heteroaryl ketones such as (-)-I were prepd. as silvestrol analogs for potential use as antitumor agents.  (-)-I inhibited protein synthesis in vitro and in vivo with similar activity to silvestrol by dose-dependent increases in the binding of RNA to eukaryotic initiation factor 4A I/II (EIF4A I/II); its soly., permeability, plasma and liver microsomal stabilities, and antitumor activities were detd.  (-)-I inhibited Eμ-Myc driven lymphomas in concert with doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojyZoAcZsiWbVg90H21EOLACvtfcHk0lg1fWxWcJJYow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGmt7fN&md5=61697bd2005df787feaf025c388dab24</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm201263k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201263k%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DC.%2BM.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DRoche%26aufirst%3DS.%2BP.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520of%2520rocaglamide%2520hydroxamates%2520and%2520related%2520compounds%2520as%2520eukaryotic%2520translation%2520inhibitors%253A%2520Synthetic%2520and%2520biological%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D558%26epage%3D562%26doi%3D10.1021%2Fjm201263k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thuaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiddon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresteil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Novel flavaglines displaying improved cytotoxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1021/jm101318b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101318b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGltrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=411-415&author=F.+Thuaudauthor=N.+Ribeiroauthor=C.+Gaiddonauthor=T.+Cresteilauthor=L.+D%C3%A9saubry&title=Novel+flavaglines+displaying+improved+cytotoxicity&doi=10.1021%2Fjm101318b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Flavaglines Displaying Improved Cytotoxicity</span></div><div class="casAuthors">Thuaud, Frederic; Ribeiro, Nigel; Gaiddon, Christian; Cresteil, Thierry; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">411-415</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel flavagline analogs were synthesized and examd. with respect to their cytotoxicity.  Structural features crit. to the potential of this class of anticancer natural products were unraveled.  We demonstrated, in particular, that the introduction of substituents at C-2 has a deleterious effect on multidrug resistance.  Replacement of the hydroxy at C-1 by an aminoformyl with the opposite configuration enhances the cytotoxicity and led to a compd. that reduces tumors growth in an allograft model at nontoxic doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWhBP9YJrszrVg90H21EOLACvtfcHk0lhpffGBImTn_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGltrvP&md5=55c09683c985fea35a885d317368c4d2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm101318b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101318b%26sid%3Dliteratum%253Aachs%26aulast%3DThuaud%26aufirst%3DF.%26aulast%3DRibeiro%26aufirst%3DN.%26aulast%3DGaiddon%26aufirst%3DC.%26aulast%3DCresteil%26aufirst%3DT.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DNovel%2520flavaglines%2520displaying%2520improved%2520cytotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D411%26epage%3D415%26doi%3D10.1021%2Fjm101318b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzacasa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span> <span> </span><span class="NLM_article-title">Simplified silvestrol analogues with potent cytotoxic activity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201400024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fcmdc.201400024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=24677741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1556-1566&author=B.+C.+Hawkinsauthor=L.+M.+Lindqvistauthor=D.+Nhuauthor=P.+P.+Sharpauthor=D.+Segalauthor=A.+K.+Powellauthor=M.+Campbellauthor=E.+Ryanauthor=J.+M.+Chambersauthor=J.+M.+Whiteauthor=M.+A.+Rizzacasaauthor=G.+Lesseneauthor=D.+C.+S.+Huangauthor=C.+J.+Burns&title=Simplified+silvestrol+analogues+with+potent+cytotoxic+activity&doi=10.1002%2Fcmdc.201400024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Simplified Silvestrol Analogues with Potent Cytotoxic Activity</span></div><div class="casAuthors">Hawkins, Bill C.; Lindqvist, Lisa M.; Nhu, Duong; Sharp, Phillip P.; Segal, David; Powell, Andrew K.; Campbell, Michael; Ryan, Eileen; Chambers, Jennifer M.; White, Jonathan M.; Rizzacasa, Mark A.; Lessene, Guillaume; Huang, David C. S.; Burns, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1556-1566</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The complex natural products silvestrol (1) and episilvestrol (2) are inhibitors of translation initiation through binding to the DEAD-box helicase eukaryotic initiation factor 4A (eIF4A).  Both compds. are potently cytotoxic to cancer cells in vitro, and 1 has demonstrated efficacy in vivo in several xenograft cancer models.  Here we show that 2 has limited plasma membrane permeability and is metabolized in liver microsomes in a manner consistent with that reported for 1.  In addn., we have prepd. a series of analogs of these compds. where the complex pseudo-sugar at C6 has been replaced with chem. simpler moieties to improve drug-likeness.  Selected compds. from this work possess excellent activity in biochem. and cellular translation assays with potent activity against leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz75BXieKh5rVg90H21EOLACvtfcHk0lhpffGBImTn_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVSrtbs%253D&md5=0798d277de73bd89340d5b6df7554f88</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201400024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201400024%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DB.%2BC.%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DNhu%26aufirst%3DD.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DA.%2BK.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DChambers%26aufirst%3DJ.%2BM.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DRizzacasa%26aufirst%3DM.%2BA.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26atitle%3DSimplified%2520silvestrol%2520analogues%2520with%2520potent%2520cytotoxic%2520activity%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1556%26epage%3D1566%26doi%3D10.1002%2Fcmdc.201400024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiddon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresteil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebigil, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Flavaglines as potent anticancer and cytoprotective agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10064</span>– <span class="NLM_lpage">10073</span>, <span class="refDoi"> DOI: 10.1021/jm301201z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301201z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10064-10073&author=N.+Ribeiroauthor=F.+Thuaudauthor=Y.+Bernardauthor=C.+Gaiddonauthor=T.+Cresteilauthor=A.+Hildauthor=E.+C.+Hirschauthor=P.+P.+Michelauthor=C.+G.+Nebigilauthor=L.+D%C3%A9saubry&title=Flavaglines+as+potent+anticancer+and+cytoprotective+agents&doi=10.1021%2Fjm301201z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Flavaglines as Potent Anticancer and Cytoprotective Agents</span></div><div class="casAuthors">Ribeiro, Nigel; Thuaud, Frederic; Bernard, Yohann; Gaiddon, Christian; Cresteil, Thierry; Hild, Audrey; Hirsch, Etienne C.; Michel, Patrick Pierre; Nebigil, Canan G.; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10064-10073</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Flavaglines represent a family of plant natural products that display potent anticancer, cardioprotective, and neuroprotective activities.  Novel flavagline derivs. were synthesized and examd. for their cytotoxicity on a panel of human cancer cell lines, their cardioprotection against doxorubicin-induced apoptosis in cardiomyocytes, and their neuroprotection in culture models of Parkinson's disease and cisplatin-induced neurotoxicity.  The structural requirements of flavaglines for cardio- and neuroprotection were for the first time unraveled and appeared to be slightly different from those for cytotoxicity on cancer cells.  We provide also the first evidence that flavaglines may alleviate cisplatin-induced neurotoxicity, suggesting a prophylactic potential of these compds. to prevent this frequently encountered adverse effect of cancer chemotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxznDznpm_wbVg90H21EOLACvtfcHk0lizsdPS7nEqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7nI&md5=8f18a70f2dcb524b663cd24decb94d02</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm301201z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301201z%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DN.%26aulast%3DThuaud%26aufirst%3DF.%26aulast%3DBernard%26aufirst%3DY.%26aulast%3DGaiddon%26aufirst%3DC.%26aulast%3DCresteil%26aufirst%3DT.%26aulast%3DHild%26aufirst%3DA.%26aulast%3DHirsch%26aufirst%3DE.%2BC.%26aulast%3DMichel%26aufirst%3DP.%2BP.%26aulast%3DNebigil%26aufirst%3DC.%2BG.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DFlavaglines%2520as%2520potent%2520anticancer%2520and%2520cytoprotective%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10064%26epage%3D10073%26doi%3D10.1021%2Fjm301201z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span> <span> </span><span class="NLM_article-title">Biomimetic photocycloaddition of 3-hydroxyflavones: Synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6533</span>– <span class="NLM_lpage">6538</span>, <span class="refDoi"> DOI: 10.1002/anie.201003212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fanie.201003212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6533-6538&author=S.+P.+Rocheauthor=R.+Cencicauthor=J.+Pelletierauthor=J.+A.+Porco&title=Biomimetic+photocycloaddition+of+3-hydroxyflavones%3A+Synthesis+and+evaluation+of+rocaglate+derivatives+as+inhibitors+of+eukaryotic+translation&doi=10.1002%2Fanie.201003212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Biomimetic Photocycloaddition of 3-Hydroxyflavones: Synthesis and Evaluation of Rocaglate Derivatives as Inhibitors of Eukaryotic Translation</span></div><div class="casAuthors">Roche, Stephane P.; Cencic, Regina; Pelletier, Jerry; Porco, John A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">6533-6538, S6533/1-S6533/76</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The biomimetic ESIPT photocycloaddn. methodol. was successfully extended to [3 + 2] photocycloaddn. reactions of a 3-hydroxyflavone deriv., 2-(4-methoxyphenyl)-3-hydroxy-5,7-dimethoxybenzopyran-4-one, with a wide range of dipolarophiles (E)-R1CH:CHR2 [R1 = Ph, R2 = CN, CO2Me, COSEt, CON(Me)OMe, Ph, etc.; R1 = 4-BrC6H4, 2-furyl, 2-naphthyl, 3-pyridyl, etc., R2 = CO2Me; etc.] for concise access to a variety of aglain derivs. I.  Evaluation of dipolarophiles revealed that donor-acceptor interactions of generated in situ phototautomers may result in increased diastereocontrol.  Subsequent base-mediated ketol or a pinacol-type rearrangement of aglains I provided enabled expedient access to novel rocaglate derivs. II.  The latter were evaluated as inhibitors of eukaryotic translation leading to identification of a modified rocaglate deriv. with potency similar to silvestrol in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-eAOOft7C0bVg90H21EOLACvtfcHk0lizsdPS7nEqCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamtbbO&md5=14f70d2d34e6c36c1f08ff370f1e387a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fanie.201003212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201003212%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DS.%2BP.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DBiomimetic%2520photocycloaddition%2520of%25203-hydroxyflavones%253A%2520Synthesis%2520and%2520evaluation%2520of%2520rocaglate%2520derivatives%2520as%2520inhibitors%2520of%2520eukaryotic%2520translation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D6533%26epage%3D6538%26doi%3D10.1002%2Fanie.201003212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas
Kinghorn, A.</span></span> <span> </span><span class="NLM_article-title">Rocaglamide, silvestrol and structurally related bioactive compounds from aglaia species</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1039/c4np00006d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1039%2Fc4np00006d" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=924-939&author=L.+Panauthor=J.+L.+Woodardauthor=D.+M.+Lucasauthor=J.+R.+Fuchsauthor=A.+Douglas%0AKinghorn&title=Rocaglamide%2C+silvestrol+and+structurally+related+bioactive+compounds+from+aglaia+species&doi=10.1039%2Fc4np00006d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc4np00006d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4np00006d%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DL.%26aulast%3DWoodard%26aufirst%3DJ.%2BL.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DFuchs%26aufirst%3DJ.%2BR.%26aulast%3DDouglas%2BKinghorn%26aufirst%3DA.%26atitle%3DRocaglamide%252C%2520silvestrol%2520and%2520structurally%2520related%2520bioactive%2520compounds%2520from%2520aglaia%2520species%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D31%26spage%3D924%26epage%3D939%26doi%3D10.1039%2Fc4np00006d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span> <span> </span><span class="NLM_article-title">Rocaglates covert DEAD-box protein eIF4A into a sequence-selective translational repressor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1038/nature17978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnature17978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=27309803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSksbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=558-561&author=S.+Iwasakiauthor=S.+N.+Floorauthor=N.+T.+Ingolia&title=Rocaglates+covert+DEAD-box+protein+eIF4A+into+a+sequence-selective+translational+repressor&doi=10.1038%2Fnature17978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor</span></div><div class="casAuthors">Iwasaki, Shintaro; Floor, Stephen N.; Ingolia, Nicholas T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7608</span>),
    <span class="NLM_cas:pages">558-561</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneuploid tumor cells and repress translation of specific mRNAs.  RocA targets eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase; its mRNA selectivity is proposed to reflect highly structured 5' untranslated regions that depend strongly on eIF4A-mediated unwinding.  However, rocaglate treatment may not phenocopy the loss of eIF4A activity, as these drugs actually increase the affinity between eIF4A and RNA.  Here we show that secondary structure in 5' untranslated regions is only a minor determinant for RocA selectivity and that RocA does not repress translation by reducing eIF4A availability.  Rather, in vitro and in cells, RocA specifically clamps eIF4A onto polypurine sequences in an ATP-independent manner.  This artificially clamped eIF4A blocks 43S scanning, leading to premature, upstream translation initiation and reducing protein expression from transcripts bearing the RocA-eIF4A target sequence.  In elucidating the mechanism of selective translation repression by this lead anti-cancer compd., we provide an example of a drug stabilizing sequence-selective RNA-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR6CpuR_XHqLVg90H21EOLACvtfcHk0lhwbC7aCozF9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSksbjN&md5=8e4735525578a70efe5731e02146c31b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature17978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17978%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26atitle%3DRocaglates%2520covert%2520DEAD-box%2520protein%2520eIF4A%2520into%2520a%2520sequence-selective%2520translational%2520repressor%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D558%26epage%3D561%26doi%3D10.1038%2Fnature17978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shichino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodeoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imataka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span> <span> </span><span class="NLM_article-title">The translation inhibitor rocaglamide targets a bimolecular cavity between eIF4A and polypurine RNA</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">738</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.molcel.2018.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=30595437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlyn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=738&author=S.+Iwasakiauthor=W.+Iwasakiauthor=M.+Takahashiauthor=A.+Sakamotoauthor=C.+Watanabeauthor=Y.+Shichinoauthor=S.+Floorauthor=K.+Fujiwaraauthor=M.+Mitoauthor=K.+Dodoauthor=M.+Sodeokaauthor=H.+Imatakaauthor=T.+Honmaauthor=K.+Fukuzawaauthor=T.+Itoauthor=N.+T.+Ingolia&title=The+translation+inhibitor+rocaglamide+targets+a+bimolecular+cavity+between+eIF4A+and+polypurine+RNA&doi=10.1016%2Fj.molcel.2018.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA</span></div><div class="casAuthors">Iwasaki, Shintaro; Iwasaki, Wakana; Takahashi, Mari; Sakamoto, Ayako; Watanabe, Chiduru; Shichino, Yuichi; Floor, Stephen N.; Fujiwara, Koichi; Mito, Mari; Dodo, Kosuke; Sodeoka, Mikiko; Imataka, Hiroaki; Honma, Teruki; Fukuzawa, Kaori; Ito, Takuhiro; Ingolia, Nicholas T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">738-748.e9</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A class of translation inhibitors, exemplified by the natural product rocaglamide A (RocA), isolated from Aglaia genus plants, exhibits antitumor activity by clamping eukaryotic translation initiation factor 4A (eIF4A) onto polypurine sequences in mRNAs.  This unusual inhibitory mechanism raises the question of how the drug imposes sequence selectivity onto a general translation factor.  Here, we detd. the crystal structure of the human eIF4A1·ATP analog·RocA·polypurine RNA complex.  RocA targets the "bi-mol. cavity" formed characteristically by eIF4A1 and a sharply bent pair of consecutive purines in the RNA.  Natural amino acid substitutions found in Aglaia eIF4As changed the cavity shape, leading to RocA resistance.  This study provides an example of an RNA-sequence-selective interfacial inhibitor fitting into the space shaped cooperatively by protein and RNA with specific sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUUblvotYlCLVg90H21EOLACvtfcHk0lhwbC7aCozF9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlyn&md5=5a79ee2e73386187b23310837d731645</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DS.%26aulast%3DIwasaki%26aufirst%3DW.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSakamoto%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DC.%26aulast%3DShichino%26aufirst%3DY.%26aulast%3DFloor%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DK.%26aulast%3DMito%26aufirst%3DM.%26aulast%3DDodo%26aufirst%3DK.%26aulast%3DSodeoka%26aufirst%3DM.%26aulast%3DImataka%26aufirst%3DH.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DFukuzawa%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26atitle%3DThe%2520translation%2520inhibitor%2520rocaglamide%2520targets%2520a%2520bimolecular%2520cavity%2520between%2520eIF4A%2520and%2520polypurine%2520RNA%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D73%26spage%3D738%26doi%3D10.1016%2Fj.molcel.2018.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Hippuristanol – a potent steroid inhibitor of eukaryotic initiation factor 4A</span>. <i>Translation</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e1137381</span> <span class="refDoi"> DOI: 10.1080/21690731.2015.1137381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1080%2F21690731.2015.1137381" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&author=R.+Cencicauthor=J.+Pelletier&title=Hippuristanol+%E2%80%93+a+potent+steroid+inhibitor+of+eukaryotic+initiation+factor+4A&doi=10.1080%2F21690731.2015.1137381"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F21690731.2015.1137381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21690731.2015.1137381%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DHippuristanol%2520%25E2%2580%2593%2520a%2520potent%2520steroid%2520inhibitor%2520of%2520eukaryotic%2520initiation%2520factor%25204A%26jtitle%3DTranslation%26date%3D2016%26volume%3D4%26doi%3D10.1080%2F21690731.2015.1137381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcote, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">RNA-mediated sequestration of the RNA helicase eIF4A by pateamine A inhibits translation initiation</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1287</span>– <span class="NLM_lpage">1295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2006.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.chembiol.2006.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=17185224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1equg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1287-1295&author=M.-E.+Bordeleauauthor=R.+Cencicauthor=L.+Lindqvistauthor=M.+Obererauthor=P.+Northcoteauthor=G.+Wagnerauthor=J.+Pelletier&title=RNA-mediated+sequestration+of+the+RNA+helicase+eIF4A+by+pateamine+A+inhibits+translation+initiation&doi=10.1016%2Fj.chembiol.2006.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-Mediated Sequestration of the RNA Helicase eIF4A by Pateamine A Inhibits Translation Initiation</span></div><div class="casAuthors">Bordeleau, Marie-Eve; Cencic, Regina; Lindqvist, Lisa; Oberer, Monika; Northcote, Peter; Wagner, Gerhard; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1287-1295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Eukaryotic initiation factor 4A (eIF4A) is a member of the DEAD-box family of putative RNA helicases whose members are involved in many aspects of RNA metab. eIF4A is thought to facilitate binding of 43S pre-initiation complexes to mRNAs by unwinding secondary structures present in the 5' untranslated region.  Pateamine A, a small-mol. inhibitor of translation initiation, acts in an unusual manner by stimulating eIF4A activity.  Herein, we report the elucidation of pateamine's mode of action.  We demonstrate that pateamine A is a chem. inducer of dimerization that forces an engagement between eIF4A and RNA and prevents eIF4A from participating in the ribosome-recruitment step of translation initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoCcRw1TsmI7Vg90H21EOLACvtfcHk0lhOHhkA1GF7ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1equg%253D%253D&md5=da430831e29847d5d9bf6cca16a9e8ae</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DBordeleau%26aufirst%3DM.-E.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DOberer%26aufirst%3DM.%26aulast%3DNorthcote%26aufirst%3DP.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DRNA-mediated%2520sequestration%2520of%2520the%2520RNA%2520helicase%2520eIF4A%2520by%2520pateamine%2520A%2520inhibits%2520translation%2520initiation%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D1287%26epage%3D1295%26doi%3D10.1016%2Fj.chembiol.2006.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadlish, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vazquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aust, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhullar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helliwell, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepfner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roggo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuierer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movva, N. R.</span></span> <span> </span><span class="NLM_article-title">Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1527</span>, <span class="refDoi"> DOI: 10.1021/cb400158t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400158t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1519-1527&author=H.+Sadlishauthor=G.+Galicia-Vazquezauthor=C.+G.+Parisauthor=T.+Austauthor=B.+Bhullarauthor=L.+Changauthor=S.+B.+Helliwellauthor=D.+Hoepfnerauthor=B.+Knappauthor=R.+Riedlauthor=S.+Roggoauthor=S.+Schuiererauthor=C.+Studerauthor=J.+A.+Porcoauthor=J.+Pelletierauthor=N.+R.+Movva&title=Evidence+for+a+functionally+relevant+rocaglamide+binding+site+on+the+eIF4A-RNA+complex&doi=10.1021%2Fcb400158t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A-RNA Complex</span></div><div class="casAuthors">Sadlish, Heather; Galicia-Vazquez, Gabriela; Paris, C. Gregory; Aust, Thomas; Bhullar, Bhupinder; Chang, Lena; Helliwell, Stephen B.; Hoepfner, Dominic; Knapp, Britta; Riedl, Ralph; Roggo, Silvio; Schuierer, Sven; Studer, Christian; Porco, John A.; Pelletier, Jerry; Movva, N. Rao</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1519-1527</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Translation initiation is an emerging target in oncol. and neurobiol. indications.  Naturally derived and synthetic rocaglamide scaffolds have been used to interrogate this pathway; however, there is uncertainty regarding their precise mechanism(s) of action.  We exploited the genetic tractability of yeast to define the primary effect of both a natural and a synthetic rocaglamide in a cellular context and characterized the mol. target using biochem. studies and in silico modeling.  Chemogenomic profiling and mutagenesis in yeast identified the eIF (eukaryotic Initiation Factor) 4A helicase homolog as the primary mol. target of rocaglamides and defined a discrete set of residues near the RNA binding motif that confer resistance to both compds.  Three of the eIF4A mutations were characterized regarding their functional consequences on activity and response to rocaglamide inhibition.  These data support a model whereby rocaglamides stabilize an eIF4A-RNA interaction to either alter the level and/or impair the activity of the eIF4F complex.  Furthermore, in silico modeling supports the annotation of a binding pocket delineated by the RNA substrate and the residues identified from our mutagenesis screen.  As expected from the high degree of conservation of the eukaryotic translation pathway, these observations are consistent with previous observations in mammalian model systems.  Importantly, we demonstrate that the chem. distinct silvestrol and synthetic rocaglamides share a common mechanism of action, which will be crit. for optimization of physiol. stable derivs.  Finally, these data confirm the value of the rocaglamide scaffold for exploring the impact of translational modulation on disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOrcE5_sJHtLVg90H21EOLACvtfcHk0lhOHhkA1GF7ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCnt7o%253D&md5=0350401f40ba15d20744d2bf3272832b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fcb400158t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400158t%26sid%3Dliteratum%253Aachs%26aulast%3DSadlish%26aufirst%3DH.%26aulast%3DGalicia-Vazquez%26aufirst%3DG.%26aulast%3DParis%26aufirst%3DC.%2BG.%26aulast%3DAust%26aufirst%3DT.%26aulast%3DBhullar%26aufirst%3DB.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DHelliwell%26aufirst%3DS.%2BB.%26aulast%3DHoepfner%26aufirst%3DD.%26aulast%3DKnapp%26aufirst%3DB.%26aulast%3DRiedl%26aufirst%3DR.%26aulast%3DRoggo%26aufirst%3DS.%26aulast%3DSchuierer%26aufirst%3DS.%26aulast%3DStuder%26aufirst%3DC.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DMovva%26aufirst%3DN.%2BR.%26atitle%3DEvidence%2520for%2520a%2520functionally%2520relevant%2520rocaglamide%2520binding%2520site%2520on%2520the%2520eIF4A-RNA%2520complex%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1519%26epage%3D1527%26doi%3D10.1021%2Fcb400158t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li-Weber, M.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1791</span>– <span class="NLM_lpage">1799</span>, <span class="refDoi"> DOI: 10.1002/ijc.29013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fijc.29013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=24895251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFequr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=1791-1799&author=M.+Li-Weber&title=Molecular+mechanisms+and+anti-cancer+aspects+of+the+medicinal+phytochemicals+rocaglamides+%28%3Dflavaglines%29&doi=10.1002%2Fijc.29013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)</span></div><div class="casAuthors">Li-Weber, Min</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1791-1799</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Rocaglamides (= flavaglines) are potent natural anti-cancer phytochems. that inhibit cancer growth at nanomolar concns. by the following mechanisms: (1) inhibition of translation initiation via inhibition of phosphorylation of the mRNA cap-binding eukaryotic translation initiation factor eIF4E and stabilization of RNA-binding of the translation initiation factor eIF4A in the eIF4F complex; (2) blocking cell cycle progression by activation of the ATM/ATR-Chk1/Chk2 checkpoint pathway; (3) inactivation of the heat shock factor 1 (HSF1) leading to up-regulation of thioredoxin-interacting protein (TXNIP) and consequent redn. of glucose uptake and (4) induction of apoptosis through activation of the MAPK p38 and JNK and inhibition of the Ras-CRaf-MEK-ERK signaling pathway.  Besides the anti-cancer activities, rocaglamides are also shown to protect primary cells from chemotherapy-induced cell death and alleviate inflammation- and drug-induced injury in neuronal tissues.  This review will focus on the recently discovered mol. mechanisms of the actions of rocaglamides and highlights the benefits of using rocaglamides in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3RA3J8dyvL7Vg90H21EOLACvtfcHk0limuvS6ut7q7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFequr0%253D&md5=ef00b49990d2ddbbb643bd5c9ce353ff</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fijc.29013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29013%26sid%3Dliteratum%253Aachs%26aulast%3DLi-Weber%26aufirst%3DM.%26atitle%3DMolecular%2520mechanisms%2520and%2520anti-cancer%2520aspects%2520of%2520the%2520medicinal%2520phytochemicals%2520rocaglamides%2520%2528%253Dflavaglines%2529%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D1791%26epage%3D1799%26doi%3D10.1002%2Fijc.29013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, C. B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballut, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamieh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seraphin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Hir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, G. R.</span></span> <span> </span><span class="NLM_article-title">Structure of the exon junction core complex with a trapped DEAD-box ATPase bound to RNA</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">1968</span>– <span class="NLM_lpage">1972</span>, <span class="refDoi"> DOI: 10.1126/science.1131981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1126%2Fscience.1131981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=16931718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSnsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2006&pages=1968-1972&author=C.+B.+F.+Andersenauthor=L.+Ballutauthor=J.+S.+Johansenauthor=H.+Chamiehauthor=K.+H.+Nielsenauthor=C.+L.+Oliveiraauthor=J.+S.+Pedersenauthor=B.+Seraphinauthor=H.+Le+Hirauthor=G.+R.+Andersen&title=Structure+of+the+exon+junction+core+complex+with+a+trapped+DEAD-box+ATPase+bound+to+RNA&doi=10.1126%2Fscience.1131981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Exon Junction Core Complex with a Trapped DEAD-Box ATPase Bound to RNA</span></div><div class="casAuthors">Andersen, Christian B. F.; Ballut, Lionel; Johansen, Jesper S.; Chamieh, Hala; Nielsen, Klaus H.; Oliveira, Cristiano L. P.; Pedersen, Jan Skov; Seraphin, Bertrand; Le Hir, Herve; Rom Andersen, Gregers</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">5795</span>),
    <span class="NLM_cas:pages">1968-1972</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">In higher eukaryotes, a multiprotein exon junction complex is deposited on spliced mRNAs.  The complex is organized around a stable core, which serves as a binding platform for numerous factors that influence mRNA function.  Here, we present the crystal structure of a tetrameric exon junction core complex contg. the DEAD-box ATPase eukaryotic initiation factor 4AIII (eIF4AIII) bound to an ATP analog, MAGOH, Y14, a fragment of MLN51, and a polyuracil mRNA mimic.  EIF4AIII interacts with the phosphate-ribose backbone of six consecutive nucleotides and prevents part of the bound RNA from being double stranded.  The MAGOH and Y14 subunits lock eIF4AIII in a prehydrolysis state, and activation of the ATPase probably requires only modest conformational changes in eIF4AIII motif I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKgZvl00N4M7Vg90H21EOLACvtfcHk0limuvS6ut7q7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSnsrnE&md5=0a1bed875b1c1ddaa4c0c26746275d96</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.1131981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1131981%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DC.%2BB.%2BF.%26aulast%3DBallut%26aufirst%3DL.%26aulast%3DJohansen%26aufirst%3DJ.%2BS.%26aulast%3DChamieh%26aufirst%3DH.%26aulast%3DNielsen%26aufirst%3DK.%2BH.%26aulast%3DOliveira%26aufirst%3DC.%2BL.%26aulast%3DPedersen%26aufirst%3DJ.%2BS.%26aulast%3DSeraphin%26aufirst%3DB.%26aulast%3DLe%2BHir%26aufirst%3DH.%26aulast%3DAndersen%26aufirst%3DG.%2BR.%26atitle%3DStructure%2520of%2520the%2520exon%2520junction%2520core%2520complex%2520with%2520a%2520trapped%2520DEAD-box%2520ATPase%2520bound%2520to%2520RNA%26jtitle%3DScience%26date%3D2006%26volume%3D313%26spage%3D1968%26epage%3D1972%26doi%3D10.1126%2Fscience.1131981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajasekhar, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghvi, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavrakis, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roderick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Meulen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teruya-Feldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rätsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, H.-G.</span></span> <span> </span><span class="NLM_article-title">RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nature13485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnature13485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=25079319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2014&pages=65-70&author=A.+L.+Wolfeauthor=K.+Singhauthor=Y.+Zhongauthor=P.+Dreweauthor=V.+K.+Rajasekharauthor=V.+R.+Sanghviauthor=K.+J.+Mavrakisauthor=M.+Jiangauthor=J.+E.+Roderickauthor=J.+Van+der+Meulenauthor=J.+H.+Schatzauthor=C.+M.+Rodrigoauthor=C.+Zhaoauthor=P.+Rondouauthor=E.+de+Stanchinaauthor=J.+Teruya-Feldsteinauthor=M.+A.+Kelliherauthor=F.+Spelemanauthor=J.+A.+Porcoauthor=J.+Pelletierauthor=G.+R%C3%A4tschauthor=H.-G.+Wendel&title=RNA+G-quadruplexes+cause+eIF4A-dependent+oncogene+translation+in+cancer&doi=10.1038%2Fnature13485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer</span></div><div class="casAuthors">Wolfe, Andrew L.; Singh, Kamini; Zhong, Yi; Drewe, Philipp; Rajasekhar, Vinagolu K.; Sanghvi, Viraj R.; Mavrakis, Konstantinos J.; Jiang, Man; Roderick, Justine E.; Van der Meulen, Joni; Schatz, Jonathan H.; Rodrigo, Christina M.; Zhao, Chunying; Rondou, Pieter; de Stanchina, Elisa; Teruya-Feldstein, Julie; Kelliher, Michelle A.; Speleman, Frank; Porco, John A.; Pelletier, Jerry; Ratsch, Gunnar; Wendel, Hans-Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">7516</span>),
    <span class="NLM_cas:pages">65-70</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The translational control of oncoprotein expression is implicated in many cancers.  Here the authors report an eIF4A RNA helicase-dependent mechanism of translational control that contributes to oncogenesis and underlies the anticancer effects of silvestrol and related compds.  For example, eIF4A promotes T-cell acute lymphoblastic leukemia development in vivo and is required for leukemia maintenance.  Accordingly, inhibition of eIF4A with silvestrol has powerful therapeutic effects against murine and human leukemic cells in vitro and in vivo.  The authors use transcriptome-scale ribosome footprinting to identify the hallmarks of eIF4A-dependent transcripts.  These include 5' untranslated region (UTR) sequences such as the 12-nucleotide guanine quartet (CGG)4 motif that can form RNA G-quadruplex structures.  Notably, among the most eIF4A-dependent and silvestrol-sensitive transcripts are a no. of oncogenes, superenhancer-assocd. transcription factors, and epigenetic regulators.  Hence, the 5' UTRs of select cancer genes harbor a targetable requirement for the eIF4A RNA helicase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OIvvYHwn7rVg90H21EOLACvtfcHk0lgimCz-qDrgFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvI&md5=8c0a22a542cac567f1ec1340b195680d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature13485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13485%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DDrewe%26aufirst%3DP.%26aulast%3DRajasekhar%26aufirst%3DV.%2BK.%26aulast%3DSanghvi%26aufirst%3DV.%2BR.%26aulast%3DMavrakis%26aufirst%3DK.%2BJ.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DRoderick%26aufirst%3DJ.%2BE.%26aulast%3DVan%2Bder%2BMeulen%26aufirst%3DJ.%26aulast%3DSchatz%26aufirst%3DJ.%2BH.%26aulast%3DRodrigo%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DRondou%26aufirst%3DP.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DKelliher%26aufirst%3DM.%2BA.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DR%25C3%25A4tsch%26aufirst%3DG.%26aulast%3DWendel%26aufirst%3DH.-G.%26atitle%3DRNA%2520G-quadruplexes%2520cause%2520eIF4A-dependent%2520oncogene%2520translation%2520in%2520cancer%26jtitle%3DNature%26date%3D2014%26volume%3D513%26spage%3D65%26epage%3D70%26doi%3D10.1038%2Fnature13485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katigbak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">CRISPR-Mediated drug-target validation reveals selective pharmacological inhibition of the RNA helicase, eIF4A</span>. <i>Cell Reports</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2340</span>– <span class="NLM_lpage">2347</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.celrep.2016.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=27239032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVSlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2340-2347&author=J.+Chuauthor=G.+Galicia-V%C3%A1zquezauthor=R.+Cencicauthor=J.+R.+Millsauthor=A.+Katigbakauthor=J.+A.+Porcoauthor=J.+Pelletier&title=CRISPR-Mediated+drug-target+validation+reveals+selective+pharmacological+inhibition+of+the+RNA+helicase%2C+eIF4A&doi=10.1016%2Fj.celrep.2016.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A</span></div><div class="casAuthors">Chu, Jennifer; Galicia-Vazquez, Gabriela; Cencic, Regina; Mills, John R.; Katigbak, Alexandra; Porco, John A., Jr.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2340-2347</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Targeting translation initiation is an emerging anti-neoplastic strategy that capitalizes on de-regulated upstream MAPK and PI3K-mTOR signaling pathways in cancers.  A key regulator of translation that controls ribosome recruitment flux is eukaryotic initiation factor (eIF) 4F, a hetero-trimeric complex composed of the cap binding protein eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A.  Small mol. inhibitors targeting eIF4F display promising anti-neoplastic activity in preclin. settings.  Among these are some rocaglate family members that are well tolerated in vivo, deplete eIF4F of its eIF4A helicase subunit, have shown activity as single agents in several xenograft models, and can reverse acquired resistance to MAPK and PI3K-mTOR targeted therapies.  Herein, we highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTlJAdKCxSfbVg90H21EOLACvtfcHk0lgimCz-qDrgFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVSlt7s%253D&md5=c84a9a808dcb119306303c6a8aa68b5b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DMills%26aufirst%3DJ.%2BR.%26aulast%3DKatigbak%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DCRISPR-Mediated%2520drug-target%2520validation%2520reveals%2520selective%2520pharmacological%2520inhibition%2520of%2520the%2520RNA%2520helicase%252C%2520eIF4A%26jtitle%3DCell%2520Reports%26date%3D2016%26volume%3D15%26spage%3D2340%26epage%3D2347%26doi%3D10.1016%2Fj.celrep.2016.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebigil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the biology and chemistry of the flavaglines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1857</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.10.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.bmc.2011.10.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=22071525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlOku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1857&author=N.+Ribeiroauthor=F.+Thuaudauthor=C.+Nebigilauthor=L.+D%C3%A9saubry&title=Recent+advances+in+the+biology+and+chemistry+of+the+flavaglines&doi=10.1016%2Fj.bmc.2011.10.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the biology and chemistry of the flavaglines</span></div><div class="casAuthors">Ribeiro, Nigel; Thuaud, Frederic; Nebigil, Canan; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The flavaglines are a family of plant natural products that induce potent anticancer and neuroprotective activities.  This review summarizes recent synthetic approaches to flavaglines and the current status of their pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP48y5yocOa7Vg90H21EOLACvtfcHk0lhO4B7c-3EF1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlOku7g%253D&md5=eed7c02d5cfb2215c1523248afeeee89</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.10.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.10.048%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DN.%26aulast%3DThuaud%26aufirst%3DF.%26aulast%3DNebigil%26aufirst%3DC.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DRecent%2520advances%2520in%2520the%2520biology%2520and%2520chemistry%2520of%2520the%2520flavaglines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1857%26doi%3D10.1016%2Fj.bmc.2011.10.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Hamdan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the synthesis of flavaglines, a family of potent bioactive natural compounds originating from traditional chinese medicine</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_fpage">5908</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201600437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fejoc.201600437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1CltLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=5908&author=Q.+Zhaoauthor=H.+Abou-Hamdanauthor=L.+D%C3%A9saubry&title=Recent+advances+in+the+synthesis+of+flavaglines%2C+a+family+of+potent+bioactive+natural+compounds+originating+from+traditional+chinese+medicine&doi=10.1002%2Fejoc.201600437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Synthesis of Flavaglines, a Family of Potent Bioactive Natural Compounds Originating from Traditional Chinese Medicine</span></div><div class="casAuthors">Zhao, Qian; Abou-Hamdan, Hussein; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">5908-5916</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Flavaglines constitute a distinctive family of plant metabolites isolated from medicinal plants of the genus Aglaia.  These compds. exhibit a broad spectrum of distinctive pharmacol. properties, including anti-inflammatory, neuroprotective, cardioprotective, and anticancer activities.  These natural cyclopenta[b]benzofurans are characterized by densely functionalized tricyclic frameworks, as exemplified by the structures of rocaglamide or silvestrol, which makes them extremely attractive targets for total synthesis, in addn. to their therapeutic potential.  In this review we describe the various synthetic approaches to the total synthesis of flavaglines, culminating in a new generation of diastereo- and enantioselective total syntheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4fgv5knkhj7Vg90H21EOLACvtfcHk0lhO4B7c-3EF1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1CltLjO&md5=c024d7a3f7142c42d508f4c7867557e4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201600437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201600437%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DAbou-Hamdan%26aufirst%3DH.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DRecent%2520advances%2520in%2520the%2520synthesis%2520of%2520flavaglines%252C%2520a%2520family%2520of%2520potent%2520bioactive%2520natural%2520compounds%2520originating%2520from%2520traditional%2520chinese%2520medicine%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2016%26spage%3D5908%26doi%3D10.1002%2Fejoc.201600437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">A Biomimetic approach to the rocaglamides employing photogeneration of oxidopyryliums derived from 3-hydroxyflavones</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">13620</span>, <span class="refDoi"> DOI: 10.1021/ja044798o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja044798o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVShsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=13620&author=B.+Gerardauthor=G.+Jonesauthor=J.+A.+Porco&title=A+Biomimetic+approach+to+the+rocaglamides+employing+photogeneration+of+oxidopyryliums+derived+from+3-hydroxyflavones&doi=10.1021%2Fja044798o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A biomimetic approach to the rocaglamides employing photogeneration of oxidopyryliums derived from 3-hydroxyflavones</span></div><div class="casAuthors">Gerard, Baudouin; Jones, Guilford, II; Porco, John A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">13620-13621</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A unified biomimetic approach to the aglain-forbaglin-rocaglamide classes of natural products is reported.  The approach involves photogeneration of oxidopyryliums via excited-state intramol. proton transfer (ESIPT) of 3-hydroxyflavones followed by [3+2] dipolar cycloaddn. to the aglain core.  An α-ketol (acyloin) rearrangement was employed to transform the aglain core to the rocaglamide framework.  This approach was successfully used for the synthesis of the natural product (±)-Me rocaglate (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNL6WYutInfbVg90H21EOLACvtfcHk0lgC-vqZPu-ZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVShsr8%253D&md5=2b68c32c480b01c4720081e9d1c23288</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fja044798o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja044798o%26sid%3Dliteratum%253Aachs%26aulast%3DGerard%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DA%2520Biomimetic%2520approach%2520to%2520the%2520rocaglamides%2520employing%2520photogeneration%2520of%2520oxidopyryliums%2520derived%2520from%25203-hydroxyflavones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2004%26volume%3D126%26spage%3D13620%26doi%3D10.1021%2Fja044798o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Enantioselective photocycloaddition mediated by chiral brønsted acids: Asymmetric synthesis of the rocaglamides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">7754</span>, <span class="refDoi"> DOI: 10.1021/ja062621j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja062621j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVOqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=7754&author=B.+Gerardauthor=S.+Sangjiauthor=D.+J.+O%E2%80%99Learyauthor=J.+A.+Porco&title=Enantioselective+photocycloaddition+mediated+by+chiral+br%C3%B8nsted+acids%3A+Asymmetric+synthesis+of+the+rocaglamides&doi=10.1021%2Fja062621j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids: Asymmetric Synthesis of the Rocaglamides</span></div><div class="casAuthors">Gerard, Baudouin; Sangji, Sheharbano; O'Leary, Daniel J.; Porco, John A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7754-7755</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enantioselective syntheses of Me rocaglate and the related natural products rocaglamide and rocaglaol are outlined.  The approach involves enantioselective [3 + 2] photocycloaddn. promoted by chiral Bronsted acids (TADDOLs) to afford an aglain precursor I followed by a ketol shift/redn. sequence to the rocaglate core.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4ob0LdqnYbLVg90H21EOLACvtfcHk0lgC-vqZPu-ZOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVOqsrs%253D&md5=6a77588a2dc8dc39da2f8b34e8f4761f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fja062621j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja062621j%26sid%3Dliteratum%253Aachs%26aulast%3DGerard%26aufirst%3DB.%26aulast%3DSangji%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DD.%2BJ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DEnantioselective%2520photocycloaddition%2520mediated%2520by%2520chiral%2520br%25C3%25B8nsted%2520acids%253A%2520Asymmetric%2520synthesis%2520of%2520the%2520rocaglamides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D7754%26doi%3D10.1021%2Fja062621j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of the complex rocaglate (−)-silvestrol</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">7831</span>, <span class="refDoi"> DOI: 10.1002/anie.200702707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fanie.200702707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1alsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=7831&author=B.+Gerardauthor=R.+Cencicauthor=J.+Pelletierauthor=J.+A.+Porco&title=Enantioselective+synthesis+of+the+complex+rocaglate+%28%E2%88%92%29-silvestrol&doi=10.1002%2Fanie.200702707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective synthesis of the complex rocaglate (-)-silvestrol</span></div><div class="casAuthors">Gerard, Baudouin; Cencic, Regina; Pelletier, Jerry; Porco, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">7831-7834</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The total synthesis of the natural product (-)-silvestrol I (R = α-H) was accomplished, and the synthesis featured enantioselective [3 + 2] photocycloaddn. of a substituted 3-hydroxyflavone II and methyl cinnamate promoted by a chiral TADDOL analog Broensted acid.  Initial biol. studies indicated a 5-10 fold greater activity of (-)-silvestrol than its diastereoisomer I (R = β-H) as inhibitors of protein synthesis in HeLa cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvjZPs05l1QrVg90H21EOLACvtfcHk0li8wBDpHfeMSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1alsLrF&md5=e42d8aa0e2d5b94fc561994f17a971f4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fanie.200702707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200702707%26sid%3Dliteratum%253Aachs%26aulast%3DGerard%26aufirst%3DB.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DEnantioselective%2520synthesis%2520of%2520the%2520complex%2520rocaglate%2520%2528%25E2%2588%2592%2529-silvestrol%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2007%26volume%3D46%26spage%3D7831%26doi%3D10.1002%2Fanie.200702707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lajkiewicz, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilmy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Biomimetic kinetic resolution: highly enantio- and diastereoselective transfer hydrogenation of aglain ketones to access flavagline natural products</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">525</span>, <span class="refDoi"> DOI: 10.1021/ja511728b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja511728b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOhu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=525&author=S.+D.+Stoneauthor=N.+J.+Lajkiewiczauthor=L.+Whitesellauthor=A.+Hilmyauthor=J.+A.+Porco&title=Biomimetic+kinetic+resolution%3A+highly+enantio-+and+diastereoselective+transfer+hydrogenation+of+aglain+ketones+to+access+flavagline+natural+products&doi=10.1021%2Fja511728b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Biomimetic Kinetic Resolution: Highly Enantio- and Diastereoselective Transfer Hydrogenation of Aglain Ketones To Access Flavagline Natural Products</span></div><div class="casAuthors">Stone, Steven D.; Lajkiewicz, Neil J.; Whitesell, Luke; Hilmy, Ahmed; Porco, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">525-530</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously reported asym. syntheses and abs. configuration assignments of the aglains (+)-ponapensin and (+)-elliptifoline and proposed a biosynthetic kinetic resoln. process to produce enantiomeric rocaglamides and aglains.  Herein, we report a biomimetic approach for the synthesis of enantiomerically enriched aglains and rocaglamides via kinetic resoln. of a bridged ketone utilizing enantioselective transfer hydrogenation [e.g., (±)-I → (+)-I + (-)-II].  The methodol. has been employed to synthesize and confirm the abs. stereochemistries of the pyrimidone rocaglamides (+)-aglaiastatin and (-)-aglaroxin C.  Addnl., the enantiomers and racemate of each metabolite were assayed for inhibition of the heat-shock response, cytotoxicity, and translation inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgZZMDHjY_uLVg90H21EOLACvtfcHk0li8wBDpHfeMSg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOhu7%252FF&md5=89141a3815f46bb46745aa8fd1d1490a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fja511728b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja511728b%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DS.%2BD.%26aulast%3DLajkiewicz%26aufirst%3DN.%2BJ.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DHilmy%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DBiomimetic%2520kinetic%2520resolution%253A%2520highly%2520enantio-%2520and%2520diastereoselective%2520transfer%2520hydrogenation%2520of%2520aglain%2520ketones%2520to%2520access%2520flavagline%2520natural%2520products%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D525%26doi%3D10.1021%2Fja511728b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeler, A. B.</span></span> <span> </span><span class="NLM_article-title">A photochemical flow reactor for large scale syntheses of aglain and rocaglate natural product analogues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6197</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.bmc.2017.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=28666859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyntLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6197&author=H.+Yuehauthor=Q.+Gaoauthor=J.+A.+Porcoauthor=A.+B.+Beeler&title=A+photochemical+flow+reactor+for+large+scale+syntheses+of+aglain+and+rocaglate+natural+product+analogues&doi=10.1016%2Fj.bmc.2017.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A photochemical flow reactor for large scale syntheses of aglain and rocaglate natural product analogues</span></div><div class="casAuthors">Yueh, Han; Gao, Qiwen; Porco, John A., Jr.; Beeler, Aaron B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6197-6202</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we report the development of continuous flow photoreactors for large scale ESIPT-mediated [3+2]-photocycloaddn. of 2-(p-methoxyphenyl)-3-hydroxyflavone and cinnamate-derived dipolarophiles.  These reactors can be efficiently numbered up to increase throughput two orders of magnitude greater than the corresponding batch reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOKc07fvnRN7Vg90H21EOLACvtfcHk0lhSIDkjtSadlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyntLfF&md5=1189057eb841aec14b29c238b56b7afc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DYueh%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DBeeler%26aufirst%3DA.%2BB.%26atitle%3DA%2520photochemical%2520flow%2520reactor%2520for%2520large%2520scale%2520syntheses%2520of%2520aglain%2520and%2520rocaglate%2520natural%2520product%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D6197%26doi%3D10.1016%2Fj.bmc.2017.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span>; <span class="NLM_string-name">Reich, S. H.</span>; <span class="NLM_string-name">Sprengeler, P. A.</span>; <span class="NLM_string-name">Tran, C. V.</span>; <span class="NLM_string-name">Packard, G. K.</span>; <span class="NLM_string-name">Xiang, A. X.</span>; <span class="NLM_string-name">Nilewski, C.</span>; <span class="NLM_string-name">Michels, T.</span></span> <span> </span><span class="NLM_article-title">eIF4A-inhibiting compounds and methods related thereto</span> U.S. Patent <span class="NLM_patent">10,577,378 B2</span>, March 3, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+T.+Ernst&author=S.+H.+Reich&author=P.+A.+Sprengeler&author=C.+V.+Tran&author=G.+K.+Packard&author=A.+X.+Xiang&author=C.+Nilewski&author=T.+Michels&title=eIF4A-inhibiting+compounds+and+methods+related+thereto"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26atitle%3DeIF4A-inhibiting%2520compounds%2520and%2520methods%2520related%2520thereto%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Algar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. P.</span></span> <span> </span><span class="NLM_article-title">New synthesis of flavonols</span>. <i>Proc. R. Ir. Acad., Sect. B</i> <span class="NLM_year" style="font-weight: bold;">1934</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADyaA2MXhtFOj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1934&pages=1&author=J.+Algarauthor=J.+P.+Flynn&title=New+synthesis+of+flavonols"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">New synthesis of flavonols</span></div><div class="casAuthors">Algar, Joseph; Flynn, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Irish Academy, Section B:  Biological, Geological and Chemical Science</span>
        (<span class="NLM_cas:date">1934</span>),
    <span class="NLM_cas:volume">B42</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">PRIBAN</span>;
        ISSN:<span class="NLM_cas:issn">0035-8983</span>.
    </div><div class="casAbstract">By satg. a mixt. of flavanone (3 g.) and HCHO (3 g.) in 40 cc. of alc. with dry HCl and refluxing for 10 h., an oily condensation product was obtained which, on redn. with alk. H2O2, gave 0.6 g. of flavonol (I).  To a soln. of o-hydroxyphenyl styryl ketone (2 g.) in 25 cc. of hot alc. was added 18 cc. of 0.5 N alc. KOH and 2 cc. of 30% H2O2.  Oxidn. occurred rapidly with rise of temp. and from the reaction mixt. I, m. 171-2°, was obtained in excellent yields.  The oxidn. of the following ketones: 2-hydroxyphenyl 4-methoxy-, 3,4-methyl-enedioxy- and 3,4-dimethoxy-styryl; 2-hydroxy-4-methoxy-Ph styryl, 4-methoxy- and 3,4-methylenedioxy styryl, and 2-hydroxy-3,4-dimethoxyphenyl 4-methoxy styryl similarly yielded the corresponding flavonols: 4'-MeO (II), C16H12O4, m. 235°; 3',4'-CH2O2, C16H10O5, m. 218-19°; 3',4'-(MeO)2, C17H14O5, m. 203°; 7-MeO, C16H12O4, m. 181°; 4',7-(MeO)2, C17H14O5, m. 195°; 7-methoxy-3',4'-methylenedioxy, C17H12O6, m. 210°, and 4',7,8-(MeO)3, C18H16O6, m. 202°.  II was also prepd. by the oxidn. of 1.5 g. of 3-anisylidene-4'-methoxyflavanone in alc. by the addn. of 14 cc. of 30% H2O2 and 2.8 g. of Na in 150 cc. of alc.  The flavonols gave fluorescent solns. in concd. H2SO4 and distinctive colorations with alc. FeCl3.  To elucidate the course of the reaction, attempts were made to isolate the intermediate products from the oxidn. of the styryl ketones.  It is possible that the 1st stage results in the transitory formation of an ethylene peroxide which might furnish a flavonol on ring closure.  The assumption of glycol formation would also afford a mechanism for the reaction.  The o-hydroxyphenyl styryl ketones are readily prepd. and their oxidn. furnishes a convenient method for the synthesis of flavonols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDFvkmnv3vF7Vg90H21EOLACvtfcHk0lhSIDkjtSadlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2MXhtFOj&md5=bc6f58a134ff152d1a9468ad2984db66</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlgar%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%2BP.%26atitle%3DNew%2520synthesis%2520of%2520flavonols%26jtitle%3DProc.%2520R.%2520Ir.%2520Acad.%252C%2520Sect.%2520B%26date%3D1934%26volume%3D42%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyamada, T.</span></span> <span> </span><span class="NLM_article-title">A new general method for the synthesis of flavonol derivatives</span>. <i>Nippon Kagaku Kaishi</i> <span class="NLM_year" style="font-weight: bold;">1934</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1256</span>, <span class="refDoi"> DOI: 10.1246/nikkashi1921.55.12_1256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1246%2Fnikkashi1921.55.12_1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADyaA2MXjtlGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1934&pages=1256&author=T.+Oyamada&title=A+new+general+method+for+the+synthesis+of+flavonol+derivatives&doi=10.1246%2Fnikkashi1921.55.12_1256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A new general method for the synthesis of flavonol derivatives</span></div><div class="casAuthors">Oyamada, Taichiro</div><div class="citationInfo"><span class="NLM_cas:title">Nippon Kagaku Kaishi (1921-47)</span>
        (<span class="NLM_cas:date">1934</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1256-61</span>CODEN:
                <span class="NLM_cas:coden">NIKWAB</span>;
        ISSN:<span class="NLM_cas:issn">0369-4208</span>.
    </div><div class="casAbstract">The method is based on the fact of the formation of flavonols when o-hydroxychalcones are treated with H2O2 in the presence of dil. alkali.  Prepn. of 7,3',4'-trimethoxy-3-hydroxyflavone (I): To 1.5 g. 4,3',-4'-trimethoxy-2-hydroxychalcone in 30 cc. MeOH, add 10 cc. 16% NaOH and 4 cc. 15% H2O2 while cooling and let stand overnight.  Add water and acidify with H2SO4.  Collect the crystals of I and recrystallize from MeOH, m. 185-6°.  In a similar manner, 3-hydroxyflavone (II), m. 169-70°, is prepd. from o-hydroxychalcone; Me ether of II, m. 114°; 3-hydroxyacetoflavone, m. 110-11°.  4'-Methoxy-2-hydroxychalcone gives 4'-methoxy-3-hydroxyflavone, m. 230-2°.  3',4'-Dimethoxy-2-hydroxychalcone gives 3',4'-dimethoxy-3-hydroxyflavone, m. 200-2°.  2-Hydroxychalcone gives flavanone, m. 75-6°.  Flavanone gives 3-hydroxyflavone, colorless needles, m. 169-70°.  4'-Methoxyflavanone gives 4'-methoxy-3 hydroxyflavone, yellow needles, m. 231-2°.  7,3',4'-Trimethoxyflavanone gives 7,3',4'-trimethoxy-3-hydroxyflavone, m. 185°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo48kngimSUAbVg90H21EOLACvtfcHk0lhSIDkjtSadlw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2MXjtlGrtA%253D%253D&md5=fc06c99439c8e3f8e9abde7eec1b56fc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1246%2Fnikkashi1921.55.12_1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fnikkashi1921.55.12_1256%26sid%3Dliteratum%253Aachs%26aulast%3DOyamada%26aufirst%3DT.%26atitle%3DA%2520new%2520general%2520method%2520for%2520the%2520synthesis%2520of%2520flavonol%2520derivatives%26jtitle%3DNippon%2520Kagaku%2520Kaishi%26date%3D1934%26volume%3D55%26spage%3D1256%26doi%3D10.1246%2Fnikkashi1921.55.12_1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyamada, T.</span></span> <span> </span><span class="NLM_article-title">A new general method for the synthesis of the derivatives of flavonol</span>. <i>Bull. Chem. Soc. Jpn.</i> <span class="NLM_year" style="font-weight: bold;">1935</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">182</span>, <span class="refDoi"> DOI: 10.1246/bcsj.10.182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1246%2Fbcsj.10.182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADyaA2MXjvFentg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1935&pages=182&author=T.+Oyamada&title=A+new+general+method+for+the+synthesis+of+the+derivatives+of+flavonol&doi=10.1246%2Fbcsj.10.182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">General method for the synthesis of the derivatives of flavonol</span></div><div class="casAuthors">Oyamada, Taichiro</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Chemical Society of Japan</span>
        (<span class="NLM_cas:date">1935</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">182-6</span>CODEN:
                <span class="NLM_cas:coden">BCSJA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2673</span>.
    </div><div class="casAbstract">See C. A. 29, 4358.7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozvL3X-kmeYrVg90H21EOLACvtfcHk0lhly6yf_dLXtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2MXjvFentg%253D%253D&md5=c765c660802c49d744684cdacf0bb41c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1246%2Fbcsj.10.182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fbcsj.10.182%26sid%3Dliteratum%253Aachs%26aulast%3DOyamada%26aufirst%3DT.%26atitle%3DA%2520new%2520general%2520method%2520for%2520the%2520synthesis%2520of%2520the%2520derivatives%2520of%2520flavonol%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1935%26volume%3D10%26spage%3D182%26doi%3D10.1246%2Fbcsj.10.182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-H.</span></span> <span> </span><span class="NLM_article-title">Ligand-mediated and copper-catalyzed C(sp<sup>3</sup>)-H bond functionalization of aryl ketones with sodium sulfinates under mild conditions</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">18391</span>, <span class="refDoi"> DOI: 10.1038/srep18391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fsrep18391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=26681470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCksL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=18391&author=X.-W.+Lanauthor=N.-X.+Wangauthor=C.-B.+Baiauthor=W.+Zhangauthor=Y.+Xingauthor=J.-L.+Wenauthor=Y.-J.+Wangauthor=Y.-H.+Li&title=Ligand-mediated+and+copper-catalyzed+C%28sp3%29-H+bond+functionalization+of+aryl+ketones+with+sodium+sulfinates+under+mild+conditions&doi=10.1038%2Fsrep18391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Mediated and Copper-Catalyzed C(sp3)-H Bond Functionalization of Aryl Ketones with Sodium Sulfinates under Mild Conditions</span></div><div class="casAuthors">Lan, Xing-Wang; Wang, Nai-Xing; Bai, Cui-Bing; Zhang, Wei; Xing, Yalan; Wen, Jia-Long; Wang, Yan-Jing; Li, Yi-He</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18391pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Novel and convenient copper(II) bromide and 1,8-diazabicyclo[5.4.1]undec-7-ene (DBU) or 1,10-phenanthroline catalysis protocol for the construction of α-alkyl-β-keto sulfones via C(sp3)-H bond functionalization followed by C(sp3)-S bond formation between aryl ketones and sodium sulfinates at room temp. was developed.  This method was applicable to a wide range of aryl ketones and sodium sulfinates.  The electronic effects of aryl ketones and ligands effects of the copper salts were crucial for this transformation.  Typically, substituted aryl ketones with electron-withdrawing group do not need any ligand to give a good to excellent yield, while substituted aryl ketones with electron-donating group and electron-rich heteroarom. ketones offer a good to excellent yield only under the nitrogen-based ligands.  The practical value of this transformation highlights the efficient and robust one-pot synthesis of α-alkyl-β-keto sulfones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCcik9YrVp17Vg90H21EOLACvtfcHk0lhly6yf_dLXtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCksL3M&md5=53ca82c5bc166c07e8beae449ea7e5ea</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fsrep18391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18391%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DX.-W.%26aulast%3DWang%26aufirst%3DN.-X.%26aulast%3DBai%26aufirst%3DC.-B.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DJ.-L.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DLi%26aufirst%3DY.-H.%26atitle%3DLigand-mediated%2520and%2520copper-catalyzed%2520C%2528sp3%2529-H%2520bond%2520functionalization%2520of%2520aryl%2520ketones%2520with%2520sodium%2520sulfinates%2520under%2520mild%2520conditions%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D18391%26doi%3D10.1038%2Fsrep18391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulmer, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherden, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nudelman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bercaw, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, K. I.</span></span> <span> </span><span class="NLM_article-title">NMR Chemical shifts of trace impurities: Common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist</span>. <i>Organometallics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2176</span>, <span class="refDoi"> DOI: 10.1021/om100106e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/om100106e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslKms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=2176&author=G.+R.+Fulmerauthor=A.+J.+M.+Millerauthor=N.+H.+Sherdenauthor=H.+E.+Gottliebauthor=A.+Nudelmanauthor=B.+M.+Stoltzauthor=J.+E.+Bercawauthor=K.+I.+Goldberg&title=NMR+Chemical+shifts+of+trace+impurities%3A+Common+laboratory+solvents%2C+organics%2C+and+gases+in+deuterated+solvents+relevant+to+the+organometallic+chemist&doi=10.1021%2Fom100106e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist</span></div><div class="casAuthors">Fulmer, Gregory R.; Miller, Alexander J. M.; Sherden, Nathaniel H.; Gottlieb, Hugo E.; Nudelman, Abraham; Stoltz, Brian M.; Bercaw, John E.; Goldberg, Karen I.</div><div class="citationInfo"><span class="NLM_cas:title">Organometallics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2176-2179</span>CODEN:
                <span class="NLM_cas:coden">ORGND7</span>;
        ISSN:<span class="NLM_cas:issn">0276-7333</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tables of 1H and 13C NMR chem. shifts have been compiled for common org. compds. often used as reagents or found as products or contaminants in deuterated org. solvents.  Building upon the work of Gottlieb, Kotlyar, and Nudelman in the Journal of Org. Chem., signals for common impurities are now reported in addnl. NMR solvents (tetrahydrofuran-d8, toluene-d8, dichloromethane-d2, chlorobenzene-d5, and 2,2,2-trifluoroethanol-d3) which are frequently used in organometallic labs.  Chem. shifts for other orgs. which are often used as reagents or internal stds. or are found as products in organometallic chem. are also reported for all the listed solvents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3GGHumCq_P7Vg90H21EOLACvtfcHk0ljY39CKSxWLxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslKms7Y%253D&md5=53317e05fe3be77fe7de48d8fe1fb8b7</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fom100106e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fom100106e%26sid%3Dliteratum%253Aachs%26aulast%3DFulmer%26aufirst%3DG.%2BR.%26aulast%3DMiller%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DSherden%26aufirst%3DN.%2BH.%26aulast%3DGottlieb%26aufirst%3DH.%2BE.%26aulast%3DNudelman%26aufirst%3DA.%26aulast%3DStoltz%26aufirst%3DB.%2BM.%26aulast%3DBercaw%26aufirst%3DJ.%2BE.%26aulast%3DGoldberg%26aufirst%3DK.%2BI.%26atitle%3DNMR%2520Chemical%2520shifts%2520of%2520trace%2520impurities%253A%2520Common%2520laboratory%2520solvents%252C%2520organics%252C%2520and%2520gases%2520in%2520deuterated%2520solvents%2520relevant%2520to%2520the%2520organometallic%2520chemist%26jtitle%3DOrganometallics%26date%3D2010%26volume%3D29%26spage%3D2176%26doi%3D10.1021%2Fom100106e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 22 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Brayden G. Schindell, Meagan Allardice, Sandhini Lockman, <span class="NLM_string-name hlFld-ContribAuthor">Jason Kindrachuk</span>. </span><span class="cited-content_cbyCitation_article-title">Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic. </span><span class="cited-content_cbyCitation_journal-name">ACS Infectious Diseases</span><span> <strong>2021,</strong> <em>7 </em>
                                    (6)
                                     , 1303-1316. <a href="https://doi.org/10.1021/acsinfecdis.0c00579" title="DOI URL">https://doi.org/10.1021/acsinfecdis.0c00579</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsinfecdis.0c00579&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsinfecdis.0c00579%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Infectious%2520Diseases%26atitle%3DIntegrating%252BProteomics%252Bfor%252BFacilitating%252BDrug%252BIdentification%252Band%252BRepurposing%252BDuring%252Ban%252BEmerging%252BVirus%252BPandemic%26aulast%3DSchindell%26aufirst%3DBrayden%2BG.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D13082020%26date%3D15122020%26volume%3D7%26issue%3D6%26spage%3D1303%26epage%3D1316" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Angela Fan, <span class="NLM_string-name hlFld-ContribAuthor">Phillip P. Sharp</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibitors of Eukaryotic Translational Machinery as Therapeutic Agents. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (5)
                                     , 2436-2465. <a href="https://doi.org/10.1021/acs.jmedchem.0c01746" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01746</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01746&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01746%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInhibitors%252Bof%252BEukaryotic%252BTranslational%252BMachinery%252Bas%252BTherapeutic%252BAgents%26aulast%3DFan%26aufirst%3DAngela%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D05102020%26date%3D16022021%26volume%3D64%26issue%3D5%26spage%3D2436%26epage%3D2465" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Christian Nilewski, Theodore D. Michels, Alan X. Xiang, Garrick K. Packard, Paul A. Sprengeler, Boreth Eam, Sarah Fish, Peggy A. Thompson, Christopher J. Wegerski, Justin T. Ernst, <span class="NLM_string-name hlFld-ContribAuthor">Siegfried H. Reich</span>. </span><span class="cited-content_cbyCitation_article-title">Strategic Diastereoselective C1 Functionalization in the Aza-Rocaglamide Scaffold toward Natural Product-Inspired eIF4A Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Organic Letters</span><span> <strong>2020,</strong> <em>22 </em>
                                    (16)
                                     , 6257-6261. <a href="https://doi.org/10.1021/acs.orglett.0c01944" title="DOI URL">https://doi.org/10.1021/acs.orglett.0c01944</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.orglett.0c01944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.orglett.0c01944%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Letters%26atitle%3DStrategic%252BDiastereoselective%252BC1%252BFunctionalization%252Bin%252Bthe%252BAza-Rocaglamide%252BScaffold%252Btoward%252BNatural%252BProduct-Inspired%252BeIF4A%252BInhibitors%26aulast%3DNilewski%26aufirst%3DChristian%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D09062020%26date%3D30072020%26volume%3D22%26issue%3D16%26spage%3D6257%26epage%3D6261" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jayanta  Dowarah</span>, <span class="hlFld-ContribAuthor ">Brilliant N.  Marak</span>, <span class="hlFld-ContribAuthor ">Umesh Chand Singh  Yadav</span>, <span class="hlFld-ContribAuthor ">Ved Prakash  Singh</span>. </span><span class="cited-content_cbyCitation_article-title">Potential drug development and therapeutic approaches for clinical intervention in COVID-19. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105016. <a href="https://doi.org/10.1016/j.bioorg.2021.105016" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105016%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPotential%252Bdrug%252Bdevelopment%252Band%252Btherapeutic%252Bapproaches%252Bfor%252Bclinical%252Bintervention%252Bin%252BCOVID-19%26aulast%3DDowarah%26aufirst%3DJayanta%26date%3D2021%26volume%3D114%26spage%3D105016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christian  Nilewski</span>, <span class="hlFld-ContribAuthor ">Theodore D.  Michels</span>, <span class="hlFld-ContribAuthor ">Garrick K.  Packard</span>, <span class="hlFld-ContribAuthor ">Alan X.  Xiang</span>, <span class="hlFld-ContribAuthor ">Paul A.  Sprengeler</span>, <span class="hlFld-ContribAuthor ">Boreth  Eam</span>, <span class="hlFld-ContribAuthor ">Sarah  Fish</span>, <span class="hlFld-ContribAuthor ">Peggy A.  Thompson</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Wegerski</span>, <span class="hlFld-ContribAuthor ">Andres  Nevarez</span>, <span class="hlFld-ContribAuthor ">Jeff  Clarine</span>, <span class="hlFld-ContribAuthor ">Samuel  Sperry</span>, <span class="hlFld-ContribAuthor ">Justin T.  Ernst</span>, <span class="hlFld-ContribAuthor ">Siegfried H.  Reich</span>. </span><span class="cited-content_cbyCitation_article-title">1-Aminomethyl SAR in a novel series of flavagline-inspired eIF4A inhibitors: Effects of amine substitution on cell potency and in vitro PK properties. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>47 </em>, 128111. <a href="https://doi.org/10.1016/j.bmcl.2021.128111" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128111</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128111%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3D1-Aminomethyl%252BSAR%252Bin%252Ba%252Bnovel%252Bseries%252Bof%252Bflavagline-inspired%252BeIF4A%252Binhibitors%25253A%252BEffects%252Bof%252Bamine%252Bsubstitution%252Bon%252Bcell%252Bpotency%252Band%252Bin%252Bvitro%252BPK%252Bproperties%26aulast%3DNilewski%26aufirst%3DChristian%26date%3D2021%26volume%3D47%26spage%3D128111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jianling  Xie</span>, <span class="hlFld-ContribAuthor ">Eric P.  Kusnadi</span>, <span class="hlFld-ContribAuthor ">Luc  Furic</span>, <span class="hlFld-ContribAuthor ">Luke A.  Selth</span>. </span><span class="cited-content_cbyCitation_article-title">Regulation of mRNA Translation by Hormone Receptors in Breast and Prostate Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (13)
                                     , 3254. <a href="https://doi.org/10.3390/cancers13133254" title="DOI URL">https://doi.org/10.3390/cancers13133254</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13133254&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13133254%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DRegulation%252Bof%252BmRNA%252BTranslation%252Bby%252BHormone%252BReceptors%252Bin%252BBreast%252Band%252BProstate%252BCancer%26aulast%3DXie%26aufirst%3DJianling%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D13%26spage%3D3254" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicholas T.  Ingolia</span>. </span><span class="cited-content_cbyCitation_article-title">eIF4A inhibitors PatA and RocA stack the deck against translation. </span><span class="cited-content_cbyCitation_journal-name">Structure</span><span> <strong>2021,</strong> <em>29 </em>
                                    (7)
                                     , 638-639. <a href="https://doi.org/10.1016/j.str.2021.06.009" title="DOI URL">https://doi.org/10.1016/j.str.2021.06.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.str.2021.06.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.str.2021.06.009%26sid%3Dliteratum%253Aachs%26jtitle%3DStructure%26atitle%3DeIF4A%252Binhibitors%252BPatA%252Band%252BRocA%252Bstack%252Bthe%252Bdeck%252Bagainst%252Btranslation%26aulast%3DIngolia%26aufirst%3DNicholas%2BT.%26date%3D2021%26volume%3D29%26issue%3D7%26spage%3D638%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Honyin  Chiu</span>, <span class="hlFld-ContribAuthor ">Roberta  Buono</span>, <span class="hlFld-ContribAuthor ">Leandra V.  Jackson</span>, <span class="hlFld-ContribAuthor ">Lee-or  Herzog</span>, <span class="hlFld-ContribAuthor ">Sharmila  Mallya</span>, <span class="hlFld-ContribAuthor ">Crystal S.  Conn</span>, <span class="hlFld-ContribAuthor ">Davide  Ruggero</span>, <span class="hlFld-ContribAuthor ">David A.  Fruman</span>. </span><span class="cited-content_cbyCitation_article-title">Reduced eIF4E function impairs B-cell leukemia without altering normal B-lymphocyte function. </span><span class="cited-content_cbyCitation_journal-name">iScience</span><span> <strong>2021,</strong> <em>24 </em>
                                    (7)
                                     , 102748. <a href="https://doi.org/10.1016/j.isci.2021.102748" title="DOI URL">https://doi.org/10.1016/j.isci.2021.102748</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.isci.2021.102748&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.isci.2021.102748%26sid%3Dliteratum%253Aachs%26jtitle%3DiScience%26atitle%3DReduced%252BeIF4E%252Bfunction%252Bimpairs%252BB-cell%252Bleukemia%252Bwithout%252Baltering%252Bnormal%252BB-lymphocyte%252Bfunction%26aulast%3DChiu%26aufirst%3DHonyin%26date%3D2021%26volume%3D24%26issue%3D7%26spage%3D102748" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harald  Greger</span>. </span><span class="cited-content_cbyCitation_article-title">Comparative phytochemistry of flavaglines (= rocaglamides), a group of highly bioactive flavolignans from Aglaia species (Meliaceae). </span><span class="cited-content_cbyCitation_journal-name">Phytochemistry Reviews</span><span> <strong>2021,</strong> <em>131 </em><a href="https://doi.org/10.1007/s11101-021-09761-5" title="DOI URL">https://doi.org/10.1007/s11101-021-09761-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11101-021-09761-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11101-021-09761-5%26sid%3Dliteratum%253Aachs%26jtitle%3DPhytochemistry%2520Reviews%26atitle%3DComparative%252Bphytochemistry%252Bof%252Bflavaglines%252B%252528%25253D%2525E2%252580%252589rocaglamides%252529%25252C%252Ba%252Bgroup%252Bof%252Bhighly%252Bbioactive%252Bflavolignans%252Bfrom%252BAglaia%252Bspecies%252B%252528Meliaceae%252529%26aulast%3DGreger%26aufirst%3DHarald%26date%3D2021%26date%3D2021%26volume%3D131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mingming  Chen</span>, <span class="hlFld-ContribAuthor ">Miwako  Asanuma</span>, <span class="hlFld-ContribAuthor ">Mari  Takahashi</span>, <span class="hlFld-ContribAuthor ">Yuichi  Shichino</span>, <span class="hlFld-ContribAuthor ">Mari  Mito</span>, <span class="hlFld-ContribAuthor ">Koichi  Fujiwara</span>, <span class="hlFld-ContribAuthor ">Hironori  Saito</span>, <span class="hlFld-ContribAuthor ">Stephen N.  Floor</span>, <span class="hlFld-ContribAuthor ">Nicholas T.  Ingolia</span>, <span class="hlFld-ContribAuthor ">Mikiko  Sodeoka</span>, <span class="hlFld-ContribAuthor ">Kosuke  Dodo</span>, <span class="hlFld-ContribAuthor ">Takuhiro  Ito</span>, <span class="hlFld-ContribAuthor ">Shintaro  Iwasaki</span>. </span><span class="cited-content_cbyCitation_article-title">Dual targeting of DDX3 and eIF4A by the translation inhibitor rocaglamide A. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2021,</strong> <em>28 </em>
                                    (4)
                                     , 475-486.e8. <a href="https://doi.org/10.1016/j.chembiol.2020.11.008" title="DOI URL">https://doi.org/10.1016/j.chembiol.2020.11.008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2020.11.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2020.11.008%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DDual%252Btargeting%252Bof%252BDDX3%252Band%252BeIF4A%252Bby%252Bthe%252Btranslation%252Binhibitor%252Brocaglamide%252BA%26aulast%3DChen%26aufirst%3DMingming%26date%3D2021%26volume%3D28%26issue%3D4%26spage%3D475%26epage%3D486.e8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Garima  Agarwal</span>, <span class="hlFld-ContribAuthor ">Long-Sheng  Chang</span>, <span class="hlFld-ContribAuthor ">Djaja Doel  Soejarto</span>, <span class="hlFld-ContribAuthor ">A. Douglas  Kinghorn</span>. </span><span class="cited-content_cbyCitation_article-title">Update on Phytochemical and Biological Studies on Rocaglate Derivatives from Aglaia Species. </span><span class="cited-content_cbyCitation_journal-name">Planta Medica</span><span> <strong>2021,</strong> <em>21 </em><a href="https://doi.org/10.1055/a-1401-9562" title="DOI URL">https://doi.org/10.1055/a-1401-9562</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/a-1401-9562&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fa-1401-9562%26sid%3Dliteratum%253Aachs%26jtitle%3DPlanta%2520Medica%26atitle%3DUpdate%252Bon%252BPhytochemical%252Band%252BBiological%252BStudies%252Bon%252BRocaglate%252BDerivatives%252Bfrom%252BAglaia%252BSpecies%26aulast%3DAgarwal%26aufirst%3DGarima%26date%3D2021%26date%3D2021%26volume%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">J. J. David  Ho</span>, <span class="hlFld-ContribAuthor ">Jeffrey H. S.  Man</span>, <span class="hlFld-ContribAuthor ">Jonathan H.  Schatz</span>, <span class="hlFld-ContribAuthor ">Philip A.  Marsden</span>. </span><span class="cited-content_cbyCitation_article-title">Translational remodeling by
              RNA
              ‐binding proteins and noncoding
              RNAs. </span><span class="cited-content_cbyCitation_journal-name">WIREs RNA</span><span> <strong>2021,</strong> <em>78 </em><a href="https://doi.org/10.1002/wrna.1647" title="DOI URL">https://doi.org/10.1002/wrna.1647</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/wrna.1647&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fwrna.1647%26sid%3Dliteratum%253Aachs%26jtitle%3DWIREs%2520RNA%26atitle%3DTranslational%252Bremodeling%252Bby%252BRNA%252B%2525E2%252580%252590binding%252Bproteins%252Band%252Bnoncoding%252BRNAs%26aulast%3DHo%26aufirst%3DJ.%2BJ.%2BDavid%26date%3D2021%26date%3D2021%26volume%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gaspar  Taroncher-Oldenburg</span>, <span class="hlFld-ContribAuthor ">Christin  Müller</span>, <span class="hlFld-ContribAuthor ">Wiebke  Obermann</span>, <span class="hlFld-ContribAuthor ">John  Ziebuhr</span>, <span class="hlFld-ContribAuthor ">Roland K.  Hartmann</span>, <span class="hlFld-ContribAuthor ">Arnold  Grünweller</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates—A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics. </span><span class="cited-content_cbyCitation_journal-name">Microorganisms</span><span> <strong>2021,</strong> <em>9 </em>
                                    (3)
                                     , 540. <a href="https://doi.org/10.3390/microorganisms9030540" title="DOI URL">https://doi.org/10.3390/microorganisms9030540</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/microorganisms9030540&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmicroorganisms9030540%26sid%3Dliteratum%253Aachs%26jtitle%3DMicroorganisms%26atitle%3DTargeting%252Bthe%252BDEAD-Box%252BRNA%252BHelicase%252BeIF4A%252Bwith%252BRocaglates%2525E2%252580%252594A%252BPan-Antiviral%252BStrategy%252Bfor%252BMinimizing%252Bthe%252BImpact%252Bof%252BFuture%252BRNA%252BVirus%252BPandemics%26aulast%3DTaroncher-Oldenburg%26aufirst%3DGaspar%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D3%26spage%3D540" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kris M.  White</span>, <span class="hlFld-ContribAuthor ">Romel  Rosales</span>, <span class="hlFld-ContribAuthor ">Soner  Yildiz</span>, <span class="hlFld-ContribAuthor ">Thomas  Kehrer</span>, <span class="hlFld-ContribAuthor ">Lisa  Miorin</span>, <span class="hlFld-ContribAuthor ">Elena  Moreno</span>, <span class="hlFld-ContribAuthor ">Sonia  Jangra</span>, <span class="hlFld-ContribAuthor ">Melissa B.  Uccellini</span>, <span class="hlFld-ContribAuthor ">Raveen  Rathnasinghe</span>, <span class="hlFld-ContribAuthor ">Lynda  Coughlan</span>, <span class="hlFld-ContribAuthor ">Carles  Martinez-Romero</span>, <span class="hlFld-ContribAuthor ">Jyoti  Batra</span>, <span class="hlFld-ContribAuthor ">Ajda  Rojc</span>, <span class="hlFld-ContribAuthor ">Mehdi  Bouhaddou</span>, <span class="hlFld-ContribAuthor ">Jacqueline M.  Fabius</span>, <span class="hlFld-ContribAuthor ">Kirsten  Obernier</span>, <span class="hlFld-ContribAuthor ">Marion  Dejosez</span>, <span class="hlFld-ContribAuthor ">María José  Guillén</span>, <span class="hlFld-ContribAuthor ">Alejandro  Losada</span>, <span class="hlFld-ContribAuthor ">Pablo  Avilés</span>, <span class="hlFld-ContribAuthor ">Michael  Schotsaert</span>, <span class="hlFld-ContribAuthor ">Thomas  Zwaka</span>, <span class="hlFld-ContribAuthor ">Marco  Vignuzzi</span>, <span class="hlFld-ContribAuthor ">Kevan M.  Shokat</span>, <span class="hlFld-ContribAuthor ">Nevan J.  Krogan</span>, <span class="hlFld-ContribAuthor ">Adolfo  García-Sastre</span>. </span><span class="cited-content_cbyCitation_article-title">Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A. </span><span class="cited-content_cbyCitation_journal-name">Science</span><span> <strong>2021,</strong> <em>371 </em>
                                    (6532)
                                     , 926-931. <a href="https://doi.org/10.1126/science.abf4058" title="DOI URL">https://doi.org/10.1126/science.abf4058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/science.abf4058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fscience.abf4058%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%26atitle%3DPlitidepsin%252Bhas%252Bpotent%252Bpreclinical%252Befficacy%252Bagainst%252BSARS-CoV-2%252Bby%252Btargeting%252Bthe%252Bhost%252Bprotein%252BeEF1A%26aulast%3DWhite%26aufirst%3DKris%2BM.%26date%3D2021%26date%3D2021%26volume%3D371%26issue%3D6532%26spage%3D926%26epage%3D931" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christin  Müller</span>, <span class="hlFld-ContribAuthor ">Wiebke  Obermann</span>, <span class="hlFld-ContribAuthor ">Nadja  Karl</span>, <span class="hlFld-ContribAuthor ">Hans-Guido  Wendel</span>, <span class="hlFld-ContribAuthor ">Gaspar  Taroncher-Oldenburg</span>, <span class="hlFld-ContribAuthor ">Stephan  Pleschka</span>, <span class="hlFld-ContribAuthor ">Roland K.  Hartmann</span>, <span class="hlFld-ContribAuthor ">Arnold  Grünweller</span>, <span class="hlFld-ContribAuthor ">John  Ziebuhr</span>. </span><span class="cited-content_cbyCitation_article-title">The rocaglate CR-31-B (−) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo. </span><span class="cited-content_cbyCitation_journal-name">Antiviral Research</span><span> <strong>2021,</strong> <em>186 </em>, 105012. <a href="https://doi.org/10.1016/j.antiviral.2021.105012" title="DOI URL">https://doi.org/10.1016/j.antiviral.2021.105012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.antiviral.2021.105012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.antiviral.2021.105012%26sid%3Dliteratum%253Aachs%26jtitle%3DAntiviral%2520Research%26atitle%3DThe%252Brocaglate%252BCR-31-B%252B%252528%2525E2%252588%252592%252529%252Binhibits%252BSARS-CoV-2%252Breplication%252Bat%252Bnon-cytotoxic%25252C%252Blow%252Bnanomolar%252Bconcentrations%252Bin%252Bvitro%252Band%252Bex%252Bvivo%26aulast%3DM%25C3%25BCller%26aufirst%3DChristin%26date%3D2021%26volume%3D186%26spage%3D105012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Viraj R.  Sanghvi</span>, <span class="hlFld-ContribAuthor ">Prathibha  Mohan</span>, <span class="hlFld-ContribAuthor ">Kamini  Singh</span>, <span class="hlFld-ContribAuthor ">Linlin  Cao</span>, <span class="hlFld-ContribAuthor ">Marjan  Berishaj</span>, <span class="hlFld-ContribAuthor ">Andrew L.  Wolfe</span>, <span class="hlFld-ContribAuthor ">Jonathan H.  Schatz</span>, <span class="hlFld-ContribAuthor ">Nathalie  Lailler</span>, <span class="hlFld-ContribAuthor ">Elisa  de Stanchina</span>, <span class="hlFld-ContribAuthor ">Agnes  Viale</span>, <span class="hlFld-ContribAuthor ">Hans-Guido  Wendel</span>. </span><span class="cited-content_cbyCitation_article-title">NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (4)
                                     , 639. <a href="https://doi.org/10.3390/cancers13040639" title="DOI URL">https://doi.org/10.3390/cancers13040639</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13040639&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13040639%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DNRF2%252BActivation%252BConfers%252BResistance%252Bto%252BeIF4A%252BInhibitors%252Bin%252BCancer%252BTherapy%26aulast%3DSanghvi%26aufirst%3DViraj%2BR.%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D4%26spage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Douglas S.  Micalizzi</span>, <span class="hlFld-ContribAuthor ">Richard Y.  Ebright</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Haber</span>, <span class="hlFld-ContribAuthor ">Shyamala  Maheswaran</span>. </span><span class="cited-content_cbyCitation_article-title">Translational Regulation of Cancer Metastasis. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2021,</strong> <em>81 </em>
                                    (3)
                                     , 517-524. <a href="https://doi.org/10.1158/0008-5472.CAN-20-2720" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-20-2720</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-20-2720&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-20-2720%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DTranslational%252BRegulation%252Bof%252BCancer%252BMetastasis%26aulast%3DMicalizzi%26aufirst%3DDouglas%2BS.%26date%3D2021%26date%3D2021%26volume%3D81%26issue%3D3%26spage%3D517%26epage%3D524" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peggy A.  Thompson</span>, <span class="hlFld-ContribAuthor ">Boreth  Eam</span>, <span class="hlFld-ContribAuthor ">Nathan P.  Young</span>, <span class="hlFld-ContribAuthor ">Sarah  Fish</span>, <span class="hlFld-ContribAuthor ">Joan  Chen</span>, <span class="hlFld-ContribAuthor ">Maria  Barrera</span>, <span class="hlFld-ContribAuthor ">Haleigh  Howard</span>, <span class="hlFld-ContribAuthor ">Eric  Sung</span>, <span class="hlFld-ContribAuthor ">Ana  Parra</span>, <span class="hlFld-ContribAuthor ">Jocelyn  Staunton</span>, <span class="hlFld-ContribAuthor ">Gary G.  Chiang</span>, <span class="hlFld-ContribAuthor ">Adina  Gerson-Gurwitz</span>, <span class="hlFld-ContribAuthor ">Christopher J.  Wegerski</span>, <span class="hlFld-ContribAuthor ">Andres  Nevarez</span>, <span class="hlFld-ContribAuthor ">Jeff  Clarine</span>, <span class="hlFld-ContribAuthor ">Samuel  Sperry</span>, <span class="hlFld-ContribAuthor ">Alan  Xiang</span>, <span class="hlFld-ContribAuthor ">Christian  Nilewski</span>, <span class="hlFld-ContribAuthor ">Garrick K.  Packard</span>, <span class="hlFld-ContribAuthor ">Theodore  Michels</span>, <span class="hlFld-ContribAuthor ">Chinh  Tran</span>, <span class="hlFld-ContribAuthor ">Paul A.  Sprengeler</span>, <span class="hlFld-ContribAuthor ">Justin T.  Ernst</span>, <span class="hlFld-ContribAuthor ">Siegfried H.  Reich</span>, <span class="hlFld-ContribAuthor ">Kevin R.  Webster</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2021,</strong> <em>20 </em>
                                    (1)
                                     , 26-36. <a href="https://doi.org/10.1158/1535-7163.MCT-19-0973" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-19-0973</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-19-0973&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-19-0973%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DTargeting%252BOncogene%252BmRNA%252BTranslation%252Bin%252BB-Cell%252BMalignancies%252Bwith%252BeFT226%25252C%252Ba%252BPotent%252Band%252BSelective%252BInhibitor%252Bof%252BeIF4A%26aulast%3DThompson%26aufirst%3DPeggy%2BA.%26date%3D2021%26date%3D2020%26volume%3D20%26issue%3D1%26spage%3D26%26epage%3D36" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Canan G.  Nebigil</span>, <span class="hlFld-ContribAuthor ">Christiane  Moog</span>, <span class="hlFld-ContribAuthor ">Stéphan  Vagner</span>, <span class="hlFld-ContribAuthor ">Nadia  Benkirane-Jessel</span>, <span class="hlFld-ContribAuthor ">Duncan R.  Smith</span>, <span class="hlFld-ContribAuthor ">Laurent  Désaubry</span>. </span><span class="cited-content_cbyCitation_article-title">Flavaglines as natural products targeting eIF4A and prohibitins: From traditional Chinese medicine to antiviral activity against coronaviruses. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112653. <a href="https://doi.org/10.1016/j.ejmech.2020.112653" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112653</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112653&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112653%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DFlavaglines%252Bas%252Bnatural%252Bproducts%252Btargeting%252BeIF4A%252Band%252Bprohibitins%25253A%252BFrom%252Btraditional%252BChinese%252Bmedicine%252Bto%252Bantiviral%252Bactivity%252Bagainst%252Bcoronaviruses%26aulast%3DNebigil%26aufirst%3DCanan%2BG.%26date%3D2020%26volume%3D203%26spage%3D112653" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">. </span><span class="cited-content_cbyCitation_article-title">Synthesis of Zotatifin. </span><span class="cited-content_cbyCitation_journal-name">Synfacts</span><span> <strong>2020,</strong>,, 1018. <a href="https://doi.org/10.1055/s-0040-1705863" title="DOI URL">https://doi.org/10.1055/s-0040-1705863</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1055/s-0040-1705863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1055%2Fs-0040-1705863%26sid%3Dliteratum%253Aachs%26jtitle%3DSynfacts%26atitle%3DSynthesis%252Bof%252BZotatifin%26date%3D2020%26date%3D2020%26volume%3D16%26issue%3D09%26spage%3D1018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Monika  Sobočan</span>, <span class="hlFld-ContribAuthor ">Maria Anna  Smolle</span>, <span class="hlFld-ContribAuthor ">Christoph  Schatz</span>, <span class="hlFld-ContribAuthor ">Johannes  Haybaeck</span>. </span><span class="cited-content_cbyCitation_article-title">The Interplay of Tumor Stroma and Translational Factors in Endometrial Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (8)
                                     , 2074. <a href="https://doi.org/10.3390/cancers12082074" title="DOI URL">https://doi.org/10.3390/cancers12082074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12082074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12082074%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DThe%252BInterplay%252Bof%252BTumor%252BStroma%252Band%252BTranslational%252BFactors%252Bin%252BEndometrial%252BCancer%26aulast%3DSobo%25C4%258Dan%26aufirst%3DMonika%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D8%26spage%3D2074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cory M.  Howard</span>, <span class="hlFld-ContribAuthor ">Matthew  Estrada</span>, <span class="hlFld-ContribAuthor ">David  Terrero</span>, <span class="hlFld-ContribAuthor ">Amit K.  Tiwari</span>, <span class="hlFld-ContribAuthor ">Dayanidhi  Raman</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Cardiac Glycosides as Novel Inhibitors of eIF4A1-Mediated Translation in Triple-Negative Breast Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (8)
                                     , 2169. <a href="https://doi.org/10.3390/cancers12082169" title="DOI URL">https://doi.org/10.3390/cancers12082169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12082169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12082169%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DIdentification%252Bof%252BCardiac%252BGlycosides%252Bas%252BNovel%252BInhibitors%252Bof%252BeIF4A1-Mediated%252BTranslation%252Bin%252BTriple-Negative%252BBreast%252BCancer%252BCells%26aulast%3DHoward%26aufirst%3DCory%2BM.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D8%26spage%3D2169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0046.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0046.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Modeled binding mode of rocaglamide A (pink) to a complex formed by poly-U RNA (light blue) and eIF4A3 (dark blue). Residues of eIF4A shown to confer resistance to rocaglamide analogues are highlighted in (yellow), PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0008.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Conformational analysis of rocaglamide A.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0009.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. X-ray structure of a ternary complex formed between rocaglamide A, eIF4A1, and a polypurine RNA sequence showing the hydrogen bond from the tertiary hydroxyl group to the purine N7, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9">5ZC9</a>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0010.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modeling of compound <b>7</b> in the binding pocket formed from eIF4A in complex with poly-U RNA, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0011.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray structure for compound <b>8</b> highlighting the intramolecular hydrogen bond between the secondary hydroxyl and the pyridine nitrogen and the 40° Ar–Ar torsion.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0012.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. LLE plot for ring A phenyl series. Iso-LLE changes between compounds are shown with yellow arrows while changes resulting in LLE improvement are shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0013.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. LLE plot for ring A pyridine series. Iso-LLE changes between compounds are shown with yellow arrows while changes resulting in LLE improvement are shown in green.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0014.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Binding model for compound <b>36</b>. The 3.9 Å contact between the pyridine nitrogen of <b>36</b> and one of the phosphate ether oxygens of the RNA backbone is shown, PDB ID <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI">2HYI</a>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0015.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. <b>eFT226</b> enhances formation of eIF4A1/RNA complex. Sensograms of eIF4A1 binding to rAGA surface in the presence (solid) or absence (dashed) of <b>eFT226</b>. The sensograms were fitted using a global fitting function to determine the equilibrium dissociation constant and binding kinetics. Running buffer contained 14.4 mM Hepes pH 7.4, 108 mM NaCl, 1 mM MgCl<sub>2</sub>, 0.36 mM TCEP, 1 mM ATP, and 1% dimethyl sulfoxide (DMSO). Data were collected at 25 °C.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. <b>eFT226</b> inhibition of reporter gene expression is dependent upon the 5′ UTR sequence. Relative luciferase expressed by luciferase reporter mRNAs containing 5′-UTRs encoding unique 6-mer sequence motifs. The luciferase reporter gene constructs were transiently transfected into the MDA-MB-231 cell line and treated with increasing concentrations of <b>eFT226</b> for 4 h in triplicate. Data were fitted to a four-parameter dose response curve. AGAGAG (green); GGCGGC (blue); CCGCCG (red) and CAACAA (black).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Downregulation of eIF4A target genes by <b>eFT226</b> is rescued with eIF4A1 F163L knock-in mutation. Protein levels of eIF4A sensitive genes after treatment with <b>eFT226</b> for 24 h in HAP1 wt or eIF4A1 F163L mutant cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. eIF4A1 mutation (F163L) rescues <b>eFT226</b> activity linking antitumor phenotype to eIF4A1 inhibition. (A) Potent inhibition of cell growth was observed with 72 h <b>eFT226</b> treatment of HAP1 wild-type cells. The HAP1 eIF4A1 F163L mutant cells were resistant to <b>eFT226</b> treatment. (B) eIF4A1 F163L mutation demonstrated resistance only to <b>eFT226</b>. Mutation at this binding site did not rescue the antiproliferative effect of hippuristanol.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. <b>eFT226</b> modulates key drivers of tumorigenesis in a dose-dependent manner. (A) Cell cycle progression was assessed by DNA staining using DRAQ5 and monitoring fluorescence by flow cytometry. Tumor cells treated with increasing concentrations of <b>eFT226</b> for 24 h resulted in G2 arrest. (B) Incubation of MDA-MB-231 tumor cells with increasing concentrations of <b>eFT226</b> for 24 h were analyzed by annexin (V+) and PI flow cytometry. A dose-dependent increase in cells undergoing apoptosis and cell death (V+ PI+) was observed with <b>eFT226</b> treatment. (C) Treatment of MDA-MB-231 cancer cells with <b>eFT226</b> downregulates the protein levels of <b>eFT226</b>-sensitive target genes (Cyclin D1 and BCL2) as analyzed by Western blot.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0006.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. <b>eFT226</b> efficacy in orthotopic MDA-MB-231 TNBC model. (A) Athymic nude mice (10 mice/group) implanted in the mammary fat pad with MDA-MB-231 cells were treated once weekly (Q1W) with either vehicle or <b>eFT226</b> by IV for 14 days to assess effect on tumor growth. Treatment with <b>eFT226</b> results in tumor regression during the treatment duration. (B) Effect of vehicle or drug treatment on body weight change over the course of treatment in tumor bearing mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0016.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Key Steps in Porco’s Synthetic Approach toward Silvestrol (<b>1</b>) and Rocaglamide a (<b>2</b>) Using a Biomimetic Photocycloaddition Strategy</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0027.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthetic Route toward Carbocyclic A-Ring Analogues <b>6</b> and <b>10–14</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0033.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0033.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. (A) Synthesis of <i>rac</i>-<b>6</b>; (a) MeI, Acetone, rt (92%); (b) <i>p</i>-MeO-benzaldehyde, NaOH, MeOH, 90%; (c) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, 20%; (d) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (e) NaOMe, MeOH, 100 °C; (f) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 36% over Three Steps; (g) LiOH, MeOH, Water, 84%; (h) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 33%; (B) Synthesis of <i>rac</i>-<b>10</b>. (a) <i>p</i>-MeO-benzaldehyde, NaOH, MeOH, 89%; (b) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, Water, 63%; (c) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (d) NaOMe, MeOH, 80 °C; (e) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 52% over Three Steps; (f) LiOH, MeOH, Water, 86%; (g) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 90%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0033.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0034.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0034.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. (A) Synthesis of <i>rac</i>-<b>11</b>; (a) <i>p</i>-Br-benzaldehyde, NaOH, MeOH, 90 °C, Quant.; (b) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, 47%; (c) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (d) NaOMe, MeOH, 90 °C; (e) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 31% over Three Steps; (f) LiOH, MeOH, Water, 93%; (g) HNMe<sub>2</sub>–HCl, EDC-HCl, HOBt, DIPEA, DCM, 85%; (h) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 120 °C, 14%; (B) Synthesis of <i>rac</i>-<b>12</b> and <i>rac</i>-<b>13</b>; (a) <i>p</i>-MeO-benzaldehyde, NaOH, MeOH, Reflux, 40%; (b) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, 46%; (c) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (d) NaOMe, MeOH, 90 °C; (e) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 29% over Three Steps; (f) LiOH, THF, Water, 71%; (g) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 69%; (h) Pd(OH)<sub>2</sub>, Ethyl Acetate, rt; (i) MeI, K<sub>2</sub>CO<sub>3</sub>, Acetone, rt, 77% over Two Steps; (j) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 120 °C, 45%; (k) <i>p</i>-MeO-benzaldehyde, NaOH, MeOH, Reflux, 81%; (l) NaOH, H<sub>2</sub>O<sub>2</sub>, Ethanol, 58%; (m) Methyl Cinnamate (<b>55</b>), 400 W UV, DCM, MeOH, MeCN; (n) NaOMe, MeOH, 80 °C; (o) NaBH(OAc)<sub>3</sub>, AcOH, MeCN, 63% over Three Steps; (p) LiOH, MeOH, Water; (q) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 95% over Two Steps; (r) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc; (s) Tf<sub>2</sub>O, DCM, 56%; (t) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 110 °C, 25%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0034.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0035.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0035.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <i>rac</i>-<b>14</b>; (a) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 100 °C, 81%; (b) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, 81%; (c) Tf<sub>2</sub>O, DIPEA, DCM, THF, 51%; (d) Zn(CN)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, DMF, 120 °C, 86%; (e) LiOH, MeOH, Water, 69%; (f) HNMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 41%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch6" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0036.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0036.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Envisioned Synthetic Route toward 8-Aza Analogues <i>rac</i>-<b>5</b> and Enantiopure <b>7–9</b> and <b>15–23</b></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0036.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch7" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0037.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0037.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. (A) Synthesis of Key Intermediate <b>90</b>; (a) NaOMe, MeOH, Reflux (85%); (b) MeMgCl, THF, −20 °C to rt, 65%; (c) HBr, AcOH, 150 °C, 35%; (d) MeI, K<sub>2</sub>CO<sub>3</sub>, Acetone 0 °C to rt; (B) Synthesis of analogues <i>rac</i>-<b>5</b> and (−)-<b>7</b>; (a) <i>para</i>-Methoxybenzaldehyde, NaOH, MeOH, Reflux; (b) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, 0 °C to rt, 23% over Two Steps; (c) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (d) NaOMe, MeOH, 80 °C; (e) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 24% over Three Steps; (f) LiOH, MeOH, H<sub>2</sub>O, rt, 77%; (g) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, 8%; (h) 4-Bromobenzaldehyde, NaOH, MeOH, Reflux; (i) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, 0 °C to rt; (j) Methyl Cinnamate, MeCN, MeOH, DCM, rt, <i>h</i>ν; (k) NaOMe, MeOH, 80 °C; (l) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 7% over Five Steps; (m) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C; (n) LiOH, MeOH, H<sub>2</sub>O, rt; (o) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, 15% over Three Steps; (p) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0037.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch8" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0038.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0038.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. (A) Synthesis of Key Intermediate <b>98</b>; (a) BnOH, NaH, THF, rt, 84%; (b) MeMgBr, THF, −30 °C to rt, 64%; (c) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, 65%; (B) Synthesis of Analogues <b>15</b> and <b>17–23</b>. (a) NaOH, 4-Substituted Benzaldehyde <b>61</b>, MeOH, Δ; (b) H<sub>2</sub>O<sub>2</sub>, NaOH, EtOH/DCM, rt; (c) Methyl Cinnamate, MeCN, MeOH, DCM, <i>h</i>ν; (d) NaOMe, MeOH, Δ; (e) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt; (f) LiOH, THF/Water, rt; (g) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM; (h) Chiral HPLC Separation; (C) Synthesis of analogue <b>8</b>. (a) <i>para</i>-Bromobenzaldehyde, NaOH, MeOH, Reflux, 61%; (b) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, DCM, rt, 31%; (c) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (d) NaOMe, MeOH, 70 °C; (e) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 55% over Three Steps; (f) LiOH, MeOH, H<sub>2</sub>O, rt, Quant.; (h) EDC, HOBt, DIPEA, DCM, 0 °C, Then Me<sub>2</sub>NH–HCl, rt, 86%; (i) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 83%; (j) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0038.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch9" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0039.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0039.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. (A) Synthesis of Key Intermediate <b>109</b>; (a) BnOH, NaH, THF, 0 °C to rt; (b) MeMgBr, THF, −30 °C to rt; (c) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, rt, 89%; (d) K<sub>2</sub>CO<sub>3</sub>, BnBr, Acetone, 94%; (B) Synthesis of Analogues (−)-<b>9</b> and (−)-<b>16</b>; (a) 4-Bromobenzaldehyde, NaOH, MeOH, 85 °C, 59%; (b) H<sub>2</sub>O<sub>2</sub>, NaOH, EtOH/DCM, rt, 53%; (c) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (d) NaOMe, MeOH, 70 °C; (e) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 38% over Three Steps; (f) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 125 °C (97%); (g) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, rt, 97%; (h) Tf<sub>2</sub>O, DIPEA, DCM, −78 °C to 0 °C, 77%; (i) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 125 °C; (j) LiOH, THF/Water, 37% over Two Steps; (k) TEA, Me<sub>2</sub>NH–HCl, T3P, DCM/EtOAc, rt, 31%; (l) Chiral HPLC Separation; (m) NaOH, 4-Methoxybenzaldehyde, MeOH, Reflux; (n) H<sub>2</sub>O<sub>2</sub>, NaOH, EtOH/DCM, rt; (o) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, <i>h</i>ν; (p) NaOMe, MeOH, 70 °C; (q) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt; (r) H<sub>2</sub>, Pd(OH)<sub>2</sub>, EtOAc, 7% over Six Steps; (s) Tf<sub>2</sub>O, DIPEA, DCM, −78 °C to rt; (t) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 85 °C; (u) LiOH, THF/Water, rt; (v) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, 19% over Four Steps; (w) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0039.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch10" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0017.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of <i>rac</i>-<b>24</b>; (a) <b>114</b>, DCC, DCM, rt; (b) AIBN, Bu<sub>3</sub>SnH, C<sub>6</sub>H<sub>6</sub>, 80 °C, 10% over Two Steps; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 16%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch11" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0018.jpeg" id="rightTab-gr26" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of <i>rac</i>-<b>27</b>, (−)-<b>31</b>, and <i>rac</i>-<b>32</b>; (a) NHMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 0 °C to rt, 76%; (b) BH<sub>3</sub>-DMS, THF, 0 °C to rt, Then MeOH, 0 °C to Reflux, 61%; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 130 °C, 46%; (d) Chiral HPLC Separation; (e) EDC, HOBt, DIPEA, 0 °C, Then <b>118</b>, 0 °C to 35 °C, 64%; (f) HCl(aq), THF, rt; (g) PPh<sub>3</sub>, I<sub>2</sub>, TEA, DCM, rt, 21% over Two Steps; (h) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 150 °C, 23%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch12" data-index="26" class="article__inlineFigure"><h2 class="fig-label">Scheme 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0019.jpeg" id="rightTab-gr27" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 12. Synthesis of <i>rac</i>-<b>32</b>, (−)-<b>25</b>, and (−)-<b>26</b>; (a) LAH, THF, 0 °C to rt, 49%; (b) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, Water, MW, 100 °C, 71%; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 125 °C, 78%; (d) LiOH, MeOH, Water, rt, 78%; (e) EDC, HOBt, DIPEA, DCM, 0 °C, Then NH<sub>4</sub>Cl, rt, 78%; (f) Chiral HPLC Separation; (g) EDC, HOBt, DIPEA, DCM, 0 °C, Then MeNH<sub>2</sub>–HCl, rt, 90%; (h) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch13" data-index="27" class="article__inlineFigure"><h2 class="fig-label">Scheme 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0020.jpeg" id="rightTab-gr28" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 13. Synthesis of <i>rac</i>-<b>28</b> and <i>rac</i>-<b>29</b>. (a) <b>121</b>, DCM, MeOH, MeCN, rt, <i>h</i>ν; (b) NaOMe, MeOH, 80 °C; (c) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 2% over Three Steps; (d) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 7%; (e) <b>123</b>, DCM, MeOH, MeCN, rt, <i>h</i>ν; (f) NaOMe, MeOH, 80 °C; (g) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 9% over Three Steps; (h) TFA, Triflic acid, DCM, 92%; (i) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 125 °C, 8%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch14" data-index="28" class="article__inlineFigure"><h2 class="fig-label">Scheme 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0021.jpeg" id="rightTab-gr29" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 14. Synthesis of (−)-<b>30</b>; (a) LiCl, DMSO, 150 °C, 33%; (b) Sodium Methanesulfinate, CuBr<sub>2</sub>, DBU, DMSO, rt; (c) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 4% over Two Steps; (d) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMSO, 150 °C, 72%; (e) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch15" data-index="29" class="article__inlineFigure"><h2 class="fig-label">Scheme 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0022.jpeg" id="rightTab-gr30" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 15. Synthesis of (−)-<b>33</b>; (a) EDC, HOBt, DIPEA, <b>129</b>-HCl, DCM, 0 °C to rt, 63%; (b) MeMgBr, THF, 0 °C to rt, 88%; (c) AcOH, HCl (aq), 100 °C, 68%; (d) 4-Bromobenzaldehyde, NaOH, MeOH, DCM, 90 °C, 97%; (e) H<sub>2</sub>O<sub>2</sub>, aq NaOH, MeOH, rt, 30%; (f) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (g) NaOMe, MeOH, 90 °C; (h) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 28% over Three Steps; (i) LiOH, THF, H<sub>2</sub>O, rt, 91%; (j) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 to 40 °C, 71%; (k) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 150 °C, 36%; (l) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch15"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch16" data-index="30" class="article__inlineFigure"><h2 class="fig-label">Scheme 16</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0023.jpeg" id="rightTab-gr31" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 16. Synthesis of <i>rac</i>-<b>34</b>; (a) NBS, DCM, 0 °C, 92%; (b) <b>137</b>, cat. PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub>, Toluene, 100 °C, Then HCl (aq) 49%; (c) NaNO<sub>2</sub>, H<sub>2</sub>SO<sub>4</sub>, Dioxane, Water, 0 to 50 °C, 37%; (d) 4-Bromobenzaldehyde, NaOH, MeOH, Reflux, 68%; (e) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, 0 °C to rt, 32%; (f) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (g) NaOMe, MeOH, 80 °C; (h) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 1% over Three Steps; (i) LiOH, THF, H<sub>2</sub>O, rt, 67%; (j) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, Quant.; (k) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 19%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch16"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch17" data-index="31" class="article__inlineFigure"><h2 class="fig-label">Scheme 17</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0024.jpeg" id="rightTab-gr32" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 17. Synthesis of (−)-<b>35</b>; (a) PMBOH, NaH, THF, 0 °C to rt, 76%; (b) NaOMe, MeOH, 80 °C, 46%; (c) MeMgBr, THF, 0 °C to rt; Then HCl(aq), rt, 52%; (d) <i>para</i>-bromobenzaldehyde, NaOH, MeOH, Reflux, 80%; (e) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, DCM, 0 °C to rt, 29%; (f) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, hn; (g) NaOMe, MeOH, 80 °C; (h) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 35% over Three Steps; (i) LiOH, MeOH, H<sub>2</sub>O, rt, 79%: (j) NHMe<sub>2</sub>–HCl, EDC, HOBt, DIPEA, DCM, 0 °C to rt, 65%; (k) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C; 50%; (l) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch17"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch18" data-index="32" class="article__inlineFigure"><h2 class="fig-label">Scheme 18</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0025.jpeg" id="rightTab-gr33" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 18. Synthesis of <i>rac</i>-<b>36</b>. (a) <i>t</i>-BuOK, MeOH, 80 °C; (b) EDC, HOBt, DIPEA, <b>129</b>-HCl, DCM, 0 °C to rt, 75% over Two Steps; (c) MeMgBr, Et<sub>2</sub>O, THF, 0 °C to rt; (d) PMB-OH, NaH, THF, 0 °C to rt, 47% over Two Steps; (e) TFA, DCM, 0 °C to rt; (f) 4-Bromobenzaldehyde, NaOH, MeOH, 80 °C; (g) H<sub>2</sub>O<sub>2</sub>, aq NaOH, EtOH, DCM, rt, 40% over Three Steps; (h) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM, rt, <i>h</i>ν; (i) NaOMe, MeOH, 80 °C; (j) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 3% over Three Steps; (k) LiOH, MeOH, H<sub>2</sub>O, rt, 93%; (l) EDC, HOBt, DIPEA, Me<sub>2</sub>NH–HCl, DCM, 0 °C to rt, 38%; (m) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 22%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch18"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch19" data-index="33" class="article__inlineFigure"><h2 class="fig-label">Scheme 19</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0026.jpeg" id="rightTab-gr34" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 19. General Synthesis of 6-Aza-2-amine analogues Enantiopure <b>37</b>, <b>40–44</b>, <b>46–48</b>, <b>50</b>, <b>51</b>, and Racemic <b>38</b>, <b>39</b>; (a) R<sub>2</sub>NH, EDC, HOBT, DCM, or R<sub>2</sub>NH, HATU, DIPEA, DMF; (b) BH<sub>3</sub>-DMS, THF, Δ, Then MeOH, Δ; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, Δ; (d) Chiral HPLC Separation (for <b>37</b>, <b>40–44</b>, <b>46–48</b>, <b>50</b>, and <b>51</b>)</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch19"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch20" data-index="34" class="article__inlineFigure"><h2 class="fig-label">Scheme 20</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0028.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0028.jpeg" id="rightTab-gr35" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 20. Synthesis of (+)-<b>45</b>. (a) TFAA, TEA, DCM, 0 °C to rt; (b) BH<sub>3</sub>-DMS, THF, 60 °C, Then MeOH, Δ; (c) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, MW, 140 °C, 24% over Three Steps; (d) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch20"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch21" data-index="35" class="article__inlineFigure"><h2 class="fig-label">Scheme 21</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0029.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0029.jpeg" id="rightTab-gr36" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 21. Synthesis of (−)-<b>49</b>. (a) TBSOTf, 2,6-Lutidine, DCM, 0<sup>o</sup>C-rt; Then (H<sub>2</sub>CO)<sub>n</sub>, NaOAc, NaBH(OAc)<sub>3</sub>, rt, 55%; (b) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0029.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch21"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch22" data-index="36" class="article__inlineFigure"><h2 class="fig-label">Scheme 22</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0030.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0030.jpeg" id="rightTab-gr37" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 22. Synthesis of <i>rac</i>-<b>52</b>; (a) BH<sub>3</sub>-DMS, THF, 0 °C to rt, Then MeOH, 70 °C, 93%; (b) MsCl, Pyridine, 0 °C to rt, 80%; (c) KCN, DMSO, 80 °C, 58%; (d) 10% NaOH (aq), THF, 125 °C, 94%; (e) Me<sub>2</sub>NH–HCl, EDC-HCl, HOBT, DIPEA, DCM, 0 °C to rt, 92%; (f) Me<sub>2</sub>NH, THF, T3P, EtOAc, 80 °C, 47%; (g) BH<sub>3</sub>-DMS, THF, 0 °C to rt, Then MeOH, 0 °C to 70 °C, 71%; (h) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, 140 °C, 19%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0030.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch22"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch23" data-index="37" class="article__inlineFigure"><h2 class="fig-label">Scheme 23</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0031.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0031.jpeg" id="rightTab-gr38" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 23. Synthesis of Azaflavonols <b>174</b> and <b>175</b>; (a) BnOH, NaH, DMF, 0 °C, 72%; (b) NaOMe, MeOH, Toluene, 70 °C, 56%; (c) <i>n</i>-BuLi, THF, −75 °C, Then Acetaldehyde, 65%; (d) DMP, DCM, 75%; (e) H<sub>2</sub>, Cat. Pd/C, EtOAc, 88%; (f) <i>para</i>-Bromobenzaldehyde, NaOMe, MeOH, DMF, Quant.; (g) NaOH (aq), H<sub>2</sub>O<sub>2</sub> (aq), EtOH, DCM, Water, 19%; (h) NaOMe, MeOH, DMF, 80 °C, 98%</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0031.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch23"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch24" data-index="38" class="article__inlineFigure"><h2 class="fig-label">Scheme 24</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0032.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0032.jpeg" id="rightTab-gr39" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 24. Completion of the Synthesis of (−)-<b>53</b> and (−)-<b>eFT226</b>; (a) Methyl Cinnamate (<b>55</b>), MeCN, MeOH, DCM (R = Cl) or Methyl Cinnamate (<b>55</b>), CHCl<sub>3</sub>, TFE (R = OMe), 0 °C, <i>h</i>ν; (b) NaOMe, MeOH, 60 °C; (c) NaHB(OAc)<sub>3</sub>, AcOH, MeCN, rt, 27% (R = Cl), 40% (R = OMe) (Yield over Three Steps); (d) LiOH, MeOH, Water, 50 °C (R = Cl), 90%, or LiOH(aq), MeOH, THF, rt (R = OMe), 93%; (e) HATU, DIPEA, Me<sub>2</sub>NH, THF, DMF, rt, 95% (R = Cl), 92% (R = OMe); (f) BH<sub>3</sub>-DMS, THF, 40 °C, Then MeOH, 65–70 °C, 88% (R = Cl), 89% (R = OMe); (g) Zn, Zn(CN)<sub>2</sub>, Pd<sub>2</sub>dba<sub>3</sub>, dppf, DMF, Water, MW, 120 °C, 63% (R = Cl), 73% (R = OMe); (h) Chiral HPLC Separation</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0032.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=sch24"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig15" data-index="39" class="article__inlineFigure"><h2 class="fig-label">Figure 15</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/medium/jm0c00182_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0007.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 15. X-ray structure of (−)-<b>eFT226</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-11/acs.jmedchem.0c00182/20200604/images/large/jm0c00182_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00182&amp;id=fig15"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i423">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_58171" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_58171" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 42 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sendoel, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunn, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodriguez, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomez, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurwitz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levorse, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dill, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schramek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, E.</span></span> <span> </span><span class="NLM_article-title">Translation from unconventional 5’ start sites drives tumour initiation</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>541</i></span>,  <span class="NLM_fpage">494</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1038/nature21036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnature21036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=28077873" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2sXos1CltA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=541&publication_year=2017&pages=494-499&author=A.+Sendoelauthor=J.+G.+Dunnauthor=E.+H.+Rodriguezauthor=S.+Naikauthor=N.+C.+Gomezauthor=B.+Hurwitzauthor=J.+Levorseauthor=B.+D.+Dillauthor=D.+Schramekauthor=H.+Molinaauthor=J.+S.+Weissmanauthor=E.+Fuchs&title=Translation+from+unconventional+5%E2%80%99+start+sites+drives+tumour+initiation&doi=10.1038%2Fnature21036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Translation from unconventional 5' start sites drives tumor initiation</span></div><div class="casAuthors">Sendoel, Ataman; Dunn, Joshua G.; Rodriguez, Edwin H.; Naik, Shruti; Gomez, Nicholas C.; Hurwitz, Brian; Levorse, John; Dill, Brian D.; Schramek, Daniel; Molina, Henrik; Weissman, Jonathan S.; Fuchs, Elaine</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">541</span>
        (<span class="NLM_cas:issue">7638</span>),
    <span class="NLM_cas:pages">494-499</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We are just beginning to understand how translational control affects tumor initiation and malignancy.  Here we use an epidermis-specific, in vivo ribosome profiling strategy to investigate the translational landscape during the transition from normal homeostasis to malignancy.  Using a mouse model of inducible SOX2, which is broadly expressed in oncogenic RAS-assocd. cancers, we show that despite widespread redns. in translation and protein synthesis, certain oncogenic mRNAs are spared.  During tumor initiation, the translational app. is redirected towards unconventional upstream initiation sites, enhancing the translational efficiency of oncogenic mRNAs.  An in vivo RNA interference screen of translational regulators revealed that depletion of conventional eIF2 complexes has adverse effects on normal but not oncogenic growth.  Conversely, the alternative initiation factor eIF2A is essential for cancer progression, during which it mediates initiation at these upstream sites, differentially skewing translation and protein expression.  Our findings unveil a role for the translation of 5' untranslated regions in cancer, and expose new targets for therapeutic intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr9_HpXewJ0wLVg90H21EOLACvtfcHk0ljT9mfnwm3ycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXos1CltA%253D%253D&md5=58b04f0f20c9c6b80893bef52758e8c6</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fnature21036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature21036%26sid%3Dliteratum%253Aachs%26aulast%3DSendoel%26aufirst%3DA.%26aulast%3DDunn%26aufirst%3DJ.%2BG.%26aulast%3DRodriguez%26aufirst%3DE.%2BH.%26aulast%3DNaik%26aufirst%3DS.%26aulast%3DGomez%26aufirst%3DN.%2BC.%26aulast%3DHurwitz%26aufirst%3DB.%26aulast%3DLevorse%26aufirst%3DJ.%26aulast%3DDill%26aufirst%3DB.%2BD.%26aulast%3DSchramek%26aufirst%3DD.%26aulast%3DMolina%26aufirst%3DH.%26aulast%3DWeissman%26aufirst%3DJ.%2BS.%26aulast%3DFuchs%26aufirst%3DE.%26atitle%3DTranslation%2520from%2520unconventional%25205%25E2%2580%2599%2520start%2520sites%2520drives%2520tumour%2520initiation%26jtitle%3DNature%26date%3D2017%26volume%3D541%26spage%3D494%26epage%3D499%26doi%3D10.1038%2Fnature21036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bhat, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaud, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hulea, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Topisirovic, I.</span></span> <span> </span><span class="NLM_article-title">Targeting the translation machinery in cancer</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">261</span>– <span class="NLM_lpage">278</span>, <span class="refDoi"> DOI: 10.1038/nrd4505</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnrd4505" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=25743081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvFOgs70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=261-278&author=M.+Bhatauthor=N.+Robichaudauthor=L.+Huleaauthor=N.+Sonenbergauthor=J.+Pelletierauthor=I.+Topisirovic&title=Targeting+the+translation+machinery+in+cancer&doi=10.1038%2Fnrd4505"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the translation machinery in cancer</span></div><div class="casAuthors">Bhat, Mamatha; Robichaud, Nathaniel; Hulea, Laura; Sonenberg, Nahum; Pelletier, Jerry; Topisirovic, Ivan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">261-278</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Dysregulation of mRNA translation is a frequent feature of neoplasia.  Many oncogenes and tumor suppressors affect the translation machinery, making aberrant translation a widespread characteristic of tumor cells, independent of the genetic make-up of the cancer.  Therefore, therapeutic agents that target components of the protein synthesis app. hold promise as novel anticancer drugs that can overcome intra-tumor heterogeneity.  In this Review, we discuss the role of translation in cancer, with a particular focus on the eIF4F (eukaryotic translation initiation factor 4F) complex, and provide an overview of recent efforts aiming to 'translate' these results to the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7a57QrdxxsbVg90H21EOLACvtfcHk0ljT9mfnwm3ycA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvFOgs70%253D&md5=51625a521b1d4f18887142383a8d28e8</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrd4505&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4505%26sid%3Dliteratum%253Aachs%26aulast%3DBhat%26aufirst%3DM.%26aulast%3DRobichaud%26aufirst%3DN.%26aulast%3DHulea%26aufirst%3DL.%26aulast%3DSonenberg%26aufirst%3DN.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DTopisirovic%26aufirst%3DI.%26atitle%3DTargeting%2520the%2520translation%2520machinery%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26spage%3D261%26epage%3D278%26doi%3D10.1038%2Fnrd4505" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Truitt, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span> <span> </span><span class="NLM_article-title">New frontiers in translational control of the cancer genome</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">288</span>– <span class="NLM_lpage">304</span>, <span class="refDoi"> DOI: 10.1038/nrc.2016.27</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnrc.2016.27" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=27112207" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC28Xms1Omsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2016&pages=288-304&author=M.+L.+Truittauthor=D.+Ruggero&title=New+frontiers+in+translational+control+of+the+cancer+genome&doi=10.1038%2Fnrc.2016.27"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">New frontiers in translational control of the cancer genome</span></div><div class="casAuthors">Truitt, Morgan L.; Ruggero, Davide</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">288-304</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The past several years have seen dramatic leaps in our understanding of how gene expression is rewired at the translation level during tumorigenesis to support the transformed phenotype.  This work has been driven by an explosion in technol. advances and is revealing previously unimagined regulatory mechanisms that dictate functional expression of the cancer genome.  In this Review we discuss emerging trends and exciting new discoveries that reveal how this translational circuitry contributes to specific aspects of tumorigenesis and cancer cell function, with a particular focus on recent insights into the role of translational control in the adaptive response to oncogenic stress conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWAtdm1QpVuLVg90H21EOLACvtfcHk0li2rAPX2QT4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xms1Omsr0%253D&md5=ed2f746a30588ab8c00022d696861ceb</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc.2016.27&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc.2016.27%26sid%3Dliteratum%253Aachs%26aulast%3DTruitt%26aufirst%3DM.%2BL.%26aulast%3DRuggero%26aufirst%3DD.%26atitle%3DNew%2520frontiers%2520in%2520translational%2520control%2520of%2520the%2520cancer%2520genome%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2016%26volume%3D16%26spage%3D288%26epage%3D304%26doi%3D10.1038%2Fnrc.2016.27" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Blagden, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willis, A. E.</span></span> <span> </span><span class="NLM_article-title">The biological and therapeutic relevance of mRNA translation in cancer</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">280</span>– <span class="NLM_lpage">291</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2011.16</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnrclinonc.2011.16" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=21364523" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3MXltl2qsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2011&pages=280-291&author=S.+P.+Blagdenauthor=A.+E.+Willis&title=The+biological+and+therapeutic+relevance+of+mRNA+translation+in+cancer&doi=10.1038%2Fnrclinonc.2011.16"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">The biological and therapeutic relevance of mRNA translation in cancer</span></div><div class="casAuthors">Blagden, Sarah P.; Willis, Anne E.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">280-291</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The translation of mRNA is a tightly regulated process that is necessary for protein synthesis, and dysregulation of this process is assocd. with the development and progression of cancers.  This Review highlights the components of translation machinery and how alterations in these proteins and their principle upstream signaling pathways can impact on cancer.  Drugs that are currently being developed to target the translational machinery are also discussed.  Protein synthesis is a tightly regulated process that enables post-transcriptional control of gene expression.  Dysregulation of this process is assocd. with the development and progression of cancers because components of the translational machinery function at the point of convergence of aberrant cell signaling pathways.  Drugs designed to inhibit mRNA translation are currently in preclin. and early clin. development, and are likely to provide effective anticancer strategies in the future.  In this Review, we summarize the main components of translation and describe how alterations in these proteins and their principle upstream signaling pathways can impact on cancer.  The first inhibitors of translation, drugs designed to target eIF4E, have been trialed in hematol. malignancies, while antisense oligonucleotides against eIF4E are also due to enter clin. trials.  Here, we discuss the mode of action of drugs designed to inhibit mRNA translation and other promising therapies that are in preclin. development with the aim of becoming anticancer agents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOj8bPdXMpxbVg90H21EOLACvtfcHk0li2rAPX2QT4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXltl2qsLc%253D&md5=c1768ad1220ec24f8ee3eee1fed27acb</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2011.16&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2011.16%26sid%3Dliteratum%253Aachs%26aulast%3DBlagden%26aufirst%3DS.%2BP.%26aulast%3DWillis%26aufirst%3DA.%2BE.%26atitle%3DThe%2520biological%2520and%2520therapeutic%2520relevance%2520of%2520mRNA%2520translation%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2011%26volume%3D8%26spage%3D280%26epage%3D291%26doi%3D10.1038%2Fnrclinonc.2011.16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruggero, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">Targeting the eIF4F translation initiation complex: a critical nexus for cancer development</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>75</i></span>,  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">263</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.can-14-2789</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1158%2F0008-5472.can-14-2789" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=25593033" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnslWjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=75&publication_year=2015&pages=250-263&author=J.+Pelletierauthor=J.+Graffauthor=D.+Ruggeroauthor=N.+Sonenberg&title=Targeting+the+eIF4F+translation+initiation+complex%3A+a+critical+nexus+for+cancer+development&doi=10.1158%2F0008-5472.can-14-2789"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the eIF4F Translation Initiation Complex: A Critical Nexus for Cancer Development</span></div><div class="casAuthors">Pelletier, Jerry; Graff, Jeremy; Ruggero, Davide; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">75</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-263</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Elevated protein synthesis is an important feature of many cancer cells and often arises as a consequence of increased signaling flux channeled to eukaryotic initiation factor 4F (eIF4F), the key regulator of the mRNA-ribosome recruitment phase of translation initiation.  In many cellular and preclin. models of cancer, eIF4F deregulation results in changes in translational efficiency of specific mRNA classes.  Importantly, many of these mRNAs code for proteins that potently regulate crit. cellular processes, such as cell growth and proliferation, enhanced cell survival and cell migration that ultimately impinge on several hallmarks of cancer, including increased angiogenesis, deregulated growth control, enhanced cellular survival, epithelial-to-mesenchymal transition, invasion, and metastasis.  By being positioned as the mol. nexus downstream of key oncogenic signaling pathways (e.g., Ras, PI3K/AKT/TOR, and MYC), eIF4F serves as a direct link between important steps in cancer development and translation initiation.  Identification of mRNAs particularly responsive to elevated eIF4F activity that typifies tumorigenesis underscores the crit. role of eIF4F in cancer and raises the exciting possibility of developing new-in-class small mols. targeting translation initiation as antineoplastic agents.  Cancer Res; 75(2); 250-63. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrANjeFfkVBWLVg90H21EOLACvtfcHk0li2rAPX2QT4SQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnslWjsQ%253D%253D&md5=2b463beb4fa91704c0eb0ea32f9f2d8f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.can-14-2789&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.can-14-2789%26sid%3Dliteratum%253Aachs%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DGraff%26aufirst%3DJ.%26aulast%3DRuggero%26aufirst%3DD.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DTargeting%2520the%2520eIF4F%2520translation%2520initiation%2520complex%253A%2520a%2520critical%2520nexus%2520for%2520cancer%2520development%26jtitle%3DCancer%2520Res.%26date%3D2015%26volume%3D75%26spage%3D250%26epage%3D263%26doi%3D10.1158%2F0008-5472.can-14-2789" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span> <span> </span><span class="NLM_article-title">eIF4F: A retrospective</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>290</i></span>,  <span class="NLM_fpage">24091</span>– <span class="NLM_lpage">24099</span>, <span class="refDoi"> DOI: 10.1074/jbc.r115.675280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1074%2Fjbc.r115.675280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=26324716" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsF2kurfP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=290&publication_year=2015&pages=24091-24099&author=W.+C.+Merrick&title=eIF4F%3A+A+retrospective&doi=10.1074%2Fjbc.r115.675280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">eIF4F: A Retrospective</span></div><div class="casAuthors">Merrick, William C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">290</span>
        (<span class="NLM_cas:issue">40</span>),
    <span class="NLM_cas:pages">24091-24099</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  The original purifn. of the heterotrimeric eIF4F was published over 30 years ago (Grifo, J. A., Tahara, S. M., Morgan, M. A., Shatkin, A. J., and Merrick, W. C. (1983) J. Biol. Chem. 258, 5804-5810).  Since that time, numerous studies have been performed with the three proteins specifically required for the translation initiation of natural mRNAs, eIF4A, eIF4B, and eIF4F.  These have involved enzymic and structural studies of the proteins and a no. of site-directed mutagenesis studies.  The regulation of translation exhibited through the mammalian target of rapamycin (mTOR) pathway is predominately seen as the phosphorylation of 4E-BP, an inhibitor of protein synthesis that functions by binding to the cap binding subunit of eIF4F (eIF4E).  A hypothesis that requires the disassembly of eIF4F during translation initiation to yield free subunits (eIF4A, eIF4E, and eIF4G) is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFQWuUV9H1Z7Vg90H21EOLACvtfcHk0lhJeZ--s-ghWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsF2kurfP&md5=22603cc62fa11d6d64b3f8b024bdeea8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.r115.675280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.r115.675280%26sid%3Dliteratum%253Aachs%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26atitle%3DeIF4F%253A%2520A%2520retrospective%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2015%26volume%3D290%26spage%3D24091%26epage%3D24099%26doi%3D10.1074%2Fjbc.r115.675280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarine, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eam, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, E. Z. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, I. N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemison, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaghafi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stumpf, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span> <span> </span><span class="NLM_article-title">Structure-based design of pyridoneaminal eFT508 targeting dysregulated translation by selective mitogenactivated protein kinase interacting kinases 1 and 2 (MNK1/2) inhibition</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">3516</span>– <span class="NLM_lpage">3540</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01795</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01795" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=3516-3540&author=S.+H.+Reichauthor=P.+A.+Sprengelerauthor=G.+G.+Chiangauthor=J.+R.+Applemanauthor=J.+Chenauthor=J.+Clarineauthor=B.+Eamauthor=J.+T.+Ernstauthor=Q.+Hanauthor=V.+K.+Goelauthor=E.+Z.+R.+Hanauthor=V.+Huangauthor=I.+N.+J.+Hungauthor=A.+Jemisonauthor=K.+A.+Jessenauthor=J.+Molterauthor=D.+Murphyauthor=M.+Nealauthor=G.+S.+Parkerauthor=M.+Shaghafiauthor=S.+Sperryauthor=J.+Stauntonauthor=C.+R.+Stumpfauthor=P.+A.+Thompsonauthor=C.+Tranauthor=S.+E.+Webberauthor=C.+J.+Wegerskiauthor=H.+Zhengauthor=K.+R.+Webster&title=Structure-based+design+of+pyridoneaminal+eFT508+targeting+dysregulated+translation+by+selective+mitogenactivated+protein+kinase+interacting+kinases+1+and+2+%28MNK1%2F2%29+inhibition&doi=10.1021%2Facs.jmedchem.7b01795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-based Design of Pyridone-Aminal eFT508 Targeting Dysregulated Translation by Selective Mitogen-activated Protein Kinase Interacting Kinases 1 and 2 (MNK1/2) Inhibition</span></div><div class="casAuthors">Reich, Siegfried H.; Sprengeler, Paul A.; Chiang, Gary G.; Appleman, James R.; Chen, Joan; Clarine, Jeff; Eam, Boreth; Ernst, Justin T.; Han, Qing; Goel, Vikas K.; Han, Edward Z. R.; Huang, Vera; Hung, Ivy N. J.; Jemison, Adrianna; Jessen, Katti A.; Molter, Jolene; Murphy, Douglas; Neal, Melissa; Parker, Gregory S.; Shaghafi, Michael; Sperry, Samuel; Staunton, Jocelyn; Stumpf, Craig R.; Thompson, Peggy A.; Tran, Chinh; Webber, Stephen E.; Wegerski, Christopher J.; Zheng, Hong; Webster, Kevin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3516-3540</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dysregulated translation of mRNA plays a major role in tumorigenesis.  Mitogen-activated protein kinase interacting kinases (MNK)1/2 are key regulators of mRNA translation integrating signals from oncogenic and immune signaling pathways through phosphorylation of eIF4E and other mRNA binding proteins.  Modulation of these key effector proteins regulates mRNA, which controls tumor/stromal cell signaling.  Compd. 23 (eFT508, 6'-((6-aminopyrimidin-4-yl)amino)-8'-methyl-2'H-spiro-[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione hydrochloride), an exquisitely selective, potent dual MNK1/2 inhibitor, was designed to assess the potential for control of oncogene signaling at the level of mRNA translation.  The crystal structure-guided design leverages stereoelectronic interactions unique to MNK culminating in a novel pyridone-aminal structure described for the first time in the kinase literature.  Compd. 23 has potent in vivo antitumor activity in models of diffuse large cell B-cell lymphoma and solid tumors, suggesting that controlling dysregulated translation has real therapeutic potential.  Compd. 23 is currently being evaluated in Phase 2 clin. trials in solid tumors and lymphoma.  Compd. 23 is the first highly selective dual MNK inhibitor targeting dysregulated translation being assessed clin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp-3GOuZu8bVg90H21EOLACvtfcHk0lhJeZ--s-ghWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktlGhs7s%253D&md5=1254b674aa7e6d2037a06bc10e64e4da</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01795%26sid%3Dliteratum%253Aachs%26aulast%3DReich%26aufirst%3DS.%2BH.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DClarine%26aufirst%3DJ.%26aulast%3DEam%26aufirst%3DB.%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26aulast%3DHan%26aufirst%3DQ.%26aulast%3DGoel%26aufirst%3DV.%2BK.%26aulast%3DHan%26aufirst%3DE.%2BZ.%2BR.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DHung%26aufirst%3DI.%2BN.%2BJ.%26aulast%3DJemison%26aufirst%3DA.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DMurphy%26aufirst%3DD.%26aulast%3DNeal%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DG.%2BS.%26aulast%3DShaghafi%26aufirst%3DM.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DStumpf%26aufirst%3DC.%2BR.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DTran%26aufirst%3DC.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DZheng%26aufirst%3DH.%26aulast%3DWebster%26aufirst%3DK.%2BR.%26atitle%3DStructure-based%2520design%2520of%2520pyridoneaminal%2520eFT508%2520targeting%2520dysregulated%2520translation%2520by%2520selective%2520mitogenactivated%2520protein%2520kinase%2520interacting%2520kinases%25201%2520and%25202%2520%2528MNK1%252F2%2529%2520inhibition%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D3516%26epage%3D3540%26doi%3D10.1021%2Facs.jmedchem.7b01795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Webster, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, I. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staunton, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chiang, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jessen, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegerski, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperry, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Appleman, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webber, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprengeler, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, S. H.</span></span> <span> </span><span class="NLM_article-title">eFT508, a potent and selective mitogen-activated protein kinase interacting kinase (MNK) 1 and 2 inhibitor, is efficacious in preclinical models of diffuse large B-cell lymphoma (DLBCL)</span>. <i>Blood</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">1554</span>, <span class="refDoi"> DOI: 10.1182/blood.v126.23.1554.1554</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1182%2Fblood.V126.23.1554.1554" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2015&pages=1554&author=K.+R.+Websterauthor=V.+K.+Goelauthor=I.+N.+Hungauthor=G.+S.+Parkerauthor=J.+Stauntonauthor=M.+Nealauthor=J.+Molterauthor=G.+G.+Chiangauthor=K.+A.+Jessenauthor=C.+J.+Wegerskiauthor=S.+Sperryauthor=V.+Huangauthor=J.+Chenauthor=P.+A.+Thompsonauthor=J.+R.+Applemanauthor=S.+E.+Webberauthor=P.+A.+Sprengelerauthor=S.+H.+Reich&title=eFT508%2C+a+potent+and+selective+mitogen-activated+protein+kinase+interacting+kinase+%28MNK%29+1+and+2+inhibitor%2C+is+efficacious+in+preclinical+models+of+diffuse+large+B-cell+lymphoma+%28DLBCL%29&doi=10.1182%2Fblood.v126.23.1554.1554"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood.V126.23.1554.1554&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood.V126.23.1554.1554%26sid%3Dliteratum%253Aachs%26aulast%3DWebster%26aufirst%3DK.%2BR.%26aulast%3DGoel%26aufirst%3DV.%2BK.%26aulast%3DHung%26aufirst%3DI.%2BN.%26aulast%3DParker%26aufirst%3DG.%2BS.%26aulast%3DStaunton%26aufirst%3DJ.%26aulast%3DNeal%26aufirst%3DM.%26aulast%3DMolter%26aufirst%3DJ.%26aulast%3DChiang%26aufirst%3DG.%2BG.%26aulast%3DJessen%26aufirst%3DK.%2BA.%26aulast%3DWegerski%26aufirst%3DC.%2BJ.%26aulast%3DSperry%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DThompson%26aufirst%3DP.%2BA.%26aulast%3DAppleman%26aufirst%3DJ.%2BR.%26aulast%3DWebber%26aufirst%3DS.%2BE.%26aulast%3DSprengeler%26aufirst%3DP.%2BA.%26aulast%3DReich%26aufirst%3DS.%2BH.%26atitle%3DeFT508%252C%2520a%2520potent%2520and%2520selective%2520mitogen-activated%2520protein%2520kinase%2520interacting%2520kinase%2520%2528MNK%2529%25201%2520and%25202%2520inhibitor%252C%2520is%2520efficacious%2520in%2520preclinical%2520models%2520of%2520diffuse%2520large%2520B-cell%2520lymphoma%2520%2528DLBCL%2529%26jtitle%3DBlood%26date%3D2015%26volume%3D126%26spage%3D1554%26doi%3D10.1182%2Fblood.v126.23.1554.1554" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dreas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mikulski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fabritius, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brzozka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rzymski, T.</span></span> <span> </span><span class="NLM_article-title">Mitogen-activated protein kinase (MAPK) interacting kinases 1 and 2 (MNK1 and MNK2) as targets for cancer therapy: Recent progress in the development of MNK inhibitors</span>. <i>Curr. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">28</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170203123427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.2174%2F0929867324666170203123427" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=1-28&author=A.+Dreasauthor=M.+Mikulskiauthor=M.+Milikauthor=C.-H.+Fabritiusauthor=K.+Brzozkaauthor=T.+Rzymski&title=Mitogen-activated+protein+kinase+%28MAPK%29+interacting+kinases+1+and+2+%28MNK1+and+MNK2%29+as+targets+for+cancer+therapy%3A+Recent+progress+in+the+development+of+MNK+inhibitors&doi=10.2174%2F0929867324666170203123427"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170203123427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170203123427%26sid%3Dliteratum%253Aachs%26aulast%3DDreas%26aufirst%3DA.%26aulast%3DMikulski%26aufirst%3DM.%26aulast%3DMilik%26aufirst%3DM.%26aulast%3DFabritius%26aufirst%3DC.-H.%26aulast%3DBrzozka%26aufirst%3DK.%26aulast%3DRzymski%26aufirst%3DT.%26atitle%3DMitogen-activated%2520protein%2520kinase%2520%2528MAPK%2529%2520interacting%2520kinases%25201%2520and%25202%2520%2528MNK1%2520and%2520MNK2%2529%2520as%2520targets%2520for%2520cancer%2520therapy%253A%2520Recent%2520progress%2520in%2520the%2520development%2520of%2520MNK%2520inhibitors%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2017%26volume%3D24%26spage%3D1%26epage%3D28%26doi%3D10.2174%2F0929867324666170203123427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polunovsky, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bitterman, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, C. R.</span></span> <span> </span><span class="NLM_article-title">Cap-dependent translation ignition factor eIF4E: An emerging anticancer drug target</span>. <i>Med. Res. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">786</span>– <span class="NLM_lpage">814</span>, <span class="refDoi"> DOI: 10.1002/med.21260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fmed.21260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=22495651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XpvVegsrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2012&pages=786-814&author=Y.+Jiaauthor=V.+Polunovskyauthor=P.+B.+Bittermanauthor=C.+R.+Wagner&title=Cap-dependent+translation+ignition+factor+eIF4E%3A+An+emerging+anticancer+drug+target&doi=10.1002%2Fmed.21260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Cap-Dependent Translation Initiation Factor eIF4E: An Emerging Anticancer Drug Target</span></div><div class="casAuthors">Jia, Yan; Polunovsky, Vitaly; Bitterman, Peter B.; Wagner, Carston R.</div><div class="citationInfo"><span class="NLM_cas:title">Medicinal Research Reviews</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">786-814</span>CODEN:
                <span class="NLM_cas:coden">MRREDD</span>;
        ISSN:<span class="NLM_cas:issn">0198-6325</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Cancer cells tend to be more highly dependent on cap-dependent translation than normal tissues.  Thus, proteins involved in the initiation of cap-dependent translation have emerged as potential anti-cancer drug targets.  Cap-dependent translation is initiated by the binding of the factor eIF4E to the cap domain of mRNA.  Detailed x-ray crystal and NMR structures are available for eIF4E in assocn. with cap-analogs, as well as domains of other initiation factors.  This review will summarize efforts to design potential antagonist of eIF4E that could be used as new pharmacol. tools and anti-cancer agents and.  Insights drawn from these studies should aid in the design of future inhibitors of eIF4E dependent translation initiation. © 2012 Wiley Periodicals, Inc.  Med Res Rev., 32, No. 4, 786-814, 2012.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5sMRELR1u_7Vg90H21EOLACvtfcHk0lj5O6_tMCwUSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpvVegsrk%253D&md5=11e00c0ba286838a71b3ec3684e53e42</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1002%2Fmed.21260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fmed.21260%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DPolunovsky%26aufirst%3DV.%26aulast%3DBitterman%26aufirst%3DP.%2BB.%26aulast%3DWagner%26aufirst%3DC.%2BR.%26atitle%3DCap-dependent%2520translation%2520ignition%2520factor%2520eIF4E%253A%2520An%2520emerging%2520anticancer%2520drug%2520target%26jtitle%3DMed.%2520Res.%2520Rev.%26date%3D2012%26volume%3D32%26spage%3D786%26epage%3D814%26doi%3D10.1002%2Fmed.21260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kopecky, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mihalic, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeffries, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heath, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deignan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guimaraes, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thibault, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardozo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kayser, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Structure-guided design, synthesis, and evaluation of guanine derived inhibitors of the eIF4E mRNA-cap interaction</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">3837</span>– <span class="NLM_lpage">3851</span>, <span class="refDoi"> DOI: 10.1021/jm300037x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300037x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVWmurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3837-3851&author=X.+Chenauthor=D.+J.+Kopeckyauthor=J.+Mihalicauthor=S.+Jeffriesauthor=X.+Minauthor=J.+Heathauthor=J.+Deignanauthor=S.+Laiauthor=Z.+Fuauthor=C.+Guimaraesauthor=S.+Shenauthor=S.+Liauthor=S.+Johnstoneauthor=S.+Thibaultauthor=H.+Xuauthor=M.+Cardozoauthor=W.+Shenauthor=N.+Walkerauthor=F.+Kayserauthor=Z.+Wang&title=Structure-guided+design%2C+synthesis%2C+and+evaluation+of+guanine+derived+inhibitors+of+the+eIF4E+mRNA-cap+interaction&doi=10.1021%2Fjm300037x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Guided Design, Synthesis, and Evaluation of Guanine-Derived Inhibitors of the eIF4E mRNA-Cap Interaction</span></div><div class="casAuthors">Chen, Xiaoqi; Kopecky, David J.; Mihalic, Jeff; Jeffries, Shawn; Min, Xiaoshan; Heath, Julie; Deignan, Jeff; Lai, SuJen; Fu, Zice; Guimaraes, Cristiano; Shen, Shanling; Li, Shyun; Johnstone, Sheree; Thibault, Stephen; Xu, Haoda; Cardozo, Mario; Shen, Wang; Walker, Nigel; Kayser, Frank; Wang, Zhulun</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">3837-3851</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The eukaryotic initiation factor 4E (eIF4E) plays a central role in the initiation of gene translation and subsequent protein synthesis by binding the 5' terminal mRNA cap structure.  We designed and synthesized a series of novel compds. that display potent binding affinity against eIF4E despite their lack of a ribose moiety, phosphate, and pos. charge as present in m7-GMP.  The biochem. activity of compd. 33 (I) is 95 nM for eIF4E in an SPA binding assay.  More importantly, the compd. has an IC50 of 2.5 μM for inhibiting cap-dependent mRNA translation in a rabbit reticular cell ext. assay (RRL-IVT).  This series of potent, truncated analogs could serve as a promising new starting point toward the design of neutral eIF4E inhibitors with physicochem. properties suitable for cellular activity assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpogPh6Sr7j9bVg90H21EOLACvtfcHk0lj5O6_tMCwUSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVWmurw%253D&md5=4e301c1c45a7770104553625e12e4a25</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1021%2Fjm300037x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300037x%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DKopecky%26aufirst%3DD.%2BJ.%26aulast%3DMihalic%26aufirst%3DJ.%26aulast%3DJeffries%26aufirst%3DS.%26aulast%3DMin%26aufirst%3DX.%26aulast%3DHeath%26aufirst%3DJ.%26aulast%3DDeignan%26aufirst%3DJ.%26aulast%3DLai%26aufirst%3DS.%26aulast%3DFu%26aufirst%3DZ.%26aulast%3DGuimaraes%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DJohnstone%26aufirst%3DS.%26aulast%3DThibault%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DCardozo%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DWalker%26aufirst%3DN.%26aulast%3DKayser%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DStructure-guided%2520design%252C%2520synthesis%252C%2520and%2520evaluation%2520of%2520guanine%2520derived%2520inhibitors%2520of%2520the%2520eIF4E%2520mRNA-cap%2520interaction%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3837%26epage%3D3851%26doi%3D10.1021%2Fjm300037x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parsyan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Svitkin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shahbazian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gkogkas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lasko, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sonenberg, N.</span></span> <span> </span><span class="NLM_article-title">mRNA helicases: the tacticians of translational control</span>. <i>Nat. Rev. Mol. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">235</span>– <span class="NLM_lpage">245</span>, <span class="refDoi"> DOI: 10.1038/nrm3083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnrm3083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=21427765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3MXjs1Cqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2011&pages=235-245&author=A.+Parsyanauthor=Y.+Svitkinauthor=D.+Shahbazianauthor=C.+Gkogkasauthor=P.+Laskoauthor=W.+C.+Merrickauthor=N.+Sonenberg&title=mRNA+helicases%3A+the+tacticians+of+translational+control&doi=10.1038%2Fnrm3083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">mRNA helicases: the tacticians of translational control</span></div><div class="casAuthors">Parsyan, Armen; Svitkin, Yuri; Shahbazian, David; Gkogkas, Christos; Lasko, Paul; Merrick, William C.; Sonenberg, Nahum</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Molecular Cell Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">235-245</span>CODEN:
                <span class="NLM_cas:coden">NRMCBP</span>;
        ISSN:<span class="NLM_cas:issn">1471-0072</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The translation initiation step in eukaryotes is highly regulated and rate-limiting.  During this process, the 40S ribosomal subunit is usually recruited to the 5' terminus of the mRNA.  It then migrates towards the initiation codon, where it is joined by the 60S ribosomal subunit to form the 80S initiation complex.  Secondary structures in the 5' untranslated region (UTR) can impede binding and movement of the 40S ribosome.  The canonical eukaryotic translation initiation factor eIF4A (also known as DDX2), together with its accessory proteins eIF4B and eIF4H, is thought to act as a helicase that unwinds secondary structures in the mRNA 5' UTR.  Growing evidence suggests that other helicases are also important for translation initiation and may promote the scanning processivity of the 40S subunit, synergize with eIF4A to 'melt' secondary structures or facilitate translation of a subset of mRNAs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5r1Ei2HDUf7Vg90H21EOLACvtfcHk0lieyziFI46mNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXjs1Cqs7o%253D&md5=4f68eebff087ecff298216068c8824fa</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fnrm3083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrm3083%26sid%3Dliteratum%253Aachs%26aulast%3DParsyan%26aufirst%3DA.%26aulast%3DSvitkin%26aufirst%3DY.%26aulast%3DShahbazian%26aufirst%3DD.%26aulast%3DGkogkas%26aufirst%3DC.%26aulast%3DLasko%26aufirst%3DP.%26aulast%3DMerrick%26aufirst%3DW.%2BC.%26aulast%3DSonenberg%26aufirst%3DN.%26atitle%3DmRNA%2520helicases%253A%2520the%2520tacticians%2520of%2520translational%2520control%26jtitle%3DNat.%2520Rev.%2520Mol.%2520Cell%2520Biol.%26date%3D2011%26volume%3D12%26spage%3D235%26epage%3D245%26doi%3D10.1038%2Fnrm3083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of translation targeting eukaryotic translation initiation factor 4A</span>. <i>Methods Enzymol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>511</i></span>,  <span class="NLM_fpage">437</span>– <span class="NLM_lpage">461</span>, <span class="refDoi"> DOI: 10.1016/b978-0-12-396546-2.00020-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2FB978-0-12-396546-2.00020-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=22713332" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFChsbnI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2012&pages=437-461&author=R.+Cencicauthor=G.+Galicia-V%C3%A1zquezauthor=J.+Pelletier&title=Inhibitors+of+translation+targeting+eukaryotic+translation+initiation+factor+4A&doi=10.1016%2Fb978-0-12-396546-2.00020-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of translation targeting eukaryotic translation initiation factor 4A</span></div><div class="casAuthors">Cencic, Regina; Galicia-Vazquez, Gabriela; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Methods in Enzymology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">RNA Helicases</span>),
    <span class="NLM_cas:pages">437-461</span>CODEN:
                <span class="NLM_cas:coden">MENZAU</span>;
        ISSN:<span class="NLM_cas:issn">0076-6879</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  DEAD-box RNA helicases eIF4AI and eIF4AII play key roles in recruiting ribosomes to mRNA templates during eukaryotic translation initiation.  Small-mol. inhibitors of eIF4AI and eIF4AII have been useful for chem. dissecting their role in translation in vitro and in vivo.  Here, the authors describe a screen performed on a small focused library of kinase inhibitors to identify a novel helicase inhibitor.  The authors describe assays that have been crit. for characterizing novel RNA helicase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3w-59Gyz4zbVg90H21EOLACvtfcHk0lieyziFI46mNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFChsbnI&md5=29a39b2b93cc52440f316cdd3e2c1e47</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2FB978-0-12-396546-2.00020-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FB978-0-12-396546-2.00020-6%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DInhibitors%2520of%2520translation%2520targeting%2520eukaryotic%2520translation%2520initiation%2520factor%25204A%26jtitle%3DMethods%2520Enzymol.%26date%3D2012%26volume%3D511%26spage%3D437%26epage%3D461%26doi%3D10.1016%2Fb978-0-12-396546-2.00020-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nair, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lescarbeau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belani, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peluso, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tillotson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hearn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slocum, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helble, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahadoor, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGovern, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palombella, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wylie, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M. R.</span></span> <span> </span><span class="NLM_article-title">Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">8859</span>– <span class="NLM_lpage">8878</span>, <span class="refDoi"> DOI: 10.1021/jm3011542</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3011542" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVejsrjK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=8859-8878&author=T.+Liuauthor=S.+J.+Nairauthor=A.+Lescarbeauauthor=J.+Belaniauthor=S.+Pelusoauthor=J.+Conleyauthor=B.+Tillotsonauthor=P.+O%E2%80%99Hearnauthor=S.+Smithauthor=K.+Slocumauthor=K.+Westauthor=J.+Helbleauthor=M.+Douglasauthor=A.+Bahadoorauthor=J.+Aliauthor=K.+McGovernauthor=C.+Fritzauthor=V.+J.+Palombellaauthor=A.+Wylieauthor=A.+C.+Castroauthor=M.+R.+Tremblay&title=Synthetic+silvestrol+analogues+as+potent+and+selective+protein+synthesis+inhibitors&doi=10.1021%2Fjm3011542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic Silvestrol Analogues as Potent and Selective Protein Synthesis Inhibitors</span></div><div class="casAuthors">Liu, Tao; Nair, Somarajan J.; Lescarbeau, Andre; Belani, Jitendra; Peluso, Stephane; Conley, James; Tillotson, Bonnie; O'Hearn, Patrick; Smith, Sherri; Slocum, Kelly; West, Kip; Helble, Joseph; Douglas, Mark; Bahadoor, Adilah; Ali, Janid; McGovern, Karen; Fritz, Christian; Palombella, Vito J.; Wylie, Andrew; Castro, Alfredo C.; Tremblay, Martin R.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8859-8878</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Misregulation of protein translation plays a crit. role in human cancer pathogenesis at many levels.  Silvestrol, a cyclopenta[b]benzofuran natural product, blocks translation at the initiation step by interfering with assembly of the eIF4F translation complex.  Silvestrol has a complex chem. structure whose functional group requirements have not been systematically investigated.  Moreover, silvestrol has limited development potential due to poor drug-like properties.  Herein, we sought to develop a practical synthesis of key intermediates of silvestrol and explore structure-activity relationships around the C6 position.  The ability of silvestrol and analogs to selectively inhibit the translation of proteins with high requirement on the translation-initiation machinery (i.e., complex 5'-untranslated region UTR) relative to simple 5'UTR was detd. by a cellular reporter assay.  Simplified analogs of silvestrol such as compds. I and II were shown to have similar cytotoxic potency and better ADME characteristics relative to those of silvestrol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGonc7fkDD0PT7Vg90H21EOLACvtfcHk0lieyziFI46mNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVejsrjK&md5=158ef1ae2b7fb17aa9cf325e8e452f0f</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm3011542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3011542%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DT.%26aulast%3DNair%26aufirst%3DS.%2BJ.%26aulast%3DLescarbeau%26aufirst%3DA.%26aulast%3DBelani%26aufirst%3DJ.%26aulast%3DPeluso%26aufirst%3DS.%26aulast%3DConley%26aufirst%3DJ.%26aulast%3DTillotson%26aufirst%3DB.%26aulast%3DO%25E2%2580%2599Hearn%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DSlocum%26aufirst%3DK.%26aulast%3DWest%26aufirst%3DK.%26aulast%3DHelble%26aufirst%3DJ.%26aulast%3DDouglas%26aufirst%3DM.%26aulast%3DBahadoor%26aufirst%3DA.%26aulast%3DAli%26aufirst%3DJ.%26aulast%3DMcGovern%26aufirst%3DK.%26aulast%3DFritz%26aufirst%3DC.%26aulast%3DPalombella%26aufirst%3DV.%2BJ.%26aulast%3DWylie%26aufirst%3DA.%26aulast%3DCastro%26aufirst%3DA.%2BC.%26aulast%3DTremblay%26aufirst%3DM.%2BR.%26atitle%3DSynthetic%2520silvestrol%2520analogues%2520as%2520potent%2520and%2520selective%2520protein%2520synthesis%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D8859%26epage%3D8878%26doi%3D10.1021%2Fjm3011542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span> <span> </span><span class="NLM_article-title">Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: Synthetic and biological studies</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1021/jm201263k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201263k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFGmt7fN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=558-562&author=C.+M.+Rodrigoauthor=R.+Cencicauthor=S.+P.+Rocheauthor=J.+Pelletierauthor=J.+A.+Porco&title=Synthesis+of+rocaglamide+hydroxamates+and+related+compounds+as+eukaryotic+translation+inhibitors%3A+Synthetic+and+biological+studies&doi=10.1021%2Fjm201263k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of Rocaglamide Hydroxamates and Related Compounds as Eukaryotic Translation Inhibitors: Synthetic and Biological Studies</span></div><div class="casAuthors">Rodrigo, Christina M.; Cencic, Regina; Roche, Stephane P.; Pelletier, Jerry; Porco, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">558-562</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Racemic and nonracemic rocaglamide hydroxamates and racemic roglamate-derived heteroaryl ketones such as (-)-I were prepd. as silvestrol analogs for potential use as antitumor agents.  (-)-I inhibited protein synthesis in vitro and in vivo with similar activity to silvestrol by dose-dependent increases in the binding of RNA to eukaryotic initiation factor 4A I/II (EIF4A I/II); its soly., permeability, plasma and liver microsomal stabilities, and antitumor activities were detd.  (-)-I inhibited Eμ-Myc driven lymphomas in concert with doxorubicin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGojyZoAcZsiWbVg90H21EOLACvtfcHk0lg6bOuqSjCqow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFGmt7fN&md5=61697bd2005df787feaf025c388dab24</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Fjm201263k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201263k%26sid%3Dliteratum%253Aachs%26aulast%3DRodrigo%26aufirst%3DC.%2BM.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DRoche%26aufirst%3DS.%2BP.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DSynthesis%2520of%2520rocaglamide%2520hydroxamates%2520and%2520related%2520compounds%2520as%2520eukaryotic%2520translation%2520inhibitors%253A%2520Synthetic%2520and%2520biological%2520studies%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D558%26epage%3D562%26doi%3D10.1021%2Fjm201263k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thuaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiddon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresteil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Novel flavaglines displaying improved cytotoxicity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">411</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1021/jm101318b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm101318b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsFGltrvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=411-415&author=F.+Thuaudauthor=N.+Ribeiroauthor=C.+Gaiddonauthor=T.+Cresteilauthor=L.+D%C3%A9saubry&title=Novel+flavaglines+displaying+improved+cytotoxicity&doi=10.1021%2Fjm101318b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Flavaglines Displaying Improved Cytotoxicity</span></div><div class="casAuthors">Thuaud, Frederic; Ribeiro, Nigel; Gaiddon, Christian; Cresteil, Thierry; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">411-415</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Novel flavagline analogs were synthesized and examd. with respect to their cytotoxicity.  Structural features crit. to the potential of this class of anticancer natural products were unraveled.  We demonstrated, in particular, that the introduction of substituents at C-2 has a deleterious effect on multidrug resistance.  Replacement of the hydroxy at C-1 by an aminoformyl with the opposite configuration enhances the cytotoxicity and led to a compd. that reduces tumors growth in an allograft model at nontoxic doses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWhBP9YJrszrVg90H21EOLACvtfcHk0lg6bOuqSjCqow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsFGltrvP&md5=55c09683c985fea35a885d317368c4d2</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm101318b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm101318b%26sid%3Dliteratum%253Aachs%26aulast%3DThuaud%26aufirst%3DF.%26aulast%3DRibeiro%26aufirst%3DN.%26aulast%3DGaiddon%26aufirst%3DC.%26aulast%3DCresteil%26aufirst%3DT.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DNovel%2520flavaglines%2520displaying%2520improved%2520cytotoxicity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D411%26epage%3D415%26doi%3D10.1021%2Fjm101318b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hawkins, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nhu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Segal, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Powell, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chambers, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">White, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rizzacasa, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lessene, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, D. C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burns, C. J.</span></span> <span> </span><span class="NLM_article-title">Simplified silvestrol analogues with potent cytotoxic activity</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1556</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201400024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fcmdc.201400024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=24677741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2cXltVSrtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1556-1566&author=B.+C.+Hawkinsauthor=L.+M.+Lindqvistauthor=D.+Nhuauthor=P.+P.+Sharpauthor=D.+Segalauthor=A.+K.+Powellauthor=M.+Campbellauthor=E.+Ryanauthor=J.+M.+Chambersauthor=J.+M.+Whiteauthor=M.+A.+Rizzacasaauthor=G.+Lesseneauthor=D.+C.+S.+Huangauthor=C.+J.+Burns&title=Simplified+silvestrol+analogues+with+potent+cytotoxic+activity&doi=10.1002%2Fcmdc.201400024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Simplified Silvestrol Analogues with Potent Cytotoxic Activity</span></div><div class="casAuthors">Hawkins, Bill C.; Lindqvist, Lisa M.; Nhu, Duong; Sharp, Phillip P.; Segal, David; Powell, Andrew K.; Campbell, Michael; Ryan, Eileen; Chambers, Jennifer M.; White, Jonathan M.; Rizzacasa, Mark A.; Lessene, Guillaume; Huang, David C. S.; Burns, Christopher J.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1556-1566</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The complex natural products silvestrol (1) and episilvestrol (2) are inhibitors of translation initiation through binding to the DEAD-box helicase eukaryotic initiation factor 4A (eIF4A).  Both compds. are potently cytotoxic to cancer cells in vitro, and 1 has demonstrated efficacy in vivo in several xenograft cancer models.  Here we show that 2 has limited plasma membrane permeability and is metabolized in liver microsomes in a manner consistent with that reported for 1.  In addn., we have prepd. a series of analogs of these compds. where the complex pseudo-sugar at C6 has been replaced with chem. simpler moieties to improve drug-likeness.  Selected compds. from this work possess excellent activity in biochem. and cellular translation assays with potent activity against leukemia cell lines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrz75BXieKh5rVg90H21EOLACvtfcHk0lg6bOuqSjCqow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXltVSrtbs%253D&md5=0798d277de73bd89340d5b6df7554f88</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201400024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201400024%26sid%3Dliteratum%253Aachs%26aulast%3DHawkins%26aufirst%3DB.%2BC.%26aulast%3DLindqvist%26aufirst%3DL.%2BM.%26aulast%3DNhu%26aufirst%3DD.%26aulast%3DSharp%26aufirst%3DP.%2BP.%26aulast%3DSegal%26aufirst%3DD.%26aulast%3DPowell%26aufirst%3DA.%2BK.%26aulast%3DCampbell%26aufirst%3DM.%26aulast%3DRyan%26aufirst%3DE.%26aulast%3DChambers%26aufirst%3DJ.%2BM.%26aulast%3DWhite%26aufirst%3DJ.%2BM.%26aulast%3DRizzacasa%26aufirst%3DM.%2BA.%26aulast%3DLessene%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DD.%2BC.%2BS.%26aulast%3DBurns%26aufirst%3DC.%2BJ.%26atitle%3DSimplified%2520silvestrol%2520analogues%2520with%2520potent%2520cytotoxic%2520activity%26jtitle%3DChemMedChem%26date%3D2014%26volume%3D9%26spage%3D1556%26epage%3D1566%26doi%3D10.1002%2Fcmdc.201400024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernard, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaiddon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cresteil, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hild, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirsch, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michel, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebigil, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Flavaglines as potent anticancer and cytoprotective agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">10064</span>– <span class="NLM_lpage">10073</span>, <span class="refDoi"> DOI: 10.1021/jm301201z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301201z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7nI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=10064-10073&author=N.+Ribeiroauthor=F.+Thuaudauthor=Y.+Bernardauthor=C.+Gaiddonauthor=T.+Cresteilauthor=A.+Hildauthor=E.+C.+Hirschauthor=P.+P.+Michelauthor=C.+G.+Nebigilauthor=L.+D%C3%A9saubry&title=Flavaglines+as+potent+anticancer+and+cytoprotective+agents&doi=10.1021%2Fjm301201z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Flavaglines as Potent Anticancer and Cytoprotective Agents</span></div><div class="casAuthors">Ribeiro, Nigel; Thuaud, Frederic; Bernard, Yohann; Gaiddon, Christian; Cresteil, Thierry; Hild, Audrey; Hirsch, Etienne C.; Michel, Patrick Pierre; Nebigil, Canan G.; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">10064-10073</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Flavaglines represent a family of plant natural products that display potent anticancer, cardioprotective, and neuroprotective activities.  Novel flavagline derivs. were synthesized and examd. for their cytotoxicity on a panel of human cancer cell lines, their cardioprotection against doxorubicin-induced apoptosis in cardiomyocytes, and their neuroprotection in culture models of Parkinson's disease and cisplatin-induced neurotoxicity.  The structural requirements of flavaglines for cardio- and neuroprotection were for the first time unraveled and appeared to be slightly different from those for cytotoxicity on cancer cells.  We provide also the first evidence that flavaglines may alleviate cisplatin-induced neurotoxicity, suggesting a prophylactic potential of these compds. to prevent this frequently encountered adverse effect of cancer chemotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxznDznpm_wbVg90H21EOLACvtfcHk0libepf3SdL-_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFSgs7nI&md5=8f18a70f2dcb524b663cd24decb94d02</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1021%2Fjm301201z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301201z%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DN.%26aulast%3DThuaud%26aufirst%3DF.%26aulast%3DBernard%26aufirst%3DY.%26aulast%3DGaiddon%26aufirst%3DC.%26aulast%3DCresteil%26aufirst%3DT.%26aulast%3DHild%26aufirst%3DA.%26aulast%3DHirsch%26aufirst%3DE.%2BC.%26aulast%3DMichel%26aufirst%3DP.%2BP.%26aulast%3DNebigil%26aufirst%3DC.%2BG.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DFlavaglines%2520as%2520potent%2520anticancer%2520and%2520cytoprotective%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D10064%26epage%3D10073%26doi%3D10.1021%2Fjm301201z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Roche, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span> <span> </span><span class="NLM_article-title">Biomimetic photocycloaddition of 3-hydroxyflavones: Synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">6533</span>– <span class="NLM_lpage">6538</span>, <span class="refDoi"> DOI: 10.1002/anie.201003212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fanie.201003212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFamtbbO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2010&pages=6533-6538&author=S.+P.+Rocheauthor=R.+Cencicauthor=J.+Pelletierauthor=J.+A.+Porco&title=Biomimetic+photocycloaddition+of+3-hydroxyflavones%3A+Synthesis+and+evaluation+of+rocaglate+derivatives+as+inhibitors+of+eukaryotic+translation&doi=10.1002%2Fanie.201003212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Biomimetic Photocycloaddition of 3-Hydroxyflavones: Synthesis and Evaluation of Rocaglate Derivatives as Inhibitors of Eukaryotic Translation</span></div><div class="casAuthors">Roche, Stephane P.; Cencic, Regina; Pelletier, Jerry; Porco, John A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">37</span>),
    <span class="NLM_cas:pages">6533-6538, S6533/1-S6533/76</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The biomimetic ESIPT photocycloaddn. methodol. was successfully extended to [3 + 2] photocycloaddn. reactions of a 3-hydroxyflavone deriv., 2-(4-methoxyphenyl)-3-hydroxy-5,7-dimethoxybenzopyran-4-one, with a wide range of dipolarophiles (E)-R1CH:CHR2 [R1 = Ph, R2 = CN, CO2Me, COSEt, CON(Me)OMe, Ph, etc.; R1 = 4-BrC6H4, 2-furyl, 2-naphthyl, 3-pyridyl, etc., R2 = CO2Me; etc.] for concise access to a variety of aglain derivs. I.  Evaluation of dipolarophiles revealed that donor-acceptor interactions of generated in situ phototautomers may result in increased diastereocontrol.  Subsequent base-mediated ketol or a pinacol-type rearrangement of aglains I provided enabled expedient access to novel rocaglate derivs. II.  The latter were evaluated as inhibitors of eukaryotic translation leading to identification of a modified rocaglate deriv. with potency similar to silvestrol in vitro and in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-eAOOft7C0bVg90H21EOLACvtfcHk0libepf3SdL-_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFamtbbO&md5=14f70d2d34e6c36c1f08ff370f1e387a</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1002%2Fanie.201003212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201003212%26sid%3Dliteratum%253Aachs%26aulast%3DRoche%26aufirst%3DS.%2BP.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DBiomimetic%2520photocycloaddition%2520of%25203-hydroxyflavones%253A%2520Synthesis%2520and%2520evaluation%2520of%2520rocaglate%2520derivatives%2520as%2520inhibitors%2520of%2520eukaryotic%2520translation%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2010%26volume%3D49%26spage%3D6533%26epage%3D6538%26doi%3D10.1002%2Fanie.201003212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodard, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucas, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Douglas
Kinghorn, A.</span></span> <span> </span><span class="NLM_article-title">Rocaglamide, silvestrol and structurally related bioactive compounds from aglaia species</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>31</i></span>,  <span class="NLM_fpage">924</span>– <span class="NLM_lpage">939</span>, <span class="refDoi"> DOI: 10.1039/c4np00006d</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1039%2Fc4np00006d" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2014&pages=924-939&author=L.+Panauthor=J.+L.+Woodardauthor=D.+M.+Lucasauthor=J.+R.+Fuchsauthor=A.+Douglas%0AKinghorn&title=Rocaglamide%2C+silvestrol+and+structurally+related+bioactive+compounds+from+aglaia+species&doi=10.1039%2Fc4np00006d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1039%2Fc4np00006d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc4np00006d%26sid%3Dliteratum%253Aachs%26aulast%3DPan%26aufirst%3DL.%26aulast%3DWoodard%26aufirst%3DJ.%2BL.%26aulast%3DLucas%26aufirst%3DD.%2BM.%26aulast%3DFuchs%26aufirst%3DJ.%2BR.%26aulast%3DDouglas%2BKinghorn%26aufirst%3DA.%26atitle%3DRocaglamide%252C%2520silvestrol%2520and%2520structurally%2520related%2520bioactive%2520compounds%2520from%2520aglaia%2520species%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D31%26spage%3D924%26epage%3D939%26doi%3D10.1039%2Fc4np00006d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span> <span> </span><span class="NLM_article-title">Rocaglates covert DEAD-box protein eIF4A into a sequence-selective translational repressor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">558</span>– <span class="NLM_lpage">561</span>, <span class="refDoi"> DOI: 10.1038/nature17978</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnature17978" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=27309803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtVSksbjN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=558-561&author=S.+Iwasakiauthor=S.+N.+Floorauthor=N.+T.+Ingolia&title=Rocaglates+covert+DEAD-box+protein+eIF4A+into+a+sequence-selective+translational+repressor&doi=10.1038%2Fnature17978"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Rocaglates convert DEAD-box protein eIF4A into a sequence-selective translational repressor</span></div><div class="casAuthors">Iwasaki, Shintaro; Floor, Stephen N.; Ingolia, Nicholas T.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7608</span>),
    <span class="NLM_cas:pages">558-561</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Rocaglamide A (RocA) typifies a class of protein synthesis inhibitors that selectively kill aneuploid tumor cells and repress translation of specific mRNAs.  RocA targets eukaryotic initiation factor 4A (eIF4A), an ATP-dependent DEAD-box RNA helicase; its mRNA selectivity is proposed to reflect highly structured 5' untranslated regions that depend strongly on eIF4A-mediated unwinding.  However, rocaglate treatment may not phenocopy the loss of eIF4A activity, as these drugs actually increase the affinity between eIF4A and RNA.  Here we show that secondary structure in 5' untranslated regions is only a minor determinant for RocA selectivity and that RocA does not repress translation by reducing eIF4A availability.  Rather, in vitro and in cells, RocA specifically clamps eIF4A onto polypurine sequences in an ATP-independent manner.  This artificially clamped eIF4A blocks 43S scanning, leading to premature, upstream translation initiation and reducing protein expression from transcripts bearing the RocA-eIF4A target sequence.  In elucidating the mechanism of selective translation repression by this lead anti-cancer compd., we provide an example of a drug stabilizing sequence-selective RNA-protein interactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpR6CpuR_XHqLVg90H21EOLACvtfcHk0lgOTsZE_Q9z-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtVSksbjN&md5=8e4735525578a70efe5731e02146c31b</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature17978&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17978%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DS.%26aulast%3DFloor%26aufirst%3DS.%2BN.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26atitle%3DRocaglates%2520covert%2520DEAD-box%2520protein%2520eIF4A%2520into%2520a%2520sequence-selective%2520translational%2520repressor%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D558%26epage%3D561%26doi%3D10.1038%2Fnature17978" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwasaki, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakamoto, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shichino, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floor, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujiwara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mito, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dodo, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sodeoka, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Imataka, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honma, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fukuzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingolia, N. T.</span></span> <span> </span><span class="NLM_article-title">The translation inhibitor rocaglamide targets a bimolecular cavity between eIF4A and polypurine RNA</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">738</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2018.11.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.molcel.2018.11.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=30595437" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC1MXntlyn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2019&pages=738&author=S.+Iwasakiauthor=W.+Iwasakiauthor=M.+Takahashiauthor=A.+Sakamotoauthor=C.+Watanabeauthor=Y.+Shichinoauthor=S.+Floorauthor=K.+Fujiwaraauthor=M.+Mitoauthor=K.+Dodoauthor=M.+Sodeokaauthor=H.+Imatakaauthor=T.+Honmaauthor=K.+Fukuzawaauthor=T.+Itoauthor=N.+T.+Ingolia&title=The+translation+inhibitor+rocaglamide+targets+a+bimolecular+cavity+between+eIF4A+and+polypurine+RNA&doi=10.1016%2Fj.molcel.2018.11.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA</span></div><div class="casAuthors">Iwasaki, Shintaro; Iwasaki, Wakana; Takahashi, Mari; Sakamoto, Ayako; Watanabe, Chiduru; Shichino, Yuichi; Floor, Stephen N.; Fujiwara, Koichi; Mito, Mari; Dodo, Kosuke; Sodeoka, Mikiko; Imataka, Hiroaki; Honma, Teruki; Fukuzawa, Kaori; Ito, Takuhiro; Ingolia, Nicholas T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">738-748.e9</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A class of translation inhibitors, exemplified by the natural product rocaglamide A (RocA), isolated from Aglaia genus plants, exhibits antitumor activity by clamping eukaryotic translation initiation factor 4A (eIF4A) onto polypurine sequences in mRNAs.  This unusual inhibitory mechanism raises the question of how the drug imposes sequence selectivity onto a general translation factor.  Here, we detd. the crystal structure of the human eIF4A1·ATP analog·RocA·polypurine RNA complex.  RocA targets the "bi-mol. cavity" formed characteristically by eIF4A1 and a sharply bent pair of consecutive purines in the RNA.  Natural amino acid substitutions found in Aglaia eIF4As changed the cavity shape, leading to RocA resistance.  This study provides an example of an RNA-sequence-selective interfacial inhibitor fitting into the space shaped cooperatively by protein and RNA with specific sequences.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUUblvotYlCLVg90H21EOLACvtfcHk0lgOTsZE_Q9z-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXntlyn&md5=5a79ee2e73386187b23310837d731645</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2018.11.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2018.11.026%26sid%3Dliteratum%253Aachs%26aulast%3DIwasaki%26aufirst%3DS.%26aulast%3DIwasaki%26aufirst%3DW.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DSakamoto%26aufirst%3DA.%26aulast%3DWatanabe%26aufirst%3DC.%26aulast%3DShichino%26aufirst%3DY.%26aulast%3DFloor%26aufirst%3DS.%26aulast%3DFujiwara%26aufirst%3DK.%26aulast%3DMito%26aufirst%3DM.%26aulast%3DDodo%26aufirst%3DK.%26aulast%3DSodeoka%26aufirst%3DM.%26aulast%3DImataka%26aufirst%3DH.%26aulast%3DHonma%26aufirst%3DT.%26aulast%3DFukuzawa%26aufirst%3DK.%26aulast%3DIto%26aufirst%3DT.%26aulast%3DIngolia%26aufirst%3DN.%2BT.%26atitle%3DThe%2520translation%2520inhibitor%2520rocaglamide%2520targets%2520a%2520bimolecular%2520cavity%2520between%2520eIF4A%2520and%2520polypurine%2520RNA%26jtitle%3DMol.%2520Cell%26date%3D2019%26volume%3D73%26spage%3D738%26doi%3D10.1016%2Fj.molcel.2018.11.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">Hippuristanol – a potent steroid inhibitor of eukaryotic initiation factor 4A</span>. <i>Translation</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>4</i></span>, <span class="NLM_elocation-id">e1137381</span> <span class="refDoi"> DOI: 10.1080/21690731.2015.1137381</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1080%2F21690731.2015.1137381" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2016&author=R.+Cencicauthor=J.+Pelletier&title=Hippuristanol+%E2%80%93+a+potent+steroid+inhibitor+of+eukaryotic+initiation+factor+4A&doi=10.1080%2F21690731.2015.1137381"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1080%2F21690731.2015.1137381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21690731.2015.1137381%26sid%3Dliteratum%253Aachs%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DHippuristanol%2520%25E2%2580%2593%2520a%2520potent%2520steroid%2520inhibitor%2520of%2520eukaryotic%2520initiation%2520factor%25204A%26jtitle%3DTranslation%26date%3D2016%26volume%3D4%26doi%3D10.1080%2F21690731.2015.1137381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bordeleau, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindqvist, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oberer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Northcote, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">RNA-mediated sequestration of the RNA helicase eIF4A by pateamine A inhibits translation initiation</span>. <i>Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">1287</span>– <span class="NLM_lpage">1295</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2006.10.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.chembiol.2006.10.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=17185224" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1equg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=1287-1295&author=M.-E.+Bordeleauauthor=R.+Cencicauthor=L.+Lindqvistauthor=M.+Obererauthor=P.+Northcoteauthor=G.+Wagnerauthor=J.+Pelletier&title=RNA-mediated+sequestration+of+the+RNA+helicase+eIF4A+by+pateamine+A+inhibits+translation+initiation&doi=10.1016%2Fj.chembiol.2006.10.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">RNA-Mediated Sequestration of the RNA Helicase eIF4A by Pateamine A Inhibits Translation Initiation</span></div><div class="casAuthors">Bordeleau, Marie-Eve; Cencic, Regina; Lindqvist, Lisa; Oberer, Monika; Northcote, Peter; Wagner, Gerhard; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1287-1295</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Eukaryotic initiation factor 4A (eIF4A) is a member of the DEAD-box family of putative RNA helicases whose members are involved in many aspects of RNA metab. eIF4A is thought to facilitate binding of 43S pre-initiation complexes to mRNAs by unwinding secondary structures present in the 5' untranslated region.  Pateamine A, a small-mol. inhibitor of translation initiation, acts in an unusual manner by stimulating eIF4A activity.  Herein, we report the elucidation of pateamine's mode of action.  We demonstrate that pateamine A is a chem. inducer of dimerization that forces an engagement between eIF4A and RNA and prevents eIF4A from participating in the ribosome-recruitment step of translation initiation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoCcRw1TsmI7Vg90H21EOLACvtfcHk0lhRpuxXplNJPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1equg%253D%253D&md5=da430831e29847d5d9bf6cca16a9e8ae</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2006.10.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2006.10.005%26sid%3Dliteratum%253Aachs%26aulast%3DBordeleau%26aufirst%3DM.-E.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DLindqvist%26aufirst%3DL.%26aulast%3DOberer%26aufirst%3DM.%26aulast%3DNorthcote%26aufirst%3DP.%26aulast%3DWagner%26aufirst%3DG.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DRNA-mediated%2520sequestration%2520of%2520the%2520RNA%2520helicase%2520eIF4A%2520by%2520pateamine%2520A%2520inhibits%2520translation%2520initiation%26jtitle%3DChem.%2520Biol.%26date%3D2006%26volume%3D13%26spage%3D1287%26epage%3D1295%26doi%3D10.1016%2Fj.chembiol.2006.10.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sadlish, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vazquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paris, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aust, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bhullar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Helliwell, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoepfner, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roggo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuierer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Studer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Movva, N. R.</span></span> <span> </span><span class="NLM_article-title">Evidence for a functionally relevant rocaglamide binding site on the eIF4A-RNA complex</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1519</span>– <span class="NLM_lpage">1527</span>, <span class="refDoi"> DOI: 10.1021/cb400158t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb400158t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmsVCnt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=1519-1527&author=H.+Sadlishauthor=G.+Galicia-Vazquezauthor=C.+G.+Parisauthor=T.+Austauthor=B.+Bhullarauthor=L.+Changauthor=S.+B.+Helliwellauthor=D.+Hoepfnerauthor=B.+Knappauthor=R.+Riedlauthor=S.+Roggoauthor=S.+Schuiererauthor=C.+Studerauthor=J.+A.+Porcoauthor=J.+Pelletierauthor=N.+R.+Movva&title=Evidence+for+a+functionally+relevant+rocaglamide+binding+site+on+the+eIF4A-RNA+complex&doi=10.1021%2Fcb400158t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Evidence for a Functionally Relevant Rocaglamide Binding Site on the eIF4A-RNA Complex</span></div><div class="casAuthors">Sadlish, Heather; Galicia-Vazquez, Gabriela; Paris, C. Gregory; Aust, Thomas; Bhullar, Bhupinder; Chang, Lena; Helliwell, Stephen B.; Hoepfner, Dominic; Knapp, Britta; Riedl, Ralph; Roggo, Silvio; Schuierer, Sven; Studer, Christian; Porco, John A.; Pelletier, Jerry; Movva, N. Rao</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1519-1527</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Translation initiation is an emerging target in oncol. and neurobiol. indications.  Naturally derived and synthetic rocaglamide scaffolds have been used to interrogate this pathway; however, there is uncertainty regarding their precise mechanism(s) of action.  We exploited the genetic tractability of yeast to define the primary effect of both a natural and a synthetic rocaglamide in a cellular context and characterized the mol. target using biochem. studies and in silico modeling.  Chemogenomic profiling and mutagenesis in yeast identified the eIF (eukaryotic Initiation Factor) 4A helicase homolog as the primary mol. target of rocaglamides and defined a discrete set of residues near the RNA binding motif that confer resistance to both compds.  Three of the eIF4A mutations were characterized regarding their functional consequences on activity and response to rocaglamide inhibition.  These data support a model whereby rocaglamides stabilize an eIF4A-RNA interaction to either alter the level and/or impair the activity of the eIF4F complex.  Furthermore, in silico modeling supports the annotation of a binding pocket delineated by the RNA substrate and the residues identified from our mutagenesis screen.  As expected from the high degree of conservation of the eukaryotic translation pathway, these observations are consistent with previous observations in mammalian model systems.  Importantly, we demonstrate that the chem. distinct silvestrol and synthetic rocaglamides share a common mechanism of action, which will be crit. for optimization of physiol. stable derivs.  Finally, these data confirm the value of the rocaglamide scaffold for exploring the impact of translational modulation on disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOrcE5_sJHtLVg90H21EOLACvtfcHk0lhRpuxXplNJPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmsVCnt7o%253D&md5=0350401f40ba15d20744d2bf3272832b</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fcb400158t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb400158t%26sid%3Dliteratum%253Aachs%26aulast%3DSadlish%26aufirst%3DH.%26aulast%3DGalicia-Vazquez%26aufirst%3DG.%26aulast%3DParis%26aufirst%3DC.%2BG.%26aulast%3DAust%26aufirst%3DT.%26aulast%3DBhullar%26aufirst%3DB.%26aulast%3DChang%26aufirst%3DL.%26aulast%3DHelliwell%26aufirst%3DS.%2BB.%26aulast%3DHoepfner%26aufirst%3DD.%26aulast%3DKnapp%26aufirst%3DB.%26aulast%3DRiedl%26aufirst%3DR.%26aulast%3DRoggo%26aufirst%3DS.%26aulast%3DSchuierer%26aufirst%3DS.%26aulast%3DStuder%26aufirst%3DC.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DMovva%26aufirst%3DN.%2BR.%26atitle%3DEvidence%2520for%2520a%2520functionally%2520relevant%2520rocaglamide%2520binding%2520site%2520on%2520the%2520eIF4A-RNA%2520complex%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2013%26volume%3D8%26spage%3D1519%26epage%3D1527%26doi%3D10.1021%2Fcb400158t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li-Weber, M.</span></span> <span> </span><span class="NLM_article-title">Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1791</span>– <span class="NLM_lpage">1799</span>, <span class="refDoi"> DOI: 10.1002/ijc.29013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fijc.29013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=24895251" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2cXpsFequr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=1791-1799&author=M.+Li-Weber&title=Molecular+mechanisms+and+anti-cancer+aspects+of+the+medicinal+phytochemicals+rocaglamides+%28%3Dflavaglines%29&doi=10.1002%2Fijc.29013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines)</span></div><div class="casAuthors">Li-Weber, Min</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Cancer</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1791-1799</span>CODEN:
                <span class="NLM_cas:coden">IJCNAW</span>;
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">A review.  Rocaglamides (= flavaglines) are potent natural anti-cancer phytochems. that inhibit cancer growth at nanomolar concns. by the following mechanisms: (1) inhibition of translation initiation via inhibition of phosphorylation of the mRNA cap-binding eukaryotic translation initiation factor eIF4E and stabilization of RNA-binding of the translation initiation factor eIF4A in the eIF4F complex; (2) blocking cell cycle progression by activation of the ATM/ATR-Chk1/Chk2 checkpoint pathway; (3) inactivation of the heat shock factor 1 (HSF1) leading to up-regulation of thioredoxin-interacting protein (TXNIP) and consequent redn. of glucose uptake and (4) induction of apoptosis through activation of the MAPK p38 and JNK and inhibition of the Ras-CRaf-MEK-ERK signaling pathway.  Besides the anti-cancer activities, rocaglamides are also shown to protect primary cells from chemotherapy-induced cell death and alleviate inflammation- and drug-induced injury in neuronal tissues.  This review will focus on the recently discovered mol. mechanisms of the actions of rocaglamides and highlights the benefits of using rocaglamides in cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3RA3J8dyvL7Vg90H21EOLACvtfcHk0lhRpuxXplNJPg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXpsFequr0%253D&md5=ef00b49990d2ddbbb643bd5c9ce353ff</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1002%2Fijc.29013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.29013%26sid%3Dliteratum%253Aachs%26aulast%3DLi-Weber%26aufirst%3DM.%26atitle%3DMolecular%2520mechanisms%2520and%2520anti-cancer%2520aspects%2520of%2520the%2520medicinal%2520phytochemicals%2520rocaglamides%2520%2528%253Dflavaglines%2529%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2015%26volume%3D137%26spage%3D1791%26epage%3D1799%26doi%3D10.1002%2Fijc.29013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, C. B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballut, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johansen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chamieh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nielsen, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oliveira, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pedersen, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seraphin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le Hir, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andersen, G. R.</span></span> <span> </span><span class="NLM_article-title">Structure of the exon junction core complex with a trapped DEAD-box ATPase bound to RNA</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>313</i></span>,  <span class="NLM_fpage">1968</span>– <span class="NLM_lpage">1972</span>, <span class="refDoi"> DOI: 10.1126/science.1131981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1126%2Fscience.1131981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=16931718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVSnsrnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=313&publication_year=2006&pages=1968-1972&author=C.+B.+F.+Andersenauthor=L.+Ballutauthor=J.+S.+Johansenauthor=H.+Chamiehauthor=K.+H.+Nielsenauthor=C.+L.+Oliveiraauthor=J.+S.+Pedersenauthor=B.+Seraphinauthor=H.+Le+Hirauthor=G.+R.+Andersen&title=Structure+of+the+exon+junction+core+complex+with+a+trapped+DEAD-box+ATPase+bound+to+RNA&doi=10.1126%2Fscience.1131981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the Exon Junction Core Complex with a Trapped DEAD-Box ATPase Bound to RNA</span></div><div class="casAuthors">Andersen, Christian B. F.; Ballut, Lionel; Johansen, Jesper S.; Chamieh, Hala; Nielsen, Klaus H.; Oliveira, Cristiano L. P.; Pedersen, Jan Skov; Seraphin, Bertrand; Le Hir, Herve; Rom Andersen, Gregers</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">313</span>
        (<span class="NLM_cas:issue">5795</span>),
    <span class="NLM_cas:pages">1968-1972</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">In higher eukaryotes, a multiprotein exon junction complex is deposited on spliced mRNAs.  The complex is organized around a stable core, which serves as a binding platform for numerous factors that influence mRNA function.  Here, we present the crystal structure of a tetrameric exon junction core complex contg. the DEAD-box ATPase eukaryotic initiation factor 4AIII (eIF4AIII) bound to an ATP analog, MAGOH, Y14, a fragment of MLN51, and a polyuracil mRNA mimic.  EIF4AIII interacts with the phosphate-ribose backbone of six consecutive nucleotides and prevents part of the bound RNA from being double stranded.  The MAGOH and Y14 subunits lock eIF4AIII in a prehydrolysis state, and activation of the ATPase probably requires only modest conformational changes in eIF4AIII motif I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKgZvl00N4M7Vg90H21EOLACvtfcHk0ljAXQe8WQOUXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVSnsrnE&md5=0a1bed875b1c1ddaa4c0c26746275d96</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1126%2Fscience.1131981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1131981%26sid%3Dliteratum%253Aachs%26aulast%3DAndersen%26aufirst%3DC.%2BB.%2BF.%26aulast%3DBallut%26aufirst%3DL.%26aulast%3DJohansen%26aufirst%3DJ.%2BS.%26aulast%3DChamieh%26aufirst%3DH.%26aulast%3DNielsen%26aufirst%3DK.%2BH.%26aulast%3DOliveira%26aufirst%3DC.%2BL.%26aulast%3DPedersen%26aufirst%3DJ.%2BS.%26aulast%3DSeraphin%26aufirst%3DB.%26aulast%3DLe%2BHir%26aufirst%3DH.%26aulast%3DAndersen%26aufirst%3DG.%2BR.%26atitle%3DStructure%2520of%2520the%2520exon%2520junction%2520core%2520complex%2520with%2520a%2520trapped%2520DEAD-box%2520ATPase%2520bound%2520to%2520RNA%26jtitle%3DScience%26date%3D2006%26volume%3D313%26spage%3D1968%26epage%3D1972%26doi%3D10.1126%2Fscience.1131981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolfe, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewe, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajasekhar, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanghvi, V. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mavrakis, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roderick, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van der Meulen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schatz, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodrigo, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rondou, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Stanchina, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Teruya-Feldstein, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kelliher, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Speleman, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rätsch, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wendel, H.-G.</span></span> <span> </span><span class="NLM_article-title">RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>513</i></span>,  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">70</span>, <span class="refDoi"> DOI: 10.1038/nature13485</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fnature13485" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=25079319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=513&publication_year=2014&pages=65-70&author=A.+L.+Wolfeauthor=K.+Singhauthor=Y.+Zhongauthor=P.+Dreweauthor=V.+K.+Rajasekharauthor=V.+R.+Sanghviauthor=K.+J.+Mavrakisauthor=M.+Jiangauthor=J.+E.+Roderickauthor=J.+Van+der+Meulenauthor=J.+H.+Schatzauthor=C.+M.+Rodrigoauthor=C.+Zhaoauthor=P.+Rondouauthor=E.+de+Stanchinaauthor=J.+Teruya-Feldsteinauthor=M.+A.+Kelliherauthor=F.+Spelemanauthor=J.+A.+Porcoauthor=J.+Pelletierauthor=G.+R%C3%A4tschauthor=H.-G.+Wendel&title=RNA+G-quadruplexes+cause+eIF4A-dependent+oncogene+translation+in+cancer&doi=10.1038%2Fnature13485"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">RNA G-quadruplexes cause eIF4A-dependent oncogene translation in cancer</span></div><div class="casAuthors">Wolfe, Andrew L.; Singh, Kamini; Zhong, Yi; Drewe, Philipp; Rajasekhar, Vinagolu K.; Sanghvi, Viraj R.; Mavrakis, Konstantinos J.; Jiang, Man; Roderick, Justine E.; Van der Meulen, Joni; Schatz, Jonathan H.; Rodrigo, Christina M.; Zhao, Chunying; Rondou, Pieter; de Stanchina, Elisa; Teruya-Feldstein, Julie; Kelliher, Michelle A.; Speleman, Frank; Porco, John A.; Pelletier, Jerry; Ratsch, Gunnar; Wendel, Hans-Guido</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">513</span>
        (<span class="NLM_cas:issue">7516</span>),
    <span class="NLM_cas:pages">65-70</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The translational control of oncoprotein expression is implicated in many cancers.  Here the authors report an eIF4A RNA helicase-dependent mechanism of translational control that contributes to oncogenesis and underlies the anticancer effects of silvestrol and related compds.  For example, eIF4A promotes T-cell acute lymphoblastic leukemia development in vivo and is required for leukemia maintenance.  Accordingly, inhibition of eIF4A with silvestrol has powerful therapeutic effects against murine and human leukemic cells in vitro and in vivo.  The authors use transcriptome-scale ribosome footprinting to identify the hallmarks of eIF4A-dependent transcripts.  These include 5' untranslated region (UTR) sequences such as the 12-nucleotide guanine quartet (CGG)4 motif that can form RNA G-quadruplex structures.  Notably, among the most eIF4A-dependent and silvestrol-sensitive transcripts are a no. of oncogenes, superenhancer-assocd. transcription factors, and epigenetic regulators.  Hence, the 5' UTRs of select cancer genes harbor a targetable requirement for the eIF4A RNA helicase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq3OIvvYHwn7rVg90H21EOLACvtfcHk0ljAXQe8WQOUXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVyhurvI&md5=8c0a22a542cac567f1ec1340b195680d</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1038%2Fnature13485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13485%26sid%3Dliteratum%253Aachs%26aulast%3DWolfe%26aufirst%3DA.%2BL.%26aulast%3DSingh%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DY.%26aulast%3DDrewe%26aufirst%3DP.%26aulast%3DRajasekhar%26aufirst%3DV.%2BK.%26aulast%3DSanghvi%26aufirst%3DV.%2BR.%26aulast%3DMavrakis%26aufirst%3DK.%2BJ.%26aulast%3DJiang%26aufirst%3DM.%26aulast%3DRoderick%26aufirst%3DJ.%2BE.%26aulast%3DVan%2Bder%2BMeulen%26aufirst%3DJ.%26aulast%3DSchatz%26aufirst%3DJ.%2BH.%26aulast%3DRodrigo%26aufirst%3DC.%2BM.%26aulast%3DZhao%26aufirst%3DC.%26aulast%3DRondou%26aufirst%3DP.%26aulast%3Dde%2BStanchina%26aufirst%3DE.%26aulast%3DTeruya-Feldstein%26aufirst%3DJ.%26aulast%3DKelliher%26aufirst%3DM.%2BA.%26aulast%3DSpeleman%26aufirst%3DF.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DR%25C3%25A4tsch%26aufirst%3DG.%26aulast%3DWendel%26aufirst%3DH.-G.%26atitle%3DRNA%2520G-quadruplexes%2520cause%2520eIF4A-dependent%2520oncogene%2520translation%2520in%2520cancer%26jtitle%3DNature%26date%3D2014%26volume%3D513%26spage%3D65%26epage%3D70%26doi%3D10.1038%2Fnature13485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galicia-Vázquez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katigbak, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span> <span> </span><span class="NLM_article-title">CRISPR-Mediated drug-target validation reveals selective pharmacological inhibition of the RNA helicase, eIF4A</span>. <i>Cell Reports</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">2340</span>– <span class="NLM_lpage">2347</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2016.05.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.celrep.2016.05.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=27239032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC28XptVSlt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2016&pages=2340-2347&author=J.+Chuauthor=G.+Galicia-V%C3%A1zquezauthor=R.+Cencicauthor=J.+R.+Millsauthor=A.+Katigbakauthor=J.+A.+Porcoauthor=J.+Pelletier&title=CRISPR-Mediated+drug-target+validation+reveals+selective+pharmacological+inhibition+of+the+RNA+helicase%2C+eIF4A&doi=10.1016%2Fj.celrep.2016.05.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">CRISPR-Mediated Drug-Target Validation Reveals Selective Pharmacological Inhibition of the RNA Helicase, eIF4A</span></div><div class="casAuthors">Chu, Jennifer; Galicia-Vazquez, Gabriela; Cencic, Regina; Mills, John R.; Katigbak, Alexandra; Porco, John A., Jr.; Pelletier, Jerry</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2340-2347</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Targeting translation initiation is an emerging anti-neoplastic strategy that capitalizes on de-regulated upstream MAPK and PI3K-mTOR signaling pathways in cancers.  A key regulator of translation that controls ribosome recruitment flux is eukaryotic initiation factor (eIF) 4F, a hetero-trimeric complex composed of the cap binding protein eIF4E, the scaffolding protein eIF4G, and the RNA helicase eIF4A.  Small mol. inhibitors targeting eIF4F display promising anti-neoplastic activity in preclin. settings.  Among these are some rocaglate family members that are well tolerated in vivo, deplete eIF4F of its eIF4A helicase subunit, have shown activity as single agents in several xenograft models, and can reverse acquired resistance to MAPK and PI3K-mTOR targeted therapies.  Herein, we highlight the power of using genetic complementation approaches and CRISPR/Cas9-mediated editing for drug-target validation ex vivo and in vivo, linking the anti-tumor properties of rocaglates to eIF4A inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTlJAdKCxSfbVg90H21EOLACvtfcHk0lgnwQbPSHhRdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XptVSlt7s%253D&md5=c84a9a808dcb119306303c6a8aa68b5b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2016.05.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2016.05.005%26sid%3Dliteratum%253Aachs%26aulast%3DChu%26aufirst%3DJ.%26aulast%3DGalicia-V%25C3%25A1zquez%26aufirst%3DG.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DMills%26aufirst%3DJ.%2BR.%26aulast%3DKatigbak%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DPelletier%26aufirst%3DJ.%26atitle%3DCRISPR-Mediated%2520drug-target%2520validation%2520reveals%2520selective%2520pharmacological%2520inhibition%2520of%2520the%2520RNA%2520helicase%252C%2520eIF4A%26jtitle%3DCell%2520Reports%26date%3D2016%26volume%3D15%26spage%3D2340%26epage%3D2347%26doi%3D10.1016%2Fj.celrep.2016.05.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ribeiro, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thuaud, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebigil, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the biology and chemistry of the flavaglines</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>20</i></span>,  <span class="NLM_fpage">1857</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2011.10.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.bmc.2011.10.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=22071525" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtlOku7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=1857&author=N.+Ribeiroauthor=F.+Thuaudauthor=C.+Nebigilauthor=L.+D%C3%A9saubry&title=Recent+advances+in+the+biology+and+chemistry+of+the+flavaglines&doi=10.1016%2Fj.bmc.2011.10.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the biology and chemistry of the flavaglines</span></div><div class="casAuthors">Ribeiro, Nigel; Thuaud, Frederic; Nebigil, Canan; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1857-1864</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The flavaglines are a family of plant natural products that induce potent anticancer and neuroprotective activities.  This review summarizes recent synthetic approaches to flavaglines and the current status of their pharmacol. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpP48y5yocOa7Vg90H21EOLACvtfcHk0lgnwQbPSHhRdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtlOku7g%253D&md5=eed7c02d5cfb2215c1523248afeeee89</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2011.10.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2011.10.048%26sid%3Dliteratum%253Aachs%26aulast%3DRibeiro%26aufirst%3DN.%26aulast%3DThuaud%26aufirst%3DF.%26aulast%3DNebigil%26aufirst%3DC.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DRecent%2520advances%2520in%2520the%2520biology%2520and%2520chemistry%2520of%2520the%2520flavaglines%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D1857%26doi%3D10.1016%2Fj.bmc.2011.10.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abou-Hamdan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Désaubry, L.</span></span> <span> </span><span class="NLM_article-title">Recent advances in the synthesis of flavaglines, a family of potent bioactive natural compounds originating from traditional chinese medicine</span>. <i>Eur. J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_fpage">5908</span>, <span class="refDoi"> DOI: 10.1002/ejoc.201600437</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fejoc.201600437" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1CltLjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&pages=5908&author=Q.+Zhaoauthor=H.+Abou-Hamdanauthor=L.+D%C3%A9saubry&title=Recent+advances+in+the+synthesis+of+flavaglines%2C+a+family+of+potent+bioactive+natural+compounds+originating+from+traditional+chinese+medicine&doi=10.1002%2Fejoc.201600437"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Recent Advances in the Synthesis of Flavaglines, a Family of Potent Bioactive Natural Compounds Originating from Traditional Chinese Medicine</span></div><div class="casAuthors">Zhao, Qian; Abou-Hamdan, Hussein; Desaubry, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">2016</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">5908-5916</span>CODEN:
                <span class="NLM_cas:coden">EJOCFK</span>;
        ISSN:<span class="NLM_cas:issn">1099-0690</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Flavaglines constitute a distinctive family of plant metabolites isolated from medicinal plants of the genus Aglaia.  These compds. exhibit a broad spectrum of distinctive pharmacol. properties, including anti-inflammatory, neuroprotective, cardioprotective, and anticancer activities.  These natural cyclopenta[b]benzofurans are characterized by densely functionalized tricyclic frameworks, as exemplified by the structures of rocaglamide or silvestrol, which makes them extremely attractive targets for total synthesis, in addn. to their therapeutic potential.  In this review we describe the various synthetic approaches to the total synthesis of flavaglines, culminating in a new generation of diastereo- and enantioselective total syntheses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4fgv5knkhj7Vg90H21EOLACvtfcHk0lgnwQbPSHhRdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1CltLjO&md5=c024d7a3f7142c42d508f4c7867557e4</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1002%2Fejoc.201600437&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fejoc.201600437%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DQ.%26aulast%3DAbou-Hamdan%26aufirst%3DH.%26aulast%3DD%25C3%25A9saubry%26aufirst%3DL.%26atitle%3DRecent%2520advances%2520in%2520the%2520synthesis%2520of%2520flavaglines%252C%2520a%2520family%2520of%2520potent%2520bioactive%2520natural%2520compounds%2520originating%2520from%2520traditional%2520chinese%2520medicine%26jtitle%3DEur.%2520J.%2520Org.%2520Chem.%26date%3D2016%26spage%3D5908%26doi%3D10.1002%2Fejoc.201600437" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, G.,  II</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">A Biomimetic approach to the rocaglamides employing photogeneration of oxidopyryliums derived from 3-hydroxyflavones</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">13620</span>, <span class="refDoi"> DOI: 10.1021/ja044798o</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja044798o" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD2cXotVShsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=2004&pages=13620&author=B.+Gerardauthor=G.+Jonesauthor=J.+A.+Porco&title=A+Biomimetic+approach+to+the+rocaglamides+employing+photogeneration+of+oxidopyryliums+derived+from+3-hydroxyflavones&doi=10.1021%2Fja044798o"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">A biomimetic approach to the rocaglamides employing photogeneration of oxidopyryliums derived from 3-hydroxyflavones</span></div><div class="casAuthors">Gerard, Baudouin; Jones, Guilford, II; Porco, John A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">42</span>),
    <span class="NLM_cas:pages">13620-13621</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A unified biomimetic approach to the aglain-forbaglin-rocaglamide classes of natural products is reported.  The approach involves photogeneration of oxidopyryliums via excited-state intramol. proton transfer (ESIPT) of 3-hydroxyflavones followed by [3+2] dipolar cycloaddn. to the aglain core.  An α-ketol (acyloin) rearrangement was employed to transform the aglain core to the rocaglamide framework.  This approach was successfully used for the synthesis of the natural product (±)-Me rocaglate (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNL6WYutInfbVg90H21EOLACvtfcHk0liSts3T-UtuMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXotVShsr8%253D&md5=2b68c32c480b01c4720081e9d1c23288</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1021%2Fja044798o&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja044798o%26sid%3Dliteratum%253Aachs%26aulast%3DGerard%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DG.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DA%2520Biomimetic%2520approach%2520to%2520the%2520rocaglamides%2520employing%2520photogeneration%2520of%2520oxidopyryliums%2520derived%2520from%25203-hydroxyflavones%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2004%26volume%3D126%26spage%3D13620%26doi%3D10.1021%2Fja044798o" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sangji, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Leary, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Enantioselective photocycloaddition mediated by chiral brønsted acids: Asymmetric synthesis of the rocaglamides</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>128</i></span>,  <span class="NLM_fpage">7754</span>, <span class="refDoi"> DOI: 10.1021/ja062621j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja062621j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD28XkvVOqsrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=128&publication_year=2006&pages=7754&author=B.+Gerardauthor=S.+Sangjiauthor=D.+J.+O%E2%80%99Learyauthor=J.+A.+Porco&title=Enantioselective+photocycloaddition+mediated+by+chiral+br%C3%B8nsted+acids%3A+Asymmetric+synthesis+of+the+rocaglamides&doi=10.1021%2Fja062621j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective Photocycloaddition Mediated by Chiral Bronsted Acids: Asymmetric Synthesis of the Rocaglamides</span></div><div class="casAuthors">Gerard, Baudouin; Sangji, Sheharbano; O'Leary, Daniel J.; Porco, John A., Jr.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">128</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">7754-7755</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Enantioselective syntheses of Me rocaglate and the related natural products rocaglamide and rocaglaol are outlined.  The approach involves enantioselective [3 + 2] photocycloaddn. promoted by chiral Bronsted acids (TADDOLs) to afford an aglain precursor I followed by a ketol shift/redn. sequence to the rocaglate core.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4ob0LdqnYbLVg90H21EOLACvtfcHk0liSts3T-UtuMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XkvVOqsrs%253D&md5=6a77588a2dc8dc39da2f8b34e8f4761f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Fja062621j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja062621j%26sid%3Dliteratum%253Aachs%26aulast%3DGerard%26aufirst%3DB.%26aulast%3DSangji%26aufirst%3DS.%26aulast%3DO%25E2%2580%2599Leary%26aufirst%3DD.%2BJ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DEnantioselective%2520photocycloaddition%2520mediated%2520by%2520chiral%2520br%25C3%25B8nsted%2520acids%253A%2520Asymmetric%2520synthesis%2520of%2520the%2520rocaglamides%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2006%26volume%3D128%26spage%3D7754%26doi%3D10.1021%2Fja062621j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gerard, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cencic, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pelletier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Enantioselective synthesis of the complex rocaglate (−)-silvestrol</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">7831</span>, <span class="refDoi"> DOI: 10.1002/anie.200702707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1002%2Fanie.200702707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1alsLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2007&pages=7831&author=B.+Gerardauthor=R.+Cencicauthor=J.+Pelletierauthor=J.+A.+Porco&title=Enantioselective+synthesis+of+the+complex+rocaglate+%28%E2%88%92%29-silvestrol&doi=10.1002%2Fanie.200702707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Enantioselective synthesis of the complex rocaglate (-)-silvestrol</span></div><div class="casAuthors">Gerard, Baudouin; Cencic, Regina; Pelletier, Jerry; Porco, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">7831-7834</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The total synthesis of the natural product (-)-silvestrol I (R = α-H) was accomplished, and the synthesis featured enantioselective [3 + 2] photocycloaddn. of a substituted 3-hydroxyflavone II and methyl cinnamate promoted by a chiral TADDOL analog Broensted acid.  Initial biol. studies indicated a 5-10 fold greater activity of (-)-silvestrol than its diastereoisomer I (R = β-H) as inhibitors of protein synthesis in HeLa cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvjZPs05l1QrVg90H21EOLACvtfcHk0liSts3T-UtuMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1alsLrF&md5=e42d8aa0e2d5b94fc561994f17a971f4</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1002%2Fanie.200702707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200702707%26sid%3Dliteratum%253Aachs%26aulast%3DGerard%26aufirst%3DB.%26aulast%3DCencic%26aufirst%3DR.%26aulast%3DPelletier%26aufirst%3DJ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DEnantioselective%2520synthesis%2520of%2520the%2520complex%2520rocaglate%2520%2528%25E2%2588%2592%2529-silvestrol%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2007%26volume%3D46%26spage%3D7831%26doi%3D10.1002%2Fanie.200702707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stone, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lajkiewicz, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitesell, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hilmy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span> <span> </span><span class="NLM_article-title">Biomimetic kinetic resolution: highly enantio- and diastereoselective transfer hydrogenation of aglain ketones to access flavagline natural products</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">525</span>, <span class="refDoi"> DOI: 10.1021/ja511728b</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja511728b" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFOhu7%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2015&pages=525&author=S.+D.+Stoneauthor=N.+J.+Lajkiewiczauthor=L.+Whitesellauthor=A.+Hilmyauthor=J.+A.+Porco&title=Biomimetic+kinetic+resolution%3A+highly+enantio-+and+diastereoselective+transfer+hydrogenation+of+aglain+ketones+to+access+flavagline+natural+products&doi=10.1021%2Fja511728b"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Biomimetic Kinetic Resolution: Highly Enantio- and Diastereoselective Transfer Hydrogenation of Aglain Ketones To Access Flavagline Natural Products</span></div><div class="casAuthors">Stone, Steven D.; Lajkiewicz, Neil J.; Whitesell, Luke; Hilmy, Ahmed; Porco, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">525-530</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We have previously reported asym. syntheses and abs. configuration assignments of the aglains (+)-ponapensin and (+)-elliptifoline and proposed a biosynthetic kinetic resoln. process to produce enantiomeric rocaglamides and aglains.  Herein, we report a biomimetic approach for the synthesis of enantiomerically enriched aglains and rocaglamides via kinetic resoln. of a bridged ketone utilizing enantioselective transfer hydrogenation [e.g., (±)-I → (+)-I + (-)-II].  The methodol. has been employed to synthesize and confirm the abs. stereochemistries of the pyrimidone rocaglamides (+)-aglaiastatin and (-)-aglaroxin C.  Addnl., the enantiomers and racemate of each metabolite were assayed for inhibition of the heat-shock response, cytotoxicity, and translation inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgZZMDHjY_uLVg90H21EOLACvtfcHk0ljWB4SIDVCXPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFOhu7%252FF&md5=89141a3815f46bb46745aa8fd1d1490a</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fja511728b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja511728b%26sid%3Dliteratum%253Aachs%26aulast%3DStone%26aufirst%3DS.%2BD.%26aulast%3DLajkiewicz%26aufirst%3DN.%2BJ.%26aulast%3DWhitesell%26aufirst%3DL.%26aulast%3DHilmy%26aufirst%3DA.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26atitle%3DBiomimetic%2520kinetic%2520resolution%253A%2520highly%2520enantio-%2520and%2520diastereoselective%2520transfer%2520hydrogenation%2520of%2520aglain%2520ketones%2520to%2520access%2520flavagline%2520natural%2520products%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2015%26volume%3D137%26spage%3D525%26doi%3D10.1021%2Fja511728b" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yueh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Porco, J. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beeler, A. B.</span></span> <span> </span><span class="NLM_article-title">A photochemical flow reactor for large scale syntheses of aglain and rocaglate natural product analogues</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">6197</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2017.06.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1016%2Fj.bmc.2017.06.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=28666859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtVyntLfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2017&pages=6197&author=H.+Yuehauthor=Q.+Gaoauthor=J.+A.+Porcoauthor=A.+B.+Beeler&title=A+photochemical+flow+reactor+for+large+scale+syntheses+of+aglain+and+rocaglate+natural+product+analogues&doi=10.1016%2Fj.bmc.2017.06.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">A photochemical flow reactor for large scale syntheses of aglain and rocaglate natural product analogues</span></div><div class="casAuthors">Yueh, Han; Gao, Qiwen; Porco, John A., Jr.; Beeler, Aaron B.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6197-6202</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Herein, we report the development of continuous flow photoreactors for large scale ESIPT-mediated [3+2]-photocycloaddn. of 2-(p-methoxyphenyl)-3-hydroxyflavone and cinnamate-derived dipolarophiles.  These reactors can be efficiently numbered up to increase throughput two orders of magnitude greater than the corresponding batch reactions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOKc07fvnRN7Vg90H21EOLACvtfcHk0ljWB4SIDVCXPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtVyntLfF&md5=1189057eb841aec14b29c238b56b7afc</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2017.06.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2017.06.010%26sid%3Dliteratum%253Aachs%26aulast%3DYueh%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DQ.%26aulast%3DPorco%26aufirst%3DJ.%2BA.%26aulast%3DBeeler%26aufirst%3DA.%2BB.%26atitle%3DA%2520photochemical%2520flow%2520reactor%2520for%2520large%2520scale%2520syntheses%2520of%2520aglain%2520and%2520rocaglate%2520natural%2520product%2520analogues%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2017%26volume%3D25%26spage%3D6197%26doi%3D10.1016%2Fj.bmc.2017.06.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ernst, J. T.</span>; <span class="NLM_string-name">Reich, S. H.</span>; <span class="NLM_string-name">Sprengeler, P. A.</span>; <span class="NLM_string-name">Tran, C. V.</span>; <span class="NLM_string-name">Packard, G. K.</span>; <span class="NLM_string-name">Xiang, A. X.</span>; <span class="NLM_string-name">Nilewski, C.</span>; <span class="NLM_string-name">Michels, T.</span></span> <span> </span><span class="NLM_article-title">eIF4A-inhibiting compounds and methods related thereto</span> U.S. Patent <span class="NLM_patent">10,577,378 B2</span>, March 3, <span class="NLM_year">2020</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+T.+Ernst&author=S.+H.+Reich&author=P.+A.+Sprengeler&author=C.+V.+Tran&author=G.+K.+Packard&author=A.+X.+Xiang&author=C.+Nilewski&author=T.+Michels&title=eIF4A-inhibiting+compounds+and+methods+related+thereto"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DErnst%26aufirst%3DJ.%2BT.%26atitle%3DeIF4A-inhibiting%2520compounds%2520and%2520methods%2520related%2520thereto%26date%3D2020" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Algar, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flynn, J. P.</span></span> <span> </span><span class="NLM_article-title">New synthesis of flavonols</span>. <i>Proc. R. Ir. Acad., Sect. B</i> <span class="NLM_year" style="font-weight: bold;">1934</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">1</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADyaA2MXhtFOj" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1934&pages=1&author=J.+Algarauthor=J.+P.+Flynn&title=New+synthesis+of+flavonols"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">New synthesis of flavonols</span></div><div class="casAuthors">Algar, Joseph; Flynn, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the Royal Irish Academy, Section B:  Biological, Geological and Chemical Science</span>
        (<span class="NLM_cas:date">1934</span>),
    <span class="NLM_cas:volume">B42</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-8</span>CODEN:
                <span class="NLM_cas:coden">PRIBAN</span>;
        ISSN:<span class="NLM_cas:issn">0035-8983</span>.
    </div><div class="casAbstract">By satg. a mixt. of flavanone (3 g.) and HCHO (3 g.) in 40 cc. of alc. with dry HCl and refluxing for 10 h., an oily condensation product was obtained which, on redn. with alk. H2O2, gave 0.6 g. of flavonol (I).  To a soln. of o-hydroxyphenyl styryl ketone (2 g.) in 25 cc. of hot alc. was added 18 cc. of 0.5 N alc. KOH and 2 cc. of 30% H2O2.  Oxidn. occurred rapidly with rise of temp. and from the reaction mixt. I, m. 171-2°, was obtained in excellent yields.  The oxidn. of the following ketones: 2-hydroxyphenyl 4-methoxy-, 3,4-methyl-enedioxy- and 3,4-dimethoxy-styryl; 2-hydroxy-4-methoxy-Ph styryl, 4-methoxy- and 3,4-methylenedioxy styryl, and 2-hydroxy-3,4-dimethoxyphenyl 4-methoxy styryl similarly yielded the corresponding flavonols: 4'-MeO (II), C16H12O4, m. 235°; 3',4'-CH2O2, C16H10O5, m. 218-19°; 3',4'-(MeO)2, C17H14O5, m. 203°; 7-MeO, C16H12O4, m. 181°; 4',7-(MeO)2, C17H14O5, m. 195°; 7-methoxy-3',4'-methylenedioxy, C17H12O6, m. 210°, and 4',7,8-(MeO)3, C18H16O6, m. 202°.  II was also prepd. by the oxidn. of 1.5 g. of 3-anisylidene-4'-methoxyflavanone in alc. by the addn. of 14 cc. of 30% H2O2 and 2.8 g. of Na in 150 cc. of alc.  The flavonols gave fluorescent solns. in concd. H2SO4 and distinctive colorations with alc. FeCl3.  To elucidate the course of the reaction, attempts were made to isolate the intermediate products from the oxidn. of the styryl ketones.  It is possible that the 1st stage results in the transitory formation of an ethylene peroxide which might furnish a flavonol on ring closure.  The assumption of glycol formation would also afford a mechanism for the reaction.  The o-hydroxyphenyl styryl ketones are readily prepd. and their oxidn. furnishes a convenient method for the synthesis of flavonols.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDFvkmnv3vF7Vg90H21EOLACvtfcHk0ljWB4SIDVCXPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2MXhtFOj&md5=bc6f58a134ff152d1a9468ad2984db66</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlgar%26aufirst%3DJ.%26aulast%3DFlynn%26aufirst%3DJ.%2BP.%26atitle%3DNew%2520synthesis%2520of%2520flavonols%26jtitle%3DProc.%2520R.%2520Ir.%2520Acad.%252C%2520Sect.%2520B%26date%3D1934%26volume%3D42%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyamada, T.</span></span> <span> </span><span class="NLM_article-title">A new general method for the synthesis of flavonol derivatives</span>. <i>Nippon Kagaku Kaishi</i> <span class="NLM_year" style="font-weight: bold;">1934</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">1256</span>, <span class="refDoi"> DOI: 10.1246/nikkashi1921.55.12_1256</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1246%2Fnikkashi1921.55.12_1256" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADyaA2MXjtlGrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1934&pages=1256&author=T.+Oyamada&title=A+new+general+method+for+the+synthesis+of+flavonol+derivatives&doi=10.1246%2Fnikkashi1921.55.12_1256"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">A new general method for the synthesis of flavonol derivatives</span></div><div class="casAuthors">Oyamada, Taichiro</div><div class="citationInfo"><span class="NLM_cas:title">Nippon Kagaku Kaishi (1921-47)</span>
        (<span class="NLM_cas:date">1934</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1256-61</span>CODEN:
                <span class="NLM_cas:coden">NIKWAB</span>;
        ISSN:<span class="NLM_cas:issn">0369-4208</span>.
    </div><div class="casAbstract">The method is based on the fact of the formation of flavonols when o-hydroxychalcones are treated with H2O2 in the presence of dil. alkali.  Prepn. of 7,3',4'-trimethoxy-3-hydroxyflavone (I): To 1.5 g. 4,3',-4'-trimethoxy-2-hydroxychalcone in 30 cc. MeOH, add 10 cc. 16% NaOH and 4 cc. 15% H2O2 while cooling and let stand overnight.  Add water and acidify with H2SO4.  Collect the crystals of I and recrystallize from MeOH, m. 185-6°.  In a similar manner, 3-hydroxyflavone (II), m. 169-70°, is prepd. from o-hydroxychalcone; Me ether of II, m. 114°; 3-hydroxyacetoflavone, m. 110-11°.  4'-Methoxy-2-hydroxychalcone gives 4'-methoxy-3-hydroxyflavone, m. 230-2°.  3',4'-Dimethoxy-2-hydroxychalcone gives 3',4'-dimethoxy-3-hydroxyflavone, m. 200-2°.  2-Hydroxychalcone gives flavanone, m. 75-6°.  Flavanone gives 3-hydroxyflavone, colorless needles, m. 169-70°.  4'-Methoxyflavanone gives 4'-methoxy-3 hydroxyflavone, yellow needles, m. 231-2°.  7,3',4'-Trimethoxyflavanone gives 7,3',4'-trimethoxy-3-hydroxyflavone, m. 185°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo48kngimSUAbVg90H21EOLACvtfcHk0li5r5cDQ0oPzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2MXjtlGrtA%253D%253D&md5=fc06c99439c8e3f8e9abde7eec1b56fc</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1246%2Fnikkashi1921.55.12_1256&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fnikkashi1921.55.12_1256%26sid%3Dliteratum%253Aachs%26aulast%3DOyamada%26aufirst%3DT.%26atitle%3DA%2520new%2520general%2520method%2520for%2520the%2520synthesis%2520of%2520flavonol%2520derivatives%26jtitle%3DNippon%2520Kagaku%2520Kaishi%26date%3D1934%26volume%3D55%26spage%3D1256%26doi%3D10.1246%2Fnikkashi1921.55.12_1256" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oyamada, T.</span></span> <span> </span><span class="NLM_article-title">A new general method for the synthesis of the derivatives of flavonol</span>. <i>Bull. Chem. Soc. Jpn.</i> <span class="NLM_year" style="font-weight: bold;">1935</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">182</span>, <span class="refDoi"> DOI: 10.1246/bcsj.10.182</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1246%2Fbcsj.10.182" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADyaA2MXjvFentg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1935&pages=182&author=T.+Oyamada&title=A+new+general+method+for+the+synthesis+of+the+derivatives+of+flavonol&doi=10.1246%2Fbcsj.10.182"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">General method for the synthesis of the derivatives of flavonol</span></div><div class="casAuthors">Oyamada, Taichiro</div><div class="citationInfo"><span class="NLM_cas:title">Bulletin of the Chemical Society of Japan</span>
        (<span class="NLM_cas:date">1935</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">182-6</span>CODEN:
                <span class="NLM_cas:coden">BCSJA8</span>;
        ISSN:<span class="NLM_cas:issn">0009-2673</span>.
    </div><div class="casAbstract">See C. A. 29, 4358.7.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozvL3X-kmeYrVg90H21EOLACvtfcHk0li5r5cDQ0oPzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaA2MXjvFentg%253D%253D&md5=c765c660802c49d744684cdacf0bb41c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1246%2Fbcsj.10.182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1246%252Fbcsj.10.182%26sid%3Dliteratum%253Aachs%26aulast%3DOyamada%26aufirst%3DT.%26atitle%3DA%2520new%2520general%2520method%2520for%2520the%2520synthesis%2520of%2520the%2520derivatives%2520of%2520flavonol%26jtitle%3DBull.%2520Chem.%2520Soc.%2520Jpn.%26date%3D1935%26volume%3D10%26spage%3D182%26doi%3D10.1246%2Fbcsj.10.182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lan, X.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, N.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, C.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-H.</span></span> <span> </span><span class="NLM_article-title">Ligand-mediated and copper-catalyzed C(sp<sup>3</sup>)-H bond functionalization of aryl ketones with sodium sulfinates under mild conditions</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">18391</span>, <span class="refDoi"> DOI: 10.1038/srep18391</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=10.1038%2Fsrep18391" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=26681470" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC2MXitVCksL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&pages=18391&author=X.-W.+Lanauthor=N.-X.+Wangauthor=C.-B.+Baiauthor=W.+Zhangauthor=Y.+Xingauthor=J.-L.+Wenauthor=Y.-J.+Wangauthor=Y.-H.+Li&title=Ligand-mediated+and+copper-catalyzed+C%28sp3%29-H+bond+functionalization+of+aryl+ketones+with+sodium+sulfinates+under+mild+conditions&doi=10.1038%2Fsrep18391"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-Mediated and Copper-Catalyzed C(sp3)-H Bond Functionalization of Aryl Ketones with Sodium Sulfinates under Mild Conditions</span></div><div class="casAuthors">Lan, Xing-Wang; Wang, Nai-Xing; Bai, Cui-Bing; Zhang, Wei; Xing, Yalan; Wen, Jia-Long; Wang, Yan-Jing; Li, Yi-He</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">18391pp.</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Novel and convenient copper(II) bromide and 1,8-diazabicyclo[5.4.1]undec-7-ene (DBU) or 1,10-phenanthroline catalysis protocol for the construction of α-alkyl-β-keto sulfones via C(sp3)-H bond functionalization followed by C(sp3)-S bond formation between aryl ketones and sodium sulfinates at room temp. was developed.  This method was applicable to a wide range of aryl ketones and sodium sulfinates.  The electronic effects of aryl ketones and ligands effects of the copper salts were crucial for this transformation.  Typically, substituted aryl ketones with electron-withdrawing group do not need any ligand to give a good to excellent yield, while substituted aryl ketones with electron-donating group and electron-rich heteroarom. ketones offer a good to excellent yield only under the nitrogen-based ligands.  The practical value of this transformation highlights the efficient and robust one-pot synthesis of α-alkyl-β-keto sulfones.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCcik9YrVp17Vg90H21EOLACvtfcHk0li5r5cDQ0oPzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXitVCksL3M&md5=53ca82c5bc166c07e8beae449ea7e5ea</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1038%2Fsrep18391&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep18391%26sid%3Dliteratum%253Aachs%26aulast%3DLan%26aufirst%3DX.-W.%26aulast%3DWang%26aufirst%3DN.-X.%26aulast%3DBai%26aufirst%3DC.-B.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DXing%26aufirst%3DY.%26aulast%3DWen%26aufirst%3DJ.-L.%26aulast%3DWang%26aufirst%3DY.-J.%26aulast%3DLi%26aufirst%3DY.-H.%26atitle%3DLigand-mediated%2520and%2520copper-catalyzed%2520C%2528sp3%2529-H%2520bond%2520functionalization%2520of%2520aryl%2520ketones%2520with%2520sodium%2520sulfinates%2520under%2520mild%2520conditions%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26spage%3D18391%26doi%3D10.1038%2Fsrep18391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulmer, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherden, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottlieb, H. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nudelman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stoltz, B. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bercaw, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, K. I.</span></span> <span> </span><span class="NLM_article-title">NMR Chemical shifts of trace impurities: Common laboratory solvents, organics, and gases in deuterated solvents relevant to the organometallic chemist</span>. <i>Organometallics</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">2176</span>, <span class="refDoi"> DOI: 10.1021/om100106e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/om100106e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;key=1%3ACAS%3A528%3ADC%252BC3cXkslKms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=2176&author=G.+R.+Fulmerauthor=A.+J.+M.+Millerauthor=N.+H.+Sherdenauthor=H.+E.+Gottliebauthor=A.+Nudelmanauthor=B.+M.+Stoltzauthor=J.+E.+Bercawauthor=K.+I.+Goldberg&title=NMR+Chemical+shifts+of+trace+impurities%3A+Common+laboratory+solvents%2C+organics%2C+and+gases+in+deuterated+solvents+relevant+to+the+organometallic+chemist&doi=10.1021%2Fom100106e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">NMR Chemical Shifts of Trace Impurities: Common Laboratory Solvents, Organics, and Gases in Deuterated Solvents Relevant to the Organometallic Chemist</span></div><div class="casAuthors">Fulmer, Gregory R.; Miller, Alexander J. M.; Sherden, Nathaniel H.; Gottlieb, Hugo E.; Nudelman, Abraham; Stoltz, Brian M.; Bercaw, John E.; Goldberg, Karen I.</div><div class="citationInfo"><span class="NLM_cas:title">Organometallics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2176-2179</span>CODEN:
                <span class="NLM_cas:coden">ORGND7</span>;
        ISSN:<span class="NLM_cas:issn">0276-7333</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Tables of 1H and 13C NMR chem. shifts have been compiled for common org. compds. often used as reagents or found as products or contaminants in deuterated org. solvents.  Building upon the work of Gottlieb, Kotlyar, and Nudelman in the Journal of Org. Chem., signals for common impurities are now reported in addnl. NMR solvents (tetrahydrofuran-d8, toluene-d8, dichloromethane-d2, chlorobenzene-d5, and 2,2,2-trifluoroethanol-d3) which are frequently used in organometallic labs.  Chem. shifts for other orgs. which are often used as reagents or internal stds. or are found as products in organometallic chem. are also reported for all the listed solvents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo3GGHumCq_P7Vg90H21EOLACvtfcHk0liZ9j514zSB5A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXkslKms7Y%253D&md5=53317e05fe3be77fe7de48d8fe1fb8b7</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1021%2Fom100106e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fom100106e%26sid%3Dliteratum%253Aachs%26aulast%3DFulmer%26aufirst%3DG.%2BR.%26aulast%3DMiller%26aufirst%3DA.%2BJ.%2BM.%26aulast%3DSherden%26aufirst%3DN.%2BH.%26aulast%3DGottlieb%26aufirst%3DH.%2BE.%26aulast%3DNudelman%26aufirst%3DA.%26aulast%3DStoltz%26aufirst%3DB.%2BM.%26aulast%3DBercaw%26aufirst%3DJ.%2BE.%26aulast%3DGoldberg%26aufirst%3DK.%2BI.%26atitle%3DNMR%2520Chemical%2520shifts%2520of%2520trace%2520impurities%253A%2520Common%2520laboratory%2520solvents%252C%2520organics%252C%2520and%2520gases%2520in%2520deuterated%2520solvents%2520relevant%2520to%2520the%2520organometallic%2520chemist%26jtitle%3DOrganometallics%26date%3D2010%26volume%3D29%26spage%3D2176%26doi%3D10.1021%2Fom100106e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2HYI','PDB','2HYI'); return false;">PDB: 2HYI</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5ZC9','PDB','5ZC9'); return false;">PDB: 5ZC9</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i421"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_21163"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00182?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00182</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic schemes, analytical data, and molecular formula strings for all compounds and molecular model PDB files (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 9 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_002.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 10 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_003.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 12A(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_004.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 12B (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_005.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 13A (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_006.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 13B (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_007.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 14A (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_008.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings of Figure 14B (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_009.csv">CSV</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_010.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_001.pdf">jm0c00182_si_001.pdf (29.62 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_002.csv">jm0c00182_si_002.csv (29.89 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_003.csv">jm0c00182_si_003.csv (0.58 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_004.csv">jm0c00182_si_004.csv (0.43 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_005.csv">jm0c00182_si_005.csv (0.43 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_006.csv">jm0c00182_si_006.csv (0.39 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_007.csv">jm0c00182_si_007.csv (0.1 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_008.csv">jm0c00182_si_008.csv (0.83 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_009.csv">jm0c00182_si_009.csv (0.75 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00182/suppl_file/jm0c00182_si_010.csv">jm0c00182_si_010.csv (5.54 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00182&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00182%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-11" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00182" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                9MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679939de0d743d18","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
